
<html lang="en"     class="pb-page"  data-request-id="ac880089-f707-42d1-a811-2c403e742ac2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-15;article:article:10.1021/acs.jmedchem.7b00010;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthetic Approaches to the New Drugs Approved During 2015" /></meta><meta name="dc.Creator" content="Andrew C.  Flick" /></meta><meta name="dc.Creator" content="Hong X.  Ding" /></meta><meta name="dc.Creator" content="Carolyn A.  Leverett" /></meta><meta name="dc.Creator" content="Robert E.  Kyne, Jr." /></meta><meta name="dc.Creator" content="Kevin K. -C.  Liu" /></meta><meta name="dc.Creator" content="Sarah J.  Fink" /></meta><meta name="dc.Creator" content="Christopher J.  O’Donnell" /></meta><meta name="dc.Description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while ..." /></meta><meta name="Description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 3, 2017" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00010" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00010" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00010" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00010" /></link>
        
    
    

<title>Synthetic Approaches to the New Drugs Approved During 2015 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00010" /></meta><meta property="og:title" content="Synthetic Approaches to the New Drugs Approved During 2015" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0044.jpeg" /></meta><meta property="og:description" content="New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 29 new chemical entities (NCEs) that were approved for the first time in 2015." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00010"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00010">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00010&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00010&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00010&amp;href=/doi/10.1021/acs.jmedchem.7b00010" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 6480-6515</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01442" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.7b00360" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="article_relation"><span class="article_relation-correction"><i class="icon-asterisk"></i><span class="relation-text"><a href="/doi/10.1021/acs.jmedchem.7b01452"><span class="relation-type">ADDITION / CORRECTION</span><span class="relation-desc">This article has been corrected. View the notice.</span></a></span></span></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthetic Approaches to the New Drugs Approved During 2015</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+C.++Flick">Andrew C. Flick</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong+X.++Ding">Hong X. Ding</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carolyn+A.++Leverett">Carolyn A. Leverett</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+E.++Kyne%2C++Jr.">Robert E. Kyne, Jr.</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+K.+%5C-C.++Liu">Kevin K. -C. Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+J.++Fink">Sarah J. Fink</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++O%E2%80%99Donnell">Christopher J. O’Donnell</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Groton Laboratories, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Pharmacodia (Beijing) Co., Ltd., Beijing, 100085, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Celgene Corporation, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai, 201203, China</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">BioDuro Co., Ltd., Shanghai, 200131, China</span></div><div class="corresp-info"><strong>*</strong>Phone: 860-715-4118. Fax: 860-715-2349. Email: <a href="/cdn-cgi/l/email-protection#07646f756e747368776f6275296d296863686969626b6b4777616e7d62752964686a"><span class="__cf_email__" data-cfemail="ff9c978d968c8b908f979a8dd195d1909b9091919a9393bf8f9996859a8dd19c9092">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00010&amp;href=/doi/10.1021%2Facs.jmedchem.7b00010" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 6480–6515</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 19, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 January 2017</li><li><span class="item_label"><b>Published</b> online</span>3 May 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 August 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00010" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00010</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editors’ Choice" /></img><span>ACS Editors’ Choice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00010"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">40464</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">59</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00010" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthetic Approaches to the New Drugs Approved During 2015&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;C. Flick&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;X. Ding&quot;},{&quot;first_name&quot;:&quot;Carolyn&quot;,&quot;last_name&quot;:&quot;A. Leverett&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;E. Kyne&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;K. -C. Liu&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;J. Fink&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. O’Donnell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;6480-6515&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00010&quot;},&quot;abstract&quot;:&quot;New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 29 new chemical entities (NCEs) that were approved for the first time in 2015.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00010&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00010" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00010&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00010" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00010&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00010" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00010&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00010&amp;href=/doi/10.1021/acs.jmedchem.7b00010" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00010" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00010" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26pmid%3D28421763%26genre%3Darticle%26aulast%3DFlick%26date%3D2017%26atitle%3DSynthetic%2BApproaches%2Bto%2Bthe%2BNew%2BDrugs%2BApproved%2BDuring%2B2015%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D15%26spage%3D6480%26epage%3D6515%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291301" title="Salts">Salts</a>,</li><li><a href="/action/doSearch?ConceptID=291650" title="Alcohols">Alcohols</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/jmcmar.2017.60.issue-15/20170810/jmcmar.2017.60.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0044.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 29 new chemical entities (NCEs) that were approved for the first time in 2015.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66075" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66075" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="quote"><p class="first">The most fruitful basis for the discovery of a new drug is to start with an old drug.</p><div class="NLM_permissions" id=""><div class="NLM_credits" id="">Sir James Whyte Black, winner of the 1988 Nobel Prize in medicine<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div></div></div><div class="NLM_p">Inaugurated 14 years ago,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> this annual review presents synthetic methods for molecular entities that were approved for the first time by governing bodies within various countries during the past year. Because drugs tend to have structural homology across similar biological targets, it is widely believed that the knowledge of new chemical entities and approaches to their construction will greatly enhance the ability to discover new drugs more efficiently. The pharmaceutical industry enjoyed a productive year during 2015: 50 new drugs consisting of new molecular entities (NMEs) and biologics were approved which spanned a variety of indications including the first treatment for female hypoactive sexual desire disorder, binge eating disorder, the first vaccine for dengue, as well as the first pharmacotherapies for three rare metabolic disorders.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The field of oncology was the most active therapeutic area in terms of numbers of drug approvals in 2015, with 14 new drugs and biologics within this class reaching the market, including four new drugs for the treatment of multiple myeloma. Furthermore, six hematologic therapies and six metabolic treatments were brought to the market. In contrast to the productivity realized industrywide during 2014 and 2015, the number of medicines approved decreased in 2016. Nonetheless, an additional 21 new drugs were in the process of approval from various governing bodies during 2015 but were not launched before the end of the year.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">This review describes the syntheses of the 29 small-molecule NCEs that were approved for the first time in 2015 around the world (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). New indications for previously launched medications, new combinations, new formulations of existing drugs, and drugs synthesized purely via bioprocesses or peptide synthesizers have been excluded from this review.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0001.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 29 NCEs approved in 2015.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Drugs presented in this review are divided into eight therapeutic categories: anti-infective, cardiovascular, neuroscience, gastrointestinal, hematologic, metabolic, musculoskeletal, and oncology. Within the therapeutic areas, drugs are ordered alphabetically by generic name. Although the scale of the synthetic routes were not explicitly disclosed in most cases, this review presents the most likely scalable routes that have been disclosed within published or patent literature beginning from commercially available starting materials.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Anti-Infective Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56651" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56651" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">2.1 Isavuconazonium Sulfate (Cresemba)</h3><div class="NLM_p">Isavuconazonium sulfate is a broad spectrum antifungal agent that was codeveloped by Basilea Pharmaceutica (a subsidiary of Hoffmann–La Roche acquired in 2000) and Astellas Pharma, which obtained its first approval by the United States Food and Drug Administration (FDA) for the treatment of invasive aspergillosis and invasive mucormycosis, available as both oral and intravenous formulations.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Isavuconazonium sulfate is a water-soluble prodrug, which is rapidly hydrolyzed by esterases (mainly butylcholinesterase) in plasma into the active moiety isavuconazole (BAL-4815) and an inactive cleavage product (BAL-8728).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Isavuconazole inhibits cytochrome P450 (CYP)-dependent enzyme lanosterol 14-ademethylase (CYP51) and thereby inhibits the synthesis of ergosterol, a key component of the fungal cell membrane.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Isavuconazole displayed potent fungistatic or fungicidal activity in vitro against a broad range of clinically important yeasts and molds, namely <i>Candida</i> spp., <i>Cryptococcus</i> spp., <i>Trichosporon</i> spp., <i>Geotrichum capitatum</i>, <i>Pichia</i> spp., <i>Rhodotorula</i> spp., <i>Saccharomyces cerevisiae</i>, <i>Aspergillus</i> spp., and most species known to cause mucormycosis (<i>Mucorales</i> mucorales). This broad range of antifungal activity renders this drug more clinically appealing compared to other azoles with narrower indications.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Furthermore, isavuconazole does not require a cyclodextrin vehicle due to its water solubility, and currently does not require therapeutic drug monitoring. Moreover, isavuconazole has displayed improved safety and tolerability compared to voriconazole.<a onclick="showRef(event, 'cit5b'); return false;" href="javascript:void(0);" class="ref cit5b">(5b)</a></div><div class="NLM_p">As a prodrug, the structure of isavuconazonium sulfate <b>I</b> consist of two parts: the active moiety isavuconazole <b>8</b> and a water-soluble, prodrug side chain <b>15</b>. Several papers have been published on the synthesis of isavuconazonium sulfate <b>I</b>,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and the approach to enantiomerically pure isavuconazole <b>8</b> has been reported through three different synthetic strategies.<a onclick="showRef(event, 'cit6a cit6c cit6e'); return false;" href="javascript:void(0);" class="ref cit6a cit6c cit6e">(6a, 6c, 6e)</a> The following <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> describe the most likely process route to both <b>8</b> and <b>15</b>, including the union of both fragments, as described by researchers at Carbo-Design LLC and Wockhardt Ltd., respectively.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Fragment <b>8</b> of Isavuconazonium Sulfate (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Isavuconazonium Sulfate (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of active moiety isavuconazole <b>8</b> was started with commercial 1-(2,5-difluorophenyl)-2-(1<i>H</i>-l,2,4-triazol-l-yl)ethanone (<b>1</b>) as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Triazole <b>1</b> was treated with <i>n</i>-BuLi followed by exposure to propionitrile (<b>2</b>) and acidic quench to give racemic alcohol <b>3</b> in 65% yield. Next, resolution of this racemic alcohol was facilitated through the use of camphor derivative <b>4</b> to provide alcohol <b>5</b> in 38% yield and 99% ee.<a onclick="showRef(event, 'cit6c'); return false;" href="javascript:void(0);" class="ref cit6c">(6c)</a> Nitrile <b>5</b> was then treated with concentrated H<sub>2</sub>SO<sub>4</sub> and H<sub>2</sub>S to furnish thioamide <b>6</b>, and this was followed by a cyclization reaction involving 4-(2-chloroacetyl)benzonitrile (<b>7</b>) which gave rise to isavuconazole <b>8</b> in 81% yield across the two-step sequence.<a onclick="showRef(event, 'cit6c'); return false;" href="javascript:void(0);" class="ref cit6c">(6c)</a></div><div class="NLM_p last">The preparation of water-soluble side chain <b>15</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was initiated from commercially available 2-chloronicotinic acid (<b>9</b>), which was converted to the corresponding <i>tert</i>-butyl ester <b>11</b> via acid halide <b>10</b> in excellent yield for the two-step protocol. Subjection of pyridyl chloride <b>11</b> to methanolic methylamine furnished aminopyridine <b>12</b> in 92% yield, and this compound was subsequently reduced with lithium aluminum hydride to give aminoalcohol <b>13</b> in 76% yield. Next, <i>N</i>-acylation of <b>13</b> with 1-chloroethyl chloroformate (<b>14</b>) followed by treatment with <i>N</i>-Boc-sarcosine under esterification conditions delivered chloroethyl ester <b>15</b> in 73% yield.<a onclick="showRef(event, 'cit6b'); return false;" href="javascript:void(0);" class="ref cit6b">(6b)</a> The union of the aminopyridyl side chain <b>15</b> with thiazoloalcohol <b>8</b> was facilitated by reacting the two compounds in the presence of KI in acetonitrile, and this alkylation was followed by removal of the Boc group with hydrochloric acid to give rise to isavuconazonium iodide hydrochloride (<b>16</b>) in 79% yield. Finally, isavuconazonium sulfate (<b>I</b>) was prepared from <b>16</b> using an anion exchange resin in 93% yield to finish the construction of the API.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2 Olanexidine Gluconate (Olanedine)</h3><div class="NLM_p">In July 2015, olanexidine gluconate, a biguanide compound with remarkable antibacterial activity, was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for skin antisepsis at surgical sites.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The drug was developed and marketed by Otsuka Pharmaceutical in Japan and is available as topical solution (1.5%). Olanexidine gluconate exhibited efficacy against a wide range of bacterial strains, especially Gram-positive bacteria. In vitro experiments exploring its mechanism of action indicated that olanexidine interacts with bacterial surface molecules (such as lipopolysaccharides and lipoteichoic acid), disrupting the cell membranes of liposomes.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> These models suggest that the drug permeates the membranes of both <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> and denatures proteins at relatively high concentrations (>160 g/mL).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">The synthesis of olanexidine gluconate is relatively straightforward, involving the linkage of an <i>n</i>-octyl side chain and a dichlorobenzylamine through a bis-guanidyl lynchpin. The synthesis began with the reaction of commercial <i>n</i>-octylamine (<b>17</b>) with sodium dicyanamide in the presence of concentrated sulfuric acid in refluxing <i>n</i>-butyl acetate to give rise to 1-cyano-3-octylguanidine (<b>18</b>) in 86% yield (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Conditions employed to subsequently secure biguanidine <b>20</b> as the HCl salt hemihydrate in 77% yield were nearly identical to those used for the conversion of <b>17</b> to <b>18</b>.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Finally, treatment of <b>20</b> with sodium hydroxide in the presence of gluconic acid (<b>21</b>) gave rise to olanexidin gluconate (<b>II</b>) in almost quantitative yield.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Olanexidine Gluconate (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.3 Ozenoxacin (Zebiax)</h3><div class="NLM_p">Ozenoxacin is a novel, nonfluorinated quinolone antibiotic discovered by Toyama Chemical Co. Ltd. and developed by Maruho Co. Ltd. Ozenoxacin was approved by the PMDA of Japan in September 2015 for the treatment of acne and skin infections.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Ozenoxacin shows potent antibacterial activity against anaerobic and aerobic, gram-positive and -negative bacteria, especially those implicated in superficial skin infections such as <i>S. aureus</i>, <i>Staphylococcus epidermidis</i>, and <i>Propionibacterium acnes</i>.<a onclick="showRef(event, 'ref3 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref11">(3, 11)</a> The mechanism of action of ozenoxacin involves the drug’s affinity for DNA gyrase and DNA topoisomerase IV and upon binding triggers bacterial apoptosis.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">A U.S. patent filed by co-workers at Toyama describes the only publicly disclosed synthetic approach to this drug.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The drug’s assembly hinges upon a key Stille coupling between a quinolonyl bromide and a stannylpyridine (<a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). Buchwald–Hartwig coupling of commercially available 2,6-dibromotoluene (<b>22</b>) and cyclopropylamine (<b>23</b>) gave <i>N</i>-cyclopropyl-3-bromo-2-methylaniline <b>24</b> in 84% yield (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), and this step was followed by reaction with diethyl ethoxymethylenemalonate (<b>25</b>) and subsequent cyclization under acidic conditions to secure bromoquinoline <b>26</b> in 43% yield over the two-step sequence. Stille coupling of <b>27</b> with bromoquinoline <b>26</b> resulted in pyridyl quinoline adduct <b>28</b> in 80% yield. Saponification of ester <b>28</b> followed by acidic removal of the <i>N</i>-acetyl group delivered the active pharmaceutical ingredient ozenoxacin (<b>III</b>) in 75% yield.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Ozenoxacin (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Fragment <b>27</b> of Ozenoxacin (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The preparation of key stannane <b>27</b>, which is not commercially available, is depicted in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> and began with the conversion of commercially available 5-bromo-2-chloro-3-methylpyridine (<b>30</b>) to aminopyridine derivative <b>31</b> upon treatment with aqueous methylamine at elevated temperature in a sealed vessel. The resulting aminopyridine was subjected to acetic anhydride in pyridine, resulting in acetamide <b>32</b> in good yield, and this coupling was followed by a modest-yielding palladium-catalyzed installation of the stannyl group to deliver subunit <b>27</b>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">3 Cardiovascular Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.1 Cangrelor Tetrasodium (Kengrexal)</h3><div class="NLM_p">Cangrelor tetrasodium is a direct purinergic platelet receptor (P2Y12) inhibitor that blocks ADP-induced platelet activation and aggregation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The drug, which was developed by The Medicine Company, binds reversibly to the P2Y12 receptor, preventing further signaling and platelet activation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Cangrelor, which was approved in June 2015 by the FDA, is indicated as an adjunct to percutaneous coronary intervention for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The most common side effect observed with the drug was bleeding.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">While several discovery-scale routes to cangrelor tetrasodium were previously reported,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> an improved procedure developed with the goal of providing a manufacturing scale route to cangrelor tetrasodium has recently been reported by Jinan Bestcomm Pharmaceutical R&D. Starting from commercially available 2-thiobarbituric acid (<b>36</b>, <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a><i>S</i>-alkylation with 3,3,3-trifluoropropyl iodide proceeded in high yield (94%) under basic conditions. Nitration of this intermediate with HNO<sub>3</sub>/AcOH generated a nitro-pyrimidine diol in 80% yield. Bis-chlorination via treatment with POCl<sub>3</sub> provided the corresponding dichloro pyrimidine (92%), and subsequent nitro reduction with AcOH/Fe under aqueous conditions yielded intermediate <b>37</b> (quantitative yield), which readily provided the bis-aniline analogue by reaction with ammonia in EtOH/H<sub>2</sub>O at 80 °C. Condensation with triethyl orthoformate/HCl at room temperature provided access to the desired purine in high yield (97%). A one-pot alkylation/amination strategy was then employed, first relying on <i>S</i>-alkylation of 2-aminoethanethiol hydrochloride with MeI/NaOH and reaction of the resulting amine with the purine chloride generated <b>38</b> in 88% across the sequence. Alkylation of <b>38</b> with commercial furanose <b>39</b> proceeded in a regioselective manner favoring <i>N</i>-9 functionalization, employing conditions similar to those previously described by Almond and co-workers.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Toward this end, silylation of <b>38</b> with <i>N</i>,<i>O</i>-bis-(trimethylsilyl)acetamide (BSA) followed by subjection to TMSOTf and <b>39</b>, resulted in the desired <i>N</i>-9 alkylated product, which was carried crude to global deacetylation with NaOH/EtOH at room temperature, making way for smooth conversion to alcohol <b>40</b> (87% from <b>38</b>). Although phosphorylation of <b>40</b> has been performed using a variety of related methods,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> the largest scale conditions reported to date consist of initial 5′ alcohol activation with POCl<sub>3</sub> and PO(OEt)<sub>3</sub><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> in the presence of 1,8-diaminonaphthalene, furnishing the 5′ monophosphonate intermediate. This intermediate was not isolated but further treated with a solution of dichloromethylenebis(phosphonic acid) tributylammonium salt and tributylamine in DMF at 0 °C, yielding cangrelor as a crude ammonium salt following quench with NH<sub>4</sub>HCO<sub>3</sub>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Purification via ion exchange chromatography provided cangrelor as its ammonium salt in 68% yield over the three-step sequence, which was subjected to aqueous NaHCO<sub>3</sub> solution and lyophilization and provided cangrelor tetrasodium salt (<b>IV</b>). This synthesis was performed starting on >100 g scale of <b>36</b> and required only one chromatography step which involved ion exchange chromatography of the cangrelor ammonium salt.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> More recently, while beyond the scope of this article, additional reports have been disclosed describing the development of specific pharmaceutical formulations for delivery of cangrelor in high purity.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Cangrelor Tetrasodium (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">3.2 Sacubitril (Entresto)</h3><div class="NLM_p">Sacubitril is a neprilysin inhibitor prodrug developed by Novartis that was approved as part of an orally administered supramolecular sodium salt complex with the angiotensin receptor blocker (ARB) valsartan in the U.S. and EU in 2015.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Sacubitril/valsartan (also known as LCZ-696) is a first-in-class dual angiotensin receptor blocker–neprilysin inhibitor (ARNI) marketed for the treatment of chronic heart failure with reduced ejection fraction (HFrEF).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> It represents a novel mechanistic approach to targeting HFrEF and is the first pharmacologic agent approved for HFrEF since 2004.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Sacubitril is metabolized by enzymatic conversion of the ethyl ester to the active diacid (LBQ-657, structure not disclosed), which inhibits neprilysin and prevents endogenous natriuretic peptide degradation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Neprilysin inhibitors like sacubitril are not effective as monotherapy and need to be combined with a renin–angiotensin–aldosterone system (RAAS) inhibitor such as valsartan. Notably, dual neprilysin and angiotensin-converting enzyme (ACE) inhibition, as in omapatrilat, was found to be associated with an increased risk of life-threatening angioedema due to increased bradykinin levels.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In phase III clinical trials, sacubitril/valsartan displayed a superior safety profile to enalapril, with a 20% decrease in heart failure hospitalizations or cardiovascular death and a 16% reduction in the risk of death from any cause. Sacubitril/valsartan is now recommended as the standard of care for HFrEF as an alternative to ACEs and ARBs.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">Several routes to sacubitril, particularly to advanced intermediates, have been published in the primary and patent literature.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> They differ generally in their choice of chiral pool starting material and their approach to introduction of the second stereocenter. The industrial scale synthesis of intermediate <b>47</b> has been reported, and this route is described in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>.<a onclick="showRef(event, 'cit23e'); return false;" href="javascript:void(0);" class="ref cit23e">(23e)</a> Accordingly, addition of the cuprate of biaryl bromide <b>41</b> to (<i>S</i>)-epichlorohydrin <b>42</b> followed by subjection to HCl provided chloropropanol <b>43</b> in 92% yield and 99% ee. Next, a Mitsunobu reaction involving succinimide <b>44</b> followed by treatment with refluxing HCl and NaOH generated the corresponding aminoalcohol, which was isolated via crystallization as the HCl salt prior to Boc protection to give <i>N</i>-Boc aminoalcohol <b>45</b> in >99% ee. Alcohol <b>45</b> was then carried through a four-step process to give acid <b>47</b> in 75% yield, starting with oxidation of the alcohol to the corresponding aldehyde with TEMPO/NaOCl. The organic phase was carried forward directly into a Wittig reaction with ylide <b>46</b>, generating an α,β-unsaturated ester which was hydrolyzed to acid <b>47</b> with LiOH in an ethanol/water mixture. Interestingly, a separate patent disclosed the stereoselective hydrogenation of the trisubstituted olefin <b>47</b>, in which subjection of <b>47</b> to catalytic [Ru(<i>p</i>-cymene)I<sub>2</sub>]<sub>2</sub> and chiral phosphine ligand Mandyphos SL-M004-1 (<b>48</b>) under 40 bar of hydrogen gas in warm ethanol delivered <b>49</b> in 99:1 dr before recrystallization.<a onclick="showRef(event, 'cit23b cit23f cit23g cit23h'); return false;" href="javascript:void(0);" class="ref cit23b cit23f cit23g cit23h">(23b, 23f-23h)</a> Subsequently, activation of the acid as the acid halide through the use of thionyl chloride and ethanol not only reestablished the ethyl ester but removed the Boc group, revealing a primary amine which then reacted with succinic anhydride to ultimately deliver sacubitril (<b>V</b>). The freebase form of sacubitril does not readily crystallize; the isolation of a number of pharmaceutically acceptable salts of sacubitril via crystallization, most preferably the calcium salt <b>50</b> or sodium salts, have been reported.<a onclick="showRef(event, 'cit23c cit23d cit23i cit23j'); return false;" href="javascript:void(0);" class="ref cit23c cit23d cit23i cit23j">(23c, 23d, 23i, 23j)</a> Preparation of the sacubitril/valsartan supramolecular complex (trisodium salt, hemihydrate) has been described on a kilo-scale from sacubitril calcium salt via neutralization to the freebase and subsequent complexation with valsartan in <i>i</i>PrOAc/acetone.<a onclick="showRef(event, 'cit23j'); return false;" href="javascript:void(0);" class="ref cit23j">(23j)</a> Addition of NaOH and crystallization then provided the desired trisodium salt hemihydrate.</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Sacubitril (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">3.3 Selexipag (Uptravi)</h3><div class="NLM_p">Selexipag and its active metabolite, the corresponding carboxylic acid, are nonprostanoid prostaglandin I2 (PGI-2) receptor agonists (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The <i>N</i>-methylsulfonamide within selexipag is hydrolyzed to the corresponding carboxylic acid in vivo by hepatic microsomes at a rate which provides a slow-release pharmacological effect.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The compound was originally discovered by Nippon Shinyaki and later licensed to Actelion for development. The drug was approved in 2015 and first launched for the oral treatment of pulmonary arterial hypertension (PAH) in the U.S. in 2016 to delay disease progression and reduce the risk of hospitalization.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Selexipag (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The synthesis of selexipag began with condensation of commercially available benzil (<b>51</b>) and glycinamide hydrochloride in the presence of concentrated sodium hydroxide in refluxing MeOH to yield hydroxypyrazine <b>52</b>. This compound was subsequently converted to 5-chloro-2,3-diphenylpyrazine (<b>53</b>) upon treatment with refluxing POCl<sub>3</sub> in the presence of a catalytic amount of H<sub>2</sub>SO<sub>4</sub>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Chloride <b>53</b> was then subjected to neat 4-(isopropylamino)-1-butanol (<b>54</b>, prepared by the reductive alkylation of 4-amino-1-butanol and acetone with hydrogen over PtO<sub>2</sub> in EtOH) at 190 °C to give aminopyrazinyl alcohol <b>55</b> in 56% yield as colorless crystals. Alcohol <b>55</b> was alkylated with <i>tert</i>-butyl bromoacetate using Bu<sub>4</sub>NHSO<sub>4</sub> as a phase-transfer catalyst and 40% aqueous KOH in benzene to give ester <b>56</b>. Although it is particularly unusual to employ benzene on a production scale, these are the only reported conditions for this transformation. The crude ester <b>56</b> was then saponified using methanolic sodium hydroxide to yield the corresponding carboxylic acid <b>57</b> in 62% as pale-yellow crystals in two steps from compound <b>55</b>. Finally, the carboxylic acid <b>57</b> was coupled with methanesulfonamide in the presence of CDI and DBU in THF to give selexipag (<b>VI</b>) in 77% yield.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">4 CNS Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14477" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14477" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">4.1 Aripiprazole Lauroxil (Aristada)</h3><div class="NLM_p">Aripiprazole lauroxil is a long acting injectable (LAI) pro-drug formulation of aripiprazole approved in the U.S. for the treatment of schizophrenia.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Aripiprazole lauroxil is a dopamine D2 receptor partial antagonist, a 5-HT<sub>2A</sub> antagonist, and a 5-HT<sub>1A</sub> partial agonist that was developed by Alkermes. It was approved for once monthly and once every six weeks injection and is the second LAI of aripiprazole (with Abilify Maintena being the first).</div><div class="NLM_p">The synthesis of aripiprazole lauroxil has only been described on gram scale in the patent literature and is highlighted in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Commercially available aripiprazole (<b>58</b>) was treated with formaldehyde to give hemiaminal <b>59</b> in 65% crude yield and was then heated with lauric anhydride to give aripiprazole lauroxil (<b>VII</b>) in 21% overall yield.</div><figure id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Aripiprazole Lauroxil (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.2 Brexpiprazole (Rexulti)</h3><div class="NLM_p">Brexpiprazole is a novel antipsychotic drug which serves as a serotonin–dopamine activity modulator and has demonstrated efficacy as an adjunctive treatment in patients with major depressive disorder (MDD).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The drug exhibits a unique pharmacological profile, acting as a partial agonist of serotonin 5-HT<sub>1A</sub> and dopamine D2 receptors and as a full antagonist of 5-HT<sub>2A</sub> and noradrenaline α<sub>1B/2C</sub> receptors, with similar subnanomolar binding affinity.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The drug, which was developed by Otsuka and Lundbeck, was approved in 2015 by the FDA for the treatment of schizophrenia and as an adjunctive treatment for depression.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Brexpiprazole is widely considered to be a successor to Otsuka’s antipsychotic drug aripiprazole (trade name Abilify) whose patent expired in August 2014.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p">The structure of brexpiprazole affords a retrosynthetic disconnection that divides the molecule into two key subunits joined by a <i>n</i>-butyl linker. The most likely process-scale synthetic approach to brexpiprazole follows a 2013 Otsuka patent which describes the kilogram scale of the final API and a key intermediate en route to the final API.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Interestingly, an improved process-scale synthesis of piperazinyl benzothiophene subunit <b>65</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>) was disclosed by a group at the Chinese Academy of Sciences in 2015.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><figure id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Piperazinyl Fragment <b>65</b> of Brexpiprazole (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Commercially available fluorobenzaldehyde (<b>60</b>) underwent a substitution reaction with commercial <i>tert</i>-butyl piperazine-1-carboxylate (<b>61</b>) under basic conditions to afford the piperazinyl benzaldehyde <b>62</b> in excellent yield. Next, the construction of the benzothiophene was affected by initial condensation of thioglycolic acid ethyl ester <b>63</b> with <i>o</i>-chlorobenzaldehyde <b>62</b> under mildly basic conditions at elevated temperatures. Treatment with aqueous base and adjustment of pH to roughly 5 through the use of 4 N HCl furnished the 2-carboxylic acid benzothiophene <b>64</b> in 80% yield across the three-step operation. Next, decarboxylation through the use of cuprous oxide using conditions slightly modified from those originally described by Goosen<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> followed by acidic removal of the Boc protecting group on the terminal piperazine nitrogen secured the key piperazinyl benzothiophene subunit <b>65</b> as the corresponding hydrochloride salt.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">The hydroxyquinolone and linker component synthesis began with alkylation of commercially available quinolone <b>66</b> with 1,4-bromochlorobutane (<b>67</b>) under basic conditions to furnish chloroalkoxyquinolone <b>68</b>. A subsequent alkylation with hydrochloride salt <b>65</b> using potassium carbonate and warm aqueous ethanol followed by recrystallizative workup resulted in clean conversion to brexpiprazole (<b>VIII</b>) in 78% yield from <b>68</b> (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>).</div><figure id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Brexpiprazole (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">4.3 Cariprazine Hydrochloride (Vraylar)</h3><div class="NLM_p">Cariprazine hydrochloride (<b>IX</b>) is an oral, brain-penetrant, atypical antipsychotic developed by the Hungarian pharmaceutical firm Gedeon Richter. It was approved by the FDA in September 2015 for treatment of schizophrenia and for the acute treatment of manic or mixed episodes of bipolar I disorder.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> While the precise mechanism of action of cariprazine is unknown, its antipsychotic and procognitive effects may be mediated through partial agonism at dopamine D2/D3 and serotonin 5-HT<sub>1A</sub> receptors as well as antagonism at serotonin 5-HT<sub>2A</sub> receptors.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Unlike many antipsychotics, cariprazine displays particular selectivity for the D3 receptor (D3, <i>K</i><sub>i</sub> = 0.085 nM; D2L, <i>K</i><sub>i</sub> = 0.49 nM; D2S, <i>K</i><sub>i</sub> = 0.69 nM).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Cariprazine is extensively metabolized by CYP3A4 and, to a lesser extent, CYP2D6; desmethyl and didesmethyl cariprazine, the primary metabolites, are pharmacologically equipotent to the parent drug.<a onclick="showRef(event, 'cit38b ref39 ref40'); return false;" href="javascript:void(0);" class="ref cit38b ref39 ref40">(38b, 39, 40)</a> In clinical trials, cariprazine demonstrated improvement compared to placebo as measured by Young Mania Rating Scale (YMRS) total scores in patients with bipolar mania and by Positive and Negative Syndrome Scale (PANSS) total scores in patients with schizophrenia.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Forest Laboratories (now Allergan) has exclusive rights to cariprazine in the U.S. and Canada, while Mitsubishi Pharma Corporation has exclusive rights to the sale of the drug in Japan and Asia.<a onclick="showRef(event, 'cit36a'); return false;" href="javascript:void(0);" class="ref cit36a">(36a)</a></div><div class="NLM_p">While the synthesis of cariprazine hydrochloride has been reported in a number of patents as well as its discovery synthesis in the publicly disclosed literature, the process route has not yet been disseminated.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The route detailed in <a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a> represents the most probable large scale route reported to date.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Starting with the reduction of commercial 2-(4-nitrophenyl)acetic acid (<b>69</b>) via hydrogenation in water in the presence of Pd/C,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> this reaction proceeds a one-pot, stepwise reduction of the nitro group. A separate reduction event converting the phenyl ring to the corresponding cyclohexane provides 4-aminocyclohexylacetic acid with 60–70% selectivity for the desired <i>trans</i> isomer. Following filtration and distillation, the crude aqueous solution was treated with HCl in refluxing ethanol to generate the corresponding ethyl ester <b>70</b>. Crystallization from acetonitrile gave the HCl salt in high purity and 40% yield over two steps (a reaction sequence that was reported on 200 kg scale). Amine <b>70</b> was transformed into intermediate <b>73</b> via Boc protection followed by ester reduction to the primary alcohol <b>71</b>, which was obtained as a solution in toluene following extraction. Next, mesylation of the alcohol followed by alkylation with commercially available piperazine <b>72</b> provided piperazinyl cyclohexane <b>73</b> in 70% over the four-step sequence. The carbamate protecting group within <b>73</b> was removed via acidic ethanolysis, and the resulting product was treated with triphosgene and dimethylamine to generate cariprazine as the freebase. Salt formation by means of methanolic HCl ultimately furnished cariprazine hydrochloride <b>IX</b> in 85% yield from <b>73</b>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><figure id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Cariprazine Hydrochloride (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">4.4 Flibanserin (Addyi)</h3><div class="NLM_p">Flibanserin is a drug originally developed by Boehringer-Ingelheim and later Sprout Pharmaceuticals, which was approved in 2015 by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The drug, which was originally developed for the treatment of depression by Boehringer-Ingelheim, is a full agonist of the 5-HT<sub>1A</sub> receptor, an antagonist of the 5-HT<sub>2A</sub> receptor, and a partial agonist of the dopamine-4 (D4) receptor, which triggers increased dopamine and norepinephrine levels along with decreased serotonin levels.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> However, the exact mechanism of action against HSDD is unknown.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In three randomized trials involving 2400 premenopausal women, the drug was found to increase the number of satisfying sexual events by 0.5–1.0 events per month and increased sexual desire on average by 10–12% over placebo. Side effects include decreased blood pressure and loss of consciousness, especially in subjects who consumed alcohol.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">Interestingly, the original submission of flibanserin to the FDA from Boehringer-Ingelheim was rejected on the basis of results from two pivotal trials in 2010, which unanimously found that the drug’s side effects were unacceptable and that the drug did not demonstrate efficacy.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Boehringer discontinued development of the drug after the rejection and sold the rights of the compound to Sprout Pharmaceuticals in 2011, which launched redevelopment and resubmission of the drug to the FDA in 2013 with data from a third pivotal trial, only to have it rejected again that year. Sprout resubmitted the drug in 2015 with additional safety data, and at the FDA advisory meeting in June, independent experts voted 18 to 6 to approve the drug with a risk evaluation and mitigation strategy (REMS).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">The large-scale synthesis of flibanserin (<b>X</b>) mostly follows a patent from Symed Laboratories Limited which demonstrated hundred-gram-scale preparation of the drug as described in <a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Starting from commercially available 1-(prop-1-en-2-yl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (<b>74</b>), installation of an ethylene side chain was accomplished under conventional alkylation conditions with 1,2-dibromoethane and base, and this event was immediately followed by a second alkylation reaction involving piperazine to secure piperazinyl benzimidazolone <b>75</b>. Interestingly, the enamine double bond within <b>74</b> was apparently reduced to the corresponding isopropyl group under these conditions. Although the authors do not comment about this reduction directly, similar examples of olefin reduction under non-hydrogenative alkylation conditions have been reported in the literature separately by both Pai<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and Ryu.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Removal of the isopropyl group was facilitated by means of aqueous sodium hydroxide to afford <b>76</b>, which underwent <i>N</i>-arylation under Buchwald conditions with 1-bromo-3-(trifluoromethyl)benzene <b>77</b> to furnish flibanserin (<b>X</b>) in 63% yield.</div><figure id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Flibanserin (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">4.5 Safinamide Methanesulfonate (Xadago)</h3><div class="NLM_p">Safinamide methanesulfonate was approved in February 2015 by the EMA for the treatment of mid- to late-stage fluctuating Parkinson’s disease. This approval included use of the drug as an add-on therapy for use with levodopa, either alone or in combination with other existing therapies for Parkinson’s disease.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Safinamide methanesulfonate, an oral α-aminoamide originally discovered by Farmitalia Carlo Erba and later developed by Newron/Zambon, functions as a highly selective and reversible inhibitor of MAO-B,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> leading to increased levels of dopamine and subsequent improvement in the motor symptoms of Parkinson’s disease,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> side effects that often result from use of other traditional treatments relying on dopamine replacement therapy.<a onclick="showRef(event, 'ref51 ref54'); return false;" href="javascript:void(0);" class="ref ref51 ref54">(51, 54)</a> Furthermore, unlike other therapies, safinamide employs several mechanisms of action, functioning as both a dopaminergic agent through inhibition of MAO-B as well as a nondopaminergic agent via selective calcium and sodium channel modulation, leading to inhibition of glutamate release.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a> At least one of several clinical studies of patients with mid- to late-stage Parkinson’s disease showed increased daily ON time (periods of symptom control) without accompanying motor complications (dyskinesias) upon treatment with safinamide,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> while studies of early stage Parkinson’s disease patients treated with this drug showed significantly improved motor symptoms during the 18-month study.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Additionally, safinamide is chemically and metabolically stable,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> is well tolerated in patients, and has not exhibited serious adverse effects even upon treatment at higher dosage ranges.<a onclick="showRef(event, 'ref54 ref57'); return false;" href="javascript:void(0);" class="ref ref54 ref57">(54, 57)</a></div><div class="NLM_p">While the reported discovery-scale synthetic approaches to safinamide methanesulfonate were similar to the process-scale approach,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> the identification of optimized and improved reaction conditions were essential for isolation of the target in high purity and without the presence of highly toxic byproducts.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> For example, initial attempts to prepare aryl benzyl ether <b>80</b> (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>) from benzyl chloride (<b>78</b>) and phenol (<b>79</b>) employed conditions which led to the desired <i>O</i>-alkyl product <b>80</b> in addition to the undesired C3-aryl alkylation product, necessitating laborious and inefficient final-stage purifications. Alternatively, employing phase transfer catalysis conditions, specifically the use of tetradecyl trimethylammonium bromide with K<sub>2</sub>CO<sub>3</sub> in refluxing toluene as shown in <a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>, have become the conditions of choice, enabling high selectivity of <i>O</i>-alkylation product <b>80</b> in 85% yield and 99.9% purity with minimal amounts of impurities arising from competitive <i>C</i>- and <i>O</i>-alkylation arising after recrystallization from diisopropyl ether.<a onclick="showRef(event, 'cit59a'); return false;" href="javascript:void(0);" class="ref cit59a">(59a)</a> From <b>80</b>, a one-pot reductive alkylation with <span class="smallcaps smallerCapital">l</span>-alaninamide hydrochloride <b>81</b> was effected under standard reductive amination conditions (NaBH<sub>3</sub>CN/MeOH). However, poor yields were observed as well as formation of undesired byproducts. Interestingly, while not a generally accepted method, an alternate one-pot route for synthesis of <b>82</b> could be realized using heterogeneous reduction conditions. Toward this end, condensation of <b>81</b> with the aldehyde <b>80</b> was followed by immediate reduction with H<sub>2</sub> on wet Pt/C in MeOH, affording safinamide <b>82</b> in 92% yield (98.4% purity). Treatment of <b>82</b> with charcoal filtration followed by salt formation with methanesulfonic acid provided safinamide methanesulfonate (<b>XI</b>) in 97% yield. In this improved synthesis, all reactions could be performed on multikg scale, yielding the final drug target in >99.9% purity and containing <0.005% of the undesired <i>C</i>,<i>O</i>-bis-alkylated derivative.</div><figure id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of Safinamide Methanesulfonate (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">5 Gastrointestinal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">5.1 Eluxadoline (Viberzi)</h3><div class="NLM_p">Eluxadoline, originally developed by Janssen and currently marketed by Allergan (formerly Actavis), was approved in May 2015 by the FDA for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Eluxadoline, an orally dosed agent, employs a unique mechanism for IBS-D treatment, as it functions simultaneously as a μ- and κ-opioid receptor agonist and a δ-opioid receptor antagonist,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> leading to a first-in-class therapy for treatment of IBS-D. Specifically, in animal studies, eluxadoline was found to interact with opioid receptors in the gut, inhibiting neurogenically mediated secretion and reducing intestinal contractility.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Additionally, the treatment led to a decrease in stress-induced acceleration of upper GI transit without causing rebound constipation,<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60-62)</a> earning its mark as a first-line therapeutic treatment for IBS-D. In two phase III clinical trials of over 2400 patients with IBS-D, patients taking eluxadoline showed a greater improvement toward the end point (≥30% improvement from their baseline IBS-D score on at least 50% of days treated with eluxadoline) compared to patients treated with placebo.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">The synthesis of eluxadoline begins with preparation of advanced coupling component <b>85</b>, which could be completed via a four-step route from commercially available <i>N</i>-Boc-protected aminoester <b>83</b> (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Triflate formation using <i>N</i>-phenyltrifluoromethanesulfinimide in DCM under basic conditions led to nearly quantitative yield of the desired triflate, which was subjected to a carbonylation reaction to yield aryl acid <b>84</b> in 94% yield. Employing NH<sub>4</sub>Cl as a source of ammonia, amidation of <b>84</b> took place in the presence of PyBOP/HOBt and DIPEA in DMF. Finally, acid <b>85</b> was revealed upon methyl ester saponification with aqueous LiOH in THF. This sequence provided <b>85</b> without purification ,and this acid could be used directly as applied in <a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><figure id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Synthesis of Eluxadoline Intermediate <b>85</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Eluxadoline (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">With coupling component <b>85</b> in hand, the synthesis of eluxadoline proceeds as described in <a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a> and initiated from a HOBt and EDC·HCl-mediated coupling of commercial <i>N</i>-Cbz-<span class="smallcaps smallerCapital">l</span>-alanine (<b>86</b>) with commercial 2-amino acetophenone hydrochloride (<b>87</b>) to provide intermediate <b>88</b> in 83% yield.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64, 65)</a> Addition of NH<sub>4</sub>OAc and AcOH to a suspension of <b>88</b> in refluxing xylenes furnished the desired imidazole in excellent yield (95%). Submission of this <i>N</i>-Cbz-imidazole to hydrogenation conditions (H<sub>2</sub>, Pd/C, MeOH) enabled liberation of the free amine to access <b>89</b> in quantitative yield following filtration and concentration. From intermediate <b>89</b>, reductive amination with commercially available aryl aldehyde <b>90</b> under standard conditions (NaBH<sub>4</sub>, MeOH) followed by subsequent coupling of the corresponding crude amine with acid <b>85</b> using HOBt/EDC·HCl enabled formation of the carbon framework of eluxadoline (<b>91</b>). Saponification of the ester within <b>91</b> with LiOH in MeOH/THF yielded the corresponding acid in quantitative yield. Immediate subjection of this intermediate to acidic conditions (HCl in EtOAc/THF) led to <i>N</i>-Boc cleavage and isolation of eluxadoline (<b>XII</b>) as the bis-HCl salt in 71% yield, requiring no further purification.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64, 65)</a> It should be noted that since this initial report, additional details for the isolation of eluxadoline in high purity in various crystal forms and as a zwitterion have been reported,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> although most reported routes described isolation of this drug in its HCl salt form.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64, 65)</a></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">5.2 Rolapitant Hydrochloride Hydrate (Varubi)</h3><div class="NLM_p">Rolapitant hydrochloride hydrate, originally discovered by Schering-Plough and later developed by TESARO, Inc., was approved by the FDA in September 2015 for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in combination with other antiemetic agents.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Rolapitant is a highly selective NK-1 receptor antagonist, exhibiting >1000-fold selectivity for NK-1 over human NK-2 and NK-3 receptors in vitro.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> In contrast to other NK-1 inhibitors that play an essential role in delayed CINV therapy,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> rolapitant shows no inhibition of CYP3A4,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> eliminating the need for concern when coadministering with CYP34A substrates. Additionally, rolapitant is an orally active agent with a relatively long half-life (180 h),<a onclick="showRef(event, 'ref68 ref70'); return false;" href="javascript:void(0);" class="ref ref68 ref70">(68, 70)</a> providing potential opportunities for single- and prechemotherapy-based treatments.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> In three large clinical trials involving patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC), subjects using rolapitant as a cotherapy with granisetron and dexamethasone showed a significant improvement in complete response compared to those receiving treatments of granisetron and dexamethasone.<a onclick="showRef(event, 'ref70 ref72'); return false;" href="javascript:void(0);" class="ref ref70 ref72">(70, 72)</a></div><div class="NLM_p">Rolapitant features a fascinating molecular architecture consisting of two tetrasubstituted stereogenic carbon centers situated at the 2- and 5-carbons within a central piperidine ring and a spirocyclic array residing at the 5-position and a phenyl ring and ethereal linkage branching from the 2-position (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>). The overall synthetic strategy to secure rolapitant hydrochloride hydrate relies upon the union of two advanced chiral building blocks that contain functional groups capable of securing the central piperidine ring. These two key intermediates, pyroglutamate derivative <b>93</b> and allylic amine <b>94</b>, each bear one of the essential stereocenters embedded within the structure of the active pharmaceutical ingredient.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The first of these advanced intermediates, amidoaldehyde <b>93</b>, is generated directly by base-mediated decomposition of pyroglutamic aminal <b>92</b>, which was prepared according to the route shown in <a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>. Subjection of <b>92</b> to triethylamine in EtOH/H<sub>2</sub>O at ambient temperatures led to generation of chiral allyl aldehyde <b>93</b>, which was not isolated but condensed immediately with amine <b>94</b> (<a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>) in the presence of refluxing toluene to provide divinyl imine <b>95</b>, which underwent immediate reduction using NaBH(OAc)<sub>3</sub> in AcOH/toluene to furnish the free amine. The free amine was converted to the corresponding tosylate monohydrate salt and triturated, providing <b>96</b> as a white crystalline powder after subjection to TsOH·H<sub>2</sub>O in <i>i</i>-PrOH/H<sub>2</sub>O. Divinyl amine <b>96</b> could then be reacted with a solution of TsOH in toluene, distilled, and directly combined with a toluene solution of Hoveyda–Grubbs second-generation catalyst (HG-II) under heating conditions, leading to the desired ring-closing metathesis product <b>97</b> as the HCl salt (85% yield over two steps) after filtration, distillation, and workup with 12N HCl. Washing of a toluene solution of <b>97</b> with aqueous NaOH and subsequent treatment of the resulting organic solution with H<sub>2</sub>, wet Pd/C, and additional granular activated carbon (Nuchar Aquaguard) led to the fully reduced piperidine product in high yield (95%). Rolapitant hydrochloride hydrate <b>XIII</b> was accessed thereafter by precipitation from a solution of EtOH/<i>i</i>-PrOH/H<sub>2</sub>O/HCl, providing the product as a white solid (91% yield).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><figure id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Rolapitant Hydrochloride Hydrate (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Fragment <b>92</b> of Rolapitant Hydrochloride Hydrate (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0020.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Fragment <b>94</b> of Rolapitant Hydrochloride Hydrate (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Aldehyde precursor <b>92</b> was accessed in a four-step sequence starting from commercially available <span class="smallcaps smallerCapital">l</span>-pyroglutamic acid <b>98</b> (<a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>).<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73, 74)</a> Condensation of <b>98</b> with trimethylacetaldehyde at elevated temperatures in the presence of methanesulfonic acid and NMP prior to careful addition of TFAA led to formation of pyrrolo-oxazolidone <b>99</b> in 72% yield. Deprotonation (LHMDS) and stereoselective alkylation of <b>99</b> with methyl formate, assisted by addition of copper chloride as a Lewis acid, provided access to carbaldehyde <b>100</b> in moderate yield (61%) as a single diastereomer<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> after aqueous workup and crystallization from MTBE. Wittig olefination of aldehyde <b>100</b> (Ph<sub>3</sub>PCH<sub>3</sub>Br/LHMDS) followed by aqueous workup and precipitation of triphenylphosphine oxide via addition of MgCl<sub>2</sub> constructed an allyl lactone intermediate in 63% yield as an off-white solid, which then immediately underwent partial reduction with LiAlH(O<i>t</i>-Bu)<sub>3</sub> to smoothly deliver the key aldehyde precursor <b>92</b> in 83% yield as an inconsequential mixture of diastereomers (the stereocenter of consequence arose from the naturally occurring <span class="smallcaps smallerCapital">l</span>-pyroglutamic acid <b>98</b>), which could be employed directly in <a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><div class="NLM_p last">Generation of <b>94</b> began with commercially available <i>N</i>-Cbz-(<i>S</i>)-phenylglycine <b>101</b> based on reports by O’Donnell and co-workers (<a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Reaction of <b>101</b> with benzaldehyde dimethylacetal under Lewis acid conditions (BF<sub>3</sub>·Et<sub>2</sub>O) in diethyl ether led to high yield, diastereoselectivity, and enantioselectivity of <i>trans</i>-disubstituted oxazolidinone <b>102</b>. In this case, selection of diethyl ether as a solvent was essential, as the use of DCM under similar reaction conditions favored formation of the undesired <i>cis</i>-product. Removal of the most acidic proton within <b>102</b> by means of KHMDS in toluene/THF, followed by alkylation with commercially available bromomethyl ether (<b>103</b>) in THF, led to 68% yield of <b>104</b> as a single diastereomer.<a onclick="showRef(event, 'ref73 ref76'); return false;" href="javascript:void(0);" class="ref ref73 ref76">(73, 76)</a> Reduction of <b>104</b> to the corresponding lactol (LiAlH<sub>4</sub>/Et<sub>2</sub>O) and subsequent ring opening with KHCO<sub>3</sub>/H<sub>2</sub>O in NMP yielded the intermediate aldehyde, which was readily converted to <b>105</b> via addition of the crude aldehyde solution to a mixture of Ph<sub>3</sub>PCH<sub>3</sub>Br and NaHMDS in toluene. As described in <a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>, triphenylphosphine oxide scavenge by way of MgCl<sub>2</sub> enabled generation of crude product in good purity after a simple filtration. TMSI-mediated Cbz removal converted <b>105</b> to the resulting free amine. Formation of the maleic acid salt enabled the product to be isolated as a crystalline solid in high purity without chromatography. Treatment of the maleate salt with NaOH in toluene provided the free base <b>94</b>, which was incorporated as previously described in <a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a> without the need for additional purification.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">6 Hematologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">6.1 Lusutrombopag (Mulpleta)</h3><div class="NLM_p">Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist developed by Shionogi for improvement of thrombocytopenia associated with chronic liver disease in patients undergoing an elective invasive procedure (e.g., liver biopsy, liver transplantation) (<a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Thrombocytopenia, which is common among patients with chronic liver disease, increases the risk of bleeding when undergoing invasive procedures, which in turn complicates therapy and increases the risk of mortality.<a onclick="showRef(event, 'ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref78 ref79">(78, 79)</a> Lusutrombopag, which was approved in Japan in September 2015, promotes platelet production by stimulating the proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes via the thrombopoietic pathway. The consequent increase in platelet levels avoids postponement of invasive procedures or transfusion of platelets and administration of platelet products, the current standard of care for thrombocytopenia in these patients.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><figure id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0021.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Lusutrombopag (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To date, only two synthetic routes to lusutrombopag have been reported: one in the Japanese patent literature which has been exemplified on kilogram scale<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> and the other a closely related discovery route which has been reported in the United States patent literature.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81, 82)</a> Commercial 2,6-dibromoanisole (<b>106</b>) was treated with isopropylmagnesium chloride to form the corresponding Grignard reagent prior to reaction with Weinreb amide <b>107</b>, furnishing a ketone which underwent immediate reduction with formic acid in the presence of chiral catalyst RuCl(<i>p</i>-cymene)[(<i>S</i>,<i>S</i>)-Ts-DPEN] (<b>108</b>) and generate the desired (<i>S</i>)-stereogenic alcohol <b>109</b>. Unfortunately, neither the yield nor the stereoselectivity of this reduction was reported in any of the disclosures. Benzyl alcohol <b>109</b> was subjected to Williamson etherification conditions with <i>n</i>-hexyl bromide to furnish ether <b>110</b>. The aryl bromide within <b>110</b> was then converted to the corresponding Grignard reagent, which was reacted with <i>N</i>-methyloxy-<i>N</i>-methyl-2-chloroacetamide (<b>111</b>), followed by subsequent treatment with thiourea in toluene/ethanol at elevated temperatures to give aminothiazole intermediate <b>112</b> in 45% yield across the two-step sequence. Next, activation of acid <b>113</b> prior to exposure to <b>112</b> facilitated amide bond formation. Saponification of the pendant ester with sodium hydroxide furnished luxutrombopag (<b>XIV</b>) in 89% yield. Although acid <b>113</b> is not commercial, it could be prepared from 3,5-dichlorobenzoic acid (<b>33</b>) via formylation with 4-formylmorpholine, followed by a Horner–Wadsworth–Emmons reaction with triethylphosphonopropionate (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>).</div><figure id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Preparation of Lusutrombopag Intermediate <b>113</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">7 Metabolic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56284" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56284" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">7.1 Deoxycholic Acid (Kybella)</h3><div class="NLM_p">Deoxycholic acid sodium salt, which is a secondary bile acid and the metabolite of intestinal bacteria, provides a nonsurgical treatment to significantly reduce submental fat in adults via injection directly into moderate-to-severe fatty tissue below the neck.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> When injected into fatty tissue, deoxycholic acid helps destroy fat cells.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Although deoxycholic acid has many applications beyond human health, the application as a dyslipidemia drug was licensed to Kythera from Los Angeles Biomedical Institute at Harbor–UCLA Medical Center in 2007. Allergan acquired Kythera recently in 2015.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><div class="NLM_p">The synthesis started from the commercially available 9-hydroxyandrost-4-ene-3,17-dione (<b>114</b>, <a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Hydrogenation of <b>114</b> gave the saturated 5β-dione <b>115</b> in 85% yield. Alcohol <b>115</b> was then dehydrated with H<sub>2</sub>SO<sub>4</sub> in CH<sub>2</sub>Cl<sub>2</sub> to provide 5β-androst-9(11)-ene-3,17-dione <b>116</b> in 95% yield as off-white solid, and this was followed by selective reduction with LiAlH(O-<i>t-</i>Bu)<sub>3</sub> to afford (3α,5β)-3-hydroxyandrost-9(11)-en-17-one (<b>117</b>). The crude ketone <b>117</b> was submitted to a Wittig reaction with triphenylethylphosphonium bromide in the presence of potassium <i>t</i>-butoxide in THF to yield (3α,5β,17<i>E</i>)-pregna-9(11),17-dien-3-ol (<b>118</b>). The crude alcohol <b>118</b> was acetylated with Ac<sub>2</sub>O in the presence of DMAP and Et<sub>3</sub>N to yield prenyl acetate <b>119</b> in 64% across the three-step sequence. Compound <b>119</b> was reacted with methyl acrylate in the presence of EtAlCl<sub>2</sub> to facilitate conjugate addition and subsequent tertiary carbocation elimination to afford adduct <b>120</b>, and this resulting olefin was hydrogenated to selectively saturate the cyclopentenyl double bond, resulting in steroid <b>121</b> in 85% yield from <b>119</b>. The remaining alkene <b>121</b> then underwent allylic oxidation with <i>tert</i>-butyl hydrogen peroxide and 10% NaOCl aqueous solution in EtOAc to give enone <b>122</b>, and this material was then hydrogenated over 10% Pd/C in EtOAc to afford the saturated ketone <b>123</b>. Next, the ketone within <b>123</b> was selectively reduced with LiAlH(O-<i>t</i>-Bu)<sub>3</sub> in THF to give the 12α-hydroxy precursor <b>124</b> in excellent yield. Finally the remaining methyl ester <b>124</b> was hydrolyzed with 20% NaOH aqueous solution in THF/MeOH and acidified with 4 M HCl to give deoxycholic acid (<b>XV</b>) in 99% yield as a white solid.</div><figure id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0023.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Deoxycholic Acid (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45">7.2 Evogliptin (Suganon)</h3><div class="NLM_p">Developed by Dong-A ST, evogliptin was approved in 2015 in the Republic of Korea for blood glucose control in patients with diabetes mellitus type 2 (type 2 DM). Evogliptin is an orally bioavailable dipeptidyl peptidase IV (DPP-4) inhibitor, which acts to prevent insulin secretion following meals. Dong-A ST arranged licensing agreements with Geropharm and Eurofarma Laboratórios for the sale of evogliptin in various countries in eastern Europe and Brazil, respectively, pending future approvals.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> While a manufacturing route has not been disclosed to date, the most scalable published route is described below.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Strategically, evolgliptin is prepared from the union of two key fragments which consist of a piperizone <b>125</b> and a β-amino acid fragment <b>136</b>.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><div class="NLM_p">The synthesis of piperizone <b>125</b> began from commercially available amino acid derivative <b>127</b> (<a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>). The alcohol within <b>125</b> was then quantitatively converted to <i>tert</i>-butyl ether <b>128</b> by treatment with isobutylene gas in the presence of acid. Subsequent hydrogenation to remove the Cbz protecting group resulted in amine <b>129</b>, and this was followed by reductive amination to provide ethylene diamine intermediate <b>130</b>. Hydrogenative carbamate removal facilitated a cyclization reaction, giving rise to piperizone <b>131</b> as the free base. Finally, treatment with a tartaric acid derivative delivered the stable piperizone salt <b>125</b>.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><figure id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0024.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Evogliptin Piperazone <b>125</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second key synthon of evogliptin is the β-amino acid fragment <b>136</b>, the synthesis of which is described in <a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>. Commercially available acid <b>132</b> was treated with CDI prior to subjection to Meldrum’s acid to afford ketodiester <b>133</b>. Subjection of <b>133</b> to warm EtOH triggered a decarboxylation event, and this was followed by reductive amination reaction involving ammonium acetate and the remaining ketone functionality to afford racemic amine <b>134</b> in 91% over the three steps. Resolution with a tartaric acid derivative followed by free base formation with sodium carbonate gave the enantiopure aminoester <b>135</b> in good yield. Finally, a two-step Boc protection followed by ester saponification furnished aminoester <b>136</b> in 89% yield over the final two-step sequence, setting the stage for the final assembly of evogliptin.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><figure id="sch24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0025.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Evogliptin Fragment <b>136</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The final API was assembled in a straightforward manner from intermediates <b>125</b> and <b>136</b> (<a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a>). Acid <b>136</b> was first activated as the mixed anhydride, followed by the addition of <b>125</b> in the presence of Hünig’s base to give penultimate product <b>137</b> in 71% over two steps. Hydrogenolytic removal of the benzyl carbamate afforded evogliptin (<b>XVI</b>), with a longest linear sequence of eight steps from simple amino acid building blocks.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><figure id="sch25" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0026.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Evogliptin (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49">7.3 Lesinurad (Zurampic)</h3><div class="NLM_p">Approved by the FDA late in 2015, lesinurad is an urate anion exchange transporter 1 (URAT1) inhibitor for use in the treatment of gout. Ardea Biosciences, which is a subsidiary of AstraZeneca, developed lesinurad to be used in a combination therapy with xanthine oxidase inhibitors for the treatment of hyperuricaemia associated with gout. The approval process is ongoing in several other countries across the globe, with the EMA Committee for Medicinal Products for Human Use giving lesinurad a positive opinion for use as an adjunctive therapy in combination with xanthine oxidase inhibitors to treat hyperuricaemia.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> While several syntheses of lesinurad have been disclosed to date,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> a patent describing hundreds of kilograms of material describes the likely process route, which is depicted in <a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a> (note: for some reactions within this route, no yields were provided).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><figure id="sch26" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0027.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Lesinurad (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The synthesis of lesinurad began with commercial 1-bromonaphthalene (<b>138</b>, <a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a>). A Kumada coupling between this bromide and cyclopropyl Grignard delivered <b>139</b>, which after selective nitration to give <b>140</b>, delivered the oxylate salt <b>141</b> (which now is commercially available). Treatment of <b>141</b> with KOH followed by thiophosgene at 5 °C delivered isothiocyanate <b>142</b> in 63% yield. Reaction of <b>142</b> with formyl hydrazine followed by addition of potassium bicarbonate and mild heating resulted in thio-1,2,4-triazole <b>144</b> by the intermediacy of <b>143</b>. Quantitative alkylation of triazolothiol <b>144</b> resulted in α-mercaptan <b>145</b>, and this was followed by NBS bromination to afford bromotriazole <b>146</b>. Ester saponification followed by acidification secured lesinurad (<b>XVII</b>) in a good yield over the final three steps.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51">7.4 Omarigliptin (Marizev)</h3><div class="NLM_p">Merck earned its first global approval for omarigliptin in Japan in 2015, and phase III development is ongoing in other countries around the globe for this interesting small molecule DPP-4 inhibitor.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Interestingly, while most DPP-4 inhibitors used to treat type 2 DM require daily administration, omarigliptin is a weekly treatment. The process-scale synthesis of omarigliptin has been nicely described in an October 2015 paper from the Merck process group.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94, 95)</a> Retrosynthetically, omarigliptin can be subdivided into two key fragments <b>147</b> and <b>148</b>, and the synthesis of each fragment, along with their union, is described in <a class="ref internalNav" href="#sch27" aria-label="Schemes 27">Schemes 27</a>–<a class="ref internalNav" href="#sch29" aria-label="29">29</a>.</div><div class="NLM_p">The synthesis began with the efficient condensation of pyrrolidinone <b>149</b> with dimethylformamide-dimethylacetal (DMF-DMA) to afford enaminoketone <b>150</b> in 88% yield (<a class="ref internalNav" href="#sch27" aria-label="Scheme 27">Scheme 27</a>). Subsequent condensation with hydrazine monohydrate gave tertiary alcohol <b>151</b> in 92% yield, and this step was followed by acid-promoted dehydration to afford fused pyrazole <b>152</b>. An initial kinetic mesylation delivered a 1:5 ratio of <b>147</b>:<b>153</b>, in favor of the undesired regioisomer. However, when the crude mixture was warmed to ambient temperature and treated with potassium <i>tert</i>-butoxide, thermodynamic equilibration provided the more stable <i>N</i>1-mesylate <b>147</b>. This process furnished the desired regioisomer <b>147</b> in a 30:1 ratio and 84% yield over the two steps (<a class="ref internalNav" href="#sch27" aria-label="Scheme 27">Scheme 27</a>). Reaction monitoring by HPLC suggests that cleavage of the mesyl group of <b>153</b> results in anion formation on the adjacent nitrogen, which then allows for mesylation at the desired position.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div><figure id="sch27" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0028.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Fragment <b>147</b> of Omarigliptin (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The innovative synthesis of the omarigliptin lactone fragment <b>148</b> is shown in <a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Ester <b>154</b> was subjected to a three-step sequence whereby alkylation with propargyl besylate followed by saponification with sodium hydroxide and Boc protection resulted in amide <b>155</b> in 75% yield over three steps. The Weinreb amide was then subjected to the Knochel “turbo Grignard” reagent derived from 1-bromo-2,4-difluorobenzene to provide ketone <b>156</b> in 89% yield. An enantioselective transfer hydrogenation was carried out utilizing (<i>R</i>,<i>R</i>)-Ts-DENEB as the chiral induction reagent to afford intermediate <b>157</b> in excellent yield and enantio- and diastereoselectivity, which underwent ruthenium-mediated cyclization with the pendant alkyne to afford dihydropyran <b>158</b> in 86% yield. A two-step hydroboration/oxidation involving the endocyclic vinyl ether furnished <b>159</b> as a mixture of diastereomers in 89% yield, and this was followed by RuCl<sub>3</sub>/NaBO<sub>3</sub>-mediated oxidation to provide the lactone fragment <b>148</b> in 80% yield.</div><figure id="sch28" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0029.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Synthesis of Fragment <b>148</b> of Omarigliptin (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The endgame assembly of omarigliptin is described in <a class="ref internalNav" href="#sch29" aria-label="Scheme 29">Scheme 29</a>.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Removal of the Boc group within <b>147</b> was effected upon treatment with TFA, affording intermediate <b>160</b>, which was not isolated but instead exposed to ketone <b>148</b> under reductive amination conditions to afford diaminopyran <b>161</b> in excellent yield and diastereoselectivity (30:1 dr). Finally, Boc deprotection and crystallization from THF/heptanes furnished omarigliptin in an impressive 45% yield over its nine-step longest linear sequence.</div><figure id="sch29" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0030.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Omarigliptin (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55">7.5 Trelagliptin Succinate (Zafatek)</h3><div class="NLM_p">Similar to omarigliptin, trelagliptin succinate (<b>XIX</b>) is a highly selective, orally delivered inhibitor of DPP-4 developed by Takeda Pharmaceuticals and approved in Japan in March 2015 for the treatment of type 2 DM.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Interestingly, trelagliptin is structurally similar to alogliptin, a DPP-4 inhibitor also marketed by Takeda and described in our 2010 review,<a onclick="showRef(event, 'cit2i'); return false;" href="javascript:void(0);" class="ref cit2i">(2i)</a> differing only in the presence of a fluorine in the 5-position of the cyanobenzyl moiety. Both trelagliptin and alogliptin are potent inhibitors of DPP-4, with IC<sub>50</sub>s of 1.3 and 5.3 nM, respectively.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Notably, while similar drugs are dosed once daily, trelagliptin is the first DPP-4 inhibitor approved for once-weekly dosing. Kinetic analysis has revealed that trelagliptin is a substrate-competitive, reversible, slow-binding inhibitor (<i>t</i><sub>1/2</sub> for dissociation = ca. 30 min) of DPP-4, although the dissociation time is insufficient to explain its long-acting effects.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> In a phase III trial, once-weekly trelagliptin (100 mg) showed similar efficacy and safety to once-daily alogliptin (25 mg) in patients with type 2 DM inadequately controlled by diet and exercise.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The medicinal chemistry discovery of trelagliptin and alogliptin<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> as well as reviews of this class of compounds have been published.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100, 101)</a></div><div class="NLM_p">The kilogram-scale synthesis of trelagliptin succinate has been reported in five steps from commercial starting material, and this is depicted in <a class="ref internalNav" href="#sch30" aria-label="Scheme 30">Scheme 30</a>.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Commercial 2-bromo-5-fluorotoluene (<b>162</b>) was reacted with copper cyanide in refluxing DMF to provide the corresponding nitrile in 60% yield. Benzylic bromination with AIBN and 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) in DCE followed by treatment with diethyl phosphite and DIPEA gave crude benzyl bromide <b>163</b>, which was substituted directly with 6-chloro-3-methyluracil (<b>164</b>) in the presence of DIPEA in NMP to provide chloride <b>165</b> in 86% yield. Reaction with commercial (<i>R</i>)-3-aminopiperidine dihydrochloride <b>166</b><a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> in the presence of K<sub>2</sub>CO<sub>3</sub> and <i>i</i>-PrOH furnished trelagliptin as the freebase. Conversion to the HCl salt and purification by crystallization from dichloromethane, followed by a freebasing via 50% NaOH, and treatment with succinic acid in THF/<i>i</i>-PrOH at 60 °C, and final recrystallization, generated trelagliptin succinate <b>XIX</b>.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><figure id="sch30" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0031.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Trelagliptin Succinate (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57">7.6 Uridine Triacetate (Xuriden, Vistogard)</h3><div class="NLM_p">Uridine triacetate is an orally available pro-drug of uridine approved by the FDA for the treatment of the rare autosomal recessive disorder called hereditary orotic aciduria.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> The drug was also approved for treating overdose of two chemotherapies (fluorouracil and capecitabine).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Uridine triacetate was developed by Wellstat Therapeutics and licensed to BTG.</div><div class="NLM_p">The synthesis of uridine triacetate is described in <a class="ref internalNav" href="#sch31" aria-label="Scheme 31">Scheme 31</a>. Commercially available uridine (<b>167</b>) was treated with acetic anhydride in the presence of catalytic boron trifluoride-etherate, and the crude product was recrystallized from ethanol to give uridine triacetate (<b>XX</b>) in 74–78% yield.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><figure id="sch31" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0032.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Synthesis of Uridine Triacetate (<b>XX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">8 Musculoskeletal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51205" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51205" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60">8.1 Esflurbiprofen (Loqoa Tape)</h3><div class="NLM_p">Marketed by Taisho Pharmaceutical Holdings Co., Ltd., and Teijin Pharma Ltd.,<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> the (<i>S</i>)-enantiomer of flurbiprofen (named Esflurbiprofen) was approved as a new drug by the PMDA of Japan in 2015. (<i>S</i>)-Flurbiprofen, a cyclooxygenase (COX)-inhibiting nonsteroidal anti-inflammatory (NSAID) drug, is formulated with mentha oil and administered by way of a patch as a treatment for osteoarthritis in the current invention. Interestingly, the (<i>R</i>)-enantiomer is responsible for minimal COX inhibition but has been implicated as a possible treatment for a variety of other diseases.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Synthetic approaches to racemic flurbiprofen have been reported in the chemical literature as early as the 1960s,<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> and the mixture was approved as a drug in the United States by the FDA in 1988, marketed by Pharmacia and Upjohn.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Toward this end, the current patent estate defines the utility of the active <i>S</i>-enantiomer, and synthetic approaches therein apply to this enantiomer only.</div><div class="NLM_p">The synthesis began with conversion of commercially available aniline <b>168</b> to racemic flurbiprofen (<b>169</b>, <a class="ref internalNav" href="#sch32" aria-label="Scheme 32">Scheme 32</a>) through a Sandmeyer reaction and subsequent phenyl group introduction through the use of sodium tetraphenylborate.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> A chiral resolution was then performed on the resulting stereogenic acid on multikilogram scale by treatment with (<i>S</i>)-1-phenylethylamine in MeOH/toluene, which gave various yields of salt <b>170</b> as reported by the authors.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Acidification with aqueous HCl delivered (<i>S</i>)-flurbiprofen (<b>XXI</b>). Importantly, with respect to green chemistry considerations, the (<i>R</i>)-enantiomer could be recycled by racemizing the undesired (<i>R</i>)-enantiomer <b>171</b> in refluxing methanolic sulfuric acid, improving the overall atom economy of the process and significantly reducing waste.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div><figure id="sch32" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0033.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Esflurbiprofen (<b>XXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62">8.2 Polmacoxib (Acelex)</h3><div class="NLM_p">Polmacoxib, also known as (CG-100649), is a first-in-class NSAID which is a dual inhibitor of COX-2 and carbonic anhydrase (CA).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The drug, which was approved in South Korea for the treatment of colorectal cancer (CRC) in 2015 and whose discovery has been described by workers at AmorePacific R&D,<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> interacts with CA in red blood cells, providing a novel “tissue-specific” transport mechanism that is designed to deliver sustained levels of drug to inflamed tissues while maintaining low systemic exposure.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Although the unique dual COX-2/CA inhibition is designed to provide potentially superior safety to cardiovascular, renal, and gastrointestinal tissues compared to traditional NSAIDs or COX-2 inhibitor drugs, the long-term safety profile of the drug, particularly cardiovascular risks notoriously associated with inhibition of COX-2,<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> has yet to be determined, and the drug is currently not approved for use in any other country outside of South Korea.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div><div class="NLM_p">The molecular structure of polmacoxib closely resembles that of several marketed COX-2 inhibitors such that it features a classic 1,2-diaryl motif arranged about a 5-<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> or 6-membered<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> hetereocyclic linker. Although no process-scale synthesis has been reported to date, preparation of polmacoxib and several structural derivatives were described in a 2004 medicinal chemistry communication by authors at AmorePacific R&D.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> It is possible that an adaptation of this sequence, which is described in <a class="ref internalNav" href="#sch33" aria-label="Scheme 33">Scheme 33</a>, could have been (or is) used for the scale preparation of the API. However, the authors from AmorePacific report that the synthetic approach depicted in <a class="ref internalNav" href="#sch33" aria-label="Scheme 33">Scheme 33</a> delivered an amount of polmacoxib totaling 200 mg.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div><figure id="sch33" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0034.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Polmacoxib (<b>XXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Subjection of commercial propargyl alcohol <b>172</b> to <i>n</i>-butyllithium at cryogenic temperatures followed by quenching with commercial benzaldehyde <b>173</b> resulted in the formation of benzyl alcohol <b>174</b> in 81% yield. This alcohol could be oxidized by three different means, but the authors report that the most suitable method on scale was through the use of manganese dioxide in methylene chloride, which furnished ketone <b>175</b> in 80%.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Next, an interesting cyclization reaction secured the key furanone residue <b>176</b>. Mechanistically, subjection of ynone <b>175</b> to dimethylamine likely resulted in a conjugate addition followed by tautomerization of the resulting allenol to the corresponding ketone. The resulting ketone then probably underwent intramolecular nucleophilic attack by the pendant tertiary alcohol and after ejection of a molecule of water through iminium-mediated lone pair assistance, hydrolysis of the iminium species to the corresponding ketone delivered <b>176</b>. Next, <i>m</i>CPBA was employed to oxidize sulfide <b>176</b> to the corresponding sulfoxide. Subsequently, iodination of the furanone through use of bis(trifluoroacetoxy)iodobenzene (BTI), followed by a three-step sequence to convert the methylsulfoxide to the corresponding primary sulfonamide <b>178</b> occurred in 41% overall from the four-step sequence. Finally, Suzuki installation of the fluorobenzene resulted in the completion of the synthesis of polmacoxib (<b>XXII</b>).<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">9 Oncology Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81653" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81653" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65">9.1 Cobimetinib (Cotellic)</h3><div class="NLM_p">Cobimetinib, codeveloped by Genentech and Exelixis, was approved in August 2015 in Switzerland and November 2015 in the U.S. and Europe for the treatment of unresectable or metastatic BRAF<sup>V600</sup> mutation-positive melanoma when used in combination with vemurafenib.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Cobimetinib is a potent, highly selective reversible inhibitor of mitogen-activated protein kinases (MEK) 1 and 2,<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> which serves to inhibit phosphorylation of ERK1/2,<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> disrupting the MAPK pathway which is responsible for cell proliferation, cell survival, and migration.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Combination of cobimetinib with vemurafenib, an important BRAF inhibitor,<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> enables targeting of multiple points on the MAPK pathway, leading to overall enhanced tumor cell apoptosis and response as compared to stand-alone treatment with vemurafenib.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Specifically, in a representative trial of previously untreated patients with BRAF<sup>V600</sup> mutation-positive, unresectable, stage IIIc or IV melanoma, combination of these two therapies led to a significantly improved progression-free survival and overall response rate versus patients treated only with vemurafenib.<a onclick="showRef(event, 'cit124a ref125'); return false;" href="javascript:void(0);" class="ref cit124a ref125">(124a, 125)</a></div><div class="NLM_p">Structurally, cobimetinib features an interesting azetidinol substructure appended to the 2-position of a piperidine, rendering the 2-carbon of the piperidine as a stereogenic center bearing the (<i>S</i>)-configuration. While the early discovery routes to cobimetinib relied on a piperidine resolution-based route<a onclick="showRef(event, 'cit120a ref126'); return false;" href="javascript:void(0);" class="ref cit120a ref126">(120a, 126)</a> for accessing the cobimetinib core, the scale route to this drug employs an impressive <i>N</i>-cyanomethyl oxazolidine chiral auxiliary-mediated sequence to induce strereocontrol,<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> generating the requisite stereocenter with excellent selectivity and requiring no chromatographic purification in the overall synthetic sequence.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Toward this end, the most likely scale synthetic approach was initiated with deprotonation of commercially available (3<i>S</i>,5<i>R</i>,8a<i>S</i>)-3-phenyl-hexahydro-oxazolo[3,2-<i>a</i>]pyridine-carbonitrile (<b>180</b>, <a class="ref internalNav" href="#sch34" aria-label="Scheme 34">Scheme 34</a>), followed by addition of commercial 3-oxo-azetidine-1-carboxylic acid <i>tert</i>-butyl ester (<b>181</b>), yielded <b>182</b> in high purity (92%) after distillation and providing a rapid route to the core structure of cobimetinib.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> One-pot ring opening and reduction of <b>182</b> was accomplished by exposing this hemiaminal to acetic acid and sodium cyanoborohydride, giving rise to intermediate <b>183</b>. This carbamate could be further reacted with aqueous HCl in toluene to liberate the azetidine amine salt in high purity (97.6%), which underwent immediate acylation with commercially available 2,3,4-trifluoro-benzoyl chloride (<b>184</b>) to enable formation of intermediate <b>185</b> in 85% purity after aqueous workup. Reductive cleavage of the chiral auxiliary of <b>185</b> with Pd/C and H<sub>2</sub> under aqueous acidic conditions (AcOH, aq HCl) yielded the desired piperidine amine, which could be isolated as a solid (99.6% pure) after trituration with aqueous HCl. Finally, aromatic fluoride substitution with commercially available aniline <b>186</b> under basic conditions provided cobimetinib in 99.7% purity after slow precipitation from toluene (it is important to note that the authors offer no comment as to the regioselectivity of this aromatic substitution reaction).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> While the drug reportedly exists as a fumarate salt, no synthetic reports describing the conversion of cobimetinib to the corresponding fumarate salt<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> were available in the chemical literature to our knowledge at the time of publication.</div><figure id="sch34" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0035.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Cobimetinib (<b>XXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67">9.2 Ixazomib Citrate (Ninlaro)</h3><div class="NLM_p">Ixazomib citrate is a proteasome inhibitor prodrug for the treatment of multiple myeloma in patients who have received at least one prior therapy in combination with lenalidomide and dexamethasone.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> The drug was developed by Takeda and reversibly inhibits the protein proteasome subunit β type-5, which is part of the 20S proteasome complex.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Ixazomib citrate (<b>XXIV</b>) is hydrolyzed quickly in vivo to give the biologically active compound ixazomib, which presumably is the corresponding boronic acid variant of <b>XXIV</b>.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><div class="NLM_p">The structure of ixazomib citrate is particularly interesting in that it is one of the relatively few marketed drugs which feature a boron atom within its structure (others of note being the oncology medication bortezomib<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and the antifungal drug tavaborole<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>). The ostensible scale synthetic approach began with reaction of commercial 2,5-dichlorobenzoyl chloride (<b>188</b>, <a class="ref internalNav" href="#sch35" aria-label="Scheme 35">Scheme 35</a>) with glycine in aqueous NaOH to furnish amide <b>189</b> in 97% yield as a white crystalline solid. Acid <b>189</b> was then coupled with commercially available 1,3,2-benzodioxaborolane <b>190</b><a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> in the presence of TBTU and DIPEA in DMF at low temperature to give diamide <b>191</b>, which was used without purification for the next step. Borane <b>191</b> was then deprotected with (2-methylpropyl)boronic acid in methanolic HCl to provide trimer <b>192</b> in 74% as a white solid. Finally, boroxin <b>192</b> was reacted with citric acid in EtOAc to dissociate the trimer, resulting in ixazomib citrate (<b>XXIV</b>) in 88% yield as a crystalline solid.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><figure id="sch35" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0036.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Ixazomib Citrate (<b>XXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69">9.3 Lenvatinib Mesylate</h3><div class="NLM_p">Developed by Eisai Inc., lenvatinib mesylate is a vascular endothelial growth factor receptor (VEGF) inhibitor which has activity against VEGF subtypes 1, 2, and 3 and was approved by the FDA in 2015 for the treatment of differentiated thyroid cancer that is either locally recurrent, metastatic, or progressive and did not respond to radioactive iodine treatment.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> In May 2016, the FDA approved the drug as a combination therapy with everolimus for the treatment of advanced renal cell carcinoma.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Because VEGF (and fibroblast growth factor receptors, known as FGFRs) are thought to play a role in cardiovascular signaling pathways, VEGF2R and FGFR inhibition are thought to be the mechanisms behind the primary side effect of lenvatinib mesylate, which is hypertension.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></div><div class="NLM_p">The most likely process scale synthetic route to the drug probably follows a patent procedure which was published by Eisai R&D Management Company, Ltd.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> In this 2007 U.S. patent application, the authors described the kilogram-scale preparation of lenvativnib.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> A separate 2004 European patent filing from Eisai dealt with the formation of the mesylate as well as several different crystalline salts and the solubility rates of each of the solid forms of these complexes.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The structure of lenvatinib consists of a diarylethereal linkage between a substituted quinoline and a urea-containing aniline, which conveniently divides the compound into two subunits in the retrosynthetic sense.</div><div class="NLM_p">The preparation of the lenvatinib quinoline subunit <b>198</b> is outlined in <a class="ref internalNav" href="#sch36" aria-label="Scheme 36">Scheme 36</a>.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Starting from commercial aniline <b>193</b>, a substitution reaction under neutral conditions in warm isopropyl alcohol with a commercial vinyl methoxy derivative of Meldrum’s acid (<b>194</b>) produced enamine <b>195</b> in good yield. Next, subjection of <b>195</b> to DOWTHERM A at 190 °C affected an intramolecular cyclizative substitution reaction, followed by loss of acetone, and a decarboxylation reaction to furnish quinolone <b>196</b>. This cyclization reaction, which is a variant of the Conrad–Limpach reaction,<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> is particularly noteworthy given the temperature and pH at which it takes place. Conrad–Limpach cyclizations typically proceed under basic conditions at temperatures well above 240 °C.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> However, a process was developed by Zeneca in 2004 which involved subjecting <b>195</b> to the DOWTHERM heat transfer fluid (commercially available from Dow and Sigma-Aldrich, consisting of a eutectic mixture of biphenyl and diphenyl oxide)<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> allowed the team to lower the temperature required for the reaction, clearly observe bubbling of gas indicating the progress of the reaction, and simple cooling and treatment with ether to facilitated precipitate formation.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> The resulting solid could be collected by filtration and required no additional purification on scale in 80% yield.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Quinoline <b>196</b> was then converted to the corresponding chloride using thionyl chloride in refluxing DMF, and the resulting ester <b>197</b> was converted to the corresponding amide through the use of 28% aqueous ammonia in warm ethanol, which ultimately produced the key chloroquinoline lenvatinib subunit <b>198</b> in 80% yield from <b>197</b>.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><figure id="sch36" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0037.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 36. Synthesis of Fragment <b>198</b> of Lenvatinib (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The final approach to the synthesis of lenvatinib mesylate is described in <a class="ref internalNav" href="#sch37" aria-label="Scheme 37">Scheme 37</a>. Commercial aminophenol <b>199</b> was converted to the corresponding carbamate through the use of phenyl chloroformate in essentially quantitative yield prior to subjection to cyclopropylamine in chilled DMF, which ultimately furnished urea <b>201</b> in 77% overall yield from <b>200</b>. Next, exposure of phenol <b>201</b> to chloroquinoline <b>198</b> (<a class="ref internalNav" href="#sch36" aria-label="Scheme 36">Scheme 36</a>) in the presence of potassium <i>t</i>-butoxide followed by treatment with methanesulfonic acid and acetic acid resulted in clean formation of lenvatinib mesylate (<b>XXV</b>) in 96% yield across the two-step sequence.<a onclick="showRef(event, 'ref137 ref138'); return false;" href="javascript:void(0);" class="ref ref137 ref138">(137, 138)</a></div><figure id="sch37" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0038.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 37. Synthesis of Lenvatinib Mesylate (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch37"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72">9.4 Osimertinib Mesylate (Tagrisso)</h3><div class="NLM_p">Osimertinib is a third-generation EGFR inhibitor which received accelerated approval from the FDA in 2015 for the treatment of non-small cell lung carcinoma.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> This drug, which reacts as a covalent inhibitor with its intended biological target, was designed by AstraZeneca to bind EGFR and target the T790 M mutation while sparing wild-type EGFR.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> While a variety of synthetic approaches to this drug have been reported in the literature,<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> the most likely scale route is depicted in <a class="ref internalNav" href="#sch38" aria-label="Scheme 38">Scheme 38</a>.</div><figure id="sch38" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Scheme 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0039.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 38. Synthesis of Osimertinib Mesylate (<b>XXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Friedel–Crafts arylation of commercial <i>N</i>-methylindole (<b>203</b>) with commercial dichloropyrimidine <b>202</b> gave the 3-pyrazinyl indole <b>204</b> in good yield. Subsequent S<sub>N</sub>Ar with nitroaniline <b>205</b> (available from a one-step nitration from the commercially available <i>des</i>-nitroaniline) provided aminopyrazine <b>206</b>. Next, S<sub>N</sub>Ar reaction of <b>206</b> with <i>N,N,N</i>′<i>-</i>trimethylated ethylenediamine delivered <b>207</b> in near quantitative yield, and this was followed by nitro reduction with iron under acidic conditions to give rise to the triaminated arene <b>208</b> in 85% yield. Because acrylates are notoriously difficult to install directly due to their highly reactive nature and propensity to polymerize, a clever two-step acylation/elimination sequence was employed using 3-chloropropanoyl chloride, and this was immediately followed by mesylate salt formation, which furnished the osimertinib mesylate (<b>XXVI</b>) in excellent yield. This seven-step process which derives from readily available feedstock delivered the final product in nearly 57% overall yield from starting materials <b>202</b> and <b>203</b> (<a class="ref internalNav" href="#sch38" aria-label="Scheme 38">Scheme 38</a>).<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div></div><div id="sec9_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74">9.5 Palbociclib (Ibrance)</h3><div class="NLM_p">Palbociclib is a cyclin-dependent kinase (CDK) 4 and CDK6 inhibitor approved by the FDA to treat hormone receptor-positive (HR+) human epidural growth factor 2-negative (HER2−) metastatic breast cancer.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> It is used in combination with letrazole as the first-line hormonal-based therapy in postmenopausal women,<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> or with fulvestrant in women with disease progression following hormonal therapy.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Palbociclib was discovered at Warner-Lambert<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> and developed by Pfizer after their merger. Pfizer is also studying the effectiveness of palbociclib in a variety of other cancers at various stages in the clinic.</div><div class="NLM_p">Numerous syntheses of palbociclib have been reported,<a onclick="showRef(event, 'ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref149 ref150">(149, 150)</a> and the commercial scale process published by scientists at Pfizer is described herein.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> The amino-pyridylpiperazine fragment <b>212</b> was prepared in two steps. Commercial piperazine <b>209</b> was added to 5-bromo-2-nitropyridine (<b>210</b>) to give nitro-pyridine <b>211</b> in 93% yield (<a class="ref internalNav" href="#sch39" aria-label="Scheme 39">Scheme 39</a>). Hydrogenation of the nitro group using catalytic palladium on carbon provided the amino-pyridylpiperazine <b>212</b> in 96% yield.</div><figure id="sch39" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0040.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 39. Synthesis of Fragment <b>212</b> of Palbociclib (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The completion of the synthesis of palbociclib is described in <a class="ref internalNav" href="#sch40" aria-label="Scheme 40">Scheme 40</a> and was initiated with the preparation of the pyridopyrimidinone fragment <b>217</b>. As such, cyclopentylamine (<b>214</b>) was added to 5-bromo-2,4-dichloropyrimidine (<b>213</b>) to give 5-bromo-2-chloro-6-cyclopentylaminopyrimidine (<b>215</b>) in 84% yield. Heck reaction with crotonic acid followed by treating the resulting product with acetic anhydride formed the mixed anhydride under elevated temperatures, and this resulted in cyclization to give pyrimidinone <b>214</b> in 81% yield. Bromination using <i>N</i>-bromosuccinimide (NBS) provided coupling partner <b>217</b> in 88% yield. Next, aminopyridine <b>212</b> was treated with cyclohexylmagnesium chloride and then reacted with <b>217</b> to give the S<sub>N</sub>Ar product <b>218</b> in 88% yield.<a onclick="showRef(event, 'cit151c'); return false;" href="javascript:void(0);" class="ref cit151c">(151c)</a> A second Heck reaction between bromide <b>218</b> and butyl vinyl ether (<b>219</b>) using palladium acetate/bis(2-diphenylphosphinophenyl)ether (DPEPhos) as the catalyst provided enol ether <b>220</b> in 84% yield.<a onclick="showRef(event, 'cit151d'); return false;" href="javascript:void(0);" class="ref cit151d">(151d)</a> Exposure of <b>220</b> to acidic conditions removed the Boc group from the piperazine while converting the enol ether to the corresponding ketone, providing palbociclib (<b>XXVII</b>) in 90% yield.<a onclick="showRef(event, 'cit151a'); return false;" href="javascript:void(0);" class="ref cit151a">(151a)</a></div><figure id="sch40" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0041.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 40. Synthesis of Palbociclib (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch40"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77">9.6 Panobinostat Lactate (Farydak)</h3><div class="NLM_p">Panobinostat lactate is a histone deacetylase (HDAC) inhibitor that was approved by the FDA for the treatment of multiple myeloma.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> It was also approved for the same indication in Japan, and the EU approved its use in combination with bortezomib and dexamethasone for the treatment of adults with relapsed and/or refractory multiple myeloma.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Panobinostat was discovered and developed by Novartis and is currently being investigated for a number of hematological cancers as well as other indications.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></div><div class="NLM_p">The synthesis of panobinostat lactate is described in <a class="ref internalNav" href="#sch41" aria-label="Scheme 41">Scheme 41</a>.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Grandberg synthesis of 2-methyltryptamine (<b>223</b>) was accomplished in 47% yield by heating phenylhydrazine (<b>221</b>) with 5-chloro-2-pentanone (<b>222</b>).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Reductive amination of <b>223</b> with (<i>E</i>)-3-(4-formyl-phenyl)-acrylic acid methyl ester (<b>224</b>) and sodium borohydride followed by formation of the hydrochloride salt provided amine hydrochloride <b>225</b> in high purity. Saponification of the methyl ester followed by reaction with hydroxylamine provided panobinostat in high overall yield. The free base was treated with racemic lactic acid and recrystallized in water to give panobinostat lactate (<b>XXVIII</b>).<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><figure id="sch41" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Scheme 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0042.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 41. Synthesis of Panobinostat Lactate (<b>XXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch41"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79">9.7 Sonidegib Phosphate</h3><div class="NLM_p">Sonidegib phosphate (<b>XXIX</b>), an orally bioavailable, small molecule smoothened (SMO) receptor antagonist developed by Novartis, was approved in 2015 in Switzerland, the U.S., and the EU for the treatment of adult patients with advanced or locally advanced basal cell carcinoma (BCC).<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> BCC is the most frequently diagnosed skin cancer, constituting 80% of all nonmelanoma skin cancers.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> While most BCCs can be treated through surgery or radiation therapy, some patients (<10%) have more advanced tumors for which surgery may be contraindicated or impractical; treatment options for these patients are limited. SMO, a G-protein coupled receptor-like protein (GPCR), is a key regulator in the hedgehog (Hh) pathway, which is activated in a number of tumors including BCC.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> In a multicenter clinical trial for sonidegib, an objective response rate of 43% was observed for patients with locally advanced BCC (dosing at 200 mg once daily), with sustained clinically meaningful responses based on an 18-month analysis.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Sonidegib joins vismodegib as marketable treatments of BCC. Vismodegib, which was approved in 2012 as a first-in-class SMO receptor antagonist, represented the first Hedgehog signaling pathway targeting agent to gain FDA approval.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></div><div class="NLM_p">While an explicit process synthetic route to sonidegib phosphate has not been reported to date, the route described in <a class="ref internalNav" href="#sch42" aria-label="Scheme 42">Scheme 42</a> represents the most likely scalable synthesis that has been reported in the patent literature.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> The synthesis was initiated with an S<sub>N</sub>Ar reaction involving commercial 2-chloro-5-nitropyridine (<b>226</b>) and <i>cis</i>-dimethylmorpholine (<b>227</b>) followed by subsequent nitro reduction via hydrogenation to provide amine <b>228</b>. The crude amine was coupled directly to 3-bromo-2-methylbenzoic acid (<b>229</b>) in an amide bond-forming reaction to construct <b>230</b> in 77% yield over three steps. The resultant bromide was coupled to 4-(trifluoromethoxy)phenylboronic acid (<b>231</b>) under Suzuki conditions to give rise to sonidegib as the freebase. Finally, treatment with 85% aqueous phosphoric acid in acetonitrile generated sonidegib phosphate (<b>XXIX</b>) in good yield.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a></div><figure id="sch42" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0043.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 42. Synthesis of Sonidegib Phosphate (<b>XXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch42"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">10 Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68686" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68686" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, the pharmaceutical industry at large enjoyed another productive year in 2015, a year which saw the advance of these 29 new molecular entities to the marketplace. Innovative synthetic chemistry, particularly new methods for bond construction and the assembly of complex molecular architectures to be realized on scale, will continue to allow for new chemical space to be reached and play a critical role in the discovery and development of new medicines in the future. This review has highlighted the application of such technology toward the production of important therapies and hopefully will provide inspiration to researchers worldwide in the discovery of new drugs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00010" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72402" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72402" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. O’Donnell</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link">http://orcid.org/0000-0003-1004-7139</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d4b7bca6bda7a0bba4bcb1a6fabefabbb0bbbabab1b8b894a4b2bdaeb1a6fab7bbb9"><span class="__cf_email__" data-cfemail="9ffcf7edf6ecebf0eff7faedb1f5b1f0fbf0f1f1faf3f3dfeff9f6e5faedb1fcf0f2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew C. Flick</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong X. Ding</span> - <span class="hlFld-Affiliation affiliation">Pharmacodia
(Beijing) Co., Ltd., Beijing, 100085, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolyn A. Leverett</span> - <span class="hlFld-Affiliation affiliation">Groton
Laboratories, Pfizer Worldwide Research
and Development, 445
Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert E. Kyne</span> - <span class="hlFld-Affiliation affiliation">Celgene
Corporation, 200 Cambridge
Park Drive, Cambridge, Massachusetts 02140, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin K. -C. Liu</span> - <span class="hlFld-Affiliation affiliation">China
Novartis Institutes for BioMedical Research Co., Ltd., Shanghai, 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah J. Fink</span> - <span class="hlFld-Affiliation affiliation">BioDuro
Co., Ltd., Shanghai, 200131, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81287" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81287" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Andrew C. Flick</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=BIO-d50e3684-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andrew C. Flick</b> earned a B.A. in Chemistry from Lake Forest College, and then he joined Abbott Laboratories’ Diagnostics Group in Abbott Park, Illinois. He then moved to Array BioPharma in Longmont as a Research Associate in their Process Chemistry Group. In 2003, he joined Professor Albert Padwa’s laboratory at Emory University, where he successfully demonstrated a Michael addition–Nitrone dipolar cycloaddition approach for the total synthesis of the marine natural alkaloid cylindricine C. After obtaining his Ph.D. in 2008, he joined the Medicine Design group at Pfizer in Groton, CT, where he has been involved with numerous discovery projects within the Neurosciences, Rare Diseases, and Inflammation & Immunology therapeutic areas. Andy has authored over 30 peer-reviewed publications and patents.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Hong X. Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=BIO-d50e3689-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hongxia X. Ding</b> (Sheryl) obtained a B.S. in Pharmaceutics in 2001 and a Ph.D. in Medicinal Chemistry in 2006 from Zhejiang University in Hangzhou, China. Hongxia is the cofounder and Chief Executive Officer of PHARMACODIA, a company founded in 2013, which is an online platform (<a href="http://www.pharmacodia.com" class="extLink">http://www.pharmacodia.com</a>) providing big data and information service in the pharmaceutical R&D field. In 2010–2013, Hongxia joined Shenogen Pharma Group, a China-based Biotech company. As senior director of the R&D department, Hongxia is responsible for the CMC development of a novel ER-α36 targeted phase II candidates drug, named Icaritin (SNG162), and the discovery and development of second-generation small molecular based on the structure optimization of SNG162. Before Shenogen, Hongxia worked at BioDuro since 2006, as senior group leader and senior research scientist.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Carolyn A. Leverett</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=BIO-d50e3697-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Carolyn A. Leverett</b> began her career at Pfizer in 2012, focusing on the development of microtubule inhibitor-based payloads for use as antibody–drug conjugates. She currently works in the Applied Synthesis Technologies group, where she is involved in the discovery of biocatalytic routes to support various chemistry therapeutic areas. Carolyn is a native of North Carolina and obtained her B.S. in chemistry from North Carolina State University. She completed her doctoral studies with Professor Albert Padwa at Emory University in Atlanta, GA, working on total synthesis of several piperidine-based natural products and the alkaloid minfiensine. Prior to joining Pfizer, she was a postdoctoral fellow working with Professor Daniel Romo at Texas A&M University, exploring new applications of nucleophile-catalyzed aldol lactonization reactions.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Robert E. Kyne, Jr.</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=BIO-d50e3702-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Robert E. Kyne, Jr.</b> is a Senior Scientist in the Chemical Biology group at Celgene Corp., located in Cambridge, MA. During his time at Celgene, Bob has contributed to the development of several target ID platforms and the expansion into new druggable modalities. Previously, Bob was a Senior Scientist in the BioTherapeutics medicinal chemistry group at Pfizer, Inc. There, in addition to working on several drug discovery programs, Bob contributed to the discovery of sulfonyl fluorides as selective tyrosine warheads, use of clickable photoaffinity labels for target ID/validation, and the use of CETSA as an orthogonal method for target confirmation. Bob received his Ph.D. from Boston College in 2012 after graduating with honors from Connecticut College in 2007.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Kevin K. -C. Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=BIO-d50e3707-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kevin K.-C. Liu</b> is currently a Director at the Global Discovery Chemistry of Novartis Institute of BioMedical Research and he is located in Shanghai, China, since 2015. He received his B.S. in Chemistry from National Taiwan University, followed by his Ph.D. in Organic Chemistry, under the mentorship of Professor Chi-Huey Wong, at Texas A&M and The Scripps Research Institute. He did his postdoctoral fellowship with Professor Samuel Danishefsky at Yale University and Memorial Sloan Kettering Cancer Center in New York. He then joined Pfizer Research Center as a medicinal chemist and worked in different therapeutic areas. He joined Lilly China Research and Development Center in 2012 as a Senior Research Director. He has more than 80 peer-reviewed journal articles and patents that cover multiple therapeutic areas.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Sarah J. Fink</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=BIO-d50e3712-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sarah J. Fink</b> is a Senior Manager for Integrated Programs at BioDuro and is based in the Boston area. She obtained a B.A. in Chemistry and English literature from Williams College, followed by a Ph.D. in Organic Chemistry from the University of Cambridge with Professor Ian Paterson. Her thesis work focused on the total synthesis of aplyronine C. After a fellowship for young international scientists at Shanghai Institute of Materia Medica, Sarah joined BioDuro in Shanghai in 2014, where she was a scientist and chemistry group leader for integrated drug discovery projects in multiple therapeutic areas. She relocated to Boston in early 2017; in her current role, she provides medicinal chemistry and scientific project management support for collaborations with pharma and biotech.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Christopher J. O’Donnell</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=BIO-d50e3717-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher J. O’Donnell</b> obtained a B.S. in Chemistry from the University of Illinois in Urbana/Champaign and a Ph.D. in Organic Chemistry from the University of Wisconsin, Madison. After postdoctoral research at the University of California—Irvine, he joined Pfizer in 1999 in the Neuroscience Medicinal Chemistry group. As a scientist, project leader, and manager, he has led project teams to the nomination of over 10 clinical candidates. In 2010, Chris moved to Oncology Medicinal Chemistry to build the Antibody Drug Conjugate chemistry group and his team has nominated 11 conjugates for clinical development. Currently Chris is the Executive Director of the newly created Applied Synthesis Technology group at Pfizer. Chris is an author/inventor of 70 peer-reviewed journal articles and patent applications.</p></figure></div><div class="ack" id="ACK-d50e3680-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61053" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61053" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank Dr. Dahui Zhou for assisting us with the translation of a few references.</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84717" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84717" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="first last">This paper was originally published ASAP on May 3, 2017. In Scheme 31, the ribose ring was missing the oxygen atoms in both structures. The corrected version was reposted on May 8, 2017.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i90" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i90"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i91" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i91"> Abbreviations Used</h2><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetyl</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">ADP</td><td class="NLM_def"><p class="first last">adenosine 5′-diphosphate</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">AIBN</td><td class="NLM_def"><p class="first last">azobis(isobutyronitrile)</p></td></tr><tr><td class="NLM_term">BINAP</td><td class="NLM_def"><p class="first last">2,2′-bis(diphenylphosphino)-1,1′-binaphthyl</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>N</i>-<i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">Bs</td><td class="NLM_def"><p class="first last">benzenesulfonyl</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide</p></td></tr><tr><td class="NLM_term">BH<sub>3</sub>-DMS</td><td class="NLM_def"><p class="first last">borane-dimethyl sulfide</p></td></tr><tr><td class="NLM_term">BTI</td><td class="NLM_def"><p class="first last">bis(trifluoroacetoxy)iodobenzene</p></td></tr><tr><td class="NLM_term">Bu, <i>n</i>-Bu</td><td class="NLM_def"><p class="first last">butyl, <i>n</i>-butyl</p></td></tr><tr><td class="NLM_term">cat</td><td class="NLM_def"><p class="first last">catalytic</p></td></tr><tr><td class="NLM_term">Cbz</td><td class="NLM_def"><p class="first last">benzyloxycarbonyl</p></td></tr><tr><td class="NLM_term">CBzCl</td><td class="NLM_def"><p class="first last">benzyl carbonochloridate</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">Cy</td><td class="NLM_def"><p class="first last">cyclohexyl</p></td></tr><tr><td class="NLM_term">DABCO</td><td class="NLM_def"><p class="first last">1,4-diazabicyclo[2.2.2]octane</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term">DBDMH</td><td class="NLM_def"><p class="first last">1,3-dibromo-5,5-dimethylhydantoin</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazobicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">DCB</td><td class="NLM_def"><p class="first last">dichlorobenzene</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">1,3-dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DDQ</td><td class="NLM_def"><p class="first last">2,3-dichloro-5,6-dicyano-1,4-benzoquinone</p></td></tr><tr><td class="NLM_term">DEAD</td><td class="NLM_def"><p class="first last">diethyl azodiformate</p></td></tr><tr><td class="NLM_term">3,4-DHP</td><td class="NLM_def"><p class="first last">3,4-dihydropyran</p></td></tr><tr><td class="NLM_term">(DHQ)<sub>2</sub>PHAL</td><td class="NLM_def"><p class="first last">hydroquinine 1,4-phthalazinediyl diether</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DIBAL</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DM</td><td class="NLM_def"><p class="first last">diabetes mellitus</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMF-DMA</td><td class="NLM_def"><p class="first last">dimethylformamide–dimethylacetal</p></td></tr><tr><td class="NLM_term">DMI</td><td class="NLM_def"><p class="first last">1,3-dimethyl-2-imidazolidinone</p></td></tr><tr><td class="NLM_term">DMPU</td><td class="NLM_def"><p class="first last">1,3-dimethyl tetrahydropyrimidin-2(1<i>H</i>)-one</p></td></tr><tr><td class="NLM_term">DMS</td><td class="NLM_def"><p class="first last">dimethylsulfide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DPEN</td><td class="NLM_def"><p class="first last">(1<i>R</i>,2<i>R</i>)-2-amino-1,2-diphenylethyl</p></td></tr><tr><td class="NLM_term">DPEPhos</td><td class="NLM_def"><p class="first last">bis[(2-diphenylphosphino)phenyl] ether</p></td></tr><tr><td class="NLM_term">dppp</td><td class="NLM_def"><p class="first last">1,3-bis(diphenylphosphino)propane</p></td></tr><tr><td class="NLM_term">DTTA</td><td class="NLM_def"><p class="first last">di-<i>p</i>-toluyl-<span class="smallcaps smallerCapital">d</span>-tartaric acid</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>o</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>,<i>N</i>-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HG-II</td><td class="NLM_def"><p class="first last">(1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(<i>o</i>-isopropylphenylmethylene)ruthenium</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole hydrate</p></td></tr><tr><td class="NLM_term"><i>i</i>-Pr</td><td class="NLM_def"><p class="first last">isopropyl</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">KHMDS</td><td class="NLM_def"><p class="first last">potassium hexamethyldisilazide</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">LHMDS</td><td class="NLM_def"><p class="first last">lithium hexamethyldisilazide</p></td></tr><tr><td class="NLM_term"><i>m</i>CPBA</td><td class="NLM_def"><p class="first last">3-chloroperoxybenzoic acid</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">Ms</td><td class="NLM_def"><p class="first last">methanesulfonyl</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">methanesulfonyl chloride</p></td></tr><tr><td class="NLM_term">MsOH</td><td class="NLM_def"><p class="first last">methanesulfonic acid</p></td></tr><tr><td class="NLM_term">MTBE</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl ether</p></td></tr><tr><td class="NLM_term">NaHMDS</td><td class="NLM_def"><p class="first last">sodium <i>bis</i>(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term"><i>n</i>-BuLi</td><td class="NLM_def"><p class="first last"><i>n</i>-butyllithium</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl morpholine</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">Pd<sub>2</sub>(dba)<sub>3</sub></td><td class="NLM_def"><p class="first last"><i>tris</i>(dibenzylideneacetone)dipalladium</p></td></tr><tr><td class="NLM_term">PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub></td><td class="NLM_def"><p class="first last">bis(triphenylphosphine)palladium(II)chloride</p></td></tr><tr><td class="NLM_term">Pd(OAc)<sub>2</sub></td><td class="NLM_def"><p class="first last">palladium acetate</p></td></tr><tr><td class="NLM_term">Ph</td><td class="NLM_def"><p class="first last">phenyl</p></td></tr><tr><td class="NLM_term">PhMe</td><td class="NLM_def"><p class="first last">toluene</p></td></tr><tr><td class="NLM_term">PPA</td><td class="NLM_def"><p class="first last">polyposphoric acid</p></td></tr><tr><td class="NLM_term"><i>p</i>-TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">PTSA</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonamide</p></td></tr><tr><td class="NLM_term">Py</td><td class="NLM_def"><p class="first last">pyridine</p></td></tr><tr><td class="NLM_term">PyBrop</td><td class="NLM_def"><p class="first last">bromotripyrrolidinophosphonium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">TBAB</td><td class="NLM_def"><p class="first last"><i>t</i>-butyl ammonium bromide</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">TBHP</td><td class="NLM_def"><p class="first last"><i>t</i>-butyl hydroperoxide</p></td></tr><tr><td class="NLM_term">TBME</td><td class="NLM_def"><p class="first last"><i>tert</i>-butylmethyl ether</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>,<i>N</i>-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term"><i>t</i>-Bu</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl</p></td></tr><tr><td class="NLM_term">TCAA</td><td class="NLM_def"><p class="first last">trichloroacetic acid</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TEMPO</td><td class="NLM_def"><p class="first last">(2,2,6,6-tetramethylpiperidin-1-yl)oxyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid anhydride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyranyl</p></td></tr><tr><td class="NLM_term">TMDS</td><td class="NLM_def"><p class="first last">1,1,3,3-tetramethyldisiloxane</p></td></tr><tr><td class="NLM_term">TMS</td><td class="NLM_def"><p class="first last">trimethylsilyl</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr><tr><td class="NLM_term">Tol</td><td class="NLM_def"><p class="first last">toluene</p></td></tr><tr><td class="NLM_term">Ts</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonyl</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 163 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Raju, T. N. K.</span><span> </span><span class="NLM_article-title">The Nobel Chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918–99), and George H Hitchings (1905–98)</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="refDoi"> DOI: 10.1016/S0140-6736(05)74775-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0140-6736%2805%2974775-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10768469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=1022&author=T.+N.+K.+Raju&title=The+Nobel+Chronicles.+1988%3A+James+Whyte+Black%2C+%28b+1924%29%2C+Gertrude+Elion+%281918%E2%80%9399%29%2C+and+George+H+Hitchings+%281905%E2%80%9398%29&doi=10.1016%2FS0140-6736%2805%2974775-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span></div><div class="casAuthors">Raju T N</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9208</span>),
    <span class="NLM_cas:pages">1022</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTWLVzWjiD66qcneEtCi92fW6udTcc2eZobMkiIlDPoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D&md5=c89d64b40317d0d0cb4a76c1cceecb58</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974775-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974775-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DT.%2BN.%2BK.%26atitle%3DThe%2520Nobel%2520Chronicles.%25201988%253A%2520James%2520Whyte%2520Black%252C%2520%2528b%25201924%2529%252C%2520Gertrude%2520Elion%2520%25281918%25E2%2580%259399%2529%252C%2520and%2520George%2520H%2520Hitchings%2520%25281905%25E2%2580%259398%2529%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D1022%26doi%3D10.1016%2FS0140-6736%2805%2974775-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span><span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0lgZQKqgPSNGvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1105</span><span class="NLM_x">–</span> <span class="NLM_lpage">1125</span><span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0lgZQKqgPSNGvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1144</span><span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.-C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0lgZQKqgPSNGvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0ljzFj0OUnLxZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1255</span><span class="NLM_x">–</span> <span class="NLM_lpage">1269</span><span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0ljzFj0OUnLxZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1526</span><span class="NLM_x">–</span> <span class="NLM_lpage">1548</span><span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0ljzFj0OUnLxZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1675</span><span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0ljHG3OQ5RXy2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1136</span><span class="NLM_x">–</span> <span class="NLM_lpage">1154</span><span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2hR"><div class="casContent"><span class="casTitleNuber">2h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0ljHG3OQ5RXy2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H. X.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1155</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span><span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0ljHG3OQ5RXy2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Ding, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2795</span><span class="NLM_x">–</span> <span class="NLM_lpage">2825</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2jR"><div class="casContent"><span class="casTitleNuber">2j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0ljHG3OQ5RXy2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group">Ding, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverett, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyne, R. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0lixRdFXinY-lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group">Ding, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverett, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyne, R. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">–</span> <span class="NLM_lpage">1922</span><span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2lR"><div class="casContent"><span class="casTitleNuber">2l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0lixRdFXinY-lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2m"><span><span class="NLM_label">(m) </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverett, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyne, R. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1937</span><span class="NLM_x">–</span> <span class="NLM_lpage">1980</span><span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2mR"><div class="casContent"><span class="casTitleNuber">2m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0lixRdFXinY-lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Graul, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruces, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stringer, M.</span><span> </span><span class="NLM_article-title">The Year’s New Drugs & Biologics 2015: Part I</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1358/dot.2016.52.1.2450695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdot.2016.52.1.2450695" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28jmtlOltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=41-89&author=A.+I.+Graulauthor=E.+Crucesauthor=M.+Stringer&title=The+Year%E2%80%99s+New+Drugs+%26+Biologics+2015%3A+Part+I&doi=10.1358%2Fdot.2016.52.1.2450695"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The year's new drugs & biologics 2015: Part I</span></div><div class="casAuthors">Graul A I; Cruces E; Stringer M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-89</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Nearly 100 new drugs and biologics, including important new line extensions, were approved or launched for the first time globally in 2015.  These products are covered in depth in part I of our annual review of the pharma and biotech industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxaB4yODpzB-2qxNLjzXe8fW6udTcc2eYCDS1pvy4zc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmtlOltw%253D%253D&md5=8f62729c75f647fc793c11b8a851f4d2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.1.2450695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.1.2450695%26sid%3Dliteratum%253Aachs%26aulast%3DGraul%26aufirst%3DA.%2BI.%26aulast%3DCruces%26aufirst%3DE.%26aulast%3DStringer%26aufirst%3DM.%26atitle%3DThe%2520Year%25E2%2580%2599s%2520New%2520Drugs%2520%2526%2520Biologics%25202015%253A%2520Part%2520I%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D41%26epage%3D89%26doi%3D10.1358%2Fdot.2016.52.1.2450695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Isavuconazonium: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">822</span><span class="refDoi"> DOI: 10.1007/s40265-015-0398-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0398-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=817-822&author=P.+L.+McCormack&title=Isavuconazonium%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0398-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0398-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0398-6%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DIsavuconazonium%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D817%26epage%3D822%26doi%3D10.1007%2Fs40265-015-0398-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Miceli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, C. A.</span><span> </span><span class="NLM_article-title">Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1558</span><span class="NLM_x">–</span> <span class="NLM_lpage">1565</span><span class="refDoi"> DOI: 10.1093/cid/civ571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1093%2Fcid%2Fciv571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26179012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWlsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1558-1565&author=M.+H.+Miceliauthor=C.+A.+Kauffman&title=Isavuconazole%3A+A+New+Broad-Spectrum+Triazole+Antifungal+Agent&doi=10.1093%2Fcid%2Fciv571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Isavuconazole: a new broad-spectrum triazole antifungal agent</span></div><div class="casAuthors">Miceli, Marisa H.; Kauffman, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1558-1565</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi.  It is approved for the treatment of invasive aspergillosis and mucormycosis.  Advantages of this triazole include the availability of a water-sol. i.v. formulation, excellent bioavailability of the oral formulation, and predictable pharmacokinetics in adults.  A randomized, double-blind comparison clin. trial for treatment of invasive aspergillosis found that the efficacy of isavuconazole was noninferior to that of voriconazole.  An open-label trial that studied primary as well as salvage therapy of invasive mucormycosis showed efficacy with isavuconazole that was similar to that reported for amphotericin B and posaconazole.  In patients in these studies, as well as in normal volunteers, isavuconazole was well tolerated, appeared to have few serious adverse effects, and had fewer drug-drug interactions than those noted with voriconazole.  As clin. experience increases, the role of this new triazole in the treatment of invasive fungal infections will be better defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2EPvD5rxahLVg90H21EOLACvtfcHk0lhKc3m_xLyzrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWlsLbF&md5=3f0ac85777dc13de0b401fc7235c1e21</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciv571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciv571%26sid%3Dliteratum%253Aachs%26aulast%3DMiceli%26aufirst%3DM.%2BH.%26aulast%3DKauffman%26aufirst%3DC.%2BA.%26atitle%3DIsavuconazole%253A%2520A%2520New%2520Broad-Spectrum%2520Triazole%2520Antifungal%2520Agent%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D61%26spage%3D1558%26epage%3D1565%26doi%3D10.1093%2Fcid%2Fciv571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Murrell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossaer, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carico, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harirforoosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluck, D.</span><span> </span><span class="NLM_article-title">Isavuconazonium Sulfate: a Triazole Prodrug for Invasive Fungal Infections</span> <span class="citation_source-journal">Int. J. Pharm. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="refDoi"> DOI: 10.1111/ijpp.12302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fijpp.12302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27569742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC2szltVahtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=18&author=D.+Murrellauthor=J.+B.+Bossaerauthor=R.+Caricoauthor=S.+Harirforooshauthor=D.+Cluck&title=Isavuconazonium+Sulfate%3A+a+Triazole+Prodrug+for+Invasive+Fungal+Infections&doi=10.1111%2Fijpp.12302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections</span></div><div class="casAuthors">Murrell Derek; Harirforoosh Sam; Bossaer John B; Carico Ronald; Cluck David</div><div class="citationInfo"><span class="NLM_cas:title">The International journal of pharmacy practice</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To review the place in therapy of isavuconazole, the active metabolite of isavuconazonium sulfate, via a review of the available literature on drug chemistry, spectrum of activity, pharmacokinetic/pharmacodynamic profile and trials assessing clinical efficacy and safety.  METHODS:  Relevant data, original research articles and reviews, were gathered primarily through the use of a PubMed database search.  The search was conducted without date restrictions in order to collect both historical and recent data regarding isavuconazole.  KEY FINDINGS:  Isavuconazole is a triazole currently approved not only for use in invasive aspergillosis and mucormycosis but also has demonstrable activity against Candida species and other common fungal pathogens.  This drug has features which make it more clinically appealing compared to other azoles with similar indications.  In specific, isavuconazole does not require a cyclodextrin vehicle due to its water solubility, and at present, does not require therapeutic drug monitoring.  Moreover, isavuconazole has displayed improved safety and tolerability compared to voriconazole.  Available data from Phase III clinical trials shows isavuconazole to be a possible therapeutic option to currently available therapies for which it is approved; however, clinical conclusions should be reserved until results have been published and more data from clinical use is reported.  CONCLUSIONS:  Isavuconazole is a new triazole with broad-spectrum antifungal activity including invasive aspergillosis and mucormycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXTqBH7GZWSevW160gIxP_fW6udTcc2eYCDS1pvy4zc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szltVahtw%253D%253D&md5=31842dac8cd4a6e87fdf85b9bd5c16db</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1111%2Fijpp.12302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fijpp.12302%26sid%3Dliteratum%253Aachs%26aulast%3DMurrell%26aufirst%3DD.%26aulast%3DBossaer%26aufirst%3DJ.%2BB.%26aulast%3DCarico%26aufirst%3DR.%26aulast%3DHarirforoosh%26aufirst%3DS.%26aulast%3DCluck%26aufirst%3DD.%26atitle%3DIsavuconazonium%2520Sulfate%253A%2520a%2520Triazole%2520Prodrug%2520for%2520Invasive%2520Fungal%2520Infections%26jtitle%3DInt.%2520J.%2520Pharm.%2520Pract.%26date%3D2017%26volume%3D25%26spage%3D18%26doi%3D10.1111%2Fijpp.12302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hayase, T.; Ichihara, S.; Isshiki, Y.; Liu, P.; Ohwada, J.; Sakai, T.; Shimma, N.; Tsukazaki, M.; Umeda, I.; Yamazaki, T.</span><span> </span><span class="NLM_article-title">3-[4-(4-Cyanophenyl)thiazol-2-y)]-1-(1<i>H</i>-1,2,4-triazol-1-yl)-butan-2-ol Derivatives Having Antifungal Activity</span>. WO 9945008A1,<span class="NLM_x"> </span><span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=T.+Hayase&author=S.+Ichihara&author=Y.+Isshiki&author=P.+Liu&author=J.+Ohwada&author=T.+Sakai&author=N.+Shimma&author=M.+Tsukazaki&author=I.+Umeda&author=T.+Yamazaki&title=3-%5B4-%284-Cyanophenyl%29thiazol-2-y%29%5D-1-%281H-1%2C2%2C4-triazol-1-yl%29-butan-2-ol+Derivatives+Having+Antifungal+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayase%26aufirst%3DT.%26atitle%3D3-%255B4-%25284-Cyanophenyl%2529thiazol-2-y%2529%255D-1-%25281H-1%252C2%252C4-triazol-1-yl%2529-butan-2-ol%2520Derivatives%2520Having%2520Antifungal%2520Activity%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isshiki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuguchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaitani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiratori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umeda, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimma, N.</span><span> </span><span class="NLM_article-title">Design, Synthesis and Antifungal Activity of a Novel Water Soluble Prodrug of Antifungal Triazole</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00892-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0960-894X%2802%2900892-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=12482421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVels7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=191-196&author=J.+Ohwadaauthor=M.+Tsukazakiauthor=T.+Hayaseauthor=N.+Oikawaauthor=Y.+Isshikiauthor=H.+Fukudaauthor=E.+Mizuguchiauthor=M.+Sakaitaniauthor=Y.+Shiratoriauthor=T.+Yamazakiauthor=S.+Ichiharaauthor=I.+Umedaauthor=N.+Shimma&title=Design%2C+Synthesis+and+Antifungal+Activity+of+a+Novel+Water+Soluble+Prodrug+of+Antifungal+Triazole&doi=10.1016%2FS0960-894X%2802%2900892-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole</span></div><div class="casAuthors">Ohwada, Jun; Tsukazaki, Masao; Hayase, Tadakatsu; Oikawa, Nobuhiro; Isshiki, Yoshiaki; Fukuda, Hiroshi; Mizuguchi, Eisaku; Sakaitani, Masahiro; Shiratori, Yasuhiko; Yamazaki, Toshikazu; Ichihara, Shigeyasu; Umeda, Isao; Shimma, Nobuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-196</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A highly potent water sol. triazole antifungal prodrug, RO0098557 (I), has been identified from its parent, the novel antifungal agent RO0094815 (II).  The prodrug, which was obtained by the coupling of II with sarcosine ester III, includes a triazolium salt linked to an aminocarboxyl moiety, which undergoes enzymic activation followed by spontaneous chem. degrdn. to release II.  Prodrug I showed high chem. stability and water soly. and exhibited strong antifungal activity against systemic candidiasis and aspergillosis as well as pulmonary aspergillosis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1j5aGGk3HYrVg90H21EOLACvtfcHk0lgSbj43lGqk3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVels7g%253D&md5=e5fa5ef54f1b4e5420caef0c329b1bfd</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900892-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900892-2%26sid%3Dliteratum%253Aachs%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DHayase%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DIsshiki%26aufirst%3DY.%26aulast%3DFukuda%26aufirst%3DH.%26aulast%3DMizuguchi%26aufirst%3DE.%26aulast%3DSakaitani%26aufirst%3DM.%26aulast%3DShiratori%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DIchihara%26aufirst%3DS.%26aulast%3DUmeda%26aufirst%3DI.%26aulast%3DShimma%26aufirst%3DN.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Antifungal%2520Activity%2520of%2520a%2520Novel%2520Water%2520Soluble%2520Prodrug%2520of%2520Antifungal%2520Triazole%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D191%26epage%3D196%26doi%3D10.1016%2FS0960-894X%2802%2900892-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Soukup, M.</span><span> </span><span class="NLM_article-title">Process for the Manufacture of Enantiomerically Pure Antifungal Azoles as Ravuconazole and Isavuconazole</span>. US 8207352,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Soukup&title=Process+for+the+Manufacture+of+Enantiomerically+Pure+Antifungal+Azoles+as+Ravuconazole+and+Isavuconazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSoukup%26aufirst%3DM.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%2520Enantiomerically%2520Pure%2520Antifungal%2520Azoles%2520as%2520Ravuconazole%2520and%2520Isavuconazole%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Soukup, M.</span><span> </span><span class="NLM_article-title">Intermediate Halophenyl Derivatives and Their Use in a Process for Preparing Azole Derivatives</span>. US 7115643,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.+Soukup&title=Intermediate+Halophenyl+Derivatives+and+Their+Use+in+a+Process+for+Preparing+Azole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSoukup%26aufirst%3DM.%26atitle%3DIntermediate%2520Halophenyl%2520Derivatives%2520and%2520Their%2520Use%2520in%2520a%2520Process%2520for%2520Preparing%2520Azole%2520Derivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Fukuda, H.; Hayase, T.; Mizuguchi, E.; Shimma, N.; Ohwada, J.; Oikawa, N.; Sakaitani, M.; Tsukazaki, M.; Umeda, I.</span><span> </span><span class="NLM_article-title">N-Substituted Carbamoyloxyalkyl-azolium Derivatives</span>. US 6812238A1,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=H.+Fukuda&author=T.+Hayase&author=E.+Mizuguchi&author=N.+Shimma&author=J.+Ohwada&author=N.+Oikawa&author=M.+Sakaitani&author=M.+Tsukazaki&author=I.+Umeda&title=N-Substituted+Carbamoyloxyalkyl-azolium+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DH.%26atitle%3DN-Substituted%2520Carbamoyloxyalkyl-azolium%2520Derivatives%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Van, S. R.; Vaessen, H.; Mink, D.; Waser, M.</span><span> </span><span class="NLM_article-title">Process for the Manufacture of Isavuconazole or Ravuconazole</span>. WO 2014023623A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+R.+Van&author=H.+Vaessen&author=D.+Mink&author=M.+Waser&title=Process+for+the+Manufacture+of+Isavuconazole+or+Ravuconazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVan%26aufirst%3DS.%2BR.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%2520Isavuconazole%2520or%2520Ravuconazole%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Khunt, R. C.; Rafeeq, M.; Merwade, A. Y.; Deo, K.</span><span> </span><span class="NLM_article-title">A Process for the Preparation of Isavuconazonium or Its Salt Thereof</span>. WO 2016016766A2,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+C.+Khunt&author=M.+Rafeeq&author=A.+Y.+Merwade&author=K.+Deo&title=A+Process+for+the+Preparation+of+Isavuconazonium+or+Its+Salt+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKhunt%26aufirst%3DR.%2BC.%26atitle%3DA%2520Process%2520for%2520the%2520Preparation%2520of%2520Isavuconazonium%2520or%2520Its%2520Salt%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span>Clarivate Analytics, July 2015; <span class="NLM_publisher-name">Clarivate Analytics</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.thomsonscientific.com.cn/lscn/drug-news/201507.shtml" class="extLink">http://www.thomsonscientific.com.cn/lscn/drug-news/201507.shtml</a> (accessed August 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clarivate+Analytics%2C+July+2015%3B+Clarivate+Analytics%2C+2015%3B+http%3A%2F%2Fwww.thomsonscientific.com.cn%2Flscn%2Fdrug-news%2F201507.shtml+%28accessed+August+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DClarivate%2520Analytics%252C%2520July%25202015%26pub%3DClarivate%2520Analytics%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hagi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsubotani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span> </span><span class="NLM_article-title">Bactericidal Effects and Mechanism of Action of Olanexidine Gluconate, a New Antiseptic</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">4551</span><span class="NLM_x">–</span> <span class="NLM_lpage">4559</span><span class="refDoi"> DOI: 10.1128/AAC.05048-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1128%2FAAC.05048-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=4551-4559&author=A.+Hagiauthor=K.+Iwataauthor=T.+Niiauthor=H.+Nakataauthor=Y.+Tsubotaniauthor=Y.+Inoue&title=Bactericidal+Effects+and+Mechanism+of+Action+of+Olanexidine+Gluconate%2C+a+New+Antiseptic&doi=10.1128%2FAAC.05048-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FAAC.05048-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05048-14%26sid%3Dliteratum%253Aachs%26aulast%3DHagi%26aufirst%3DA.%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DNii%26aufirst%3DT.%26aulast%3DNakata%26aufirst%3DH.%26aulast%3DTsubotani%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DY.%26atitle%3DBactericidal%2520Effects%2520and%2520Mechanism%2520of%2520Action%2520of%2520Olanexidine%2520Gluconate%252C%2520a%2520New%2520Antiseptic%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D4551%26epage%3D4559%26doi%3D10.1128%2FAAC.05048-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Okaichi, Y.; Tada, N.; Nomi, D.; Fujita, N.; Tsuji, K.; Yamaguchi, T.; Muguruma, Y.; Tsujimori, H.</span><span> </span><span class="NLM_article-title">Process for Producing 1-(3, 4-Dichlorobenzyl)-5-octylbiguanide or a Salt Thereof</span>. US7868207B2,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Y.+Okaichi&author=N.+Tada&author=D.+Nomi&author=N.+Fujita&author=K.+Tsuji&author=T.+Yamaguchi&author=Y.+Muguruma&author=H.+Tsujimori&title=Process+for+Producing+1-%283%2C+4-Dichlorobenzyl%29-5-octylbiguanide+or+a+Salt+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOkaichi%26aufirst%3DY.%26atitle%3DProcess%2520for%2520Producing%25201-%25283%252C%25204-Dichlorobenzyl%2529-5-octylbiguanide%2520or%2520a%2520Salt%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Hathaway, R. D.; Sclafani, J. R.,  Jr</span><span> </span><span class="NLM_article-title">Method and Apparatus for Preparing a Solution of a Shear Sensitive Material</span>. US 9034256B2,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+D.+Hathaway&author=J.+R.+Sclafani&title=Method+and+Apparatus+for+Preparing+a+Solution+of+a+Shear+Sensitive+Material"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHathaway%26aufirst%3DR.%2BD.%26atitle%3DMethod%2520and%2520Apparatus%2520for%2520Preparing%2520a%2520Solution%2520of%2520a%2520Shear%2520Sensitive%2520Material%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Santos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gropper, S.</span><span> </span><span class="NLM_article-title">In Vitro Percutaneous Absorption and Metabolism of Ozenoxacin in Excised Human Skin</span> <span class="citation_source-journal">Future Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">S9</span><span class="refDoi"> DOI: 10.2217/fmb.14.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2217%2Ffmb.14.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25209522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFejt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=S3-S9&author=B.+Santosauthor=J.+Ortizauthor=S.+Gropper&title=In+Vitro+Percutaneous+Absorption+and+Metabolism+of+Ozenoxacin+in+Excised+Human+Skin&doi=10.2217%2Ffmb.14.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro percutaneous absorption and metabolism of ozenoxacin in excised human skin</span></div><div class="casAuthors">Santos, Benjamin; Ortiz, Jordi; Gropper, Savion</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8s</span>),
    <span class="NLM_cas:pages">S3-S9</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">In vitro studies using excised human skin samples were conducted to evaluate the percutaneous absorption and skin metab. of ozenoxacin.  The formulations studied were 1% ointment, 1% cream and 2% cream.  Permeation assays met the conditions for infinite dose expts.  In all but one case, ozenoxacin concns. in receptor fluid samples of Franz diffusion cells were below the limits of quantification (0.04 μg/mL) by liq. chromatog./mass spectrometry/electrospray ionization at the designated time points.  Across all four absorption studies, ≤0.015% of the applied ozenoxacin dose permeated through the skin over the course of 24 or 48 h.  Ethnic origin had no influence on absorption.  Ozenoxacin at concns. of 7, 35 and 70 μM was metabolically stable in the presence of freshly prepd. human skin disks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2UUvC1tj-SrVg90H21EOLACvtfcHk0lgkNIhE_R_U7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFejt7jI&md5=b93d7696e0114cc3c3e03df7dabed455</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2217%2Ffmb.14.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb.14.81%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DB.%26aulast%3DOrtiz%26aufirst%3DJ.%26aulast%3DGropper%26aufirst%3DS.%26atitle%3DIn%2520Vitro%2520Percutaneous%2520Absorption%2520and%2520Metabolism%2520of%2520Ozenoxacin%2520in%2520Excised%2520Human%2520Skin%26jtitle%3DFuture%2520Microbiol.%26date%3D2014%26volume%3D9%26spage%3DS3%26epage%3DS9%26doi%3D10.2217%2Ffmb.14.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Hayashi, K.; Kito, T.; Mitsuyama, J.; Yamakawa, T.; Kuroda, H.; Kawafuchi, H.</span><span> </span><span class="NLM_article-title">Quinolonecarboxylic Acid Derivatives or Salts Thereof</span>. US 6335447B1,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=K.+Hayashi&author=T.+Kito&author=J.+Mitsuyama&author=T.+Yamakawa&author=H.+Kuroda&author=H.+Kawafuchi&title=Quinolonecarboxylic+Acid+Derivatives+or+Salts+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DK.%26atitle%3DQuinolonecarboxylic%2520Acid%2520Derivatives%2520or%2520Salts%2520Thereof%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Erlinge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schersten, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omerovic, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostlund, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallentin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frobert, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, S.</span><span> </span><span class="NLM_article-title">Bivalirudin Versus Heparin in Non-ST and ST-segment Elevation Myocardial Infarction-a Registry-based Randomized Clinical Trial in the SWEDEHEART Registry (the VALIDATE-SWEDEHEART Trial)</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1016/j.ahj.2016.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.ahj.2016.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2016&pages=36-46&author=D.+Erlingeauthor=S.+Koulauthor=P.+Erikssonauthor=F.+Scherstenauthor=E.+Omerovicauthor=R.+Linderauthor=O.+P.+Ostlundauthor=L.+Wallentinauthor=O.+Frobertauthor=S.+James&title=Bivalirudin+Versus+Heparin+in+Non-ST+and+ST-segment+Elevation+Myocardial+Infarction-a+Registry-based+Randomized+Clinical+Trial+in+the+SWEDEHEART+Registry+%28the+VALIDATE-SWEDEHEART+Trial%29&doi=10.1016%2Fj.ahj.2016.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2016.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2016.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DErlinge%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DS.%26aulast%3DEriksson%26aufirst%3DP.%26aulast%3DSchersten%26aufirst%3DF.%26aulast%3DOmerovic%26aufirst%3DE.%26aulast%3DLinder%26aufirst%3DR.%26aulast%3DOstlund%26aufirst%3DO.%2BP.%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DFrobert%26aufirst%3DO.%26aulast%3DJames%26aufirst%3DS.%26atitle%3DBivalirudin%2520Versus%2520Heparin%2520in%2520Non-ST%2520and%2520ST-segment%2520Elevation%2520Myocardial%2520Infarction-a%2520Registry-based%2520Randomized%2520Clinical%2520Trial%2520in%2520the%2520SWEDEHEART%2520Registry%2520%2528the%2520VALIDATE-SWEDEHEART%2520Trial%2529%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2016%26volume%3D175%26spage%3D36%26epage%3D46%26doi%3D10.1016%2Fj.ahj.2016.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInally, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindon, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teobald, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, W.</span><span> </span><span class="NLM_article-title">Antagonists of the Platelet P2T Receptor: A Novel Approach to Antithrombotic Therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1021/jm981072s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm981072s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=213-220&author=A.+H.+Ingallauthor=J.+Dixonauthor=A.+Baileyauthor=M.+E.+Coombsauthor=D.+Coxauthor=J.+I.+McInallyauthor=S.+F.+Huntauthor=N.+D.+Kindonauthor=B.+J.+Teobaldauthor=P.+A.+Willisauthor=R.+G.+Humphriesauthor=P.+Leffauthor=J.+A.+Cleggauthor=J.+A.+Smithauthor=W.+Tomlinson&title=Antagonists+of+the+Platelet+P2T+Receptor%3A+A+Novel+Approach+to+Antithrombotic+Therapy&doi=10.1021%2Fjm981072s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm981072s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm981072s%26sid%3Dliteratum%253Aachs%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DDixon%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCoombs%26aufirst%3DM.%2BE.%26aulast%3DCox%26aufirst%3DD.%26aulast%3DMcInally%26aufirst%3DJ.%2BI.%26aulast%3DHunt%26aufirst%3DS.%2BF.%26aulast%3DKindon%26aufirst%3DN.%2BD.%26aulast%3DTeobald%26aufirst%3DB.%2BJ.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26aulast%3DHumphries%26aufirst%3DR.%2BG.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DClegg%26aufirst%3DJ.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DTomlinson%26aufirst%3DW.%26atitle%3DAntagonists%2520of%2520the%2520Platelet%2520P2T%2520Receptor%253A%2520A%2520Novel%2520Approach%2520to%2520Antithrombotic%2520Therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D213%26epage%3D220%26doi%3D10.1021%2Fjm981072s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ingall, A. H.; Cage, P. A.; Kindon, N. D.</span><span> </span><span class="NLM_article-title">Preparation of N-Alkyl-2-substituted ATP Analogs as Platelet Aggregation Inhibitors</span>. WO 1994018216A1,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=A.+H.+Ingall&author=P.+A.+Cage&author=N.+D.+Kindon&title=Preparation+of+N-Alkyl-2-substituted+ATP+Analogs+as+Platelet+Aggregation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIngall%26aufirst%3DA.%2BH.%26atitle%3DPreparation%2520of%2520N-Alkyl-2-substituted%2520ATP%2520Analogs%2520as%2520Platelet%2520Aggregation%2520Inhibitors%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Diaz-Ricart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escolar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serradell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolos, J.</span><span> </span><span class="NLM_article-title">Cangrelor Tetrasodium: P2Y12 Antagonist Antiplatelet Agent</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1358/dof.2008.033.02.1178068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdof.2008.033.02.1178068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=101-110&author=M.+Diaz-Ricartauthor=G.+Escolarauthor=N.+Serradellauthor=E.+Rosaauthor=J.+Bolos&title=Cangrelor+Tetrasodium%3A+P2Y12+Antagonist+Antiplatelet+Agent&doi=10.1358%2Fdof.2008.033.02.1178068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Cangrelor tetrasodium: P2Y12 antagonist antiplatelet agent</span></div><div class="casAuthors">Diaz-Ricart, Maribel; Escolar, Gines</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-110</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Cangrelor (AR-C69931MX) is a nonthienopyridine direct-acting P2Y12 antagonist under development for the treatment of acute coronary syndrome and as an ultrafast-acting i.v. antithrombotic agent.  Cangrelor inhibits platelet aggregation with a rapid onset and offset and does not require metab. for therapeutic activity.  In ex vivo samples of blood from patients with acute coronary syndromes, cangrelor reduced platelet-leukocyte interactions, suggesting that the drug may possess addnl. disease-modifying activity.  Phase II studies have shown a good safety profile and a greater inhibitory effect on platelet aggregation compared to clopidogrel.  Results of clin. studies indicate that cangrelor may possibly inhibit the potentiation of platelet aggregation assocd. with heparin.  In comparative studies with gpIIb/IIIa receptor antagonists, cangrelor showed similar inhibitory effects on platelet aggregation responses, with a slightly more favorable impact on bleeding time.  Cangrelor has shown promising results as an adjunct to fibrinolysis with tissue-type plasminogen activator (t-PA).  Ongoing phase III trials will provide more definitive information on clin. efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9GLZ3Efd2krVg90H21EOLACvtfcHk0liawKD-13XmBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gjsbo%253D&md5=ecb66b3eee8ecb90ee659a67ae9a5cdd</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1358%2Fdof.2008.033.02.1178068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2008.033.02.1178068%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz-Ricart%26aufirst%3DM.%26aulast%3DEscolar%26aufirst%3DG.%26aulast%3DSerradell%26aufirst%3DN.%26aulast%3DRosa%26aufirst%3DE.%26aulast%3DBolos%26aufirst%3DJ.%26atitle%3DCangrelor%2520Tetrasodium%253A%2520P2Y12%2520Antagonist%2520Antiplatelet%2520Agent%26jtitle%3DDrugs%2520Future%26date%3D2008%26volume%3D33%26spage%3D101%26epage%3D110%26doi%3D10.1358%2Fdof.2008.033.02.1178068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Zhou, F.; Jin, H.; Yongyong, Z.; Huang, M.; Meng, X.</span><span> </span><span class="NLM_article-title">Preparation Method of Cangrelor Intermediate</span>. CN105481922A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+Zhou&author=H.+Jin&author=Z.+Yongyong&author=M.+Huang&author=X.+Meng&title=Preparation+Method+of+Cangrelor+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26atitle%3DPreparation%2520Method%2520of%2520Cangrelor%2520Intermediate%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Almond, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitter, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rideout, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Clair, M. H.</span><span> </span><span class="NLM_article-title">Synthesis of 2-Amino-9-(3′-azido-2′,3′-dideoxy-beta-D-erythro-pentofuranosyl)-6-methoxy-9H-purine (AzddMAP) and AzddGuo</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">5745</span><span class="NLM_x">–</span> <span class="NLM_lpage">5748</span><span class="refDoi"> DOI: 10.1016/S0040-4039(00)93545-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0040-4039%2800%2993545-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=5745-5748&author=M.+R.+Almondauthor=J.+L.+Collinsauthor=B.+E.+Reitterauthor=J.+L.+Rideoutauthor=G.+A.+Freemanauthor=M.+H.+St+Clair&title=Synthesis+of+2-Amino-9-%283%E2%80%B2-azido-2%E2%80%B2%2C3%E2%80%B2-dideoxy-beta-D-erythro-pentofuranosyl%29-6-methoxy-9H-purine+%28AzddMAP%29+and+AzddGuo&doi=10.1016%2FS0040-4039%2800%2993545-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2993545-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252993545-7%26sid%3Dliteratum%253Aachs%26aulast%3DAlmond%26aufirst%3DM.%2BR.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DReitter%26aufirst%3DB.%2BE.%26aulast%3DRideout%26aufirst%3DJ.%2BL.%26aulast%3DFreeman%26aufirst%3DG.%2BA.%26aulast%3DSt%2BClair%26aufirst%3DM.%2BH.%26atitle%3DSynthesis%2520of%25202-Amino-9-%25283%25E2%2580%25B2-azido-2%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxy-beta-D-erythro-pentofuranosyl%2529-6-methoxy-9H-purine%2520%2528AzddMAP%2529%2520and%2520AzddGuo%26jtitle%3DTetrahedron%2520Lett.%26date%3D1991%26volume%3D32%26spage%3D5745%26epage%3D5748%26doi%3D10.1016%2FS0040-4039%2800%2993545-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Yoshikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenishi, T.</span><span> </span><span class="NLM_article-title">A Novel Method for Phosphorylation of Nucleosides to 5′-Nucleotides</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">5065</span><span class="NLM_x">–</span> <span class="NLM_lpage">5068</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)89915-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0040-4039%2801%2989915-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1967&pages=5065-5068&author=M.+Yoshikawaauthor=T.+Katoauthor=T.+Takenishi&title=A+Novel+Method+for+Phosphorylation+of+Nucleosides+to+5%E2%80%B2-Nucleotides&doi=10.1016%2FS0040-4039%2801%2989915-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2989915-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252989915-9%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DTakenishi%26aufirst%3DT.%26atitle%3DA%2520Novel%2520Method%2520for%2520Phosphorylation%2520of%2520Nucleosides%2520to%25205%25E2%2580%25B2-Nucleotides%26jtitle%3DTetrahedron%2520Lett.%26date%3D1967%26volume%3D8%26spage%3D5065%26epage%3D5068%26doi%3D10.1016%2FS0040-4039%2801%2989915-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Dutta, P.; Far, A. R.; Ding, M.; Motheram, R.</span><span> </span><span class="NLM_article-title">Pharmaceutical Formulations Comprising High Purity Cangrelor and Methods for Preparing and Using the Same</span>. US 9295687B1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+Dutta&author=A.+R.+Far&author=M.+Ding&author=R.+Motheram&title=Pharmaceutical+Formulations+Comprising+High+Purity+Cangrelor+and+Methods+for+Preparing+and+Using+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DP.%26atitle%3DPharmaceutical%2520Formulations%2520Comprising%2520High%2520Purity%2520Cangrelor%2520and%2520Methods%2520for%2520Preparing%2520and%2520Using%2520the%2520Same%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span><span class="refDoi"> DOI: 10.1007/s40265-016-0544-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-016-0544-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=387-396&author=P.+L.+McCormack&title=Sacubitril%2FValsartan%3A+A+Review+in+Chronic+Heart+Failure+with+Reduced+Ejection+Fraction&doi=10.1007%2Fs40265-016-0544-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0544-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0544-9%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DSacubitril%252FValsartan%253A%2520A%2520Review%2520in%2520Chronic%2520Heart%2520Failure%2520with%2520Reduced%2520Ejection%2520Fraction%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D387%26epage%3D396%26doi%3D10.1007%2Fs40265-016-0544-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span>FDA Approves New Drug to Treat Heart Failure; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, July 7,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm</a> (accessed August 20, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+New+Drug+to+Treat+Heart+Failure%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+July+7%2C+2015%3B+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm453845.htm+%28accessed+August+20%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520New%2520Drug%2520to%2520Treat%2520Heart%2520Failure%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span>Novartis' Heart Failure Medicine Entresto Receives EU Approval; <span class="NLM_publisher-name">Novartis</span>, Nov 24,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-entrestotm-receives-eu-approval" class="extLink">https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-entrestotm-receives-eu-approval</a> (accessed August 20, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis%27+Heart+Failure+Medicine+Entresto+Receives+EU+Approval%3B+Novartis%2C+Nov+24%2C+2015%3B+https%3A%2F%2Fwww.novartis.com%2Fnews%2Fmedia-releases%2Fnovartis-heart-failure-medicine-entrestotm-receives-eu-approval+%28accessed+August+20%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNovartis%2527%2520Heart%2520Failure%2520Medicine%2520Entresto%2520Receives%2520EU%2520Approval%26pub%3DNovartis%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Prenner, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancy, C. W.</span><span> </span><span class="NLM_article-title">Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure</span> <span class="citation_source-journal">Curr. Atheroscler. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="refDoi"> DOI: 10.1007/s11883-016-0603-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs11883-016-0603-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27324636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC2s7itlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=48&author=S.+B.+Prennerauthor=S.+J.+Shahauthor=C.+W.+Yancy&title=Role+of+Angiotensin+Receptor-Neprilysin+Inhibition+in+Heart+Failure&doi=10.1007%2Fs11883-016-0603-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure</span></div><div class="casAuthors">Prenner Stuart B; Shah Sanjiv J; Yancy Clyde W</div><div class="citationInfo"><span class="NLM_cas:title">Current atherosclerosis reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">48</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Numerous evidence-based medical and device therapies proven to reduce morbidity and mortality have advanced care for heart failure with reduced ejection fraction (HFrEF).  The primacy of this approach has now been superseded by striking new data resulting in the approval of the combination of valsartan and sacubitril, a neprilysin inhibitor (also known as LCZ696), in 2015 for the treatment of HFrEF.  LCZ696 is a novel heart failure drug that simultaneously inhibits the renin-angiotensin system and potentiates the natriuretic peptide system.  RECENT FINDINGS:  In the Prospective Comparison of ARNI with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, LCZ696 significantly improved cardiovascular outcomes compared to current guideline-directed medical therapy.  Compared to an angiotensin-converting enzyme (ACE) inhibitor, LCZ696 was associated with a 20 % reduction in cardiovascular mortality (number needed to treat [NNT] 32) and a similar reduction in total mortality (NNT 36).  Morbidity benefits of the drug were seen within 1 month of initiation.  However, hypotension due to enalapril or the LCZ696 regimen during a run-in phase eliminated 20 % of patients.  Safety concerns included the risk of angioedema and the theoretical concern of neurocognitive dysfunction due to the protean effects of neprilysin inhibition.  The role of LCZ696 in patients with asymptomatic left ventricular systolic dysfunction is uncertain.  LCZ696 is currently being evaluated in patients with heart failure with preserved ejection fraction, with promising initial results.  LCZ696 represents a novel mechanistic approach to targeting heart failure with reduced ejection fraction, and ongoing studies will address its use in other cardiovascular populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbp8ONwNt92ZNiNltV31zlfW6udTcc2ea9HvcBiyuUTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7itlGkug%253D%253D&md5=46182bd70b4249e61534e58cd23eb924</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs11883-016-0603-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11883-016-0603-4%26sid%3Dliteratum%253Aachs%26aulast%3DPrenner%26aufirst%3DS.%2BB.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DYancy%26aufirst%3DC.%2BW.%26atitle%3DRole%2520of%2520Angiotensin%2520Receptor-Neprilysin%2520Inhibition%2520in%2520Heart%2520Failure%26jtitle%3DCurr.%2520Atheroscler.%2520Rep.%26date%3D2016%26volume%3D18%26spage%3D48%26doi%3D10.1007%2Fs11883-016-0603-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">McMurray, J. J.</span><span> </span><span class="NLM_article-title">Neprilysin Inhibition to Treat Heart Failure: a Tale of Science, Serendipity, and Second Chances</span> <span class="citation_source-journal">Eur. J. Heart Failure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">247</span><span class="refDoi"> DOI: 10.1002/ejhf.250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fejhf.250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25756942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFygu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=242-247&author=J.+J.+McMurray&title=Neprilysin+Inhibition+to+Treat+Heart+Failure%3A+a+Tale+of+Science%2C+Serendipity%2C+and+Second+Chances&doi=10.1002%2Fejhf.250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances</span></div><div class="casAuthors">McMurray, John J. V.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-247</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">This review describes the role of neprilysin (also known as neutral endopeptidase or enkephalinase) in the degrdn. of natriuretic and other vasoactive peptides, including bradykinin and adrenomedullin.  The initial development of neprilysin inhibitors, then angiotensin converting enzyme-neprilysin inhibitors and, most recently, the angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 (sacubitril valsartan) as an extension of the nurohumoral basis for the treatment of heart failure is also summarised.  Finally, the implications of the compelling benefits of LCZ696 compared with enalapril in the Prospective comparison of ARNI with ACEI to Det. Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5R0zzNbIQIbVg90H21EOLACvtfcHk0lihJR5AhMmMfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFygu74%253D&md5=34af6eb1dd544c0e239afad1f2b7f3d7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fejhf.250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejhf.250%26sid%3Dliteratum%253Aachs%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26atitle%3DNeprilysin%2520Inhibition%2520to%2520Treat%2520Heart%2520Failure%253A%2520a%2520Tale%2520of%2520Science%252C%2520Serendipity%252C%2520and%2520Second%2520Chances%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2015%26volume%3D17%26spage%3D242%26epage%3D247%26doi%3D10.1002%2Fejhf.250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span>Novartis' Entresto Given Strong Class I Recommendation in Both US and EU Heart Failure Guidelines, Less than a Year after Regulatory Approvals; <span class="NLM_publisher-name">Novartis</span>, May 21,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="https://www.novartis.com/news/media-releases/novartis-entrestor-given-strong-class-i-recommendation-both-us-and-eu-heart" class="extLink">https://www.novartis.com/news/media-releases/novartis-entrestor-given-strong-class-i-recommendation-both-us-and-eu-heart</a> (accessed August 20, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis%27+Entresto+Given+Strong+Class+I+Recommendation+in+Both+US+and+EU+Heart+Failure+Guidelines%2C+Less+than+a+Year+after+Regulatory+Approvals%3B+Novartis%2C+May+21%2C+2016%3B+https%3A%2F%2Fwww.novartis.com%2Fnews%2Fmedia-releases%2Fnovartis-entrestor-given-strong-class-i-recommendation-both-us-and-eu-heart+%28accessed+August+20%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNovartis%2527%2520Entresto%2520Given%2520Strong%2520Class%2520I%2520Recommendation%2520in%2520Both%2520US%2520and%2520EU%2520Heart%2520Failure%2520Guidelines%252C%2520Less%2520than%2520a%2520Year%2520after%2520Regulatory%2520Approvals%26pub%3DNovartis%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yancy, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessup, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bozkurt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, D. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colvin, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drazner, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippatos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonarow, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Givertz, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindenfeld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masoudi, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlake, C.</span><span> </span><span class="NLM_article-title">2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1476</span><span class="NLM_x">–</span> <span class="NLM_lpage">1488</span><span class="refDoi"> DOI: 10.1016/j.jacc.2016.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.jacc.2016.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27216111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FisF2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=1476-1488&author=C.+W.+Yancyauthor=M.+Jessupauthor=B.+Bozkurtauthor=J.+Butlerauthor=D.+E.+Caseyauthor=M.+M.+Colvinauthor=M.+H.+Draznerauthor=G.+Filippatosauthor=G.+C.+Fonarowauthor=M.+M.+Givertzauthor=S.+M.+Hollenbergauthor=J.+Lindenfeldauthor=F.+A.+Masoudiauthor=P.+E.+McBrideauthor=P.+N.+Petersonauthor=L.+W.+Stevensonauthor=C.+Westlake&title=2016+ACC%2FAHA%2FHFSA+Focused+Update+on+New+Pharmacological+Therapy+for+Heart+Failure%3A+An+Update+of+the+2013+ACCF%2FAHA+Guideline+for+the+Management+of+Heart+Failure%3A+A+Report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+Task+Force+on+Clinical+Practice+Guidelines+and+the+Heart+Failure+Society+of+America&doi=10.1016%2Fj.jacc.2016.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America</span></div><div class="casAuthors">Yancy Clyde W; Jessup Mariell; Bozkurt Biykem; Butler Javed; Casey Donald E Jr; Colvin Monica M; Drazner Mark H; Filippatos Gerasimos; Fonarow Gregg C; Givertz Michael M; Hollenberg Steven M; Lindenfeld JoAnn; Masoudi Frederick A; McBride Patrick E; Peterson Pamela N; Stevenson Lynne Warner; Westlake Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1476-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYB68hSi23Frt7lRqEFUJVfW6udTcc2eY-abIN0xifKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FisF2gsw%253D%253D&md5=11947ffec59c4819ae86def4c83e2fc1</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2016.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2016.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DYancy%26aufirst%3DC.%2BW.%26aulast%3DJessup%26aufirst%3DM.%26aulast%3DBozkurt%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DCasey%26aufirst%3DD.%2BE.%26aulast%3DColvin%26aufirst%3DM.%2BM.%26aulast%3DDrazner%26aufirst%3DM.%2BH.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DFonarow%26aufirst%3DG.%2BC.%26aulast%3DGivertz%26aufirst%3DM.%2BM.%26aulast%3DHollenberg%26aufirst%3DS.%2BM.%26aulast%3DLindenfeld%26aufirst%3DJ.%26aulast%3DMasoudi%26aufirst%3DF.%2BA.%26aulast%3DMcBride%26aufirst%3DP.%2BE.%26aulast%3DPeterson%26aufirst%3DP.%2BN.%26aulast%3DStevenson%26aufirst%3DL.%2BW.%26aulast%3DWestlake%26aufirst%3DC.%26atitle%3D2016%2520ACC%252FAHA%252FHFSA%2520Focused%2520Update%2520on%2520New%2520Pharmacological%2520Therapy%2520for%2520Heart%2520Failure%253A%2520An%2520Update%2520of%2520the%25202013%2520ACCF%252FAHA%2520Guideline%2520for%2520the%2520Management%2520of%2520Heart%2520Failure%253A%2520A%2520Report%2520of%2520the%2520American%2520College%2520of%2520Cardiology%252FAmerican%2520Heart%2520Association%2520Task%2520Force%2520on%2520Clinical%2520Practice%2520Guidelines%2520and%2520the%2520Heart%2520Failure%2520Society%2520of%2520America%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2016%26volume%3D68%26spage%3D1476%26epage%3D1488%26doi%3D10.1016%2Fj.jacc.2016.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hook, D.; Ruch, T.; Riss, B.; Wietfeld, B.; Sedelmeier, G.; Napp, M.; Bänziger, M.; Hawker, S.; Ciszewski, L.; Waykole, L. M.</span><span> </span><span class="NLM_article-title">Process for Preparing 5-Biphenyl-4-amino-2-methyl pentanoic Acid</span>. WO 2008083967A2,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+Hook&author=T.+Ruch&author=B.+Riss&author=B.+Wietfeld&author=G.+Sedelmeier&author=M.+Napp&author=M.+B%C3%A4nziger&author=S.+Hawker&author=L.+Ciszewski&author=L.+M.+Waykole&title=Process+for+Preparing+5-Biphenyl-4-amino-2-methyl+pentanoic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DProcess%2520for%2520Preparing%25205-Biphenyl-4-amino-2-methyl%2520pentanoic%2520Acid%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hook, D.; Zhou, J.; Li, Y.; Ku, J.</span><span> </span><span class="NLM_article-title">Intermediates of Neutral Endopeptidase Inhibitors and Preparation Method Thereof</span>. WO 2011088797A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+Hook&author=J.+Zhou&author=Y.+Li&author=J.+Ku&title=Intermediates+of+Neutral+Endopeptidase+Inhibitors+and+Preparation+Method+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DIntermediates%2520of%2520Neutral%2520Endopeptidase%2520Inhibitors%2520and%2520Preparation%2520Method%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hook, D.; Zhou, J.; Li, Y.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Intermediates for the Manufacture of Nep Inhibitors</span>. WO 2012025501A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Hook&author=J.+Zhou&author=Y.+Li&title=Process+for+the+Preparation+of+Intermediates+for+the+Manufacture+of+Nep+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Intermediates%2520for%2520the%2520Manufacture%2520of%2520Nep%2520Inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hook, D.; Riss, B.; Zhou, J.; Li, Y.; Bappert, E.</span><span> </span><span class="NLM_article-title">New Process for the Preparation of Intermediates Useful for the Manufacture Nep Inhibitors</span>. WO 2012025502A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Hook&author=B.+Riss&author=J.+Zhou&author=Y.+Li&author=E.+Bappert&title=New+Process+for+the+Preparation+of+Intermediates+Useful+for+the+Manufacture+Nep+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DNew%2520Process%2520for%2520the%2520Preparation%2520of%2520Intermediates%2520Useful%2520for%2520the%2520Manufacture%2520Nep%2520Inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Zhu, G.; Ye, W.; Zheng, H.; Qian, L.; Wei, J.; Yang, L.; LI, Y.; Luo, L.</span><span> </span><span class="NLM_article-title">New Process</span>. WO 2014032627A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=G.+Zhu&author=W.+Ye&author=H.+Zheng&author=L.+Qian&author=J.+Wei&author=L.+Yang&author=Y.+LI&author=L.+Luo&title=New+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DNew%2520Process%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Hook, D.; Wietfeld, B.; Lotz, M.</span><span> </span><span class="NLM_article-title">Process for Preparing Biaryl Substituted 4-Amino-butyric Acid or Derivatives Thereof and Their Use in the Production of Nep Inhibitors</span>. WO 2008031567A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+Hook&author=B.+Wietfeld&author=M.+Lotz&title=Process+for+Preparing+Biaryl+Substituted+4-Amino-butyric+Acid+or+Derivatives+Thereof+and+Their+Use+in+the+Production+of+Nep+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DProcess%2520for%2520Preparing%2520Biaryl%2520Substituted%25204-Amino-butyric%2520Acid%2520or%2520Derivatives%2520Thereof%2520and%2520Their%2520Use%2520in%2520the%2520Production%2520of%2520Nep%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Ksander, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghai, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deJesus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diefenbacher, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakane, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapani, A.</span><span> </span><span class="NLM_article-title">Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1700</span><span class="refDoi"> DOI: 10.1021/jm00010a014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00010a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADyaK2MXltlyktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1689-1700&author=G.+M.+Ksanderauthor=R.+D.+Ghaiauthor=R.+deJesusauthor=C.+G.+Diefenbacherauthor=A.+Yuanauthor=C.+Berryauthor=Y.+Sakaneauthor=A.+Trapani&title=Dicarboxylic+Acid+Dipeptide+Neutral+Endopeptidase+Inhibitors&doi=10.1021%2Fjm00010a014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23gR"><div class="casContent"><span class="casTitleNuber">23g</span><div class="casTitle"><span class="NLM_cas:atitle">Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors</span></div><div class="casAuthors">Ksander, Gary M.; Ghai, Raj D.; deJesus, Reynalda; Diefenbacher, Clive; Yuan, Andrew; Berry, Carol; Sakane, Yumi; Trapani, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1689-700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of three series of dicarboxylic acid dipeptide neutral endopeptidase 24.11 (NEP) inhibitors is described.  In particular, the amino butyramide I exhibited potent NEP inhibitory activity (IC50 = 5.0 nM) in vitro and in vivo.  Blood levels of I were detd. using an ex vivo method by measuring plasma inhibitory activity in conscious rats, mongrel dogs, and cynomolgus monkeys.  Free drug concns. were 10-1500 times greater than the inhibitory const. for NEP over the course of a 6 h expt.  A good correlation of free drug concns. was obtained when comparing values detd. by the ex vivo anal. to those calcd. from direct HPLC measurements.  Plasma atrial natriuretic factor (exogenous) levels were elevated in rats and dogs after oral administration of II.  Urinary vol. and urinary sodium excretion were also potentiated in anesthetized dogs treated with I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfdx8WNNtF-rVg90H21EOLACvtfcHk0lh-OHBYGkyS_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltlyktbY%253D&md5=6eb89f1f3ba783d4448d3558027cda82</span></div><a href="/servlet/linkout?suffix=cit23g&amp;dbid=16384&amp;doi=10.1021%2Fjm00010a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00010a014%26sid%3Dliteratum%253Aachs%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3DGhai%26aufirst%3DR.%2BD.%26aulast%3DdeJesus%26aufirst%3DR.%26aulast%3DDiefenbacher%26aufirst%3DC.%2BG.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DBerry%26aufirst%3DC.%26aulast%3DSakane%26aufirst%3DY.%26aulast%3DTrapani%26aufirst%3DA.%26atitle%3DDicarboxylic%2520Acid%2520Dipeptide%2520Neutral%2520Endopeptidase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1689%26epage%3D1700%26doi%3D10.1021%2Fjm00010a014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Ksander, G.</span><span> </span><span class="NLM_article-title">Biaryl Substituted 4-Amino-butyric Acid Amides</span>. US 5217996A,<span class="NLM_x"> </span><span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=G.+Ksander&title=Biaryl+Substituted+4-Amino-butyric+Acid+Amides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKsander%26aufirst%3DG.%26atitle%3DBiaryl%2520Substituted%25204-Amino-butyric%2520Acid%2520Amides%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Halama, A.; Zvatora, P.; Dammer, O.; Stach, J.; Zapadlo, M.; Krejcik, L.; Voslar, M.</span><span> </span><span class="NLM_article-title">A Method for the Preparation, Isolation and Purification of Pharmaceutically Applicable Forms of Ahu-377</span>. WO 2016074651A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=A.+Halama&author=P.+Zvatora&author=O.+Dammer&author=J.+Stach&author=M.+Zapadlo&author=L.+Krejcik&author=M.+Voslar&title=A+Method+for+the+Preparation%2C+Isolation+and+Purification+of+Pharmaceutically+Applicable+Forms+of+Ahu-377"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23i&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHalama%26aufirst%3DA.%26atitle%3DA%2520Method%2520for%2520the%2520Preparation%252C%2520Isolation%2520and%2520Purification%2520of%2520Pharmaceutically%2520Applicable%2520Forms%2520of%2520Ahu-377%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Feng, L.; Godtfredsen, S. E.; Karpinski, P.; Sutton, P. A.; Prashad, M.; Girgis, M. J.; Hu, B.; Liu, Y.; Blacklock, T. J.</span><span> </span><span class="NLM_article-title">Pharmaceutical Combinations of an Angiotensin Receptor Antagonist and an Nep Inhibitor</span>. WO 2007056546A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+Feng&author=S.+E.+Godtfredsen&author=P.+Karpinski&author=P.+A.+Sutton&author=M.+Prashad&author=M.+J.+Girgis&author=B.+Hu&author=Y.+Liu&author=T.+J.+Blacklock&title=Pharmaceutical+Combinations+of+an+Angiotensin+Receptor+Antagonist+and+an+Nep+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DL.%26atitle%3DPharmaceutical%2520Combinations%2520of%2520an%2520Angiotensin%2520Receptor%2520Antagonist%2520and%2520an%2520Nep%2520Inhibitor%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7128</span><span class="NLM_x">–</span> <span class="NLM_lpage">7137</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00698</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00698" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOjurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7128-7137&author=T.+Asakiauthor=K.+Kuwanoauthor=K.+Morrisonauthor=J.+Gatfieldauthor=T.+Hamamotoauthor=M.+Clozel&title=Selexipag%3A+An+Oral+and+Selective+IP+Prostacyclin+Receptor+Agonist+for+the+Treatment+of+Pulmonary+Arterial+Hypertension&doi=10.1021%2Facs.jmedchem.5b00698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Asaki, Tetsuo; Kuwano, Keiichi; Morrison, Keith; Gatfield, John; Hamamoto, Taisuke; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7128-7137</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor.  Decreased prostacyclin prodn. occurs in several cardiovascular diseases.  However, the clin. use of prostacyclin and its analogs is complicated by their chem. and metabolic instability.  A medicinal chem. program searched for novel nonprostanoid prostacyclin receptor agonists not subject to these limitations.  A compd. with a diphenylpyrazine structural core was synthesized.  Metabolic stability and agonist potency were optimized through modification of the linear side chain.  Compd. 12b (MRE-269, ACT-333679) was identified as a potent and highly selective prostacyclin receptor agonist.  Replacement of the terminal carboxyl group with an N-acylsulfonamide group yielded parent compd. 26a (selexipag, NS-304, ACT-293987), which is orally active and provides sustained plasma exposure of 12b.  Compd. 26a was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouZjQo25LkGrVg90H21EOLACvtfcHk0liyrs7pirJBJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOjurzO&md5=4b09d302b4852c75be29c94578483d8d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00698%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DSelexipag%253A%2520An%2520Oral%2520and%2520Selective%2520IP%2520Prostacyclin%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7128%26epage%3D7137%26doi%3D10.1021%2Facs.jmedchem.5b00698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Skoro-Sajer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, I. M.</span><span> </span><span class="NLM_article-title">Selexipag for the Treatment of Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span><span class="refDoi"> DOI: 10.1517/14656566.2014.876007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14656566.2014.876007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24392948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=429-436&author=N.+Skoro-Sajerauthor=I.+M.+Lang&title=Selexipag+for+the+Treatment+of+Pulmonary+Arterial+Hypertension&doi=10.1517%2F14656566.2014.876007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">For the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Skoro-Sajer, Nika; Lang, Irene Marthe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-436</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: is a first-in-class orally available selective non-prostanoid IP receptor agonist.  This review was based on a PubMed search and focuses on the potential role of selexipag in the treatment of pulmonary arterial hypertension (PAH).  Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679.  Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors.  This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.  In addn., the selexipag metabolite has a half-life of 7.9 h, thus permitting oral dosing twice daily.  Selexipag showed effects on pharmacodynamic end points obtained with right heart catheterization in a Phase II trial in patients with PAH, and is being evaluated in the ongoing Phase III trial (GRIPHON trial, Clinicaltrials.gov NCT01106014).  Expert opinion: The signal of a beneficial effect of selexipag on disease progression may become more robust for long term under prolonged exposure.  Pending the GRIPHON trial results, selexipag could provide a convenient first-line prostacyclin treatment option for patients with PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFroy7uy1YmLVg90H21EOLACvtfcHk0liyrs7pirJBJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygtro%253D&md5=195fc1b70201dd8388bfc53dd59692fa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1517%2F14656566.2014.876007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2014.876007%26sid%3Dliteratum%253Aachs%26aulast%3DSkoro-Sajer%26aufirst%3DN.%26aulast%3DLang%26aufirst%3DI.%2BM.%26atitle%3DSelexipag%2520for%2520the%2520Treatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2014%26volume%3D15%26spage%3D429%26epage%3D436%26doi%3D10.1517%2F14656566.2014.876007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Karmas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerri, P. E.</span><span> </span><span class="NLM_article-title">The Preparation of Hydroxypyrazines and Derived Chloropyrazines</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1952</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1580</span><span class="NLM_x">–</span> <span class="NLM_lpage">1584</span><span class="refDoi"> DOI: 10.1021/ja01126a070</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01126a070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1952&pages=1580-1584&author=G.+Karmasauthor=P.+E.+Spoerri&title=The+Preparation+of+Hydroxypyrazines+and+Derived+Chloropyrazines&doi=10.1021%2Fja01126a070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fja01126a070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01126a070%26sid%3Dliteratum%253Aachs%26aulast%3DKarmas%26aufirst%3DG.%26aulast%3DSpoerri%26aufirst%3DP.%2BE.%26atitle%3DThe%2520Preparation%2520of%2520Hydroxypyrazines%2520and%2520Derived%2520Chloropyrazines%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1952%26volume%3D74%26spage%3D1580%26epage%3D1584%26doi%3D10.1021%2Fja01126a070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwabara, K.</span><span> </span><span class="NLM_article-title">Structure-activity Studies on Diphenylpyrazine Derivatives: a Novel Class of Prostacyclin Receptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6692</span><span class="NLM_x">–</span> <span class="NLM_lpage">6704</span><span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2007.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=17764960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCisbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=6692-6704&author=T.+Asakiauthor=T.+Hamamotoauthor=Y.+Sugiyamaauthor=K.+Kuwanoauthor=K.+Kuwabara&title=Structure-activity+Studies+on+Diphenylpyrazine+Derivatives%3A+a+Novel+Class+of+Prostacyclin+Receptor+Agonists&doi=10.1016%2Fj.bmc.2007.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists</span></div><div class="casAuthors">Asaki, Tetsuo; Hamamoto, Taisuke; Sugiyama, Yukiteru; Kuwano, Keiichi; Kuwabara, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6692-6704</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To develop nonprostanoid prostacyclin receptor agonists with a high degree of metabolic resistance and an extended duration of action, a novel series of diphenylpyrazine derivs. was synthesized and evaluated for their inhibition of ADP-induced human platelet aggregation.  Structure-activity relationship studies on the side chain contg. the carboxylic acid moiety of the lead compd. (I) showed that the length of the linker and the presence of the concatenating nitrogen atom adjacent to the pyrazine ring are crit. for the antiaggregatory activity.  This study led to the discovery of 2-amino-5,6-diphenylpyrazine derivs. (II, III, and IV), which showed potent inhibition of platelet aggregation with IC50 values of 0.2 μM.  Among these compds., IV is an orally available and long-lasting prostacyclin receptor agonist which is promising for the treatment of various vascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQelakXM9KLVg90H21EOLACvtfcHk0liHoGP8I5U1kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCisbfL&md5=e6abc169bee888ab0a33576a84eed962</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DKuwabara%26aufirst%3DK.%26atitle%3DStructure-activity%2520Studies%2520on%2520Diphenylpyrazine%2520Derivatives%253A%2520a%2520Novel%2520Class%2520of%2520Prostacyclin%2520Receptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D6692%26epage%3D6704%26doi%3D10.1016%2Fj.bmc.2007.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Aggarwal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopalakrishna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauriello, J.</span><span> </span><span class="NLM_article-title">Aripiprazole Lauroxil Long-acting Injectable: the Latest Addition to Second-generation Long-acting Agents</span> <span class="citation_source-journal">Clin. Schizophr. Relat. Psychoses.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.3371/csrp.AGGA.040316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.3371%2Fcsrp.AGGA.040316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27074333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28fpvVKhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=58-63&author=A.+Aggarwalauthor=G.+Gopalakrishnaauthor=J.+Lauriello&title=Aripiprazole+Lauroxil+Long-acting+Injectable%3A+the+Latest+Addition+to+Second-generation+Long-acting+Agents&doi=10.3371%2Fcsrp.AGGA.040316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents</span></div><div class="casAuthors">Aggarwal Arpit; Gopalakrishna Ganesh; Lauriello John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical schizophrenia & related psychoses</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-63</span>
        ISSN:<span class="NLM_cas:issn">1935-1232</span>.
    </div><div class="casAbstract">Antipsychotics have long been the mainstay for the treatment of schizophrenia and other psychotic disorders.  Long-acting injectables (LAI) of antipsychotics-provided once every two weeks to once every three months-promise to reduce the incidence of nonadherence.  ARISTADA(®) (aripiprazole lauroxil; ALLAI) extended-release injectable suspension was approved by the U.S.  Food and Drug Administration in October 2015 for the treatment of schizophrenia, and is the newest entrant in the LAI market.  ALLAI is available as a single-use, pre-filled syringe, can be started in three different dosages, and also has the option of every six-week dosing.  Treatment with oral aripiprazole is recommended for the first twenty-one days after the first ALLAI injection, which is a potential disadvantage.  Adverse effects include sensitivity to extrapyramidal symptoms, especially akathisia, which is well documented in other aripiprazole preparations.  There is no available data comparing ALLAI to other antipsychotics, and more head-to-head trials comparing different LAI formulations are needed.  Based on the available data, ALLAI is an effective and safe option for treatment of schizophrenia.  Further studies and post-marketing data will provide better understanding of this formulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzQJin4VT_ZpZoeNcnHOQ9fW6udTcc2eZ8bVzZOhomubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fpvVKhtg%253D%253D&md5=68cc1a216790ba91d6fd651f36f8c48d</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.3371%2Fcsrp.AGGA.040316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3371%252Fcsrp.AGGA.040316%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DA.%26aulast%3DGopalakrishna%26aufirst%3DG.%26aulast%3DLauriello%26aufirst%3DJ.%26atitle%3DAripiprazole%2520Lauroxil%2520Long-acting%2520Injectable%253A%2520the%2520Latest%2520Addition%2520to%2520Second-generation%2520Long-acting%2520Agents%26jtitle%3DClin.%2520Schizophr.%2520Relat.%2520Psychoses.%26date%3D2016%26volume%3D10%26spage%3D58%26epage%3D63%26doi%3D10.3371%2Fcsrp.AGGA.040316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasrallah, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zummo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stankovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrich, E. W.</span><span> </span><span class="NLM_article-title">A Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">–</span> <span class="NLM_lpage">1090</span><span class="refDoi"> DOI: 10.4088/JCP.14m09741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.4088%2FJCP.14m09741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbnt1Oqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=1085-1090&author=H.+Y.+Meltzerauthor=R.+Risingerauthor=H.+A.+Nasrallahauthor=Y.+Duauthor=J.+Zummoauthor=L.+Coreyauthor=A.+Boseauthor=S.+Stankovicauthor=B.+L.+Silvermanauthor=E.+W.+Ehrich&title=A+Randomized%2C+Double-blind%2C+Placebo-controlled+Trial+of+Aripiprazole+Lauroxil+in+Acute+Exacerbation+of+Schizophrenia&doi=10.4088%2FJCP.14m09741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia</span></div><div class="casAuthors">Meltzer Herbert Y; Risinger Robert; Nasrallah Henry A; Du Yangchun; Zummo Jacqueline; Corey Lisa; Bose Anjana; Stankovic Srdjan; Silverman Bernard L; Ehrich Elliot W</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1085-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study evaluated the efficacy, safety, and tolerability of aripiprazole lauroxil, a novel long-acting injectable atypical antipsychotic, for the treatment of schizophrenia.  METHOD:  An international multicenter, randomized, double-blind, placebo-controlled trial was conducted between December 2011 and March 2014.  Patients (N = 623) aged 18 to 70 years with schizophrenia (DSM-IV-TR criteria), experiencing an acute exacerbation, were randomized in a 1:1:1 ratio to receive gluteal intramuscular injection of aripiprazole lauroxil 441 mg, aripiprazole lauroxil 882 mg, or matching placebo once monthly for 12 weeks.  The primary efficacy outcome was change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to day 85.  The Clinical Global Impressions-Improvement scale (CGI-I) score at day 85 was the secondary efficacy outcome.  Safety and tolerability were assessed.  RESULTS:  The PANSS total score (mean ± standard error [SE]) improved significantly from baseline to day 85 in the aripiprazole lauroxil 441 mg and 882 mg groups, with placebo-adjusted differences of -10.9 ± 1.8 (P < .001) and -11.9 ± 1.8 (P < .001), respectively.  Significant (P ≤ .004) improvements in both active treatment groups were demonstrated as early as day 8 and continued throughout the treatment period.  The proportion of patients who were very much or much improved on the CGI-I was significantly greater with aripiprazole lauroxil 441 mg and 882 mg treatment versus placebo (P < .001).  The most common treatment-emergent adverse events were insomnia, akathisia, headache, and anxiety.  The incidence of injection site reactions was low, predominantly described as injection site pain, and was associated with the first injection.  CONCLUSIONS:  Aripiprazole lauroxil demonstrated robust efficacy for treatment of patients experiencing acute exacerbation of schizophrenia.  The improvement in psychotic symptoms was statistically significant and clinically meaningful.  Symptom improvement occurred rapidly after initiation of aripiprazole lauroxil treatment and was maintained throughout the study.  Both aripiprazole lauroxil 441 mg and 882 mg doses were well tolerated.  These results support aripiprazole lauroxil as an important new treatment option for schizophrenia.  TRIAL REGISTRATION:  ClinicalTrials.gov identifier: NCT01469039; Clinicaltrialsregister.eu identifier: 2012-003445-15.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBDudtqhw_bgvupmecNw_lfW6udTcc2eZ8bVzZOhomubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbnt1Oqug%253D%253D&md5=5f9bee56ad2a236490e2e4641c9c01e3</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.4088%2FJCP.14m09741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.14m09741%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRisinger%26aufirst%3DR.%26aulast%3DNasrallah%26aufirst%3DH.%2BA.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DZummo%26aufirst%3DJ.%26aulast%3DCorey%26aufirst%3DL.%26aulast%3DBose%26aufirst%3DA.%26aulast%3DStankovic%26aufirst%3DS.%26aulast%3DSilverman%26aufirst%3DB.%2BL.%26aulast%3DEhrich%26aufirst%3DE.%2BW.%26atitle%3DA%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%2520Trial%2520of%2520Aripiprazole%2520Lauroxil%2520in%2520Acute%2520Exacerbation%2520of%2520Schizophrenia%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2015%26volume%3D76%26spage%3D1085%26epage%3D1090%26doi%3D10.4088%2FJCP.14m09741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Remenar, J. F.; Blumberg, L. C.; Zeidan, T. A.</span><span> </span><span class="NLM_article-title">Lactam Derivatives as Prodrugs for the Treatment of Neurological and Psychiatric Disorders, Their Preparation and Drug Delivery Systems</span>. WO 2010151689A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+F.+Remenar&author=L.+C.+Blumberg&author=T.+A.+Zeidan&title=Lactam+Derivatives+as+Prodrugs+for+the+Treatment+of+Neurological+and+Psychiatric+Disorders%2C+Their+Preparation+and+Drug+Delivery+Systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRemenar%26aufirst%3DJ.%2BF.%26atitle%3DLactam%2520Derivatives%2520as%2520Prodrugs%2520for%2520the%2520Treatment%2520of%2520Neurological%2520and%2520Psychiatric%2520Disorders%252C%2520Their%2520Preparation%2520and%2520Drug%2520Delivery%2520Systems%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Weisler, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuneyoshi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. V.</span><span> </span><span class="NLM_article-title">Brexpiprazole as An Adjunctive Treatment in Young Adults with Major Depressive Disorder Who Are in a School or Work Environment</span> <span class="citation_source-journal">J. Affective Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1016/j.jad.2016.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.jad.2016.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27322768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtValtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2016&pages=40-47&author=R.+H.+Weislerauthor=A.+Otaauthor=K.+Tsuneyoshiauthor=P.+Perryauthor=E.+Weillerauthor=R.+A.+Bakerauthor=D.+V.+Sheehan&title=Brexpiprazole+as+An+Adjunctive+Treatment+in+Young+Adults+with+Major+Depressive+Disorder+Who+Are+in+a+School+or+Work+Environment&doi=10.1016%2Fj.jad.2016.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment</span></div><div class="casAuthors">Weisler, Richard H.; Ota, Ai; Tsuneyoshi, Kana; Perry, Pamela; Weiller, Emmanuelle; Baker, Ross A.; Sheehan, David V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-47</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Major depressive disorder (MDD) is a common, debilitating disorder with substantial socioeconomic burden.  Many patients with MDD experience symptoms that impair functioning and productivity, often neg. affecting work or educational pursuits.  This Phase 3b open-label study evaluated adjunctive brexpiprazole in young adults with MDD, who were in work or study.  Young patients (18-35 years) with MDD (inadequate responders to 1-3 antidepressant treatments [ADT] for their current episode) received brexpiprazole 1-3 mg/day (target dose, 2 mg/day) adjunctive to the same stable dose of ADT for 12 wk.  Depressive symptoms improved during treatment with adjunctive brexpiprazole (primary endpoint, least squares [LS] mean change from baseline in Montgomery-Åsberg Depression Rating Scale [MADRS] total score, -18.1 [p<0.0001]).  Redns. from baseline in Sheehan Disability Scale Score (SDS; LS mean change -11.2 [p<0.0001]) and Work Limitations Questionnaire (WLQ; p<0.0001) indicated improvements in the effects of patients' symptoms on functioning (work/school, social life, and home responsibilities).  Changes from baseline in addnl. measures supported improvements in patient functioning and depression symptoms.  The most common adverse events were headache (21.3%), wt. increase (17.0%), and somnolence (17.0%); reported rates of akathisia were low (6.4%).  Clin. relevant increases in wt. (≥7%) occurred in 10.5% of patients.  Open-label design; absence of comparator.  Brexpiprazole may represent an effective therapy for adjunctive treatment strategy of young adults with MDD who are working or studying.  The obsd. improvements in work/school functioning in patients with MDD, whose depression was treated with ADT+brexpiprazole, suggests potential to reduce socioeconomic burden.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4AoTUSQx5PbVg90H21EOLACvtfcHk0liexFKkye6LwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtValtLbP&md5=5bf5112974010254c1a4eca1bf3214b1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2016.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2016.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DWeisler%26aufirst%3DR.%2BH.%26aulast%3DOta%26aufirst%3DA.%26aulast%3DTsuneyoshi%26aufirst%3DK.%26aulast%3DPerry%26aufirst%3DP.%26aulast%3DWeiller%26aufirst%3DE.%26aulast%3DBaker%26aufirst%3DR.%2BA.%26aulast%3DSheehan%26aufirst%3DD.%2BV.%26atitle%3DBrexpiprazole%2520as%2520An%2520Adjunctive%2520Treatment%2520in%2520Young%2520Adults%2520with%2520Major%2520Depressive%2520Disorder%2520Who%2520Are%2520in%2520a%2520School%2520or%2520Work%2520Environment%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2016%26volume%3D204%26spage%3D40%26epage%3D47%26doi%3D10.1016%2Fj.jad.2016.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuade, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mork, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pehrson, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentzer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundgaard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensbol, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span> </span><span class="NLM_article-title">Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span><span class="refDoi"> DOI: 10.1124/jpet.114.213793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1124%2Fjpet.114.213793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24947465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1artLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2014&pages=589-604&author=K.+Maedaauthor=H.+Suginoauthor=H.+Akazawaauthor=N.+Amadaauthor=J.+Shimadaauthor=T.+Futamuraauthor=H.+Yamashitaauthor=N.+Itoauthor=R.+D.+McQuadeauthor=A.+Morkauthor=A.+L.+Pehrsonauthor=M.+Hentzerauthor=V.+Nielsenauthor=C.+Bundgaardauthor=J.+Arntauthor=T.+B.+Stensbolauthor=T.+Kikuchi&title=Brexpiprazole+I%3A+In+Vitro+and+In+Vivo+Characterization+of+a+Novel+Serotonin-Dopamine+Activity+Modulator&doi=10.1124%2Fjpet.114.213793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator</span></div><div class="casAuthors">Maeda, Kenji; Sugino, Haruhiko; Akazawa, Hitomi; Amada, Naoki; Shimada, Jun; Futamura, Takashi; Yamashita, Hiroshi; Ito, Nobuaki; McQuade, Robert D.; Moerk, Arne; Pehrson, Alan L.; Hentzer, Morten; Nielsen, Vibeke; Bundgaard, Christoffer; Arnt, Joern; Stensboel, Tine Bryan; Kikuchi, Tetsuro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">589-604, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clin. development for psychiatric disorders with high affinity for serotonin, dopamine, and noradrenaline receptors.  In particular, it bound with high affinity (Ki < 1 nM) to human serotonin 1A (h5-HT1A)-, h5-HT2A-, long form of human D2(hD2L)-, hα1B-, and hα2C-adrenergic receptors.  It displayed partial agonism at h5-HT1A and hD2 receptors in cloned receptor systems and potent antagonism of h5-HT2A receptors and hα1B/2C-adrenoceptors.  Brexpiprazole also had affinity (Ki < 5 nM) for hD3-, h5-HT2B-, h5-HT7-, hα1A-, and hα1D-adrenergic receptors, moderate affinity for hH1 (Ki = 19 nM), and low affinity for hM1 receptors (K1 > 1000 nM).  Brexpiprazole potently bound to rat 5-HT2A and D2 receptors in vivo, and ex vivo binding studies further confirmed high 5-HT1A receptor binding potency.  Brexpiprazole inhibited DOI (2,5-dimethoxy-4-iodoamphetamine)-induced head twitches in rats, suggestive of 5-HT2A antagonism.  Furthermore, in vivo D2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats.  In rat microdialysis studies, brexpiprazole slightly reduced extracellular dopamine in nucleus accumbens but not in prefrontal cortex, whereas moderate increases of the dopamine metabolites, homovanillic acid and DOPAC (3,4-dihydroxy-phenyl-acetic acid), in these areas also suggested in vivo D2 partial agonist activity.  In particular, based on a lower intrinsic activity at D2 receptors and higher binding affinities for 5-HT1A/2A receptors than aripiprazole, brexpiprazole would have a favorable antipsychotic potential without D2 receptor agonist- and antagonist-related adverse effects.  In conclusion, brexpiprazole is a serotonin-dopamine activity modulator with a unique pharmacol., which may offer novel treatment options across a broad spectrum of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOd8uBhM0Ua7Vg90H21EOLACvtfcHk0liexFKkye6LwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1artLrI&md5=9e0436e35bbb10762bc42b3552a33341</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.213793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.213793%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSugino%26aufirst%3DH.%26aulast%3DAkazawa%26aufirst%3DH.%26aulast%3DAmada%26aufirst%3DN.%26aulast%3DShimada%26aufirst%3DJ.%26aulast%3DFutamura%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DMcQuade%26aufirst%3DR.%2BD.%26aulast%3DMork%26aufirst%3DA.%26aulast%3DPehrson%26aufirst%3DA.%2BL.%26aulast%3DHentzer%26aufirst%3DM.%26aulast%3DNielsen%26aufirst%3DV.%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DArnt%26aufirst%3DJ.%26aulast%3DStensbol%26aufirst%3DT.%2BB.%26aulast%3DKikuchi%26aufirst%3DT.%26atitle%3DBrexpiprazole%2520I%253A%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Characterization%2520of%2520a%2520Novel%2520Serotonin-Dopamine%2520Activity%2520Modulator%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D350%26spage%3D589%26epage%3D604%26doi%3D10.1124%2Fjpet.114.213793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Citrome, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensboel, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span> </span><span class="NLM_article-title">The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1229</span><span class="refDoi"> DOI: 10.1586/14737175.2015.1086269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1586%2F14737175.2015.1086269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26402059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGisLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1219-1229&author=L.+Citromeauthor=T.+B.+Stensboelauthor=K.+Maeda&title=The+preclinical+profile+of+brexpiprazole%3A+what+is+its+clinical+relevance+for+the+treatment+of+psychiatric+disorders%3F&doi=10.1586%2F14737175.2015.1086269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?</span></div><div class="casAuthors">Citrome, Leslie; Stensboel, Tine Bryan; Maeda, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1219-1229</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Brexpiprazole is a serotonin-dopamine activity modulator in clin. development for schizophrenia, adjunctive treatment of major depressive disorder, agitation in Alzheimer's disease and post-traumatic stress disorder.  It is a partial agonist at 5-HT1A and D2 receptors with similar potency, and an antagonist at 5-HT2A and adrenergic α1B/2C receptors.  Compared with aripiprazole, brexpiprazole is more potent at 5-HT1A receptors and displays less intrinsic activity at D2 receptors.  This unique serotonin and dopamine modulatory activity has shown robust antipsychotic, antidepressant-like and anxiolytic activities, and limited extrapyramidal symptom liability with pro-cognitive efficacy in animal models.  Phase III clin. trials have been successfully completed in schizophrenia and adjunctive use in major depressive disorder, with the US FDA approval obtained for these uses; Phase III studies in Alzheimer's disease and post-traumatic stress disorder are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr62dpR7QlGNrVg90H21EOLACvtfcHk0liexFKkye6LwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGisLvE&md5=7b83282ea1e4e757532bda70188ec15d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1586%2F14737175.2015.1086269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2015.1086269%26sid%3Dliteratum%253Aachs%26aulast%3DCitrome%26aufirst%3DL.%26aulast%3DStensboel%26aufirst%3DT.%2BB.%26aulast%3DMaeda%26aufirst%3DK.%26atitle%3DThe%2520preclinical%2520profile%2520of%2520brexpiprazole%253A%2520what%2520is%2520its%2520clinical%2520relevance%2520for%2520the%2520treatment%2520of%2520psychiatric%2520disorders%253F%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2015%26volume%3D15%26spage%3D1219%26epage%3D1229%26doi%3D10.1586%2F14737175.2015.1086269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Yamashita, H.; Sato, T.; Minowa, T.; Hoshika, Y.; Toyofuku, H.; Yamaguchi, T.; Sota, M.; Kawano, S.; Nakamura, T.; Eto, R.</span><span> </span><span class="NLM_article-title">Dihydrate of Benzothiophene Compound or of a Salt Thereof, and Process for Producing the Same</span>. WO 2013162046A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Yamashita&author=T.+Sato&author=T.+Minowa&author=Y.+Hoshika&author=H.+Toyofuku&author=T.+Yamaguchi&author=M.+Sota&author=S.+Kawano&author=T.+Nakamura&author=R.+Eto&title=Dihydrate+of+Benzothiophene+Compound+or+of+a+Salt+Thereof%2C+and+Process+for+Producing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DH.%26atitle%3DDihydrate%2520of%2520Benzothiophene%2520Compound%2520or%2520of%2520a%2520Salt%2520Thereof%252C%2520and%2520Process%2520for%2520Producing%2520the%2520Same%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span> </span><span class="NLM_article-title">An Improved Synthesis of 4-(1-Piperazinyl)benzo[b]thiophene Dihydrochloride</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">–</span> <span class="NLM_lpage">558</span><span class="refDoi"> DOI: 10.1021/acs.oprd.5b00027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=555-558&author=C.+Wuauthor=W.+Chenauthor=D.+Jiangauthor=X.+Jiangauthor=J.+Shen&title=An+Improved+Synthesis+of+4-%281-Piperazinyl%29benzo%5Bb%5Dthiophene+Dihydrochloride&doi=10.1021%2Facs.oprd.5b00027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00027%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DAn%2520Improved%2520Synthesis%2520of%25204-%25281-Piperazinyl%2529benzo%255Bb%255Dthiophene%2520Dihydrochloride%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D555%26epage%3D558%26doi%3D10.1021%2Facs.oprd.5b00027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Goossen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manjolinho, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, N.</span><span> </span><span class="NLM_article-title">Microwave-assisted Cu-catalyzed Protodecarboxylation of Aromatic Carboxylic Acids</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2620</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span><span class="refDoi"> DOI: 10.1021/jo802628z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo802628z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVKrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=2620-2623&author=L.+J.+Goossenauthor=F.+Manjolinhoauthor=B.+A.+Khanauthor=N.+Rodriguez&title=Microwave-assisted+Cu-catalyzed+Protodecarboxylation+of+Aromatic+Carboxylic+Acids&doi=10.1021%2Fjo802628z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave-Assisted Cu-Catalyzed Protodecarboxylation of Aromatic Carboxylic Acids</span></div><div class="casAuthors">Goossen, Lukas J.; Manjolinho, Filipe; Khan, Bilal A.; Rodriguez, Nuria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2620-2623</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An effective protocol has been developed that allows the smooth protodecarboxylation of diversely functionalized arom. carboxylic acids within 5-15 min.  In the presence of at most 5 mol % of an inexpensive catalyst generated in situ from copper(I) oxide and 1,10-phenanthroline, even nonactivated benzoates were converted in high yields and with great preparative ease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2qwnbnNrFyrVg90H21EOLACvtfcHk0li9LMFl0rrD0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVKrurc%253D&md5=cc6cd095378d6972aeaebae14c4a0048</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo802628z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo802628z%26sid%3Dliteratum%253Aachs%26aulast%3DGoossen%26aufirst%3DL.%2BJ.%26aulast%3DManjolinho%26aufirst%3DF.%26aulast%3DKhan%26aufirst%3DB.%2BA.%26aulast%3DRodriguez%26aufirst%3DN.%26atitle%3DMicrowave-assisted%2520Cu-catalyzed%2520Protodecarboxylation%2520of%2520Aromatic%2520Carboxylic%2520Acids%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2009%26volume%3D74%26spage%3D2620%26epage%3D2623%26doi%3D10.1021%2Fjo802628z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Cariprazine: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">2035</span><span class="NLM_x">–</span> <span class="NLM_lpage">2043</span><span class="refDoi"> DOI: 10.1007/s40265-015-0494-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0494-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2035-2043&author=P.+L.+McCormack&title=Cariprazine%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0494-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0494-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0494-7%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DCariprazine%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D2035%26epage%3D2043%26doi%3D10.1007%2Fs40265-015-0494-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span>Turn to Vraylar; <span class="NLM_publisher-name">Allergan</span>: <span class="NLM_publisher-loc">Parsippany, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.vraylarhcp.com/" class="extLink">http://www.vraylarhcp.com/</a> (accessed August 5, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Turn+to+Vraylar%3B+Allergan%3A+Parsippany%2C+NJ%2C+2016%3B+http%3A%2F%2Fwww.vraylarhcp.com%2F+%28accessed+August+5%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DTurn%2520to%2520Vraylar%26pub%3DAllergan%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Veselinovic, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulzen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunder, G.</span><span> </span><span class="NLM_article-title">Cariprazine, a New, Orally Active Dopamine D2/3 Receptor Partial Agonist for the Treatment of Schizophrenia, Bipolar Mania and Depression</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1141</span><span class="NLM_x">–</span> <span class="NLM_lpage">1159</span><span class="refDoi"> DOI: 10.1586/14737175.2013.853448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1586%2F14737175.2013.853448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24175719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjsLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1141-1159&author=T.+Veselinovicauthor=M.+Paulzenauthor=G.+Grunder&title=Cariprazine%2C+a+New%2C+Orally+Active+Dopamine+D2%2F3+Receptor+Partial+Agonist+for+the+Treatment+of+Schizophrenia%2C+Bipolar+Mania+and+Depression&doi=10.1586%2F14737175.2013.853448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression</span></div><div class="casAuthors">Veselinovic, Tanja; Paulzen, Michael; Gruender, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1141-1159</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Cariprazine is a novel drug with partial agonist activity at dopamine D2/3 receptors and six- to eightfold higher affinity for human dopamine D3 over D2 receptors.  Results from several placebo-controlled Phase II/III trials in patients with a The Diagnostic and Statistical Manual of Mental Disorders IV diagnosis of schizophrenia or bipolar I disorder suggest that cariprazine is superior to placebo with respect to antipsychotic and antimanic activity.  Reports concerning safety and tolerability of cariprazine are mainly favorable, although the rates of treatment-assocd. adverse events, which most commonly included akathisia and extrapyramidal symptom, are rather high.  However, only minor alterations of clin. lab. values, prolactin concns. and ECG parameters are reported in cariprazine-treated patients.  A new drug application to the U.S. F DA for cariprazine for the treatment of both schizophrenia and manic or mixed episodes assocd. with bipolar I disorder was submitted in Nov. 2012.  A more precise assessment of the clin. properties of this new drug will require addnl. studies, aimed to compare and contrast cariprazine with other antipsychotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPsIaMWyuixrVg90H21EOLACvtfcHk0li9LMFl0rrD0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjsLjF&md5=b30e0bf57bb1004c626be6913c0393f9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1586%2F14737175.2013.853448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2013.853448%26sid%3Dliteratum%253Aachs%26aulast%3DVeselinovic%26aufirst%3DT.%26aulast%3DPaulzen%26aufirst%3DM.%26aulast%3DGrunder%26aufirst%3DG.%26atitle%3DCariprazine%252C%2520a%2520New%252C%2520Orally%2520Active%2520Dopamine%2520D2%252F3%2520Receptor%2520Partial%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Schizophrenia%252C%2520Bipolar%2520Mania%2520and%2520Depression%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2013%26volume%3D13%26spage%3D1141%26epage%3D1159%26doi%3D10.1586%2F14737175.2013.853448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Citrome, L.</span><span> </span><span class="NLM_article-title">Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy</span> <span class="citation_source-journal">Adv. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1007/s12325-013-0006-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs12325-013-0006-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=114-126&author=L.+Citrome&title=Cariprazine+in+Schizophrenia%3A+Clinical+Efficacy%2C+Tolerability%2C+and+Place+in+Therapy&doi=10.1007%2Fs12325-013-0006-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1007%2Fs12325-013-0006-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-013-0006-7%26sid%3Dliteratum%253Aachs%26aulast%3DCitrome%26aufirst%3DL.%26atitle%3DCariprazine%2520in%2520Schizophrenia%253A%2520Clinical%2520Efficacy%252C%2520Tolerability%252C%2520and%2520Place%2520in%2520Therapy%26jtitle%3DAdv.%2520Ther.%26date%3D2013%26volume%3D30%26spage%3D114%26epage%3D126%26doi%3D10.1007%2Fs12325-013-0006-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Caccia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Invernizzi, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nobili, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasina, L.</span><span> </span><span class="NLM_article-title">A New Generation of Antipsychotics: Pharmacology and Clinical Utility of Cariprazine in Schizophrenia</span> <span class="citation_source-journal">Ther. Clin. Risk Manage.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.2147/TCRM.S35137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2147%2FTCRM.S35137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=23966785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGjtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-328&author=S.+Cacciaauthor=R.+W.+Invernizziauthor=A.+Nobiliauthor=L.+Pasina&title=A+New+Generation+of+Antipsychotics%3A+Pharmacology+and+Clinical+Utility+of+Cariprazine+in+Schizophrenia&doi=10.2147%2FTCRM.S35137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia</span></div><div class="casAuthors">Caccia, Silvio; Invernizzi, Roberto William; Nobili, Alessandro; Pasina, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">319-328</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration.  It is a dopamine D2- and D3-receptor partial agonist, with higher affinity for D3 receptors, as opposed to the D2 antagonism of most older antipsychotic agents.  Like most lipophilic antipsychotics, it undergoes extensive hepatic metab. by cytochrome P 450 (CYP), mainly the highly variable 3A4, with the formation of active metabolites.  However, the parent compd. - particularly its active didesmethyl deriv. - is cleared very slowly, with elimination half-lives in schizophrenic patients ranging from 2-5 days for cariprazine to 2-3 wk for didesmethyl-cariprazine.  Exposure to the latter was several times that for cariprazine, although didesmethyl-cariprazine did not reach steady state within the 3 wk of 12.5 mg/day dosing.  Preliminary information on its therapeutic role comes from press releases and a few abstrs. presented at scientific meetings.  In short-term controlled trials, it was more effective than placebo in reducing pos. and neg. symptoms of schizophrenia, with an ED range of 1.5-12 mg/day.  Although cariprazine was assocd. with a higher incidence of akathisia and extrapyramidal side effects than placebo, it did not cause wt. gain, metabolic abnormalities, prolactin increase or cor. QT prolongation.  Similarly, cariprazine's efficacy and tolerability for the treatment of bipolar disorder (manic/mixed and depressive episodes) was established in the dose range of 3-12 mg/day, although again no long-term data are available.  Well-designed clin. trials, mainly direct "head-to-head" comparisons with other second-generation antipsychotic agents, are needed to define the therapeutic role and safety profile of cariprazine in schizophrenia and bipolar mania.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqskxYb8cxgErVg90H21EOLACvtfcHk0lhb2CZn4gSPxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGjtb%252FM&md5=0f8ad133c73e50a93dd99bdb40f4124f</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S35137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S35137%26sid%3Dliteratum%253Aachs%26aulast%3DCaccia%26aufirst%3DS.%26aulast%3DInvernizzi%26aufirst%3DR.%2BW.%26aulast%3DNobili%26aufirst%3DA.%26aulast%3DPasina%26aufirst%3DL.%26atitle%3DA%2520New%2520Generation%2520of%2520Antipsychotics%253A%2520Pharmacology%2520and%2520Clinical%2520Utility%2520of%2520Cariprazine%2520in%2520Schizophrenia%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D328%26doi%3D10.2147%2FTCRM.S35137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">De Deurwaerdere, P.</span><span> </span><span class="NLM_article-title">Cariprazine: New Dopamine Biased Agonist for Neuropsychiatric Disorders</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1358/dot.2016.52.2.2461868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdot.2016.52.2.2461868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28bhsVartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=97-110&author=P.+De+Deurwaerdere&title=Cariprazine%3A+New+Dopamine+Biased+Agonist+for+Neuropsychiatric+Disorders&doi=10.1358%2Fdot.2016.52.2.2461868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cariprazine:New dopamine biased agonist for neuropsychiatric disorders</span></div><div class="casAuthors">De Deurwaerdere P</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-110</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Cariprazine (RGH-188, MP-214, Vraylar[TM]) is a new dopamine receptor ligand developed for the treatment of several neuropsychiatric diseases including schizophrenia and bipolar disorders.  Cariprazine displays higher affinity at dopamine D3 receptors and a similar affinity at D2 and 5-HT2B receptors.  At variance with some atypical antipsychotics, its affinity at 5-HT1A, 5-HT2A and histamine H1 receptors is modest compared with its three main targets.  Cariprazine could correspond to a biased agonist at dopamine receptors, displaying either antagonist or partial agonist properties depending on the signaling pathways linked to D2/D3 receptors.  The compound crosses the blood-brain barrier, as revealed by positron emission tomography and pharmacokinetic studies in various species.  Two main metabolites result mainly from the activity of CYP34A and display properties similar to those of the parent drug.  Behavioral data report that cariprazine is efficacious in animal models addressing positive, negative and cognitive symptoms of schizophrenia with no extrapyramidal side effects.  In September 2015, the FDA approved the use of cariprazine for the treatment of schizophrenia and type I bipolar disorder.  The efficacy of cariprazine in other neuropsychiatric diseases is currently being evaluated in preclinical and clinical studies.  Side effects have been observed in humans, including extrapyramidal side effects and akathisia of mild to moderate intensity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPNpp60_KrnoqdXsLcGTEUfW6udTcc2eaHURmFJh2Hhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhsVartA%253D%253D&md5=7b4def336acc97a8ef2d15c1fd9d2e51</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.2.2461868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.2.2461868%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BDeurwaerdere%26aufirst%3DP.%26atitle%3DCariprazine%253A%2520New%2520Dopamine%2520Biased%2520Agonist%2520for%2520Neuropsychiatric%2520Disorders%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D97%26epage%3D110%26doi%3D10.1358%2Fdot.2016.52.2.2461868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span>Vraylar; <span class="NLM_publisher-name">Actavis Pharma, Inc.</span>: <span class="NLM_publisher-loc">Parsippany, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf</a> (accessed August 5, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vraylar%3B+Actavis+Pharma%2C+Inc.%3A+Parsippany%2C+NJ%2C+2016%3B+http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F204370lbl.pdf+%28accessed+August+5%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DVraylar%26pub%3DActavis%2520Pharma%252C%2520Inc%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span>Allergan and Gedeon Richter Plc. Receive FDA Approval of VRAYLAR (Cariprazine) for Treatment of Manic or Mixed Episodes of Bipolar I Disorder and Schizophrenia in Adults; <span class="NLM_publisher-name">Allergan plc</span>: <span class="NLM_publisher-loc">Coolock, Dublin, Ireland</span>, September 17,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.allergan.com/news/news/thomson-reuters/allergan-and-gedeon-richter-plc-receive-fda-approv" class="extLink">http://www.allergan.com/news/news/thomson-reuters/allergan-and-gedeon-richter-plc-receive-fda-approv</a>. (accessed August 5, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Allergan+and+Gedeon+Richter+Plc.+Receive+FDA+Approval+of+VRAYLAR+%28Cariprazine%29+for+Treatment+of+Manic+or+Mixed+Episodes+of+Bipolar+I+Disorder+and+Schizophrenia+in+Adults%3B+Allergan+plc%3A+Coolock%2C+Dublin%2C+Ireland%2C+September+17%2C+2015%3B+http%3A%2F%2Fwww.allergan.com%2Fnews%2Fnews%2Fthomson-reuters%2Fallergan-and-gedeon-richter-plc-receive-fda-approv.+%28accessed+August+5%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DAllergan%2520and%2520Gedeon%2520Richter%2520Plc.%2520Receive%2520FDA%2520Approval%2520of%2520VRAYLAR%2520%2528Cariprazine%2529%2520for%2520Treatment%2520of%2520Manic%2520or%2520Mixed%2520Episodes%2520of%2520Bipolar%2520I%2520Disorder%2520and%2520Schizophrenia%2520in%2520Adults%26pub%3DAllergan%2520plc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Csongor, E.; Galambos, J.; Nogradi, K.; Vago, I.; Gyertyan, I.; Kiss, B.; Laszlovszky, I.; Laszy, J.; Saghy, K.</span><span> </span><span class="NLM_article-title">(Thio) Carbamoyl-cyclohexane Derivatives as D3/D2 Receptor Antagonists</span>. US 20060229297A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=E.+Csongor&author=J.+Galambos&author=K.+Nogradi&author=I.+Vago&author=I.+Gyertyan&author=B.+Kiss&author=I.+Laszlovszky&author=J.+Laszy&author=K.+Saghy&title=%28Thio%29+Carbamoyl-cyclohexane+Derivatives+as+D3%2FD2+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCsongor%26aufirst%3DE.%26atitle%3D%2528Thio%2529%2520Carbamoyl-cyclohexane%2520Derivatives%2520as%2520D3%252FD2%2520Receptor%2520Antagonists%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ágainé, C. É.; Galambos, J.; Nógrádi, K.; Vágó, I.; Gyertyán, I.; Kiss, B.; Laszlovszky, I.; Laszy, J.; Sághy, K.</span><span> </span><span class="NLM_article-title">(Thio) Carbamoyl-Cyclohexane Derivatives as D3/D2 Receptor Antagonists</span>. WO 2005012266A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=C.+%C3%89.+%C3%81gain%C3%A9&author=J.+Galambos&author=K.+N%C3%B3gr%C3%A1di&author=I.+V%C3%A1g%C3%B3&author=I.+Gyerty%C3%A1n&author=B.+Kiss&author=I.+Laszlovszky&author=J.+Laszy&author=K.+S%C3%A1ghy&title=%28Thio%29+Carbamoyl-Cyclohexane+Derivatives+as+D3%2FD2+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581gain%25C3%25A9%26aufirst%3DC.%2B%25C3%2589.%26atitle%3D%2528Thio%2529%2520Carbamoyl-Cyclohexane%2520Derivatives%2520as%2520D3%252FD2%2520Receptor%2520Antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Czibula, L.; Juhász, B.; Ágainé, C. É.; Sebok, F.; Galambos, J.; Nógrádi, K.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Piperazine Compounds and Hydrochloride Salts Thereof</span>. WO 2010070370A8,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+Czibula&author=B.+Juh%C3%A1sz&author=C.+%C3%89.+%C3%81gain%C3%A9&author=F.+Sebok&author=J.+Galambos&author=K.+N%C3%B3gr%C3%A1di&title=Process+for+the+Preparation+of+Piperazine+Compounds+and+Hydrochloride+Salts+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCzibula%26aufirst%3DL.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Piperazine%2520Compounds%2520and%2520Hydrochloride%2520Salts%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ágainé, C. É.; Czibula, L.; Sebők, F.; Juhász, B.; Galambos, J.; Nográdi, K.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Piperazine Derivatives</span>. WO 2010070371A8,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=C.+%C3%89.+%C3%81gain%C3%A9&author=L.+Czibula&author=F.+Seb%C5%91k&author=B.+Juh%C3%A1sz&author=J.+Galambos&author=K.+Nogr%C3%A1di&title=Process+for+the+Preparation+of+Piperazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581gain%25C3%25A9%26aufirst%3DC.%2B%25C3%2589.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Piperazine%2520Derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Czibula, L.; Juhász, B.; Ágainé, C. É.; Sebők, F.; Galambos, J.; Nógrádi, K.</span><span> </span><span class="NLM_article-title">Novel Process for the Preparation of Piperazine Compounds and Hydrochloride Salts Thereof</span>. WO 2011073705A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+Czibula&author=B.+Juh%C3%A1sz&author=C.+%C3%89.+%C3%81gain%C3%A9&author=F.+Seb%C5%91k&author=J.+Galambos&author=K.+N%C3%B3gr%C3%A1di&title=Novel+Process+for+the+Preparation+of+Piperazine+Compounds+and+Hydrochloride+Salts+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCzibula%26aufirst%3DL.%26atitle%3DNovel%2520Process%2520for%2520the%2520Preparation%2520of%2520Piperazine%2520Compounds%2520and%2520Hydrochloride%2520Salts%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Agai-Csongor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domany, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogradi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galambos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vago, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greiner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laszlovszky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gere, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiss, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vastag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tihanyi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laszy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyertyan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zajer-Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemesi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szombathelyi, Z.</span><span> </span><span class="NLM_article-title">Discovery of Cariprazine (RGH-188): A Novel Antipsychotic Acting on Dopamine D3/D2 Receptors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3437</span><span class="NLM_x">–</span> <span class="NLM_lpage">3440</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmcl.2012.03.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22537450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFeksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3437-3440&author=E.+Agai-Csongorauthor=G.+Domanyauthor=K.+Nogradiauthor=J.+Galambosauthor=I.+Vagoauthor=G.+M.+Keseruauthor=I.+Greinerauthor=I.+Laszlovszkyauthor=A.+Gereauthor=E.+Schmidtauthor=B.+Kissauthor=M.+Vastagauthor=K.+Tihanyiauthor=K.+Saghyauthor=J.+Laszyauthor=I.+Gyertyanauthor=M.+Zajer-Balazsauthor=L.+Gemesiauthor=M.+Kapasauthor=Z.+Szombathelyi&title=Discovery+of+Cariprazine+%28RGH-188%29%3A+A+Novel+Antipsychotic+Acting+on+Dopamine+D3%2FD2+Receptors&doi=10.1016%2Fj.bmcl.2012.03.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42fR"><div class="casContent"><span class="casTitleNuber">42f</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors</span></div><div class="casAuthors">Agai-Csongor, Eva; Domany, Gyorgy; Nogradi, Katalin; Galambos, Janos; Vago, Istvan; Keseru, Gyorgy Miklos; Greiner, Istvan; Laszlovszky, Istvan; Gere, Aniko; Schmidt, Eva; Kiss, Bela; Vastag, Monika; Tihanyi, Karoly; Saghy, Katalin; Laszy, Judit; Gyertyan, Istvan; Zajer-Balazs, Maria; Gemesi, Larisza; Kapas, Margit; Szombathelyi, Zsolt</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3437-3440</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Medicinal chem. optimization of an impurity isolated during the scale-up synthesis of a pyridylsulfonamide type dopamine D3/D2 compd. (1, I) led to a series of new piperazine derivs. having affinity to both dopamine D3 and D2 receptors.  Several members of this group showed excellent pharmacokinetic and pharmacodynamic properties as demonstrated by outstanding activities in different antipsychotic tests.  The most promising representative, 2m (cariprazine) had good absorption, excellent brain penetration and advantageous safety profile.  Based on its successful clin. development we are looking forward to the NDA filing of cariprazine in 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgEXo42Fb5i7Vg90H21EOLACvtfcHk0liYsg1MvdScqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFeksLY%253D&md5=c70cd98791c4d5c2da5ac1f3904a8b98</span></div><a href="/servlet/linkout?suffix=cit42f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.104%26sid%3Dliteratum%253Aachs%26aulast%3DAgai-Csongor%26aufirst%3DE.%26aulast%3DDomany%26aufirst%3DG.%26aulast%3DNogradi%26aufirst%3DK.%26aulast%3DGalambos%26aufirst%3DJ.%26aulast%3DVago%26aufirst%3DI.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DGreiner%26aufirst%3DI.%26aulast%3DLaszlovszky%26aufirst%3DI.%26aulast%3DGere%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DE.%26aulast%3DKiss%26aufirst%3DB.%26aulast%3DVastag%26aufirst%3DM.%26aulast%3DTihanyi%26aufirst%3DK.%26aulast%3DSaghy%26aufirst%3DK.%26aulast%3DLaszy%26aufirst%3DJ.%26aulast%3DGyertyan%26aufirst%3DI.%26aulast%3DZajer-Balazs%26aufirst%3DM.%26aulast%3DGemesi%26aufirst%3DL.%26aulast%3DKapas%26aufirst%3DM.%26aulast%3DSzombathelyi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Cariprazine%2520%2528RGH-188%2529%253A%2520A%2520Novel%2520Antipsychotic%2520Acting%2520on%2520Dopamine%2520D3%252FD2%2520Receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3437%26epage%3D3440%26doi%3D10.1016%2Fj.bmcl.2012.03.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Czibula, L.; Againe, C. E.; Nogradi, K.; Juhasz, B.; Sebok, F.; Galambos, J.; Vago, I.</span><span> </span><span class="NLM_article-title">Piperazine Salt and a Process for the Preparation Thereof</span>. WO 2010070369A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=L.+Czibula&author=C.+E.+Againe&author=K.+Nogradi&author=B.+Juhasz&author=F.+Sebok&author=J.+Galambos&author=I.+Vago&title=Piperazine+Salt+and+a+Process+for+the+Preparation+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCzibula%26aufirst%3DL.%26atitle%3DPiperazine%2520Salt%2520and%2520a%2520Process%2520for%2520the%2520Preparation%2520Thereof%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Mathe, T. B.; Hegedus, L.; Czibula, L.; Juhasz, B.; Nagyne, B. J.; Markos, D.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Trans 4-amino-cyclohexyl Acetic Acid Ethyl Ester HCl</span>. WO 2010070368A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=T.+B.+Mathe&author=L.+Hegedus&author=L.+Czibula&author=B.+Juhasz&author=B.+J.+Nagyne&author=D.+Markos&title=Process+for+the+Preparation+of+Trans+4-amino-cyclohexyl+Acetic+Acid+Ethyl+Ester+HCl"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMathe%26aufirst%3DT.%2BB.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Trans%25204-amino-cyclohexyl%2520Acetic%2520Acid%2520Ethyl%2520Ester%2520HCl%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Ágainé, C. É.; Czibula, L.; Sebök, F.; Domany, G.; Greiner, I.</span><span> </span><span class="NLM_article-title">Novel Piperazine Salts as d3/d2 Antagonists</span>. WO 2008139235A2,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+%C3%89.+%C3%81gain%C3%A9&author=L.+Czibula&author=F.+Seb%C3%B6k&author=G.+Domany&author=I.+Greiner&title=Novel+Piperazine+Salts+as+d3%2Fd2+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581gain%25C3%25A9%26aufirst%3DC.%2B%25C3%2589.%26atitle%3DNovel%2520Piperazine%2520Salts%2520as%2520d3%252Fd2%2520Antagonists%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Borsini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jason, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohde, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollentier, S.</span><span> </span><span class="NLM_article-title">Pharmacology of Flibanserin</span> <span class="citation_source-journal">CNS Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1111/j.1527-3458.2002.tb00219.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fj.1527-3458.2002.tb00219.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=117-142&author=F.+Borsiniauthor=K.+Evansauthor=K.+Jasonauthor=F.+Rohdeauthor=B.+Alexanderauthor=S.+Pollentier&title=Pharmacology+of+Flibanserin&doi=10.1111%2Fj.1527-3458.2002.tb00219.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2002.tb00219.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2002.tb00219.x%26sid%3Dliteratum%253Aachs%26aulast%3DBorsini%26aufirst%3DF.%26aulast%3DEvans%26aufirst%3DK.%26aulast%3DJason%26aufirst%3DK.%26aulast%3DRohde%26aufirst%3DF.%26aulast%3DAlexander%26aufirst%3DB.%26aulast%3DPollentier%26aufirst%3DS.%26atitle%3DPharmacology%2520of%2520Flibanserin%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2002%26volume%3D8%26spage%3D117%26epage%3D142%26doi%3D10.1111%2Fj.1527-3458.2002.tb00219.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Mullard, A.</span><span> </span><span class="NLM_article-title">FDA Approves Female Sexual Dysfunction Drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">669</span><span class="refDoi"> DOI: 10.1038/nrd4757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1038%2Fnrd4757" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=669&author=A.+Mullard&title=FDA+Approves+Female+Sexual+Dysfunction+Drug&doi=10.1038%2Fnrd4757"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrd4757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4757%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DFDA%2520Approves%2520Female%2520Sexual%2520Dysfunction%2520Drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D669%26doi%3D10.1038%2Fnrd4757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Mohan, R. D.; Krishna, R. P.; Venkat, R. B.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Flibanserin Involving Novel Intermediates</span>. WO 2010128516A2,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+D.+Mohan&author=R.+P.+Krishna&author=R.+B.+Venkat&title=Process+for+the+Preparation+of+Flibanserin+Involving+Novel+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%26aufirst%3DR.%2BD.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Flibanserin%2520Involving%2520Novel%2520Intermediates%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Pai, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusalkar, D.</span><span> </span><span class="NLM_article-title">Pharmacological Screening of Novel Indolo[2,3-<i>b</i>]quinoxaline Derivatives</span> <span class="citation_source-journal">J. Chem. Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlWitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=485-493&author=N.+R.+Paiauthor=D.+Pusalkar&title=Pharmacological+Screening+of+Novel+Indolo%5B2%2C3-b%5Dquinoxaline+Derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological screening of novel indolo[2,3-b]quinoxaline derivatives</span></div><div class="casAuthors">Pai, Nandini R.; Pusalkar, Deeptaunshu Atul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical and Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-493</span>CODEN:
                <span class="NLM_cas:coden">JCPRC5</span>;
        ISSN:<span class="NLM_cas:issn">0975-7384</span>.
    
            (<span class="NLM_cas:orgname">Journal of Chemical and Pharmaceutical Research</span>)
        </div><div class="casAbstract">A condensation reaction of benzenediamine with isatin (1H-indole-2,3-dione) in refluxing glacial acetic acid provided indolo[2,3-b]quinoxaline.  The synthesis of the target compds. was achieved by a subsequent reaction of indolo[2,3-b]quinoxaline with carbostyril derivs. [6-(haloalkoxy)-2(1H)-quinolinone and 7-(haloalkoxy)-2(1H)-quinolinone] using NaI, K2CO3, TBAB as catalyst system.  The title compds. were evaluated against Gram-pos. bacteria and Gram-neg. bacteria (Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli) and it was discovered that they displayed slight antibacterial activity.  These compds. were also evaluated in rat models and mouse models for their antipsychotic activity (APO-induced stereotypy, DA autoreceptor agonist activity, induced catalepsy, α1-adrenoceptor antagonist activity) and it was found that these compds. displayed moderate antipsychotic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUOZxDfXzxQLVg90H21EOLACvtfcHk0lh0aoT5BPBHGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlWitw%253D%253D&md5=136810a158eefafeafaf0b86780900f7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DN.%2BR.%26aulast%3DPusalkar%26aufirst%3DD.%26atitle%3DPharmacological%2520Screening%2520of%2520Novel%2520Indolo%255B2%252C3-b%255Dquinoxaline%2520Derivatives%26jtitle%3DJ.%2520Chem.%2520Pharm.%2520Res.%26date%3D2010%26volume%3D2%26spage%3D485%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Ryu, S. E.; Kim, S. J.; Jeong, D. G.; Lee, S. H.; Jung, S. K.; Kim, H. M.; Park, S. K.; Lee, K. H.; Lee, C. W.; Choi, J. K.</span><span> </span><span class="NLM_article-title">Rhodandse Derivarives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same</span>. WO 2007081091A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+E.+Ryu&author=S.+J.+Kim&author=D.+G.+Jeong&author=S.+H.+Lee&author=S.+K.+Jung&author=H.+M.+Kim&author=S.+K.+Park&author=K.+H.+Lee&author=C.+W.+Lee&author=J.+K.+Choi&title=Rhodandse+Derivarives%2C+a+Process+for+the+Preparation+Thereof+and+Pharmaceutical+Composition+Containing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DS.%2BE.%26atitle%3DRhodandse%2520Derivarives%252C%2520a%2520Process%2520for%2520the%2520Preparation%2520Thereof%2520and%2520Pharmaceutical%2520Composition%2520Containing%2520the%2520Same%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Deeks, E. D.</span><span> </span><span class="NLM_article-title">Safinamide: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span><span class="refDoi"> DOI: 10.1007/s40265-015-0389-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0389-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25851099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1Ols7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=705-711&author=E.+D.+Deeks&title=Safinamide%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0389-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Safinamide: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">705-711</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Safinamide (Xadago) is an oral α-aminoamide deriv. developed by Newron for the treatment of Parkinson's disease (PD).  The drug has both dopaminergic properties (highly selective and reversible inhibition of monoamine oxidase-B) and non-dopaminergic properties (selective sodium channel blockade and calcium channel modulation, with consequent inhibition of excessive glutamate release).  Safinamide is approved in the EU, Iceland, Lichtenstein and Norway, as an add-on therapy to stable-dose levodopa, alone or in combination with other PD therapies in mid- to late-stage fluctuating PD patients; regulatory submissions have also been filed in the USA and Switzerland for its use in this indication.  Addnl. submissions have been made in the USA, Iceland, Lichtenstein, Norway and Switzerland for early-stage PD.  Safinamide has also undergone phase II investigation in PD patients with drug-induced dyskinesia (France, Germany, Austria, Canada and South Africa) or cognitive impairment (USA and Spain).  This article summarizes the milestones in the development of safinamide leading to its first approval for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiB6K6JgNCR7Vg90H21EOLACvtfcHk0lh0aoT5BPBHGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1Ols7Y%253D&md5=627dd1d0e6939b77f46fdf716aaa35e9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0389-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0389-7%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DSafinamide%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D705%26epage%3D711%26doi%3D10.1007%2Fs40265-015-0389-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fariello, R. G.</span><span> </span><span class="NLM_article-title">Safinamide</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1016/j.nurt.2006.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.nurt.2006.11.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=110-116&author=R.+G.+Fariello&title=Safinamide&doi=10.1016%2Fj.nurt.2006.11.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2006.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2006.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DFariello%26aufirst%3DR.%2BG.%26atitle%3DSafinamide%26jtitle%3DNeurotherapeutics%26date%3D2007%26volume%3D4%26spage%3D110%26epage%3D116%26doi%3D10.1016%2Fj.nurt.2006.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit52b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span> </span><span class="NLM_article-title">Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease: a Review of Symptomatic and Potential Disease-Modifying Effects</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.2165/11596310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2165%2F11596310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22133327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1061-1071&author=A.+H.+V.+Schapira&title=Monoamine+Oxidase+B+Inhibitors+for+the+Treatment+of+Parkinson%E2%80%99s+Disease%3A+a+Review+of+Symptomatic+and+Potential+Disease-Modifying+Effects&doi=10.2165%2F11596310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52bR"><div class="casContent"><span class="casTitleNuber">52b</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects</span></div><div class="casAuthors">Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1061-1071</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease is a disorder characterized pathol. by progressive neurodegeneration of the dopaminergic cells of the nigrostriatal pathway.  Although the resulting dopamine deficiency is the cause of the typical motor features of Parkinson's disease (bradykinesia, rigidity, tremor), addnl. non-motor symptoms appear at various timepoints and are the result of non-dopamine nerve degeneration.  Monoamine oxidase B (MAO-B) inhibitors are used in the symptomatic treatment of Parkinson's disease as they increase synaptic dopamine by blocking its degrdn.  Two MAO-B inhibitors, selegiline and rasagiline, are currently licensed in Europe and North America for the symptomatic improvement of early Parkinson's disease and to reduce off-time in patients with more advanced Parkinson's disease and motor fluctuations related to levodopa.  A third MAO-B inhibitor (safinamide), which also combines addnl. non-dopaminergic properties of potential benefit to Parkinson's disease, is currently under development in phase III clin. trials as adjuvant therapy to either a dopamine agonist or levodopa.  MAO-B inhibitors have also been studied extensively for possible neuroprotective or disease-modifying actions.  There is considerable lab. evidence that MAO-B inhibitors do exert some neuroprotective properties, at least in the Parkinson's disease models currently available.  However, these models have significant limitations and caution is required in assuming that such results may easily be extrapolated to clin. trials.  Rasagiline 1 mg/day has been shown to provide improved motor control in terms of Unified Parkinson's Disease Rating Scale (UPDRS) score at 18 mo in those patients with early disease who began the drag 9 mo before a second group.  There are a no. of possible explanations for this effect that may include a disease-modifying action; however, the US FDA recently declined an application for the licence of rasagiline to be extended to cover disease modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2AHDUDO6Ch7Vg90H21EOLACvtfcHk0lh0aoT5BPBHGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D&md5=a6c6a9380eaa9056a877fa0df9e39446</span></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=10.2165%2F11596310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DMonoamine%2520Oxidase%2520B%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520a%2520Review%2520of%2520Symptomatic%2520and%2520Potential%2520Disease-Modifying%2520Effects%26jtitle%3DCNS%2520Drugs%26date%3D2011%26volume%3D25%26spage%3D1061%26epage%3D1071%26doi%3D10.2165%2F11596310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Von Raison, F.; Weiner, D.; Roach, A.; Cuenoud, B.; Bartoszyk, G.</span><span> </span><span class="NLM_article-title">Safinamide in the Treatment of Dyskinesia</span>. WO 2011098456A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=F.+Von+Raison&author=D.+Weiner&author=A.+Roach&author=B.+Cuenoud&author=G.+Bartoszyk&title=Safinamide+in+the+Treatment+of+Dyskinesia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BRaison%26aufirst%3DF.%26atitle%3DSafinamide%2520in%2520the%2520Treatment%2520of%2520Dyskinesia%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Mueller, T.</span><span> </span><span class="NLM_article-title">Current Status of Safinamide for the Drug Portfolio of Parkinson’s Disease Therapy</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">969</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span><span class="refDoi"> DOI: 10.1586/14737175.2013.827488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1586%2F14737175.2013.827488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24053341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqsbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=969-977&author=T.+Mueller&title=Current+Status+of+Safinamide+for+the+Drug+Portfolio+of+Parkinson%E2%80%99s+Disease+Therapy&doi=10.1586%2F14737175.2013.827488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of safinamide for the drug portfolio of Parkinson's disease therapy</span></div><div class="casAuthors">Mueller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">969-977</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is characterized by a slowly ongoing neuronal death.  This alters dopaminergic and glutamatergic neurotransmission and causes a wide variety of motor and non-motor features.  Safinamide has a unique pharmacol. profile, which combines modulation of dopamine metab. by reversible, highly specific monoamine oxidase-B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release induced by abnormal neuronal activity.  Therefore, safinamide represents an ideal candidate for the treatment of PD.  This compd. asks for one time daily intake only within an optimum dose range between 50 and 100 mg.  In clin. trials, safinamide was well tolerated and safe, improved motor behavior even in combination with dopamine agonist only, ameliorated levodopa-assocd. motor complications.  Safinamide has the potential to become an important compd. for the therapy of PD, since its symptomatic efficacy appears to be superior to available monoamine oxidase-B inhibitors or N-methyl-d-aspartate receptor antagonists like amantadine, according to available trial outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepGBJXUO_RbVg90H21EOLACvtfcHk0lj0e_7EkCKbqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqsbzM&md5=5fad5977d10a9896d0856e4632c19f28</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1586%2F14737175.2013.827488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2013.827488%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DT.%26atitle%3DCurrent%2520Status%2520of%2520Safinamide%2520for%2520the%2520Drug%2520Portfolio%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%2520Therapy%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2013%26volume%3D13%26spage%3D969%26epage%3D977%26doi%3D10.1586%2F14737175.2013.827488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Caccia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabresi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maestroni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faravelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curatolo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fariello, R. G.</span><span> </span><span class="NLM_article-title">Safinamide From Molecular Targets to a New Anti-Parkinson Drug</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">S18</span><span class="NLM_x">–</span> <span class="NLM_lpage">S23</span><span class="refDoi"> DOI: 10.1212/WNL.67.7_suppl_2.S18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1212%2FWNL.67.7_suppl_2.S18" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=S18-S23&author=C.+Cacciaauthor=R.+Majauthor=M.+Calabresiauthor=S.+Maestroniauthor=L.+Faravelliauthor=L.+Curatoloauthor=P.+Salvatiauthor=R.+G.+Fariello&title=Safinamide+From+Molecular+Targets+to+a+New+Anti-Parkinson+Drug&doi=10.1212%2FWNL.67.7_suppl_2.S18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1212%2FWNL.67.7_suppl_2.S18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.67.7_suppl_2.S18%26sid%3Dliteratum%253Aachs%26aulast%3DCaccia%26aufirst%3DC.%26aulast%3DMaj%26aufirst%3DR.%26aulast%3DCalabresi%26aufirst%3DM.%26aulast%3DMaestroni%26aufirst%3DS.%26aulast%3DFaravelli%26aufirst%3DL.%26aulast%3DCuratolo%26aufirst%3DL.%26aulast%3DSalvati%26aufirst%3DP.%26aulast%3DFariello%26aufirst%3DR.%2BG.%26atitle%3DSafinamide%2520From%2520Molecular%2520Targets%2520to%2520a%2520New%2520Anti-Parkinson%2520Drug%26jtitle%3DNeurology%26date%3D2006%26volume%3D67%26spage%3DS18%26epage%3DS23%26doi%3D10.1212%2FWNL.67.7_suppl_2.S18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szasz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanzione, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meshram, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirilineau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">N/A Two-year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson’s Disease</span> <span class="citation_source-journal">Mov. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1273</span><span class="NLM_x">–</span> <span class="NLM_lpage">1280</span><span class="refDoi"> DOI: 10.1002/mds.25961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fmds.25961" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=1273-1280&author=R.+Borgohainauthor=J.+Szaszauthor=P.+Stanzioneauthor=C.+Meshramauthor=M.+H.+Bhattauthor=D.+Chirilineauauthor=F.+Stocchiauthor=V.+Luciniauthor=R.+Giulianiauthor=E.+Forrestauthor=P.+Riceauthor=R.+Anand&title=N%2FA+Two-year%2C+Randomized%2C+Controlled+Study+of+Safinamide+as+Add-on+to+Levodopa+in+Mid+to+Late+Parkinson%E2%80%99s+Disease&doi=10.1002%2Fmds.25961"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.1002%2Fmds.25961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25961%26sid%3Dliteratum%253Aachs%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DSzasz%26aufirst%3DJ.%26aulast%3DStanzione%26aufirst%3DP.%26aulast%3DMeshram%26aufirst%3DC.%26aulast%3DBhatt%26aufirst%3DM.%2BH.%26aulast%3DChirilineau%26aufirst%3DD.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DForrest%26aufirst%3DE.%26aulast%3DRice%26aufirst%3DP.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DN%252FA%2520Two-year%252C%2520Randomized%252C%2520Controlled%2520Study%2520of%2520Safinamide%2520as%2520Add-on%2520to%2520Levodopa%2520in%2520Mid%2520to%2520Late%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DMov.%2520Disord.%26date%3D2014%26volume%3D29%26spage%3D1273%26epage%3D1280%26doi%3D10.1002%2Fmds.25961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit56b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szasz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanzione, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meshram, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirilineau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">Randomized Trial of Safinamide Add-on to Levodopa in Parkinson’s Disease with Motor Fluctuations</span> <span class="citation_source-journal">Mov. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1002/mds.25751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fmds.25751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24323641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1ymsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=229-237&author=R.+Borgohainauthor=J.+Szaszauthor=P.+Stanzioneauthor=C.+Meshramauthor=M.+Bhattauthor=D.+Chirilineauauthor=F.+Stocchiauthor=V.+Luciniauthor=R.+Giulianiauthor=E.+Forrestauthor=P.+Riceauthor=R.+Anand&title=Randomized+Trial+of+Safinamide+Add-on+to+Levodopa+in+Parkinson%E2%80%99s+Disease+with+Motor+Fluctuations&doi=10.1002%2Fmds.25751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56bR"><div class="casContent"><span class="casTitleNuber">56b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations</span></div><div class="casAuthors">Borgohain, Rupam; Szasz, J.; Stanzione, P.; Meshram, C.; Bhatt, M.; Chirilineau, D.; Stocchi, F.; Lucini, V.; Giuliani, R.; Forrest, E.; Rice, P.; Anand, R.</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">229-237</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Levodopa is effective for the motor symptoms of Parkinson's disease (PD), but is assocd. with motor fluctuations and dyskinesia.  Many patients require add-on therapy to improve motor fluctuations without exacerbating dyskinesia.  The objective of this Phase III, multicenter, double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy and safety of safinamide, an α-aminoamide with dopaminergic and nondopaminergic mechanisms, as add-on to Ldopa in the treatment of patients with PD and motor fluctuations.  Patients were randomized to oral safinamide 100 mg/day (n = 224), 50 mg/day (n = 223), or placebo (n = 222) for 24 wk.  The primary endpoint was total on time with no or nontroublesome dyskinesia (assessed using the Hauser patient diaries).  Secondary endpoints included off time, Unified Parkinson's Disease Rating Scale (UPDRS) Part III (motor) scores, and Clin. Global Impression-Change (CGI-C).  At week 24, mean ± SD increases in total on time with no or nontroublesome dyskinesia were 1.36 ± 2.625 h for safinamide 100 mg/day, 1.37 ± 2.745 h for safinamide 50 mg/day, and 0.97 ± 2.375 h for placebo.  Least squares means differences in both safinamide groups were significantly higher vs. placebo.  Improvements in off time, UPDRS Part III, and CGI-C were significantly greater in both safinamide groups vs. placebo.  There were no significant between-group differences for incidences of treatment-emergent adverse events (TEAEs) or TEAEs leading to discontinuation.  The addn. of safinamide 50 mg/day or 100 mg/day to L-dopa in patients with PD and motor fluctuations significantly increased total on time with no or nontroublesome dyskinesia, decreased off time, and improved parkinsonism, indicating that safinamide improves motor symptoms and parkinsonism without worsening dyskinesia. © 2013 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM1jhniIed4bVg90H21EOLACvtfcHk0lj0e_7EkCKbqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1ymsL4%253D&md5=6b69b2ce44f29f27be5a43ef7c0be826</span></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1002%2Fmds.25751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25751%26sid%3Dliteratum%253Aachs%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DSzasz%26aufirst%3DJ.%26aulast%3DStanzione%26aufirst%3DP.%26aulast%3DMeshram%26aufirst%3DC.%26aulast%3DBhatt%26aufirst%3DM.%26aulast%3DChirilineau%26aufirst%3DD.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DForrest%26aufirst%3DE.%26aulast%3DRice%26aufirst%3DP.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DRandomized%2520Trial%2520of%2520Safinamide%2520Add-on%2520to%2520Levodopa%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%2520with%2520Motor%2520Fluctuations%26jtitle%3DMov.%2520Disord.%26date%3D2014%26volume%3D29%26spage%3D229%26epage%3D237%26doi%3D10.1002%2Fmds.25751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onofrj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">A Randomized, Double-blind, Placebo-controlled Trial of Safinamide as Add-on Therapy in Early Parkinson’s Disease Patients</span> <span class="citation_source-journal">Mov. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1002/mds.23954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fmds.23954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=21913224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWmsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=106-112&author=F.+Stocchiauthor=R.+Borgohainauthor=M.+Onofrjauthor=A.+H.+V.+Schapiraauthor=M.+Bhattauthor=V.+Luciniauthor=R.+Giulianiauthor=R.+Anand&title=A+Randomized%2C+Double-blind%2C+Placebo-controlled+Trial+of+Safinamide+as+Add-on+Therapy+in+Early+Parkinson%E2%80%99s+Disease+Patients&doi=10.1002%2Fmds.23954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57aR"><div class="casContent"><span class="casTitleNuber">57a</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients</span></div><div class="casAuthors">Stocchi, Fabrizio; Borgohain, Rupam; Onofrj, Marco; Schapira, Anthony H. V.; Bhatt, Mohit; Lucini, Valentina; Giuliani, Rodolfo; Anand, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">106-112</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Safinamide is an α-aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add-on to dopamine agonist (DA) therapy in early-stage PD.  In this 24-wk, double-blind study, patients with early PD receiving a stable dose of a single DA were randomized to once-daily safinamide 100 mg, safinamide 200 mg, or placebo.  The primary efficacy variable was UPDRS part III (motor examn.) total score.  Anal. was hierarchical: 200 mg of safinamide vs. placebo was tested first; the success of safinamide 100 mg vs. placebo was contingent on this.  Two hundred sixty-nine patients received safinamide 100 mg (n = 90), safinamide 200 mg (n = 89), or placebo (n = 90); 70, 81, and 81 patients, resp., completed the study.  Mean improvements from baseline to week 24 in UPDRS III total scores were -3.90 for safinamide 200 mg, -6.0 for safinamide 100 mg and -3.60 for placebo.  The difference between safinamide 200 mg and placebo was not significant [point est.: -0.4; 95% confidence interval (CI): -2.3-1.4; P = 0.6504].  Although the difference between 100 mg/day and placebo was significant (point est.: -1.9; 95% CI: -3.7 to -0.1; P = 0.0419), these results are considered exploratory.  No clin. meaningful differences from placebo were obsd. for any safety variables.  This study did not demonstrate a significant improvement of the primary endpoint for safinamide 200 mg/day.  Exploratory anal. of the primary endpoint for 100 mg/day demonstrated that the addn. of safinamide to a stable dose of DA improves motor symptoms in early PD and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPC0oQPAUMJLVg90H21EOLACvtfcHk0lg-sGKOjCzn_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWmsL7J&md5=8472a24b3d72016247cf6ba2b8abecda</span></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=10.1002%2Fmds.23954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.23954%26sid%3Dliteratum%253Aachs%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DOnofrj%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26aulast%3DBhatt%26aufirst%3DM.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DA%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%2520Trial%2520of%2520Safinamide%2520as%2520Add-on%2520Therapy%2520in%2520Early%2520Parkinson%25E2%2580%2599s%2520Disease%2520Patients%26jtitle%3DMov.%2520Disord.%26date%3D2012%26volume%3D27%26spage%3D106%26epage%3D112%26doi%3D10.1002%2Fmds.23954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit57b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onofrj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">Long-term Efficacy and Safety of Safinamide as Add-on Therapy in Early Parkinson’s Disease</span> <span class="citation_source-journal">Eur. J. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1111/j.1468-1331.2012.03840.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fj.1468-1331.2012.03840.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22967035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC38bmtV2qsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=271-280&author=A.+H.+V.+Schapiraauthor=F.+Stocchiauthor=R.+Borgohainauthor=M.+Onofrjauthor=M.+Bhattauthor=P.+Lorenzanaauthor=V.+Luciniauthor=R.+Giulianiauthor=R.+Anand&title=Long-term+Efficacy+and+Safety+of+Safinamide+as+Add-on+Therapy+in+Early+Parkinson%E2%80%99s+Disease&doi=10.1111%2Fj.1468-1331.2012.03840.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57bR"><div class="casContent"><span class="casTitleNuber">57b</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease</span></div><div class="casAuthors">Schapira A H V; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology : the official journal of the European Federation of Neurological Societies</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Safinamide is an α-aminoamide with both dopaminergic and non-dopaminergic mechanisms of action in Phase III clinical development as a once-daily add-on to dopamine agonist (DA) therapy for early Parkinson's disease (PD).  METHODS:  Study 017 was a 12-month, randomized, double-blind, placebo-controlled pre-planned extension study to the previously reported Study 015.  Patients received safinamide 100 or 200 mg/day or placebo added to a single DA in early PD.  The primary efficacy endpoint was the time from baseline (Study 015 randomization) to 'intervention', defined as increase in DA dose; addition of another DA, levodopa or other PD treatment; or discontinuation due to lack of efficacy.  Safinamide groups were pooled for the primary efficacy endpoint analysis; post hoc analyses were performed on each separate dose group.  RESULTS:  Of the 269 patients randomized in Study 015, 227 (84%) enrolled in Study 017 and 187/227 (82%) patients completed the extension study.  Median time to intervention was 559 and 466 days in the pooled safinamide and placebo groups, respectively (log-rank test; P = 0.3342).  In post hoc analyses, patients receiving safinamide 100 mg/day experienced a significantly lower rate of intervention compared with placebo (25% vs. 51%, respectively) and a delay in median time to intervention of 9 days (P < 0.05; 240- to 540-day analysis).  CONCLUSIONS:  The pooled data from the safinamide groups failed to reach statistical significance for the primary endpoint of median time from baseline to additional drug intervention.  Post hoc analyses indicate that safinamide 100 mg/day may be effective as add-on treatment to DA in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTW8Q7CptAmznthwrmtH4OBfW6udTcc2eZjInAiVFtFw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bmtV2qsw%253D%253D&md5=ae238c6d3d0f0952fc6993bd03615335</span></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1331.2012.03840.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1331.2012.03840.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DOnofrj%26aufirst%3DM.%26aulast%3DBhatt%26aufirst%3DM.%26aulast%3DLorenzana%26aufirst%3DP.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DLong-term%2520Efficacy%2520and%2520Safety%2520of%2520Safinamide%2520as%2520Add-on%2520Therapy%2520in%2520Early%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2013%26volume%3D20%26spage%3D271%26epage%3D280%26doi%3D10.1111%2Fj.1468-1331.2012.03840.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonsignori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidempergher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinciroli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fariello, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span> </span><span class="NLM_article-title">Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">590</span><span class="refDoi"> DOI: 10.1021/jm970599m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970599m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADyaK1cXms1Oitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=579-590&author=P.+Pevarelloauthor=A.+Bonsignoriauthor=P.+Dostertauthor=F.+Heidempergherauthor=V.+Pinciroliauthor=M.+Colomboauthor=R.+A.+McArthurauthor=P.+Salvatiauthor=C.+Postauthor=R.+G.+Farielloauthor=M.+Varasi&title=Synthesis+and+Anticonvulsant+Activity+of+a+New+Class+of+2-%5B%28Arylalkyl%29amino%5Dalkanamide+Derivatives&doi=10.1021%2Fjm970599m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58aR"><div class="casContent"><span class="casTitleNuber">58a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives</span></div><div class="casAuthors">Pevarello, Paolo; Bonsignori, Alberto; Dostert, Philippe; Heidempergher, Franco; Pinciroli, Vittorio; Colombo, Maristella; McArthur, Robert A.; Salvati, Patricia; Post, Claes; Fariello, Ruggero G.; Varasi, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-590</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from milacemide, a weak anticonvulsant, trying to elucidate its mechanism of action a structurally novel class of potent and preclinically safe anticonvulsants was discovered.  The structure-activity relationship study within this series of compds was reported.  Different parts of the structural lead 2-[[4-(3-chlorobenzoxy)benzyl]amino]acetamide were varied, and many potent anticonvulsants were found.  (S)-2-[[4-(3-fluorobenzoxy)benzyl]amino]propanamide methanesulfonate, (PNU-151774E), emerged as the promising candidate for further development for its potent anticonvulsant activity and outstanding therapeutic indexes in different animal tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy8FzAw312mrVg90H21EOLACvtfcHk0lhHS5X5-eJ2aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1Oitw%253D%253D&md5=2297e82ce9a4feb069a761bd0a1d87f5</span></div><a href="/servlet/linkout?suffix=cit58a&amp;dbid=16384&amp;doi=10.1021%2Fjm970599m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970599m%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBonsignori%26aufirst%3DA.%26aulast%3DDostert%26aufirst%3DP.%26aulast%3DHeidempergher%26aufirst%3DF.%26aulast%3DPinciroli%26aufirst%3DV.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DMcArthur%26aufirst%3DR.%2BA.%26aulast%3DSalvati%26aufirst%3DP.%26aulast%3DPost%26aufirst%3DC.%26aulast%3DFariello%26aufirst%3DR.%2BG.%26aulast%3DVarasi%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Anticonvulsant%2520Activity%2520of%2520a%2520New%2520Class%2520of%25202-%255B%2528Arylalkyl%2529amino%255Dalkanamide%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D579%26epage%3D590%26doi%3D10.1021%2Fjm970599m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit58b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dostert, P.; Pevarello, P.; Heidempergher, F.; Varasi, M.; Bonsignori, A.; Roncucci, R.</span><span> </span><span class="NLM_article-title">Preparation of α-(phenylalkylamino)carboxamides as drugs</span>. EP 400495A1,<span class="NLM_x"> </span><span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=P.+Dostert&author=P.+Pevarello&author=F.+Heidempergher&author=M.+Varasi&author=A.+Bonsignori&author=R.+Roncucci&title=Preparation+of+%CE%B1-%28phenylalkylamino%29carboxamides+as+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDostert%26aufirst%3DP.%26atitle%3DPreparation%2520of%2520%25CE%25B1-%2528phenylalkylamino%2529carboxamides%2520as%2520drugs%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Barbanti, E.; Caccia, C.; Salvati, P.; Velardi, F.; Ruffilli, T.; Bogogna, L.</span><span> </span><span class="NLM_article-title">Process for the Production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino]propanamides</span>. WO 20090156678A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=E.+Barbanti&author=C.+Caccia&author=P.+Salvati&author=F.+Velardi&author=T.+Ruffilli&author=L.+Bogogna&title=Process+for+the+Production+of+2-%5B4-%283-+and+2-fluorobenzyloxy%29+benzylamino%5Dpropanamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbanti%26aufirst%3DE.%26atitle%3DProcess%2520for%2520the%2520Production%2520of%25202-%255B4-%25283-%2520and%25202-fluorobenzyloxy%2529%2520benzylamino%255Dpropanamides%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit59b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barbanti, E.; Faravelli, L.; Salvati, P.; Canevotti, R.; Ponzini, F.</span><span> </span><span class="NLM_article-title">Process for the Production of Highly Pure 2-[4-(3- or 2-Fluorobenzyloxy)benzylamino]propanamides as Cytochrome P450 Inhibitors and Their Pharmaceutical Compositions and Use in the Treatment of Diseases</span>. WO 2009074478A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=E.+Barbanti&author=L.+Faravelli&author=P.+Salvati&author=R.+Canevotti&author=F.+Ponzini&title=Process+for+the+Production+of+Highly+Pure+2-%5B4-%283-+or+2-Fluorobenzyloxy%29benzylamino%5Dpropanamides+as+Cytochrome+P450+Inhibitors+and+Their+Pharmaceutical+Compositions+and+Use+in+the+Treatment+of+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbanti%26aufirst%3DE.%26atitle%3DProcess%2520for%2520the%2520Production%2520of%2520Highly%2520Pure%25202-%255B4-%25283-%2520or%25202-Fluorobenzyloxy%2529benzylamino%255Dpropanamides%2520as%2520Cytochrome%2520P450%2520Inhibitors%2520and%2520Their%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit59c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Barbanti, E.; Caccia, C.; Salvati, P.; Velardi, F.; Rufilli, T.; Bogogna, L.</span><span> </span><span class="NLM_article-title">Process for the Production of 2-[4-(3- and 2-Fluorobenzyloxy)benzylamino]propanamides (Safinamide and Ralfinamide) of High Purity by Catalytic Hydrogenation of Schiff Base Intermediates and Their Use for Treating CNS Disorders</span>. WO 2007147491A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=E.+Barbanti&author=C.+Caccia&author=P.+Salvati&author=F.+Velardi&author=T.+Rufilli&author=L.+Bogogna&title=Process+for+the+Production+of+2-%5B4-%283-+and+2-Fluorobenzyloxy%29benzylamino%5Dpropanamides+%28Safinamide+and+Ralfinamide%29+of+High+Purity+by+Catalytic+Hydrogenation+of+Schiff+Base+Intermediates+and+Their+Use+for+Treating+CNS+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbanti%26aufirst%3DE.%26atitle%3DProcess%2520for%2520the%2520Production%2520of%25202-%255B4-%25283-%2520and%25202-Fluorobenzyloxy%2529benzylamino%255Dpropanamides%2520%2528Safinamide%2520and%2520Ralfinamide%2529%2520of%2520High%2520Purity%2520by%2520Catalytic%2520Hydrogenation%2520of%2520Schiff%2520Base%2520Intermediates%2520and%2520Their%2520Use%2520for%2520Treating%2520CNS%2520Disorders%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Eluxadoline: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1305</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span><span class="refDoi"> DOI: 10.1007/s40265-015-0436-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0436-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26149369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCjt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1305-1310&author=K.+P.+Garnock-Jones&title=Eluxadoline%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0436-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Eluxadoline: First Global Approval</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1305-1310</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Eluxadoline (Viberzi), developed by Actavis (now Allergan), is an orally administered, first-in-class compd. that functions as both a μ-opioid receptor agonist and a δ-opioid receptor antagonist, and is indicated for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in adults.  The agent was originally developed by Janssen Pharmaceutica.  Eluxadoline has been approved in the US, and submissions to other global authorities are being contemplated or planned.  This article summarizes the milestones in the development of eluxadoline leading to this first approval for IBS-D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5dpEIm3WsLrVg90H21EOLACvtfcHk0lhRlETqG_vO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCjt7jF&md5=bf9bac23ac14a233f703f2d0565558f9</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0436-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0436-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DEluxadoline%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1305%26epage%3D1310%26doi%3D10.1007%2Fs40265-015-0436-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Davenport, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonifacio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venitz, J.</span><span> </span><span class="NLM_article-title">Effect of Uptake Transporters OAT3 and OATP1B1 and Efflux Transporter MRP2 on the Pharmacokinetics of Eluxadoline</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.1002/jcph.442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fjcph.442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25491493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslKhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=534-542&author=J.+M.+Davenportauthor=P.+Covingtonauthor=L.+Bonifacioauthor=G.+McIntyreauthor=J.+Venitz&title=Effect+of+Uptake+Transporters+OAT3+and+OATP1B1+and+Efflux+Transporter+MRP2+on+the+Pharmacokinetics+of+Eluxadoline&doi=10.1002%2Fjcph.442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline</span></div><div class="casAuthors">Davenport, J. Michael; Covington, Paul; Bonifacio, Laura; McIntyre, Gail; Venitz, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">534-542</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The effects of OATP1B1, OAT3, and MRP2 on the pharmacokinetics of eluxadoline, an oral, locally active, opioid receptor agonist/antagonist being developed for treatment of IBS-d were assessed in vivo.  Coadministration of a single 200 mg dose of eluxadoline with cyclosporine, and probenecid increased eluxadoline systemic exposure [AUC(0-inf)] by 4.4- and 1.4-fold, resp., whereas peak exposure (Cmax) increased 6.2-fold and 1.3-fold, resp.  Cyclosporine had little effect on renal clearance (CLren) of eluxadoline whereas probenecid reduced CLren by nearly 50%.  These study results suggested that sinusoidal OATP1B1-mediated hepatic uptake of eluxadoline (during first-pass and systemic extn.) plays a major role in its absorption and disposition, whereas OAT3-mediated basolateral uptake in the proximal renal tubules and MRP2-mediated canalicular and renal tubular apical efflux play only minor roles in its overall disposition.  All treatments were safe and well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGornZGN3p0yFrVg90H21EOLACvtfcHk0lhRlETqG_vO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslKhtLY%253D&md5=a45df657a815cd10239dd7da2f8cc5be</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fjcph.442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.442%26sid%3Dliteratum%253Aachs%26aulast%3DDavenport%26aufirst%3DJ.%2BM.%26aulast%3DCovington%26aufirst%3DP.%26aulast%3DBonifacio%26aufirst%3DL.%26aulast%3DMcIntyre%26aufirst%3DG.%26aulast%3DVenitz%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520Uptake%2520Transporters%2520OAT3%2520and%2520OATP1B1%2520and%2520Efflux%2520Transporter%2520MRP2%2520on%2520the%2520Pharmacokinetics%2520of%2520Eluxadoline%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D55%26spage%3D534%26epage%3D542%26doi%3D10.1002%2Fjcph.442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Wade, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenigs, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevalier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabus, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornby, P. J.</span><span> </span><span class="NLM_article-title">Modulation of Gastrointestinal Function by MuDelta, a Mixed μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1125</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02068.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fj.1476-5381.2012.02068.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22671931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1111-1125&author=P.+R.+Wadeauthor=J.+M.+Palmerauthor=S.+McKenneyauthor=V.+Kenigsauthor=K.+Chevalierauthor=B.+A.+Mooreauthor=J.+R.+Mabusauthor=P.+R.+Saundersauthor=N.+H.+Wallaceauthor=C.+R.+Schneiderauthor=E.+S.+Kimballauthor=H.+J.+Breslinauthor=W.+Heauthor=P.+J.+Hornby&title=Modulation+of+Gastrointestinal+Function+by+MuDelta%2C+a+Mixed+%CE%BC+Opioid+Receptor+Agonist%2F%CE%B4+Opioid+Receptor+Antagonist&doi=10.1111%2Fj.1476-5381.2012.02068.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/δ opioid receptor antagonist</span></div><div class="casAuthors">Wade, P. R.; Palmer, J. M.; McKenney, S.; Kenigs, V.; Chevalier, K.; Moore, B. A.; Mabus, J. R.; Saunders, P. R.; Wallace, N. H.; Schneider, C. R.; Kimball, E. S.; Breslin, H. J.; He, W.; Hornby, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1111-1125</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background & Purpose: Loperamide is a selective μ opioid receptor agonist acting locally in the gastrointestinal (GI) tract as an effective anti-diarrheal but can cause constipation.  We tested whether modulating μ opioid receptor agonism with δ opioid receptor antagonism, by combining ref. compds. or using a novel compd. ("MuDelta"), could normalize GI motility without constipation.  Exptl. Approach: MuDelta was characterized in vitro as a potent μ opioid receptor agonist and high-affinity δ opioid receptor antagonist.  Ref. compds., MuDelta and loperamide were assessed in the following ex vivo and in vivo expts.: guinea pig intestinal smooth muscle contractility, mouse intestinal epithelial ion transport and upper GI tract transit, entire GI transit or fecal output in novel environment stressed mice, or four weeks after intracolonic mustard oil (post-inflammatory).  Colonic δ opioid receptor immunoreactivity was quantified.  Key Results: δ Opioid receptor antagonism opposed μ opioid receptor agonist inhibition of intestinal contractility and motility.  MuDelta reduced intestinal contractility and inhibited neurogenically-mediated secretion.  Very low plasma levels of MuDelta were detected after oral administration.  Stress up-regulated δ opioid receptor expression in colonic epithelial cells.  In stressed mice, MuDelta normalized GI transit and fecal output to control levels over a wide dose range, whereas loperamide had a narrow dose range.  MuDelta and loperamide reduced upper GI transit in the post-inflammatory model.  Conclusions and Implications: MuDelta normalizes, but does not prevent, perturbed GI transit over a wide dose-range in mice.  These data support the subsequent assessment of MuDelta in a clin. phase II trial in patients with diarrhea-predominant irritable bowel syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQG0V55ljlfbVg90H21EOLACvtfcHk0lhRlETqG_vO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7fI&md5=5afeecf803cf0cbf8860ab13f23807c8</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02068.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02068.x%26sid%3Dliteratum%253Aachs%26aulast%3DWade%26aufirst%3DP.%2BR.%26aulast%3DPalmer%26aufirst%3DJ.%2BM.%26aulast%3DMcKenney%26aufirst%3DS.%26aulast%3DKenigs%26aufirst%3DV.%26aulast%3DChevalier%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DB.%2BA.%26aulast%3DMabus%26aufirst%3DJ.%2BR.%26aulast%3DSaunders%26aufirst%3DP.%2BR.%26aulast%3DWallace%26aufirst%3DN.%2BH.%26aulast%3DSchneider%26aufirst%3DC.%2BR.%26aulast%3DKimball%26aufirst%3DE.%2BS.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DHornby%26aufirst%3DP.%2BJ.%26atitle%3DModulation%2520of%2520Gastrointestinal%2520Function%2520by%2520MuDelta%252C%2520a%2520Mixed%2520%25CE%25BC%2520Opioid%2520Receptor%2520Agonist%252F%25CE%25B4%2520Opioid%2520Receptor%2520Antagonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1111%26epage%3D1125%26doi%3D10.1111%2Fj.1476-5381.2012.02068.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Lembo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacy, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuckerman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dove, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrae, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, P. S.</span><span> </span><span class="NLM_article-title">Eluxadoline for Irritable Bowel Syndrome with Diarrhea</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1056/NEJMoa1505180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1056%2FNEJMoa1505180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26789872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2murzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=242-253&author=A.+J.+Lemboauthor=B.+E.+Lacyauthor=M.+J.+Zuckermanauthor=R.+Scheyauthor=L.+S.+Doveauthor=D.+A.+Andraeauthor=J.+M.+Davenportauthor=G.+McIntyreauthor=R.+Lopezauthor=L.+Turnerauthor=P.+S.+Covington&title=Eluxadoline+for+Irritable+Bowel+Syndrome+with+Diarrhea&doi=10.1056%2FNEJMoa1505180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Eluxadoline for irritable bowel syndrome with diarrhea</span></div><div class="casAuthors">Lembo, Anthony J.; Lacy, Brian E.; Zuckerman, Marc J.; Schey, Ron; Dove, Leonard S.; Andrae, David A.; Davenport, J. Michael; McIntyre, Gail; Lopez, Rocio; Turner, Lisa; Covington, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-253</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea.  We conducted two phase 3 trials to assess the efficacy and safety of eluxadoline, a new oral agent with mixed opioid effects (μ- and κ-opioid receptor agonist and d-opioid receptor antagonist), in patients with IBS with diarrhea.  METHODS We randomly assigned 2427 adults who had IBS with diarrhea to eluxadoline (at a dose of 75 mg or 100 mg) or placebo twice daily for 26 wk (IBS-3002 trial) or 52 wk (IBS-3001 trial).  The primary end point was the proportion of patients who had a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50% of the days from weeks 1 through 12 and from weeks 1 through 26.  RESULTS For weeks 1 through 12, more patients in the eluxadoline groups (75 mg and 100 mg) than in the placebo group reached the primary end point (IBS-3001 trial, 23.9% with the 75-mg dose and 25.1% with the 100-mg dose vs. 17.1% with placebo; P = 0.01 and P = 0.004, resp.; IBS-3002 trial, 28.9% and 29.6%, resp., vs. 16.2%; P<0.001 for both comparisons).  For weeks 1 through 26, the corresponding rates in IBS-3001 were 23.4% and 29.3% vs. 19.0% (P = 0.11 and P<0.001, resp.), and the corresponding rates in IBS-3002 were 30.4% and 32.7% vs. 20.2% (P = 0.001 and P<0.001, resp.).  The most common adverse events assocd. with 75 mg of eluxadoline and 100 mg of eluxadoline, as compared with placebo, were nausea (8.1% and 7.5% vs. 5.1%), constipation (7.4% and 8.6% vs. 2.5%), and abdominal pain (5.8% and 7.2% vs. 4.1%).  Pancreatitis developed in 5 (2 in the 75-mg group and 3 in the 100-mg group) of the 1666 patients in the safety population (0.3%).  CONCLUSIONS Eluxadoline is a new therapeutic agent that reduced symptoms of IBS with diarrhea in men and women, with sustained efficacy over 6 mo in patients who received the 100-mg dose twice daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_84WD0f6Ic7Vg90H21EOLACvtfcHk0lhRlETqG_vO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2murzL&md5=9f9c72c794d938e8117d8a961daed793</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1505180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1505180%26sid%3Dliteratum%253Aachs%26aulast%3DLembo%26aufirst%3DA.%2BJ.%26aulast%3DLacy%26aufirst%3DB.%2BE.%26aulast%3DZuckerman%26aufirst%3DM.%2BJ.%26aulast%3DSchey%26aufirst%3DR.%26aulast%3DDove%26aufirst%3DL.%2BS.%26aulast%3DAndrae%26aufirst%3DD.%2BA.%26aulast%3DDavenport%26aufirst%3DJ.%2BM.%26aulast%3DMcIntyre%26aufirst%3DG.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DTurner%26aufirst%3DL.%26aulast%3DCovington%26aufirst%3DP.%2BS.%26atitle%3DEluxadoline%2520for%2520Irritable%2520Bowel%2520Syndrome%2520with%2520Diarrhea%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D242%26epage%3D253%26doi%3D10.1056%2FNEJMoa1505180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Breslin, H. J.; Cai, C.; He, W.; Kavash, R. W.</span><span> </span><span class="NLM_article-title">Preparation of Imidazole Derivatives as Opioid Receptor Modulators</span>. WO 20050203143A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=H.+J.+Breslin&author=C.+Cai&author=W.+He&author=R.+W.+Kavash&title=Preparation+of+Imidazole+Derivatives+as+Opioid+Receptor+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26atitle%3DPreparation%2520of%2520Imidazole%2520Derivatives%2520as%2520Opioid%2520Receptor%2520Modulators%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Cai, C.; He, W.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Amino Acid Derivatives as Opioid Modulators</span>. WO 2006099060A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=C.+Cai&author=W.+He&title=Process+for+the+Preparation+of+Amino+Acid+Derivatives+as+Opioid+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DC.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Amino%2520Acid%2520Derivatives%2520as%2520Opioid%2520Modulators%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Anzalone, L.; Villani, F. J.; Teleha, C. A.; Feibush, P.; Fegely, B.</span><span> </span><span class="NLM_article-title">Novel Crystals and Process of Making 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1<i>H</i>-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxybenzoic Acid</span>. WO 2009009480A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=L.+Anzalone&author=F.+J.+Villani&author=C.+A.+Teleha&author=P.+Feibush&author=B.+Fegely&title=Novel+Crystals+and+Process+of+Making+5-%28%7B%5B2-Amino-3-%284-carbamoyl-2%2C6-dimethyl-phenyl%29-propionyl%5D-%5B1-%284-phenyl-1H-imidazol-2-yl%29-ethyl%5D-amino%7D-methyl%29-2-methoxybenzoic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAnzalone%26aufirst%3DL.%26atitle%3DNovel%2520Crystals%2520and%2520Process%2520of%2520Making%25205-%2528%257B%255B2-Amino-3-%25284-carbamoyl-2%252C6-dimethyl-phenyl%2529-propionyl%255D-%255B1-%25284-phenyl-1H-imidazol-2-yl%2529-ethyl%255D-amino%257D-methyl%2529-2-methoxybenzoic%2520Acid%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Syed, Y. Y.</span><span> </span><span class="NLM_article-title">Rolapitant: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1941</span><span class="NLM_x">–</span> <span class="NLM_lpage">1945</span><span class="refDoi"> DOI: 10.1007/s40265-015-0485-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0485-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26467681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1941-1945&author=Y.+Y.+Syed&title=Rolapitant%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0485-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1941-1945</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Rolapitant (Varubi) is an orally active neurokinin-1 receptor antagonist developed by TESARO and approved in the USA for use in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.  Unlike other approved agents in this class, rolapitant does not interact with cytochrome P 450 (CYP) enzyme CYP3A4.  It also has a long elimination half-life which means that a single dose could prevent CINV during the entire at-risk period (0-120 h).  An i.v. formulation of rolapitant is under clin. development in the USA.  Phase II development of rolapitant in postoperative nausea and vomiting, and cough appears to have been discontinued.  This article summarizes the milestones in the development of rolapitant leading to the first approval for the prevention of CINV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYwyS3mfly17Vg90H21EOLACvtfcHk0ljET0IAKp7_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbvM&md5=053f47d986332d2442b6fc8a08066814</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0485-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0485-8%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DRolapitant%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1941%26epage%3D1945%26doi%3D10.1007%2Fs40265-015-0485-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Duffy, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varty, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, E. M.</span><span> </span><span class="NLM_article-title">Rolapitant (SCH 619734): A Potent, Selective and Orally Active Neurokinin NK1 Receptor Antagonist with Centrally-mediated Antiemetic Effects in Ferrets</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1016/j.pbb.2012.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.pbb.2012.03.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22497992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2012&pages=95-100&author=R.+A.+Duffyauthor=C.+Morganauthor=R.+Naylorauthor=G.+A.+Higginsauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=E.+M.+Parker&title=Rolapitant+%28SCH+619734%29%3A+A+Potent%2C+Selective+and+Orally+Active+Neurokinin+NK1+Receptor+Antagonist+with+Centrally-mediated+Antiemetic+Effects+in+Ferrets&doi=10.1016%2Fj.pbb.2012.03.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant (SCH 619734): A potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets</span></div><div class="casAuthors">Duffy, Ruth A.; Morgan, Cynthia; Naylor, Robert; Higgins, Guy A.; Varty, Geoffrey B.; Lachowicz, Jean E.; Parker, Eric M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-100</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NK1 receptor antagonists have been shown to have a variety of physiol. and potential therapeutic effects in animal models and in humans.  The present studies demonstrate that Rolapitant (SCH 619734, (5S)-8(S)-[[1(R)-[3,5 bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one) is a selective, bioavailable, CNS penetrant neurokinin NK1 receptor antagonist that shows behavioral effects in animals models of emesis.  In vitro studies indicate that rolapitant has a high affinity for the human NK1 receptor of 0.66 nM and high selectivity over the human NK2 and NK3 subtypes of > 1000-fold, as well as preferential affinity for human, guinea pig, gerbil and monkey NK1 receptors over rat, mouse and rabbit.  Rolapitant is a functionally competitive antagonist, as measured by calcium efflux, with a calcd. Kb of 0.17 nM.  Rolapitant reversed NK1 agonist-induced foot tapping in gerbils following both i.v. and oral administration up to 24 h at a minimal ED (MED) of 0.1 mg/kg.  Rolapitant was active at 0.1 and 1 mg/kg in both acute and delayed emesis models in ferrets, resp., consistent with clin. data for other NK1 antagonists.  Clin. efficacy of anti-emetics is highly correlated with efficacy in the ferret emesis model, suggesting rolapitant is a viable clin. candidate for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeOZ_Iy_LTMLVg90H21EOLACvtfcHk0ljET0IAKp7_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFagu7w%253D&md5=a2eeef1c15adfb885e89c0c2a5ab4cbe</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2012.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2012.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DR.%2BA.%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DNaylor%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DParker%26aufirst%3DE.%2BM.%26atitle%3DRolapitant%2520%2528SCH%2520619734%2529%253A%2520A%2520Potent%252C%2520Selective%2520and%2520Orally%2520Active%2520Neurokinin%2520NK1%2520Receptor%2520Antagonist%2520with%2520Centrally-mediated%2520Antiemetic%2520Effects%2520in%2520Ferrets%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2012%26volume%3D102%26spage%3D95%26epage%3D100%26doi%3D10.1016%2Fj.pbb.2012.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Janelsins, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tejani, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peoples, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustian, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, G. R.</span><span> </span><span class="NLM_article-title">Current Pharmacotherapy for Chemotherapy-induced Nausea and Vomiting in Cancer Patients</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">757</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span><span class="refDoi"> DOI: 10.1517/14656566.2013.776541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14656566.2013.776541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=23496347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=757-766&author=M.+C.+Janelsinsauthor=M.+A.+Tejaniauthor=C.+Kamenauthor=A.+R.+Peoplesauthor=K.+M.+Mustianauthor=G.+R.+Morrow&title=Current+Pharmacotherapy+for+Chemotherapy-induced+Nausea+and+Vomiting+in+Cancer+Patients&doi=10.1517%2F14656566.2013.776541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients</span></div><div class="casAuthors">Janelsins, Michelle C.; Tejani, Mohamedtaki A.; Kamen, Charles; Peoples, Anita R.; Mustian, Karen M.; Morrow, Gary R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">757-766</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Nausea and vomiting are two of the most frequent and troubling side effects patients experience during chemotherapy, interfering with compliance with cancer therapies and quality of life.  While newly available treatments have improved our ability to manage nausea and vomiting, anticipatory and delayed nausea and vomiting are still major problems for patients receiving chemotherapy.  Many cancer patients consider delaying future chemotherapy cycles and some contemplate stopping chemotherapy altogether because of their fear of experiencing further nausea and vomiting.Areas covered: The purpose of this article is to provide an overview of the pathopsychophysiol. of chemotherapy-induced nausea and vomiting (CINV), the recommended guidelines for treatment, and current agents in late-stage clin. trials, and future research needs to address the continued challenges of treatment-related nausea and vomiting.Expert opinion: Despite advances in pharmaceutical and behavioral therapies, and the provision of std. clin. guidelines for effectively managing CINV, patients continue to experience it.  Moreover, control of nausea, acute and delayed, and anticipatory nausea and vomiting remains an important, unmet need among cancer patients.  It is crit. to focus attention on better understanding the mechanisms underlying nausea, anticipatory symptoms and delayed symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGxPTxNlvA_LVg90H21EOLACvtfcHk0lg7EkqQVXth9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKmsLs%253D&md5=d012824f6f138da7286175cf9253141f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.776541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.776541%26sid%3Dliteratum%253Aachs%26aulast%3DJanelsins%26aufirst%3DM.%2BC.%26aulast%3DTejani%26aufirst%3DM.%2BA.%26aulast%3DKamen%26aufirst%3DC.%26aulast%3DPeoples%26aufirst%3DA.%2BR.%26aulast%3DMustian%26aufirst%3DK.%2BM.%26aulast%3DMorrow%26aufirst%3DG.%2BR.%26atitle%3DCurrent%2520Pharmacotherapy%2520for%2520Chemotherapy-induced%2520Nausea%2520and%2520Vomiting%2520in%2520Cancer%2520Patients%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D757%26epage%3D766%26doi%3D10.1517%2F14656566.2013.776541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Navari, R. M.</span><span> </span><span class="NLM_article-title">Rolapitant for the Treatment of Chemotherapy-induced Nausea and Vomiting</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1133</span><span class="refDoi"> DOI: 10.1586/14737140.2015.1088787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1586%2F14737140.2015.1088787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26366937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCmsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1127-1133&author=R.+M.+Navari&title=Rolapitant+for+the+Treatment+of+Chemotherapy-induced+Nausea+and+Vomiting&doi=10.1586%2F14737140.2015.1088787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant for the treatment of chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Navari, Rudolph M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1127-1133</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Chemotherapy-induced nausea and vomiting is a significant clin. issue which affects patient's quality of life and treatment decisions.  Significant improvements in the control of chemotherapy-induced nausea and vomiting have occurred in the past 15 years with the introduction of new antiemetic agents 5-HT3, receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and olanzapine.  Aprepitant was the first NK-1 receptor antagonist introduced (2003) for the prevention of chemotherapy-induced nausea and vomiting in combination with a 5-HT3 receptor antagonist and dexamethasone.  A second NK-1 receptor antagonist netupitant was approved for use in Oct. 2014.  Phase III clin. trials of an addnl. NK-1 receptor antagonist rolapitant have been completed, and the data have been submitted for regulatory approval.  A description of rolapitant and its role in chemotherapy-induced nausea and vomiting will be presented, along with a comparison of the other neurolinin-1 receptor antagonists aprepitant and netupitant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAnPqNsv07zrVg90H21EOLACvtfcHk0lg7EkqQVXth9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCmsb%252FM&md5=2014c10630544b888f3500a82d62e03e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1586%2F14737140.2015.1088787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2015.1088787%26sid%3Dliteratum%253Aachs%26aulast%3DNavari%26aufirst%3DR.%2BM.%26atitle%3DRolapitant%2520for%2520the%2520Treatment%2520of%2520Chemotherapy-induced%2520Nausea%2520and%2520Vomiting%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2015%26volume%3D15%26spage%3D1127%26epage%3D1133%26doi%3D10.1586%2F14737140.2015.1088787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Romero, D.</span><span> </span><span class="NLM_article-title">Chemotherapy Rolapitant - a New and Safer Antiemetic Agent</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">562</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2015.144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1038%2Fnrclinonc.2015.144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26305036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVahtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=562&author=D.+Romero&title=Chemotherapy+Rolapitant+-+a+New+and+Safer+Antiemetic+Agent&doi=10.1038%2Fnrclinonc.2015.144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy Rolapitant - a new and safer antiemetic agent</span></div><div class="casAuthors">Romero, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">562</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chemotherapy rolapitant is a new and safer antiemetic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUJb9EH4aWrVg90H21EOLACvtfcHk0lg7EkqQVXth9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVahtLzJ&md5=41f53e4afa8d1aff98f97a7b846f29f2</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.144%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%26atitle%3DChemotherapy%2520Rolapitant%2520-%2520a%2520New%2520and%2520Safer%2520Antiemetic%2520Agent%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D562%26doi%3D10.1038%2Fnrclinonc.2015.144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schwartzberg, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modiano, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapoport, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chasen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gridelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navari, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnadig, I. D.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of Rolapitant for Prevention of Chemotherapy-induced Nausea and Vomiting after Administration of Moderately Emetogenic Chemotherapy or Anthracycline and Cyclophosphamide Regimens in Patients with Cancer: a Randomised, Active-controlled, Double-blind, Phase 3 Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">–</span> <span class="NLM_lpage">1078</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00034-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS1470-2045%2815%2900034-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26272768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWgt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1071-1078&author=L.+S.+Schwartzbergauthor=M.+R.+Modianoauthor=B.+L.+Rapoportauthor=M.+R.+Chasenauthor=C.+Gridelliauthor=L.+Urbanauthor=A.+Pomaauthor=S.+Aroraauthor=R.+M.+Navariauthor=I.+D.+Schnadig&title=Safety+and+Efficacy+of+Rolapitant+for+Prevention+of+Chemotherapy-induced+Nausea+and+Vomiting+after+Administration+of+Moderately+Emetogenic+Chemotherapy+or+Anthracycline+and+Cyclophosphamide+Regimens+in+Patients+with+Cancer%3A+a+Randomised%2C+Active-controlled%2C+Double-blind%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2815%2900034-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72aR"><div class="casContent"><span class="casTitleNuber">72a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial</span></div><div class="casAuthors">Schwartzberg, Lee S.; Modiano, Manuel R.; Rapoport, Bernardo L.; Chasen, Martin R.; Gridelli, Cesare; Urban, Laszlo; Poma, Allen; Arora, Sujata; Navari, Rudolph M.; Schnadig, Ian D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1071-1078</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chemotherapy-induced nausea and vomiting is a common side-effect of many antineoplastic regimens and can occur for several days after treatment.  We aimed to assess the neurokinin-1 receptor antagonist rolapitant, in combination with a serotonin (5-HT3) receptor antagonist and dexamethasone, for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of moderately emetogenic chemotherapy or regimens contg. an anthracycline and cyclophosphamide.  We conducted a global, randomised, double-blind, active-controlled, phase 3 study at 170 cancer centers in 23 countries.  We included patients with cancer aged 18 years or older, who had not received moderately or highly emetogenic chemotherapy before, with a Karnofsky performance score of 60 or higher, and a predicted life expectancy of 4 mo or longer.  We used an interactive web-based randomisation system to randomly allocate patients to receive either oral rolapitant (one 180 mg dose; rolapitant group) or a placebo that was identical in appearance (active control group) 1-2 h before administration of moderately emetogenic chemotherapy.  Patients were stratified by sex.  All patients also received granisetron (2 mg orally) and dexamethasone (20 mg orally) on day 1 (except for patients receiving taxanes as part of moderately emetogenic chemotherapy, who received dexamethasone according to the package insert) and granisetron (2 mg orally) on days 2-3.  Every cycle was a min. of 14 days.  In up to five subsequent cycles, patients received the same study drug they were assigned in cycle 1, unless they chose to leave the study or were removed at the treating clinician's discretion.  Efficacy anal. was done in the modified intention-to-treat population (comprising all patients who received at least one dose of study drug at a study site compliant with Good Clin. Practice [GCP]).  The primary endpoint was the proportion of patients achieving a complete response (defined as no emesis or use of rescue medication) in the delayed phase (>24-120 h after initiation of chemotherapy) in cycle 1.  This study is registered with ClinicalTrials.gov, no. NCT01500226.  The study has been completed.  Between March 5, 2012, and Sept 6, 2013, 1369 patients were randomised to receive either rolapitant (n=684) or active control (n=685). 666 patients in each group received at least one dose of study drug at a GCP-compliant site and were included in the modified intention-to-treat population.  A significantly greater proportion of patients receiving rolapitant had complete responses in the delayed phase than did those receiving active control (475 [71%] vs 410 [62%]; odds ratio 1·6, 95% CI 1·2-2·0; p=0·0002).  The incidence of adverse events was similar in the rolapitant and control groups, with the most frequently reported treatment-related treatment-emergent adverse events being fatigue, constipation, and headache.  For cycle 1, the most common grade 3-4 adverse event in the rolapitant vs. active control groups was neutropenia (32 [5%] vs 23 [3%] patients).  No serious adverse event was treatment-related, and no treatment-related treatment-emergent adverse event resulted in death.  Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well tolerated and shows superiority over active control for the prevention of chemotherapy-induced nausea and vomiting during the 5-day (0-120 h) at-risk period after administration of moderately emetogenic chemotherapy or regimens contg. an anthracycline and cyclophosphamide.TESARO, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1Gd_H8w0YbVg90H21EOLACvtfcHk0lhEdrusG8uTOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWgt7zO&md5=ff42f7d4553124c60386e186fcac1da5</span></div><a href="/servlet/linkout?suffix=cit72a&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900034-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900034-0%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartzberg%26aufirst%3DL.%2BS.%26aulast%3DModiano%26aufirst%3DM.%2BR.%26aulast%3DRapoport%26aufirst%3DB.%2BL.%26aulast%3DChasen%26aufirst%3DM.%2BR.%26aulast%3DGridelli%26aufirst%3DC.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3DPoma%26aufirst%3DA.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DNavari%26aufirst%3DR.%2BM.%26aulast%3DSchnadig%26aufirst%3DI.%2BD.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Rolapitant%2520for%2520Prevention%2520of%2520Chemotherapy-induced%2520Nausea%2520and%2520Vomiting%2520after%2520Administration%2520of%2520Moderately%2520Emetogenic%2520Chemotherapy%2520or%2520Anthracycline%2520and%2520Cyclophosphamide%2520Regimens%2520in%2520Patients%2520with%2520Cancer%253A%2520a%2520Randomised%252C%2520Active-controlled%252C%2520Double-blind%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1071%26epage%3D1078%26doi%3D10.1016%2FS1470-2045%2815%2900034-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit72b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rapoport, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chasen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnadig, I.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of Rolapitant for Prevention of Chemotherapy-induced Nausea and Vomiting Over Multiple Cycles of Moderately or Highly Emetogenic Chemotherapy</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1016/j.ejca.2015.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.ejca.2015.12.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=23-30&author=B.+Rapoportauthor=L.+Schwartzbergauthor=M.+Chasenauthor=D.+Powersauthor=S.+Aroraauthor=R.+Navariauthor=I.+Schnadig&title=Efficacy+and+Safety+of+Rolapitant+for+Prevention+of+Chemotherapy-induced+Nausea+and+Vomiting+Over+Multiple+Cycles+of+Moderately+or+Highly+Emetogenic+Chemotherapy&doi=10.1016%2Fj.ejca.2015.12.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DRapoport%26aufirst%3DB.%26aulast%3DSchwartzberg%26aufirst%3DL.%26aulast%3DChasen%26aufirst%3DM.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DNavari%26aufirst%3DR.%26aulast%3DSchnadig%26aufirst%3DI.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Rolapitant%2520for%2520Prevention%2520of%2520Chemotherapy-induced%2520Nausea%2520and%2520Vomiting%2520Over%2520Multiple%2520Cycles%2520of%2520Moderately%2520or%2520Highly%2520Emetogenic%2520Chemotherapy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D57%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.ejca.2015.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Wu, G. G.; Werne, G.; Fu, X.; Orr, R. K.; Chen, F. X.; Cui, J.; Sprague, V. M.; Zhang, F.; Xie, J.; Zeng, L.; Castellanos, L. P.; Chen, Y.; Poirier, M.; Mergelsberg, I.</span><span> </span><span class="NLM_article-title">Process and Intermediates for the Synthesis of 8-[[1-[3,5-bis-(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one Compounds</span>. WO 2010028232A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=G.+G.+Wu&author=G.+Werne&author=X.+Fu&author=R.+K.+Orr&author=F.+X.+Chen&author=J.+Cui&author=V.+M.+Sprague&author=F.+Zhang&author=J.+Xie&author=L.+Zeng&author=L.+P.+Castellanos&author=Y.+Chen&author=M.+Poirier&author=I.+Mergelsberg&title=Process+and+Intermediates+for+the+Synthesis+of+8-%5B%5B1-%5B3%2C5-bis-%28trifluoromethyl%29phenyl%5Dethoxy%5Dmethyl%5D-8-phenyl-1%2C7-diazaspiro%5B4.5%5Ddecan-2-one+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%2BG.%26atitle%3DProcess%2520and%2520Intermediates%2520for%2520the%2520Synthesis%2520of%25208-%255B%255B1-%255B3%252C5-bis-%2528trifluoromethyl%2529phenyl%255Dethoxy%255Dmethyl%255D-8-phenyl-1%252C7-diazaspiro%255B4.5%255Ddecan-2-one%2520Compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Dikshit, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheshwari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panday, S. K.</span><span> </span><span class="NLM_article-title">Self Reproduction of Chirality in Pyroglutamates: Reactions at α-Position with Electrophiles</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">6131</span><span class="NLM_x">–</span> <span class="NLM_lpage">6134</span><span class="refDoi"> DOI: 10.1016/0040-4039(95)01160-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2F0040-4039%2895%2901160-J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=6131-6134&author=D.+K.+Dikshitauthor=A.+Maheshwariauthor=S.+K.+Panday&title=Self+Reproduction+of+Chirality+in+Pyroglutamates%3A+Reactions+at+%CE%B1-Position+with+Electrophiles&doi=10.1016%2F0040-4039%2895%2901160-J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2895%2901160-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252895%252901160-J%26sid%3Dliteratum%253Aachs%26aulast%3DDikshit%26aufirst%3DD.%2BK.%26aulast%3DMaheshwari%26aufirst%3DA.%26aulast%3DPanday%26aufirst%3DS.%2BK.%26atitle%3DSelf%2520Reproduction%2520of%2520Chirality%2520in%2520Pyroglutamates%253A%2520Reactions%2520at%2520%25CE%25B1-Position%2520with%2520Electrophiles%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D6131%26epage%3D6134%26doi%3D10.1016%2F0040-4039%2895%2901160-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">O’Donnell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffman, J. C.</span><span> </span><span class="NLM_article-title">New Methodology for the Synthesis of α,α-Dialkylamino Acids Using the ″Self-regeneration of Stereocenters″ Method: α-Ethyl-α-phenylglycine</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.3987/COM-97-S83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.3987%2FCOM-97-S83" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1997&pages=617-630&author=M.+J.+O%E2%80%99Donnellauthor=Z.+Fangauthor=X.+Maauthor=J.+C.+Huffman&title=New+Methodology+for+the+Synthesis+of+%CE%B1%2C%CE%B1-Dialkylamino+Acids+Using+the+%E2%80%B3Self-regeneration+of+Stereocenters%E2%80%B3+Method%3A+%CE%B1-Ethyl-%CE%B1-phenylglycine&doi=10.3987%2FCOM-97-S83"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.3987%2FCOM-97-S83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-97-S83%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BJ.%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DHuffman%26aufirst%3DJ.%2BC.%26atitle%3DNew%2520Methodology%2520for%2520the%2520Synthesis%2520of%2520%25CE%25B1%252C%25CE%25B1-Dialkylamino%2520Acids%2520Using%2520the%2520%25E2%2580%25B3Self-regeneration%2520of%2520Stereocenters%25E2%2580%25B3%2520Method%253A%2520%25CE%25B1-Ethyl-%25CE%25B1-phenylglycine%26jtitle%3DHeterocycles%26date%3D1997%26volume%3D46%26spage%3D617%26epage%3D630%26doi%3D10.3987%2FCOM-97-S83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Paliwal, S.; Reichard, G. A.; Wang, C.; Xiao, D.; Tsui, H.-C.; Shih, N.-Y.; Arredondo, J. D.; Wrobleski, M. L.; Palani, A.</span><span> </span><span class="NLM_article-title">Preparation of Pyrrolidine and Piperidine Derivatives for Therapeutic Use as Neurokinin 1 (NK1) Receptor Antagonists</span>. WO 2003051840A1,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=S.+Paliwal&author=G.+A.+Reichard&author=C.+Wang&author=D.+Xiao&author=H.-C.+Tsui&author=N.-Y.+Shih&author=J.+D.+Arredondo&author=M.+L.+Wrobleski&author=A.+Palani&title=Preparation+of+Pyrrolidine+and+Piperidine+Derivatives+for+Therapeutic+Use+as+Neurokinin+1+%28NK1%29+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPaliwal%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Pyrrolidine%2520and%2520Piperidine%2520Derivatives%2520for%2520Therapeutic%2520Use%2520as%2520Neurokinin%25201%2520%2528NK1%2529%2520Receptor%2520Antagonists%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, E. S.</span><span> </span><span class="NLM_article-title">Lusutrombopag: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.1007/s40265-015-0525-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0525-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=155-158&author=E.+S.+Kim&title=Lusutrombopag%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0525-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0525-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0525-4%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DLusutrombopag%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D155%26epage%3D158%26doi%3D10.1007%2Fs40265-015-0525-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit77b"><span><span class="NLM_label">(b) </span>Shionogi Receives Marketing and Manufacturing Approval in Japan for Mulpleta Tablets 3 mg for Improvement of Thrombocytopenia; <span class="NLM_publisher-name">Shionogi and Co., Ltd.</span>: <span class="NLM_publisher-loc">Osaka</span>, September 28,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.shionogi.co.jp/en/company/news/2015/pmrltj0000002g0l-att/e_150928.pdf" class="extLink">http://www.shionogi.co.jp/en/company/news/2015/pmrltj0000002g0l-att/e_150928.pdf</a> (accessed August 2, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Shionogi+Receives+Marketing+and+Manufacturing+Approval+in+Japan+for+Mulpleta+Tablets+3+mg+for+Improvement+of+Thrombocytopenia%3B+Shionogi+and+Co.%2C+Ltd.%3A+Osaka%2C+September+28%2C+2015%3B+http%3A%2F%2Fwww.shionogi.co.jp%2Fen%2Fcompany%2Fnews%2F2015%2Fpmrltj0000002g0l-att%2Fe_150928.pdf+%28accessed+August+2%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DShionogi%2520Receives%2520Marketing%2520and%2520Manufacturing%2520Approval%2520in%2520Japan%2520for%2520Mulpleta%2520Tablets%25203%2520mg%2520for%2520Improvement%2520of%2520Thrombocytopenia%26pub%3DShionogi%2520and%2520Co.%252C%2520Ltd%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Poordad, F.</span><span> </span><span class="NLM_article-title">Review Article: Thrombocytopenia in Chronic Liver Disease</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">s1</span><span class="NLM_x">) </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1111/j.1365-2036.2007.03510.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fj.1365-2036.2007.03510.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=17958514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVyjt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5-11&issue=s1&author=F.+Poordad&title=Review+Article%3A+Thrombocytopenia+in+Chronic+Liver+Disease&doi=10.1111%2Fj.1365-2036.2007.03510.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Review article: thrombocytopenia in chronic liver disease</span></div><div class="casAuthors">Poordad, F.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">5-11</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Thrombocytopenia is a common finding in advanced liver disease.  It is predominantly a result of portal hypertension and platelet sequestration in the enlarged spleen, but other mechanisms may contribute.  The liver is the site of thrombopoietin (TPO) synthesis, a hormone that leads to proliferation and differentiation of megakaryocytes and platelet formation.  Reduced TPO prodn. further reduces measurable serum platelet counts.  Aim: This paper describes the scope of thrombocytopenia in chronic liver disease and assesses the clin. impact in this patient population.  Methods: A medline review of the literature was performed pertaining to thrombocytopenia and advanced liver disease.  This data is compiled into a review of the impact of low platelets in liver disease.  Results: The incidence of thrombocytopenia, its impact on clin. decision making and the use of platelet transfusions are addressed.  Emerging novel therapeutics for thrombocytopenia is also discussed.  Conclusions: Thrombocytopenia is a common and challenging clin. disorder in patients with chronic liver disease.  New therapeutic options are needed to safely increase platelet counts prior to invasive medical procedures as well as to counteract therapies that further exacerbate low platelets, such as interferon.  An ideal compd. would be orally available and safe, with rapid onset of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNXdgpRG6LjrVg90H21EOLACvtfcHk0ljziba2L7mdKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVyjt7fI&md5=d79c936da344709430146538569862d9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2007.03510.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2007.03510.x%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26atitle%3DReview%2520Article%253A%2520Thrombocytopenia%2520in%2520Chronic%2520Liver%2520Disease%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2007%26volume%3D26%26issue%3Ds1%26spage%3D5%26epage%3D11%26doi%3D10.1111%2Fj.1365-2036.2007.03510.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Maan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Knegt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veldt, B. J.</span><span> </span><span class="NLM_article-title">Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1981</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1007/s40265-015-0480-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0480-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1981-1992&author=R.+Maanauthor=R.+J.+de+Knegtauthor=B.+J.+Veldt&title=Management+of+Thrombocytopenia+in+Chronic+Liver+Disease%3A+Focus+on+Pharmacotherapeutic+Strategies&doi=10.1007%2Fs40265-015-0480-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0480-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0480-0%26sid%3Dliteratum%253Aachs%26aulast%3DMaan%26aufirst%3DR.%26aulast%3Dde%2BKnegt%26aufirst%3DR.%2BJ.%26aulast%3DVeldt%26aufirst%3DB.%2BJ.%26atitle%3DManagement%2520of%2520Thrombocytopenia%2520in%2520Chronic%2520Liver%2520Disease%253A%2520Focus%2520on%2520Pharmacotherapeutic%2520Strategies%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1981%26epage%3D1992%26doi%3D10.1007%2Fs40265-015-0480-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Fukui, Y.; Maegawa, Y.; Matsuura, T.; Kurita, T.</span><span> </span><span class="NLM_article-title">Methods Respectively for Producing Optically Active Compound Having Agonistic Activity on Thrombopoietin Receptors and Intermediate of Said Compound</span>. WO 2015093586A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Fukui&author=Y.+Maegawa&author=T.+Matsuura&author=T.+Kurita&title=Methods+Respectively+for+Producing+Optically+Active+Compound+Having+Agonistic+Activity+on+Thrombopoietin+Receptors+and+Intermediate+of+Said+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFukui%26aufirst%3DY.%26atitle%3DMethods%2520Respectively%2520for%2520Producing%2520Optically%2520Active%2520Compound%2520Having%2520Agonistic%2520Activity%2520on%2520Thrombopoietin%2520Receptors%2520and%2520Intermediate%2520of%2520Said%2520Compound%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Takayama, M.; Kurose, N.</span><span> </span><span class="NLM_article-title">Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity, and Intermediate Therefor</span>. US 20130217885A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Takayama&author=N.+Kurose&title=Pharmaceutical+Composition+Containing+Optically+Active+Compound+Having+Thrombopoietin+Receptor+Agonist+Activity%2C+and+Intermediate+Therefor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTakayama%26aufirst%3DM.%26atitle%3DPharmaceutical%2520Composition%2520Containing%2520Optically%2520Active%2520Compound%2520Having%2520Thrombopoietin%2520Receptor%2520Agonist%2520Activity%252C%2520and%2520Intermediate%2520Therefor%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Takayama, M.; Yoshida, Y.</span><span> </span><span class="NLM_article-title">Compounds Exhibiting Thrombopoietin Receptor Agonism</span>. US 20070043087A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Takayama&author=Y.+Yoshida&title=Compounds+Exhibiting+Thrombopoietin+Receptor+Agonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTakayama%26aufirst%3DM.%26atitle%3DCompounds%2520Exhibiting%2520Thrombopoietin%2520Receptor%2520Agonism%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Duncan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotunda, A. M.</span><span> </span><span class="NLM_article-title">Injectable Therapies for Localized Fat Loss: State of the Art</span> <span class="citation_source-journal">Clin. Plastic Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1016/j.cps.2011.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.cps.2011.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=21824545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC3Mjks1KgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=489-501&author=D.+Duncanauthor=A.+M.+Rotunda&title=Injectable+Therapies+for+Localized+Fat+Loss%3A+State+of+the+Art&doi=10.1016%2Fj.cps.2011.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Injectable therapies for localized fat loss: state of the art</span></div><div class="casAuthors">Duncan Diane; Rotunda Adam M</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in plastic surgery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">489-501, vii</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review presents mechanisms of action and a review of the clinical applications of injections currently in development for localized fat reduction.  After being received with initial enthusiasm earlier in the decade, mesotherapy and other injectable methods for fat loss (Lipodissolve, PC/DC, DC, injection lipolysis, adipolysis) have been subjects of critical scrutiny by the media and the US Food and Drug Administration.  Several medications with novel detergent and lipolytic activity are in development and have demonstrated potential as minimally invasive fat reducing treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYfkom1nzjE91QT_1O5WBYfW6udTcc2eZpQGrfr748sLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mjks1KgtQ%253D%253D&md5=e21b0e3067a169afb91defb87f61132b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.cps.2011.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cps.2011.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DDuncan%26aufirst%3DD.%26aulast%3DRotunda%26aufirst%3DA.%2BM.%26atitle%3DInjectable%2520Therapies%2520for%2520Localized%2520Fat%2520Loss%253A%2520State%2520of%2520the%2520Art%26jtitle%3DClin.%2520Plastic%2520Surg.%26date%3D2011%26volume%3D38%26spage%3D489%26epage%3D501%26doi%3D10.1016%2Fj.cps.2011.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Wollina, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, A.</span><span> </span><span class="NLM_article-title">ATX-101 for Reduction of Submental Fat</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span><span class="refDoi"> DOI: 10.1517/14656566.2015.1019465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14656566.2015.1019465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25724831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktlCisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=755-762&author=U.+Wollinaauthor=A.+Goldman&title=ATX-101+for+Reduction+of+Submental+Fat&doi=10.1517%2F14656566.2015.1019465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">ATX-101 for reduction of submental fat</span></div><div class="casAuthors">Wollina, Uwe; Goldman, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">755-762</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Facial esthetics are important for self-esteem.  Undesired submental fat (SMF) deposits lead to an unappealing submental profile assocd. with aging and overweight.  Compd. is a proprietary formulation of purified synthetic deoxycholic acid for pharmacol. submental contouring.  Review areas covered: This reviews covers anatomy of SMF, biochem. of deoxycholic acid related to adipose tissue and tissue response to injection of ATX-101.  Data from clin. trials were analyzed for efficacy and safety.  Methodol.: Published studies using PubMed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ5EozonBD8rVg90H21EOLACvtfcHk0liXOG8Cts1TYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktlCisrc%253D&md5=352cd9b44db592a9e770c5467ce9825f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1019465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1019465%26sid%3Dliteratum%253Aachs%26aulast%3DWollina%26aufirst%3DU.%26aulast%3DGoldman%26aufirst%3DA.%26atitle%3DATX-101%2520for%2520Reduction%2520of%2520Submental%2520Fat%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D755%26epage%3D762%26doi%3D10.1517%2F14656566.2015.1019465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Moriarty, R. M.; Reid, J. G.; Swaringen, J. R. A.</span><span> </span><span class="NLM_article-title">Methods for the Purification of Deoxycholic Acid</span>. WO 2011075701A3,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+M.+Moriarty&author=J.+G.+Reid&author=J.+R.+A.+Swaringen&title=Methods+for+the+Purification+of+Deoxycholic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DR.%2BM.%26atitle%3DMethods%2520for%2520the%2520Purification%2520of%2520Deoxycholic%2520Acid%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Evogliptin: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2049</span><span class="refDoi"> DOI: 10.1007/s40265-015-0496-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0496-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2045-2049&author=P.+L.+McCormack&title=Evogliptin%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0496-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0496-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0496-5%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DEvogliptin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D2045%26epage%3D2049%26doi%3D10.1007%2Fs40265-015-0496-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. J.</span><span> </span><span class="NLM_article-title">Discovery of DA-1229: a Potent, Long Acting Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3809</span><span class="NLM_x">–</span> <span class="NLM_lpage">3812</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmcl.2011.04.029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3809-3812&author=H.+J.+Kimauthor=W.+Y.+Kwakauthor=J.+P.+Minauthor=J.+Y.+Leeauthor=T.+H.+Yoonauthor=H.+D.+Kimauthor=C.+Y.+Shinauthor=M.+K.+Kimauthor=S.+H.+Choiauthor=H.+S.+Kimauthor=E.+K.+Yangauthor=Y.+H.+Cheongauthor=Y.+N.+Chaeauthor=K.+J.+Parkauthor=J.+M.+Jangauthor=S.+J.+Choiauthor=M.+H.+Sonauthor=S.+H.+Kimauthor=M.+Yooauthor=B.+J.+Lee&title=Discovery+of+DA-1229%3A+a+Potent%2C+Long+Acting+Dipeptidyl+Peptidase-4+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1016%2Fj.bmcl.2011.04.029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.029%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DKwak%26aufirst%3DW.%2BY.%26aulast%3DMin%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DYoon%26aufirst%3DT.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BD.%26aulast%3DShin%26aufirst%3DC.%2BY.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DYang%26aufirst%3DE.%2BK.%26aulast%3DCheong%26aufirst%3DY.%2BH.%26aulast%3DChae%26aufirst%3DY.%2BN.%26aulast%3DPark%26aufirst%3DK.%2BJ.%26aulast%3DJang%26aufirst%3DJ.%2BM.%26aulast%3DChoi%26aufirst%3DS.%2BJ.%26aulast%3DSon%26aufirst%3DM.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DYoo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DB.%2BJ.%26atitle%3DDiscovery%2520of%2520DA-1229%253A%2520a%2520Potent%252C%2520Long%2520Acting%2520Dipeptidyl%2520Peptidase-4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3809%26epage%3D3812%26doi%3D10.1016%2Fj.bmcl.2011.04.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit87b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kwak, W. Y.; Kim, H. J.; Min, J. P.; Yoon, T. H.; Yoo, M.</span><span> </span><span class="NLM_article-title">Improved Method for Preparing Dipeptidyl Peptidase-IV Inhibitor and Intermediate</span>. WO 2010114291A2,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=W.+Y.+Kwak&author=H.+J.+Kim&author=J.+P.+Min&author=T.+H.+Yoon&author=M.+Yoo&title=Improved+Method+for+Preparing+Dipeptidyl+Peptidase-IV+Inhibitor+and+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DW.%2BY.%26atitle%3DImproved%2520Method%2520for%2520Preparing%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitor%2520and%2520Intermediate%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit87c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shin, C. Y.; Choi, S. H.; Chae, Y. N.; Yang, E. K.; Ahn, G. J.</span><span> </span><span class="NLM_article-title">Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and Other Antidiabetic or Antiobesity Agents as Active Ingredients</span>. WO 2010044637A2,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+Y.+Shin&author=S.+H.+Choi&author=Y.+N.+Chae&author=E.+K.+Yang&author=G.+J.+Ahn&title=Pharmaceutical+Composition+for+Prevention+and+Treatment+of+Diabetes+or+Obesity+Comprising+a+Compound+that+Inhibits+Activity+of+Dipeptidyl+Peptidase-IV%2C+and+Other+Antidiabetic+or+Antiobesity+Agents+as+Active+Ingredients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DC.%2BY.%26atitle%3DPharmaceutical%2520Composition%2520for%2520Prevention%2520and%2520Treatment%2520of%2520Diabetes%2520or%2520Obesity%2520Comprising%2520a%2520Compound%2520that%2520Inhibits%2520Activity%2520of%2520Dipeptidyl%2520Peptidase-IV%252C%2520and%2520Other%2520Antidiabetic%2520or%2520Antiobesity%2520Agents%2520as%2520Active%2520Ingredients%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit87d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kim, H. J.; Kwak, W. Y.; Shin, C. Y.; Kim, H.; Min, J. P.; Park, K. J.; Lee, J. Y.; Choi, S. H.; Yoon, T. H.; Kim, H. S.</span><span> </span><span class="NLM_article-title">Dpp-IV Inhibitor Including Beta-Amino Group, Preparation Method Thereof and Pharmaceutical Composition Containing the Same for Preventing and Treating a Diabetes or an Obesity</span>. WO 2008130151A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=H.+J.+Kim&author=W.+Y.+Kwak&author=C.+Y.+Shin&author=H.+Kim&author=J.+P.+Min&author=K.+J.+Park&author=J.+Y.+Lee&author=S.+H.+Choi&author=T.+H.+Yoon&author=H.+S.+Kim&title=Dpp-IV+Inhibitor+Including+Beta-Amino+Group%2C+Preparation+Method+Thereof+and+Pharmaceutical+Composition+Containing+the+Same+for+Preventing+and+Treating+a+Diabetes+or+an+Obesity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26atitle%3DDpp-IV%2520Inhibitor%2520Including%2520Beta-Amino%2520Group%252C%2520Preparation%2520Method%2520Thereof%2520and%2520Pharmaceutical%2520Composition%2520Containing%2520the%2520Same%2520for%2520Preventing%2520and%2520Treating%2520a%2520Diabetes%2520or%2520an%2520Obesity%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Kwak, W. Y.; Kim, H. J.; Min, J. P.; Yoon, T. H.; Shim, H. J.; Yoo, M.</span><span> </span><span class="NLM_article-title">Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate</span>. US 20120016126A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=W.+Y.+Kwak&author=H.+J.+Kim&author=J.+P.+Min&author=T.+H.+Yoon&author=H.+J.+Shim&author=M.+Yoo&title=Method+for+Manufacturing+Dipeptidyl+Peptidase-IV+Inhibitor+and+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DW.%2BY.%26atitle%3DMethod%2520for%2520Manufacturing%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitor%2520and%2520Intermediate%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Kwak, W. Y.; Kim, H. J.; Min, J. P.; Yoon, T. H.; Shim, H. J.; Yoo, M.</span><span> </span><span class="NLM_article-title">Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate</span>. EP 2415754A2,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=W.+Y.+Kwak&author=H.+J.+Kim&author=J.+P.+Min&author=T.+H.+Yoon&author=H.+J.+Shim&author=M.+Yoo&title=Improved+Method+for+Manufacturing+Dipeptidyl+Peptidase-IV+Inhibitor+and+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DW.%2BY.%26atitle%3DImproved%2520Method%2520for%2520Manufacturing%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitor%2520and%2520Intermediate%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Hoy, S. M.</span><span> </span><span class="NLM_article-title">Lesinurad: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1007/s40265-016-0550-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-016-0550-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26861027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=509-516&author=S.+M.+Hoy&title=Lesinurad%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0550-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Lesinurad: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-516</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Lesinurad (ZURAMPIC) is an oral urate-anion exchanger transporter 1 (URAT1) inhibitor developed by Ardea Biosciences (a subsidiary of AstraZeneca) for the treatment of hyperuricemia assocd. with gout.  It reduces serum uric acid (sUA) levels by inhibiting the function of the transporter proteins (URAT1 and org. anion transporter 4) involved in uric acid reabsorption in the kidney.  In Dec. 2015, lesinurad was approved in the USA as combination therapy with a xanthine oxidase inhibitor for the treatment of hyperuricemia assocd. with gout in patients who have not achieved sUA target levels with a xanthine oxidase inhibitor alone.  Lesinurad has also received a pos. opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for this indication and is in phase III development as a combination therapy in several other countries.  This article summarizes the milestones in the development of lesinurad leading to this first approval for hyperuricemia assocd. with gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYLnXR_1pferVg90H21EOLACvtfcHk0lgOWDjPskjT3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGrsr4%253D&md5=adff81ec4e67f65711573f15444765c8</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0550-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0550-y%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DLesinurad%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D509%26epage%3D516%26doi%3D10.1007%2Fs40265-016-0550-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, Y.; Xu, H.; Zhang, Y.; Zheng, F.</span><span> </span><span class="NLM_article-title">Axially Chiral Enantiomers of Drug Lesinurad</span>. CN 105399694A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Huang&author=H.+Xu&author=Y.+Zhang&author=F.+Zheng&title=Axially+Chiral+Enantiomers+of+Drug+Lesinurad"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26atitle%3DAxially%2520Chiral%2520Enantiomers%2520of%2520Drug%2520Lesinurad%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit91b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fan, L.; Chen, K.; Li, X.; Chen, Y.</span><span> </span><span class="NLM_article-title">Compound for Treating Gout</span>. WO 2016000568A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Fan&author=K.+Chen&author=X.+Li&author=Y.+Chen&title=Compound+for+Treating+Gout"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DL.%26atitle%3DCompound%2520for%2520Treating%2520Gout%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit91c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wang, P.; Li, P.; GU, X.</span><span> </span><span class="NLM_article-title">Gout Drug Lesinurad Preparation Method, and Lesinurad Intermediate</span>. WO 2015054960A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Wang&author=P.+Li&author=X.+GU&title=Gout+Drug+Lesinurad+Preparation+Method%2C+and+Lesinurad+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26atitle%3DGout%2520Drug%2520Lesinurad%2520Preparation%2520Method%252C%2520and%2520Lesinurad%2520Intermediate%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit91d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Chen, W.; Luo, J.; Liu, L.; Fan, Y.</span><span> </span><span class="NLM_article-title">Thio-1,2,4-triazole Derivatives and Method for Preparing the Same</span>. WO 2014198241A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=W.+Chen&author=J.+Luo&author=L.+Liu&author=Y.+Fan&title=Thio-1%2C2%2C4-triazole+Derivatives+and+Method+for+Preparing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26atitle%3DThio-1%252C2%252C4-triazole%2520Derivatives%2520and%2520Method%2520for%2520Preparing%2520the%2520Same%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit91e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Gunic, E.; Girardet, J. L.; Vernier, J. M.; Tedder, M. E.; Paisner, D. A.</span><span> </span><span class="NLM_article-title">Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels</span>. US 20100056464A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=E.+Gunic&author=J.+L.+Girardet&author=J.+M.+Vernier&author=M.+E.+Tedder&author=D.+A.+Paisner&title=Compounds%2C+Compositions+and+Methods+of+Using+Same+for+Modulating+Uric+Acid+Levels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGunic%26aufirst%3DE.%26atitle%3DCompounds%252C%2520Compositions%2520and%2520Methods%2520of%2520Using%2520Same%2520for%2520Modulating%2520Uric%2520Acid%2520Levels%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit91f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Gunic, E.; Girardet, J. L.; Vernier, J. M.; Tedder, M. E.; Paisner, D. A.</span><span> </span><span class="NLM_article-title">Compounds</span>. US 20100056465A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=E.+Gunic&author=J.+L.+Girardet&author=J.+M.+Vernier&author=M.+E.+Tedder&author=D.+A.+Paisner&title=Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGunic%26aufirst%3DE.%26atitle%3DCompounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit91g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Quart, B. D.; Girardet, J. L.; Gunic, E.; Yeh, L. T.</span><span> </span><span class="NLM_article-title">Novel Compounds and Compositions and Methods of Use</span>. WO 2009070740A2,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=B.+D.+Quart&author=J.+L.+Girardet&author=E.+Gunic&author=L.+T.+Yeh&title=Novel+Compounds+and+Compositions+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQuart%26aufirst%3DB.%2BD.%26atitle%3DNovel%2520Compounds%2520and%2520Compositions%2520and%2520Methods%2520of%2520Use%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Gunic, E.; Galvin, G.</span><span> </span><span class="NLM_article-title">Manufacture of 2-(5-Bromo-4 (-cyclopropylnaphthalen-1-yl)-4<i>H</i>-1,2,4-triazol-3-ylthio) Acetic Acid</span>. WO 2014008295A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=E.+Gunic&author=G.+Galvin&title=Manufacture+of+2-%285-Bromo-4+%28-cyclopropylnaphthalen-1-yl%29-4H-1%2C2%2C4-triazol-3-ylthio%29+Acetic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGunic%26aufirst%3DE.%26atitle%3DManufacture%2520of%25202-%25285-Bromo-4%2520%2528-cyclopropylnaphthalen-1-yl%2529-4H-1%252C2%252C4-triazol-3-ylthio%2529%2520Acetic%2520Acid%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Burness, C. B.</span><span> </span><span class="NLM_article-title">Omarigliptin: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1947</span><span class="NLM_x">–</span> <span class="NLM_lpage">1952</span><span class="refDoi"> DOI: 10.1007/s40265-015-0493-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0493-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26507988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyksrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1947-1952&author=C.+B.+Burness&title=Omarigliptin%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0493-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Omarigliptin: First Global Approval</span></div><div class="casAuthors">Burness, Celeste B.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1947-1952</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Omarigliptin [Marizev (Japan)] is a small-mol. dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck for the oral treatment of type 2 diabetes (T2DM).  Unlike the majority of other approved agents of its class, which are usually administered once daily, omarigliptin can be administered once weekly.  Once-weekly omarigliptin has received its first global approval in this indication in Japan, for use in adults.  Phase III clin. development of the product is underway in several other countries.  This article summarizes the milestones in the development of omarigliptin leading to this first approval for the treatment of T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgSdQVZsR52bVg90H21EOLACvtfcHk0lgOWDjPskjT3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyksrrF&md5=23bed0f5d7cf0db1595b520d8b22cc08</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0493-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0493-8%26sid%3Dliteratum%253Aachs%26aulast%3DBurness%26aufirst%3DC.%2BB.%26atitle%3DOmarigliptin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1947%26epage%3D1952%26doi%3D10.1007%2Fs40265-015-0493-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, Y.</span><span> </span><span class="NLM_article-title">Synthetic Method for Omarigliptin</span>. CN 105399744A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Huang&title=Synthetic+Method+for+Omarigliptin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26atitle%3DSynthetic%2520Method%2520for%2520Omarigliptin%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit94b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chung, J. Y. L.; Peng, F.; Chen, Y.; Kassim, A. M.; Chen, C. Y.; Maust, M.; Mclaughlin, M.; Zacuto, M. J.; Chen, Q.; Tan, L.</span><span> </span><span class="NLM_article-title">Process for Preparing Chiral Dipeptidyl Peptidase-IV Inhibitors</span>. WO 2016014324A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Y.+L.+Chung&author=F.+Peng&author=Y.+Chen&author=A.+M.+Kassim&author=C.+Y.+Chen&author=M.+Maust&author=M.+Mclaughlin&author=M.+J.+Zacuto&author=Q.+Chen&author=L.+Tan&title=Process+for+Preparing+Chiral+Dipeptidyl+Peptidase-IV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26atitle%3DProcess%2520for%2520Preparing%2520Chiral%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit94c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Schwink, L.; Buning, C.; Glombik, H.; Gossel, M.; Kadereit, D.; Halland, N.; Lohmann, M.; Pöverlein, C.; Ritter, K.</span><span> </span><span class="NLM_article-title">Isoindolinone Compounds as Gpr119 Modulators For the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders</span>. WO 2015150565A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+Schwink&author=C.+Buning&author=H.+Glombik&author=M.+Gossel&author=D.+Kadereit&author=N.+Halland&author=M.+Lohmann&author=C.+P%C3%B6verlein&author=K.+Ritter&title=Isoindolinone+Compounds+as+Gpr119+Modulators+For+the+Treatment+of+Diabetes%2C+Obesity%2C+Dyslipidemia+and+Related+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchwink%26aufirst%3DL.%26atitle%3DIsoindolinone%2520Compounds%2520as%2520Gpr119%2520Modulators%2520For%2520the%2520Treatment%2520of%2520Diabetes%252C%2520Obesity%252C%2520Dyslipidemia%2520and%2520Related%2520Disorders%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit94d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">De, L. O.; Rosso, E.; Zaramella, S.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Key Intermediates of Omarigliptin</span>. WO 2015139859A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+O.+De&author=E.+Rosso&author=S.+Zaramella&title=Process+for+the+Preparation+of+Key+Intermediates+of+Omarigliptin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DL.%2BO.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Key%2520Intermediates%2520of%2520Omarigliptin%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit94e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Biftu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha-Roy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuethe, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sewall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">Omarigliptin (MK-3102): a Novel Long-acting DPP-4 Inhibitor for Once-weekly Treatment of Type 2 Diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3205</span><span class="NLM_x">–</span> <span class="NLM_lpage">3212</span><span class="refDoi"> DOI: 10.1021/jm401992e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401992e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslaltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3205-3212&author=T.+Biftuauthor=R.+Sinha-Royauthor=P.+Chenauthor=X.+Qianauthor=D.+Fengauthor=J.+T.+Kuetheauthor=G.+Scapinauthor=Y.+D.+Gaoauthor=Y.+Yanauthor=D.+Kruegerauthor=A.+Bakauthor=G.+Eiermannauthor=J.+Heauthor=J.+Coxauthor=J.+Hicksauthor=K.+Lyonsauthor=H.+Heauthor=G.+Salituroauthor=S.+Tongauthor=S.+Patelauthor=G.+Dossauthor=A.+Petrovauthor=J.+Wuauthor=S.+S.+Xuauthor=C.+Sewallauthor=X.+Zhangauthor=B.+Zhangauthor=N.+A.+Thornberryauthor=A.+E.+Weber&title=Omarigliptin+%28MK-3102%29%3A+a+Novel+Long-acting+DPP-4+Inhibitor+for+Once-weekly+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm401992e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94eR"><div class="casContent"><span class="casTitleNuber">94e</span><div class="casTitle"><span class="NLM_cas:atitle">Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Biftu, Tesfaye; Sinha-Roy, Ranabir; Chen, Ping; Qian, Xiaoxia; Feng, Dennis; Kuethe, Jeffrey T.; Scapin, Giovanna; Gao, Ying Duo; Yan, Youwei; Krueger, Davida; Bak, Annette; Eiermann, George; He, Jiafang; Cox, Jason; Hicks, Jacqueline; Lyons, Kathy; He, Huaibing; Salituro, Gino; Tong, Sharon; Patel, Sangita; Doss, George; Petrov, Aleksandr; Wu, Joseph; Xu, Shiyao Sherrie; Sewall, Charles; Zhang, Xiaoping; Zhang, Bei; Thornberry, Nancy A.; Weber, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3205-3212</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our effort to discover DPP-4 inhibitors with added benefits over currently com. available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clin. development candidate.  This manuscript summarizes the mechanism of action, scientific rationale, medicinal chem., pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGeQnvAA8cBbVg90H21EOLACvtfcHk0lg2PyQ6XsXxIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslaltb4%253D&md5=14b15f61cd5cd6c981d93459ad372e62</span></div><a href="/servlet/linkout?suffix=cit94e&amp;dbid=16384&amp;doi=10.1021%2Fjm401992e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401992e%26sid%3Dliteratum%253Aachs%26aulast%3DBiftu%26aufirst%3DT.%26aulast%3DSinha-Roy%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DKuethe%26aufirst%3DJ.%2BT.%26aulast%3DScapin%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DY.%2BD.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DKrueger%26aufirst%3DD.%26aulast%3DBak%26aufirst%3DA.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DJ.%26aulast%3DHicks%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DDoss%26aufirst%3DG.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%2BS.%26aulast%3DSewall%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DOmarigliptin%2520%2528MK-3102%2529%253A%2520a%2520Novel%2520Long-acting%2520DPP-4%2520Inhibitor%2520for%2520Once-weekly%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3205%26epage%3D3212%26doi%3D10.1021%2Fjm401992e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit94f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zacuto, M. J.; Dunn, R. F.; Moment, A. J.; Janey, J. M.; Lieberman, D.; Sheen, F.; Bremeyer, N.; Scott, J.; Kuethe, J. T.; Tan, L.</span><span> </span><span class="NLM_article-title">Process for Preparing Chiral Dipeptidyl Peptidase-IV Inhibitors</span>. WO 2013003250A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+J.+Zacuto&author=R.+F.+Dunn&author=A.+J.+Moment&author=J.+M.+Janey&author=D.+Lieberman&author=F.+Sheen&author=N.+Bremeyer&author=J.+Scott&author=J.+T.+Kuethe&author=L.+Tan&title=Process+for+Preparing+Chiral+Dipeptidyl+Peptidase-IV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZacuto%26aufirst%3DM.%2BJ.%26atitle%3DProcess%2520for%2520Preparing%2520Chiral%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit94g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Biftu, T.; Chen, P.; Cox, J. M.; Weber, A. E.</span><span> </span><span class="NLM_article-title">Aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes</span>. US 20100120863A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=T.+Biftu&author=P.+Chen&author=J.+M.+Cox&author=A.+E.+Weber&title=Aminotetrahydropyrans+as+Dipeptidyl+Peptidase-IV+Inhibitors+for+the+Treatment+or+Prevention+of+Diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBiftu%26aufirst%3DT.%26atitle%3DAminotetrahydropyrans%2520as%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitors%2520for%2520the%2520Treatment%2520or%2520Prevention%2520of%2520Diabetes%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Chung, J. Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremeyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moment, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacuto, M.</span><span> </span><span class="NLM_article-title">Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1760</span><span class="NLM_x">–</span> <span class="NLM_lpage">1768</span><span class="refDoi"> DOI: 10.1021/acs.oprd.5b00267</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00267" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2ltL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1760-1768&author=J.+Y.+L.+Chungauthor=J.+P.+Scottauthor=C.+Andersonauthor=B.+Bishopauthor=N.+Bremeyerauthor=Y.+Caoauthor=Q.+Chenauthor=R.+Dunnauthor=A.+Kassimauthor=D.+Liebermanauthor=A.+J.+Momentauthor=F.+Sheenauthor=M.+Zacuto&title=Evolution+of+a+Manufacturing+Route+to+Omarigliptin%2C+A+Long-Acting+DPP-4+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Facs.oprd.5b00267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Chung, John Y. L.; Scott, Jeremy P.; Anderson, Camille; Bishop, Brian; Bremeyer, Nadine; Cao, Yang; Chen, Qinghao; Dunn, Robert; Kassim, Amude; Lieberman, David; Moment, Aaron J.; Sheen, Faye; Zacuto, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1760-1768</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of a convergent synthesis of omarigliptin [MK-3102, I (R = H; Ms = MeSO2)] suitable for com. manuf. is described.  I (R = H) was prepd. by the diastereoselective reductive amination of a nonracemic Boc-protected amino(aryl)pyranone II with mesylated pyrrolopyrazole III•PhSO3H (R1 = H) [generated in situ from its Boc-protected precursor III (R1 = Boc) due to its instability and potential genotoxicity] followed by Boc deprotection.  The synthesis of II relies on three Ru-catalyzed reactions: the dynamic kinetic resoln./hydrogenation of a rac-α-aminoketone in the presence of an areneruthenium diamine complex, cycloisomerization of the bis-homopropargylic alc. product to a dihydropyran, and ruthenium-catalyzed oxidn. of a pyranol (generated by hydroboration of the dihydropyran).  III (R1 = Boc) was prepd. regioselectively in 30:1 regioselectivity by mesylation followed by base-promoted isomerization.  The Boc deprotection of III (R1 = Boc) and its reductive amination reaction with II were telescoped by using the crystn. of I (R = Boc) to remove byproducts, allowing handling of III•PhSO3H (R1 = H) to be avoided and improving the overall diastereoselectivity and efficiency of the route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpob8Zs2c4xP7Vg90H21EOLACvtfcHk0lg0cu67GlahoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2ltL%252FF&md5=a2728e45654628f53385f711f4ee9b91</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00267%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26aulast%3DScott%26aufirst%3DJ.%2BP.%26aulast%3DAnderson%26aufirst%3DC.%26aulast%3DBishop%26aufirst%3DB.%26aulast%3DBremeyer%26aufirst%3DN.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DDunn%26aufirst%3DR.%26aulast%3DKassim%26aufirst%3DA.%26aulast%3DLieberman%26aufirst%3DD.%26aulast%3DMoment%26aufirst%3DA.%2BJ.%26aulast%3DSheen%26aufirst%3DF.%26aulast%3DZacuto%26aufirst%3DM.%26atitle%3DEvolution%2520of%2520a%2520Manufacturing%2520Route%2520to%2520Omarigliptin%252C%2520A%2520Long-Acting%2520DPP-4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D1760%26epage%3D1768%26doi%3D10.1021%2Facs.oprd.5b00267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McKeage, K.</span><span> </span><span class="NLM_article-title">Trelagliptin: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1164</span><span class="refDoi"> DOI: 10.1007/s40265-015-0431-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0431-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26115728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCjsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1161-1164&author=K.+McKeage&title=Trelagliptin%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0431-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96aR"><div class="casContent"><span class="casTitleNuber">96a</span><div class="casTitle"><span class="NLM_cas:atitle">Trelagliptin: First Global Approval</span></div><div class="casAuthors">McKeage, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1161-1164</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Trelagliptin (Zafatek) is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus (T2DM).  Unlike other approved agents of its class, which are usually administered once daily, trelagliptin can be administered once weekly.  Phase II development of trelagliptin was discontinued in the USA and EU, as Takeda considered that the costs assocd. with obtaining approval in these markets were prohibitive.  This article summarizes the milestones in the development of trelagliptin leading to this first approval for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZLxvdSf4LZLVg90H21EOLACvtfcHk0lg0cu67GlahoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCjsrjF&md5=0b23f6b1990e67f8e475c377c12112e1</span></div><a href="/servlet/linkout?suffix=cit96a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0431-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0431-9%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeage%26aufirst%3DK.%26atitle%3DTrelagliptin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1161%26epage%3D1164%26doi%3D10.1007%2Fs40265-015-0431-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit96b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kaku, K.</span><span> </span><span class="NLM_article-title">First Novel Once-Weekly DPP-4 Inhibitor, Trelagliptin, for the Treatment of Type 2 Diabetes Mellitus</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2539</span><span class="NLM_x">–</span> <span class="NLM_lpage">2547</span><span class="refDoi"> DOI: 10.1517/14656566.2015.1099630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14656566.2015.1099630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26523434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWntb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=2539-2547&author=K.+Kaku&title=First+Novel+Once-Weekly+DPP-4+Inhibitor%2C+Trelagliptin%2C+for+the+Treatment+of+Type+2+Diabetes+Mellitus&doi=10.1517%2F14656566.2015.1099630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96bR"><div class="casContent"><span class="casTitleNuber">96b</span><div class="casTitle"><span class="NLM_cas:atitle">First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Kaku, Kohei</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2539-2547</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Dipeptidyl peptidase-4 (DPP-4) inhibitors are wt. neutral and well tolerated, and provide better glycemic control for a longer period compared to conventional therapies.  Despite the fact that various drugs are available, glycemic control remains suboptimal in approx. half of patients with type 2 diabetes mellitus; one of the major reasons for low medication adherence.: A novel DPP-4 inhibitor, trelagliptin, was approved in Japan in March 2015, and is the first once-weekly oral antidiabetic agent in the world.  In this review, current issues concerning medication adherence for the treatment of diabetes are discussed followed by a summary of the characteristics and future expectations of trelagliptin, by reviewing the recent phase I, II, and III clin. studies of trelagliptin.: Trelagliptin has demonstrated superiority to placebo and non-inferiority to alogliptin, indicating its efficacy and tolerance in Japanese patients.  Trelagliptin is expected to improve adherence and prevent complications.  Due to the convenient dosing regimen, it is expected to be widely used in the clin. setting.  A large-scale long-term study will help further confirm its long-term efficacy and safety, patients' satisfaction, and medication adherence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVV5QAW5eQc7Vg90H21EOLACvtfcHk0lg0cu67GlahoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWntb%252FF&md5=12f32e70a258b92cae700e1d09c91504</span></div><a href="/servlet/linkout?suffix=cit96b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1099630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1099630%26sid%3Dliteratum%253Aachs%26aulast%3DKaku%26aufirst%3DK.%26atitle%3DFirst%2520Novel%2520Once-Weekly%2520DPP-4%2520Inhibitor%252C%2520Trelagliptin%252C%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D2539%26epage%3D2547%26doi%3D10.1517%2F14656566.2015.1099630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Grimshaw, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishigaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinugawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koumura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span> </span><span class="NLM_article-title">Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0157509</span><span class="refDoi"> DOI: 10.1371/journal.pone.0157509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1371%2Fjournal.pone.0157509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27328054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOntrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0157509&author=C.+E.+Grimshawauthor=A.+Jenningsauthor=R.+Kamranauthor=H.+Uenoauthor=N.+Nishigakiauthor=T.+Kosakaauthor=A.+Taniauthor=H.+Sanoauthor=Y.+Kinugawaauthor=E.+Koumuraauthor=L.+Shiauthor=K.+Takeuchi&title=Trelagliptin+%28SYR-472%2C+Zafatek%29%2C+Novel+Once-Weekly+Treatment+for+Type+2+Diabetes%2C+Inhibits+Dipeptidyl+Peptidase-4+%28DPP-4%29+via+a+Non-Covalent+Mechanism&doi=10.1371%2Fjournal.pone.0157509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Trelagliptin (SYR-472, zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (DPP-4) via a non-covalent mechanism</span></div><div class="casAuthors">Grimshaw, Charles E.; Jennings, Andy; Kamran, Ruhi; Ueno, Hikaru; Nishigaki, Nobuhiro; Kosaka, Takuo; Tani, Akiyoshi; Sano, Hiroki; Kinugawa, Yoshinobu; Koumura, Emiko; Shi, Lihong; Takeuchi, Koji</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0157509/1-e0157509/14</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients.  In this study, we characterized in vitro properties of trelagliptin, which exhibited approx. 4- and 12-fold more potent inhibition against human dipeptidyl peptidase-4 than alogliptin and sitagliptin, resp., and >10,000-fold selectivity over related proteases including dipeptidyl peptidase-8 and dipeptidyl peptidase-9.  Kinetic anal. revealed reversible, competitive and slow-binding inhibition of dipeptidyl peptidase-4 by trelagliptin (t1/2 for dissocn. ≈ 30 min).  X-ray diffraction data indicated a noncovalent interaction between dipeptidyl peptidase and trelagliptin.  Taken together, potent dipeptidyl peptidase inhibitionmay partially contribute to sustained efficacy of trelagliptin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl6c2Doi2qG7Vg90H21EOLACvtfcHk0lg0cu67GlahoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOntrnK&md5=8eeb09f31af53706b0f6a6b40bd4c590</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0157509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0157509%26sid%3Dliteratum%253Aachs%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DKamran%26aufirst%3DR.%26aulast%3DUeno%26aufirst%3DH.%26aulast%3DNishigaki%26aufirst%3DN.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DTani%26aufirst%3DA.%26aulast%3DSano%26aufirst%3DH.%26aulast%3DKinugawa%26aufirst%3DY.%26aulast%3DKoumura%26aufirst%3DE.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DTakeuchi%26aufirst%3DK.%26atitle%3DTrelagliptin%2520%2528SYR-472%252C%2520Zafatek%2529%252C%2520Novel%2520Once-Weekly%2520Treatment%2520for%2520Type%25202%2520Diabetes%252C%2520Inhibits%2520Dipeptidyl%2520Peptidase-4%2520%2528DPP-4%2529%2520via%2520a%2520Non-Covalent%2520Mechanism%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0157509%26doi%3D10.1371%2Fjournal.pone.0157509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Inagaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onouchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maezawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaku, K.</span><span> </span><span class="NLM_article-title">Once-weekly Trelagliptin Versus Daily Alogliptin in Japanese Patients with Type 2 Diabetes: a Randomised, Double-blind, Phase 3, Non-inferiority Study</span> <span class="citation_source-journal">Lancet Diabetes Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span><span class="refDoi"> DOI: 10.1016/S2213-8587(14)70251-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS2213-8587%2814%2970251-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25609193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFelur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=191-197&author=N.+Inagakiauthor=H.+Onouchiauthor=H.+Maezawaauthor=S.+Kurodaauthor=K.+Kaku&title=Once-weekly+Trelagliptin+Versus+Daily+Alogliptin+in+Japanese+Patients+with+Type+2+Diabetes%3A+a+Randomised%2C+Double-blind%2C+Phase+3%2C+Non-inferiority+Study&doi=10.1016%2FS2213-8587%2814%2970251-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study</span></div><div class="casAuthors">Inagaki, Nobuya; Onouchi, Hitoshi; Maezawa, Hideaki; Kuroda, Shingo; Kaku, Kohei</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Diabetes & Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-197</span>CODEN:
                <span class="NLM_cas:coden">LDEAAS</span>;
        ISSN:<span class="NLM_cas:issn">2213-8587</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Trelagliptin is a novel once-weekly oral DPP-4 inhibitor.  We assessed the efficacy and safety of trelagliptin vs. the daily oral DPP-4 inhibitor alogliptin in Japanese patients with type 2 diabetes.  We did a randomised, double-blind, active-controlled, parallel-group, phase 3, non-inferiority study at 26 sites in Japan.  We included individuals with type 2 diabetes inadequately controlled by diet and exercise.  We randomly assigned patients (2:2:1) to receive trelagliptin (100 mg) once per wk, alogliptin (25 mg) once per day, or placebo for 24 wk.  Randomisation was done electronically and independently from the study with permuted blocks of ten patients.  Patients and clinicians were masked to group assignment.  Patients in the trelagliptin group were given trelagliptin once a week and oral alogliptin placebo every day, whereas patients in the alogliptin group were given oral trelagliptin placebo once a week and oral alogliptin every day (double-dummy design).  Patients in the placebo group were given an oral alogliptin placebo once a day and an oral trelagliptin placebo once a week.  Our primary outcome was between-groups difference in change in HbA1c concn. from baseline to the end of treatment.  The non-inferiority margin was 0·4%.  Our anal. included all patients who were randomised and received at least one dose of study drug.  The study is registered with ClinicalTrials.gov, no. NCT01632007.  Between May 26, 2012, and Nov 20, 2012, we enrolled 357 patients. 243 patients were included in the anal. (101 for trelagliptin, 92 for alogliptin, and 50 for placebo).  In the primary anal., the least squares mean change in HbA1c concn. was -0·33% in the trelagliptin group (SE 0·059) and -0·45% in the alogliptin group (0·061) based on the ANCOVA model.  The least squares mean difference (trelagliptin minus alogliptin) of change from baseline in HbA1c concn. was 0·11% (95% CI -0·054 to 0·281).  Trelagliptin was non-inferior to alogliptin.  Both active groups had significantly reduced mean HbA1c concns. at end of treatment compared with placebo (p<0·0001).  The frequency of adverse events was similar between groups.  No hypoglycemia was reported with trelagliptin and the drug was well tolerated.  The once-weekly DPP-4 inhibitor trelagliptin showed similar efficacy and safety to alogliptin once daily in Japanese patients with type 2 diabetes.  Trelagliptin could be a useful new antidiabetes drug that needs to be given once a week.Takeda Pharmaceutical Company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWOQAmwxxS57Vg90H21EOLACvtfcHk0ljzOJGeJkUpxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFelur8%253D&md5=d902f6a2ec1c0b04806c44b28ab0e49b</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2FS2213-8587%2814%2970251-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-8587%252814%252970251-7%26sid%3Dliteratum%253Aachs%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DOnouchi%26aufirst%3DH.%26aulast%3DMaezawa%26aufirst%3DH.%26aulast%3DKuroda%26aufirst%3DS.%26aulast%3DKaku%26aufirst%3DK.%26atitle%3DOnce-weekly%2520Trelagliptin%2520Versus%2520Daily%2520Alogliptin%2520in%2520Japanese%2520Patients%2520with%2520Type%25202%2520Diabetes%253A%2520a%2520Randomised%252C%2520Double-blind%252C%2520Phase%25203%252C%2520Non-inferiority%2520Study%26jtitle%3DLancet%2520Diabetes%2520Endocrinol.%26date%3D2015%26volume%3D3%26spage%3D191%26epage%3D197%26doi%3D10.1016%2FS2213-8587%2814%2970251-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwaltney, S. L.</span><span> </span><span class="NLM_article-title">Design and Synthesis of Pyrimidinone and Pyrimidinedione Inhibitors of Dipeptidyl Peptidase IV</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">510</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span><span class="refDoi"> DOI: 10.1021/jm101016w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101016w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1WgtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=510-524&author=Z.+Zhangauthor=M.+B.+Wallaceauthor=J.+Fengauthor=J.+A.+Staffordauthor=R.+J.+Skeneauthor=L.+Shiauthor=B.+Leeauthor=K.+Aertgeertsauthor=A.+Jenningsauthor=R.+Xuauthor=D.+B.+Kasselauthor=S.+W.+Kaldorauthor=M.+Navreauthor=D.+R.+Webbauthor=S.+L.+Gwaltney&title=Design+and+Synthesis+of+Pyrimidinone+and+Pyrimidinedione+Inhibitors+of+Dipeptidyl+Peptidase+IV&doi=10.1021%2Fjm101016w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV</span></div><div class="casAuthors">Zhang, Zhi-Yuan; Wallace, Michael B.; Feng, Jun; Stafford, Jeffrey A.; Skene, Robert J.; Shi, Li-Hong; Lee, Bum-Sup; Aertgeerts, Kathleen; Jennings, Andy; Xu, Rong-Da; Kassel, Daniel B.; Kaldor, Stephen W.; Navre, Marc; Webb, David R.; Gwaltney, Stephen L., II</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">510-524</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described.  After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained redn. of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes.  Compds. I, II, and III were selected for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxInStuMRjfbVg90H21EOLACvtfcHk0ljzOJGeJkUpxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1WgtL7M&md5=7e3b66916acf243ad7943add0eaf6b1f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm101016w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101016w%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWallace%26aufirst%3DM.%2BB.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DKaldor%26aufirst%3DS.%2BW.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DWebb%26aufirst%3DD.%2BR.%26aulast%3DGwaltney%26aufirst%3DS.%2BL.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Pyrimidinone%2520and%2520Pyrimidinedione%2520Inhibitors%2520of%2520Dipeptidyl%2520Peptidase%2520IV%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D510%26epage%3D524%26doi%3D10.1021%2Fjm101016w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Kushwaha, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haq, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katti, S.</span><span> </span><span class="NLM_article-title">Discovery of 17 Gliptins in 17 Years of Research for the Treatment of Type 2 Diabetes: A Synthetic Overview</span> <span class="citation_source-journal">Chem. Biol. Interface</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=137-162&author=R.+N.+Kushwahaauthor=W.+Haqauthor=S.+Katti&title=Discovery+of+17+Gliptins+in+17+Years+of+Research+for+the+Treatment+of+Type+2+Diabetes%3A+A+Synthetic+Overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: a synthetic overview</span></div><div class="casAuthors">Kushwaha, Ram Najar; Haq, W.; Katti, S. B.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology Interface</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">137-162, 26 pp.</span>CODEN:
                <span class="NLM_cas:coden">CBIHAO</span>;
        ISSN:<span class="NLM_cas:issn">2249-4820</span>.
    
            (<span class="NLM_cas:orgname">Indian Society of Chemists and Biologist</span>)
        </div><div class="casAbstract">A review.  Gliptins, commonly known as clin. DPP-IV inhibitors have become a new class of potential drug candidate and are being hoped as a permanent eraser for type 2 diabetes.  Therefore, gliptins have been a center of research and development.  As a result of the efforts made towards developing effective gliptins, the first clin. proof of concept for efficacy was confirmed in 1998 when NVP-DPP728 came into focus.  Thus, from 1998 to 2014, these 17-years of the heightened research towards drug discovery has resulted in seventeen gliptins.  Among these, eight gliptins are currently approved and in clin. usages for type 2 diabetes therapies, while others are in different stages of clin. trials.  This review covers the various approaches and methodologies used in the syntheses of only those DPP-IV inhibitors in clin. uses having suffix gliptin.  In addn., it also encompasses their biol. activity and their binding interactions in the active site of DPP-IV that are responsible for their drug candidacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUzq9ENsKIBbVg90H21EOLACvtfcHk0ljzOJGeJkUpxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelsrrK&md5=d7e444bb8bac3247b8227c981b1d5e8b</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKushwaha%26aufirst%3DR.%2BN.%26aulast%3DHaq%26aufirst%3DW.%26aulast%3DKatti%26aufirst%3DS.%26atitle%3DDiscovery%2520of%252017%2520Gliptins%2520in%252017%2520Years%2520of%2520Research%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%253A%2520A%2520Synthetic%2520Overview%26jtitle%3DChem.%2520Biol.%2520Interface%26date%3D2014%26volume%3D4%26spage%3D137%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Deacon, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebovitz, H. E.</span><span> </span><span class="NLM_article-title">Comparative Review of Dipeptidyl Peptidase-4 Inhibitors and Sulphonylureas</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.1111/dom.12610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fdom.12610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26597596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=333-347&author=C.+F.+Deaconauthor=H.+E.+Lebovitz&title=Comparative+Review+of+Dipeptidyl+Peptidase-4+Inhibitors+and+Sulphonylureas&doi=10.1111%2Fdom.12610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas</span></div><div class="casAuthors">Deacon, C. F.; Lebovitz, H. E.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-347</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent does not generally provide durable glycemic control over the long term.  Sulfonylurea (SU) drugs have a history stretching back over 60 years, and have traditionally been the mainstay choice as second-line agents to be added to metformin once glycemic control with metformin monotherapy deteriorates; however, they are assocd. with undesirable side effects, including increased hypoglycemia risk and wt. gain.  Dipeptidyl peptidase (DPP)-4 inhibitors are, by comparison, more recent, with the first compd. being launched in 2006, but the class now globally encompasses at least 11 different compds.  DPP-4 inhibitors improve glycemic control with similar efficacy to SUs, but do not usually provoke hypoglycemia or wt. gain, are relatively free from adverse side effects, and have recently been shown not to increase cardiovascular risk in large prospective safety trials.  Because of these factors, DPP-4 inhibitors have become an established therapy for T2DM and are increasingly being positioned earlier in treatment algorithms.  The present article reviews these two classes of oral antidiabetic drugs (DPP-4 inhibitors and SUs), highlighting differences and similarities between members of the same class, as well as discussing the potential advantages and disadvantages of the two drug classes.  While both classes have their merits, the choice of which to use depends on the characteristics of each individual patient; however, for the majority of patients, DPP-4 inhibitors are now the preferred choice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPNH17i_BaXbVg90H21EOLACvtfcHk0lhx5NMPqNmuTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFGhtbo%253D&md5=bab1171a0f304fc52296637feb9ffbbf</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1111%2Fdom.12610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12610%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26aulast%3DLebovitz%26aufirst%3DH.%2BE.%26atitle%3DComparative%2520Review%2520of%2520Dipeptidyl%2520Peptidase-4%2520Inhibitors%2520and%2520Sulphonylureas%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26spage%3D333%26epage%3D347%26doi%3D10.1111%2Fdom.12610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Feng, J.; Gwaltney, S. L.; Stafford, J. A.; Zhang, Z.; Elder, B. J.; Isbester, P. K.; Palmer, G. J.; Salsbury, J. S.; Ulysse, L.; Fornicola, R. S.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Pyrimidinedione Derivatives</span>. WO 2007035629A2,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Feng&author=S.+L.+Gwaltney&author=J.+A.+Stafford&author=Z.+Zhang&author=B.+J.+Elder&author=P.+K.+Isbester&author=G.+J.+Palmer&author=J.+S.+Salsbury&author=L.+Ulysse&author=R.+S.+Fornicola&title=Process+for+the+Preparation+of+Pyrimidinedione+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Pyrimidinedione%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Wallace, M. B.; Cody, J.; Fornicola, R.; Garcia-Rubio, S.; Kisanga, P. B.; Reeve, M. M.; Wilson, C.</span><span> </span><span class="NLM_article-title">Preparation of (<i>R</i>)-3-Aminopiperidine Dihydrochloride</span>. WO 2007112368A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+B.+Wallace&author=J.+Cody&author=R.+Fornicola&author=S.+Garcia-Rubio&author=P.+B.+Kisanga&author=M.+M.+Reeve&author=C.+Wilson&title=Preparation+of+%28R%29-3-Aminopiperidine+Dihydrochloride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DM.%2BB.%26atitle%3DPreparation%2520of%2520%2528R%2529-3-Aminopiperidine%2520Dihydrochloride%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Kelly, R. C.; Koztecki, L. H.</span><span> </span><span class="NLM_article-title">Polymorphs of Succinate Salt of 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2<i>H</i>-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and Methods of Use Therefor</span>. WO 2008067465A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+C.+Kelly&author=L.+H.+Koztecki&title=Polymorphs+of+Succinate+Salt+of+2-%5B6-%283-Amino-piperidin-1-yl%29-3-methyl-2%2C4-dioxo-3%2C4-dihydro-2H-pyrimidin-1-ylmethy%5D-4-fluor-benzonitrile+and+Methods+of+Use+Therefor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DR.%2BC.%26atitle%3DPolymorphs%2520of%2520Succinate%2520Salt%2520of%25202-%255B6-%25283-Amino-piperidin-1-yl%2529-3-methyl-2%252C4-dioxo-3%252C4-dihydro-2H-pyrimidin-1-ylmethy%255D-4-fluor-benzonitrile%2520and%2520Methods%2520of%2520Use%2520Therefor%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span> </span><span class="NLM_article-title">Anonymous In Brief: Uridine Triacetate (Xuriden) for Hereditary Orotic Aciduria</span>.  <span class="citation_source-journal">Med. Lett. Drugs Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span>, <span class="NLM_issue">1491</span><span class="NLM_x">) </span> <span class="NLM_fpage">e49</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27027693" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Anonymous+In+Brief%3A+Uridine+Triacetate+%28Xuriden%29+for+Hereditary+Orotic+Aciduria.+Med.+Lett.+Drugs+Ther.+2016%2C+58%2C+1491%29+e49."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DAnonymous%2520In%2520Brief%253A%2520Uridine%2520Triacetate%2520%2528Xuriden%2529%2520for%2520Hereditary%2520Orotic%2520Aciduria%26jtitle%3DMed.%2520Lett.%2520Drugs%2520Ther.%26date%3D2016%26volume%3D58%26issue%3D1491%26spage%3De49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McEvilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popelas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tremmel, B.</span><span> </span><span class="NLM_article-title">Use of Uridine Triacetate for the Management of Fluorouracil Overdose</span> <span class="citation_source-journal">Am. J. Health-Syst. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1806</span><span class="NLM_x">–</span> <span class="NLM_lpage">1809</span><span class="refDoi"> DOI: 10.2146/ajhp100434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2146%2Fajhp100434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=21930638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFKhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=1806-1809&author=M.+McEvillyauthor=C.+Popelasauthor=B.+Tremmel&title=Use+of+Uridine+Triacetate+for+the+Management+of+Fluorouracil+Overdose&doi=10.2146%2Fajhp100434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106aR"><div class="casContent"><span class="casTitleNuber">106a</span><div class="casTitle"><span class="NLM_cas:atitle">Use of uridine triacetate for the management of fluorouracil overdose</span></div><div class="casAuthors">McEvilly, Margaret; Popelas, Carl; Tremmel, Bob</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1806-1809</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">Purpose: The use of uridine triacetate for the management of fluorouracil toxicity is reported.  Summary: A 55-yr-old man with malignant neoplasm of the sigmoid colon (stage IIIC) was seen in an outpatient chemotherapy center for his first six-month regimen of leucovorin calcium, fluorouracil, and oxaliplatin.  Fluorouracil 2400 mg/m2 i.v. was prescribed to be given over the next 46 h at a home infusion center.  Due to a medication error, a home infusion pharmacist incorrectly programmed the 46-h infusion of fluorouracil to be administered over 4 h.  To manage the fluorouracil overdose, the physician decided to start the patient on uridine triacetate.  The patient received his first dose of uridine triacetate 18 h after the fluorouracil overdose.  He was admitted to the hospital for observation and daily lab. tests during treatment with uridine triacetate.  He received ondansetron (as the hydrochloride salt) 8 mg orally 20 min before each dose of uridine triacetate to prevent nausea and vomiting.  Uridine triacetate 11 g every 6 h was administered orally for a total of 20 doses.  It was mixed with applesauce at the time of administration and followed with 8 oz of water.  The patient's lab. values remained stable.  The patient did not experience any nausea or vomiting during treatment.  He was discharged from the hospital on day 5, with no clin. complications and an Eastern Cooperative Oncol. Group Performance score of 0.  Conclusion: A patient with colon cancer who had received an overdose of fluorouracil was successfully treated with a five-day course of oral uridine triacetate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzZgNd_hTZT7Vg90H21EOLACvtfcHk0lhx5NMPqNmuTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFKhu78%253D&md5=c9c529a8b49a769acab45fc33cb7aced</span></div><a href="/servlet/linkout?suffix=cit106a&amp;dbid=16384&amp;doi=10.2146%2Fajhp100434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fajhp100434%26sid%3Dliteratum%253Aachs%26aulast%3DMcEvilly%26aufirst%3DM.%26aulast%3DPopelas%26aufirst%3DC.%26aulast%3DTremmel%26aufirst%3DB.%26atitle%3DUse%2520of%2520Uridine%2520Triacetate%2520for%2520the%2520Management%2520of%2520Fluorouracil%2520Overdose%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2011%26volume%3D68%26spage%3D1806%26epage%3D1809%26doi%3D10.2146%2Fajhp100434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit106b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O’Malley, P. A.</span><span> </span><span class="NLM_article-title">Vistogard (Uridine Triacetate): The First and Only Drug Approved for the Treatment of 5-Fluorouracil or Capecitabine Overdose: Implications for the Clinical Nurse Specialist</span> <span class="citation_source-journal">CNS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1097/NUR.0000000000000198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1097%2FNUR.0000000000000198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27055035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28fotVChtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=145-147&author=P.+A.+O%E2%80%99Malley&title=Vistogard+%28Uridine+Triacetate%29%3A+The+First+and+Only+Drug+Approved+for+the+Treatment+of+5-Fluorouracil+or+Capecitabine+Overdose%3A+Implications+for+the+Clinical+Nurse+Specialist&doi=10.1097%2FNUR.0000000000000198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106bR"><div class="casContent"><span class="casTitleNuber">106b</span><div class="casTitle"><span class="NLM_cas:atitle">Vistogard (Uridine Triacetate): The First and Only Drug Approved for the Treatment of 5-Fluorouracil or Capecitabine Overdose: Implications for the Clinical Nurse Specialist</span></div><div class="casAuthors">O'Malley Patricia Anne</div><div class="citationInfo"><span class="NLM_cas:title">Clinical nurse specialist CNS</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">145-7; quiz E11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7cJg5Kf8S1Qqdek-gHSrIfW6udTcc2eaRKbN7Fszr_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fotVChtg%253D%253D&md5=9975bbd95ef1efcc8c9111629ba1de34</span></div><a href="/servlet/linkout?suffix=cit106b&amp;dbid=16384&amp;doi=10.1097%2FNUR.0000000000000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FNUR.0000000000000198%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DP.%2BA.%26atitle%3DVistogard%2520%2528Uridine%2520Triacetate%2529%253A%2520The%2520First%2520and%2520Only%2520Drug%2520Approved%2520for%2520the%2520Treatment%2520of%25205-Fluorouracil%2520or%2520Capecitabine%2520Overdose%253A%2520Implications%2520for%2520the%2520Clinical%2520Nurse%2520Specialist%26jtitle%3DCNS%26date%3D2016%26volume%3D30%26spage%3D145%26epage%3D147%26doi%3D10.1097%2FNUR.0000000000000198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit106c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Saif, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diasio, R. B.</span><span> </span><span class="NLM_article-title">Benefit of Uridine Triacetate (Vistogard) in Rescuing Severe 5-Fluorouracil Toxicity in Patients with Dihydropyrimidine Dehydrogenase (DPYD) Deficiency</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1007/s00280-016-3063-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs00280-016-3063-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27278667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Sitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=151-156&author=M.+W.+Saifauthor=R.+B.+Diasio&title=Benefit+of+Uridine+Triacetate+%28Vistogard%29+in+Rescuing+Severe+5-Fluorouracil+Toxicity+in+Patients+with+Dihydropyrimidine+Dehydrogenase+%28DPYD%29+Deficiency&doi=10.1007%2Fs00280-016-3063-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106cR"><div class="casContent"><span class="casTitleNuber">106c</span><div class="casTitle"><span class="NLM_cas:atitle">Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency</span></div><div class="casAuthors">Saif, Muhammad Wasif; Diasio, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-156</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: 5-Fluorouracil (5-FU), an analog of uracil, is one of the most commonly used chemotherapeutic agents and like other agents has a narrow therapeutic index limited by toxicity.  Compared to previous attempts, uridine triacetate (Vistogard) has shown to increase the potential efficacy of 5-FU by allowing administering a higher dose and decreasing the toxicity.  Recently, Vistogard received orphan drug designation from the FDA as an antidote in the treatment of 5-FU poisoning and from the European Medicines Agency as a treatment for 5-FU overdose.  However, no data have been published to date in humans who were rescued by this agent following severe toxicity assocd. with 5-FU due to dihydropyrimidine dehydrogenase (DPYD) deficiency, the enzyme which is responsible for the elimination of approx. 80 % of the administered dose of 5-FU.  Patients and methods: We identified two patients with advanced pancreatic cancer who were referred to us for testing of DPYD status following severe toxicity assocd. with 5-FU administered at a dose of 1400 mg/m2 weekly bolus high-dose 5-FU followed by oral uridine triacetate as a part of a clin. trail.  One patient developed grade 3 thrombocytopenia and grade 3 skin rash that resolved with discontinuation of 5-FU and supportive care, while second patient developed grade 4 thrombocytopenia, grade 3 coagulopathy and grade 3 neurol. toxicity with a fatal outcome.  DPYD status was evaluated as we have previously published.  Results: The first patient was found to have an abnormally low DPYD activity of 0.087-nmol/min/mg protein by radioisotopic assay (ref. normal range 0.182-0.688 nmol/min/mg protein).  Because of pancytopenia, DPYD enzyme activity could not be assessed in patient 2; genotypic anal. of DPYD during autopsy revealed the presence of the heterozygous mutation, IVS14+1 G>A, DPYD*2A, now recognized as the most common cause of DPYD deficiency.  Conclusion: These two patients present the first two cases of DPYD deficiency that had either delay in severe toxicity or recovered from severe toxicity as they received oral Vistogard as a part of the conical trial.  Toxicity was delayed in both patients by a mean of 3.5 wk (range 3-4 wk), indicating that Vistogard might be able to delay 5-FU toxicity despite higher doses than std. bolus dose of 5-FU used in gastrointestinal malignancies and the appearance of a potentially less toxic adverse effect of 5-FU at an unusual site (cutaneous) in one patient.  The role of uridine triacetate with 5-FU in DPYD-deficient patients needs further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosGx07She5BrVg90H21EOLACvtfcHk0litHTmXGP1xPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Sitrs%253D&md5=057d96a1f452a6b52135d3cd09e7e78f</span></div><a href="/servlet/linkout?suffix=cit106c&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3063-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3063-1%26sid%3Dliteratum%253Aachs%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26atitle%3DBenefit%2520of%2520Uridine%2520Triacetate%2520%2528Vistogard%2529%2520in%2520Rescuing%2520Severe%25205-Fluorouracil%2520Toxicity%2520in%2520Patients%2520with%2520Dihydropyrimidine%2520Dehydrogenase%2520%2528DPYD%2529%2520Deficiency%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D78%26spage%3D151%26epage%3D156%26doi%3D10.1007%2Fs00280-016-3063-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Rajabalee, F. J. M.</span><span> </span><span class="NLM_article-title">Convenient Synthesis of 2′,3′,5′-Tri-O-acetyladenosine and -Uridine</span> <span class="citation_source-journal">Angew. Chem., Int. Ed. Engl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="refDoi"> DOI: 10.1002/anie.197100751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fanie.197100751" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1971&pages=75&author=F.+J.+M.+Rajabalee&title=Convenient+Synthesis+of+2%E2%80%B2%2C3%E2%80%B2%2C5%E2%80%B2-Tri-O-acetyladenosine+and+-Uridine&doi=10.1002%2Fanie.197100751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1002%2Fanie.197100751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.197100751%26sid%3Dliteratum%253Aachs%26aulast%3DRajabalee%26aufirst%3DF.%2BJ.%2BM.%26atitle%3DConvenient%2520Synthesis%2520of%25202%25E2%2580%25B2%252C3%25E2%2580%25B2%252C5%25E2%2580%25B2-Tri-O-acetyladenosine%2520and%2520-Uridine%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1971%26volume%3D10%26spage%3D75%26doi%3D10.1002%2Fanie.197100751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108a"><span><span class="NLM_label">(a) </span>Teijin Pharma to Co-market New Anti-inflammatory Analgesic Patch Formulation; <span class="NLM_publisher-name">Teijin Ltd.</span>: <span class="NLM_publisher-loc">Tokyo</span>, February 1,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.teijin.com/news/2016/ebd160201_28.html" class="extLink">http://www.teijin.com/news/2016/ebd160201_28.html</a> (accessed June 26,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Teijin+Pharma+to+Co-market+New+Anti-inflammatory+Analgesic+Patch+Formulation%3B+Teijin+Ltd.%3A+Tokyo%2C+February+1%2C+2016%3B+http%3A%2F%2Fwww.teijin.com%2Fnews%2F2016%2Febd160201_28.html+%28accessed+June+26%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DTeijin%2520Pharma%2520to%2520Co-market%2520New%2520Anti-inflammatory%2520Analgesic%2520Patch%2520Formulation%26pub%3DTeijin%2520Ltd%26date%3D2016%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit108b"><span><span class="NLM_label">(b) </span>Acquisition of Manufacturing and Marketing Approval in Japan for the Transdermal Anti-inflammatory Analgesic Patch Formulation LOQOA Tape; <span class="NLM_publisher-name">Taisho Pharmaceutical Holdings</span>: <span class="NLM_publisher-loc">Tokyo</span>, September 28,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.evaluategroup.com/Universal/View.aspx?type=Story&amp;id=618759" class="extLink">https://www.evaluategroup.com/Universal/View.aspx?type=Story&id=618759</a> (accessed June 26, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Acquisition+of+Manufacturing+and+Marketing+Approval+in+Japan+for+the+Transdermal+Anti-inflammatory+Analgesic+Patch+Formulation+LOQOA+Tape%3B+Taisho+Pharmaceutical+Holdings%3A+Tokyo%2C+September+28%2C+2015%3B+https%3A%2F%2Fwww.evaluategroup.com%2FUniversal%2FView.aspx%3Ftype%3DStory%26id%3D618759+%28accessed+June+26%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DAcquisition%2520of%2520Manufacturing%2520and%2520Marketing%2520Approval%2520in%2520Japan%2520for%2520the%2520Transdermal%2520Anti-inflammatory%2520Analgesic%2520Patch%2520Formulation%2520LOQOA%2520Tape%26pub%3DTaisho%2520Pharmaceutical%2520Holdings%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Smith, H. J.; Williams, H.</span> <span class="citation_source-book">Smith and Williams’ Introduction to the Principles of Drug Design and Action</span>, <span class="NLM_edition">4th</span> ed.; <span class="NLM_publisher-name">CRC Press</span>: <span class="NLM_publisher-loc">Boca Raton, FL</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=H.+J.+Smith&author=H.+Williams&title=Smith+and+Williams%E2%80%99+Introduction+to+the+Principles+of+Drug+Design+and+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DH.%2BJ.%26btitle%3DSmith%2520and%2520Williams%25E2%2580%2599%2520Introduction%2520to%2520the%2520Principles%2520of%2520Drug%2520Design%2520and%2520Action%26pub%3DCRC%2520Press%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Alder, C. M.; Baldwin, I. R.; Barton, N. P.; Campbell, A. J.; Champigny, A. C.; Harling, J. D.; Maxwell, A. C.; Simpson, J. K.; Smith, I. E. D.; Tame, C. J.</span><span> </span><span class="NLM_article-title">Pyrimidine Derivatives Used as ITK Inhibitors</span>. WO 2010106016A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+M.+Alder&author=I.+R.+Baldwin&author=N.+P.+Barton&author=A.+J.+Campbell&author=A.+C.+Champigny&author=J.+D.+Harling&author=A.+C.+Maxwell&author=J.+K.+Simpson&author=I.+E.+D.+Smith&author=C.+J.+Tame&title=Pyrimidine+Derivatives+Used+as+ITK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlder%26aufirst%3DC.%2BM.%26atitle%3DPyrimidine%2520Derivatives%2520Used%2520as%2520ITK%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="d793a5a2b0a497919396">[email protected]</a>: FDA Approved Drug Products; <span class="NLM_publisher-name">U.S. Food and Drug Administratio</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails" class="extLink">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails</a> (accessed June 26, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs%40FDA%3A+FDA+Approved+Drug+Products%3B+U.S.+Food+and+Drug+Administratio%3A+Silver+Spring%2C+MD%2C+2016%3B+http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdrugsatfda%2Findex.cfm%3Ffuseaction%3DSearch.DrugDetails+%28accessed+June+26%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%2540FDA%253A%2520FDA%2520Approved%2520Drug%2520Products%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administratio%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Reid, G.</span><span> </span><span class="NLM_article-title">Process for the Manufacture of <i>S</i>-(+)-Flurbiprofen</span>. WO 2015145163A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=G.+Reid&title=Process+for+the+Manufacture+of+S-%28%2B%29-Flurbiprofen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReid%26aufirst%3DG.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%2520S-%2528%252B%2529-Flurbiprofen%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Hirankarn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alamuddin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FitzGerald, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skarke, C.</span><span> </span><span class="NLM_article-title">GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies</span> <span class="citation_source-journal">Clin. Pharmacol. Drug Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">386</span><span class="refDoi"> DOI: 10.1002/cpdd.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fcpdd.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27121942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=379-386&author=S.+Hirankarnauthor=J.+S.+Barrettauthor=N.+Alamuddinauthor=G.+A.+FitzGeraldauthor=C.+Skarke&title=GCG100649%2C+A+Novel+Cyclooxygenase-2+Inhibitor%2C+Exhibits+a+Drug+Disposition+Profile+in+Healthy+Volunteers+Compatible+With+High+Affinity+to+Carbonic+Anhydrase-I%2FII%3A+Preliminary+Dose-Exposure+Relationships+to+Define+Clinical+Development+Strategies&doi=10.1002%2Fcpdd.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">GCG100649, a novel cyclooxygenase-2 inhibitor, exhibits a drug disposition profile in healthy volunteers compatible with high affinity to carbonic anhydrase-I/II: preliminary dose-exposure relationships to define clinical development strategies</span></div><div class="casAuthors">Hirankarn, Sarapee; Barrett, Jeffrey S.; Alamuddin, Naji; FitzGerald, Garret A.; Skarke, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">379-386, 8</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">CG100649, proposed as a dual inhibitor of cyclooxygenase (COX)-2 and carbonic anhydrase (CA)-I/-II, is long-lived in plasma and whole blood.  The mean ± SD half-lives were 131 ± 19 and 127 ± 33 h, resp., after administration of oral single doses of 2 or 8 mg CG100649 to healthy volunteers.  The whole blood to plasma concn. ratio (78 ± 23) for CG100649 is linear over the dosing interval reflecting a biodistribution pattern consistent with other strong CA-inhibitors (e.g., acetazolamide, methazolamide).  A one compartment model with first order absorption and elimination described CG100649 concn.-time profiles well.  Ests. (%relative SD) between plasma and whole blood were in agreement for the absorption rate const., 1.54 (58.6) and 1.43 (28.0) hour-1, resp., but considerably different for clearance, 3.29 (10.4) and 0.04 (7.7) L/h/70 kg, and for vol. of distribution, 559 (6.7) and 7.6 (2.4) L/70 kg, resp.  The extent to which these unique PK characteristics of CG100649 discriminate it from other COX-2 inhibitors will be the subject of future investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYcIXe7ZmAH7Vg90H21EOLACvtfcHk0lg-jBEzDRuvSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gtLnK&md5=17e5e4422b53f5f4f9490077d6427166</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.47%26sid%3Dliteratum%253Aachs%26aulast%3DHirankarn%26aufirst%3DS.%26aulast%3DBarrett%26aufirst%3DJ.%2BS.%26aulast%3DAlamuddin%26aufirst%3DN.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26aulast%3DSkarke%26aufirst%3DC.%26atitle%3DGCG100649%252C%2520A%2520Novel%2520Cyclooxygenase-2%2520Inhibitor%252C%2520Exhibits%2520a%2520Drug%2520Disposition%2520Profile%2520in%2520Healthy%2520Volunteers%2520Compatible%2520With%2520High%2520Affinity%2520to%2520Carbonic%2520Anhydrase-I%252FII%253A%2520Preliminary%2520Dose-Exposure%2520Relationships%2520to%2520Define%2520Clinical%2520Development%2520Strategies%26jtitle%3DClin.%2520Pharmacol.%2520Drug%2520Dev.%26date%3D2013%26volume%3D2%26spage%3D379%26epage%3D386%26doi%3D10.1002%2Fcpdd.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Shin, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moh, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, Y. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noh, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S.</span><span> </span><span class="NLM_article-title">In Vitro Structure-Activity Relationship and In Vivo Studies for a Novel Class of Cyclooxygenase-2 Inhibitors: 5-Aryl-2,2-dialkyl-4-phenyl-3(2H)furanone Derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">792</span><span class="NLM_x">–</span> <span class="NLM_lpage">804</span><span class="refDoi"> DOI: 10.1021/jm020545z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020545z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=792-804&author=S.+S.+Shinauthor=Y.+Byunauthor=K.+M.+Limauthor=J.+K.+Choiauthor=K.+W.+Leeauthor=J.+H.+Mohauthor=J.+K.+Kimauthor=Y.+S.+Jeongauthor=J.+Y.+Kimauthor=Y.+H.+Choiauthor=H.+J.+Kohauthor=Y.+H.+Parkauthor=Y.+I.+Ohauthor=M.+S.+Nohauthor=S.+Chung&title=In+Vitro+Structure-Activity+Relationship+and+In+Vivo+Studies+for+a+Novel+Class+of+Cyclooxygenase-2+Inhibitors%3A+5-Aryl-2%2C2-dialkyl-4-phenyl-3%282H%29furanone+Derivatives&doi=10.1021%2Fjm020545z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm020545z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020545z%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DS.%2BS.%26aulast%3DByun%26aufirst%3DY.%26aulast%3DLim%26aufirst%3DK.%2BM.%26aulast%3DChoi%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DMoh%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DChoi%26aufirst%3DY.%2BH.%26aulast%3DKoh%26aufirst%3DH.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DOh%26aufirst%3DY.%2BI.%26aulast%3DNoh%26aufirst%3DM.%2BS.%26aulast%3DChung%26aufirst%3DS.%26atitle%3DIn%2520Vitro%2520Structure-Activity%2520Relationship%2520and%2520In%2520Vivo%2520Studies%2520for%2520a%2520Novel%2520Class%2520of%2520Cyclooxygenase-2%2520Inhibitors%253A%25205-Aryl-2%252C2-dialkyl-4-phenyl-3%25282H%2529furanone%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D792%26epage%3D804%26doi%3D10.1021%2Fjm020545z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margalit, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holla, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuBois, R. N.</span><span> </span><span class="NLM_article-title">CG100649, a Novel COX-2 Inhibitor, Inhibits Colorectal Adenoma and Carcinoma Growth in Mouse Models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1105</span><span class="NLM_x">–</span> <span class="NLM_lpage">1112</span><span class="refDoi"> DOI: 10.1007/s10637-014-0144-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs10637-014-0144-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1105-1112&author=S.+H.+Kimauthor=O.+Margalitauthor=H.+Katohauthor=D.+Wangauthor=H.+Wuauthor=D.+Xiaauthor=V.+R.+Hollaauthor=P.+Yangauthor=R.+N.+DuBois&title=CG100649%2C+a+Novel+COX-2+Inhibitor%2C+Inhibits+Colorectal+Adenoma+and+Carcinoma+Growth+in+Mouse+Models&doi=10.1007%2Fs10637-014-0144-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0144-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0144-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DMargalit%26aufirst%3DO.%26aulast%3DKatoh%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DD.%26aulast%3DHolla%26aufirst%3DV.%2BR.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DCG100649%252C%2520a%2520Novel%2520COX-2%2520Inhibitor%252C%2520Inhibits%2520Colorectal%2520Adenoma%2520and%2520Carcinoma%2520Growth%2520in%2520Mouse%2520Models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2014%26volume%3D32%26spage%3D1105%26epage%3D1112%26doi%3D10.1007%2Fs10637-014-0144-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Kearney, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baigent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halls, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emberson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrono, C.</span><span> </span><span class="NLM_article-title">Do Selective Cyclo-oxygenase-2 Inhibitors and Traditional Non-steroidal Anti-inflammatory Drugs Increase the Risk of Atherothrombosis? Meta-analysis of Randomised Trials</span> <span class="citation_source-journal">BMJ</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x"> (</span><span class="NLM_issue">7553</span><span class="NLM_x">) </span> <span class="NLM_fpage">1302</span><span class="NLM_x">–</span> <span class="NLM_lpage">1308</span><span class="refDoi"> DOI: 10.1136/bmj.332.7553.1302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1136%2Fbmj.332.7553.1302" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2006&pages=1302-1308&issue=7553&author=P.+M.+Kearneyauthor=C.+Baigentauthor=J.+Godwinauthor=H.+Hallsauthor=J.+R.+Embersonauthor=C.+Patrono&title=Do+Selective+Cyclo-oxygenase-2+Inhibitors+and+Traditional+Non-steroidal+Anti-inflammatory+Drugs+Increase+the+Risk+of+Atherothrombosis%3F+Meta-analysis+of+Randomised+Trials&doi=10.1136%2Fbmj.332.7553.1302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1136%2Fbmj.332.7553.1302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.332.7553.1302%26sid%3Dliteratum%253Aachs%26aulast%3DKearney%26aufirst%3DP.%2BM.%26aulast%3DBaigent%26aufirst%3DC.%26aulast%3DGodwin%26aufirst%3DJ.%26aulast%3DHalls%26aufirst%3DH.%26aulast%3DEmberson%26aufirst%3DJ.%2BR.%26aulast%3DPatrono%26aufirst%3DC.%26atitle%3DDo%2520Selective%2520Cyclo-oxygenase-2%2520Inhibitors%2520and%2520Traditional%2520Non-steroidal%2520Anti-inflammatory%2520Drugs%2520Increase%2520the%2520Risk%2520of%2520Atherothrombosis%253F%2520Meta-analysis%2520of%2520Randomised%2520Trials%26jtitle%3DBMJ%26date%3D2006%26volume%3D332%26issue%3D7553%26spage%3D1302%26epage%3D1308%26doi%3D10.1136%2Fbmj.332.7553.1302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Prasit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brideau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charleson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cromlish, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford-Hutchinson, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gresser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kargman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riendeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodger, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamboni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupniak, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D.</span><span> </span><span class="NLM_article-title">The Discovery of Rofecxib, [MK 966, Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an Orally Active Cyclooxygenase-2-inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1773</span><span class="NLM_x">–</span> <span class="NLM_lpage">1778</span><span class="refDoi"> DOI: 10.1016/S0960-894X(99)00288-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0960-894X%2899%2900288-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=1773-1778&author=P.+Prasitauthor=Z.+Wangauthor=C.+Brideauauthor=C.+C.+Chanauthor=S.+Charlesonauthor=W.+Cromlishauthor=D.+Ethierauthor=J.+F.+Evansauthor=A.+W.+Ford-Hutchinsonauthor=J.+Y.+Gauthierauthor=R.+Gordonauthor=J.+Guayauthor=M.+Gresserauthor=S.+Kargmanauthor=B.+Kennedyauthor=Y.+Leblancauthor=S.+Legerauthor=J.+Manciniauthor=G.+P.+O%E2%80%99Neillauthor=M.+Ouelletauthor=M.+D.+Percivalauthor=H.+Perrierauthor=D.+Riendeauauthor=I.+Rodgerauthor=P.+Tagariauthor=M.+Therienauthor=P.+Vickersauthor=E.+Wongauthor=L.-J.+Xuauthor=R.+N.+Youngauthor=R.+Zamboniauthor=S.+Boyceauthor=N.+Rupniakauthor=M.+Forrestauthor=D.+Viscoauthor=D.+Patrick&title=The+Discovery+of+Rofecxib%2C+%5BMK+966%2C+Vioxx%2C+4-%284%E2%80%B2-Methylsulfonylphenyl%29-3-phenyl-2%285H%29-furanone%5D%2C+an+Orally+Active+Cyclooxygenase-2-inhibitor&doi=10.1016%2FS0960-894X%2899%2900288-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900288-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900288-7%26sid%3Dliteratum%253Aachs%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBrideau%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DC.%2BC.%26aulast%3DCharleson%26aufirst%3DS.%26aulast%3DCromlish%26aufirst%3DW.%26aulast%3DEthier%26aufirst%3DD.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DFord-Hutchinson%26aufirst%3DA.%2BW.%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGuay%26aufirst%3DJ.%26aulast%3DGresser%26aufirst%3DM.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DKennedy%26aufirst%3DB.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DLeger%26aufirst%3DS.%26aulast%3DMancini%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DG.%2BP.%26aulast%3DOuellet%26aufirst%3DM.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DPerrier%26aufirst%3DH.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DRodger%26aufirst%3DI.%26aulast%3DTagari%26aufirst%3DP.%26aulast%3DTherien%26aufirst%3DM.%26aulast%3DVickers%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DL.-J.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DBoyce%26aufirst%3DS.%26aulast%3DRupniak%26aufirst%3DN.%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DVisco%26aufirst%3DD.%26aulast%3DPatrick%26aufirst%3DD.%26atitle%3DThe%2520Discovery%2520of%2520Rofecxib%252C%2520%255BMK%2520966%252C%2520Vioxx%252C%25204-%25284%25E2%2580%25B2-Methylsulfonylphenyl%2529-3-phenyl-2%25285H%2529-furanone%255D%252C%2520an%2520Orally%2520Active%2520Cyclooxygenase-2-inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D1773%26epage%3D1778%26doi%3D10.1016%2FS0960-894X%2899%2900288-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit117b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertenshaw, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Docter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graneto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malecha, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogier, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogburn, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboldt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veenhuizen, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakson, P. C.</span><span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze Nesulfonamide (SC-58635, Celecoxib)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1365</span><span class="refDoi"> DOI: 10.1021/jm960803q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960803q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1347-1365&author=T.+D.+Penningauthor=J.+J.+Talleyauthor=S.+R.+Bertenshawauthor=J.+S.+Carterauthor=P.+W.+Collinsauthor=S.+Docterauthor=M.+J.+Granetoauthor=L.+F.+Leeauthor=J.+W.+Malechaauthor=J.+M.+Miyashiroauthor=R.+S.+Rogersauthor=D.+J.+Rogierauthor=S.+S.+Yuauthor=G.+D.+Andersonauthor=E.+G.+Burtonauthor=J.+N.+Cogburnauthor=S.+A.+Gregoryauthor=C.+M.+Koboldtauthor=W.+E.+Perkinsauthor=K.+Seibertauthor=A.+W.+Veenhuizenauthor=Y.+Y.+Zhangauthor=P.+C.+Isakson&title=Synthesis+and+Biological+Evaluation+of+the+1%2C5-Diarylpyrazole+Class+of+Cyclooxygenase-2+inhibitors%3A+Identification+of+4-%5B5-%284-methylphenyl%29-3-%28trifluoromethyl%29-1H-pyrazol-1-yl%5Dbenze+Nesulfonamide+%28SC-58635%2C+Celecoxib%29&doi=10.1021%2Fjm960803q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117b&amp;dbid=16384&amp;doi=10.1021%2Fjm960803q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960803q%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DTalley%26aufirst%3DJ.%2BJ.%26aulast%3DBertenshaw%26aufirst%3DS.%2BR.%26aulast%3DCarter%26aufirst%3DJ.%2BS.%26aulast%3DCollins%26aufirst%3DP.%2BW.%26aulast%3DDocter%26aufirst%3DS.%26aulast%3DGraneto%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DL.%2BF.%26aulast%3DMalecha%26aufirst%3DJ.%2BW.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BM.%26aulast%3DRogers%26aufirst%3DR.%2BS.%26aulast%3DRogier%26aufirst%3DD.%2BJ.%26aulast%3DYu%26aufirst%3DS.%2BS.%26aulast%3DAnderson%26aufirst%3DG.%2BD.%26aulast%3DBurton%26aufirst%3DE.%2BG.%26aulast%3DCogburn%26aufirst%3DJ.%2BN.%26aulast%3DGregory%26aufirst%3DS.%2BA.%26aulast%3DKoboldt%26aufirst%3DC.%2BM.%26aulast%3DPerkins%26aufirst%3DW.%2BE.%26aulast%3DSeibert%26aufirst%3DK.%26aulast%3DVeenhuizen%26aufirst%3DA.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DIsakson%26aufirst%3DP.%2BC.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520the%25201%252C5-Diarylpyrazole%2520Class%2520of%2520Cyclooxygenase-2%2520inhibitors%253A%2520Identification%2520of%25204-%255B5-%25284-methylphenyl%2529-3-%2528trifluoromethyl%2529-1H-pyrazol-1-yl%255Dbenze%2520Nesulfonamide%2520%2528SC-58635%252C%2520Celecoxib%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1347%26epage%3D1365%26doi%3D10.1021%2Fjm960803q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit117c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Talley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graneto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboldt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masferrer, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibert, K.</span><span> </span><span class="NLM_article-title">4-[5-Methyl-3-Phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">777</span><span class="refDoi"> DOI: 10.1021/jm990577v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990577v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1aiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=775-777&author=J.+J.+Talleyauthor=D.+L.+Brownauthor=J.+S.+Carterauthor=M.+J.+Granetoauthor=C.+M.+Koboldtauthor=J.+L.+Masferrerauthor=W.+E.+Perkinsauthor=R.+S.+Rogersauthor=A.+F.+Shafferauthor=Y.+Y.+Zhangauthor=B.+S.+Zweifelauthor=K.+Seibert&title=4-%5B5-Methyl-3-Phenylisoxazol-4-yl%5D-benzenesulfonamide%2C+Valdecoxib%3A+A+Potent+and+Selective+Inhibitor+of+COX-2&doi=10.1021%2Fjm990577v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117cR"><div class="casContent"><span class="casTitleNuber">117c</span><div class="casTitle"><span class="NLM_cas:atitle">4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2</span></div><div class="casAuthors">Talley, John J.; Brown, David L.; Carter, Jeffery S.; Graneto, Matthew J.; Koboldt, Carol M.; Masferrer, Jaime L.; Perkins, William E.; Rogers, Roland S.; Shaffer, Alexander F.; Zhang, Yan Y.; Zweifel, Ben S.; Seibert, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">775-777</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Valdecoxib (SC 65872) was a highly selective and potent inhibitor of COX-2 in human whole blood and against the recombinant human enzyme with an IC50 = 140 ± 19 μM (n = 10).  In animal models of acute and chronic inflammation, valdecoxib showed exceptional potency after oral administration.  An active metabolite of valdecoxib, formed in rodents and dogs, was also found to be a COX-2 selective inhibitor.  Valdecoxib is currently in clin. evaluation for the treatment of arthritis and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK0MUnhzUFEbVg90H21EOLACvtfcHk0lhttAg9HtP3AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1aiurw%253D&md5=61255dca3e0b7d879de06a3185e69d7c</span></div><a href="/servlet/linkout?suffix=cit117c&amp;dbid=16384&amp;doi=10.1021%2Fjm990577v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990577v%26sid%3Dliteratum%253Aachs%26aulast%3DTalley%26aufirst%3DJ.%2BJ.%26aulast%3DBrown%26aufirst%3DD.%2BL.%26aulast%3DCarter%26aufirst%3DJ.%2BS.%26aulast%3DGraneto%26aufirst%3DM.%2BJ.%26aulast%3DKoboldt%26aufirst%3DC.%2BM.%26aulast%3DMasferrer%26aufirst%3DJ.%2BL.%26aulast%3DPerkins%26aufirst%3DW.%2BE.%26aulast%3DRogers%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DA.%2BF.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DZweifel%26aufirst%3DB.%2BS.%26aulast%3DSeibert%26aufirst%3DK.%26atitle%3D4-%255B5-Methyl-3-Phenylisoxazol-4-yl%255D-benzenesulfonamide%252C%2520Valdecoxib%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520COX-2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D775%26epage%3D777%26doi%3D10.1021%2Fjm990577v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Friesen, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brideau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charleson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschenes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riendeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savoie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span> </span><span class="NLM_article-title">2-Pyridinyl-3-(4-Methylsulfonyl)phenylpyridines: Selective and Orally Active Cyclooxygenase-2 Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2777</span><span class="NLM_x">–</span> <span class="NLM_lpage">2782</span><span class="refDoi"> DOI: 10.1016/S0960-894X(98)00499-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0960-894X%2898%2900499-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=9873621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADyaK1cXntFSitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=2777-2782&author=R.+W.+Friesenauthor=C.+Brideauauthor=C.+C.+Chanauthor=S.+Charlesonauthor=D.+Deschenesauthor=D.+Dubeauthor=D.+Ethierauthor=R.+Fortinauthor=J.+Y.+Gauthierauthor=Y.+Girardauthor=R.+Gordonauthor=G.+M.+Greigauthor=D.+Riendeauauthor=C.+Savoieauthor=Z.+Wangauthor=E.+Wongauthor=D.+Viscoauthor=L.+J.+Xuauthor=R.+N.+Young&title=2-Pyridinyl-3-%284-Methylsulfonyl%29phenylpyridines%3A+Selective+and+Orally+Active+Cyclooxygenase-2+Inhibitors&doi=10.1016%2FS0960-894X%2898%2900499-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">2-Pyridinyl-3-[4-(methylsulfonyl)phenyl]pyridines: selective and orally active cyclooxygenase-2 inhibitors</span></div><div class="casAuthors">Friesen, Richard W.; Brideau, Christine; Chan, Chi Chung; Charleson, Stella; Deschenes, Denis; Dube, Daniel; Ethier, Diane; Fortin, Rejean; Gauthier, Jacques Yves; Girard, Yves; Gordon, Robert; Greig, Gillian M.; Riendeau, Denis; Savoie, Chantal; Wang, Zhaoyin; Wong, Elizabeth; Visco, Denise; Xu, Li Jing; Young, Robert N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2777-2782</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The title compds. were prepd. and evaluated for their ability to inhibit the isoenzymes of cyclooxygenase, COX-1 and COX-2.  Optimum COX-2 activity was obsd. by introduction of a substituent at C5 of the central pyridine.  Pyridine deriv. I was identified as the optimum compd. in this series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmMcvhjPWNvLVg90H21EOLACvtfcHk0lj3aelyd8dzxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFSitb0%253D&md5=b424a5b5c095d49b6dc1410a7c7335e4</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900499-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900499-5%26sid%3Dliteratum%253Aachs%26aulast%3DFriesen%26aufirst%3DR.%2BW.%26aulast%3DBrideau%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DC.%2BC.%26aulast%3DCharleson%26aufirst%3DS.%26aulast%3DDeschenes%26aufirst%3DD.%26aulast%3DDube%26aufirst%3DD.%26aulast%3DEthier%26aufirst%3DD.%26aulast%3DFortin%26aufirst%3DR.%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DGirard%26aufirst%3DY.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGreig%26aufirst%3DG.%2BM.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DSavoie%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DVisco%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DL.%2BJ.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26atitle%3D2-Pyridinyl-3-%25284-Methylsulfonyl%2529phenylpyridines%253A%2520Selective%2520and%2520Orally%2520Active%2520Cyclooxygenase-2%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D2777%26epage%3D2782%26doi%3D10.1016%2FS0960-894X%2898%2900499-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span>Cobimetinib; <span class="NLM_publisher-name">Exelixis</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.exelixis.com/pipeline/GDC_0973_xl518" class="extLink">http://www.exelixis.com/pipeline/GDC_0973_xl518</a>; accessed August 2, 2016.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cobimetinib%3B+Exelixis%3A+San+Francisco%2C+CA%2C+2016%3B+http%3A%2F%2Fwww.exelixis.com%2Fpipeline%2FGDC_0973_xl518%3B+accessed+August+2%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DCobimetinib%26pub%3DExelixis%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rice, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aay, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blazey, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowles, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussenius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defina, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubenko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koltun, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manalo, J.-C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peto, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, S.</span><span> </span><span class="NLM_article-title">Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span><span class="refDoi"> DOI: 10.1021/ml300049d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300049d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=416-421&author=K.+D.+Riceauthor=N.+Aayauthor=N.+K.+Anandauthor=C.+M.+Blazeyauthor=O.+J.+Bowlesauthor=J.+Busseniusauthor=S.+Costanzoauthor=J.+K.+Curtisauthor=S.+C.+Definaauthor=L.+Dubenkoauthor=S.+Engstauthor=A.+A.+Joshiauthor=A.+R.+Kennedyauthor=A.+I.+Kimauthor=E.+S.+Koltunauthor=J.+C.+Lougheedauthor=J.-C.+L.+Manaloauthor=J.-F.+Martiniauthor=J.+M.+Nussauthor=C.+J.+Petoauthor=T.+H.+Tsangauthor=P.+Yuauthor=S.+Johnston&title=Novel+Carboxamide-Based+Allosteric+MEK+Inhibitors%3A+Discovery+and+Optimization+Efforts+toward+XL518+%28GDC-0973%29&doi=10.1021%2Fml300049d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120aR"><div class="casContent"><span class="casTitleNuber">120a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)</span></div><div class="casAuthors">Rice, Kenneth D.; Aay, Naing; Anand, Neel K.; Blazey, Charles M.; Bowles, Owen J.; Bussenius, Joerg; Costanzo, Simona; Curtis, Jeffry K.; Defina, Steven C.; Dubenko, Larisa; Engst, Stefan; Joshi, Anagha A.; Kennedy, Abigail R.; Kim, Angie I.; Koltun, Elena S.; Lougheed, Julie C.; Manalo, Jean-Claire L.; Martini, Jean-Francois; Nuss, John M.; Peto, Csaba J.; Tsang, Tsze H.; Yu, Peiwen; Johnston, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">416-421</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types.  Mutations assocd. with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK.  Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer.  Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metab. and safety profile vs. PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (I).  I exhibits robust in vitro and in vivo potency and efficacy in preclin. models with sustained duration of action and is currently in early stage clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOx-Upr00b8LVg90H21EOLACvtfcHk0lj3aelyd8dzxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D&md5=04aa82afd24efe83a3b888140781bfc6</span></div><a href="/servlet/linkout?suffix=cit120a&amp;dbid=16384&amp;doi=10.1021%2Fml300049d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300049d%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DK.%2BD.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DAnand%26aufirst%3DN.%2BK.%26aulast%3DBlazey%26aufirst%3DC.%2BM.%26aulast%3DBowles%26aufirst%3DO.%2BJ.%26aulast%3DBussenius%26aufirst%3DJ.%26aulast%3DCostanzo%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%2BK.%26aulast%3DDefina%26aufirst%3DS.%2BC.%26aulast%3DDubenko%26aufirst%3DL.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%2BA.%26aulast%3DKennedy%26aufirst%3DA.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BI.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DManalo%26aufirst%3DJ.-C.%2BL.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DPeto%26aufirst%3DC.%2BJ.%26aulast%3DTsang%26aufirst%3DT.%2BH.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DS.%26atitle%3DNovel%2520Carboxamide-Based%2520Allosteric%2520MEK%2520Inhibitors%253A%2520Discovery%2520and%2520Optimization%2520Efforts%2520toward%2520XL518%2520%2528GDC-0973%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D416%26epage%3D421%26doi%3D10.1021%2Fml300049d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit120b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Den Otter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, N.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F0008-5472.CAN-11-1515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22084396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=210-219&author=K.+P.+Hoeflichauthor=M.+Merchantauthor=C.+Orrauthor=J.+Chanauthor=D.+Den+Otterauthor=L.+Berryauthor=I.+Kasmanauthor=H.+Koeppenauthor=K.+Riceauthor=N.-Y.+Yangauthor=S.+Engstauthor=S.+Johnstonauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Intermittent+Administration+of+MEK+Inhibitor+GDC-0973+plus+PI3K+Inhibitor+GDC-0941+Triggers+Robust+Apoptosis+and+Tumor+Growth+Inhibition&doi=10.1158%2F0008-5472.CAN-11-1515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120bR"><div class="casContent"><span class="casTitleNuber">120b</span><div class="casTitle"><span class="NLM_cas:atitle">Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition</span></div><div class="casAuthors">Hoeflich, Klaus P.; Merchant, Mark; Orr, Christine; Chan, Jocelyn; Den Otter, Doug; Berry, Leanne; Kasman, Ian; Koeppen, Hartmut; Rice, Ken; Yang, Nai-Ying; Engst, Stefan; Johnston, Stuart; Friedman, Lori S.; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-219</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclin. cancer models, leading to the initiation of clin. trials cotargeting these two key cancer signaling pathways.  GDC-0973, a novel selective MEK inhibitor, and GDC-0941, a class I PI3K inhibitor, are in early stage clin. trials as both single agents and in combination.  The discovery of these selective inhibitors has allowed investigation into the precise effects of combining inhibitors of two major signaling branches downstream of RAS.  Here, we investigated multiple biomarkers in the mitogen-activated protein kinase (MAPK) and PI3K pathway to search for points of convergence that explain the increased apoptosis seen in combination.  Using washout studies in vitro and alternate dosing schedules in mice, we showed that intermittent inhibition of the PI3K and MAPK pathway is sufficient for efficacy in BRAF and KRAS mutant cancer cells.  The combination of GDC-0973 with the PI3K inhibitor GDC-0941 resulted in combination efficacy in vitro and in vivo via induction of biomarkers assocd. with apoptosis, including Bcl-2 family proapoptotic regulators.  Therefore, these data suggest that continuous exposure of MEK and PI3K inhibitors in combination is not required for efficacy in preclin. cancer models and that sustained effects on downstream apoptosis biomarkers can be obsd. in response to intermittent dosing.  Cancer Res; 72(1); 210-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHbA7g6hLGrVg90H21EOLACvtfcHk0lj3aelyd8dzxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D&md5=40032bf35d5e6335856a645d5c331df8</span></div><a href="/servlet/linkout?suffix=cit120b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1515%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DDen%2BOtter%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DN.-Y.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DIntermittent%2520Administration%2520of%2520MEK%2520Inhibitor%2520GDC-0973%2520plus%2520PI3K%2520Inhibitor%2520GDC-0941%2520Triggers%2520Robust%2520Apoptosis%2520and%2520Tumor%2520Growth%2520Inhibition%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D210%26epage%3D219%26doi%3D10.1158%2F0008-5472.CAN-11-1515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernillet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Rosario, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aftab, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prescott, J.</span><span> </span><span class="NLM_article-title">Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3090</span><span class="NLM_x">–</span> <span class="NLM_lpage">3099</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F1078-0432.CCR-12-0445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22496205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3090-3099&author=H.+Wongauthor=L.+Vernilletauthor=A.+Petersonauthor=J.+A.+Wareauthor=L.+Leeauthor=J.-F.+Martiniauthor=P.+Yuauthor=C.+Liauthor=G.+Del+Rosarioauthor=E.+F.+Chooauthor=K.+P.+Hoeflichauthor=Y.+Shiauthor=B.+T.+Aftabauthor=R.+Aoyamaauthor=S.+T.+Lamauthor=M.+Belvinauthor=J.+Prescott&title=Bridging+the+Gap+between+Preclinical+and+Clinical+Studies+Using+Pharmacokinetic-Pharmacodynamic+Modeling%3A+An+Analysis+of+GDC-0973%2C+a+MEK+Inhibitor&doi=10.1158%2F1078-0432.CCR-12-0445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor</span></div><div class="casAuthors">Wong, Harvey; Vernillet, Laurent; Peterson, Amy; Ware, Joseph A.; Lee, Lillian; Martini, Jean-Francois; Yu, Peiwen; Li, Congfen; Del Rosario, Geoffrey; Choo, Edna F.; Hoeflich, Klaus P.; Shi, Yongchang; Aftab, Blake T.; Aoyama, Ron; Lam, Sanh Tan; Belvin, Marcia; Prescott, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3090-3099</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling was used to relate GDC-0973 plasma and tumor concns., tumor pharmacodynamics and antitumor efficacy to establish pharmacokinetic endpoints and predict active doses in the clinic.  Exptl. Design: A PK-PD model was used to characterize GDC-0973 tumor disposition and in vivo potency in WM-266-4 xenograft mice.  Simulations were conducted using the PK-PD model along with human pharmacokinetics to identify a target plasma concn. and predict active doses.  In vivo potency and antitumor efficacy were characterized in A375 melanoma xenograft mice, and a population-based integrated PK-PD-efficacy model was used to relate tumor pharmacodynamics (%pERK decrease) to antitumor activity.  Results: GDC-0973 showed a sustained tumor pharmacodynamic response due to longer residence in tumor than in plasma.  Following single doses of GDC-0973, estd. in vivo IC50 values of %pERK decrease based on tumor concns. in xenograft mice were 0.78 (WM-266-4) and 0.52 μmol/L (A375).  Following multiple doses of GDC-0973, the estd. in vivo IC50 value in WM-266-4 increased (3.89 μmol/L).  Human simulations predicted a min. target plasma concn. of 83 nmol/L and an active dose range of 28 to 112 mg.  The steep relationship between tumor pharmacodynamics (%pERK decrease) and antitumor efficacy suggests a pathway modulation threshold beyond which antitumor efficacy switches on.  Conclusions: Clin. observations of %pERK decrease and antitumor activity were consistent with model predictions.  This article illustrates how PK-PD modeling can improve the translation of preclin. data to humans by providing a means to integrate preclin. and early clin. data.  Clin Cancer Res; 18(11); 3090-9. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq36HE1lLsI8bVg90H21EOLACvtfcHk0ljbzQ4FW1hF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOgtbg%253D&md5=9ae14cf08c84e63fcdf98e3507a92cd0</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0445%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DH.%26aulast%3DVernillet%26aufirst%3DL.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DAftab%26aufirst%3DB.%2BT.%26aulast%3DAoyama%26aufirst%3DR.%26aulast%3DLam%26aufirst%3DS.%2BT.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DPrescott%26aufirst%3DJ.%26atitle%3DBridging%2520the%2520Gap%2520between%2520Preclinical%2520and%2520Clinical%2520Studies%2520Using%2520Pharmacokinetic-Pharmacodynamic%2520Modeling%253A%2520An%2520Analysis%2520of%2520GDC-0973%252C%2520a%2520MEK%2520Inhibitor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3090%26epage%3D3099%26doi%3D10.1158%2F1078-0432.CCR-12-0445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Baudy, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores-Mercado, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Bruggen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S.-P.</span><span> </span><span class="NLM_article-title">FDG-PET is a Good Biomarker of Both Early Response and Acquired Resistance in BRAFV600 Mutant Melanomas Treated with Vemurafenib and the MEK Inhibitor GDC-0973</span> <span class="citation_source-journal">EJNMMI Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="refDoi"> DOI: 10.1186/2191-219X-2-22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1186%2F2191-219X-2-22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22651703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyitbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=22&author=A.+R.+Baudyauthor=T.+Doganauthor=J.+E.+Flores-Mercadoauthor=K.+P.+Hoeflichauthor=F.+Suauthor=N.+van+Bruggenauthor=S.-P.+Williams&title=FDG-PET+is+a+Good+Biomarker+of+Both+Early+Response+and+Acquired+Resistance+in+BRAFV600+Mutant+Melanomas+Treated+with+Vemurafenib+and+the+MEK+Inhibitor+GDC-0973&doi=10.1186%2F2191-219X-2-22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973</span></div><div class="casAuthors">Baudy, Andreas R.; Dogan, Taner; Flores-Mercado, Judith E.; Hoeflich, Klaus P.; Su, Fei; van Bruggen, Nicholas; Williams, Simon-Peter</div><div class="citationInfo"><span class="NLM_cas:title">EJNMMI Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22/1-22/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">ERJEAI</span>;
        ISSN:<span class="NLM_cas:issn">2191-219X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Background: The BRAF inhibitor, vemurafenib, has recently been approved for the treatment of metastatic melanoma in patients harboring BRAFV600 mutations.  Currently, dual BRAF and MEK inhibition are ongoing in clin. trials with the goal of overcoming the acquired resistance that has unfortunately developed in some vemurafenib patients.  FDG-PET measures of metabolic activity are increasingly employed as a pharmacodynamic biomarker for guiding single-agent or combination therapies by gauging initial drug response and monitoring disease progression.  However, since tumors are inherently heterogeneous, investigating the effects of BRAF and MEK inhibition on FDG uptake in a panel of different melanomas could help interpret imaging outcomes.  Methods: 18F-FDG uptake was measured in vitro in cells with wild-type and mutant (V600) BRAF, and in melanoma cells with an acquired resistance to vemurafenib.  We treated the cells with vemurafenib alone or in combination with MEK inhibitor GDC-0973.  PET imaging was used in mice to measure FDG uptake in A375 melanoma xenografts and in A375 R1, a vemurafenib-resistant deriv.  Histol. and biochem. studies of glucose transporters, the MAPK and glycolytic pathways were also undertaken.  Results: We demonstrate that vemurafenib is equally effective at reducing FDG uptake in cell lines harboring either heterozygous or homozygous BRAFV600 but ineffective in cells with acquired resistance or having WT BRAF status.  However, combination with GDC-0973 results in a highly significant increase of efficacy and inhibition of FDG uptake across all twenty lines.  Drug-induced changes in FDG uptake were assocd. with altered levels of membrane GLUT-1, and cell lines harboring RAS mutations displayed enhanced FDG uptake upon exposure to vemurafenib.  Interestingly, we found that vemurafenib treatment in mice bearing drug-resistant A375 xenografts also induced increased FDG tumor uptake, accompanied by increases in Hif-1α, Sp1 and Ksr protein levels.  Vemurafenib and GDC-0973 combination efficacy was assocd. with decreased levels of hexokinase II, c-RAF, Ksr and p-MEK protein.  Conclusions: We have demonstrated that 18F-FDG-PET imaging reflects vemurafenib and GDC-0973 action across a wide range of metastatic melanomas.  A delayed post-treatment increase in tumor FDG uptake should be considered carefully as it may well be an indication of acquired drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFfhSHK_0cVbVg90H21EOLACvtfcHk0ljbzQ4FW1hF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyitbbP&md5=915b9a76a80aab9c7d7944a539512b1f</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1186%2F2191-219X-2-22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2191-219X-2-22%26sid%3Dliteratum%253Aachs%26aulast%3DBaudy%26aufirst%3DA.%2BR.%26aulast%3DDogan%26aufirst%3DT.%26aulast%3DFlores-Mercado%26aufirst%3DJ.%2BE.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DSu%26aufirst%3DF.%26aulast%3Dvan%2BBruggen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DS.-P.%26atitle%3DFDG-PET%2520is%2520a%2520Good%2520Biomarker%2520of%2520Both%2520Early%2520Response%2520and%2520Acquired%2520Resistance%2520in%2520BRAFV600%2520Mutant%2520Melanomas%2520Treated%2520with%2520Vemurafenib%2520and%2520the%2520MEK%2520Inhibitor%2520GDC-0973%26jtitle%3DEJNMMI%2520Res.%26date%3D2012%26volume%3D2%26spage%3D22%26doi%3D10.1186%2F2191-219X-2-22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Luke, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodi, F. S.</span><span> </span><span class="NLM_article-title">Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F1078-0432.CCR-11-2197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22083257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=9-14&author=J.+J.+Lukeauthor=F.+S.+Hodi&title=Vemurafenib+and+BRAF+Inhibition%3A+A+New+Class+of+Treatment+for+Metastatic+Melanoma&doi=10.1158%2F1078-0432.CCR-11-2197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma</span></div><div class="casAuthors">Luke, Jason J.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-14</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The U.S. Food and Drug Administration recently approved vemurafenib for the treatment of BRAF valine in exon 15, at codon 600 (V600E) mutant metastatic melanoma.  Vemurafenib is a competitive small-mol. serine-threonine kinase inhibitor that functions by binding to the ATP-binding domain of mutant BRAF.  Compared with dacarbazine chemotherapy, vemurafenib significantly improved the 6-mo overall survival of patients from 64% to 84% and exhibited a response rate of approx. 50%.  Median progression-free survival was also significantly improved with vemurafenib as compared with dacarbazine (5.3 vs. 1.6 mo, resp.), and this was consistent among groups analyzed, including age, sex, geog., Eastern Cooperative Oncol. Group status, disease stage, and serum lactate dehydrogenase.  The success of targeting melanoma genomics has created a paradigm shift for future drug development.  Currently, the elucidation of resistant mechanisms to vemurafenib therapy remains an important area of active investigation that will shape rational drug treatments for melanoma.  The development of vemurafenib, the role of BRAF targeting, and the changing landscape of treatment for melanoma provide a new foundation for clin. investigation.  Clin Cancer Res; 18(1); 9-14.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSUtT4uGz8MbVg90H21EOLACvtfcHk0ljbzQ4FW1hF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsQ%253D%253D&md5=e3e3a4623a5120026adc3c0aca4136ee</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2197%26sid%3Dliteratum%253Aachs%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DVemurafenib%2520and%2520BRAF%2520Inhibition%253A%2520A%2520New%2520Class%2520of%2520Treatment%2520for%2520Metastatic%2520Melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D9%26epage%3D14%26doi%3D10.1158%2F1078-0432.CCR-11-2197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Keating, G. M.</span><span> </span><span class="NLM_article-title">Cobimetinib Plus Vemurafenib: A Review in BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span><span class="refDoi"> DOI: 10.1007/s40265-016-0562-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-016-0562-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=605-615&author=G.+M.+Keating&title=Cobimetinib+Plus+Vemurafenib%3A+A+Review+in+BRAFV600+Mutation-Positive+Unresectable+or+Metastatic+Melanoma&doi=10.1007%2Fs40265-016-0562-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0562-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0562-7%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DCobimetinib%2520Plus%2520Vemurafenib%253A%2520A%2520Review%2520in%2520BRAFV600%2520Mutation-Positive%2520Unresectable%2520or%2520Metastatic%2520Melanoma%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D605%26epage%3D615%26doi%3D10.1007%2Fs40265-016-0562-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit124b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dossett, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudchadkar, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zager, J. S.</span><span> </span><span class="NLM_article-title">BRAF and MEK Inhibition in Melanoma</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span><span class="refDoi"> DOI: 10.1517/14740338.2015.1011618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14740338.2015.1011618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25648338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVOrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=559-570&author=L.+A.+Dossettauthor=R.+R.+Kudchadkarauthor=J.+S.+Zager&title=BRAF+and+MEK+Inhibition+in+Melanoma&doi=10.1517%2F14740338.2015.1011618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124bR"><div class="casContent"><span class="casTitleNuber">124b</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF and MEK inhibition in melanoma</span></div><div class="casAuthors">Dossett, Lesly A.; Kudchadkar, Ragini R.; Zager, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">559-570</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Selective inhibition of the MAPK pathway with either BRAF or MEK inhibition has emerged as a key component for the treatment of BRAF-mutant metastatic melanoma.  New evidence suggests that the combination of BRAF and MEK inhibitors improves tumor response rate and progression-free survival, while potentially attenuating some of the serious adverse events obsd. with monotherapy.  Areas covered: This review covers the current data on the efficacy and safety of the selective BRAF (vemurafenib and dabrafenib) and MEK (trametinib) inhibitors as well as the available data on BRAF inhibitor + MEK inhibitor combination therapy (dabrafenib + trametinib and vemurafenib + cobimetinib).  The efficacy, safety and toxicity data are discussed from Phase I, Phase II and Phase III trials of these drugs.  Expert opinion: Combination therapy with the BRAF and MEK inhibitors improves response rates and progression-free survival in patients with BRAF-mutant metastatic melanoma.  Some of the serious adverse events, in particular, the incidence of cutaneous squamous cell carcinoma, are attenuated with combination therapy, whereas milder side effects such as pyrexia can be more common with combination therapy.  Although dose redns. and dose interruptions are slightly more common with combination therapy, overall data supports the notion that combination therapy is safe and improves the outcomes for patients compared to single agent BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowwkN6ePq_TbVg90H21EOLACvtfcHk0lhrvijG3twYEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVOrt70%253D&md5=9485736bc70be9bec4e396756113113b</span></div><a href="/servlet/linkout?suffix=cit124b&amp;dbid=16384&amp;doi=10.1517%2F14740338.2015.1011618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2015.1011618%26sid%3Dliteratum%253Aachs%26aulast%3DDossett%26aufirst%3DL.%2BA.%26aulast%3DKudchadkar%26aufirst%3DR.%2BR.%26aulast%3DZager%26aufirst%3DJ.%2BS.%26atitle%3DBRAF%2520and%2520MEK%2520Inhibition%2520in%2520Melanoma%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2015%26volume%3D14%26spage%3D559%26epage%3D570%26doi%3D10.1517%2F14740338.2015.1011618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liszkay, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroyakovskiy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Cruz-Merino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutriaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sovak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choong, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hack, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span> </span><span class="NLM_article-title">Combined Vemurafenib and Cobimetinib in BRAF-mutated Melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">1867</span><span class="NLM_x">–</span> <span class="NLM_lpage">1876</span><span class="refDoi"> DOI: 10.1056/NEJMoa1408868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1056%2FNEJMoa1408868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25265494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1867-1876&author=J.+Larkinauthor=P.+A.+Asciertoauthor=B.+Drenoauthor=V.+Atkinsonauthor=G.+Liszkayauthor=M.+Maioauthor=M.+Mandalaauthor=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=M.+A.+Sovakauthor=I.+Changauthor=N.+Choongauthor=S.+P.+Hackauthor=G.+A.+McArthurauthor=A.+Ribas&title=Combined+Vemurafenib+and+Cobimetinib+in+BRAF-mutated+Melanoma&doi=10.1056%2FNEJMoa1408868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span></div><div class="casAuthors">Larkin, James; Ascierto, Paolo A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.; McArthur, Grant A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1876, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The combined inhibition of BRAF and MEK is hypothesized to improve clin. outcomes in patients with melanoma by preventing or delaying the onset of resistance obsd. with BRAF inhibitors alone.  This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib.  We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-pos. melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).  The primary end point was investigator-assessed progression-free survival.  The median progression-free survival was 9.9 mo in the combination group and 6.2 mo in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001).  The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group.  Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival.  Interim analyses of overall survival showed 9-mo survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group.  Vemurafenib and cobimetinib was assocd. with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation.  The no. of secondary cutaneous cancers decreased with the combination therapy.  The addn. of cobimetinib to vemurafenib was assocd. with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpErdkeTyZ9rVg90H21EOLACvtfcHk0lhrvijG3twYEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D&md5=9b6fb4f9ea883da579d6435ccb5742eb</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408868%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DChoong%26aufirst%3DN.%26aulast%3DHack%26aufirst%3DS.%2BP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DCombined%2520Vemurafenib%2520and%2520Cobimetinib%2520in%2520BRAF-mutated%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1867%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1408868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lamb, P.</span><span> </span><span class="NLM_article-title"><i>N</i>-Acylazetidine Derivatives as MEK Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Cancer</span>. WO 2008076415A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Lamb&title=N-Acylazetidine+Derivatives+as+MEK+Inhibitors+and+Their+Preparation%2C+Pharmaceutical+Compositions+and+Use+in+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DP.%26atitle%3DN-Acylazetidine%2520Derivatives%2520as%2520MEK%2520Inhibitors%2520and%2520Their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Cancer%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Beak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. K.</span><span> </span><span class="NLM_article-title">α-Lithioamine Synthetic Equivalents: Syntheses of Diastereoisomers from the Boc-piperidines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2578</span><span class="NLM_x">–</span> <span class="NLM_lpage">2580</span><span class="refDoi"> DOI: 10.1021/jo00296a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00296a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1990&pages=2578-2580&author=P.+Beakauthor=W.+K.+Lee&title=%CE%B1-Lithioamine+Synthetic+Equivalents%3A+Syntheses+of+Diastereoisomers+from+the+Boc-piperidines&doi=10.1021%2Fjo00296a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126b&amp;dbid=16384&amp;doi=10.1021%2Fjo00296a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00296a008%26sid%3Dliteratum%253Aachs%26aulast%3DBeak%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DW.%2BK.%26atitle%3D%25CE%25B1-Lithioamine%2520Synthetic%2520Equivalents%253A%2520Syntheses%2520of%2520Diastereoisomers%2520from%2520the%2520Boc-piperidines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1990%26volume%3D55%26spage%3D2578%26epage%3D2580%26doi%3D10.1021%2Fjo00296a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Royer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husson, H. P.</span><span> </span><span class="NLM_article-title">2-Cyano-6-oxazolopiperidine: A Powerful Tool for the Asymmetric Synthesis of Piperidine Derivatives</span> <span class="citation_source-journal">Janssen Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADyaK2cXkvVelurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1993&pages=3-8&author=J.+Royerauthor=H.+P.+Husson&title=2-Cyano-6-oxazolopiperidine%3A+A+Powerful+Tool+for+the+Asymmetric+Synthesis+of+Piperidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127aR"><div class="casContent"><span class="casTitleNuber">127a</span><div class="casTitle"><span class="NLM_cas:atitle">2-Cyano-6-oxazolopiperidine: a powerful tool for the asymmetric synthesis of piperidine derivatives</span></div><div class="casAuthors">Royer, J.; Husson, H. P.</div><div class="citationInfo"><span class="NLM_cas:title">Janssen Chimica Acta</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">JCACEN</span>;
        ISSN:<span class="NLM_cas:issn">0771-4602</span>.
    </div><div class="casAbstract">The title compd. (-)-I, a synthetic equiv. of 1,4-dihydropyridine, was prepd. by reaction of R-(-)-phenylglycinol with OHC(CH2)3CHO and KCN, followed by equilibration with ZnBr2.  (-)-I was used in the synthesis of natural piperidine alkaloids and derivs.  E.g., deprotonation of (-)-I, followed by treatment with PrBr and reductive ring opening with NaBH4 gave (+)-coniine (II) in 90% overall yield and 95% ee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3CfCcwfLOF7Vg90H21EOLACvtfcHk0ljCnHpYZlcFww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvVelurg%253D&md5=ccf09c4611158358601f7faf65632a14</span></div><a href="/servlet/linkout?suffix=cit127a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoyer%26aufirst%3DJ.%26aulast%3DHusson%26aufirst%3DH.%2BP.%26atitle%3D2-Cyano-6-oxazolopiperidine%253A%2520A%2520Powerful%2520Tool%2520for%2520the%2520Asymmetric%2520Synthesis%2520of%2520Piperidine%2520Derivatives%26jtitle%3DJanssen%2520Chim.%2520Acta%26date%3D1993%26volume%3D11%26spage%3D3%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit127b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Husson, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royer, J.</span><span> </span><span class="NLM_article-title">Chiral Non-racemic N-cyanomethyloxazolidines: the Pivotal System of the CN(R,S) Method</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span><span class="refDoi"> DOI: 10.1039/a900153k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1039%2Fa900153k" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1999&pages=383-394&author=H.-P.+Hussonauthor=J.+Royer&title=Chiral+Non-racemic+N-cyanomethyloxazolidines%3A+the+Pivotal+System+of+the+CN%28R%2CS%29+Method&doi=10.1039%2Fa900153k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127b&amp;dbid=16384&amp;doi=10.1039%2Fa900153k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fa900153k%26sid%3Dliteratum%253Aachs%26aulast%3DHusson%26aufirst%3DH.-P.%26aulast%3DRoyer%26aufirst%3DJ.%26atitle%3DChiral%2520Non-racemic%2520N-cyanomethyloxazolidines%253A%2520the%2520Pivotal%2520System%2520of%2520the%2520CN%2528R%252CS%2529%2520Method%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D1999%26volume%3D28%26spage%3D383%26epage%3D394%26doi%3D10.1039%2Fa900153k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Naganathan, S.; Guz, N.; Pfeiffer, M.</span><span> </span><span class="NLM_article-title">Preparation of Phenylaminophenylhydroxypiperidinylazetidinylmethanone Derivatives for Use as MEK Inhibitors</span>. WO 2014059422A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Naganathan&author=N.+Guz&author=M.+Pfeiffer&title=Preparation+of+Phenylaminophenylhydroxypiperidinylazetidinylmethanone+Derivatives+for+Use+as+MEK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNaganathan%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Phenylaminophenylhydroxypiperidinylazetidinylmethanone%2520Derivatives%2520for%2520Use%2520as%2520MEK%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit128b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Aay, N.; Anand, N. K.; Bowles, O. J.; Bussenius, J.; Costanzo, S.; Curtis, J. K.; Dubenko, L.; Joshi, A. A.; Kennedy, A. R.; Kim, A. I.; Koltun, E.; Manalo, J.-C. L.; Peto, C. J.; Rice, K. D.; Tsang, T. H.</span><span> </span><span class="NLM_article-title">Preparation of Azetidines as MEK Kinase Inhibitors for the Treatment of Proliferative Diseases, Especially Cancer</span>. WO 2007044515A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+Aay&author=N.+K.+Anand&author=O.+J.+Bowles&author=J.+Bussenius&author=S.+Costanzo&author=J.+K.+Curtis&author=L.+Dubenko&author=A.+A.+Joshi&author=A.+R.+Kennedy&author=A.+I.+Kim&author=E.+Koltun&author=J.-C.+L.+Manalo&author=C.+J.+Peto&author=K.+D.+Rice&author=T.+H.+Tsang&title=Preparation+of+Azetidines+as+MEK+Kinase+Inhibitors+for+the+Treatment+of+Proliferative+Diseases%2C+Especially+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAay%26aufirst%3DN.%26atitle%3DPreparation%2520of%2520Azetidines%2520as%2520MEK%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Proliferative%2520Diseases%252C%2520Especially%2520Cancer%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Guz, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeiffer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickman, D.</span><span> </span><span class="NLM_article-title">A Kilolaboratory Preparation of the CNRS Chiral Auxiliary</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1476</span><span class="NLM_x">–</span> <span class="NLM_lpage">1478</span><span class="refDoi"> DOI: 10.1021/op1002227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op1002227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=1476-1478&author=N.+R.+Guzauthor=M.+Pfeifferauthor=D.+Dickman&title=A+Kilolaboratory+Preparation+of+the+CNRS+Chiral+Auxiliary&doi=10.1021%2Fop1002227"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fop1002227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop1002227%26sid%3Dliteratum%253Aachs%26aulast%3DGuz%26aufirst%3DN.%2BR.%26aulast%3DPfeiffer%26aufirst%3DM.%26aulast%3DDickman%26aufirst%3DD.%26atitle%3DA%2520Kilolaboratory%2520Preparation%2520of%2520the%2520CNRS%2520Chiral%2520Auxiliary%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2010%26volume%3D14%26spage%3D1476%26epage%3D1478%26doi%3D10.1021%2Fop1002227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span>Cotellic; <span class="NLM_publisher-name">Genentech USA, Inc.</span>: <span class="NLM_publisher-loc">South San Francisco, CA</span>, November<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf</a>; accessed August 4, 2016.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cotellic%3B+Genentech+USA%2C+Inc.%3A+South+San+Francisco%2C+CA%2C+November+2015%3B+http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F206192s000lbl.pdf%3B+accessed+August+4%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DCotellic%26pub%3DGenentech%2520USA%252C%2520Inc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Moreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masszi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grzasko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahlis, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pour, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganly, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoppa, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimsing, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garderet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Touzeau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buadi, F. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bacco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Velde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. G.</span><span> </span><span class="NLM_article-title">Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">1621</span><span class="NLM_x">–</span> <span class="NLM_lpage">1634</span><span class="refDoi"> DOI: 10.1056/NEJMoa1516282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1056%2FNEJMoa1516282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27119237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOltLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1621-1634&author=P.+Moreauauthor=T.+Massziauthor=N.+Grzaskoauthor=N.+J.+Bahlisauthor=M.+Hanssonauthor=L.+Pourauthor=I.+Sandhuauthor=P.+Ganlyauthor=B.+W.+Bakerauthor=S.+R.+Jacksonauthor=A.+M.+Stoppaauthor=D.+R.+Simpsonauthor=P.+Gimsingauthor=A.+Palumboauthor=L.+Garderetauthor=M.+Cavoauthor=S.+Kumarauthor=C.+Touzeauauthor=F.+K.+Buadiauthor=J.+P.+Laubachauthor=D.+T.+Bergauthor=J.+Linauthor=A.+Di+Baccoauthor=A.+M.+Huiauthor=H.+van+de+Veldeauthor=P.+G.+Richardson&title=Oral+Ixazomib%2C+Lenalidomide%2C+and+Dexamethasone+for+Multiple+Myeloma&doi=10.1056%2FNEJMoa1516282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma</span></div><div class="casAuthors">Moreau, P.; Masszi, T.; Grzasko, N.; Bahlis, N. J.; Hansson, M.; Pour, L.; Sandhu, I.; Ganly, P.; Baker, B. W.; Jackson, S. R.; Stoppa, A.-M.; Simpson, D. R.; Gimsing, P.; Palumbo, A.; Garderet, L.; Cavo, M.; Kumar, S.; Touzeau, C.; Buadi, F. K.; Laubach, J. P.; Berg, D. T.; Lin, J.; Di Bacco, A.; Hui, A.-M.; van de Velde, H.; Richardson, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1621-1634</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.  In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group).  The primary end point was progression-free survival.  Progression-free survival was significantly longer in the ixazomib group than in the placebo group at a median follow-up of 14.7 mo (median progression-free survival, 20.6 mo vs. 14.7 mo; hazard ratio for disease progression or death in the ixazomib group, 0.74; P = 0.01); a benefit with respect to progression-free survival was obsd. with the ixazomib regimen, as compared with the placebo regimen, in all prespecified patient subgroups, including in patients with high-risk cytogenetic abnormalities.  The overall rates of response were 78% in the ixazomib group and 72% in the placebo group, and the corresponding rates of complete response plus very good partial response were 48% and 39%.  The median time to response was 1.1 mo in the ixazomib group and 1.9 mo in the placebo group and the corresponding median duration of response was 20.5 mo and 15.0 mo.  At a median follow-up of approx. 23 mo, the median overall survival has not been reached in either study group, and follow-up is ongoing.  The rates of serious adverse events were similar in the two study groups (47% in the ixazomib group and 49% in the placebo group), as were the rates of death during the study period (4% and 6%, resp.); adverse events of at least grade 3 severity occurred in 74% and 69% of the patients, resp.  Thrombocytopenia of grade 3 and grade 4 severity occurred more frequently in the ixazomib group (12% and 7% of the patients, resp.) than in the placebo group (5% and 4% of the patients, resp.).  Rash occurred more frequently in the ixazomib group than in the placebo group (36% vs. 23% of the patients), as did gastrointestinal adverse events, which were predominantly low grade.  The incidence of peripheral neuropathy was 27% in the ixazomib group and 22% in the placebo group (grade 3 events occurred in 2% of the patients in each study group).  Patient-reported quality of life was similar in the two study groups.  The addn. of ixazomib to a regimen of lenalidomide and dexamethasone was assocd. with significantly longer progression-free survival; the addnl. toxic effects with this all-oral regimen were limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe5omTDIjGVLVg90H21EOLACvtfcHk0lh55bNTWP4pSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOltLjN&md5=b71bd9b8d3afd6c02e1c541abdb44c0e</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1516282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1516282%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DGrzasko%26aufirst%3DN.%26aulast%3DBahlis%26aufirst%3DN.%2BJ.%26aulast%3DHansson%26aufirst%3DM.%26aulast%3DPour%26aufirst%3DL.%26aulast%3DSandhu%26aufirst%3DI.%26aulast%3DGanly%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DB.%2BW.%26aulast%3DJackson%26aufirst%3DS.%2BR.%26aulast%3DStoppa%26aufirst%3DA.%2BM.%26aulast%3DSimpson%26aufirst%3DD.%2BR.%26aulast%3DGimsing%26aufirst%3DP.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DGarderet%26aufirst%3DL.%26aulast%3DCavo%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DTouzeau%26aufirst%3DC.%26aulast%3DBuadi%26aufirst%3DF.%2BK.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DBerg%26aufirst%3DD.%2BT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DDi%2BBacco%26aufirst%3DA.%26aulast%3DHui%26aufirst%3DA.%2BM.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DOral%2520Ixazomib%252C%2520Lenalidomide%252C%2520and%2520Dexamethasone%2520for%2520Multiple%2520Myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1621%26epage%3D1634%26doi%3D10.1056%2FNEJMoa1516282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Cvek, B.</span><span> </span><span class="NLM_article-title">IXAZOMIB CITRATE Proteasome Inhibitor Oncolytic</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">565</span><span class="refDoi"> DOI: 10.1358/dof.2012.037.08.1835040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdof.2012.037.08.1835040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFSgurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=561-565&author=B.+Cvek&title=IXAZOMIB+CITRATE+Proteasome+Inhibitor+Oncolytic&doi=10.1358%2Fdof.2012.037.08.1835040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Ixazomib citrate: proteasome inhibitor oncolytic</span></div><div class="casAuthors">Cvek, B.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">561-565</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Thomson Reuters</span>)
        </div><div class="casAbstract">A review.  Ixazomib citrate, produced and patented by Millennium Pharmaceuticals, is one of the "new-generation" proteasome inhibitors following the success story of the first-in-class proteasome inhibitor bortezomib.  Today, bortezomib is approved for multiple myeloma and mantle cell lymphoma, but has failed In clin. trials in patients with solid tumors.  According to available preclin. data, ixazomib citrate may be more active in solid tumors.  It also appears to be better tolerated by patients, as the most serious adverse event for bortezomib, neuropathy, has not yet been obsd. in clin. trials with ixazomib citrate.  Ixazomib citrate can be administered both i.v. and orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ8hnaYJsr-bVg90H21EOLACvtfcHk0lh55bNTWP4pSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFSgurg%253D&md5=a0b5ca7386027e57384b5f52b3e65aa9</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1358%2Fdof.2012.037.08.1835040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2012.037.08.1835040%26sid%3Dliteratum%253Aachs%26aulast%3DCvek%26aufirst%3DB.%26atitle%3DIXAZOMIB%2520CITRATE%2520Proteasome%2520Inhibitor%2520Oncolytic%26jtitle%3DDrugs%2520Future%26date%3D2012%26volume%3D37%26spage%3D561%26epage%3D565%26doi%3D10.1358%2Fdof.2012.037.08.1835040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Elliott, E. L.; Ferdous, A. J.; Kaufman, M. J.; Komar, S. A.; Mazaik, D. L.; McCubbin, Q. J.; Nguyen, P.; Palaniappan, V.; Skwierczynski, R. D.; Truong, N. T.</span><span> </span><span class="NLM_article-title">Boronate Ester Compounds and Pharmaceutical Compositions Thereof</span>. US 20090325903A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=E.+L.+Elliott&author=A.+J.+Ferdous&author=M.+J.+Kaufman&author=S.+A.+Komar&author=D.+L.+Mazaik&author=Q.+J.+McCubbin&author=P.+Nguyen&author=V.+Palaniappan&author=R.+D.+Skwierczynski&author=N.+T.+Truong&title=Boronate+Ester+Compounds+and+Pharmaceutical+Compositions+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DElliott%26aufirst%3DE.%2BL.%26atitle%3DBoronate%2520Ester%2520Compounds%2520and%2520Pharmaceutical%2520Compositions%2520Thereof%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Pickersgill, I. F.; Bishop, J.; Koellner, C.; Gomez, J. M.; Geiser, A.; Hett, R.; Ammoscato, V.; Munk, S.; Lo, Y.; Chui, F. T.</span><span> </span><span class="NLM_article-title">Synthesis of Boronic Ester and Acid Compounds</span>. WO 2005097809A2,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=I.+F.+Pickersgill&author=J.+Bishop&author=C.+Koellner&author=J.+M.+Gomez&author=A.+Geiser&author=R.+Hett&author=V.+Ammoscato&author=S.+Munk&author=Y.+Lo&author=F.+T.+Chui&title=Synthesis+of+Boronic+Ester+and+Acid+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPickersgill%26aufirst%3DI.%2BF.%26atitle%3DSynthesis%2520of%2520Boronic%2520Ester%2520and%2520Acid%2520Compounds%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Matsui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span> </span><span class="NLM_article-title">Multi-kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5459</span><span class="NLM_x">–</span> <span class="NLM_lpage">5465</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-5270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F1078-0432.CCR-07-5270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=18765537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5459-5465&author=J.+Matsuiauthor=Y.+Funahashiauthor=T.+Uenakaauthor=T.+Watanabeauthor=A.+Tsuruokaauthor=M.+Asada&title=Multi-kinase+Inhibitor+E7080+Suppresses+Lymph+Node+and+Lung+Metastases+of+Human+Mammary+Breast+Tumor+MDA-MB-231+via+Inhibition+of+Vascular+Endothelial+Growth+Factor-Receptor+%28VEGF-R%29+2+and+VEGF-R3+Kinase&doi=10.1158%2F1078-0432.CCR-07-5270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase</span></div><div class="casAuthors">Matsui, Junji; Funahashi, Yasuhiro; Uenaka, Toshimitsu; Watanabe, Tatsuo; Tsuruoka, Akihiko; Asada, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5459-5465</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Vascular endothelial growth factor (VEGF)-C/VEGF-receptor 3 (VEGF-R3) signal plays a significant role in lymphangiogenesis and tumor metastasis based on its effects on lymphatic vessels.  However, little is known about the effect of inhibiting VEGF-R3 on lymphangiogenesis and lymph node metastases using a small-mol. kinase inhibitor.  Exptl. Design: We evaluated the effect of E7080, a potent inhibitor of both VEGF-R2 and VEGF-R3 kinase, and bevacizumab on lymphangiogenesis and angiogenesis in a mammary fat pad xenograft model of human breast cancer using MDA-MB-231 cells that express excessive amts. of VEGF-C.  Lymphangiogenesis was detd. by lymphatic vessel d. (LVD) and angiogenesis by microvessel d. (MVD).  RESULTS: In contrast to MDA-MB-435 cells, which expressed a similar amt. of VEGF to MDA-MB-231 cells with an undetectable amt. of VEGF-C, only MDA-MB-231 exhibited lymphangiogenesis in the primary tumor.  E7080 but not bevacizumab significantly decreased LVD within the MDA-MB-231 tumor.  E7080 and bevacizumab decreased MVD in both the MDA-MB-231 and MDA-MB-435 models.  E7080 significantly suppressed regional lymph nodes and distant lung metastases of MDA-MB-231, whereas bevacizumab significantly inhibited only lung metastases.  E7080 also decreased both MVD and LVD within the metastatic nodules at lymph nodes after resection of the primary tumor.  CONCLUSIONS: Inhibition of VEGF-R3 kinase with E7080 effectively decreased LVD within MDA-MB-231 tumors, which express VEGF-C.  Simultaneous inhibition of both VEGF-R2 and VEGF-R3 kinases by E7080 may be a promising new strategy to control regional lymph node and distant lung metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrBisu80xI7Vg90H21EOLACvtfcHk0liiShG_-YCv0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbjP&md5=0a73511c46d0f668f09f84d89c718417</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-5270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-5270%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DAsada%26aufirst%3DM.%26atitle%3DMulti-kinase%2520Inhibitor%2520E7080%2520Suppresses%2520Lymph%2520Node%2520and%2520Lung%2520Metastases%2520of%2520Human%2520Mammary%2520Breast%2520Tumor%2520MDA-MB-231%2520via%2520Inhibition%2520of%2520Vascular%2520Endothelial%2520Growth%2520Factor-Receptor%2520%2528VEGF-R%2529%25202%2520and%2520VEGF-R3%2520Kinase%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D5459%26epage%3D5465%26doi%3D10.1158%2F1078-0432.CCR-07-5270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span>Lenvatinib in Combination with Everolimus; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, May 16,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501070.htm" class="extLink">http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501070.htm</a> (accessed March 1, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lenvatinib+in+Combination+with+Everolimus%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+May+16%2C+2016%3B+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm501070.htm+%28accessed+March+1%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLenvatinib%2520in%2520Combination%2520with%2520Everolimus%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Sakaguchi, T.; Tsuruoka, A.</span><span> </span><span class="NLM_article-title">Amorphous Salt of 4-(3-Chloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and Process for Preparing the Same</span>. US 20070004773A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Sakaguchi&author=A.+Tsuruoka&title=Amorphous+Salt+of+4-%283-Chloro-4-%28cycloproplylaminocarbonyl%29aminophenoxy%29-7-method-6-quinolinecarboxamide+and+Process+for+Preparing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSakaguchi%26aufirst%3DT.%26atitle%3DAmorphous%2520Salt%2520of%25204-%25283-Chloro-4-%2528cycloproplylaminocarbonyl%2529aminophenoxy%2529-7-method-6-quinolinecarboxamide%2520and%2520Process%2520for%2520Preparing%2520the%2520Same%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">Matsushima, T.; Nakamura, T.; Yoshizawa, K.; Kamada, A.; Ayata, Y.; Suzuki, N.; Arimoto, I. E. C. L.; Sakaguchi, T.; Gotoda, M.</span><span> </span><span class="NLM_article-title">Crystal of Salt of 4-(3-Chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of Solvate Thereof and Processes for Producing These</span>. EP 1698623A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=T.+Matsushima&author=T.+Nakamura&author=K.+Yoshizawa&author=A.+Kamada&author=Y.+Ayata&author=N.+Suzuki&author=I.+E.+C.+L.+Arimoto&author=T.+Sakaguchi&author=M.+Gotoda&title=Crystal+of+Salt+of+4-%283-Chloro-4-%28cyclopropylaminocarbonyl%29amino-phenoxy%29-7-methoxy-6-quinolinecarboxamide+or+of+Solvate+Thereof+and+Processes+for+Producing+These"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushima%26aufirst%3DT.%26atitle%3DCrystal%2520of%2520Salt%2520of%25204-%25283-Chloro-4-%2528cyclopropylaminocarbonyl%2529amino-phenoxy%2529-7-methoxy-6-quinolinecarboxamide%2520or%2520of%2520Solvate%2520Thereof%2520and%2520Processes%2520for%2520Producing%2520These%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Barker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huddleston, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Thienopyridines. Part 2. Application of the Conrad–Limpach and Gould–Jacobs reactions to the synthesis of thieno[3,4-<i>b</i>]pyridin-4(1<i>H</i>)-ones</span> <span class="citation_source-journal">J. Chem. Res., Synop.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1980&pages=4-5&author=J.+M.+Barkerauthor=P.+R.+Huddlestonauthor=A.+W.+Jonesauthor=M.+Edwards&title=Thienopyridines.+Part+2.+Application+of+the+Conrad%E2%80%93Limpach+and+Gould%E2%80%93Jacobs+reactions+to+the+synthesis+of+thieno%5B3%2C4-b%5Dpyridin-4%281H%29-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DJ.%2BM.%26aulast%3DHuddleston%26aufirst%3DP.%2BR.%26aulast%3DJones%26aufirst%3DA.%2BW.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DThienopyridines.%2520Part%25202.%2520Application%2520of%2520the%2520Conrad%25E2%2580%2593Limpach%2520and%2520Gould%25E2%2580%2593Jacobs%2520reactions%2520to%2520the%2520synthesis%2520of%2520thieno%255B3%252C4-b%255Dpyridin-4%25281H%2529-ones%26jtitle%3DJ.%2520Chem.%2520Res.%252C%2520Synop.%26date%3D1980%26volume%3D1%26spage%3D4%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Brouet, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peet, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. D.</span><span> </span><span class="NLM_article-title">Survey of Solvents for the Conrad–Limpach Synthesis of 4-Hydroxyquinolones</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1563</span><span class="NLM_x">–</span> <span class="NLM_lpage">1569</span><span class="refDoi"> DOI: 10.1080/00397910802542044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1080%2F00397910802542044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=1563-1569&author=J.-C.+Brouetauthor=S.+Guauthor=N.+P.+Peetauthor=J.+D.+Williams&title=Survey+of+Solvents+for+the+Conrad%E2%80%93Limpach+Synthesis+of+4-Hydroxyquinolones&doi=10.1080%2F00397910802542044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Survey of solvents for the Conrad-Limpach synthesis of 4-hydroxyquinolines</span></div><div class="casAuthors">Brouet, Jean-Cristophe; Gu, Shen; Peet, Norton P.; Williams, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1563-1569</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A study of the synthesis of a 4-hydroxyquinoline deriv. using the Conrad-Limpach reaction led to the identification of inexpensive and user-friendly solvents for this thermal condensation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIPa3qHEVOWrVg90H21EOLACvtfcHk0liiShG_-YCv0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCisL4%253D&md5=94f46df0795fc34f2277c3157e954f1d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1080%2F00397910802542044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910802542044%26sid%3Dliteratum%253Aachs%26aulast%3DBrouet%26aufirst%3DJ.-C.%26aulast%3DGu%26aufirst%3DS.%26aulast%3DPeet%26aufirst%3DN.%2BP.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26atitle%3DSurvey%2520of%2520Solvents%2520for%2520the%2520Conrad%25E2%2580%2593Limpach%2520Synthesis%2520of%25204-Hydroxyquinolones%26jtitle%3DSynth.%2520Commun.%26date%3D2009%26volume%3D39%26spage%3D1563%26epage%3D1569%26doi%3D10.1080%2F00397910802542044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span>Dowtherm Synthetic Organic Fluids; <span class="NLM_publisher-name">Dow Chemical Company</span>: <span class="NLM_publisher-loc">Midland, MI</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.dow.com/heattrans/products/synthetic/dowtherm.htm" class="extLink">http://www.dow.com/heattrans/products/synthetic/dowtherm.htm</a> (accessed March 1, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Dowtherm+Synthetic+Organic+Fluids%3B+Dow+Chemical+Company%3A+Midland%2C+MI%2C+2017%3B+http%3A%2F%2Fwww.dow.com%2Fheattrans%2Fproducts%2Fsynthetic%2Fdowtherm.htm+%28accessed+March+1%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDowtherm%2520Synthetic%2520Organic%2520Fluids%26pub%3DDow%2520Chemical%2520Company%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Thomas, A. P.; Hennequin, L. F. A.; Ple, P.</span><span> </span><span class="NLM_article-title">Quinoline Derivatives Inhibiting the Effect of Growth Factors Such as VEGF</span>. US 6809097B1,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=A.+P.+Thomas&author=L.+F.+A.+Hennequin&author=P.+Ple&title=Quinoline+Derivatives+Inhibiting+the+Effect+of+Growth+Factors+Such+as+VEGF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BP.%26atitle%3DQuinoline%2520Derivatives%2520Inhibiting%2520the%2520Effect%2520of%2520Growth%2520Factors%2520Such%2520as%2520VEGF%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Greig, S. L.</span><span> </span><span class="NLM_article-title">Osimertinib: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1007/s40265-015-0533-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0533-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26729184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=263-273&author=S.+L.+Greig&title=Osimertinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0533-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: First Global Approval</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-273</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC).  Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR.  In Nov. 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-pos. NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy.  Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-pos. NSCLC in several countries.  Phase I trials in patients with advanced solid tumors are also being conducted.  This article summarizes the milestones in the development of osimertinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-OV6l6JC5rVg90H21EOLACvtfcHk0lhAupe-2sxiCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D&md5=fb46898918bdfe76320c26177710fb11</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0533-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0533-4%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DOsimertinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D263%26epage%3D273%26doi%3D10.1007%2Fs40265-015-0533-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, W. S.; Gong, Y.; Li, F.; Bencivenga, N. E.; Dalgarno, D. C.; Kohlmann, A.; Shakespeare, W. C.; Thomas, R. M.; Zhu, X.; West, A. V.</span><span> </span><span class="NLM_article-title">Heteroaryl Compounds for Kinase Inhibition</span>. WO 2015195228A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+S.+Huang&author=Y.+Gong&author=F.+Li&author=N.+E.+Bencivenga&author=D.+C.+Dalgarno&author=A.+Kohlmann&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=X.+Zhu&author=A.+V.+West&title=Heteroaryl+Compounds+for+Kinase+Inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26atitle%3DHeteroaryl%2520Compounds%2520for%2520Kinase%2520Inhibition%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Xu, X.</span><span> </span><span class="NLM_article-title">AZD9291 Intermediates and Preparation Method</span>. CN 104910049B,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=X.+Xu&title=AZD9291+Intermediates+and+Preparation+Method"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26atitle%3DAZD9291%2520Intermediates%2520and%2520Preparation%2520Method%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ji, M.; Li, Y.; Liu, H.; Li, R.; Cai, J.; Hu, H.</span><span> </span><span class="NLM_article-title">Synthetic Method of Anti-tumor Medicine</span>. CN 104817541A,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Ji&author=Y.+Li&author=H.+Liu&author=R.+Li&author=J.+Cai&author=H.+Hu&title=Synthetic+Method+of+Anti-tumor+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DM.%26atitle%3DSynthetic%2520Method%2520of%2520Anti-tumor%2520Medicine%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span> </span><span class="NLM_article-title">A Novel and Efficient Synthesis of Anti-cancer Agent, Mereletinib</span> <span class="citation_source-journal">J. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span><span class="refDoi"> DOI: 10.3184/174751915X14320297505570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.3184%2F174751915X14320297505570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KqtrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=318-320&author=H.+Liuauthor=Y.+Lvauthor=Y.+Liauthor=J.+Caiauthor=J.+Chenauthor=Y.+Qinauthor=M.+Ji&title=A+Novel+and+Efficient+Synthesis+of+Anti-cancer+Agent%2C+Mereletinib&doi=10.3184%2F174751915X14320297505570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144dR"><div class="casContent"><span class="casTitleNuber">144d</span><div class="casTitle"><span class="NLM_cas:atitle">A novel and efficient synthesis of anti-cancer agent, mereletinib</span></div><div class="casAuthors">Liu, Haidong; Lv, Yongfeng; Li, Yuan; Cai, Jin; Chen, Junqing; Qin, Yu; Ji, Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">318-320</span>CODEN:
                <span class="NLM_cas:coden">JCROA4</span>;
        ISSN:<span class="NLM_cas:issn">1747-5198</span>.
    
            (<span class="NLM_cas:orgname">Science Reviews 2000 Ltd.</span>)
        </div><div class="casAbstract">A convenient route for the synthesis of a third-generation epidermal growth factor receptor inhibitor, mereletinib (AZD9291) using starting materials that are com. available has been achieved through reactions that are readily conducted under mild conditions.  Importantly, a 5 g scale synthesis was also accomplished and this method could therefore be useful in the synthesis of similar drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxwgrrR3p59LVg90H21EOLACvtfcHk0lhAupe-2sxiCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KqtrfN&md5=c48ac88282a3c3b8efd84ed55de2f27c</span></div><a href="/servlet/linkout?suffix=cit144d&amp;dbid=16384&amp;doi=10.3184%2F174751915X14320297505570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3184%252F174751915X14320297505570%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLv%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DM.%26atitle%3DA%2520Novel%2520and%2520Efficient%2520Synthesis%2520of%2520Anti-cancer%2520Agent%252C%2520Mereletinib%26jtitle%3DJ.%2520Chem.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D318%26epage%3D320%26doi%3D10.3184%2F174751915X14320297505570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations that Spares the Wild Type Form of the Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8249</span><span class="NLM_x">–</span> <span class="NLM_lpage">8267</span><span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+Potent+and+Selective+EGFR+Inhibitor+%28AZD9291%29+of+Both+Sensitizing+and+T790M+Resistance+Mutations+that+Spares+the+Wild+Type+Form+of+the+Receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144eR"><div class="casContent"><span class="casTitleNuber">144e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0ljLABNhw4y8fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit144e&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520EGFR%2520Inhibitor%2520%2528AZD9291%2529%2520of%2520Both%2520Sensitizing%2520and%2520T790M%2520Resistance%2520Mutations%2520that%2520Spares%2520the%2520Wild%2520Type%2520Form%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Butterworth, S.; Finlay, M. R. V.; Ward, R. A.; Kadambar, V. K.; Chandrashekar, R. C.; Murugan, A.; Redfearn, H. M.</span><span> </span><span class="NLM_article-title">2-(2-, 4-, 5-Substituted-anilino) Pyrimidine Derivatives as EGFR Modulators Useful for Treating Cancer</span>. WO 2013014448A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Butterworth&author=M.+R.+V.+Finlay&author=R.+A.+Ward&author=V.+K.+Kadambar&author=R.+C.+Chandrashekar&author=A.+Murugan&author=H.+M.+Redfearn&title=2-%282-%2C+4-%2C+5-Substituted-anilino%29+Pyrimidine+Derivatives+as+EGFR+Modulators+Useful+for+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DButterworth%26aufirst%3DS.%26atitle%3D2-%25282-%252C%25204-%252C%25205-Substituted-anilino%2529%2520Pyrimidine%2520Derivatives%2520as%2520EGFR%2520Modulators%2520Useful%2520for%2520Treating%2520Cancer%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Beaver, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiri-Kordestani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlab, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tilley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zirkelbach, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomquist, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluetz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortazar, P.</span><span> </span><span class="NLM_article-title">FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4760</span><span class="NLM_x">–</span> <span class="NLM_lpage">4766</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F1078-0432.CCR-15-1185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26324739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4760-4766&author=J.+A.+Beaverauthor=L.+Amiri-Kordestaniauthor=R.+Charlabauthor=W.+Chenauthor=T.+Palmbyauthor=A.+Tilleyauthor=J.+F.+Zirkelbachauthor=J.+Yuauthor=Q.+Liuauthor=L.+Zhaoauthor=J.+Crichauthor=X.+H.+Chenauthor=M.+Hughesauthor=E.+Bloomquistauthor=S.+Tangauthor=R.+Sridharaauthor=P.+G.+Kluetzauthor=G.+Kimauthor=A.+Ibrahimauthor=R.+Pazdurauthor=P.+Cortazar&title=FDA+Approval%3A+Palbociclib+for+the+Treatment+of+Postmenopausal+Patients+with+Estrogen+Receptor-Positive%2C+HER2-Negative+Metastatic+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-15-1185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146aR"><div class="casContent"><span class="casTitleNuber">146a</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer</span></div><div class="casAuthors">Beaver, Julia A.; Amiri-Kordestani, Laleh; Charlab, Rosane; Chen, Wei; Palmby, Todd; Tilley, Amy; Zirkelbach, Jeanne Fourie; Yu, Jingyu; Liu, Qi; Zhao, Liang; Crich, Joyce; Chen, Xiao Hong; Hughes, Minerva; Bloomquist, Erik; Tang, Shenghui; Sridhara, Rajeshwari; Kluetz, Paul G.; Kim, Geoffrey; Ibrahim, Amna; Pazdur, Richard; Cortazar, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4760-4766</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Feb. 3, 2015, the FDA granted accelerated approval to palbociclib (IBRANCE, Pfizer Inc.), an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-pos., HER2-neg. advanced breast cancer as initial endocrine-based therapy for their metastatic disease.  The approval is based on a randomized, multicenter, open-label phase I/II trial (PALOMA-1) in 165 patients randomized to palbociclib (125 mg orally daily for 21 consecutive days, followed by 7 days off treatment) plus letrozole (2.5 mg orally daily) or letrozole alone.  The phase II portion of the trial was divided into two cohorts: cohort 1 enrolled 66 biomarker-unselected patients and cohort 2 enrolled 99 biomarker-pos. patients.  The major efficacy outcome measure was investigator-assessed progression-free survival (PFS).  A large magnitude of improvement in PFS was obsd. in patients receiving palbociclib plus letrozole compared with patients receiving letrozole alone (HR, 0.488; 95% confidence interval, 0.319-0.748).  Multiple sensitivity analyses were supportive of clin. benefit.  The most common adverse reaction in patients receiving palbociclib plus letrozole was neutropenia.  This article summarizes the FDA thought process and data supporting accelerated approval based on PALOMA-1 that may be contingent upon verification and description of clin. benefit in the ongoing and fully accrued confirmatory trial PALOMA-2.  Clin Cancer Res; 21(21); 4760-6. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTc7NV9QVmZ7Vg90H21EOLACvtfcHk0ljLABNhw4y8fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsrvO&md5=1c82d9a1d34b061f2c0bbc6833561c07</span></div><a href="/servlet/linkout?suffix=cit146a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1185%26sid%3Dliteratum%253Aachs%26aulast%3DBeaver%26aufirst%3DJ.%2BA.%26aulast%3DAmiri-Kordestani%26aufirst%3DL.%26aulast%3DCharlab%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DPalmby%26aufirst%3DT.%26aulast%3DTilley%26aufirst%3DA.%26aulast%3DZirkelbach%26aufirst%3DJ.%2BF.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DCrich%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DHughes%26aufirst%3DM.%26aulast%3DBloomquist%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DKluetz%26aufirst%3DP.%2BG.%26aulast%3DKim%26aufirst%3DG.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26aulast%3DCortazar%26aufirst%3DP.%26atitle%3DFDA%2520Approval%253A%2520Palbociclib%2520for%2520the%2520Treatment%2520of%2520Postmenopausal%2520Patients%2520with%2520Estrogen%2520Receptor-Positive%252C%2520HER2-Negative%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4760%26epage%3D4766%26doi%3D10.1158%2F1078-0432.CCR-15-1185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit146b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Owsley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, J. R.</span><span> </span><span class="NLM_article-title">Palbociclib: CDK4/6 Inhibition in the Treatment of ER-positive Breast Cancer</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1358/dot.2016.52.2.2440528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdot.2016.52.2.2440528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28bhsVarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=119-129&author=J.+Owsleyauthor=A.+Jimenoauthor=J.+R.+Diamond&title=Palbociclib%3A+CDK4%2F6+Inhibition+in+the+Treatment+of+ER-positive+Breast+Cancer&doi=10.1358%2Fdot.2016.52.2.2440528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146bR"><div class="casContent"><span class="casTitleNuber">146b</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer</span></div><div class="casAuthors">Owsley J; Jimeno A; Diamond J R</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-29</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Maintaining cell-cycle control has become a mainstay in treatment for many cancers.  Cell-cycle manipulation can be especially valuable in breast cancer tumor cells that will often express hormone receptors that are amenable to anti-hormone receptor-targeted therapies.  Despite these treatments, patients often progress, leading to other targeted agents being investigated to help promote progression-free survival.  Cyclin-dependent kinases (CDKs) have been identified as contributors in the process of cell division.  Combining inhibitors of CDKs with traditional endocrine treatments has shown significant progression-free survival in patients with metastatic breast cancer.  One such CDK inhibitor, palbociclib, has shown great promise in the treatment of hormone receptor-positive breast cancer.  In this article we review the traditional hormonal treatments of breast cancer, how CDK inhibition is beneficial in the treatment of this disease, and the preclinical and clinical data supporting the use of this medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPNpp60_KrnkodMGTatQ7LfW6udTcc2ebGFe8r8B8ABLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhsVarug%253D%253D&md5=4b95fd49ae63b35a2c87d0d0cbce0b93</span></div><a href="/servlet/linkout?suffix=cit146b&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.2.2440528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.2.2440528%26sid%3Dliteratum%253Aachs%26aulast%3DOwsley%26aufirst%3DJ.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26atitle%3DPalbociclib%253A%2520CDK4%252F6%2520Inhibition%2520in%2520the%2520Treatment%2520of%2520ER-positive%2520Breast%2520Cancer%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D119%26epage%3D129%26doi%3D10.1358%2Fdot.2016.52.2.2440528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Mangini, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesolowski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaswamy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lustberg, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, M. J.</span><span> </span><span class="NLM_article-title">Palbociclib: a Novel Cyclin-dependent Kinase Inhibitor for Hormone Receptor-positive Advanced Breast Cancer</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span><span class="refDoi"> DOI: 10.1177/1060028015602273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1177%2F1060028015602273" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2015&pages=1252-1260&author=N.+S.+Manginiauthor=R.+Wesolowskiauthor=B.+Ramaswamyauthor=M.+B.+Lustbergauthor=M.+J.+Berger&title=Palbociclib%3A+a+Novel+Cyclin-dependent+Kinase+Inhibitor+for+Hormone+Receptor-positive+Advanced+Breast+Cancer&doi=10.1177%2F1060028015602273"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1177%2F1060028015602273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028015602273%26sid%3Dliteratum%253Aachs%26aulast%3DMangini%26aufirst%3DN.%2BS.%26aulast%3DWesolowski%26aufirst%3DR.%26aulast%3DRamaswamy%26aufirst%3DB.%26aulast%3DLustberg%26aufirst%3DM.%2BB.%26aulast%3DBerger%26aufirst%3DM.%2BJ.%26atitle%3DPalbociclib%253A%2520a%2520Novel%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520for%2520Hormone%2520Receptor-positive%2520Advanced%2520Breast%2520Cancer%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2015%26volume%3D49%26spage%3D1252%26epage%3D1260%26doi%3D10.1177%2F1060028015602273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Cristofanilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colleoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMichele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeck, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theall, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D.</span><span> </span><span class="NLM_article-title">Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-receptor-positive, HER2-negative Metastatic Breast Cancer that Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-blind, Phase 3 Randomised Controlled Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00613-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS1470-2045%2815%2900613-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26947331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=425-439&author=M.+Cristofanilliauthor=N.+C.+Turnerauthor=I.+Bondarenkoauthor=J.+Roauthor=S.-A.+Imauthor=N.+Masudaauthor=M.+Colleoniauthor=A.+DeMicheleauthor=S.+Loiauthor=S.+Vermaauthor=H.+Iwataauthor=N.+Harbeckauthor=K.+Zhangauthor=K.+P.+Theallauthor=Y.+Jiangauthor=C.+H.+Bartlettauthor=M.+Koehlerauthor=D.+Slamon&title=Fulvestrant+plus+Palbociclib+versus+Fulvestrant+plus+Placebo+for+Treatment+of+Hormone-receptor-positive%2C+HER2-negative+Metastatic+Breast+Cancer+that+Progressed+on+Previous+Endocrine+Therapy+%28PALOMA-3%29%3A+Final+Analysis+of+the+Multicentre%2C+Double-blind%2C+Phase+3+Randomised+Controlled+Trial&doi=10.1016%2FS1470-2045%2815%2900613-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial</span></div><div class="casAuthors">Cristofanilli, Massimo; Turner, Nicholas C.; Bondarenko, Igor; Ro, Jungsil; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Zhang, Ke; Theall, Kathy Puyana; Jiang, Yuqiu; Bartlett, Cynthia Huang; Koehler, Maria; Slamon, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-439</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was assocd. with significant improvements in progression-free survival compared with fulvestrant plus placebo in patients with metastatic breast cancer.  Identification of patients most suitable for the addn. of palbociclib to endocrine therapy after tumor recurrence is crucial for treatment optimization in metastatic breast cancer.  We aimed to confirm our earlier findings with this extended follow-up and show our results for subgroup and biomarker analyses.  In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with hormone-receptor-pos., HER2-neg. metastatic breast cancer that had progressed on previous endocrine therapy were stratified by sensitivity to previous hormonal therapy, menopausal status, and presence of visceral metastasis at 144 centers in 17 countries.  Eligible patients-ie, any menopausal status, Eastern Cooperative Oncol. Group performance status 0-1, measurable disease or bone disease only, and disease relapse or progression after previous endocrine therapy for advanced disease during treatment or within 12 mo of completion of adjuvant therapy-were randomly assigned (2:1) via a centralised interactive web-based and voice-based randomisation system to receive oral palbociclib (125 mg daily for 3 wk followed by a week off over 28-day cycles) plus 500 mg fulvestrant (i.m. injection on days 1 and 15 of cycle 1; then on day 1 of subsequent 28-day cycles) or placebo plus fulvestrant.  The primary endpoint was investigator-assessed progression-free survival.  Anal. was by intention to treat.  We also assessed endocrine therapy resistance by clin. parameters, quant. hormone-receptor expression, and tumor PIK3CA mutational status in circulating DNA at baseline.  This study is registered with ClinicalTrials.gov, NCT01942135.  Between Oct 7, 2013, and Aug 26, 2014, 521 patients were randomly assigned, 347 to fulvestrant plus palbociclib and 174 to fulvestrant plus placebo.  Study enrolment is closed and overall survival follow-up is in progress.  By March 16, 2015, 259 progression-free-survival events had occurred (145 in the fulvestrant plus palbociclib group and 114 in the fulvestrant plus placebo group); median follow-up was 8·9 mo (IQR 8·7-9·2).  Median progression-free survival was 9·5 mo (95% CI 9·2-11·0) in the fulvestrant plus palbociclib group and 4·6 mo (3·5-5·6) in the fulvestrant plus placebo group (hazard ratio 0·46, 95% CI 0·36-0·59, p<0·0001).  Grade 3 or 4 adverse events occurred in 251 (73%) of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fulvestrant plus placebo group.  The most common grade 3 or 4 adverse events were neutropenia (223 [65%] in the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus placebo group), anemia (ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]).  Serious adverse events (all causalities) occurred in 44 patients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) of 172 patients in the fulvestrant plus placebo group.  PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients for whom these data were available.  Neither PIK3CA status nor hormone-receptor expression level significantly affected treatment response.  Fulvestrant plus palbociclib was assocd. with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo, irresp. of the degree of endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status.  The combination could be considered as a therapeutic option for patients with recurrent hormone-receptor-pos., HER2-neg. metastatic breast cancer that has progressed on previous endocrine therapy.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmN_mxQq1lWrVg90H21EOLACvtfcHk0lijIE4v_cVjow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yhsLo%253D&md5=393ef72549634e00f26a0a1916565472</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900613-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900613-0%26sid%3Dliteratum%253Aachs%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DRo%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DTheall%26aufirst%3DK.%2BP.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DBartlett%26aufirst%3DC.%2BH.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DSlamon%26aufirst%3DD.%26atitle%3DFulvestrant%2520plus%2520Palbociclib%2520versus%2520Fulvestrant%2520plus%2520Placebo%2520for%2520Treatment%2520of%2520Hormone-receptor-positive%252C%2520HER2-negative%2520Metastatic%2520Breast%2520Cancer%2520that%2520Progressed%2520on%2520Previous%2520Endocrine%2520Therapy%2520%2528PALOMA-3%2529%253A%2520Final%2520Analysis%2520of%2520the%2520Multicentre%252C%2520Double-blind%252C%2520Phase%25203%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D425%26epage%3D439%26doi%3D10.1016%2FS1470-2045%2815%2900613-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span><span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+Potent+and+Selective+Inhibitor+of+Cyclin-Dependent+Kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lijIE4v_cVjow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Cyclin-Dependent%2520Kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Coutable, L.</span><span> </span><span class="NLM_article-title">Method of Producing Palbociclib and Pharmaceutical Compositions Comprising the Same</span>. WO 2016030439A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Coutable&title=Method+of+Producing+Palbociclib+and+Pharmaceutical+Compositions+Comprising+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCoutable%26aufirst%3DL.%26atitle%3DMethod%2520of%2520Producing%2520Palbociclib%2520and%2520Pharmaceutical%2520Compositions%2520Comprising%2520the%2520Same%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit150b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Erdman, D. T.; Flamme, C. M.; Nelson, J. D.</span><span> </span><span class="NLM_article-title">Preparation of 2-(Pyridin-2-ylamino)-pyrido[2,3-<i>d</i>]pyrimidin-7-ones</span>. WO 2008032157A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+T.+Erdman&author=C.+M.+Flamme&author=J.+D.+Nelson&title=Preparation+of+2-%28Pyridin-2-ylamino%29-pyrido%5B2%2C3-d%5Dpyrimidin-7-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErdman%26aufirst%3DD.%2BT.%26atitle%3DPreparation%2520of%25202-%2528Pyridin-2-ylamino%2529-pyrido%255B2%252C3-d%255Dpyrimidin-7-ones%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit150c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tyagi, V.; Mohammad, K.; Rai, B. P.; Prasad, M.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Palbociclib</span>. WO 2016016769A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=V.+Tyagi&author=K.+Mohammad&author=B.+P.+Rai&author=M.+Prasad&title=Process+for+the+Preparation+of+Palbociclib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DV.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Palbociclib%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chekal, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guinness, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ide, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Withbroe, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keane, J.</span><span> </span><span class="NLM_article-title">Palbociclib Commercial Manufacturing Process Development. Part III. Deprotection Followed by Crystallization for API Particle Property Control</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1226</span><span class="refDoi"> DOI: 10.1021/acs.oprd.6b00071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1217-1226&author=B.+P.+Chekalauthor=J.+Ewersauthor=S.+M.+Guinnessauthor=N.+D.+Ideauthor=K.+R.+Leemanauthor=R.+J.+Postauthor=A.+M.+Raneauthor=K.+Sutherlandauthor=K.+Wangauthor=M.+Websterauthor=G.+J.+Withbroeauthor=J.+Draperauthor=D.+Lynchauthor=M.+McAuliffeauthor=J.+Keane&title=Palbociclib+Commercial+Manufacturing+Process+Development.+Part+III.+Deprotection+Followed+by+Crystallization+for+API+Particle+Property+Control&doi=10.1021%2Facs.oprd.6b00071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151aR"><div class="casContent"><span class="casTitleNuber">151a</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib Commercial Manufacturing Process Development. Part III. Deprotection Followed by Crystallization for API Particle Property Control</span></div><div class="casAuthors">Chekal, Brian P.; Ewers, Jason; Guinness, Steven M.; Ide, Nathan D.; Leeman, Kyle R.; Post, Ronald J.; Rane, Anil M.; Sutherland, Karen; Wang, Ke; Webster, Mark; Withbroe, Gregory J.; Draper, John; Lynch, Denis; McAuliffe, Marie; Keane, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1217-1226</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A three-step com. manufg. route has been developed for palbociclib, a highly selective, reversible inhibitor of CDK 4/6.  The third step of the palbociclib process is composed of an acid-catalyzed deprotection reaction telescoped through extractive workup and distn. operations into a controlled crystn. process.  The selection of n-butanol and anisole as the cosolvents for this step allowed for the development of a robust process for each unit operation and for tight control of the API particle size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8gzyM12cOILVg90H21EOLACvtfcHk0lhzh8Ny3zt2uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSntbc%253D&md5=80e7571615687e4a026bf9555d8c9587</span></div><a href="/servlet/linkout?suffix=cit151a&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00071%26sid%3Dliteratum%253Aachs%26aulast%3DChekal%26aufirst%3DB.%2BP.%26aulast%3DEwers%26aufirst%3DJ.%26aulast%3DGuinness%26aufirst%3DS.%2BM.%26aulast%3DIde%26aufirst%3DN.%2BD.%26aulast%3DLeeman%26aufirst%3DK.%2BR.%26aulast%3DPost%26aufirst%3DR.%2BJ.%26aulast%3DRane%26aufirst%3DA.%2BM.%26aulast%3DSutherland%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWebster%26aufirst%3DM.%26aulast%3DWithbroe%26aufirst%3DG.%2BJ.%26aulast%3DDraper%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DD.%26aulast%3DMcAuliffe%26aufirst%3DM.%26aulast%3DKeane%26aufirst%3DJ.%26atitle%3DPalbociclib%2520Commercial%2520Manufacturing%2520Process%2520Development.%2520Part%2520III.%2520Deprotection%2520Followed%2520by%2520Crystallization%2520for%2520API%2520Particle%2520Property%2520Control%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1217%26epage%3D1226%26doi%3D10.1021%2Facs.oprd.6b00071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit151b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chekal, B. P.; Ide, N. D.</span><span> </span><span class="NLM_article-title">Preparation of Acetylcyclopentylmethylpiperazinylpyridinylaminopyridopyrimidinone Derivatives for Use as Selective CDK4/6 Inhibitors</span>. WO 2014128588A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=B.+P.+Chekal&author=N.+D.+Ide&title=Preparation+of+Acetylcyclopentylmethylpiperazinylpyridinylaminopyridopyrimidinone+Derivatives+for+Use+as+Selective+CDK4%2F6+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChekal%26aufirst%3DB.%2BP.%26atitle%3DPreparation%2520of%2520Acetylcyclopentylmethylpiperazinylpyridinylaminopyridopyrimidinone%2520Derivatives%2520for%2520Use%2520as%2520Selective%2520CDK4%252F6%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit151c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Duan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Place, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perfect, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ide, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price Wiglesworth, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blunt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Sullivan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D.</span><span> </span><span class="NLM_article-title">Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1191</span><span class="NLM_x">–</span> <span class="NLM_lpage">1202</span><span class="refDoi"> DOI: 10.1021/acs.oprd.6b00070</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslCqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1191-1202&author=S.+Duanauthor=D.+Placeauthor=H.+H.+Perfectauthor=N.+D.+Ideauthor=M.+Maloneyauthor=K.+Sutherlandauthor=K.+E.+Price+Wiglesworthauthor=K.+Wangauthor=M.+Olivierauthor=F.+Kongauthor=K.+Leemanauthor=J.+Bluntauthor=J.+Draperauthor=M.+McAuliffeauthor=M.+O%E2%80%99Sullivanauthor=D.+Lynch&title=Palbociclib+Commercial+Manufacturing+Process+Development.+Part+I%3A+Control+of+Regioselectivity+in+a+Grignard-Mediated+SNAr+Coupling&doi=10.1021%2Facs.oprd.6b00070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151cR"><div class="casContent"><span class="casTitleNuber">151c</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling</span></div><div class="casAuthors">Duan, Shengquan; Place, David; Perfect, Hahdi H.; Ide, Nathan D.; Maloney, Mark; Sutherland, Karen; Price Wiglesworth, Kristin E.; Wang, Ke; Olivier, Mark; Kong, Fangming; Leeman, Kyle; Blunt, Jon; Draper, John; McAuliffe, Marie; O'Sullivan, Maria; Lynch, Denis</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1191-1202</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is the first in a series of three papers describing com. manufg. process development for palbociclib (I).  This manuscript focuses on the SNAr coupling between aminopyridine II and chloropyrimidine III.  The regioselectivity of the SNAr coupling was studied from a synthetic and mechanistic perspective.  Grignard bases were identified as the preferred class of bases for this reaction, allowing for a simplified process and reduced usage factor for aminopyridine II.  The development of this SNAr reaction into a scalable com. manufg. process is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQyIHT73K4u7Vg90H21EOLACvtfcHk0lhzh8Ny3zt2uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslCqtbs%253D&md5=0ce25584ce0f099fbeded818cdb74249</span></div><a href="/servlet/linkout?suffix=cit151c&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00070%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DPlace%26aufirst%3DD.%26aulast%3DPerfect%26aufirst%3DH.%2BH.%26aulast%3DIde%26aufirst%3DN.%2BD.%26aulast%3DMaloney%26aufirst%3DM.%26aulast%3DSutherland%26aufirst%3DK.%26aulast%3DPrice%2BWiglesworth%26aufirst%3DK.%2BE.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DOlivier%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DF.%26aulast%3DLeeman%26aufirst%3DK.%26aulast%3DBlunt%26aufirst%3DJ.%26aulast%3DDraper%26aufirst%3DJ.%26aulast%3DMcAuliffe%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DM.%26aulast%3DLynch%26aufirst%3DD.%26atitle%3DPalbociclib%2520Commercial%2520Manufacturing%2520Process%2520Development.%2520Part%2520I%253A%2520Control%2520of%2520Regioselectivity%2520in%2520a%2520Grignard-Mediated%2520SNAr%2520Coupling%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1191%26epage%3D1202%26doi%3D10.1021%2Facs.oprd.6b00070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit151d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Maloney, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ide, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palm, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bill, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keane, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuohy, J.</span><span> </span><span class="NLM_article-title">Palbociclib Commercial Manufacturing Process Development. Part II: Regioselective Heck Coupling with Polymorph Control for Processability</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1203</span><span class="NLM_x">–</span> <span class="NLM_lpage">1216</span><span class="refDoi"> DOI: 10.1021/acs.oprd.6b00069</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00069" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1203-1216&author=M.+T.+Maloneyauthor=B.+P.+Jonesauthor=M.+A.+Olivierauthor=J.+Maganoauthor=K.+Wangauthor=N.+D.+Ideauthor=A.+S.+Palmauthor=D.+R.+Billauthor=K.+R.+Leemanauthor=K.+Sutherlandauthor=J.+Draperauthor=A.+M.+Dalyauthor=J.+Keaneauthor=D.+Lynchauthor=M.+O%E2%80%99Brienauthor=J.+Tuohy&title=Palbociclib+Commercial+Manufacturing+Process+Development.+Part+II%3A+Regioselective+Heck+Coupling+with+Polymorph+Control+for+Processability&doi=10.1021%2Facs.oprd.6b00069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151d&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00069%26sid%3Dliteratum%253Aachs%26aulast%3DMaloney%26aufirst%3DM.%2BT.%26aulast%3DJones%26aufirst%3DB.%2BP.%26aulast%3DOlivier%26aufirst%3DM.%2BA.%26aulast%3DMagano%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DIde%26aufirst%3DN.%2BD.%26aulast%3DPalm%26aufirst%3DA.%2BS.%26aulast%3DBill%26aufirst%3DD.%2BR.%26aulast%3DLeeman%26aufirst%3DK.%2BR.%26aulast%3DSutherland%26aufirst%3DK.%26aulast%3DDraper%26aufirst%3DJ.%26aulast%3DDaly%26aufirst%3DA.%2BM.%26aulast%3DKeane%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%26aulast%3DTuohy%26aufirst%3DJ.%26atitle%3DPalbociclib%2520Commercial%2520Manufacturing%2520Process%2520Development.%2520Part%2520II%253A%2520Regioselective%2520Heck%2520Coupling%2520with%2520Polymorph%2520Control%2520for%2520Processability%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1203%26epage%3D1216%26doi%3D10.1021%2Facs.oprd.6b00069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Atadja, P.</span><span> </span><span class="NLM_article-title">Development of the Pan-DAC Inhibitor Panobinostat (LBH589): Successes and Challenges</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.1016/j.canlet.2009.02.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.canlet.2009.02.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=19344997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=233-241&author=P.+Atadja&title=Development+of+the+Pan-DAC+Inhibitor+Panobinostat+%28LBH589%29%3A+Successes+and+Challenges&doi=10.1016%2Fj.canlet.2009.02.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152aR"><div class="casContent"><span class="casTitleNuber">152a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges</span></div><div class="casAuthors">Atadja, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-241</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The histone deacetylase (HDAC) inhibitors are emerging as a highly useful class of anticancer agents that inhibit the enzyme HDAC involved in the deacetylation of histone and non-histone cellular proteins.  The HDAC inhibitor, panobinostat (LBH589, Novartis Pharmaceuticals), achieves potent inhibition of all HDAC enzymes implicated in cancer and has demonstrated potent anti-tumor activity in preclin. models and promising clin. efficacy in cancer patients.  In this review we discuss the successes and challenges surrounding the development of panobinostat, focusing on its proposed mechanism of action, preclin. anti-tumor activity, and early clin. efficacy in hematol. and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSTYxNKUMt7bVg90H21EOLACvtfcHk0lhacyWdE0NRYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtL4%253D&md5=4c487a2f8dc13f72cecf105d9fae97d9</span></div><a href="/servlet/linkout?suffix=cit152a&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.019%26sid%3Dliteratum%253Aachs%26aulast%3DAtadja%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520the%2520Pan-DAC%2520Inhibitor%2520Panobinostat%2520%2528LBH589%2529%253A%2520Successes%2520and%2520Challenges%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D233%26epage%3D241%26doi%3D10.1016%2Fj.canlet.2009.02.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit152b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cheng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, J.</span><span> </span><span class="NLM_article-title">Panobinostat, a Pan-histone Deacetylase Inhibitor: Rationale for and Application to Treatment of Multiple Myeloma</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span><span class="refDoi"> DOI: 10.1358/dot.2015.51.8.2362311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdot.2015.51.8.2362311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC283js1WlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=491-504&author=T.+Chengauthor=L.+Grasseauthor=J.+Chandraauthor=J.+Shah&title=Panobinostat%2C+a+Pan-histone+Deacetylase+Inhibitor%3A+Rationale+for+and+Application+to+Treatment+of+Multiple+Myeloma&doi=10.1358%2Fdot.2015.51.8.2362311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152bR"><div class="casContent"><span class="casTitleNuber">152b</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma</span></div><div class="casAuthors">Cheng T; Grasse L; Chandra J; Shah J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">491-504</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Histone deacetylase inhibitors (HDACis) have emerged as novel therapeutic agents for cancer.  Currently, four HDACis are approved by the Food and Drug Administration (FDA) to treat various hematologic malignancies.  Panobinostat (LBH-589, trade name Farydak®, developed and marketed by Novartis) is a potent pan-HDACi with demonstrated anticancer activities against multiple myeloma, a B-cell malignancy, at a low nanomolar range in preclinical settings, and in 2015 was granted FDA approval for the treatment of relapsed and refractory multiple myeloma.  Here, we review the development of HDACis, the unique features of panobinostat, and the rationale for developing panobinostat in a combination setting for the treatment of multiple myeloma.  We also review the completed and ongoing clinical trials testing the efficacy of panobinostat in combination therapies and highlight future therapeutically relevant strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdrHqiOVCAxdts4TFFB11gfW6udTcc2ebzxebOs_gj77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283js1WlsA%253D%253D&md5=6840a213c7bcd49b260ad853d1c66fcc</span></div><a href="/servlet/linkout?suffix=cit152b&amp;dbid=16384&amp;doi=10.1358%2Fdot.2015.51.8.2362311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2015.51.8.2362311%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DGrasse%26aufirst%3DL.%26aulast%3DChandra%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DJ.%26atitle%3DPanobinostat%252C%2520a%2520Pan-histone%2520Deacetylase%2520Inhibitor%253A%2520Rationale%2520for%2520and%2520Application%2520to%2520Treatment%2520of%2520Multiple%2520Myeloma%26jtitle%3DDrugs%2520Today%26date%3D2015%26volume%3D51%26spage%3D491%26epage%3D504%26doi%3D10.1358%2Fdot.2015.51.8.2362311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit152c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Revill, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mealy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serradell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, E.</span><span> </span><span class="NLM_article-title">Panobinostat: Histone Deacetylase (HDAC) Inhibitor Apoptosis Inducer Oncolytic</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1358/dof.2007.032.04.1094476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdof.2007.032.04.1094476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslOjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=315-322&author=P.+Revillauthor=N.+Mealyauthor=N.+Serradellauthor=J.+Bolosauthor=E.+Rosa&title=Panobinostat%3A+Histone+Deacetylase+%28HDAC%29+Inhibitor+Apoptosis+Inducer+Oncolytic&doi=10.1358%2Fdof.2007.032.04.1094476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152cR"><div class="casContent"><span class="casTitleNuber">152c</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat: histone deacetylase (HDAC) inhibitor apoptosis inducer oncolytic</span></div><div class="casAuthors">Revill, P.; Mealy, N.; Serradell, N.; Bolos, J.; Rosa, E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Panobinostat (LBH-589) is a member of the hydroxamic acid group of histone deacetylase (HDAC) inhibitors that have been shown to impede multiple pathways implicated in cancer and reverse epigenetic events assocd. with cancer, thereby reducing survival and inducing apoptosis in cancer cells.  Panobinostat is being investigated in various hematol. malignancies, including chronic myelogenous leukemia (CML) and multiple myeloma, and in solid tumors.  Preclin. data indicate efficacy against drug-resistant cancer cells, both as a single agent and in combination with other therapies.  A phase I clin. study has demonstrated activity in treatment-experienced patients with cutaneous T-cell lymphoma (CTCL) and phase II/III trials for this condition and other hematol. malignancies are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbKnZsI4DrhrVg90H21EOLACvtfcHk0lhggRBC9FIe_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslOjt7k%253D&md5=6356345859a9e34eebecacc0088cb062</span></div><a href="/servlet/linkout?suffix=cit152c&amp;dbid=16384&amp;doi=10.1358%2Fdof.2007.032.04.1094476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2007.032.04.1094476%26sid%3Dliteratum%253Aachs%26aulast%3DRevill%26aufirst%3DP.%26aulast%3DMealy%26aufirst%3DN.%26aulast%3DSerradell%26aufirst%3DN.%26aulast%3DBolos%26aufirst%3DJ.%26aulast%3DRosa%26aufirst%3DE.%26atitle%3DPanobinostat%253A%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitor%2520Apoptosis%2520Inducer%2520Oncolytic%26jtitle%3DDrugs%2520Future%26date%3D2007%26volume%3D32%26spage%3D315%26epage%3D322%26doi%3D10.1358%2Fdof.2007.032.04.1094476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Anne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sammartino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barginear, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budman, D.</span><span> </span><span class="NLM_article-title">Profile of Panobinostat and Its Potential for Treatment in Solid Tumors: an Update</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1613</span><span class="NLM_x">–</span> <span class="NLM_lpage">1624</span><span class="refDoi"> DOI: 10.2147/OTT.S30773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2147%2FOTT.S30773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24265556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntVartLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1613-1624&author=M.+Anneauthor=D.+Sammartinoauthor=M.+F.+Barginearauthor=D.+Budman&title=Profile+of+Panobinostat+and+Its+Potential+for+Treatment+in+Solid+Tumors%3A+an+Update&doi=10.2147%2FOTT.S30773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of panobinostat and its potential for treatment in solid tumors: an update</span></div><div class="casAuthors">Anne, Madhurima; Sammartino, Daniel; Barginear, Myra F.; Budman, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1613-1624</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer.  Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase inhibitor that is being evaluated in both i.v. and oral formulations across multiple tumor types.  Comparable to the other HDACs, panobinostat leads to hyperacetylation of histones and other intracellular proteins, allowing for the expression of otherwise repressed genes, leading to inhibition of cellular proliferation and induction of apoptosis in malignant cells.  Panobinostat, analogous to other HDAC inhibitors, also induces apoptosis by directly activating cellular death receptor pathways.  Preclin. data suggests that panobinostat has inhibitory activity at nanomolar concns. and appears to be the most potent clin. available HDAC inhibitor.  Here we review the current status of panobinostat and discuss its role in the treatment of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhDG-Z7mmMb7Vg90H21EOLACvtfcHk0lhggRBC9FIe_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntVartLo%253D&md5=1747201adba8ef6d10e729cc13015117</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.2147%2FOTT.S30773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S30773%26sid%3Dliteratum%253Aachs%26aulast%3DAnne%26aufirst%3DM.%26aulast%3DSammartino%26aufirst%3DD.%26aulast%3DBarginear%26aufirst%3DM.%2BF.%26aulast%3DBudman%26aufirst%3DD.%26atitle%3DProfile%2520of%2520Panobinostat%2520and%2520Its%2520Potential%2520for%2520Treatment%2520in%2520Solid%2520Tumors%253A%2520an%2520Update%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D1613%26epage%3D1624%26doi%3D10.2147%2FOTT.S30773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Acemoglu, M.; Bajwa, J. S.; Parker, D. J.; Slade, J.</span><span> </span><span class="NLM_article-title">Process for Preparation of (2<i>E</i>)-<i>N</i>-Hydroxy-3-[4-[[[2-(2-methyl-1<i>H</i>-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide</span>. WO 2007146718A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Acemoglu&author=J.+S.+Bajwa&author=D.+J.+Parker&author=J.+Slade&title=Process+for+Preparation+of+%282E%29-N-Hydroxy-3-%5B4-%5B%5B%5B2-%282-methyl-1H-indol-3-yl%29ethyl%5Damino%5Dmethyl%5Dphenyl%5D-2-propenamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAcemoglu%26aufirst%3DM.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520%25282E%2529-N-Hydroxy-3-%255B4-%255B%255B%255B2-%25282-methyl-1H-indol-3-yl%2529ethyl%255Damino%255Dmethyl%255Dphenyl%255D-2-propenamide%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit154b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bair, K. W.; Green, M. A.; Perez, L. B.; Remiszewski, S. W.; Sambucetti, L.; Versace, R. W.; Sharma, S. K.</span><span> </span><span class="NLM_article-title">Preparation of Hydroxamic Acids as Deacetylase Inhibitors</span>. WO 2002022577A1,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=K.+W.+Bair&author=M.+A.+Green&author=L.+B.+Perez&author=S.+W.+Remiszewski&author=L.+Sambucetti&author=R.+W.+Versace&author=S.+K.+Sharma&title=Preparation+of+Hydroxamic+Acids+as+Deacetylase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBair%26aufirst%3DK.%2BW.%26atitle%3DPreparation%2520of%2520Hydroxamic%2520Acids%2520as%2520Deacetylase%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Slade, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girgis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repic, O.</span><span> </span><span class="NLM_article-title">Optimization and Scale-Up of the Grandberg Synthesis of 2-Methyltryptamine</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1021/op7000518</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op7000518" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=721-725&author=J.+Sladeauthor=D.+Parkerauthor=M.+Girgisauthor=R.+Wuauthor=S.+Josephauthor=O.+Repic&title=Optimization+and+Scale-Up+of+the+Grandberg+Synthesis+of+2-Methyltryptamine&doi=10.1021%2Fop7000518"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Fop7000518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop7000518%26sid%3Dliteratum%253Aachs%26aulast%3DSlade%26aufirst%3DJ.%26aulast%3DParker%26aufirst%3DD.%26aulast%3DGirgis%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DS.%26aulast%3DRepic%26aufirst%3DO.%26atitle%3DOptimization%2520and%2520Scale-Up%2520of%2520the%2520Grandberg%2520Synthesis%2520of%25202-Methyltryptamine%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2007%26volume%3D11%26spage%3D721%26epage%3D725%26doi%3D10.1021%2Fop7000518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Bajwa, J. S.; Parker, D. J.; Slade, J.</span><span> </span><span class="NLM_article-title">Preparation of Salts of <i>N</i>-Hydroxy-3-[4-[[[2-(2-methyl-1<i>H</i>-indol-3-yl)ethyl]amino]methyl]phenyl]-2<i>E</i>-2-propenamide</span>. WO 2007146717A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+S.+Bajwa&author=D.+J.+Parker&author=J.+Slade&title=Preparation+of+Salts+of+N-Hydroxy-3-%5B4-%5B%5B%5B2-%282-methyl-1H-indol-3-yl%29ethyl%5Damino%5Dmethyl%5Dphenyl%5D-2E-2-propenamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBajwa%26aufirst%3DJ.%2BS.%26atitle%3DPreparation%2520of%2520Salts%2520of%2520N-Hydroxy-3-%255B4-%255B%255B%255B2-%25282-methyl-1H-indol-3-yl%2529ethyl%255Damino%255Dmethyl%255Dphenyl%255D-2E-2-propenamide%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burness, C. B.</span><span> </span><span class="NLM_article-title">Sonidegib: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1559</span><span class="NLM_x">–</span> <span class="NLM_lpage">1566</span><span class="refDoi"> DOI: 10.1007/s40265-015-0458-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0458-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1559-1566&author=C.+B.+Burness&title=Sonidegib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0458-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0458-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0458-y%26sid%3Dliteratum%253Aachs%26aulast%3DBurness%26aufirst%3DC.%2BB.%26atitle%3DSonidegib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1559%26epage%3D1566%26doi%3D10.1007%2Fs40265-015-0458-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit157b"><span><span class="NLM_label">(b) </span>FDA Approves New Treatment for Most Common Form of Advanced Skin Cancer; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, July 24,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm</a> (accessed September 8, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+New+Treatment+for+Most+Common+Form+of+Advanced+Skin+Cancer%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+July+24%2C+2015%3B+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm455862.htm+%28accessed+September+8%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520New%2520Treatment%2520for%2520Most%2520Common%2520Form%2520of%2520Advanced%2520Skin%2520Cancer%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Dreier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felderer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nageli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunstfeld, R.</span><span> </span><span class="NLM_article-title">Emerging Drugs and Combination Strategies for Basal Cell Carcinoma</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span><span class="refDoi"> DOI: 10.1517/14728214.2014.914171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14728214.2014.914171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24773312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyjtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=353-365&author=J.+Dreierauthor=R.+Dummerauthor=L.+Feldererauthor=M.+Nageliauthor=S.+Gobbiauthor=R.+Kunstfeld&title=Emerging+Drugs+and+Combination+Strategies+for+Basal+Cell+Carcinoma&doi=10.1517%2F14728214.2014.914171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs and combination strategies for basal cell carcinoma</span></div><div class="casAuthors">Dreier, Jil; Dummer, Reinhard; Felderer, Lea; Naegeli, Mirjam; Gobbi, Sharon; Kunstfeld, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-365</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Basal cell carcinoma (BCC) is a malignancy that is driven by an activated Hedgehog (Hh) pathway.  Smoothened inhibitors are a new promising treatment option for patients with locally advanced or metastatic BCC or basal cell nevus syndrome.  But long-term data are still limited, the optimal treatment duration is not yet defined and there are already documented cases with acquired resistance.  Areas covered: Treatment modalities with Hh inhibitors, side effects and potential pharmacol. combination options are discussed.  The current literature, including PubMed, Cochrane database and registered trials on ClinicalTrials.gov, was searched.  Expert opinion: BCCs typically regress during therapy with Hh inhibitors.  Muscle toxicity, dysgeusia and hair loss can be considered as on target adverse reactions.  Muscle toxicity is the dose-limiting toxicity of sonidegib.  It was not seen with vismodegib because of its high binding to plasma protein α-1-acid glycoprotein.  Sonidegib is different and shows a clear dose-toxicity relationship, which allows to address the question of whether there is a dose dependency of regression rate, cure rate and progression-free survival.  In addn., basic research has offered strategies to enhance efficacy by the combination with other mols., such as EGFR inhibitors, MEK inhibitors or immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozaVeQjReUuLVg90H21EOLACvtfcHk0ljKF5neawu5ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyjtbzL&md5=aace7f145ff3d7628420b12092b29b7c</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1517%2F14728214.2014.914171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2014.914171%26sid%3Dliteratum%253Aachs%26aulast%3DDreier%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DFelderer%26aufirst%3DL.%26aulast%3DNageli%26aufirst%3DM.%26aulast%3DGobbi%26aufirst%3DS.%26aulast%3DKunstfeld%26aufirst%3DR.%26atitle%3DEmerging%2520Drugs%2520and%2520Combination%2520Strategies%2520for%2520Basal%2520Cell%2520Carcinoma%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2014%26volume%3D19%26spage%3D353%26epage%3D365%26doi%3D10.1517%2F14728214.2014.914171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Brechbiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller-Moslin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Crosstalk Between Hedgehog and Other Signaling Pathways as a Basis for Combination Therapies in Cancer</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">750</span><span class="NLM_x">–</span> <span class="NLM_lpage">759</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2014.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.ctrv.2014.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24613036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVWjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=750-759&author=J.+Brechbielauthor=K.+Miller-Moslinauthor=A.+A.+Adjei&title=Crosstalk+Between+Hedgehog+and+Other+Signaling+Pathways+as+a+Basis+for+Combination+Therapies+in+Cancer&doi=10.1016%2Fj.ctrv.2014.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159aR"><div class="casContent"><span class="casTitleNuber">159a</span><div class="casTitle"><span class="NLM_cas:atitle">Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer</span></div><div class="casAuthors">Brechbiel, Jillian; Miller-Moslin, Karen; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">750-759</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The hedgehog (Hh) pathway is aberrantly activated in a no. of tumors.  In medulloblastoma, basal cell carcinoma, and rhabdomyosarcoma, mutations in Hh pathway genes lead to ligand-independent pathway activation.  In many other tumor types, ligand-dependent activation of Hh signaling is potentiated through crosstalk with other crit. mol. signaling pathways.  Among such pathways, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch are of particular interest because agents that selectively inhibit these pathways are available and can be readily combined with agents such as vismodegib, sonidegib (LDE225), and BMS-833923, which target smoothened-a key Hh pathway regulator.  Numerous preclin. studies have revealed the ways in which Hh intersects with each of these pathways, and combination therapies have resulted in improved antitumor efficacy and survival in animal models.  Hh also plays an important role in hematopoiesis and in the maintenance of BCR-ABL-driven leukemic stem cells.  Thus, combined inhibition of the Hh pathway and BCR-ABL has emerged as a promising potential therapeutic strategy in chronic myeloid leukemia (CML).  A no. of clin. trials evaluating combinations of Hh inhibitors with other targeted agents are now underway in CML and a variety of solid tumors.  This review highlights these trials and summarizes preclin. evidence of crosstalk between Hh and four other actionable pathways-RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch-as well as the role of Hh in the maintenance of BCR-ABL-driven leukemic stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0QBuqlma6TbVg90H21EOLACvtfcHk0ljKF5neawu5ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVWjsbY%253D&md5=f3975d97baf71723f2c4fc62779844e0</span></div><a href="/servlet/linkout?suffix=cit159a&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DBrechbiel%26aufirst%3DJ.%26aulast%3DMiller-Moslin%26aufirst%3DK.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DCrosstalk%2520Between%2520Hedgehog%2520and%2520Other%2520Signaling%2520Pathways%2520as%2520a%2520Basis%2520for%2520Combination%2520Therapies%2520in%2520Cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D750%26epage%3D759%26doi%3D10.1016%2Fj.ctrv.2014.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit159b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gan, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span> </span><span class="NLM_article-title">Emerging from Their Burrow: Hedgehog Pathway Inhibitors for Cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1166</span><span class="refDoi"> DOI: 10.1080/13543784.2016.1216973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1080%2F13543784.2016.1216973" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1153-1166&author=G.+N.+Ganauthor=A.+Jimeno&title=Emerging+from+Their+Burrow%3A+Hedgehog+Pathway+Inhibitors+for+Cancer&doi=10.1080%2F13543784.2016.1216973"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159b&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1216973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1216973%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DG.%2BN.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DEmerging%2520from%2520Their%2520Burrow%253A%2520Hedgehog%2520Pathway%2520Inhibitors%2520for%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1153%26epage%3D1166%26doi%3D10.1080%2F13543784.2016.1216973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Burness, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, L. J.</span><span> </span><span class="NLM_article-title">Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma</span> <span class="citation_source-journal">Targ. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span><span class="refDoi"> DOI: 10.1007/s11523-016-0418-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs11523-016-0418-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26867946" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=239-246&author=C.+B.+Burnessauthor=L.+J.+Scott&title=Sonidegib%3A+A+Review+in+Locally+Advanced+Basal+Cell+Carcinoma&doi=10.1007%2Fs11523-016-0418-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1007%2Fs11523-016-0418-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-016-0418-9%26sid%3Dliteratum%253Aachs%26aulast%3DBurness%26aufirst%3DC.%2BB.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DSonidegib%253A%2520A%2520Review%2520in%2520Locally%2520Advanced%2520Basal%2520Cell%2520Carcinoma%26jtitle%3DTarg.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3D239%26epage%3D246%26doi%3D10.1007%2Fs11523-016-0418-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1038/nrd3714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1038%2Fnrd3714" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=257-258&author=M.+Guha&title=Hedgehog+inhibitor+gets+landmark+skin+cancer+approval%2C+but+questions+remain+for+wider+potential&doi=10.1038%2Fnrd3714"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fnrd3714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3714%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DHedgehog%2520inhibitor%2520gets%2520landmark%2520skin%2520cancer%2520approval%252C%2520but%2520questions%2520remain%2520for%2520wider%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D257%26epage%3D258%26doi%3D10.1038%2Fnrd3714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Englund, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peukert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller-Moslin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vattay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniara, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelleher, J. F.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsch, M.</span><span> </span><span class="NLM_article-title">Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1021/ml1000307</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1000307" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1Cqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=130-134&author=S.+Panauthor=X.+Wuauthor=J.+Jiangauthor=W.+Gaoauthor=Y.+Wanauthor=D.+Chengauthor=D.+Hanauthor=J.+Liuauthor=N.+P.+Englundauthor=Y.+Wangauthor=S.+Peukertauthor=K.+Miller-Moslinauthor=J.+Yuanauthor=R.+Guoauthor=M.+Matsumotoauthor=A.+Vattayauthor=Y.+Jiangauthor=J.+Tsaoauthor=F.+Sunauthor=A.+C.+Pferdekamperauthor=S.+Doddauthor=T.+Tuntlandauthor=W.+Maniaraauthor=J.+F.+Kelleherauthor=Y.+M.+Yaoauthor=M.+Warmuthauthor=J.+Williamsauthor=M.+Dorsch&title=Discovery+of+NVP-LDE225%2C+a+Potent+and+Selective+Smoothened+Antagonist&doi=10.1021%2Fml1000307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162aR"><div class="casContent"><span class="casTitleNuber">162a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist</span></div><div class="casAuthors">Pan, Shifeng; Wu, Xu; Jiang, Jiqing; Gao, Wenqi; Wan, Yongqin; Cheng, Dai; Han, Dong; Liu, Jun; Englund, Nathan P.; Wang, Yan; Peukert, Stefan; Miller-Moslin, Karen; Yuan, Jing; Guo, Ribo; Matsumoto, Melissa; Vattay, Anthony; Jiang, Yun; Tsao, Jeffrey; Sun, Fangxian; Pferdekamper, AnneMarie C.; Dodd, Stephanie; Tuntland, Tove; Maniara, Wieslawa; Kelleher, Joseph F., III; Yao, Yung-mae; Warmuth, Markus; Williams, Juliet; Dorsch, Marion</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">130-134</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The blockade of aberrant hedgehog (Hh) signaling has shown promise for therapeutic intervention in cancer.  A cell-based phenotypic high-throughput screen was performed, and the lead structure (1) was identified as an inhibitor of the Hh pathway via antagonism of the Smoothened receptor (Smo).  Structure-activity relation studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide (5m, NVP-LDE225), which is currently in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkXrdZB74WfbVg90H21EOLACvtfcHk0ljCnQeSPwbyXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1Cqt7c%253D&md5=c4d1348e8d47ed9561151ce59305531e</span></div><a href="/servlet/linkout?suffix=cit162a&amp;dbid=16384&amp;doi=10.1021%2Fml1000307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1000307%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DEnglund%26aufirst%3DN.%2BP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPeukert%26aufirst%3DS.%26aulast%3DMiller-Moslin%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DVattay%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DTsao%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DDodd%26aufirst%3DS.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DManiara%26aufirst%3DW.%26aulast%3DKelleher%26aufirst%3DJ.%2BF.%26aulast%3DYao%26aufirst%3DY.%2BM.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DDorsch%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520NVP-LDE225%252C%2520a%2520Potent%2520and%2520Selective%2520Smoothened%2520Antagonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D130%26epage%3D134%26doi%3D10.1021%2Fml1000307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit162b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gao, W.; Jiang, J.; Wan, Y.; Cheng, D.; Han, D.; Wu, X.; Pan, S.</span><span> </span><span class="NLM_article-title">Compounds and Compositions as Hedgehog Pathway Modulators</span>. WO 2008/154259A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=W.+Gao&author=J.+Jiang&author=Y.+Wan&author=D.+Cheng&author=D.+Han&author=X.+Wu&author=S.+Pan&title=Compounds+and+Compositions+as+Hedgehog+Pathway+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DW.%26atitle%3DCompounds%2520and%2520Compositions%2520as%2520Hedgehog%2520Pathway%2520Modulators%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit162c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dierks, C.; Warmuth, M.; Wu, X.</span><span> </span><span class="NLM_article-title">Biphenylcarboxamide Derivatives as Hedgehog Pathway Modulators</span>. WO 2008154259A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Dierks&author=M.+Warmuth&author=X.+Wu&title=Biphenylcarboxamide+Derivatives+as+Hedgehog+Pathway+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDierks%26aufirst%3DC.%26atitle%3DBiphenylcarboxamide%2520Derivatives%2520as%2520Hedgehog%2520Pathway%2520Modulators%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit162d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Fritze, A.; Corcelle, K.; Grubesa, M. E.</span><span> </span><span class="NLM_article-title">Pharmaceutical Compositions</span>. WO 2011009852A2,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Fritze&author=K.+Corcelle&author=M.+E.+Grubesa&title=Pharmaceutical+Compositions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFritze%26aufirst%3DA.%26atitle%3DPharmaceutical%2520Compositions%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Bajwa, J. S.; De, L. C. M.; Dodd, S. K.; Waykole, L. M.; Wu, R.</span><span> </span><span class="NLM_article-title">Salts of <i>N</i>-[6-<i>cis</i>-2,6-Dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide</span>. WO 2010033481A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+S.+Bajwa&author=L.+C.+M.+De&author=S.+K.+Dodd&author=L.+M.+Waykole&author=R.+Wu&title=Salts+of+N-%5B6-cis-2%2C6-Dimethylmorpholin-4yl%29pyridine-3yl%5D-2-methyl-4%E2%80%B2-%28trifluoromethoxy%29%5B1%2C1%E2%80%B2-biphenyl%5D-3-carboxamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBajwa%26aufirst%3DJ.%2BS.%26atitle%3DSalts%2520of%2520N-%255B6-cis-2%252C6-Dimethylmorpholin-4yl%2529pyridine-3yl%255D-2-methyl-4%25E2%2580%25B2-%2528trifluoromethoxy%2529%255B1%252C1%25E2%2580%25B2-biphenyl%255D-3-carboxamide%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c','cit2d','cit2e','cit2f','cit2g','cit2h','cit2i','cit2j','cit2k','cit2l','cit2m'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f','cit6g'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b','cit14c'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22a','cit22b'],'ref23':['cit23a','cit23b','cit23c','cit23d','cit23e','cit23f','cit23g','cit23h','cit23i','cit23j'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28a','cit28b'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36a','cit36b'],'ref37':['cit37'],'ref38':['cit38a','cit38b'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42a','cit42b','cit42c','cit42d','cit42e','cit42f'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52a','cit52b'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56a','cit56b'],'ref57':['cit57a','cit57b'],'ref58':['cit58a','cit58b'],'ref59':['cit59a','cit59b','cit59c'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72a','cit72b'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77a','cit77b'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87a','cit87b','cit87c','cit87d'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91a','cit91b','cit91c','cit91d','cit91e','cit91f','cit91g'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94a','cit94b','cit94c','cit94d','cit94e','cit94f','cit94g'],'ref95':['cit95'],'ref96':['cit96a','cit96b'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106a','cit106b','cit106c'],'ref107':['cit107'],'ref108':['cit108a','cit108b'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117a','cit117b','cit117c'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120a','cit120b'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124a','cit124b'],'ref125':['cit125'],'ref126':['cit126a','cit126b'],'ref127':['cit127a','cit127b'],'ref128':['cit128a','cit128b'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144a','cit144b','cit144c','cit144d','cit144e'],'ref145':['cit145'],'ref146':['cit146a','cit146b'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150a','cit150b','cit150c'],'ref151':['cit151a','cit151b','cit151c','cit151d'],'ref152':['cit152a','cit152b','cit152c'],'ref153':['cit153'],'ref154':['cit154a','cit154b'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157a','cit157b'],'ref158':['cit158'],'ref159':['cit159a','cit159b'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162a','cit162b','cit162c','cit162d'],'ref163':['cit163']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 59 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiang Liu, Jinlei Zhou, Jiatong Lin, Zemin Zhang, Suying Wu, Qiuxing He, <span class="NLM_string-name hlFld-ContribAuthor">Hua Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Controllable Site-Selective Construction of 2- and 4-Substituted Pyrimido[1,2-b]indazole from 3-Aminoindazoles and Ynals. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (13)
                                     , 9107-9116. <a href="https://doi.org/10.1021/acs.joc.1c01094" title="DOI URL">https://doi.org/10.1021/acs.joc.1c01094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c01094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c01094%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DControllable%252BSite-Selective%252BConstruction%252Bof%252B2-%252Band%252B4-Substituted%252BPyrimido%25255B1%25252C2-b%25255Dindazole%252Bfrom%252B3-Aminoindazoles%252Band%252BYnals%26aulast%3DLiu%26aufirst%3DXiang%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D10052021%26date%3D16062021%26volume%3D86%26issue%3D13%26spage%3D9107%26epage%3D9116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved during 2019. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3604-3657. <a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252Bduring%252B2019%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03022021%26date%3D30032021%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lei Ning, Hengzhao Li, Zemin Lai, Michal Szostak, Xingyue Chen, Yanhong Dong, Shuhui Jin, <span class="NLM_string-name hlFld-ContribAuthor">Jie An</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of α-Deuterated Primary Amines via Reductive Deuteration of Oximes Using D2O as a Deuterium Source. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (3)
                                     , 2907-2916. <a href="https://doi.org/10.1021/acs.joc.0c02829" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02829%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B%2525CE%2525B1-Deuterated%252BPrimary%252BAmines%252Bvia%252BReductive%252BDeuteration%252Bof%252BOximes%252BUsing%252BD2O%252Bas%252Ba%252BDeuterium%252BSource%26aulast%3DNing%26aufirst%3DLei%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26112020%26date%3D25012021%26volume%3D86%26issue%3D3%26spage%3D2907%26epage%3D2916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, Jacob C. DeForest, Peter D. Morse, Subham Mahapatra, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to New Drugs Approved during 2018. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10652-10704. <a href="https://doi.org/10.1021/acs.jmedchem.0c00345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252BNew%252BDrugs%252BApproved%252Bduring%252B2018%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D22052020%26date%3D27042020%26volume%3D63%26issue%3D19%26spage%3D10652%26epage%3D10704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Phani Ghanakota, Pieter H. Bos, Kyle D. Konze, Joshua Staker, Gabriel Marques, Kyle Marshall, Karl Leswing, Robert Abel, <span class="NLM_string-name hlFld-ContribAuthor">Sathesh Bhat</span>. </span><span class="cited-content_cbyCitation_article-title">Combining Cloud-Based Free-Energy Calculations, Synthetically Aware Enumerations, and Goal-Directed Generative Machine Learning for Rapid Large-Scale Chemical Exploration and Optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (9)
                                     , 4311-4325. <a href="https://doi.org/10.1021/acs.jcim.0c00120" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00120%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DCombining%252BCloud-Based%252BFree-Energy%252BCalculations%25252C%252BSynthetically%252BAware%252BEnumerations%25252C%252Band%252BGoal-Directed%252BGenerative%252BMachine%252BLearning%252Bfor%252BRapid%252BLarge-Scale%252BChemical%252BExploration%252Band%252BOptimization%26aulast%3DGhanakota%26aufirst%3DPhani%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31012020%26date%3D19062020%26date%3D02062020%26volume%3D60%26issue%3D9%26spage%3D4311%26epage%3D4325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rohitesh Kumar, Charles L. Bidgood, Claire Levrier, Jennifer H. Gunter, Colleen C. Nelson, Martin C. Sadowski, <span class="NLM_string-name hlFld-ContribAuthor">Rohan A. Davis</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of a Unique Psammaplysin F Library and Functional Evaluation in Prostate Cancer Cells by Multiparametric Quantitative Single Cell Imaging. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2020,</strong> <em>83 </em>
                                    (8)
                                     , 2357-2366. <a href="https://doi.org/10.1021/acs.jnatprod.0c00121" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.0c00121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.0c00121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.0c00121%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DSynthesis%252Bof%252Ba%252BUnique%252BPsammaplysin%252BF%252BLibrary%252Band%252BFunctional%252BEvaluation%252Bin%252BProstate%252BCancer%252BCells%252Bby%252BMultiparametric%252BQuantitative%252BSingle%252BCell%252BImaging%26aulast%3DKumar%26aufirst%3DRohitesh%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01022020%26date%3D21072020%26volume%3D83%26issue%3D8%26spage%3D2357%26epage%3D2366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">José Tiago M. Correia, Gustavo Piva da Silva, Camila M. Kisukuri, Elias André, Bruno Pires, Pablo S. Carneiro, <span class="NLM_string-name hlFld-ContribAuthor">Márcio W. Paixão</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-Free Photoinduced Hydroalkylation Cascade Enabled by an Electron-Donor–Acceptor Complex. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (15)
                                     , 9820-9834. <a href="https://doi.org/10.1021/acs.joc.0c01130" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01130%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMetal-Free%252BPhotoinduced%252BHydroalkylation%252BCascade%252BEnabled%252Bby%252Ban%252BElectron-Donor%2525E2%252580%252593Acceptor%252BComplex%26aulast%3DCorreia%26aufirst%3DJos%25C3%25A9%2BTiago%2BM.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10052020%26date%3D09072020%26date%3D26062020%26volume%3D85%26issue%3D15%26spage%3D9820%26epage%3D9834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chen Zhang, Fei Ye, Jianmin Wang, Ping He, Ming Lei, Longbin Huang, Anbang Huang, Pingming Tang, Hongjun Lin, Yuting Liao, Yong Liang, Jia Ni, <span class="NLM_string-name hlFld-ContribAuthor">Pangke Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7108-7126. <a href="https://doi.org/10.1021/acs.jmedchem.0c00374" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00374%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%252Bof%252Ba%252BSeries%252Bof%252BNovel%252BSuper%252BLong-Acting%252BDPP-4%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BType%252B2%252BDiabetes%26aulast%3DZhang%26aufirst%3DChen%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11032020%26date%3D12062020%26date%3D26052020%26volume%3D63%26issue%3D13%26spage%3D7108%26epage%3D7126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew
C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved During 2017. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (16)
                                     , 7340-7382. <a href="https://doi.org/10.1021/acs.jmedchem.9b00196" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00196%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252BDuring%252B2017%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30012019%26date%3D15042019%26date%3D02042019%26volume%3D62%26issue%3D16%26spage%3D7340%26epage%3D7382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qinghe Gao, Xinya Han, Peiyuan Tong, Zhiang Zhang, Haotian Shen, Yanrong Guo, <span class="NLM_string-name hlFld-ContribAuthor">Suping Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Aerobic α,β-C(sp3)–H Bond Difunctionalization and C–N Bond Cleavage of Triethylamine: Difunctional Ammonium Iodide Enabling the Regioselective Synthesis of 4-Arylpyrimido[1,2-b]indazoles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (15)
                                     , 6074-6078. <a href="https://doi.org/10.1021/acs.orglett.9b02218" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02218%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAerobic%252B%2525CE%2525B1%25252C%2525CE%2525B2-C%252528sp3%252529%2525E2%252580%252593H%252BBond%252BDifunctionalization%252Band%252BC%2525E2%252580%252593N%252BBond%252BCleavage%252Bof%252BTriethylamine%25253A%252BDifunctional%252BAmmonium%252BIodide%252BEnabling%252Bthe%252BRegioselective%252BSynthesis%252Bof%252B4-Arylpyrimido%25255B1%25252C2-b%25255Dindazoles%26aulast%3DGao%26aufirst%3DQinghe%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27062019%26date%3D18072019%26volume%3D21%26issue%3D15%26spage%3D6074%26epage%3D6078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Caleb Karmel, Zhewei Chen, <span class="NLM_string-name hlFld-ContribAuthor">John F. Hartwig</span>. </span><span class="cited-content_cbyCitation_article-title">Iridium-Catalyzed Silylation of C–H Bonds in Unactivated Arenes: A Sterically Encumbered Phenanthroline Ligand Accelerates Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (17)
                                     , 7063-7072. <a href="https://doi.org/10.1021/jacs.9b01972" title="DOI URL">https://doi.org/10.1021/jacs.9b01972</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b01972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b01972%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DIridium-Catalyzed%252BSilylation%252Bof%252BC%2525E2%252580%252593H%252BBonds%252Bin%252BUnactivated%252BArenes%25253A%252BA%252BSterically%252BEncumbered%252BPhenanthroline%252BLigand%252BAccelerates%252BCatalysis%26aulast%3DKarmel%26aufirst%3DCaleb%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20022019%26date%3D23042019%26date%3D11042019%26volume%3D141%26issue%3D17%26spage%3D7063%26epage%3D7072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuan Wang, Hui Sun, Jiaxiang Liu, Wenge Zhong, Mingqiang Zhang, Hu Zhou, Dongcheng Dai, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojie Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Promoted DNA-Compatible Heck Reaction. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (3)
                                     , 719-723. <a href="https://doi.org/10.1021/acs.orglett.8b03926" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03926</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03926%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPalladium-Promoted%252BDNA-Compatible%252BHeck%252BReaction%26aulast%3DWang%26aufirst%3DXuan%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D09122018%26date%3D24012019%26volume%3D21%26issue%3D3%26spage%3D719%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew
C. Flick, Hong X. Ding, Carolyn A. Leverett, Sarah J. Fink, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to New Drugs Approved During 2016. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (16)
                                     , 7004-7031. <a href="https://doi.org/10.1021/acs.jmedchem.8b00260" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00260%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252BNew%252BDrugs%252BApproved%252BDuring%252B2016%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15022018%26date%3D19042018%26date%3D05042018%26volume%3D61%26issue%3D16%26spage%3D7004%26epage%3D7031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Connor
W. Coley, William H. Green, <span class="NLM_string-name hlFld-ContribAuthor">Klavs F. Jensen</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning in Computer-Aided Synthesis Planning. </span><span class="cited-content_cbyCitation_journal-name">Accounts of Chemical Research</span><span> <strong>2018,</strong> <em>51 </em>
                                    (5)
                                     , 1281-1289. <a href="https://doi.org/10.1021/acs.accounts.8b00087" title="DOI URL">https://doi.org/10.1021/acs.accounts.8b00087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.accounts.8b00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.accounts.8b00087%26sid%3Dliteratum%253Aachs%26jtitle%3DAccounts%2520of%2520Chemical%2520Research%26atitle%3DMachine%252BLearning%252Bin%252BComputer-Aided%252BSynthesis%252BPlanning%26aulast%3DColey%26aufirst%3DConnor%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D28022018%26date%3D01052018%26volume%3D51%26issue%3D5%26spage%3D1281%26epage%3D1289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Connor W.  Coley</span>, <span class="hlFld-ContribAuthor ">Luke  Rogers</span>, <span class="hlFld-ContribAuthor ">William H.  Green</span>, and <span class="hlFld-ContribAuthor ">Klavs F.  Jensen</span>  . </span><span class="cited-content_cbyCitation_article-title">SCScore: Synthetic Complexity Learned from a Reaction Corpus. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2018,</strong> <em>58 </em>
                                    (2)
                                     , 252-261. <a href="https://doi.org/10.1021/acs.jcim.7b00622" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00622%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DSCScore%25253A%252BSynthetic%252BComplexity%252BLearned%252Bfrom%252Ba%252BReaction%252BCorpus%26aulast%3DColey%26aufirst%3DConnor%2BW.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D23102017%26date%3D26012018%26date%3D26022018%26date%3D08012018%26volume%3D58%26issue%3D2%26spage%3D252%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing-Hai  Jin</span>, <span class="hlFld-ContribAuthor ">Hao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhong-Tao  Yang</span>, <span class="hlFld-ContribAuthor ">Wu-Lin  Yang</span>, <span class="hlFld-ContribAuthor ">Wenjun  Tang</span>, and <span class="hlFld-ContribAuthor ">Wei-Ping  Deng</span>  . </span><span class="cited-content_cbyCitation_article-title">Asymmetric Synthesis of 3,4-Dihydroquinolin-2-ones via a Stereoselective Palladium-Catalyzed Decarboxylative [4 + 2]- Cycloaddition. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (1)
                                     , 104-107. <a href="https://doi.org/10.1021/acs.orglett.7b03467" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b03467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b03467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b03467%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAsymmetric%252BSynthesis%252Bof%252B3%25252C4-Dihydroquinolin-2-ones%252Bvia%252Ba%252BStereoselective%252BPalladium-Catalyzed%252BDecarboxylative%252B%25255B4%252B%25252B%252B2%25255D-%252BCycloaddition%26aulast%3DJin%26aufirst%3DJing-Hai%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D08112017%26date%3D11122017%26date%3D05012018%26volume%3D20%26issue%3D1%26spage%3D104%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">José Tiago M.  Correia</span>, <span class="hlFld-ContribAuthor ">Marilia S.  Santos</span>, <span class="hlFld-ContribAuthor ">Emanuele F.  Pissinati</span>, <span class="hlFld-ContribAuthor ">Gustavo P.  Silva</span>, <span class="hlFld-ContribAuthor ">Márcio W.  Paixão</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances on Photoinduced Cascade Strategies for the Synthesis of
              N
              ‐Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">The Chemical Record</span><span> <strong>2021,</strong> <em>23 </em><a href="https://doi.org/10.1002/tcr.202100160" title="DOI URL">https://doi.org/10.1002/tcr.202100160</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/tcr.202100160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Ftcr.202100160%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Chemical%2520Record%26atitle%3DRecent%252BAdvances%252Bon%252BPhotoinduced%252BCascade%252BStrategies%252Bfor%252Bthe%252BSynthesis%252Bof%252BN%252B%2525E2%252580%252590Heterocycles%26aulast%3DCorreia%26aufirst%3DJos%25C3%25A9%2BTiago%2BM.%26date%3D2021%26date%3D2021%26volume%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossein  Mousavi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive survey upon diverse and prolific applications of chitosan-based catalytic systems in one-pot multi-component synthesis of heterocyclic rings. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>57 </em><a href="https://doi.org/10.1016/j.ijbiomac.2021.06.123" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2021.06.123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2021.06.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2021.06.123%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DA%252Bcomprehensive%252Bsurvey%252Bupon%252Bdiverse%252Band%252Bprolific%252Bapplications%252Bof%252Bchitosan-based%252Bcatalytic%252Bsystems%252Bin%252Bone-pot%252Bmulti-component%252Bsynthesis%252Bof%252Bheterocyclic%252Brings%26aulast%3DMousavi%26aufirst%3DHossein%26date%3D2021%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xumu  Zhang</span>, <span class="hlFld-ContribAuthor ">Pan‐Lin  Shao</span>. </span><span class="cited-content_cbyCitation_article-title">Industrial Applications of Asymmetric (Transfer) Hydrogenation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 175-219. <a href="https://doi.org/10.1002/9783527822294.ch6" title="DOI URL">https://doi.org/10.1002/9783527822294.ch6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527822294.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527822294.ch6%26sid%3Dliteratum%253Aachs%26atitle%3DIndustrial%252BApplications%252Bof%252BAsymmetric%252B%252528Transfer%252529%252BHydrogenation%26aulast%3DZhang%26aufirst%3DXumu%26date%3D2021%26date%3D2021%26spage%3D175%26epage%3D219%26pub%3DWiley%26atitle%3DAsymmetric%252BHydrogenation%252Band%252BTransfer%252BHydrogenation%26aulast%3DRatovelomanana%25E2%2580%2590Vidal%26aufirst%3DVirginie%26date%3D2021%26date%3D2021%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ravi Kumar  Sadineni</span>, <span class="hlFld-ContribAuthor ">Rajesh Kumar  Rapolu</span>, <span class="hlFld-ContribAuthor ">V. V. N. K. V. Prasada  Raju</span>, <span class="hlFld-ContribAuthor ">N.  Srinivasu</span>, <span class="hlFld-ContribAuthor ">Sireesha  Malladi</span>, <span class="hlFld-ContribAuthor ">Naveen  Mulakayala</span>. </span><span class="cited-content_cbyCitation_article-title">Novel method for the synthesis of lenvatinib using 4-nitrophenyl cyclopropylcarbamate and their pharmaceutical salts. </span><span class="cited-content_cbyCitation_journal-name">Chemical Papers</span><span> <strong>2021,</strong> <em>75 </em>
                                    (4)
                                     , 1475-1483. <a href="https://doi.org/10.1007/s11696-020-01402-z" title="DOI URL">https://doi.org/10.1007/s11696-020-01402-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11696-020-01402-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11696-020-01402-z%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Papers%26atitle%3DNovel%252Bmethod%252Bfor%252Bthe%252Bsynthesis%252Bof%252Blenvatinib%252Busing%252B4-nitrophenyl%252Bcyclopropylcarbamate%252Band%252Btheir%252Bpharmaceutical%252Bsalts%26aulast%3DSadineni%26aufirst%3DRavi%2BKumar%26date%3D2021%26date%3D2020%26volume%3D75%26issue%3D4%26spage%3D1475%26epage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-Han  Yuan</span>, <span class="hlFld-ContribAuthor ">Sai-Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiao-Bing  Chen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113218. <a href="https://doi.org/10.1016/j.ejmech.2021.113218" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113218%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFDA-approved%252Bpyrimidine-fused%252Bbicyclic%252Bheterocycles%252Bfor%252Bcancer%252Btherapy%25253A%252BSynthesis%252Band%252Bclinical%252Bapplication%26aulast%3DWang%26aufirst%3DShuai%26date%3D2021%26volume%3D214%26spage%3D113218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Some Drug Molecules. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 565-572. <a href="https://doi.org/10.1002/9783527828166.ch14" title="DOI URL">https://doi.org/10.1002/9783527828166.ch14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527828166.ch14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527828166.ch14%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Bof%252BSome%252BDrug%252BMolecules%26date%3D2021%26date%3D2020%26spage%3D565%26epage%3D572%26pub%3DWiley%26atitle%3DApplied%252BOrganic%252BChemistry%26aulast%3DDe%26aufirst%3DSurya%2BK.%26date%3D2021%26date%3D2020%26volume%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garima  Tripathi</span>, <span class="hlFld-ContribAuthor ">Abhijeet  Kumar</span>, <span class="hlFld-ContribAuthor ">Sanchayita  Rajkhowa</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of biologically relevant heterocyclic skeletons under solvent-free condition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 421-459. <a href="https://doi.org/10.1016/B978-0-12-820586-0.00013-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-820586-0.00013-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820586-0.00013-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820586-0.00013-3%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Bof%252Bbiologically%252Brelevant%252Bheterocyclic%252Bskeletons%252Bunder%252Bsolvent-free%252Bcondition%26aulast%3DTripathi%26aufirst%3DGarima%26date%3D2021%26spage%3D421%26epage%3D459%26pub%3DElsevier%26atitle%3DGreen%252BSynthetic%252BApproaches%252Bfor%252BBiologically%252BRelevant%252BHeterocycles%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priyanka  Bose</span>, <span class="hlFld-ContribAuthor ">Anand K.  Agrahari</span>, <span class="hlFld-ContribAuthor ">Sumit K.  Singh</span>, <span class="hlFld-ContribAuthor ">Anoop S.  Singh</span>, <span class="hlFld-ContribAuthor ">Mangal S.  Yadav</span>, <span class="hlFld-ContribAuthor ">Sanchayita  Rajkhowa</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments on ionic liquids-mediated synthetic protocols for biologically relevant five- and six-membered heterocyclic skeletons. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 301-364. <a href="https://doi.org/10.1016/B978-0-12-820792-5.00015-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-820792-5.00015-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820792-5.00015-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820792-5.00015-9%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252Bdevelopments%252Bon%252Bionic%252Bliquids-mediated%252Bsynthetic%252Bprotocols%252Bfor%252Bbiologically%252Brelevant%252Bfive-%252Band%252Bsix-membered%252Bheterocyclic%252Bskeletons%26aulast%3DBose%26aufirst%3DPriyanka%26date%3D2021%26spage%3D301%26epage%3D364%26pub%3DElsevier%26atitle%3DGreen%252BSynthetic%252BApproaches%252Bfor%252BBiologically%252BRelevant%252BHeterocycles%26date%3D2021%26volume%3D1%25E2%2580%259315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingming  Dang</span>, <span class="hlFld-ContribAuthor ">Minhua  Liu</span>, <span class="hlFld-ContribAuthor ">Lu  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Ou</span>, <span class="hlFld-ContribAuthor ">Chuyun  Long</span>, <span class="hlFld-ContribAuthor ">Xingping  Liu</span>, <span class="hlFld-ContribAuthor ">Yeguo  Ren</span>, <span class="hlFld-ContribAuthor ">Ping  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingzhi  Huang</span>, <span class="hlFld-ContribAuthor ">Aiping  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and bioactivities of novel pyridazinone derivatives containing
              2‐phenylthiazole
              or oxazole skeletons. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2020,</strong> <em>57 </em>
                                    (11)
                                     , 4088-4098. <a href="https://doi.org/10.1002/jhet.4118" title="DOI URL">https://doi.org/10.1002/jhet.4118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.4118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.4118%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbioactivities%252Bof%252Bnovel%252Bpyridazinone%252Bderivatives%252Bcontaining%252B2%2525E2%252580%252590phenylthiazole%252Bor%252Boxazole%252Bskeletons%26aulast%3DDang%26aufirst%3DMingming%26date%3D2020%26date%3D2020%26volume%3D57%26issue%3D11%26spage%3D4088%26epage%3D4098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martina  Ferri</span>, <span class="hlFld-ContribAuthor ">Manuel  Alunno</span>, <span class="hlFld-ContribAuthor ">Francesco Antonio  Greco</span>, <span class="hlFld-ContribAuthor ">Andrea  Mammoli</span>, <span class="hlFld-ContribAuthor ">Giorgio  Saluti</span>, <span class="hlFld-ContribAuthor ">Andrea  Carotti</span>, <span class="hlFld-ContribAuthor ">Roccaldo  Sardella</span>, <span class="hlFld-ContribAuthor ">Antonio  Macchiarulo</span>, <span class="hlFld-ContribAuthor ">Emidio  Camaioni</span>, <span class="hlFld-ContribAuthor ">Paride  Liscio</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment based drug design and diversity-oriented synthesis of carboxylic acid isosteres. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (22)
                                     , 115731. <a href="https://doi.org/10.1016/j.bmc.2020.115731" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115731%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DFragment%252Bbased%252Bdrug%252Bdesign%252Band%252Bdiversity-oriented%252Bsynthesis%252Bof%252Bcarboxylic%252Bacid%252Bisosteres%26aulast%3DFerri%26aufirst%3DMartina%26date%3D2020%26volume%3D28%26issue%3D22%26spage%3D115731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ipek  Süntar</span>. </span><span class="cited-content_cbyCitation_article-title">Importance of ethnopharmacological studies in drug discovery: role of medicinal plants. </span><span class="cited-content_cbyCitation_journal-name">Phytochemistry Reviews</span><span> <strong>2020,</strong> <em>19 </em>
                                    (5)
                                     , 1199-1209. <a href="https://doi.org/10.1007/s11101-019-09629-9" title="DOI URL">https://doi.org/10.1007/s11101-019-09629-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11101-019-09629-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11101-019-09629-9%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytochemistry%2520Reviews%26atitle%3DImportance%252Bof%252Bethnopharmacological%252Bstudies%252Bin%252Bdrug%252Bdiscovery%25253A%252Brole%252Bof%252Bmedicinal%252Bplants%26aulast%3DS%25C3%25BCntar%26aufirst%3DIpek%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D5%26spage%3D1199%26epage%3D1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tejas M.  Dhameliya</span>, <span class="hlFld-ContribAuthor ">Hiren A.  Donga</span>, <span class="hlFld-ContribAuthor ">Punit V.  Vaghela</span>, <span class="hlFld-ContribAuthor ">Bhoomi G.  Panchal</span>, <span class="hlFld-ContribAuthor ">Dipen K.  Sureja</span>, <span class="hlFld-ContribAuthor ">Kunjan B.  Bodiwala</span>, <span class="hlFld-ContribAuthor ">Mahesh T.  Chhabria</span>. </span><span class="cited-content_cbyCitation_article-title">A decennary update on applications of metal nanoparticles (MNPs) in the synthesis of nitrogen- and oxygen-containing heterocyclic scaffolds. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (54)
                                     , 32740-32820. <a href="https://doi.org/10.1039/D0RA02272A" title="DOI URL">https://doi.org/10.1039/D0RA02272A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA02272A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA02272A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Bdecennary%252Bupdate%252Bon%252Bapplications%252Bof%252Bmetal%252Bnanoparticles%252B%252528MNPs%252529%252Bin%252Bthe%252Bsynthesis%252Bof%252Bnitrogen-%252Band%252Boxygen-containing%252Bheterocyclic%252Bscaffolds%26aulast%3DDhameliya%26aufirst%3DTejas%2BM.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D54%26spage%3D32740%26epage%3D32820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Issa  Yavari</span>, <span class="hlFld-ContribAuthor ">Zohreh  Taheri</span>, <span class="hlFld-ContribAuthor ">Sara  Sheikhi</span>, <span class="hlFld-ContribAuthor ">Samira  Bahemmat</span>, <span class="hlFld-ContribAuthor ">Mohammad R.  Halvagar</span>. </span><span class="cited-content_cbyCitation_article-title">A synthesis of N-(1H-pyrazol-5-yl)-1,3,4-thiadiazol-2(3H)-imines from nitrile imines and Erlenmeyer thioazlactones. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2020,</strong> <em>24 </em>
                                    (3)
                                     , 727-735. <a href="https://doi.org/10.1007/s11030-019-09981-0" title="DOI URL">https://doi.org/10.1007/s11030-019-09981-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-019-09981-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-019-09981-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DA%252Bsynthesis%252Bof%252BN-%2525281H-pyrazol-5-yl%252529-1%25252C3%25252C4-thiadiazol-2%2525283H%252529-imines%252Bfrom%252Bnitrile%252Bimines%252Band%252BErlenmeyer%252Bthioazlactones%26aulast%3DYavari%26aufirst%3DIssa%26date%3D2020%26date%3D2019%26volume%3D24%26issue%3D3%26spage%3D727%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irina A.  Utepova</span>, <span class="hlFld-ContribAuthor ">Alexey I.  Nemytov</span>, <span class="hlFld-ContribAuthor ">Victoria A.  Ishkhanian</span>, <span class="hlFld-ContribAuthor ">Oleg N.  Chupakhin</span>, <span class="hlFld-ContribAuthor ">Valery N.  Charushin</span>. </span><span class="cited-content_cbyCitation_article-title">Metal-free C–H/C–H coupling of 1,3-diazines and 1,2,4-triazines with 2-naphthols facilitated by Brønsted acids. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (33)
                                     , 131391. <a href="https://doi.org/10.1016/j.tet.2020.131391" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131391%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DMetal-free%252BC%2525E2%252580%252593H%25252FC%2525E2%252580%252593H%252Bcoupling%252Bof%252B1%25252C3-diazines%252Band%252B1%25252C2%25252C4-triazines%252Bwith%252B2-naphthols%252Bfacilitated%252Bby%252BBr%2525C3%2525B8nsted%252Bacids%26aulast%3DUtepova%26aufirst%3DIrina%2BA.%26date%3D2020%26volume%3D76%26issue%3D33%26spage%3D131391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeongseob  Seo</span>, <span class="hlFld-ContribAuthor ">Daegeun  Kim</span>, <span class="hlFld-ContribAuthor ">Haye Min  Ko</span>. </span><span class="cited-content_cbyCitation_article-title">Benzyne‐Induced Ring Opening Reactions of DABCO: Synthesis of 1,4‐Disubstituted Piperazines and Piperidines. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (13)
                                     , 2739-2743. <a href="https://doi.org/10.1002/adsc.202000375" title="DOI URL">https://doi.org/10.1002/adsc.202000375</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000375%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DBenzyne%2525E2%252580%252590Induced%252BRing%252BOpening%252BReactions%252Bof%252BDABCO%25253A%252BSynthesis%252Bof%252B1%25252C4%2525E2%252580%252590Disubstituted%252BPiperazines%252Band%252BPiperidines%26aulast%3DSeo%26aufirst%3DJeongseob%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D13%26spage%3D2739%26epage%3D2743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernhard  Kutscher</span>. </span><span class="cited-content_cbyCitation_article-title">Antithrombotics (
              B01
              ) and Antihemorrhagics (
              B02
              ). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-34. <a href="https://doi.org/10.1002/14356007.w02_w03" title="DOI URL">https://doi.org/10.1002/14356007.w02_w03</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.w02_w03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.w02_w03%26sid%3Dliteratum%253Aachs%26atitle%3DAntithrombotics%252B%252528%252BB01%252B%252529%252Band%252BAntihemorrhagics%252B%252528%252BB02%252B%252529%26aulast%3DKutscher%26aufirst%3DBernhard%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D34%26pub%3DWiley%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Junbiao  Chang</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of Biologically Important Biaryl Scaffolds through Direct C–H Bond Activation: Advances and Prospects. </span><span class="cited-content_cbyCitation_journal-name">Topics in Current Chemistry</span><span> <strong>2020,</strong> <em>378 </em>
                                    (2)
                                     <a href="https://doi.org/10.1007/s41061-020-0285-9" title="DOI URL">https://doi.org/10.1007/s41061-020-0285-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s41061-020-0285-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs41061-020-0285-9%26sid%3Dliteratum%253Aachs%26jtitle%3DTopics%2520in%2520Current%2520Chemistry%26atitle%3DConstruction%252Bof%252BBiologically%252BImportant%252BBiaryl%252BScaffolds%252Bthrough%252BDirect%252BC%2525E2%252580%252593H%252BBond%252BActivation%25253A%252BAdvances%252Band%252BProspects%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26date%3D2020%26volume%3D378%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Venkata Rama Prabhakara Sastry  Regella</span>, <span class="hlFld-ContribAuthor ">Venkatesan Chidambaram  Subramanian</span>, <span class="hlFld-ContribAuthor ">Sarveswara Sastry  Bhetanabhotla</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and structural characterization of four novel degradation products and a process impurity of isavuconazonium sulfate for injection formulation bulk by LC-ESI-QTOF-MS/MS. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Mass Spectrometry</span><span> <strong>2020,</strong> <em>26 </em>
                                    (2)
                                     , 144-152. <a href="https://doi.org/10.1177/1469066719884402" title="DOI URL">https://doi.org/10.1177/1469066719884402</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1469066719884402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1469066719884402%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Mass%2520Spectrometry%26atitle%3DIdentification%252Band%252Bstructural%252Bcharacterization%252Bof%252Bfour%252Bnovel%252Bdegradation%252Bproducts%252Band%252Ba%252Bprocess%252Bimpurity%252Bof%252Bisavuconazonium%252Bsulfate%252Bfor%252Binjection%252Bformulation%252Bbulk%252Bby%252BLC-ESI-QTOF-MS%25252FMS%26aulast%3DRegella%26aufirst%3DVenkata%2BRama%2BPrabhakara%2BSastry%26date%3D2020%26date%3D2019%26volume%3D26%26issue%3D2%26spage%3D144%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaser  Shahbakhsh</span>, <span class="hlFld-ContribAuthor ">Sayyed Mostafa  Habibi-Khorassani</span>, <span class="hlFld-ContribAuthor ">Mehdi  Shahraki</span>. </span><span class="cited-content_cbyCitation_article-title">Experimental and theoretical approaches on the reaction mechanism and kinetics of dimethyl 2-(6-oxopyridazin-1(6H)-yl)fumarate: Micelle and salt effects. </span><span class="cited-content_cbyCitation_journal-name">Phosphorus, Sulfur, and Silicon and the Related Elements</span><span> <strong>2020,</strong> <em>195 </em>
                                    (2)
                                     , 96-106. <a href="https://doi.org/10.1080/10426507.2019.1639702" title="DOI URL">https://doi.org/10.1080/10426507.2019.1639702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10426507.2019.1639702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10426507.2019.1639702%26sid%3Dliteratum%253Aachs%26jtitle%3DPhosphorus%252C%2520Sulfur%252C%2520and%2520Silicon%2520and%2520the%2520Related%2520Elements%26atitle%3DExperimental%252Band%252Btheoretical%252Bapproaches%252Bon%252Bthe%252Breaction%252Bmechanism%252Band%252Bkinetics%252Bof%252Bdimethyl%252B2-%2525286-oxopyridazin-1%2525286H%252529-yl%252529fumarate%25253A%252BMicelle%252Band%252Bsalt%252Beffects%26aulast%3DShahbakhsh%26aufirst%3DYaser%26date%3D2020%26date%3D2019%26volume%3D195%26issue%3D2%26spage%3D96%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James G.  Speight</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmaceuticals. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 553-595. <a href="https://doi.org/10.1016/B978-0-12-809923-0.00013-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-809923-0.00013-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809923-0.00013-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809923-0.00013-8%26sid%3Dliteratum%253Aachs%26atitle%3DPharmaceuticals%26aulast%3DSpeight%26aufirst%3DJames%2BG.%26date%3D2020%26spage%3D553%26epage%3D595%26pub%3DElsevier%26atitle%3DHandbook%252Bof%252BIndustrial%252BHydrocarbon%252BProcesses%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vinod G.  Landge</span>, <span class="hlFld-ContribAuthor ">Michael C.  Young</span>. </span><span class="cited-content_cbyCitation_article-title">Teaching an old ligand new tricks. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (1)
                                     , 12-14. <a href="https://doi.org/10.1038/s41557-019-0395-6" title="DOI URL">https://doi.org/10.1038/s41557-019-0395-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41557-019-0395-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41557-019-0395-6%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemistry%26atitle%3DTeaching%252Ban%252Bold%252Bligand%252Bnew%252Btricks%26aulast%3DLandge%26aufirst%3DVinod%2BG.%26date%3D2020%26date%3D2019%26volume%3D12%26issue%3D1%26spage%3D12%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laila Fathy  Awad</span>, <span class="hlFld-ContribAuthor ">Mohammed Salah  Ayoup</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorinated phenylalanines: synthesis and pharmaceutical applications. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>16 </em>, 1022-1050. <a href="https://doi.org/10.3762/bjoc.16.91" title="DOI URL">https://doi.org/10.3762/bjoc.16.91</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.16.91&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.16.91%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DFluorinated%252Bphenylalanines%25253A%252Bsynthesis%252Band%252Bpharmaceutical%252Bapplications%26aulast%3DAwad%26aufirst%3DLaila%2BFathy%26date%3D2020%26date%3D2020%26volume%3D16%26spage%3D1022%26epage%3D1050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renzo  Rossi</span>, <span class="hlFld-ContribAuthor ">Maurizio  Ciofalo</span>. </span><span class="cited-content_cbyCitation_article-title">Current Advances in the Synthesis and Biological Evaluation of Pharmacologically Relevant 1,2,4,5-Tetrasubstituted-1H-Imidazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2019,</strong> <em>23 </em>
                                    (19)
                                     , 2016-2101. <a href="https://doi.org/10.2174/1385272823666191014154129" title="DOI URL">https://doi.org/10.2174/1385272823666191014154129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272823666191014154129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272823666191014154129%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DCurrent%252BAdvances%252Bin%252Bthe%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BPharmacologically%252BRelevant%252B1%25252C2%25252C4%25252C5-Tetrasubstituted-1H-Imidazole%252BDerivatives%26aulast%3DRossi%26aufirst%3DRenzo%26date%3D2019%26volume%3D23%26issue%3D19%26spage%3D2016%26epage%3D2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shoji  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Tomoki  Tamura</span>, <span class="hlFld-ContribAuthor ">Saki  Yoshimoto</span>, <span class="hlFld-ContribAuthor ">Takashi  Kawakami</span>, <span class="hlFld-ContribAuthor ">Araki  Masuyama</span>. </span><span class="cited-content_cbyCitation_article-title">4‐Methyltetrahydropyran (4‐MeTHP): Application as an Organic Reaction Solvent. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – An Asian Journal</span><span> <strong>2019,</strong> <em>14 </em>
                                    (21)
                                     , 3921-3937. <a href="https://doi.org/10.1002/asia.201901169" title="DOI URL">https://doi.org/10.1002/asia.201901169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.201901169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.201901169%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520An%2520Asian%2520Journal%26atitle%3D4%2525E2%252580%252590Methyltetrahydropyran%252B%2525284%2525E2%252580%252590MeTHP%252529%25253A%252BApplication%252Bas%252Ban%252BOrganic%252BReaction%252BSolvent%26aulast%3DKobayashi%26aufirst%3DShoji%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D21%26spage%3D3921%26epage%3D3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei-Yi  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Bing  Lan</span>, <span class="hlFld-ContribAuthor ">Chang  Xu</span>, <span class="hlFld-ContribAuthor ">Hua-Gang  Yao</span>, <span class="hlFld-ContribAuthor ">Tian  Li</span>, <span class="hlFld-ContribAuthor ">Feng-Shou  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Rigid hindered N-heterocyclic carbene palladium precatalysts: synthesis, characterization and catalytic amination. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (18)
                                     , 3292-3299. <a href="https://doi.org/10.1039/C9QO00726A" title="DOI URL">https://doi.org/10.1039/C9QO00726A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO00726A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO00726A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DRigid%252Bhindered%252BN-heterocyclic%252Bcarbene%252Bpalladium%252Bprecatalysts%25253A%252Bsynthesis%25252C%252Bcharacterization%252Band%252Bcatalytic%252Bamination%26aulast%3DZhang%26aufirst%3DFei-Yi%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D18%26spage%3D3292%26epage%3D3299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virendra  Prasad</span>, <span class="hlFld-ContribAuthor ">Nidhi  Mishra</span>, <span class="hlFld-ContribAuthor ">Anand K.  Agrahari</span>, <span class="hlFld-ContribAuthor ">Sumit K.  Singh</span>, <span class="hlFld-ContribAuthor ">Prabhu P.  Mohapatra</span>, <span class="hlFld-ContribAuthor ">Vinod K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">Cycloelimination-assisted Combinatorial Synthesis of Diverse Heterocyclic Scaffolds of Chemotherapeutic Values. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2019,</strong> <em>23 </em>
                                    (7)
                                     , 768-808. <a href="https://doi.org/10.2174/1385272823666190405145805" title="DOI URL">https://doi.org/10.2174/1385272823666190405145805</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272823666190405145805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272823666190405145805%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DCycloelimination-assisted%252BCombinatorial%252BSynthesis%252Bof%252BDiverse%252BHeterocyclic%252BScaffolds%252Bof%252BChemotherapeutic%252BValues%26aulast%3DPrasad%26aufirst%3DVirendra%26date%3D2019%26volume%3D23%26issue%3D7%26spage%3D768%26epage%3D808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linlin  Shi</span>, <span class="hlFld-ContribAuthor ">Yingdong  He</span>, <span class="hlFld-ContribAuthor ">Jianxian  Gong</span>, <span class="hlFld-ContribAuthor ">Zhen  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Pd‐Catalyzed Decarboxylative Allylation for Stereoselective Syntheses of Allylic Alcohols bearing a Quaternary Carbon Center. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>8 </em>
                                    (6)
                                     , 823-827. <a href="https://doi.org/10.1002/ajoc.201900208" title="DOI URL">https://doi.org/10.1002/ajoc.201900208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201900208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201900208%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPd%2525E2%252580%252590Catalyzed%252BDecarboxylative%252BAllylation%252Bfor%252BStereoselective%252BSyntheses%252Bof%252BAllylic%252BAlcohols%252Bbearing%252Ba%252BQuaternary%252BCarbon%252BCenter%26aulast%3DShi%26aufirst%3DLinlin%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D6%26spage%3D823%26epage%3D827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amina  Asghar</span>, <span class="hlFld-ContribAuthor ">Muhammad  Yousuf</span>, <span class="hlFld-ContribAuthor ">Hifsa  Mubeen</span>, <span class="hlFld-ContribAuthor ">Rabia  Nazir</span>, <span class="hlFld-ContribAuthor ">Kabiru  Haruna</span>, <span class="hlFld-ContribAuthor ">Abdulmujeeb T.  Onawole</span>, <span class="hlFld-ContribAuthor ">Lubna  Rasheed</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, spectroscopic characterization, molecular docking and theoretical studies (DFT) of N-(4-aminophenylsulfonyl)-2-(4-isobutylphenyl) propanamide having potential enzyme inhibition applications. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (12)
                                     , 2397-2404. <a href="https://doi.org/10.1016/j.bmc.2019.01.012" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.01.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.01.012%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bspectroscopic%252Bcharacterization%25252C%252Bmolecular%252Bdocking%252Band%252Btheoretical%252Bstudies%252B%252528DFT%252529%252Bof%252BN-%2525284-aminophenylsulfonyl%252529-2-%2525284-isobutylphenyl%252529%252Bpropanamide%252Bhaving%252Bpotential%252Benzyme%252Binhibition%252Bapplications%26aulast%3DAsghar%26aufirst%3DAmina%26date%3D2019%26volume%3D27%26issue%3D12%26spage%3D2397%26epage%3D2404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wael Abdelgayed Ahmed  Arafa</span>, <span class="hlFld-ContribAuthor ">Hamada Mohamed  Ibrahim</span>. </span><span class="cited-content_cbyCitation_article-title">Sustainable and scalable synthesis of polysubstituted bis-1,2,4-triazoles, bis-2-iminothiazolines and bis-thiobarbiturates using bis-
              N
              ,
              N
              -disubstituted thioureas as versatile substrate. </span><span class="cited-content_cbyCitation_journal-name">Royal Society Open Science</span><span> <strong>2019,</strong> <em>6 </em>
                                    (6)
                                     , 181963. <a href="https://doi.org/10.1098/rsos.181963" title="DOI URL">https://doi.org/10.1098/rsos.181963</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1098/rsos.181963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1098%2Frsos.181963%26sid%3Dliteratum%253Aachs%26jtitle%3DRoyal%2520Society%2520Open%2520Science%26atitle%3DSustainable%252Band%252Bscalable%252Bsynthesis%252Bof%252Bpolysubstituted%252Bbis-1%25252C2%25252C4-triazoles%25252C%252Bbis-2-iminothiazolines%252Band%252Bbis-thiobarbiturates%252Busing%252Bbis-%252BN%252B%25252C%252BN%252B-disubstituted%252Bthioureas%252Bas%252Bversatile%252Bsubstrate%26aulast%3DArafa%26aufirst%3DWael%2BAbdelgayed%2BAhmed%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D6%26spage%3D181963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Péter  Bana</span>, <span class="hlFld-ContribAuthor ">Áron  Szigetvári</span>, <span class="hlFld-ContribAuthor ">János  Kóti</span>, <span class="hlFld-ContribAuthor ">János  Éles</span>, <span class="hlFld-ContribAuthor ">István  Greiner</span>. </span><span class="cited-content_cbyCitation_article-title">Flow-oriented synthetic design in the continuous preparation of the aryl piperazine drug flibanserin. </span><span class="cited-content_cbyCitation_journal-name">Reaction Chemistry & Engineering</span><span> <strong>2019,</strong> <em>4 </em>
                                    (4)
                                     , 652-657. <a href="https://doi.org/10.1039/C8RE00266E" title="DOI URL">https://doi.org/10.1039/C8RE00266E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RE00266E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RE00266E%26sid%3Dliteratum%253Aachs%26jtitle%3DReaction%2520Chemistry%2520%2526%2520Engineering%26atitle%3DFlow-oriented%252Bsynthetic%252Bdesign%252Bin%252Bthe%252Bcontinuous%252Bpreparation%252Bof%252Bthe%252Baryl%252Bpiperazine%252Bdrug%252Bflibanserin%26aulast%3DBana%26aufirst%3DP%25C3%25A9ter%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D4%26spage%3D652%26epage%3D657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandra A.  Ageshina</span>, <span class="hlFld-ContribAuthor ">Grigorii K.  Sterligov</span>, <span class="hlFld-ContribAuthor ">Sergey A.  Rzhevskiy</span>, <span class="hlFld-ContribAuthor ">Maxim A.  Topchiy</span>, <span class="hlFld-ContribAuthor ">Gleb A.  Chesnokov</span>, <span class="hlFld-ContribAuthor ">Pavel S.  Gribanov</span>, <span class="hlFld-ContribAuthor ">Elizaveta K.  Melnikova</span>, <span class="hlFld-ContribAuthor ">Mikhail S.  Nechaev</span>, <span class="hlFld-ContribAuthor ">Andrey F.  Asachenko</span>, <span class="hlFld-ContribAuthor ">Maxim V.  Bermeshev</span>. </span><span class="cited-content_cbyCitation_article-title">Mixed er-NHC/phosphine Pd(
              ii
              ) complexes and their catalytic activity in the Buchwald–Hartwig reaction under solvent-free conditions. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2019,</strong> <em>48 </em>
                                    (10)
                                     , 3447-3452. <a href="https://doi.org/10.1039/C9DT00216B" title="DOI URL">https://doi.org/10.1039/C9DT00216B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9DT00216B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9DT00216B%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DMixed%252Ber-NHC%25252Fphosphine%252BPd%252528%252Bii%252B%252529%252Bcomplexes%252Band%252Btheir%252Bcatalytic%252Bactivity%252Bin%252Bthe%252BBuchwald%2525E2%252580%252593Hartwig%252Breaction%252Bunder%252Bsolvent-free%252Bconditions%26aulast%3DAgeshina%26aufirst%3DAlexandra%2BA.%26date%3D2019%26date%3D2019%26volume%3D48%26issue%3D10%26spage%3D3447%26epage%3D3452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belen’kii</span>, <span class="hlFld-ContribAuthor ">Yulia. B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The literature of heterocyclic chemistry, part XVII, 2017. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 337-418. <a href="https://doi.org/10.1016/bs.aihch.2019.01.003" title="DOI URL">https://doi.org/10.1016/bs.aihch.2019.01.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2019.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2019.01.003%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252Bliterature%252Bof%252Bheterocyclic%252Bchemistry%25252C%252Bpart%252BXVII%25252C%252B2017%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DLeonid%2BI.%26date%3D2019%26spage%3D337%26epage%3D418%26pub%3DElsevier%26date%3D2019%26volume%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Su</span>, <span class="hlFld-ContribAuthor ">Li  Han</span>, <span class="hlFld-ContribAuthor ">Xueshi  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Potential targets for the development of new antifungal drugs. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Antibiotics</span><span> <strong>2018,</strong> <em>71 </em>
                                    (12)
                                     , 978-991. <a href="https://doi.org/10.1038/s41429-018-0100-9" title="DOI URL">https://doi.org/10.1038/s41429-018-0100-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41429-018-0100-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41429-018-0100-9%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Antibiotics%26atitle%3DPotential%252Btargets%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bnew%252Bantifungal%252Bdrugs%26aulast%3DSu%26aufirst%3DHao%26date%3D2018%26date%3D2018%26volume%3D71%26issue%3D12%26spage%3D978%26epage%3D991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hisae  Nishioka</span>, <span class="hlFld-ContribAuthor ">Akihiro  Nagahama</span>, <span class="hlFld-ContribAuthor ">Yasuhide  Inoue</span>, <span class="hlFld-ContribAuthor ">Akifumi  Hagi</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of fast-acting bactericidal activity and substantivity of an antiseptic agent, olanexidine gluconate, using an ex vivo skin model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medical Microbiology</span><span> <strong>2018,</strong> <em>67 </em>
                                    (12)
                                     , 1796-1803. <a href="https://doi.org/10.1099/jmm.0.000870" title="DOI URL">https://doi.org/10.1099/jmm.0.000870</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1099/jmm.0.000870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1099%2Fjmm.0.000870%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medical%2520Microbiology%26atitle%3DEvaluation%252Bof%252Bfast-acting%252Bbactericidal%252Bactivity%252Band%252Bsubstantivity%252Bof%252Ban%252Bantiseptic%252Bagent%25252C%252Bolanexidine%252Bgluconate%25252C%252Busing%252Ban%252Bex%252Bvivo%252Bskin%252Bmodel%26aulast%3DNishioka%26aufirst%3DHisae%26date%3D2018%26volume%3D67%26issue%3D12%26spage%3D1796%26epage%3D1803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiquan  Liu</span>, <span class="hlFld-ContribAuthor ">Yeping  Xu</span>, <span class="hlFld-ContribAuthor ">Pedro B.  Groszewicz</span>, <span class="hlFld-ContribAuthor ">Martin  Brodrecht</span>, <span class="hlFld-ContribAuthor ">Claudia  Fasel</span>, <span class="hlFld-ContribAuthor ">Kathrin  Hofmann</span>, <span class="hlFld-ContribAuthor ">Xijuan  Tan</span>, <span class="hlFld-ContribAuthor ">Torsten  Gutmann</span>, <span class="hlFld-ContribAuthor ">Gerd  Buntkowsky</span>. </span><span class="cited-content_cbyCitation_article-title">Novel dirhodium coordination polymers: the impact of side chains on cyclopropanation. </span><span class="cited-content_cbyCitation_journal-name">Catalysis Science & Technology</span><span> <strong>2018,</strong> <em>8 </em>
                                    (20)
                                     , 5190-5200. <a href="https://doi.org/10.1039/C8CY01493K" title="DOI URL">https://doi.org/10.1039/C8CY01493K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8CY01493K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8CY01493K%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysis%2520Science%2520%2526%2520Technology%26atitle%3DNovel%252Bdirhodium%252Bcoordination%252Bpolymers%25253A%252Bthe%252Bimpact%252Bof%252Bside%252Bchains%252Bon%252Bcyclopropanation%26aulast%3DLiu%26aufirst%3DJiquan%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D20%26spage%3D5190%26epage%3D5200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulio  Bertuzzi</span>, <span class="hlFld-ContribAuthor ">Simone  Crotti</span>, <span class="hlFld-ContribAuthor ">Pierpaolo  Calandro</span>, <span class="hlFld-ContribAuthor ">Bianca Flavia  Bonini</span>, <span class="hlFld-ContribAuthor ">Ilaria  Monaco</span>, <span class="hlFld-ContribAuthor ">Erica  Locatelli</span>, <span class="hlFld-ContribAuthor ">Mariafrancesca  Fochi</span>, <span class="hlFld-ContribAuthor ">Paolo  Zani</span>, <span class="hlFld-ContribAuthor ">Elena  Strocchi</span>, <span class="hlFld-ContribAuthor ">Andrea  Mazzanti</span>, <span class="hlFld-ContribAuthor ">Mario  Chiariello</span>, <span class="hlFld-ContribAuthor ">Mauro Comes  Franchini</span>. </span><span class="cited-content_cbyCitation_article-title">Quinone-Fused Pyrazoles through 1,3-Dipolar Cycloadditions: Synthesis of Tricyclic Scaffolds and in vitro Cytotoxic Activity Evaluation on Glioblastoma Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (17)
                                     , 1744-1750. <a href="https://doi.org/10.1002/cmdc.201800251" title="DOI URL">https://doi.org/10.1002/cmdc.201800251</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800251%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DQuinone-Fused%252BPyrazoles%252Bthrough%252B1%25252C3-Dipolar%252BCycloadditions%25253A%252BSynthesis%252Bof%252BTricyclic%252BScaffolds%252Band%252Bin%252Bvitro%252BCytotoxic%252BActivity%252BEvaluation%252Bon%252BGlioblastoma%252BCancer%252BCells%26aulast%3DBertuzzi%26aufirst%3DGiulio%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D17%26spage%3D1744%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A Sravanth  Kumar</span>, <span class="hlFld-ContribAuthor ">Sai Giridhar Sarma  Kandanur</span>, <span class="hlFld-ContribAuthor ">Saikat  Sen</span>, <span class="hlFld-ContribAuthor ">Srinivas  Oruganti</span>. </span><span class="cited-content_cbyCitation_article-title">Delineating an alternate convergent synthesis of brexpiprazole: a novel use of commercial 6,7-dihydrobenzo[b]thiophen-4(5H)-one as precursor to an efficacious Buchwald–Hartwig amination step. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Sciences</span><span> <strong>2018,</strong> <em>130 </em>
                                    (6)
                                     <a href="https://doi.org/10.1007/s12039-018-1470-z" title="DOI URL">https://doi.org/10.1007/s12039-018-1470-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12039-018-1470-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12039-018-1470-z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Sciences%26atitle%3DDelineating%252Ban%252Balternate%252Bconvergent%252Bsynthesis%252Bof%252Bbrexpiprazole%25253A%252Ba%252Bnovel%252Buse%252Bof%252Bcommercial%252B6%25252C7-dihydrobenzo%25255Bb%25255Dthiophen-4%2525285H%252529-one%252Bas%252Bprecursor%252Bto%252Ban%252Befficacious%252BBuchwald%2525E2%252580%252593Hartwig%252Bamination%252Bstep%26aulast%3DKumar%26aufirst%3DA%2BSravanth%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiwei  Wang</span>, <span class="hlFld-ContribAuthor ">Chen  Ma</span>, <span class="hlFld-ContribAuthor ">Xueyan  Li</span>, <span class="hlFld-ContribAuthor ">Xiaofen  Wang</span>, <span class="hlFld-ContribAuthor ">Ruixue  Rong</span>, <span class="hlFld-ContribAuthor ">Chao  Wei</span>, <span class="hlFld-ContribAuthor ">Pingzhu  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoliu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of novel sugar or azasugar modified anthra[1,2- d ] imidazole-6,11-dione derivatives and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Carbohydrate Research</span><span> <strong>2018,</strong> <em>460 </em>, 29-33. <a href="https://doi.org/10.1016/j.carres.2018.02.012" title="DOI URL">https://doi.org/10.1016/j.carres.2018.02.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.carres.2018.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.carres.2018.02.012%26sid%3Dliteratum%253Aachs%26jtitle%3DCarbohydrate%2520Research%26atitle%3DSynthesis%252Bof%252Bnovel%252Bsugar%252Bor%252Bazasugar%252Bmodified%252Banthra%25255B1%25252C2-%252Bd%252B%25255D%252Bimidazole-6%25252C11-dione%252Bderivatives%252Band%252Bbiological%252Bevaluation%26aulast%3DWang%26aufirst%3DQiwei%26date%3D2018%26volume%3D460%26spage%3D29%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David C.  Blakemore</span>, <span class="hlFld-ContribAuthor ">Luis  Castro</span>, <span class="hlFld-ContribAuthor ">Ian  Churcher</span>, <span class="hlFld-ContribAuthor ">David C.  Rees</span>, <span class="hlFld-ContribAuthor ">Andrew W.  Thomas</span>, <span class="hlFld-ContribAuthor ">David M.  Wilson</span>, <span class="hlFld-ContribAuthor ">Anthony  Wood</span>. </span><span class="cited-content_cbyCitation_article-title">Organic synthesis provides opportunities to transform drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (4)
                                     , 383-394. <a href="https://doi.org/10.1038/s41557-018-0021-z" title="DOI URL">https://doi.org/10.1038/s41557-018-0021-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41557-018-0021-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41557-018-0021-z%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemistry%26atitle%3DOrganic%252Bsynthesis%252Bprovides%252Bopportunities%252Bto%252Btransform%252Bdrug%252Bdiscovery%26aulast%3DBlakemore%26aufirst%3DDavid%2BC.%26date%3D2018%26date%3D2018%26volume%3D10%26issue%3D4%26spage%3D383%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandip Gangadhar  Balwe</span>, <span class="hlFld-ContribAuthor ">Yeon Tae  Jeong</span>. </span><span class="cited-content_cbyCitation_article-title">An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds
              via
              GBB reaction. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (8)
                                     , 1287-1296. <a href="https://doi.org/10.1039/C7OB02933K" title="DOI URL">https://doi.org/10.1039/C7OB02933K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB02933K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB02933K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DAn%252Bapproach%252Btowards%252Bthe%252Bsynthesis%252Bof%252Bnovel%252Bfused%252Bnitrogen%252Btricyclic%252Bheterocyclic%252Bscaffolds%252Bvia%252BGBB%252Breaction%26aulast%3DBalwe%26aufirst%3DSandip%2BGangadhar%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D8%26spage%3D1287%26epage%3D1296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandip Gangadhar  Balwe</span>, <span class="hlFld-ContribAuthor ">Yeon Tae  Jeong</span>. </span><span class="cited-content_cbyCitation_article-title">One-step construction of complex polyheterocycles
              via
              a sequential post-GBB cyclization/spiro ring expansion triggered by a [1,5]-hydride shift. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2018,</strong> <em>5 </em>
                                    (10)
                                     , 1628-1632. <a href="https://doi.org/10.1039/C8QO00071A" title="DOI URL">https://doi.org/10.1039/C8QO00071A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8QO00071A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8QO00071A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DOne-step%252Bconstruction%252Bof%252Bcomplex%252Bpolyheterocycles%252Bvia%252Ba%252Bsequential%252Bpost-GBB%252Bcyclization%25252Fspiro%252Bring%252Bexpansion%252Btriggered%252Bby%252Ba%252B%25255B1%25252C5%25255D-hydride%252Bshift%26aulast%3DBalwe%26aufirst%3DSandip%2BGangadhar%26date%3D2018%26date%3D2018%26volume%3D5%26issue%3D10%26spage%3D1628%26epage%3D1632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">JULIANA M. DE  SOUZA</span>, <span class="hlFld-ContribAuthor ">RENAN  GALAVERNA</span>, <span class="hlFld-ContribAuthor ">ALINE A.N. DE  SOUZA</span>, <span class="hlFld-ContribAuthor ">TIMOTHY J.  BROCKSOM</span>, <span class="hlFld-ContribAuthor ">JULIO C.  PASTRE</span>, <span class="hlFld-ContribAuthor ">RODRIGO O.M.A. DE  SOUZA</span>, <span class="hlFld-ContribAuthor ">KLEBER T. DE  OLIVEIRA</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of continuous flow chemistry in the synthesis of natural products and active pharmaceutical ingredients. </span><span class="cited-content_cbyCitation_journal-name">Anais da Academia Brasileira de Ciências</span><span> <strong>2018,</strong> <em>90 </em>
                                    (1 suppl 2)
                                     , 1131-1174. <a href="https://doi.org/10.1590/0001-3765201820170778" title="DOI URL">https://doi.org/10.1590/0001-3765201820170778</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1590/0001-3765201820170778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1590%2F0001-3765201820170778%26sid%3Dliteratum%253Aachs%26jtitle%3DAnais%2520da%2520Academia%2520Brasileira%2520de%2520Ci%25C3%25AAncias%26atitle%3DImpact%252Bof%252Bcontinuous%252Bflow%252Bchemistry%252Bin%252Bthe%252Bsynthesis%252Bof%252Bnatural%252Bproducts%252Band%252Bactive%252Bpharmaceutical%252Bingredients%26aulast%3DSOUZA%26aufirst%3DJULIANA%2BM.%2BDE%26date%3D2018%26date%3D2018%26volume%3D90%26issue%3D1%2520suppl%25202%26spage%3D1131%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mariana C. F. C. B.  Damião</span>, <span class="hlFld-ContribAuthor ">Renan  Galaverna</span>, <span class="hlFld-ContribAuthor ">Alan P.  Kozikowski</span>, <span class="hlFld-ContribAuthor ">James  Eubanks</span>, <span class="hlFld-ContribAuthor ">Julio C.  Pastre</span>. </span><span class="cited-content_cbyCitation_article-title">Telescoped continuous flow generation of a library of highly substituted 3-thio-1,2,4-triazoles. </span><span class="cited-content_cbyCitation_journal-name">Reaction Chemistry & Engineering</span><span> <strong>2017,</strong> <em>2 </em>
                                    (6)
                                     , 896-907. <a href="https://doi.org/10.1039/C7RE00125H" title="DOI URL">https://doi.org/10.1039/C7RE00125H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RE00125H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RE00125H%26sid%3Dliteratum%253Aachs%26jtitle%3DReaction%2520Chemistry%2520%2526%2520Engineering%26atitle%3DTelescoped%252Bcontinuous%252Bflow%252Bgeneration%252Bof%252Ba%252Blibrary%252Bof%252Bhighly%252Bsubstituted%252B3-thio-1%25252C2%25252C4-triazoles%26aulast%3DDami%25C3%25A3o%26aufirst%3DMariana%2BC.%2BF.%2BC.%2BB.%26date%3D2017%26date%3D2017%26volume%3D2%26issue%3D6%26spage%3D896%26epage%3D907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0044.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0001.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of 29 NCEs approved in 2015.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Fragment <b>8</b> of Isavuconazonium Sulfate (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Isavuconazonium Sulfate (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Olanexidine Gluconate (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Ozenoxacin (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Fragment <b>27</b> of Ozenoxacin (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Cangrelor Tetrasodium (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Sacubitril (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Selexipag (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Aripiprazole Lauroxil (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Piperazinyl Fragment <b>65</b> of Brexpiprazole (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Brexpiprazole (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Cariprazine Hydrochloride (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Flibanserin (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of Safinamide Methanesulfonate (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Synthesis of Eluxadoline Intermediate <b>85</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Eluxadoline (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Rolapitant Hydrochloride Hydrate (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Fragment <b>92</b> of Rolapitant Hydrochloride Hydrate (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0020.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Fragment <b>94</b> of Rolapitant Hydrochloride Hydrate (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0021.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Lusutrombopag (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Preparation of Lusutrombopag Intermediate <b>113</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0023.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Deoxycholic Acid (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0024.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Evogliptin Piperazone <b>125</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0025.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Synthesis of Evogliptin Fragment <b>136</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch25" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0026.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Evogliptin (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch26" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0027.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Lesinurad (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch27" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0028.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Fragment <b>147</b> of Omarigliptin (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch28" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0029.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Synthesis of Fragment <b>148</b> of Omarigliptin (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch29" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0030.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Omarigliptin (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch30" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0031.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Trelagliptin Succinate (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch31" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0032.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Synthesis of Uridine Triacetate (<b>XX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch32" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0033.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Esflurbiprofen (<b>XXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch33" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0034.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Polmacoxib (<b>XXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch34" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0035.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Cobimetinib (<b>XXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch35" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0036.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Ixazomib Citrate (<b>XXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch36" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0037.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 36. Synthesis of Fragment <b>198</b> of Lenvatinib (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch37" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0038.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 37. Synthesis of Lenvatinib Mesylate (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch38" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Scheme 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0039.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 38. Synthesis of Osimertinib Mesylate (<b>XXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch39" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0040.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 39. Synthesis of Fragment <b>212</b> of Palbociclib (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch40" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0041.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 40. Synthesis of Palbociclib (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch41" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Scheme 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0042.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 41. Synthesis of Panobinostat Lactate (<b>XXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch42" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/medium/jm-2017-00010w_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0043.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 42. Synthesis of Sonidegib Phosphate (<b>XXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-15/acs.jmedchem.7b00010/20170804/images/large/jm-2017-00010w_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00010&amp;id=sch42"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i92">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80218" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80218" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 163 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Raju, T. N. K.</span><span> </span><span class="NLM_article-title">The Nobel Chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918–99), and George H Hitchings (1905–98)</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="refDoi"> DOI: 10.1016/S0140-6736(05)74775-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0140-6736%2805%2974775-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10768469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2000&pages=1022&author=T.+N.+K.+Raju&title=The+Nobel+Chronicles.+1988%3A+James+Whyte+Black%2C+%28b+1924%29%2C+Gertrude+Elion+%281918%E2%80%9399%29%2C+and+George+H+Hitchings+%281905%E2%80%9398%29&doi=10.1016%2FS0140-6736%2805%2974775-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98)</span></div><div class="casAuthors">Raju T N</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">9208</span>),
    <span class="NLM_cas:pages">1022</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTWLVzWjiD66qcneEtCi92fW6udTcc2eYmW3HzFiKhQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ivV2mtA%253D%253D&md5=c89d64b40317d0d0cb4a76c1cceecb58</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2974775-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252974775-9%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DT.%2BN.%2BK.%26atitle%3DThe%2520Nobel%2520Chronicles.%25201988%253A%2520James%2520Whyte%2520Black%252C%2520%2528b%25201924%2529%252C%2520Gertrude%2520Elion%2520%25281918%25E2%2580%259399%2529%252C%2520and%2520George%2520H%2520Hitchings%2520%25281905%25E2%2580%259398%2529%26jtitle%3DLancet%26date%3D2000%26volume%3D355%26spage%3D1022%26doi%3D10.1016%2FS0140-6736%2805%2974775-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">207</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span><span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0lg1aUXlPWlYeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1105</span><span class="NLM_x">–</span> <span class="NLM_lpage">1125</span><span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0lg1aUXlPWlYeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1144</span><span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.-C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0lg1aUXlPWlYeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.-C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2dR"><div class="casContent"><span class="casTitleNuber">2d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0lhD_EQHznYgwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit2d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1255</span><span class="NLM_x">–</span> <span class="NLM_lpage">1269</span><span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2eR"><div class="casContent"><span class="casTitleNuber">2e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0lhD_EQHznYgwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit2e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1526</span><span class="NLM_x">–</span> <span class="NLM_lpage">1548</span><span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2fR"><div class="casContent"><span class="casTitleNuber">2f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0lhD_EQHznYgwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit2f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span> <span class="citation_source-journal">Mini-Rev. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1675</span><span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2gR"><div class="casContent"><span class="casTitleNuber">2g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0lj5TKtyLT7GKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit2g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1136</span><span class="NLM_x">–</span> <span class="NLM_lpage">1154</span><span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2hR"><div class="casContent"><span class="casTitleNuber">2h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0lj5TKtyLT7GKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit2h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Liu, K. K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H. X.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1155</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span><span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2iR"><div class="casContent"><span class="casTitleNuber">2i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0lguH1RmLLeHLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit2i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Ding, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2795</span><span class="NLM_x">–</span> <span class="NLM_lpage">2825</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2jR"><div class="casContent"><span class="casTitleNuber">2j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0libjfbgpual5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit2j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2k"><span><span class="NLM_label">(k) </span><span class="NLM_contrib-group">Ding, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverett, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyne, R. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakya, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2kR"><div class="casContent"><span class="casTitleNuber">2k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0libjfbgpual5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit2k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2l"><span><span class="NLM_label">(l) </span><span class="NLM_contrib-group">Ding, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverett, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyne, R. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">–</span> <span class="NLM_lpage">1922</span><span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2lR"><div class="casContent"><span class="casTitleNuber">2l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0lhXwNZ4z2n74w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit2l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2m"><span><span class="NLM_label">(m) </span><span class="NLM_contrib-group">Flick, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leverett, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyne, R. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1937</span><span class="NLM_x">–</span> <span class="NLM_lpage">1980</span><span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2mR"><div class="casContent"><span class="casTitleNuber">2m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0lhXwNZ4z2n74w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit2m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Graul, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruces, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stringer, M.</span><span> </span><span class="NLM_article-title">The Year’s New Drugs & Biologics 2015: Part I</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span><span class="refDoi"> DOI: 10.1358/dot.2016.52.1.2450695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdot.2016.52.1.2450695" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28jmtlOltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=41-89&author=A.+I.+Graulauthor=E.+Crucesauthor=M.+Stringer&title=The+Year%E2%80%99s+New+Drugs+%26+Biologics+2015%3A+Part+I&doi=10.1358%2Fdot.2016.52.1.2450695"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The year's new drugs & biologics 2015: Part I</span></div><div class="casAuthors">Graul A I; Cruces E; Stringer M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-89</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Nearly 100 new drugs and biologics, including important new line extensions, were approved or launched for the first time globally in 2015.  These products are covered in depth in part I of our annual review of the pharma and biotech industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxaB4yODpzB-2qxNLjzXe8fW6udTcc2ebloF3oaxVE27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jmtlOltw%253D%253D&md5=8f62729c75f647fc793c11b8a851f4d2</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.1.2450695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.1.2450695%26sid%3Dliteratum%253Aachs%26aulast%3DGraul%26aufirst%3DA.%2BI.%26aulast%3DCruces%26aufirst%3DE.%26aulast%3DStringer%26aufirst%3DM.%26atitle%3DThe%2520Year%25E2%2580%2599s%2520New%2520Drugs%2520%2526%2520Biologics%25202015%253A%2520Part%2520I%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D41%26epage%3D89%26doi%3D10.1358%2Fdot.2016.52.1.2450695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Isavuconazonium: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">822</span><span class="refDoi"> DOI: 10.1007/s40265-015-0398-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0398-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=817-822&author=P.+L.+McCormack&title=Isavuconazonium%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0398-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0398-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0398-6%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DIsavuconazonium%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D817%26epage%3D822%26doi%3D10.1007%2Fs40265-015-0398-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Miceli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, C. A.</span><span> </span><span class="NLM_article-title">Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1558</span><span class="NLM_x">–</span> <span class="NLM_lpage">1565</span><span class="refDoi"> DOI: 10.1093/cid/civ571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1093%2Fcid%2Fciv571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26179012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFWlsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1558-1565&author=M.+H.+Miceliauthor=C.+A.+Kauffman&title=Isavuconazole%3A+A+New+Broad-Spectrum+Triazole+Antifungal+Agent&doi=10.1093%2Fcid%2Fciv571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Isavuconazole: a new broad-spectrum triazole antifungal agent</span></div><div class="casAuthors">Miceli, Marisa H.; Kauffman, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1558-1565</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi.  It is approved for the treatment of invasive aspergillosis and mucormycosis.  Advantages of this triazole include the availability of a water-sol. i.v. formulation, excellent bioavailability of the oral formulation, and predictable pharmacokinetics in adults.  A randomized, double-blind comparison clin. trial for treatment of invasive aspergillosis found that the efficacy of isavuconazole was noninferior to that of voriconazole.  An open-label trial that studied primary as well as salvage therapy of invasive mucormycosis showed efficacy with isavuconazole that was similar to that reported for amphotericin B and posaconazole.  In patients in these studies, as well as in normal volunteers, isavuconazole was well tolerated, appeared to have few serious adverse effects, and had fewer drug-drug interactions than those noted with voriconazole.  As clin. experience increases, the role of this new triazole in the treatment of invasive fungal infections will be better defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2EPvD5rxahLVg90H21EOLACvtfcHk0ljRRRTN9yZeNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFWlsLbF&md5=3f0ac85777dc13de0b401fc7235c1e21</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciv571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciv571%26sid%3Dliteratum%253Aachs%26aulast%3DMiceli%26aufirst%3DM.%2BH.%26aulast%3DKauffman%26aufirst%3DC.%2BA.%26atitle%3DIsavuconazole%253A%2520A%2520New%2520Broad-Spectrum%2520Triazole%2520Antifungal%2520Agent%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D61%26spage%3D1558%26epage%3D1565%26doi%3D10.1093%2Fcid%2Fciv571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Murrell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossaer, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carico, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harirforoosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cluck, D.</span><span> </span><span class="NLM_article-title">Isavuconazonium Sulfate: a Triazole Prodrug for Invasive Fungal Infections</span> <span class="citation_source-journal">Int. J. Pharm. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="refDoi"> DOI: 10.1111/ijpp.12302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fijpp.12302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27569742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC2szltVahtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=18&author=D.+Murrellauthor=J.+B.+Bossaerauthor=R.+Caricoauthor=S.+Harirforooshauthor=D.+Cluck&title=Isavuconazonium+Sulfate%3A+a+Triazole+Prodrug+for+Invasive+Fungal+Infections&doi=10.1111%2Fijpp.12302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections</span></div><div class="casAuthors">Murrell Derek; Harirforoosh Sam; Bossaer John B; Carico Ronald; Cluck David</div><div class="citationInfo"><span class="NLM_cas:title">The International journal of pharmacy practice</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To review the place in therapy of isavuconazole, the active metabolite of isavuconazonium sulfate, via a review of the available literature on drug chemistry, spectrum of activity, pharmacokinetic/pharmacodynamic profile and trials assessing clinical efficacy and safety.  METHODS:  Relevant data, original research articles and reviews, were gathered primarily through the use of a PubMed database search.  The search was conducted without date restrictions in order to collect both historical and recent data regarding isavuconazole.  KEY FINDINGS:  Isavuconazole is a triazole currently approved not only for use in invasive aspergillosis and mucormycosis but also has demonstrable activity against Candida species and other common fungal pathogens.  This drug has features which make it more clinically appealing compared to other azoles with similar indications.  In specific, isavuconazole does not require a cyclodextrin vehicle due to its water solubility, and at present, does not require therapeutic drug monitoring.  Moreover, isavuconazole has displayed improved safety and tolerability compared to voriconazole.  Available data from Phase III clinical trials shows isavuconazole to be a possible therapeutic option to currently available therapies for which it is approved; however, clinical conclusions should be reserved until results have been published and more data from clinical use is reported.  CONCLUSIONS:  Isavuconazole is a new triazole with broad-spectrum antifungal activity including invasive aspergillosis and mucormycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXTqBH7GZWSevW160gIxP_fW6udTcc2eakavInMLi2Mbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szltVahtw%253D%253D&md5=31842dac8cd4a6e87fdf85b9bd5c16db</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1111%2Fijpp.12302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fijpp.12302%26sid%3Dliteratum%253Aachs%26aulast%3DMurrell%26aufirst%3DD.%26aulast%3DBossaer%26aufirst%3DJ.%2BB.%26aulast%3DCarico%26aufirst%3DR.%26aulast%3DHarirforoosh%26aufirst%3DS.%26aulast%3DCluck%26aufirst%3DD.%26atitle%3DIsavuconazonium%2520Sulfate%253A%2520a%2520Triazole%2520Prodrug%2520for%2520Invasive%2520Fungal%2520Infections%26jtitle%3DInt.%2520J.%2520Pharm.%2520Pract.%26date%3D2017%26volume%3D25%26spage%3D18%26doi%3D10.1111%2Fijpp.12302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hayase, T.; Ichihara, S.; Isshiki, Y.; Liu, P.; Ohwada, J.; Sakai, T.; Shimma, N.; Tsukazaki, M.; Umeda, I.; Yamazaki, T.</span><span> </span><span class="NLM_article-title">3-[4-(4-Cyanophenyl)thiazol-2-y)]-1-(1<i>H</i>-1,2,4-triazol-1-yl)-butan-2-ol Derivatives Having Antifungal Activity</span>. WO 9945008A1,<span class="NLM_x"> </span><span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=T.+Hayase&author=S.+Ichihara&author=Y.+Isshiki&author=P.+Liu&author=J.+Ohwada&author=T.+Sakai&author=N.+Shimma&author=M.+Tsukazaki&author=I.+Umeda&author=T.+Yamazaki&title=3-%5B4-%284-Cyanophenyl%29thiazol-2-y%29%5D-1-%281H-1%2C2%2C4-triazol-1-yl%29-butan-2-ol+Derivatives+Having+Antifungal+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayase%26aufirst%3DT.%26atitle%3D3-%255B4-%25284-Cyanophenyl%2529thiazol-2-y%2529%255D-1-%25281H-1%252C2%252C4-triazol-1-yl%2529-butan-2-ol%2520Derivatives%2520Having%2520Antifungal%2520Activity%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayase, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isshiki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuguchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaitani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiratori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umeda, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimma, N.</span><span> </span><span class="NLM_article-title">Design, Synthesis and Antifungal Activity of a Novel Water Soluble Prodrug of Antifungal Triazole</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00892-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0960-894X%2802%2900892-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=12482421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVels7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=191-196&author=J.+Ohwadaauthor=M.+Tsukazakiauthor=T.+Hayaseauthor=N.+Oikawaauthor=Y.+Isshikiauthor=H.+Fukudaauthor=E.+Mizuguchiauthor=M.+Sakaitaniauthor=Y.+Shiratoriauthor=T.+Yamazakiauthor=S.+Ichiharaauthor=I.+Umedaauthor=N.+Shimma&title=Design%2C+Synthesis+and+Antifungal+Activity+of+a+Novel+Water+Soluble+Prodrug+of+Antifungal+Triazole&doi=10.1016%2FS0960-894X%2802%2900892-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole</span></div><div class="casAuthors">Ohwada, Jun; Tsukazaki, Masao; Hayase, Tadakatsu; Oikawa, Nobuhiro; Isshiki, Yoshiaki; Fukuda, Hiroshi; Mizuguchi, Eisaku; Sakaitani, Masahiro; Shiratori, Yasuhiko; Yamazaki, Toshikazu; Ichihara, Shigeyasu; Umeda, Isao; Shimma, Nobuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-196</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A highly potent water sol. triazole antifungal prodrug, RO0098557 (I), has been identified from its parent, the novel antifungal agent RO0094815 (II).  The prodrug, which was obtained by the coupling of II with sarcosine ester III, includes a triazolium salt linked to an aminocarboxyl moiety, which undergoes enzymic activation followed by spontaneous chem. degrdn. to release II.  Prodrug I showed high chem. stability and water soly. and exhibited strong antifungal activity against systemic candidiasis and aspergillosis as well as pulmonary aspergillosis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1j5aGGk3HYrVg90H21EOLACvtfcHk0lgDzyKcHu6mOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVels7g%253D&md5=e5fa5ef54f1b4e5420caef0c329b1bfd</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900892-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900892-2%26sid%3Dliteratum%253Aachs%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DTsukazaki%26aufirst%3DM.%26aulast%3DHayase%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DIsshiki%26aufirst%3DY.%26aulast%3DFukuda%26aufirst%3DH.%26aulast%3DMizuguchi%26aufirst%3DE.%26aulast%3DSakaitani%26aufirst%3DM.%26aulast%3DShiratori%26aufirst%3DY.%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DIchihara%26aufirst%3DS.%26aulast%3DUmeda%26aufirst%3DI.%26aulast%3DShimma%26aufirst%3DN.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Antifungal%2520Activity%2520of%2520a%2520Novel%2520Water%2520Soluble%2520Prodrug%2520of%2520Antifungal%2520Triazole%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D191%26epage%3D196%26doi%3D10.1016%2FS0960-894X%2802%2900892-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Soukup, M.</span><span> </span><span class="NLM_article-title">Process for the Manufacture of Enantiomerically Pure Antifungal Azoles as Ravuconazole and Isavuconazole</span>. US 8207352,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Soukup&title=Process+for+the+Manufacture+of+Enantiomerically+Pure+Antifungal+Azoles+as+Ravuconazole+and+Isavuconazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSoukup%26aufirst%3DM.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%2520Enantiomerically%2520Pure%2520Antifungal%2520Azoles%2520as%2520Ravuconazole%2520and%2520Isavuconazole%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Soukup, M.</span><span> </span><span class="NLM_article-title">Intermediate Halophenyl Derivatives and Their Use in a Process for Preparing Azole Derivatives</span>. US 7115643,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.+Soukup&title=Intermediate+Halophenyl+Derivatives+and+Their+Use+in+a+Process+for+Preparing+Azole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSoukup%26aufirst%3DM.%26atitle%3DIntermediate%2520Halophenyl%2520Derivatives%2520and%2520Their%2520Use%2520in%2520a%2520Process%2520for%2520Preparing%2520Azole%2520Derivatives%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Fukuda, H.; Hayase, T.; Mizuguchi, E.; Shimma, N.; Ohwada, J.; Oikawa, N.; Sakaitani, M.; Tsukazaki, M.; Umeda, I.</span><span> </span><span class="NLM_article-title">N-Substituted Carbamoyloxyalkyl-azolium Derivatives</span>. US 6812238A1,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=H.+Fukuda&author=T.+Hayase&author=E.+Mizuguchi&author=N.+Shimma&author=J.+Ohwada&author=N.+Oikawa&author=M.+Sakaitani&author=M.+Tsukazaki&author=I.+Umeda&title=N-Substituted+Carbamoyloxyalkyl-azolium+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DH.%26atitle%3DN-Substituted%2520Carbamoyloxyalkyl-azolium%2520Derivatives%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Van, S. R.; Vaessen, H.; Mink, D.; Waser, M.</span><span> </span><span class="NLM_article-title">Process for the Manufacture of Isavuconazole or Ravuconazole</span>. WO 2014023623A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+R.+Van&author=H.+Vaessen&author=D.+Mink&author=M.+Waser&title=Process+for+the+Manufacture+of+Isavuconazole+or+Ravuconazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVan%26aufirst%3DS.%2BR.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%2520Isavuconazole%2520or%2520Ravuconazole%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Khunt, R. C.; Rafeeq, M.; Merwade, A. Y.; Deo, K.</span><span> </span><span class="NLM_article-title">A Process for the Preparation of Isavuconazonium or Its Salt Thereof</span>. WO 2016016766A2,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+C.+Khunt&author=M.+Rafeeq&author=A.+Y.+Merwade&author=K.+Deo&title=A+Process+for+the+Preparation+of+Isavuconazonium+or+Its+Salt+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKhunt%26aufirst%3DR.%2BC.%26atitle%3DA%2520Process%2520for%2520the%2520Preparation%2520of%2520Isavuconazonium%2520or%2520Its%2520Salt%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span>Clarivate Analytics, July 2015; <span class="NLM_publisher-name">Clarivate Analytics</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.thomsonscientific.com.cn/lscn/drug-news/201507.shtml" class="extLink">http://www.thomsonscientific.com.cn/lscn/drug-news/201507.shtml</a> (accessed August 10, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clarivate+Analytics%2C+July+2015%3B+Clarivate+Analytics%2C+2015%3B+http%3A%2F%2Fwww.thomsonscientific.com.cn%2Flscn%2Fdrug-news%2F201507.shtml+%28accessed+August+10%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DClarivate%2520Analytics%252C%2520July%25202015%26pub%3DClarivate%2520Analytics%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hagi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nii, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsubotani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span> </span><span class="NLM_article-title">Bactericidal Effects and Mechanism of Action of Olanexidine Gluconate, a New Antiseptic</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">4551</span><span class="NLM_x">–</span> <span class="NLM_lpage">4559</span><span class="refDoi"> DOI: 10.1128/AAC.05048-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1128%2FAAC.05048-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=4551-4559&author=A.+Hagiauthor=K.+Iwataauthor=T.+Niiauthor=H.+Nakataauthor=Y.+Tsubotaniauthor=Y.+Inoue&title=Bactericidal+Effects+and+Mechanism+of+Action+of+Olanexidine+Gluconate%2C+a+New+Antiseptic&doi=10.1128%2FAAC.05048-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FAAC.05048-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05048-14%26sid%3Dliteratum%253Aachs%26aulast%3DHagi%26aufirst%3DA.%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DNii%26aufirst%3DT.%26aulast%3DNakata%26aufirst%3DH.%26aulast%3DTsubotani%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DY.%26atitle%3DBactericidal%2520Effects%2520and%2520Mechanism%2520of%2520Action%2520of%2520Olanexidine%2520Gluconate%252C%2520a%2520New%2520Antiseptic%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D4551%26epage%3D4559%26doi%3D10.1128%2FAAC.05048-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Okaichi, Y.; Tada, N.; Nomi, D.; Fujita, N.; Tsuji, K.; Yamaguchi, T.; Muguruma, Y.; Tsujimori, H.</span><span> </span><span class="NLM_article-title">Process for Producing 1-(3, 4-Dichlorobenzyl)-5-octylbiguanide or a Salt Thereof</span>. US7868207B2,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=Y.+Okaichi&author=N.+Tada&author=D.+Nomi&author=N.+Fujita&author=K.+Tsuji&author=T.+Yamaguchi&author=Y.+Muguruma&author=H.+Tsujimori&title=Process+for+Producing+1-%283%2C+4-Dichlorobenzyl%29-5-octylbiguanide+or+a+Salt+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOkaichi%26aufirst%3DY.%26atitle%3DProcess%2520for%2520Producing%25201-%25283%252C%25204-Dichlorobenzyl%2529-5-octylbiguanide%2520or%2520a%2520Salt%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Hathaway, R. D.; Sclafani, J. R.,  Jr</span><span> </span><span class="NLM_article-title">Method and Apparatus for Preparing a Solution of a Shear Sensitive Material</span>. US 9034256B2,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+D.+Hathaway&author=J.+R.+Sclafani&title=Method+and+Apparatus+for+Preparing+a+Solution+of+a+Shear+Sensitive+Material"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHathaway%26aufirst%3DR.%2BD.%26atitle%3DMethod%2520and%2520Apparatus%2520for%2520Preparing%2520a%2520Solution%2520of%2520a%2520Shear%2520Sensitive%2520Material%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Santos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gropper, S.</span><span> </span><span class="NLM_article-title">In Vitro Percutaneous Absorption and Metabolism of Ozenoxacin in Excised Human Skin</span> <span class="citation_source-journal">Future Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">S9</span><span class="refDoi"> DOI: 10.2217/fmb.14.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2217%2Ffmb.14.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25209522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFejt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=S3-S9&author=B.+Santosauthor=J.+Ortizauthor=S.+Gropper&title=In+Vitro+Percutaneous+Absorption+and+Metabolism+of+Ozenoxacin+in+Excised+Human+Skin&doi=10.2217%2Ffmb.14.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro percutaneous absorption and metabolism of ozenoxacin in excised human skin</span></div><div class="casAuthors">Santos, Benjamin; Ortiz, Jordi; Gropper, Savion</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8s</span>),
    <span class="NLM_cas:pages">S3-S9</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">In vitro studies using excised human skin samples were conducted to evaluate the percutaneous absorption and skin metab. of ozenoxacin.  The formulations studied were 1% ointment, 1% cream and 2% cream.  Permeation assays met the conditions for infinite dose expts.  In all but one case, ozenoxacin concns. in receptor fluid samples of Franz diffusion cells were below the limits of quantification (0.04 μg/mL) by liq. chromatog./mass spectrometry/electrospray ionization at the designated time points.  Across all four absorption studies, ≤0.015% of the applied ozenoxacin dose permeated through the skin over the course of 24 or 48 h.  Ethnic origin had no influence on absorption.  Ozenoxacin at concns. of 7, 35 and 70 μM was metabolically stable in the presence of freshly prepd. human skin disks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2UUvC1tj-SrVg90H21EOLACvtfcHk0ljI_eE2gQJgmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFejt7jI&md5=b93d7696e0114cc3c3e03df7dabed455</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2217%2Ffmb.14.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffmb.14.81%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DB.%26aulast%3DOrtiz%26aufirst%3DJ.%26aulast%3DGropper%26aufirst%3DS.%26atitle%3DIn%2520Vitro%2520Percutaneous%2520Absorption%2520and%2520Metabolism%2520of%2520Ozenoxacin%2520in%2520Excised%2520Human%2520Skin%26jtitle%3DFuture%2520Microbiol.%26date%3D2014%26volume%3D9%26spage%3DS3%26epage%3DS9%26doi%3D10.2217%2Ffmb.14.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Hayashi, K.; Kito, T.; Mitsuyama, J.; Yamakawa, T.; Kuroda, H.; Kawafuchi, H.</span><span> </span><span class="NLM_article-title">Quinolonecarboxylic Acid Derivatives or Salts Thereof</span>. US 6335447B1,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=K.+Hayashi&author=T.+Kito&author=J.+Mitsuyama&author=T.+Yamakawa&author=H.+Kuroda&author=H.+Kawafuchi&title=Quinolonecarboxylic+Acid+Derivatives+or+Salts+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DK.%26atitle%3DQuinolonecarboxylic%2520Acid%2520Derivatives%2520or%2520Salts%2520Thereof%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Erlinge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eriksson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schersten, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omerovic, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostlund, O. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallentin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frobert, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, S.</span><span> </span><span class="NLM_article-title">Bivalirudin Versus Heparin in Non-ST and ST-segment Elevation Myocardial Infarction-a Registry-based Randomized Clinical Trial in the SWEDEHEART Registry (the VALIDATE-SWEDEHEART Trial)</span> <span class="citation_source-journal">Am. Heart J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">46</span><span class="refDoi"> DOI: 10.1016/j.ahj.2016.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.ahj.2016.02.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2016&pages=36-46&author=D.+Erlingeauthor=S.+Koulauthor=P.+Erikssonauthor=F.+Scherstenauthor=E.+Omerovicauthor=R.+Linderauthor=O.+P.+Ostlundauthor=L.+Wallentinauthor=O.+Frobertauthor=S.+James&title=Bivalirudin+Versus+Heparin+in+Non-ST+and+ST-segment+Elevation+Myocardial+Infarction-a+Registry-based+Randomized+Clinical+Trial+in+the+SWEDEHEART+Registry+%28the+VALIDATE-SWEDEHEART+Trial%29&doi=10.1016%2Fj.ahj.2016.02.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2016.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2016.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DErlinge%26aufirst%3DD.%26aulast%3DKoul%26aufirst%3DS.%26aulast%3DEriksson%26aufirst%3DP.%26aulast%3DSchersten%26aufirst%3DF.%26aulast%3DOmerovic%26aufirst%3DE.%26aulast%3DLinder%26aufirst%3DR.%26aulast%3DOstlund%26aufirst%3DO.%2BP.%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DFrobert%26aufirst%3DO.%26aulast%3DJames%26aufirst%3DS.%26atitle%3DBivalirudin%2520Versus%2520Heparin%2520in%2520Non-ST%2520and%2520ST-segment%2520Elevation%2520Myocardial%2520Infarction-a%2520Registry-based%2520Randomized%2520Clinical%2520Trial%2520in%2520the%2520SWEDEHEART%2520Registry%2520%2528the%2520VALIDATE-SWEDEHEART%2520Trial%2529%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2016%26volume%3D175%26spage%3D36%26epage%3D46%26doi%3D10.1016%2Fj.ahj.2016.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInally, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindon, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teobald, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leff, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, W.</span><span> </span><span class="NLM_article-title">Antagonists of the Platelet P2T Receptor: A Novel Approach to Antithrombotic Therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1021/jm981072s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm981072s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=213-220&author=A.+H.+Ingallauthor=J.+Dixonauthor=A.+Baileyauthor=M.+E.+Coombsauthor=D.+Coxauthor=J.+I.+McInallyauthor=S.+F.+Huntauthor=N.+D.+Kindonauthor=B.+J.+Teobaldauthor=P.+A.+Willisauthor=R.+G.+Humphriesauthor=P.+Leffauthor=J.+A.+Cleggauthor=J.+A.+Smithauthor=W.+Tomlinson&title=Antagonists+of+the+Platelet+P2T+Receptor%3A+A+Novel+Approach+to+Antithrombotic+Therapy&doi=10.1021%2Fjm981072s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm981072s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm981072s%26sid%3Dliteratum%253Aachs%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DDixon%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCoombs%26aufirst%3DM.%2BE.%26aulast%3DCox%26aufirst%3DD.%26aulast%3DMcInally%26aufirst%3DJ.%2BI.%26aulast%3DHunt%26aufirst%3DS.%2BF.%26aulast%3DKindon%26aufirst%3DN.%2BD.%26aulast%3DTeobald%26aufirst%3DB.%2BJ.%26aulast%3DWillis%26aufirst%3DP.%2BA.%26aulast%3DHumphries%26aufirst%3DR.%2BG.%26aulast%3DLeff%26aufirst%3DP.%26aulast%3DClegg%26aufirst%3DJ.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DTomlinson%26aufirst%3DW.%26atitle%3DAntagonists%2520of%2520the%2520Platelet%2520P2T%2520Receptor%253A%2520A%2520Novel%2520Approach%2520to%2520Antithrombotic%2520Therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D213%26epage%3D220%26doi%3D10.1021%2Fjm981072s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ingall, A. H.; Cage, P. A.; Kindon, N. D.</span><span> </span><span class="NLM_article-title">Preparation of N-Alkyl-2-substituted ATP Analogs as Platelet Aggregation Inhibitors</span>. WO 1994018216A1,<span class="NLM_x"> </span><span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=A.+H.+Ingall&author=P.+A.+Cage&author=N.+D.+Kindon&title=Preparation+of+N-Alkyl-2-substituted+ATP+Analogs+as+Platelet+Aggregation+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIngall%26aufirst%3DA.%2BH.%26atitle%3DPreparation%2520of%2520N-Alkyl-2-substituted%2520ATP%2520Analogs%2520as%2520Platelet%2520Aggregation%2520Inhibitors%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Diaz-Ricart, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escolar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serradell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolos, J.</span><span> </span><span class="NLM_article-title">Cangrelor Tetrasodium: P2Y12 Antagonist Antiplatelet Agent</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1358/dof.2008.033.02.1178068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdof.2008.033.02.1178068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=101-110&author=M.+Diaz-Ricartauthor=G.+Escolarauthor=N.+Serradellauthor=E.+Rosaauthor=J.+Bolos&title=Cangrelor+Tetrasodium%3A+P2Y12+Antagonist+Antiplatelet+Agent&doi=10.1358%2Fdof.2008.033.02.1178068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Cangrelor tetrasodium: P2Y12 antagonist antiplatelet agent</span></div><div class="casAuthors">Diaz-Ricart, Maribel; Escolar, Gines</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-110</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Cangrelor (AR-C69931MX) is a nonthienopyridine direct-acting P2Y12 antagonist under development for the treatment of acute coronary syndrome and as an ultrafast-acting i.v. antithrombotic agent.  Cangrelor inhibits platelet aggregation with a rapid onset and offset and does not require metab. for therapeutic activity.  In ex vivo samples of blood from patients with acute coronary syndromes, cangrelor reduced platelet-leukocyte interactions, suggesting that the drug may possess addnl. disease-modifying activity.  Phase II studies have shown a good safety profile and a greater inhibitory effect on platelet aggregation compared to clopidogrel.  Results of clin. studies indicate that cangrelor may possibly inhibit the potentiation of platelet aggregation assocd. with heparin.  In comparative studies with gpIIb/IIIa receptor antagonists, cangrelor showed similar inhibitory effects on platelet aggregation responses, with a slightly more favorable impact on bleeding time.  Cangrelor has shown promising results as an adjunct to fibrinolysis with tissue-type plasminogen activator (t-PA).  Ongoing phase III trials will provide more definitive information on clin. efficacy and safety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9GLZ3Efd2krVg90H21EOLACvtfcHk0lgbhnw7E5rSRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gjsbo%253D&md5=ecb66b3eee8ecb90ee659a67ae9a5cdd</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1358%2Fdof.2008.033.02.1178068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2008.033.02.1178068%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz-Ricart%26aufirst%3DM.%26aulast%3DEscolar%26aufirst%3DG.%26aulast%3DSerradell%26aufirst%3DN.%26aulast%3DRosa%26aufirst%3DE.%26aulast%3DBolos%26aufirst%3DJ.%26atitle%3DCangrelor%2520Tetrasodium%253A%2520P2Y12%2520Antagonist%2520Antiplatelet%2520Agent%26jtitle%3DDrugs%2520Future%26date%3D2008%26volume%3D33%26spage%3D101%26epage%3D110%26doi%3D10.1358%2Fdof.2008.033.02.1178068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Zhou, F.; Jin, H.; Yongyong, Z.; Huang, M.; Meng, X.</span><span> </span><span class="NLM_article-title">Preparation Method of Cangrelor Intermediate</span>. CN105481922A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+Zhou&author=H.+Jin&author=Z.+Yongyong&author=M.+Huang&author=X.+Meng&title=Preparation+Method+of+Cangrelor+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26atitle%3DPreparation%2520Method%2520of%2520Cangrelor%2520Intermediate%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Almond, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitter, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rideout, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Clair, M. H.</span><span> </span><span class="NLM_article-title">Synthesis of 2-Amino-9-(3′-azido-2′,3′-dideoxy-beta-D-erythro-pentofuranosyl)-6-methoxy-9H-purine (AzddMAP) and AzddGuo</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">5745</span><span class="NLM_x">–</span> <span class="NLM_lpage">5748</span><span class="refDoi"> DOI: 10.1016/S0040-4039(00)93545-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0040-4039%2800%2993545-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1991&pages=5745-5748&author=M.+R.+Almondauthor=J.+L.+Collinsauthor=B.+E.+Reitterauthor=J.+L.+Rideoutauthor=G.+A.+Freemanauthor=M.+H.+St+Clair&title=Synthesis+of+2-Amino-9-%283%E2%80%B2-azido-2%E2%80%B2%2C3%E2%80%B2-dideoxy-beta-D-erythro-pentofuranosyl%29-6-methoxy-9H-purine+%28AzddMAP%29+and+AzddGuo&doi=10.1016%2FS0040-4039%2800%2993545-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2993545-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252993545-7%26sid%3Dliteratum%253Aachs%26aulast%3DAlmond%26aufirst%3DM.%2BR.%26aulast%3DCollins%26aufirst%3DJ.%2BL.%26aulast%3DReitter%26aufirst%3DB.%2BE.%26aulast%3DRideout%26aufirst%3DJ.%2BL.%26aulast%3DFreeman%26aufirst%3DG.%2BA.%26aulast%3DSt%2BClair%26aufirst%3DM.%2BH.%26atitle%3DSynthesis%2520of%25202-Amino-9-%25283%25E2%2580%25B2-azido-2%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxy-beta-D-erythro-pentofuranosyl%2529-6-methoxy-9H-purine%2520%2528AzddMAP%2529%2520and%2520AzddGuo%26jtitle%3DTetrahedron%2520Lett.%26date%3D1991%26volume%3D32%26spage%3D5745%26epage%3D5748%26doi%3D10.1016%2FS0040-4039%2800%2993545-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Yoshikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenishi, T.</span><span> </span><span class="NLM_article-title">A Novel Method for Phosphorylation of Nucleosides to 5′-Nucleotides</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">5065</span><span class="NLM_x">–</span> <span class="NLM_lpage">5068</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)89915-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0040-4039%2801%2989915-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1967&pages=5065-5068&author=M.+Yoshikawaauthor=T.+Katoauthor=T.+Takenishi&title=A+Novel+Method+for+Phosphorylation+of+Nucleosides+to+5%E2%80%B2-Nucleotides&doi=10.1016%2FS0040-4039%2801%2989915-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2989915-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252989915-9%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DTakenishi%26aufirst%3DT.%26atitle%3DA%2520Novel%2520Method%2520for%2520Phosphorylation%2520of%2520Nucleosides%2520to%25205%25E2%2580%25B2-Nucleotides%26jtitle%3DTetrahedron%2520Lett.%26date%3D1967%26volume%3D8%26spage%3D5065%26epage%3D5068%26doi%3D10.1016%2FS0040-4039%2801%2989915-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Dutta, P.; Far, A. R.; Ding, M.; Motheram, R.</span><span> </span><span class="NLM_article-title">Pharmaceutical Formulations Comprising High Purity Cangrelor and Methods for Preparing and Using the Same</span>. US 9295687B1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+Dutta&author=A.+R.+Far&author=M.+Ding&author=R.+Motheram&title=Pharmaceutical+Formulations+Comprising+High+Purity+Cangrelor+and+Methods+for+Preparing+and+Using+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%26aufirst%3DP.%26atitle%3DPharmaceutical%2520Formulations%2520Comprising%2520High%2520Purity%2520Cangrelor%2520and%2520Methods%2520for%2520Preparing%2520and%2520Using%2520the%2520Same%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span><span class="refDoi"> DOI: 10.1007/s40265-016-0544-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-016-0544-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=387-396&author=P.+L.+McCormack&title=Sacubitril%2FValsartan%3A+A+Review+in+Chronic+Heart+Failure+with+Reduced+Ejection+Fraction&doi=10.1007%2Fs40265-016-0544-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0544-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0544-9%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DSacubitril%252FValsartan%253A%2520A%2520Review%2520in%2520Chronic%2520Heart%2520Failure%2520with%2520Reduced%2520Ejection%2520Fraction%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D387%26epage%3D396%26doi%3D10.1007%2Fs40265-016-0544-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span>FDA Approves New Drug to Treat Heart Failure; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, July 7,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453845.htm</a> (accessed August 20, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+New+Drug+to+Treat+Heart+Failure%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+July+7%2C+2015%3B+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm453845.htm+%28accessed+August+20%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520New%2520Drug%2520to%2520Treat%2520Heart%2520Failure%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span>Novartis' Heart Failure Medicine Entresto Receives EU Approval; <span class="NLM_publisher-name">Novartis</span>, Nov 24,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-entrestotm-receives-eu-approval" class="extLink">https://www.novartis.com/news/media-releases/novartis-heart-failure-medicine-entrestotm-receives-eu-approval</a> (accessed August 20, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis%27+Heart+Failure+Medicine+Entresto+Receives+EU+Approval%3B+Novartis%2C+Nov+24%2C+2015%3B+https%3A%2F%2Fwww.novartis.com%2Fnews%2Fmedia-releases%2Fnovartis-heart-failure-medicine-entrestotm-receives-eu-approval+%28accessed+August+20%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNovartis%2527%2520Heart%2520Failure%2520Medicine%2520Entresto%2520Receives%2520EU%2520Approval%26pub%3DNovartis%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Prenner, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancy, C. W.</span><span> </span><span class="NLM_article-title">Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure</span> <span class="citation_source-journal">Curr. Atheroscler. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="refDoi"> DOI: 10.1007/s11883-016-0603-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs11883-016-0603-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27324636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC2s7itlGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=48&author=S.+B.+Prennerauthor=S.+J.+Shahauthor=C.+W.+Yancy&title=Role+of+Angiotensin+Receptor-Neprilysin+Inhibition+in+Heart+Failure&doi=10.1007%2Fs11883-016-0603-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure</span></div><div class="casAuthors">Prenner Stuart B; Shah Sanjiv J; Yancy Clyde W</div><div class="citationInfo"><span class="NLM_cas:title">Current atherosclerosis reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">48</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  Numerous evidence-based medical and device therapies proven to reduce morbidity and mortality have advanced care for heart failure with reduced ejection fraction (HFrEF).  The primacy of this approach has now been superseded by striking new data resulting in the approval of the combination of valsartan and sacubitril, a neprilysin inhibitor (also known as LCZ696), in 2015 for the treatment of HFrEF.  LCZ696 is a novel heart failure drug that simultaneously inhibits the renin-angiotensin system and potentiates the natriuretic peptide system.  RECENT FINDINGS:  In the Prospective Comparison of ARNI with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, LCZ696 significantly improved cardiovascular outcomes compared to current guideline-directed medical therapy.  Compared to an angiotensin-converting enzyme (ACE) inhibitor, LCZ696 was associated with a 20 % reduction in cardiovascular mortality (number needed to treat [NNT] 32) and a similar reduction in total mortality (NNT 36).  Morbidity benefits of the drug were seen within 1 month of initiation.  However, hypotension due to enalapril or the LCZ696 regimen during a run-in phase eliminated 20 % of patients.  Safety concerns included the risk of angioedema and the theoretical concern of neurocognitive dysfunction due to the protean effects of neprilysin inhibition.  The role of LCZ696 in patients with asymptomatic left ventricular systolic dysfunction is uncertain.  LCZ696 is currently being evaluated in patients with heart failure with preserved ejection fraction, with promising initial results.  LCZ696 represents a novel mechanistic approach to targeting heart failure with reduced ejection fraction, and ongoing studies will address its use in other cardiovascular populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbp8ONwNt92ZNiNltV31zlfW6udTcc2eYKxnqRVQsHtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7itlGkug%253D%253D&md5=46182bd70b4249e61534e58cd23eb924</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs11883-016-0603-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11883-016-0603-4%26sid%3Dliteratum%253Aachs%26aulast%3DPrenner%26aufirst%3DS.%2BB.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DYancy%26aufirst%3DC.%2BW.%26atitle%3DRole%2520of%2520Angiotensin%2520Receptor-Neprilysin%2520Inhibition%2520in%2520Heart%2520Failure%26jtitle%3DCurr.%2520Atheroscler.%2520Rep.%26date%3D2016%26volume%3D18%26spage%3D48%26doi%3D10.1007%2Fs11883-016-0603-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">McMurray, J. J.</span><span> </span><span class="NLM_article-title">Neprilysin Inhibition to Treat Heart Failure: a Tale of Science, Serendipity, and Second Chances</span> <span class="citation_source-journal">Eur. J. Heart Failure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">247</span><span class="refDoi"> DOI: 10.1002/ejhf.250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fejhf.250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25756942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFygu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=242-247&author=J.+J.+McMurray&title=Neprilysin+Inhibition+to+Treat+Heart+Failure%3A+a+Tale+of+Science%2C+Serendipity%2C+and+Second+Chances&doi=10.1002%2Fejhf.250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances</span></div><div class="casAuthors">McMurray, John J. V.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-247</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">This review describes the role of neprilysin (also known as neutral endopeptidase or enkephalinase) in the degrdn. of natriuretic and other vasoactive peptides, including bradykinin and adrenomedullin.  The initial development of neprilysin inhibitors, then angiotensin converting enzyme-neprilysin inhibitors and, most recently, the angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 (sacubitril valsartan) as an extension of the nurohumoral basis for the treatment of heart failure is also summarised.  Finally, the implications of the compelling benefits of LCZ696 compared with enalapril in the Prospective comparison of ARNI with ACEI to Det. Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5R0zzNbIQIbVg90H21EOLACvtfcHk0lgpSVLCWY4Q8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFygu74%253D&md5=34af6eb1dd544c0e239afad1f2b7f3d7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fejhf.250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejhf.250%26sid%3Dliteratum%253Aachs%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26atitle%3DNeprilysin%2520Inhibition%2520to%2520Treat%2520Heart%2520Failure%253A%2520a%2520Tale%2520of%2520Science%252C%2520Serendipity%252C%2520and%2520Second%2520Chances%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2015%26volume%3D17%26spage%3D242%26epage%3D247%26doi%3D10.1002%2Fejhf.250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span>Novartis' Entresto Given Strong Class I Recommendation in Both US and EU Heart Failure Guidelines, Less than a Year after Regulatory Approvals; <span class="NLM_publisher-name">Novartis</span>, May 21,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="https://www.novartis.com/news/media-releases/novartis-entrestor-given-strong-class-i-recommendation-both-us-and-eu-heart" class="extLink">https://www.novartis.com/news/media-releases/novartis-entrestor-given-strong-class-i-recommendation-both-us-and-eu-heart</a> (accessed August 20, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis%27+Entresto+Given+Strong+Class+I+Recommendation+in+Both+US+and+EU+Heart+Failure+Guidelines%2C+Less+than+a+Year+after+Regulatory+Approvals%3B+Novartis%2C+May+21%2C+2016%3B+https%3A%2F%2Fwww.novartis.com%2Fnews%2Fmedia-releases%2Fnovartis-entrestor-given-strong-class-i-recommendation-both-us-and-eu-heart+%28accessed+August+20%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNovartis%2527%2520Entresto%2520Given%2520Strong%2520Class%2520I%2520Recommendation%2520in%2520Both%2520US%2520and%2520EU%2520Heart%2520Failure%2520Guidelines%252C%2520Less%2520than%2520a%2520Year%2520after%2520Regulatory%2520Approvals%26pub%3DNovartis%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yancy, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessup, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bozkurt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, D. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colvin, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drazner, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippatos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonarow, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Givertz, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindenfeld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masoudi, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlake, C.</span><span> </span><span class="NLM_article-title">2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America</span> <span class="citation_source-journal">J. Am. Coll. Cardiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1476</span><span class="NLM_x">–</span> <span class="NLM_lpage">1488</span><span class="refDoi"> DOI: 10.1016/j.jacc.2016.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.jacc.2016.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27216111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FisF2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=1476-1488&author=C.+W.+Yancyauthor=M.+Jessupauthor=B.+Bozkurtauthor=J.+Butlerauthor=D.+E.+Caseyauthor=M.+M.+Colvinauthor=M.+H.+Draznerauthor=G.+Filippatosauthor=G.+C.+Fonarowauthor=M.+M.+Givertzauthor=S.+M.+Hollenbergauthor=J.+Lindenfeldauthor=F.+A.+Masoudiauthor=P.+E.+McBrideauthor=P.+N.+Petersonauthor=L.+W.+Stevensonauthor=C.+Westlake&title=2016+ACC%2FAHA%2FHFSA+Focused+Update+on+New+Pharmacological+Therapy+for+Heart+Failure%3A+An+Update+of+the+2013+ACCF%2FAHA+Guideline+for+the+Management+of+Heart+Failure%3A+A+Report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+Task+Force+on+Clinical+Practice+Guidelines+and+the+Heart+Failure+Society+of+America&doi=10.1016%2Fj.jacc.2016.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America</span></div><div class="casAuthors">Yancy Clyde W; Jessup Mariell; Bozkurt Biykem; Butler Javed; Casey Donald E Jr; Colvin Monica M; Drazner Mark H; Filippatos Gerasimos; Fonarow Gregg C; Givertz Michael M; Hollenberg Steven M; Lindenfeld JoAnn; Masoudi Frederick A; McBride Patrick E; Peterson Pamela N; Stevenson Lynne Warner; Westlake Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1476-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYB68hSi23Frt7lRqEFUJVfW6udTcc2eYKxnqRVQsHtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FisF2gsw%253D%253D&md5=11947ffec59c4819ae86def4c83e2fc1</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2016.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2016.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DYancy%26aufirst%3DC.%2BW.%26aulast%3DJessup%26aufirst%3DM.%26aulast%3DBozkurt%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DCasey%26aufirst%3DD.%2BE.%26aulast%3DColvin%26aufirst%3DM.%2BM.%26aulast%3DDrazner%26aufirst%3DM.%2BH.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DFonarow%26aufirst%3DG.%2BC.%26aulast%3DGivertz%26aufirst%3DM.%2BM.%26aulast%3DHollenberg%26aufirst%3DS.%2BM.%26aulast%3DLindenfeld%26aufirst%3DJ.%26aulast%3DMasoudi%26aufirst%3DF.%2BA.%26aulast%3DMcBride%26aufirst%3DP.%2BE.%26aulast%3DPeterson%26aufirst%3DP.%2BN.%26aulast%3DStevenson%26aufirst%3DL.%2BW.%26aulast%3DWestlake%26aufirst%3DC.%26atitle%3D2016%2520ACC%252FAHA%252FHFSA%2520Focused%2520Update%2520on%2520New%2520Pharmacological%2520Therapy%2520for%2520Heart%2520Failure%253A%2520An%2520Update%2520of%2520the%25202013%2520ACCF%252FAHA%2520Guideline%2520for%2520the%2520Management%2520of%2520Heart%2520Failure%253A%2520A%2520Report%2520of%2520the%2520American%2520College%2520of%2520Cardiology%252FAmerican%2520Heart%2520Association%2520Task%2520Force%2520on%2520Clinical%2520Practice%2520Guidelines%2520and%2520the%2520Heart%2520Failure%2520Society%2520of%2520America%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2016%26volume%3D68%26spage%3D1476%26epage%3D1488%26doi%3D10.1016%2Fj.jacc.2016.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hook, D.; Ruch, T.; Riss, B.; Wietfeld, B.; Sedelmeier, G.; Napp, M.; Bänziger, M.; Hawker, S.; Ciszewski, L.; Waykole, L. M.</span><span> </span><span class="NLM_article-title">Process for Preparing 5-Biphenyl-4-amino-2-methyl pentanoic Acid</span>. WO 2008083967A2,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+Hook&author=T.+Ruch&author=B.+Riss&author=B.+Wietfeld&author=G.+Sedelmeier&author=M.+Napp&author=M.+B%C3%A4nziger&author=S.+Hawker&author=L.+Ciszewski&author=L.+M.+Waykole&title=Process+for+Preparing+5-Biphenyl-4-amino-2-methyl+pentanoic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DProcess%2520for%2520Preparing%25205-Biphenyl-4-amino-2-methyl%2520pentanoic%2520Acid%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hook, D.; Zhou, J.; Li, Y.; Ku, J.</span><span> </span><span class="NLM_article-title">Intermediates of Neutral Endopeptidase Inhibitors and Preparation Method Thereof</span>. WO 2011088797A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+Hook&author=J.+Zhou&author=Y.+Li&author=J.+Ku&title=Intermediates+of+Neutral+Endopeptidase+Inhibitors+and+Preparation+Method+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DIntermediates%2520of%2520Neutral%2520Endopeptidase%2520Inhibitors%2520and%2520Preparation%2520Method%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hook, D.; Zhou, J.; Li, Y.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Intermediates for the Manufacture of Nep Inhibitors</span>. WO 2012025501A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Hook&author=J.+Zhou&author=Y.+Li&title=Process+for+the+Preparation+of+Intermediates+for+the+Manufacture+of+Nep+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Intermediates%2520for%2520the%2520Manufacture%2520of%2520Nep%2520Inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Hook, D.; Riss, B.; Zhou, J.; Li, Y.; Bappert, E.</span><span> </span><span class="NLM_article-title">New Process for the Preparation of Intermediates Useful for the Manufacture Nep Inhibitors</span>. WO 2012025502A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Hook&author=B.+Riss&author=J.+Zhou&author=Y.+Li&author=E.+Bappert&title=New+Process+for+the+Preparation+of+Intermediates+Useful+for+the+Manufacture+Nep+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DNew%2520Process%2520for%2520the%2520Preparation%2520of%2520Intermediates%2520Useful%2520for%2520the%2520Manufacture%2520Nep%2520Inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Zhu, G.; Ye, W.; Zheng, H.; Qian, L.; Wei, J.; Yang, L.; LI, Y.; Luo, L.</span><span> </span><span class="NLM_article-title">New Process</span>. WO 2014032627A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=G.+Zhu&author=W.+Ye&author=H.+Zheng&author=L.+Qian&author=J.+Wei&author=L.+Yang&author=Y.+LI&author=L.+Luo&title=New+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DNew%2520Process%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Hook, D.; Wietfeld, B.; Lotz, M.</span><span> </span><span class="NLM_article-title">Process for Preparing Biaryl Substituted 4-Amino-butyric Acid or Derivatives Thereof and Their Use in the Production of Nep Inhibitors</span>. WO 2008031567A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+Hook&author=B.+Wietfeld&author=M.+Lotz&title=Process+for+Preparing+Biaryl+Substituted+4-Amino-butyric+Acid+or+Derivatives+Thereof+and+Their+Use+in+the+Production+of+Nep+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHook%26aufirst%3DD.%26atitle%3DProcess%2520for%2520Preparing%2520Biaryl%2520Substituted%25204-Amino-butyric%2520Acid%2520or%2520Derivatives%2520Thereof%2520and%2520Their%2520Use%2520in%2520the%2520Production%2520of%2520Nep%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Ksander, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghai, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deJesus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diefenbacher, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakane, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapani, A.</span><span> </span><span class="NLM_article-title">Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1700</span><span class="refDoi"> DOI: 10.1021/jm00010a014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00010a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADyaK2MXltlyktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1689-1700&author=G.+M.+Ksanderauthor=R.+D.+Ghaiauthor=R.+deJesusauthor=C.+G.+Diefenbacherauthor=A.+Yuanauthor=C.+Berryauthor=Y.+Sakaneauthor=A.+Trapani&title=Dicarboxylic+Acid+Dipeptide+Neutral+Endopeptidase+Inhibitors&doi=10.1021%2Fjm00010a014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23gR"><div class="casContent"><span class="casTitleNuber">23g</span><div class="casTitle"><span class="NLM_cas:atitle">Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors</span></div><div class="casAuthors">Ksander, Gary M.; Ghai, Raj D.; deJesus, Reynalda; Diefenbacher, Clive; Yuan, Andrew; Berry, Carol; Sakane, Yumi; Trapani, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1689-700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of three series of dicarboxylic acid dipeptide neutral endopeptidase 24.11 (NEP) inhibitors is described.  In particular, the amino butyramide I exhibited potent NEP inhibitory activity (IC50 = 5.0 nM) in vitro and in vivo.  Blood levels of I were detd. using an ex vivo method by measuring plasma inhibitory activity in conscious rats, mongrel dogs, and cynomolgus monkeys.  Free drug concns. were 10-1500 times greater than the inhibitory const. for NEP over the course of a 6 h expt.  A good correlation of free drug concns. was obtained when comparing values detd. by the ex vivo anal. to those calcd. from direct HPLC measurements.  Plasma atrial natriuretic factor (exogenous) levels were elevated in rats and dogs after oral administration of II.  Urinary vol. and urinary sodium excretion were also potentiated in anesthetized dogs treated with I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfdx8WNNtF-rVg90H21EOLACvtfcHk0li-XqryorehTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltlyktbY%253D&md5=6eb89f1f3ba783d4448d3558027cda82</span></div><a href="/servlet/linkout?suffix=cit23g&amp;dbid=16384&amp;doi=10.1021%2Fjm00010a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00010a014%26sid%3Dliteratum%253Aachs%26aulast%3DKsander%26aufirst%3DG.%2BM.%26aulast%3DGhai%26aufirst%3DR.%2BD.%26aulast%3DdeJesus%26aufirst%3DR.%26aulast%3DDiefenbacher%26aufirst%3DC.%2BG.%26aulast%3DYuan%26aufirst%3DA.%26aulast%3DBerry%26aufirst%3DC.%26aulast%3DSakane%26aufirst%3DY.%26aulast%3DTrapani%26aufirst%3DA.%26atitle%3DDicarboxylic%2520Acid%2520Dipeptide%2520Neutral%2520Endopeptidase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1689%26epage%3D1700%26doi%3D10.1021%2Fjm00010a014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Ksander, G.</span><span> </span><span class="NLM_article-title">Biaryl Substituted 4-Amino-butyric Acid Amides</span>. US 5217996A,<span class="NLM_x"> </span><span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=G.+Ksander&title=Biaryl+Substituted+4-Amino-butyric+Acid+Amides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKsander%26aufirst%3DG.%26atitle%3DBiaryl%2520Substituted%25204-Amino-butyric%2520Acid%2520Amides%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Halama, A.; Zvatora, P.; Dammer, O.; Stach, J.; Zapadlo, M.; Krejcik, L.; Voslar, M.</span><span> </span><span class="NLM_article-title">A Method for the Preparation, Isolation and Purification of Pharmaceutically Applicable Forms of Ahu-377</span>. WO 2016074651A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=A.+Halama&author=P.+Zvatora&author=O.+Dammer&author=J.+Stach&author=M.+Zapadlo&author=L.+Krejcik&author=M.+Voslar&title=A+Method+for+the+Preparation%2C+Isolation+and+Purification+of+Pharmaceutically+Applicable+Forms+of+Ahu-377"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23i&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHalama%26aufirst%3DA.%26atitle%3DA%2520Method%2520for%2520the%2520Preparation%252C%2520Isolation%2520and%2520Purification%2520of%2520Pharmaceutically%2520Applicable%2520Forms%2520of%2520Ahu-377%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Feng, L.; Godtfredsen, S. E.; Karpinski, P.; Sutton, P. A.; Prashad, M.; Girgis, M. J.; Hu, B.; Liu, Y.; Blacklock, T. J.</span><span> </span><span class="NLM_article-title">Pharmaceutical Combinations of an Angiotensin Receptor Antagonist and an Nep Inhibitor</span>. WO 2007056546A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=L.+Feng&author=S.+E.+Godtfredsen&author=P.+Karpinski&author=P.+A.+Sutton&author=M.+Prashad&author=M.+J.+Girgis&author=B.+Hu&author=Y.+Liu&author=T.+J.+Blacklock&title=Pharmaceutical+Combinations+of+an+Angiotensin+Receptor+Antagonist+and+an+Nep+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23j&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DL.%26atitle%3DPharmaceutical%2520Combinations%2520of%2520an%2520Angiotensin%2520Receptor%2520Antagonist%2520and%2520an%2520Nep%2520Inhibitor%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span> </span><span class="NLM_article-title">Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7128</span><span class="NLM_x">–</span> <span class="NLM_lpage">7137</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00698</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00698" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOjurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7128-7137&author=T.+Asakiauthor=K.+Kuwanoauthor=K.+Morrisonauthor=J.+Gatfieldauthor=T.+Hamamotoauthor=M.+Clozel&title=Selexipag%3A+An+Oral+and+Selective+IP+Prostacyclin+Receptor+Agonist+for+the+Treatment+of+Pulmonary+Arterial+Hypertension&doi=10.1021%2Facs.jmedchem.5b00698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Asaki, Tetsuo; Kuwano, Keiichi; Morrison, Keith; Gatfield, John; Hamamoto, Taisuke; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7128-7137</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor.  Decreased prostacyclin prodn. occurs in several cardiovascular diseases.  However, the clin. use of prostacyclin and its analogs is complicated by their chem. and metabolic instability.  A medicinal chem. program searched for novel nonprostanoid prostacyclin receptor agonists not subject to these limitations.  A compd. with a diphenylpyrazine structural core was synthesized.  Metabolic stability and agonist potency were optimized through modification of the linear side chain.  Compd. 12b (MRE-269, ACT-333679) was identified as a potent and highly selective prostacyclin receptor agonist.  Replacement of the terminal carboxyl group with an N-acylsulfonamide group yielded parent compd. 26a (selexipag, NS-304, ACT-293987), which is orally active and provides sustained plasma exposure of 12b.  Compd. 26a was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouZjQo25LkGrVg90H21EOLACvtfcHk0lgVNrVvWIa65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOjurzO&md5=4b09d302b4852c75be29c94578483d8d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00698%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DSelexipag%253A%2520An%2520Oral%2520and%2520Selective%2520IP%2520Prostacyclin%2520Receptor%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7128%26epage%3D7137%26doi%3D10.1021%2Facs.jmedchem.5b00698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Skoro-Sajer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, I. M.</span><span> </span><span class="NLM_article-title">Selexipag for the Treatment of Pulmonary Arterial Hypertension</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span><span class="refDoi"> DOI: 10.1517/14656566.2014.876007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14656566.2014.876007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24392948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=429-436&author=N.+Skoro-Sajerauthor=I.+M.+Lang&title=Selexipag+for+the+Treatment+of+Pulmonary+Arterial+Hypertension&doi=10.1517%2F14656566.2014.876007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">For the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Skoro-Sajer, Nika; Lang, Irene Marthe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-436</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: is a first-in-class orally available selective non-prostanoid IP receptor agonist.  This review was based on a PubMed search and focuses on the potential role of selexipag in the treatment of pulmonary arterial hypertension (PAH).  Areas covered: Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679.  Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors.  This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized.  In addn., the selexipag metabolite has a half-life of 7.9 h, thus permitting oral dosing twice daily.  Selexipag showed effects on pharmacodynamic end points obtained with right heart catheterization in a Phase II trial in patients with PAH, and is being evaluated in the ongoing Phase III trial (GRIPHON trial, Clinicaltrials.gov NCT01106014).  Expert opinion: The signal of a beneficial effect of selexipag on disease progression may become more robust for long term under prolonged exposure.  Pending the GRIPHON trial results, selexipag could provide a convenient first-line prostacyclin treatment option for patients with PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFroy7uy1YmLVg90H21EOLACvtfcHk0lgVNrVvWIa65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygtro%253D&md5=195fc1b70201dd8388bfc53dd59692fa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1517%2F14656566.2014.876007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2014.876007%26sid%3Dliteratum%253Aachs%26aulast%3DSkoro-Sajer%26aufirst%3DN.%26aulast%3DLang%26aufirst%3DI.%2BM.%26atitle%3DSelexipag%2520for%2520the%2520Treatment%2520of%2520Pulmonary%2520Arterial%2520Hypertension%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2014%26volume%3D15%26spage%3D429%26epage%3D436%26doi%3D10.1517%2F14656566.2014.876007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Karmas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerri, P. E.</span><span> </span><span class="NLM_article-title">The Preparation of Hydroxypyrazines and Derived Chloropyrazines</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1952</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1580</span><span class="NLM_x">–</span> <span class="NLM_lpage">1584</span><span class="refDoi"> DOI: 10.1021/ja01126a070</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01126a070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1952&pages=1580-1584&author=G.+Karmasauthor=P.+E.+Spoerri&title=The+Preparation+of+Hydroxypyrazines+and+Derived+Chloropyrazines&doi=10.1021%2Fja01126a070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fja01126a070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01126a070%26sid%3Dliteratum%253Aachs%26aulast%3DKarmas%26aufirst%3DG.%26aulast%3DSpoerri%26aufirst%3DP.%2BE.%26atitle%3DThe%2520Preparation%2520of%2520Hydroxypyrazines%2520and%2520Derived%2520Chloropyrazines%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1952%26volume%3D74%26spage%3D1580%26epage%3D1584%26doi%3D10.1021%2Fja01126a070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwabara, K.</span><span> </span><span class="NLM_article-title">Structure-activity Studies on Diphenylpyrazine Derivatives: a Novel Class of Prostacyclin Receptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6692</span><span class="NLM_x">–</span> <span class="NLM_lpage">6704</span><span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmc.2007.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=17764960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCisbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=6692-6704&author=T.+Asakiauthor=T.+Hamamotoauthor=Y.+Sugiyamaauthor=K.+Kuwanoauthor=K.+Kuwabara&title=Structure-activity+Studies+on+Diphenylpyrazine+Derivatives%3A+a+Novel+Class+of+Prostacyclin+Receptor+Agonists&doi=10.1016%2Fj.bmc.2007.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists</span></div><div class="casAuthors">Asaki, Tetsuo; Hamamoto, Taisuke; Sugiyama, Yukiteru; Kuwano, Keiichi; Kuwabara, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6692-6704</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To develop nonprostanoid prostacyclin receptor agonists with a high degree of metabolic resistance and an extended duration of action, a novel series of diphenylpyrazine derivs. was synthesized and evaluated for their inhibition of ADP-induced human platelet aggregation.  Structure-activity relationship studies on the side chain contg. the carboxylic acid moiety of the lead compd. (I) showed that the length of the linker and the presence of the concatenating nitrogen atom adjacent to the pyrazine ring are crit. for the antiaggregatory activity.  This study led to the discovery of 2-amino-5,6-diphenylpyrazine derivs. (II, III, and IV), which showed potent inhibition of platelet aggregation with IC50 values of 0.2 μM.  Among these compds., IV is an orally available and long-lasting prostacyclin receptor agonist which is promising for the treatment of various vascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQelakXM9KLVg90H21EOLACvtfcHk0lgVNrVvWIa65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCisbfL&md5=e6abc169bee888ab0a33576a84eed962</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DKuwabara%26aufirst%3DK.%26atitle%3DStructure-activity%2520Studies%2520on%2520Diphenylpyrazine%2520Derivatives%253A%2520a%2520Novel%2520Class%2520of%2520Prostacyclin%2520Receptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D6692%26epage%3D6704%26doi%3D10.1016%2Fj.bmc.2007.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Aggarwal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopalakrishna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauriello, J.</span><span> </span><span class="NLM_article-title">Aripiprazole Lauroxil Long-acting Injectable: the Latest Addition to Second-generation Long-acting Agents</span> <span class="citation_source-journal">Clin. Schizophr. Relat. Psychoses.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.3371/csrp.AGGA.040316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.3371%2Fcsrp.AGGA.040316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27074333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28fpvVKhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=58-63&author=A.+Aggarwalauthor=G.+Gopalakrishnaauthor=J.+Lauriello&title=Aripiprazole+Lauroxil+Long-acting+Injectable%3A+the+Latest+Addition+to+Second-generation+Long-acting+Agents&doi=10.3371%2Fcsrp.AGGA.040316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents</span></div><div class="casAuthors">Aggarwal Arpit; Gopalakrishna Ganesh; Lauriello John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical schizophrenia & related psychoses</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-63</span>
        ISSN:<span class="NLM_cas:issn">1935-1232</span>.
    </div><div class="casAbstract">Antipsychotics have long been the mainstay for the treatment of schizophrenia and other psychotic disorders.  Long-acting injectables (LAI) of antipsychotics-provided once every two weeks to once every three months-promise to reduce the incidence of nonadherence.  ARISTADA(®) (aripiprazole lauroxil; ALLAI) extended-release injectable suspension was approved by the U.S.  Food and Drug Administration in October 2015 for the treatment of schizophrenia, and is the newest entrant in the LAI market.  ALLAI is available as a single-use, pre-filled syringe, can be started in three different dosages, and also has the option of every six-week dosing.  Treatment with oral aripiprazole is recommended for the first twenty-one days after the first ALLAI injection, which is a potential disadvantage.  Adverse effects include sensitivity to extrapyramidal symptoms, especially akathisia, which is well documented in other aripiprazole preparations.  There is no available data comparing ALLAI to other antipsychotics, and more head-to-head trials comparing different LAI formulations are needed.  Based on the available data, ALLAI is an effective and safe option for treatment of schizophrenia.  Further studies and post-marketing data will provide better understanding of this formulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzQJin4VT_ZpZoeNcnHOQ9fW6udTcc2eblwItjF6_BNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fpvVKhtg%253D%253D&md5=68cc1a216790ba91d6fd651f36f8c48d</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.3371%2Fcsrp.AGGA.040316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3371%252Fcsrp.AGGA.040316%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DA.%26aulast%3DGopalakrishna%26aufirst%3DG.%26aulast%3DLauriello%26aufirst%3DJ.%26atitle%3DAripiprazole%2520Lauroxil%2520Long-acting%2520Injectable%253A%2520the%2520Latest%2520Addition%2520to%2520Second-generation%2520Long-acting%2520Agents%26jtitle%3DClin.%2520Schizophr.%2520Relat.%2520Psychoses.%26date%3D2016%26volume%3D10%26spage%3D58%26epage%3D63%26doi%3D10.3371%2Fcsrp.AGGA.040316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasrallah, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zummo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stankovic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehrich, E. W.</span><span> </span><span class="NLM_article-title">A Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia</span> <span class="citation_source-journal">J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1085</span><span class="NLM_x">–</span> <span class="NLM_lpage">1090</span><span class="refDoi"> DOI: 10.4088/JCP.14m09741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.4088%2FJCP.14m09741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26114240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbnt1Oqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=1085-1090&author=H.+Y.+Meltzerauthor=R.+Risingerauthor=H.+A.+Nasrallahauthor=Y.+Duauthor=J.+Zummoauthor=L.+Coreyauthor=A.+Boseauthor=S.+Stankovicauthor=B.+L.+Silvermanauthor=E.+W.+Ehrich&title=A+Randomized%2C+Double-blind%2C+Placebo-controlled+Trial+of+Aripiprazole+Lauroxil+in+Acute+Exacerbation+of+Schizophrenia&doi=10.4088%2FJCP.14m09741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia</span></div><div class="casAuthors">Meltzer Herbert Y; Risinger Robert; Nasrallah Henry A; Du Yangchun; Zummo Jacqueline; Corey Lisa; Bose Anjana; Stankovic Srdjan; Silverman Bernard L; Ehrich Elliot W</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1085-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study evaluated the efficacy, safety, and tolerability of aripiprazole lauroxil, a novel long-acting injectable atypical antipsychotic, for the treatment of schizophrenia.  METHOD:  An international multicenter, randomized, double-blind, placebo-controlled trial was conducted between December 2011 and March 2014.  Patients (N = 623) aged 18 to 70 years with schizophrenia (DSM-IV-TR criteria), experiencing an acute exacerbation, were randomized in a 1:1:1 ratio to receive gluteal intramuscular injection of aripiprazole lauroxil 441 mg, aripiprazole lauroxil 882 mg, or matching placebo once monthly for 12 weeks.  The primary efficacy outcome was change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to day 85.  The Clinical Global Impressions-Improvement scale (CGI-I) score at day 85 was the secondary efficacy outcome.  Safety and tolerability were assessed.  RESULTS:  The PANSS total score (mean ± standard error [SE]) improved significantly from baseline to day 85 in the aripiprazole lauroxil 441 mg and 882 mg groups, with placebo-adjusted differences of -10.9 ± 1.8 (P < .001) and -11.9 ± 1.8 (P < .001), respectively.  Significant (P ≤ .004) improvements in both active treatment groups were demonstrated as early as day 8 and continued throughout the treatment period.  The proportion of patients who were very much or much improved on the CGI-I was significantly greater with aripiprazole lauroxil 441 mg and 882 mg treatment versus placebo (P < .001).  The most common treatment-emergent adverse events were insomnia, akathisia, headache, and anxiety.  The incidence of injection site reactions was low, predominantly described as injection site pain, and was associated with the first injection.  CONCLUSIONS:  Aripiprazole lauroxil demonstrated robust efficacy for treatment of patients experiencing acute exacerbation of schizophrenia.  The improvement in psychotic symptoms was statistically significant and clinically meaningful.  Symptom improvement occurred rapidly after initiation of aripiprazole lauroxil treatment and was maintained throughout the study.  Both aripiprazole lauroxil 441 mg and 882 mg doses were well tolerated.  These results support aripiprazole lauroxil as an important new treatment option for schizophrenia.  TRIAL REGISTRATION:  ClinicalTrials.gov identifier: NCT01469039; Clinicaltrialsregister.eu identifier: 2012-003445-15.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBDudtqhw_bgvupmecNw_lfW6udTcc2eblwItjF6_BNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbnt1Oqug%253D%253D&md5=5f9bee56ad2a236490e2e4641c9c01e3</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.4088%2FJCP.14m09741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FJCP.14m09741%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRisinger%26aufirst%3DR.%26aulast%3DNasrallah%26aufirst%3DH.%2BA.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DZummo%26aufirst%3DJ.%26aulast%3DCorey%26aufirst%3DL.%26aulast%3DBose%26aufirst%3DA.%26aulast%3DStankovic%26aufirst%3DS.%26aulast%3DSilverman%26aufirst%3DB.%2BL.%26aulast%3DEhrich%26aufirst%3DE.%2BW.%26atitle%3DA%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%2520Trial%2520of%2520Aripiprazole%2520Lauroxil%2520in%2520Acute%2520Exacerbation%2520of%2520Schizophrenia%26jtitle%3DJ.%2520Clin.%2520Psychiatry%26date%3D2015%26volume%3D76%26spage%3D1085%26epage%3D1090%26doi%3D10.4088%2FJCP.14m09741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Remenar, J. F.; Blumberg, L. C.; Zeidan, T. A.</span><span> </span><span class="NLM_article-title">Lactam Derivatives as Prodrugs for the Treatment of Neurological and Psychiatric Disorders, Their Preparation and Drug Delivery Systems</span>. WO 2010151689A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+F.+Remenar&author=L.+C.+Blumberg&author=T.+A.+Zeidan&title=Lactam+Derivatives+as+Prodrugs+for+the+Treatment+of+Neurological+and+Psychiatric+Disorders%2C+Their+Preparation+and+Drug+Delivery+Systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRemenar%26aufirst%3DJ.%2BF.%26atitle%3DLactam%2520Derivatives%2520as%2520Prodrugs%2520for%2520the%2520Treatment%2520of%2520Neurological%2520and%2520Psychiatric%2520Disorders%252C%2520Their%2520Preparation%2520and%2520Drug%2520Delivery%2520Systems%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Weisler, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuneyoshi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. V.</span><span> </span><span class="NLM_article-title">Brexpiprazole as An Adjunctive Treatment in Young Adults with Major Depressive Disorder Who Are in a School or Work Environment</span> <span class="citation_source-journal">J. Affective Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1016/j.jad.2016.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.jad.2016.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27322768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtValtLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2016&pages=40-47&author=R.+H.+Weislerauthor=A.+Otaauthor=K.+Tsuneyoshiauthor=P.+Perryauthor=E.+Weillerauthor=R.+A.+Bakerauthor=D.+V.+Sheehan&title=Brexpiprazole+as+An+Adjunctive+Treatment+in+Young+Adults+with+Major+Depressive+Disorder+Who+Are+in+a+School+or+Work+Environment&doi=10.1016%2Fj.jad.2016.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment</span></div><div class="casAuthors">Weisler, Richard H.; Ota, Ai; Tsuneyoshi, Kana; Perry, Pamela; Weiller, Emmanuelle; Baker, Ross A.; Sheehan, David V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-47</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Major depressive disorder (MDD) is a common, debilitating disorder with substantial socioeconomic burden.  Many patients with MDD experience symptoms that impair functioning and productivity, often neg. affecting work or educational pursuits.  This Phase 3b open-label study evaluated adjunctive brexpiprazole in young adults with MDD, who were in work or study.  Young patients (18-35 years) with MDD (inadequate responders to 1-3 antidepressant treatments [ADT] for their current episode) received brexpiprazole 1-3 mg/day (target dose, 2 mg/day) adjunctive to the same stable dose of ADT for 12 wk.  Depressive symptoms improved during treatment with adjunctive brexpiprazole (primary endpoint, least squares [LS] mean change from baseline in Montgomery-Åsberg Depression Rating Scale [MADRS] total score, -18.1 [p<0.0001]).  Redns. from baseline in Sheehan Disability Scale Score (SDS; LS mean change -11.2 [p<0.0001]) and Work Limitations Questionnaire (WLQ; p<0.0001) indicated improvements in the effects of patients' symptoms on functioning (work/school, social life, and home responsibilities).  Changes from baseline in addnl. measures supported improvements in patient functioning and depression symptoms.  The most common adverse events were headache (21.3%), wt. increase (17.0%), and somnolence (17.0%); reported rates of akathisia were low (6.4%).  Clin. relevant increases in wt. (≥7%) occurred in 10.5% of patients.  Open-label design; absence of comparator.  Brexpiprazole may represent an effective therapy for adjunctive treatment strategy of young adults with MDD who are working or studying.  The obsd. improvements in work/school functioning in patients with MDD, whose depression was treated with ADT+brexpiprazole, suggests potential to reduce socioeconomic burden.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4AoTUSQx5PbVg90H21EOLACvtfcHk0liXnexFPoKHjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtValtLbP&md5=5bf5112974010254c1a4eca1bf3214b1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2016.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2016.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DWeisler%26aufirst%3DR.%2BH.%26aulast%3DOta%26aufirst%3DA.%26aulast%3DTsuneyoshi%26aufirst%3DK.%26aulast%3DPerry%26aufirst%3DP.%26aulast%3DWeiller%26aufirst%3DE.%26aulast%3DBaker%26aufirst%3DR.%2BA.%26aulast%3DSheehan%26aufirst%3DD.%2BV.%26atitle%3DBrexpiprazole%2520as%2520An%2520Adjunctive%2520Treatment%2520in%2520Young%2520Adults%2520with%2520Major%2520Depressive%2520Disorder%2520Who%2520Are%2520in%2520a%2520School%2520or%2520Work%2520Environment%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2016%26volume%3D204%26spage%3D40%26epage%3D47%26doi%3D10.1016%2Fj.jad.2016.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugino, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuade, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mork, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pehrson, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hentzer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bundgaard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensbol, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span> </span><span class="NLM_article-title">Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">589</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span><span class="refDoi"> DOI: 10.1124/jpet.114.213793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1124%2Fjpet.114.213793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24947465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1artLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2014&pages=589-604&author=K.+Maedaauthor=H.+Suginoauthor=H.+Akazawaauthor=N.+Amadaauthor=J.+Shimadaauthor=T.+Futamuraauthor=H.+Yamashitaauthor=N.+Itoauthor=R.+D.+McQuadeauthor=A.+Morkauthor=A.+L.+Pehrsonauthor=M.+Hentzerauthor=V.+Nielsenauthor=C.+Bundgaardauthor=J.+Arntauthor=T.+B.+Stensbolauthor=T.+Kikuchi&title=Brexpiprazole+I%3A+In+Vitro+and+In+Vivo+Characterization+of+a+Novel+Serotonin-Dopamine+Activity+Modulator&doi=10.1124%2Fjpet.114.213793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator</span></div><div class="casAuthors">Maeda, Kenji; Sugino, Haruhiko; Akazawa, Hitomi; Amada, Naoki; Shimada, Jun; Futamura, Takashi; Yamashita, Hiroshi; Ito, Nobuaki; McQuade, Robert D.; Moerk, Arne; Pehrson, Alan L.; Hentzer, Morten; Nielsen, Vibeke; Bundgaard, Christoffer; Arnt, Joern; Stensboel, Tine Bryan; Kikuchi, Tetsuro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">589-604, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clin. development for psychiatric disorders with high affinity for serotonin, dopamine, and noradrenaline receptors.  In particular, it bound with high affinity (Ki < 1 nM) to human serotonin 1A (h5-HT1A)-, h5-HT2A-, long form of human D2(hD2L)-, hα1B-, and hα2C-adrenergic receptors.  It displayed partial agonism at h5-HT1A and hD2 receptors in cloned receptor systems and potent antagonism of h5-HT2A receptors and hα1B/2C-adrenoceptors.  Brexpiprazole also had affinity (Ki < 5 nM) for hD3-, h5-HT2B-, h5-HT7-, hα1A-, and hα1D-adrenergic receptors, moderate affinity for hH1 (Ki = 19 nM), and low affinity for hM1 receptors (K1 > 1000 nM).  Brexpiprazole potently bound to rat 5-HT2A and D2 receptors in vivo, and ex vivo binding studies further confirmed high 5-HT1A receptor binding potency.  Brexpiprazole inhibited DOI (2,5-dimethoxy-4-iodoamphetamine)-induced head twitches in rats, suggestive of 5-HT2A antagonism.  Furthermore, in vivo D2 partial agonist activity of brexpiprazole was confirmed by its inhibitory effect on reserpine-induced DOPA accumulation in rats.  In rat microdialysis studies, brexpiprazole slightly reduced extracellular dopamine in nucleus accumbens but not in prefrontal cortex, whereas moderate increases of the dopamine metabolites, homovanillic acid and DOPAC (3,4-dihydroxy-phenyl-acetic acid), in these areas also suggested in vivo D2 partial agonist activity.  In particular, based on a lower intrinsic activity at D2 receptors and higher binding affinities for 5-HT1A/2A receptors than aripiprazole, brexpiprazole would have a favorable antipsychotic potential without D2 receptor agonist- and antagonist-related adverse effects.  In conclusion, brexpiprazole is a serotonin-dopamine activity modulator with a unique pharmacol., which may offer novel treatment options across a broad spectrum of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOd8uBhM0Ua7Vg90H21EOLACvtfcHk0lh9ykG2uZH0Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1artLrI&md5=9e0436e35bbb10762bc42b3552a33341</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.213793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.213793%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSugino%26aufirst%3DH.%26aulast%3DAkazawa%26aufirst%3DH.%26aulast%3DAmada%26aufirst%3DN.%26aulast%3DShimada%26aufirst%3DJ.%26aulast%3DFutamura%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DMcQuade%26aufirst%3DR.%2BD.%26aulast%3DMork%26aufirst%3DA.%26aulast%3DPehrson%26aufirst%3DA.%2BL.%26aulast%3DHentzer%26aufirst%3DM.%26aulast%3DNielsen%26aufirst%3DV.%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DArnt%26aufirst%3DJ.%26aulast%3DStensbol%26aufirst%3DT.%2BB.%26aulast%3DKikuchi%26aufirst%3DT.%26atitle%3DBrexpiprazole%2520I%253A%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Characterization%2520of%2520a%2520Novel%2520Serotonin-Dopamine%2520Activity%2520Modulator%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D350%26spage%3D589%26epage%3D604%26doi%3D10.1124%2Fjpet.114.213793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Citrome, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stensboel, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span> </span><span class="NLM_article-title">The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1219</span><span class="NLM_x">–</span> <span class="NLM_lpage">1229</span><span class="refDoi"> DOI: 10.1586/14737175.2015.1086269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1586%2F14737175.2015.1086269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26402059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGisLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1219-1229&author=L.+Citromeauthor=T.+B.+Stensboelauthor=K.+Maeda&title=The+preclinical+profile+of+brexpiprazole%3A+what+is+its+clinical+relevance+for+the+treatment+of+psychiatric+disorders%3F&doi=10.1586%2F14737175.2015.1086269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?</span></div><div class="casAuthors">Citrome, Leslie; Stensboel, Tine Bryan; Maeda, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1219-1229</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Brexpiprazole is a serotonin-dopamine activity modulator in clin. development for schizophrenia, adjunctive treatment of major depressive disorder, agitation in Alzheimer's disease and post-traumatic stress disorder.  It is a partial agonist at 5-HT1A and D2 receptors with similar potency, and an antagonist at 5-HT2A and adrenergic α1B/2C receptors.  Compared with aripiprazole, brexpiprazole is more potent at 5-HT1A receptors and displays less intrinsic activity at D2 receptors.  This unique serotonin and dopamine modulatory activity has shown robust antipsychotic, antidepressant-like and anxiolytic activities, and limited extrapyramidal symptom liability with pro-cognitive efficacy in animal models.  Phase III clin. trials have been successfully completed in schizophrenia and adjunctive use in major depressive disorder, with the US FDA approval obtained for these uses; Phase III studies in Alzheimer's disease and post-traumatic stress disorder are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr62dpR7QlGNrVg90H21EOLACvtfcHk0lh9ykG2uZH0Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGisLvE&md5=7b83282ea1e4e757532bda70188ec15d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1586%2F14737175.2015.1086269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2015.1086269%26sid%3Dliteratum%253Aachs%26aulast%3DCitrome%26aufirst%3DL.%26aulast%3DStensboel%26aufirst%3DT.%2BB.%26aulast%3DMaeda%26aufirst%3DK.%26atitle%3DThe%2520preclinical%2520profile%2520of%2520brexpiprazole%253A%2520what%2520is%2520its%2520clinical%2520relevance%2520for%2520the%2520treatment%2520of%2520psychiatric%2520disorders%253F%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2015%26volume%3D15%26spage%3D1219%26epage%3D1229%26doi%3D10.1586%2F14737175.2015.1086269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Yamashita, H.; Sato, T.; Minowa, T.; Hoshika, Y.; Toyofuku, H.; Yamaguchi, T.; Sota, M.; Kawano, S.; Nakamura, T.; Eto, R.</span><span> </span><span class="NLM_article-title">Dihydrate of Benzothiophene Compound or of a Salt Thereof, and Process for Producing the Same</span>. WO 2013162046A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Yamashita&author=T.+Sato&author=T.+Minowa&author=Y.+Hoshika&author=H.+Toyofuku&author=T.+Yamaguchi&author=M.+Sota&author=S.+Kawano&author=T.+Nakamura&author=R.+Eto&title=Dihydrate+of+Benzothiophene+Compound+or+of+a+Salt+Thereof%2C+and+Process+for+Producing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DH.%26atitle%3DDihydrate%2520of%2520Benzothiophene%2520Compound%2520or%2520of%2520a%2520Salt%2520Thereof%252C%2520and%2520Process%2520for%2520Producing%2520the%2520Same%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span> </span><span class="NLM_article-title">An Improved Synthesis of 4-(1-Piperazinyl)benzo[b]thiophene Dihydrochloride</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">–</span> <span class="NLM_lpage">558</span><span class="refDoi"> DOI: 10.1021/acs.oprd.5b00027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=555-558&author=C.+Wuauthor=W.+Chenauthor=D.+Jiangauthor=X.+Jiangauthor=J.+Shen&title=An+Improved+Synthesis+of+4-%281-Piperazinyl%29benzo%5Bb%5Dthiophene+Dihydrochloride&doi=10.1021%2Facs.oprd.5b00027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00027%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DAn%2520Improved%2520Synthesis%2520of%25204-%25281-Piperazinyl%2529benzo%255Bb%255Dthiophene%2520Dihydrochloride%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D555%26epage%3D558%26doi%3D10.1021%2Facs.oprd.5b00027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Goossen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manjolinho, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, N.</span><span> </span><span class="NLM_article-title">Microwave-assisted Cu-catalyzed Protodecarboxylation of Aromatic Carboxylic Acids</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2620</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span><span class="refDoi"> DOI: 10.1021/jo802628z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo802628z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVKrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=2620-2623&author=L.+J.+Goossenauthor=F.+Manjolinhoauthor=B.+A.+Khanauthor=N.+Rodriguez&title=Microwave-assisted+Cu-catalyzed+Protodecarboxylation+of+Aromatic+Carboxylic+Acids&doi=10.1021%2Fjo802628z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave-Assisted Cu-Catalyzed Protodecarboxylation of Aromatic Carboxylic Acids</span></div><div class="casAuthors">Goossen, Lukas J.; Manjolinho, Filipe; Khan, Bilal A.; Rodriguez, Nuria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2620-2623</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An effective protocol has been developed that allows the smooth protodecarboxylation of diversely functionalized arom. carboxylic acids within 5-15 min.  In the presence of at most 5 mol % of an inexpensive catalyst generated in situ from copper(I) oxide and 1,10-phenanthroline, even nonactivated benzoates were converted in high yields and with great preparative ease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2qwnbnNrFyrVg90H21EOLACvtfcHk0li56fzyzvxGtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVKrurc%253D&md5=cc6cd095378d6972aeaebae14c4a0048</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo802628z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo802628z%26sid%3Dliteratum%253Aachs%26aulast%3DGoossen%26aufirst%3DL.%2BJ.%26aulast%3DManjolinho%26aufirst%3DF.%26aulast%3DKhan%26aufirst%3DB.%2BA.%26aulast%3DRodriguez%26aufirst%3DN.%26atitle%3DMicrowave-assisted%2520Cu-catalyzed%2520Protodecarboxylation%2520of%2520Aromatic%2520Carboxylic%2520Acids%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2009%26volume%3D74%26spage%3D2620%26epage%3D2623%26doi%3D10.1021%2Fjo802628z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Cariprazine: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">2035</span><span class="NLM_x">–</span> <span class="NLM_lpage">2043</span><span class="refDoi"> DOI: 10.1007/s40265-015-0494-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0494-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2035-2043&author=P.+L.+McCormack&title=Cariprazine%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0494-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0494-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0494-7%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DCariprazine%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D2035%26epage%3D2043%26doi%3D10.1007%2Fs40265-015-0494-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span>Turn to Vraylar; <span class="NLM_publisher-name">Allergan</span>: <span class="NLM_publisher-loc">Parsippany, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.vraylarhcp.com/" class="extLink">http://www.vraylarhcp.com/</a> (accessed August 5, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Turn+to+Vraylar%3B+Allergan%3A+Parsippany%2C+NJ%2C+2016%3B+http%3A%2F%2Fwww.vraylarhcp.com%2F+%28accessed+August+5%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DTurn%2520to%2520Vraylar%26pub%3DAllergan%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Veselinovic, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paulzen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunder, G.</span><span> </span><span class="NLM_article-title">Cariprazine, a New, Orally Active Dopamine D2/3 Receptor Partial Agonist for the Treatment of Schizophrenia, Bipolar Mania and Depression</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1141</span><span class="NLM_x">–</span> <span class="NLM_lpage">1159</span><span class="refDoi"> DOI: 10.1586/14737175.2013.853448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1586%2F14737175.2013.853448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24175719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjsLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1141-1159&author=T.+Veselinovicauthor=M.+Paulzenauthor=G.+Grunder&title=Cariprazine%2C+a+New%2C+Orally+Active+Dopamine+D2%2F3+Receptor+Partial+Agonist+for+the+Treatment+of+Schizophrenia%2C+Bipolar+Mania+and+Depression&doi=10.1586%2F14737175.2013.853448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression</span></div><div class="casAuthors">Veselinovic, Tanja; Paulzen, Michael; Gruender, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1141-1159</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Cariprazine is a novel drug with partial agonist activity at dopamine D2/3 receptors and six- to eightfold higher affinity for human dopamine D3 over D2 receptors.  Results from several placebo-controlled Phase II/III trials in patients with a The Diagnostic and Statistical Manual of Mental Disorders IV diagnosis of schizophrenia or bipolar I disorder suggest that cariprazine is superior to placebo with respect to antipsychotic and antimanic activity.  Reports concerning safety and tolerability of cariprazine are mainly favorable, although the rates of treatment-assocd. adverse events, which most commonly included akathisia and extrapyramidal symptom, are rather high.  However, only minor alterations of clin. lab. values, prolactin concns. and ECG parameters are reported in cariprazine-treated patients.  A new drug application to the U.S. F DA for cariprazine for the treatment of both schizophrenia and manic or mixed episodes assocd. with bipolar I disorder was submitted in Nov. 2012.  A more precise assessment of the clin. properties of this new drug will require addnl. studies, aimed to compare and contrast cariprazine with other antipsychotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPsIaMWyuixrVg90H21EOLACvtfcHk0li56fzyzvxGtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjsLjF&md5=b30e0bf57bb1004c626be6913c0393f9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1586%2F14737175.2013.853448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2013.853448%26sid%3Dliteratum%253Aachs%26aulast%3DVeselinovic%26aufirst%3DT.%26aulast%3DPaulzen%26aufirst%3DM.%26aulast%3DGrunder%26aufirst%3DG.%26atitle%3DCariprazine%252C%2520a%2520New%252C%2520Orally%2520Active%2520Dopamine%2520D2%252F3%2520Receptor%2520Partial%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Schizophrenia%252C%2520Bipolar%2520Mania%2520and%2520Depression%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2013%26volume%3D13%26spage%3D1141%26epage%3D1159%26doi%3D10.1586%2F14737175.2013.853448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Citrome, L.</span><span> </span><span class="NLM_article-title">Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy</span> <span class="citation_source-journal">Adv. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1007/s12325-013-0006-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs12325-013-0006-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=114-126&author=L.+Citrome&title=Cariprazine+in+Schizophrenia%3A+Clinical+Efficacy%2C+Tolerability%2C+and+Place+in+Therapy&doi=10.1007%2Fs12325-013-0006-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1007%2Fs12325-013-0006-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-013-0006-7%26sid%3Dliteratum%253Aachs%26aulast%3DCitrome%26aufirst%3DL.%26atitle%3DCariprazine%2520in%2520Schizophrenia%253A%2520Clinical%2520Efficacy%252C%2520Tolerability%252C%2520and%2520Place%2520in%2520Therapy%26jtitle%3DAdv.%2520Ther.%26date%3D2013%26volume%3D30%26spage%3D114%26epage%3D126%26doi%3D10.1007%2Fs12325-013-0006-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Caccia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Invernizzi, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nobili, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasina, L.</span><span> </span><span class="NLM_article-title">A New Generation of Antipsychotics: Pharmacology and Clinical Utility of Cariprazine in Schizophrenia</span> <span class="citation_source-journal">Ther. Clin. Risk Manage.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.2147/TCRM.S35137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2147%2FTCRM.S35137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=23966785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGjtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-328&author=S.+Cacciaauthor=R.+W.+Invernizziauthor=A.+Nobiliauthor=L.+Pasina&title=A+New+Generation+of+Antipsychotics%3A+Pharmacology+and+Clinical+Utility+of+Cariprazine+in+Schizophrenia&doi=10.2147%2FTCRM.S35137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia</span></div><div class="casAuthors">Caccia, Silvio; Invernizzi, Roberto William; Nobili, Alessandro; Pasina, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">319-328</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1178-203X</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration.  It is a dopamine D2- and D3-receptor partial agonist, with higher affinity for D3 receptors, as opposed to the D2 antagonism of most older antipsychotic agents.  Like most lipophilic antipsychotics, it undergoes extensive hepatic metab. by cytochrome P 450 (CYP), mainly the highly variable 3A4, with the formation of active metabolites.  However, the parent compd. - particularly its active didesmethyl deriv. - is cleared very slowly, with elimination half-lives in schizophrenic patients ranging from 2-5 days for cariprazine to 2-3 wk for didesmethyl-cariprazine.  Exposure to the latter was several times that for cariprazine, although didesmethyl-cariprazine did not reach steady state within the 3 wk of 12.5 mg/day dosing.  Preliminary information on its therapeutic role comes from press releases and a few abstrs. presented at scientific meetings.  In short-term controlled trials, it was more effective than placebo in reducing pos. and neg. symptoms of schizophrenia, with an ED range of 1.5-12 mg/day.  Although cariprazine was assocd. with a higher incidence of akathisia and extrapyramidal side effects than placebo, it did not cause wt. gain, metabolic abnormalities, prolactin increase or cor. QT prolongation.  Similarly, cariprazine's efficacy and tolerability for the treatment of bipolar disorder (manic/mixed and depressive episodes) was established in the dose range of 3-12 mg/day, although again no long-term data are available.  Well-designed clin. trials, mainly direct "head-to-head" comparisons with other second-generation antipsychotic agents, are needed to define the therapeutic role and safety profile of cariprazine in schizophrenia and bipolar mania.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqskxYb8cxgErVg90H21EOLACvtfcHk0li56fzyzvxGtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGjtb%252FM&md5=0f8ad133c73e50a93dd99bdb40f4124f</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.2147%2FTCRM.S35137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FTCRM.S35137%26sid%3Dliteratum%253Aachs%26aulast%3DCaccia%26aufirst%3DS.%26aulast%3DInvernizzi%26aufirst%3DR.%2BW.%26aulast%3DNobili%26aufirst%3DA.%26aulast%3DPasina%26aufirst%3DL.%26atitle%3DA%2520New%2520Generation%2520of%2520Antipsychotics%253A%2520Pharmacology%2520and%2520Clinical%2520Utility%2520of%2520Cariprazine%2520in%2520Schizophrenia%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D328%26doi%3D10.2147%2FTCRM.S35137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">De Deurwaerdere, P.</span><span> </span><span class="NLM_article-title">Cariprazine: New Dopamine Biased Agonist for Neuropsychiatric Disorders</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1358/dot.2016.52.2.2461868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdot.2016.52.2.2461868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28bhsVartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=97-110&author=P.+De+Deurwaerdere&title=Cariprazine%3A+New+Dopamine+Biased+Agonist+for+Neuropsychiatric+Disorders&doi=10.1358%2Fdot.2016.52.2.2461868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cariprazine:New dopamine biased agonist for neuropsychiatric disorders</span></div><div class="casAuthors">De Deurwaerdere P</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-110</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Cariprazine (RGH-188, MP-214, Vraylar[TM]) is a new dopamine receptor ligand developed for the treatment of several neuropsychiatric diseases including schizophrenia and bipolar disorders.  Cariprazine displays higher affinity at dopamine D3 receptors and a similar affinity at D2 and 5-HT2B receptors.  At variance with some atypical antipsychotics, its affinity at 5-HT1A, 5-HT2A and histamine H1 receptors is modest compared with its three main targets.  Cariprazine could correspond to a biased agonist at dopamine receptors, displaying either antagonist or partial agonist properties depending on the signaling pathways linked to D2/D3 receptors.  The compound crosses the blood-brain barrier, as revealed by positron emission tomography and pharmacokinetic studies in various species.  Two main metabolites result mainly from the activity of CYP34A and display properties similar to those of the parent drug.  Behavioral data report that cariprazine is efficacious in animal models addressing positive, negative and cognitive symptoms of schizophrenia with no extrapyramidal side effects.  In September 2015, the FDA approved the use of cariprazine for the treatment of schizophrenia and type I bipolar disorder.  The efficacy of cariprazine in other neuropsychiatric diseases is currently being evaluated in preclinical and clinical studies.  Side effects have been observed in humans, including extrapyramidal side effects and akathisia of mild to moderate intensity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPNpp60_KrnoqdXsLcGTEUfW6udTcc2ebafuR9xl0GO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhsVartA%253D%253D&md5=7b4def336acc97a8ef2d15c1fd9d2e51</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.2.2461868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.2.2461868%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BDeurwaerdere%26aufirst%3DP.%26atitle%3DCariprazine%253A%2520New%2520Dopamine%2520Biased%2520Agonist%2520for%2520Neuropsychiatric%2520Disorders%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D97%26epage%3D110%26doi%3D10.1358%2Fdot.2016.52.2.2461868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span>Vraylar; <span class="NLM_publisher-name">Actavis Pharma, Inc.</span>: <span class="NLM_publisher-loc">Parsippany, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf</a> (accessed August 5, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vraylar%3B+Actavis+Pharma%2C+Inc.%3A+Parsippany%2C+NJ%2C+2016%3B+http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F204370lbl.pdf+%28accessed+August+5%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DVraylar%26pub%3DActavis%2520Pharma%252C%2520Inc%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span>Allergan and Gedeon Richter Plc. Receive FDA Approval of VRAYLAR (Cariprazine) for Treatment of Manic or Mixed Episodes of Bipolar I Disorder and Schizophrenia in Adults; <span class="NLM_publisher-name">Allergan plc</span>: <span class="NLM_publisher-loc">Coolock, Dublin, Ireland</span>, September 17,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.allergan.com/news/news/thomson-reuters/allergan-and-gedeon-richter-plc-receive-fda-approv" class="extLink">http://www.allergan.com/news/news/thomson-reuters/allergan-and-gedeon-richter-plc-receive-fda-approv</a>. (accessed August 5, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Allergan+and+Gedeon+Richter+Plc.+Receive+FDA+Approval+of+VRAYLAR+%28Cariprazine%29+for+Treatment+of+Manic+or+Mixed+Episodes+of+Bipolar+I+Disorder+and+Schizophrenia+in+Adults%3B+Allergan+plc%3A+Coolock%2C+Dublin%2C+Ireland%2C+September+17%2C+2015%3B+http%3A%2F%2Fwww.allergan.com%2Fnews%2Fnews%2Fthomson-reuters%2Fallergan-and-gedeon-richter-plc-receive-fda-approv.+%28accessed+August+5%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DAllergan%2520and%2520Gedeon%2520Richter%2520Plc.%2520Receive%2520FDA%2520Approval%2520of%2520VRAYLAR%2520%2528Cariprazine%2529%2520for%2520Treatment%2520of%2520Manic%2520or%2520Mixed%2520Episodes%2520of%2520Bipolar%2520I%2520Disorder%2520and%2520Schizophrenia%2520in%2520Adults%26pub%3DAllergan%2520plc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Csongor, E.; Galambos, J.; Nogradi, K.; Vago, I.; Gyertyan, I.; Kiss, B.; Laszlovszky, I.; Laszy, J.; Saghy, K.</span><span> </span><span class="NLM_article-title">(Thio) Carbamoyl-cyclohexane Derivatives as D3/D2 Receptor Antagonists</span>. US 20060229297A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=E.+Csongor&author=J.+Galambos&author=K.+Nogradi&author=I.+Vago&author=I.+Gyertyan&author=B.+Kiss&author=I.+Laszlovszky&author=J.+Laszy&author=K.+Saghy&title=%28Thio%29+Carbamoyl-cyclohexane+Derivatives+as+D3%2FD2+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCsongor%26aufirst%3DE.%26atitle%3D%2528Thio%2529%2520Carbamoyl-cyclohexane%2520Derivatives%2520as%2520D3%252FD2%2520Receptor%2520Antagonists%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ágainé, C. É.; Galambos, J.; Nógrádi, K.; Vágó, I.; Gyertyán, I.; Kiss, B.; Laszlovszky, I.; Laszy, J.; Sághy, K.</span><span> </span><span class="NLM_article-title">(Thio) Carbamoyl-Cyclohexane Derivatives as D3/D2 Receptor Antagonists</span>. WO 2005012266A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=C.+%C3%89.+%C3%81gain%C3%A9&author=J.+Galambos&author=K.+N%C3%B3gr%C3%A1di&author=I.+V%C3%A1g%C3%B3&author=I.+Gyerty%C3%A1n&author=B.+Kiss&author=I.+Laszlovszky&author=J.+Laszy&author=K.+S%C3%A1ghy&title=%28Thio%29+Carbamoyl-Cyclohexane+Derivatives+as+D3%2FD2+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581gain%25C3%25A9%26aufirst%3DC.%2B%25C3%2589.%26atitle%3D%2528Thio%2529%2520Carbamoyl-Cyclohexane%2520Derivatives%2520as%2520D3%252FD2%2520Receptor%2520Antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Czibula, L.; Juhász, B.; Ágainé, C. É.; Sebok, F.; Galambos, J.; Nógrádi, K.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Piperazine Compounds and Hydrochloride Salts Thereof</span>. WO 2010070370A8,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+Czibula&author=B.+Juh%C3%A1sz&author=C.+%C3%89.+%C3%81gain%C3%A9&author=F.+Sebok&author=J.+Galambos&author=K.+N%C3%B3gr%C3%A1di&title=Process+for+the+Preparation+of+Piperazine+Compounds+and+Hydrochloride+Salts+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCzibula%26aufirst%3DL.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Piperazine%2520Compounds%2520and%2520Hydrochloride%2520Salts%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ágainé, C. É.; Czibula, L.; Sebők, F.; Juhász, B.; Galambos, J.; Nográdi, K.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Piperazine Derivatives</span>. WO 2010070371A8,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=C.+%C3%89.+%C3%81gain%C3%A9&author=L.+Czibula&author=F.+Seb%C5%91k&author=B.+Juh%C3%A1sz&author=J.+Galambos&author=K.+Nogr%C3%A1di&title=Process+for+the+Preparation+of+Piperazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581gain%25C3%25A9%26aufirst%3DC.%2B%25C3%2589.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Piperazine%2520Derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Czibula, L.; Juhász, B.; Ágainé, C. É.; Sebők, F.; Galambos, J.; Nógrádi, K.</span><span> </span><span class="NLM_article-title">Novel Process for the Preparation of Piperazine Compounds and Hydrochloride Salts Thereof</span>. WO 2011073705A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=L.+Czibula&author=B.+Juh%C3%A1sz&author=C.+%C3%89.+%C3%81gain%C3%A9&author=F.+Seb%C5%91k&author=J.+Galambos&author=K.+N%C3%B3gr%C3%A1di&title=Novel+Process+for+the+Preparation+of+Piperazine+Compounds+and+Hydrochloride+Salts+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCzibula%26aufirst%3DL.%26atitle%3DNovel%2520Process%2520for%2520the%2520Preparation%2520of%2520Piperazine%2520Compounds%2520and%2520Hydrochloride%2520Salts%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Agai-Csongor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domany, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nogradi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galambos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vago, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greiner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laszlovszky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gere, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiss, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vastag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tihanyi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laszy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyertyan, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zajer-Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemesi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szombathelyi, Z.</span><span> </span><span class="NLM_article-title">Discovery of Cariprazine (RGH-188): A Novel Antipsychotic Acting on Dopamine D3/D2 Receptors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3437</span><span class="NLM_x">–</span> <span class="NLM_lpage">3440</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.03.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmcl.2012.03.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22537450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFeksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3437-3440&author=E.+Agai-Csongorauthor=G.+Domanyauthor=K.+Nogradiauthor=J.+Galambosauthor=I.+Vagoauthor=G.+M.+Keseruauthor=I.+Greinerauthor=I.+Laszlovszkyauthor=A.+Gereauthor=E.+Schmidtauthor=B.+Kissauthor=M.+Vastagauthor=K.+Tihanyiauthor=K.+Saghyauthor=J.+Laszyauthor=I.+Gyertyanauthor=M.+Zajer-Balazsauthor=L.+Gemesiauthor=M.+Kapasauthor=Z.+Szombathelyi&title=Discovery+of+Cariprazine+%28RGH-188%29%3A+A+Novel+Antipsychotic+Acting+on+Dopamine+D3%2FD2+Receptors&doi=10.1016%2Fj.bmcl.2012.03.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42fR"><div class="casContent"><span class="casTitleNuber">42f</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors</span></div><div class="casAuthors">Agai-Csongor, Eva; Domany, Gyorgy; Nogradi, Katalin; Galambos, Janos; Vago, Istvan; Keseru, Gyorgy Miklos; Greiner, Istvan; Laszlovszky, Istvan; Gere, Aniko; Schmidt, Eva; Kiss, Bela; Vastag, Monika; Tihanyi, Karoly; Saghy, Katalin; Laszy, Judit; Gyertyan, Istvan; Zajer-Balazs, Maria; Gemesi, Larisza; Kapas, Margit; Szombathelyi, Zsolt</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3437-3440</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Medicinal chem. optimization of an impurity isolated during the scale-up synthesis of a pyridylsulfonamide type dopamine D3/D2 compd. (1, I) led to a series of new piperazine derivs. having affinity to both dopamine D3 and D2 receptors.  Several members of this group showed excellent pharmacokinetic and pharmacodynamic properties as demonstrated by outstanding activities in different antipsychotic tests.  The most promising representative, 2m (cariprazine) had good absorption, excellent brain penetration and advantageous safety profile.  Based on its successful clin. development we are looking forward to the NDA filing of cariprazine in 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgEXo42Fb5i7Vg90H21EOLACvtfcHk0lhueK7iojqQig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFeksLY%253D&md5=c70cd98791c4d5c2da5ac1f3904a8b98</span></div><a href="/servlet/linkout?suffix=cit42f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.03.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.03.104%26sid%3Dliteratum%253Aachs%26aulast%3DAgai-Csongor%26aufirst%3DE.%26aulast%3DDomany%26aufirst%3DG.%26aulast%3DNogradi%26aufirst%3DK.%26aulast%3DGalambos%26aufirst%3DJ.%26aulast%3DVago%26aufirst%3DI.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26aulast%3DGreiner%26aufirst%3DI.%26aulast%3DLaszlovszky%26aufirst%3DI.%26aulast%3DGere%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DE.%26aulast%3DKiss%26aufirst%3DB.%26aulast%3DVastag%26aufirst%3DM.%26aulast%3DTihanyi%26aufirst%3DK.%26aulast%3DSaghy%26aufirst%3DK.%26aulast%3DLaszy%26aufirst%3DJ.%26aulast%3DGyertyan%26aufirst%3DI.%26aulast%3DZajer-Balazs%26aufirst%3DM.%26aulast%3DGemesi%26aufirst%3DL.%26aulast%3DKapas%26aufirst%3DM.%26aulast%3DSzombathelyi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Cariprazine%2520%2528RGH-188%2529%253A%2520A%2520Novel%2520Antipsychotic%2520Acting%2520on%2520Dopamine%2520D3%252FD2%2520Receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3437%26epage%3D3440%26doi%3D10.1016%2Fj.bmcl.2012.03.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Czibula, L.; Againe, C. E.; Nogradi, K.; Juhasz, B.; Sebok, F.; Galambos, J.; Vago, I.</span><span> </span><span class="NLM_article-title">Piperazine Salt and a Process for the Preparation Thereof</span>. WO 2010070369A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=L.+Czibula&author=C.+E.+Againe&author=K.+Nogradi&author=B.+Juhasz&author=F.+Sebok&author=J.+Galambos&author=I.+Vago&title=Piperazine+Salt+and+a+Process+for+the+Preparation+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCzibula%26aufirst%3DL.%26atitle%3DPiperazine%2520Salt%2520and%2520a%2520Process%2520for%2520the%2520Preparation%2520Thereof%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Mathe, T. B.; Hegedus, L.; Czibula, L.; Juhasz, B.; Nagyne, B. J.; Markos, D.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Trans 4-amino-cyclohexyl Acetic Acid Ethyl Ester HCl</span>. WO 2010070368A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=T.+B.+Mathe&author=L.+Hegedus&author=L.+Czibula&author=B.+Juhasz&author=B.+J.+Nagyne&author=D.+Markos&title=Process+for+the+Preparation+of+Trans+4-amino-cyclohexyl+Acetic+Acid+Ethyl+Ester+HCl"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMathe%26aufirst%3DT.%2BB.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Trans%25204-amino-cyclohexyl%2520Acetic%2520Acid%2520Ethyl%2520Ester%2520HCl%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Ágainé, C. É.; Czibula, L.; Sebök, F.; Domany, G.; Greiner, I.</span><span> </span><span class="NLM_article-title">Novel Piperazine Salts as d3/d2 Antagonists</span>. WO 2008139235A2,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+%C3%89.+%C3%81gain%C3%A9&author=L.+Czibula&author=F.+Seb%C3%B6k&author=G.+Domany&author=I.+Greiner&title=Novel+Piperazine+Salts+as+d3%2Fd2+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3D%25C3%2581gain%25C3%25A9%26aufirst%3DC.%2B%25C3%2589.%26atitle%3DNovel%2520Piperazine%2520Salts%2520as%2520d3%252Fd2%2520Antagonists%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Borsini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jason, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohde, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollentier, S.</span><span> </span><span class="NLM_article-title">Pharmacology of Flibanserin</span> <span class="citation_source-journal">CNS Drug Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1111/j.1527-3458.2002.tb00219.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fj.1527-3458.2002.tb00219.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=117-142&author=F.+Borsiniauthor=K.+Evansauthor=K.+Jasonauthor=F.+Rohdeauthor=B.+Alexanderauthor=S.+Pollentier&title=Pharmacology+of+Flibanserin&doi=10.1111%2Fj.1527-3458.2002.tb00219.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2002.tb00219.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2002.tb00219.x%26sid%3Dliteratum%253Aachs%26aulast%3DBorsini%26aufirst%3DF.%26aulast%3DEvans%26aufirst%3DK.%26aulast%3DJason%26aufirst%3DK.%26aulast%3DRohde%26aufirst%3DF.%26aulast%3DAlexander%26aufirst%3DB.%26aulast%3DPollentier%26aufirst%3DS.%26atitle%3DPharmacology%2520of%2520Flibanserin%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2002%26volume%3D8%26spage%3D117%26epage%3D142%26doi%3D10.1111%2Fj.1527-3458.2002.tb00219.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Mullard, A.</span><span> </span><span class="NLM_article-title">FDA Approves Female Sexual Dysfunction Drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">669</span><span class="refDoi"> DOI: 10.1038/nrd4757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1038%2Fnrd4757" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=669&author=A.+Mullard&title=FDA+Approves+Female+Sexual+Dysfunction+Drug&doi=10.1038%2Fnrd4757"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrd4757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4757%26sid%3Dliteratum%253Aachs%26aulast%3DMullard%26aufirst%3DA.%26atitle%3DFDA%2520Approves%2520Female%2520Sexual%2520Dysfunction%2520Drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D669%26doi%3D10.1038%2Fnrd4757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Mohan, R. D.; Krishna, R. P.; Venkat, R. B.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Flibanserin Involving Novel Intermediates</span>. WO 2010128516A2,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+D.+Mohan&author=R.+P.+Krishna&author=R.+B.+Venkat&title=Process+for+the+Preparation+of+Flibanserin+Involving+Novel+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%26aufirst%3DR.%2BD.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Flibanserin%2520Involving%2520Novel%2520Intermediates%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Pai, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusalkar, D.</span><span> </span><span class="NLM_article-title">Pharmacological Screening of Novel Indolo[2,3-<i>b</i>]quinoxaline Derivatives</span> <span class="citation_source-journal">J. Chem. Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlWitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=485-493&author=N.+R.+Paiauthor=D.+Pusalkar&title=Pharmacological+Screening+of+Novel+Indolo%5B2%2C3-b%5Dquinoxaline+Derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological screening of novel indolo[2,3-b]quinoxaline derivatives</span></div><div class="casAuthors">Pai, Nandini R.; Pusalkar, Deeptaunshu Atul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical and Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-493</span>CODEN:
                <span class="NLM_cas:coden">JCPRC5</span>;
        ISSN:<span class="NLM_cas:issn">0975-7384</span>.
    
            (<span class="NLM_cas:orgname">Journal of Chemical and Pharmaceutical Research</span>)
        </div><div class="casAbstract">A condensation reaction of benzenediamine with isatin (1H-indole-2,3-dione) in refluxing glacial acetic acid provided indolo[2,3-b]quinoxaline.  The synthesis of the target compds. was achieved by a subsequent reaction of indolo[2,3-b]quinoxaline with carbostyril derivs. [6-(haloalkoxy)-2(1H)-quinolinone and 7-(haloalkoxy)-2(1H)-quinolinone] using NaI, K2CO3, TBAB as catalyst system.  The title compds. were evaluated against Gram-pos. bacteria and Gram-neg. bacteria (Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli) and it was discovered that they displayed slight antibacterial activity.  These compds. were also evaluated in rat models and mouse models for their antipsychotic activity (APO-induced stereotypy, DA autoreceptor agonist activity, induced catalepsy, α1-adrenoceptor antagonist activity) and it was found that these compds. displayed moderate antipsychotic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUOZxDfXzxQLVg90H21EOLACvtfcHk0lhueK7iojqQig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlWitw%253D%253D&md5=136810a158eefafeafaf0b86780900f7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DN.%2BR.%26aulast%3DPusalkar%26aufirst%3DD.%26atitle%3DPharmacological%2520Screening%2520of%2520Novel%2520Indolo%255B2%252C3-b%255Dquinoxaline%2520Derivatives%26jtitle%3DJ.%2520Chem.%2520Pharm.%2520Res.%26date%3D2010%26volume%3D2%26spage%3D485%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Ryu, S. E.; Kim, S. J.; Jeong, D. G.; Lee, S. H.; Jung, S. K.; Kim, H. M.; Park, S. K.; Lee, K. H.; Lee, C. W.; Choi, J. K.</span><span> </span><span class="NLM_article-title">Rhodandse Derivarives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same</span>. WO 2007081091A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+E.+Ryu&author=S.+J.+Kim&author=D.+G.+Jeong&author=S.+H.+Lee&author=S.+K.+Jung&author=H.+M.+Kim&author=S.+K.+Park&author=K.+H.+Lee&author=C.+W.+Lee&author=J.+K.+Choi&title=Rhodandse+Derivarives%2C+a+Process+for+the+Preparation+Thereof+and+Pharmaceutical+Composition+Containing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DS.%2BE.%26atitle%3DRhodandse%2520Derivarives%252C%2520a%2520Process%2520for%2520the%2520Preparation%2520Thereof%2520and%2520Pharmaceutical%2520Composition%2520Containing%2520the%2520Same%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Deeks, E. D.</span><span> </span><span class="NLM_article-title">Safinamide: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">711</span><span class="refDoi"> DOI: 10.1007/s40265-015-0389-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0389-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25851099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1Ols7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=705-711&author=E.+D.+Deeks&title=Safinamide%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0389-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Safinamide: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">705-711</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Safinamide (Xadago) is an oral α-aminoamide deriv. developed by Newron for the treatment of Parkinson's disease (PD).  The drug has both dopaminergic properties (highly selective and reversible inhibition of monoamine oxidase-B) and non-dopaminergic properties (selective sodium channel blockade and calcium channel modulation, with consequent inhibition of excessive glutamate release).  Safinamide is approved in the EU, Iceland, Lichtenstein and Norway, as an add-on therapy to stable-dose levodopa, alone or in combination with other PD therapies in mid- to late-stage fluctuating PD patients; regulatory submissions have also been filed in the USA and Switzerland for its use in this indication.  Addnl. submissions have been made in the USA, Iceland, Lichtenstein, Norway and Switzerland for early-stage PD.  Safinamide has also undergone phase II investigation in PD patients with drug-induced dyskinesia (France, Germany, Austria, Canada and South Africa) or cognitive impairment (USA and Spain).  This article summarizes the milestones in the development of safinamide leading to its first approval for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiB6K6JgNCR7Vg90H21EOLACvtfcHk0lj-xp3vEkhqsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1Ols7Y%253D&md5=627dd1d0e6939b77f46fdf716aaa35e9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0389-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0389-7%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DSafinamide%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D705%26epage%3D711%26doi%3D10.1007%2Fs40265-015-0389-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fariello, R. G.</span><span> </span><span class="NLM_article-title">Safinamide</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1016/j.nurt.2006.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.nurt.2006.11.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=110-116&author=R.+G.+Fariello&title=Safinamide&doi=10.1016%2Fj.nurt.2006.11.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2006.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2006.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DFariello%26aufirst%3DR.%2BG.%26atitle%3DSafinamide%26jtitle%3DNeurotherapeutics%26date%3D2007%26volume%3D4%26spage%3D110%26epage%3D116%26doi%3D10.1016%2Fj.nurt.2006.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit52b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span> </span><span class="NLM_article-title">Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease: a Review of Symptomatic and Potential Disease-Modifying Effects</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.2165/11596310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2165%2F11596310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22133327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1061-1071&author=A.+H.+V.+Schapira&title=Monoamine+Oxidase+B+Inhibitors+for+the+Treatment+of+Parkinson%E2%80%99s+Disease%3A+a+Review+of+Symptomatic+and+Potential+Disease-Modifying+Effects&doi=10.2165%2F11596310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52bR"><div class="casContent"><span class="casTitleNuber">52b</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects</span></div><div class="casAuthors">Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1061-1071</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease is a disorder characterized pathol. by progressive neurodegeneration of the dopaminergic cells of the nigrostriatal pathway.  Although the resulting dopamine deficiency is the cause of the typical motor features of Parkinson's disease (bradykinesia, rigidity, tremor), addnl. non-motor symptoms appear at various timepoints and are the result of non-dopamine nerve degeneration.  Monoamine oxidase B (MAO-B) inhibitors are used in the symptomatic treatment of Parkinson's disease as they increase synaptic dopamine by blocking its degrdn.  Two MAO-B inhibitors, selegiline and rasagiline, are currently licensed in Europe and North America for the symptomatic improvement of early Parkinson's disease and to reduce off-time in patients with more advanced Parkinson's disease and motor fluctuations related to levodopa.  A third MAO-B inhibitor (safinamide), which also combines addnl. non-dopaminergic properties of potential benefit to Parkinson's disease, is currently under development in phase III clin. trials as adjuvant therapy to either a dopamine agonist or levodopa.  MAO-B inhibitors have also been studied extensively for possible neuroprotective or disease-modifying actions.  There is considerable lab. evidence that MAO-B inhibitors do exert some neuroprotective properties, at least in the Parkinson's disease models currently available.  However, these models have significant limitations and caution is required in assuming that such results may easily be extrapolated to clin. trials.  Rasagiline 1 mg/day has been shown to provide improved motor control in terms of Unified Parkinson's Disease Rating Scale (UPDRS) score at 18 mo in those patients with early disease who began the drag 9 mo before a second group.  There are a no. of possible explanations for this effect that may include a disease-modifying action; however, the US FDA recently declined an application for the licence of rasagiline to be extended to cover disease modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2AHDUDO6Ch7Vg90H21EOLACvtfcHk0lj-xp3vEkhqsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWjurg%253D&md5=a6c6a9380eaa9056a877fa0df9e39446</span></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=10.2165%2F11596310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DMonoamine%2520Oxidase%2520B%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520a%2520Review%2520of%2520Symptomatic%2520and%2520Potential%2520Disease-Modifying%2520Effects%26jtitle%3DCNS%2520Drugs%26date%3D2011%26volume%3D25%26spage%3D1061%26epage%3D1071%26doi%3D10.2165%2F11596310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Von Raison, F.; Weiner, D.; Roach, A.; Cuenoud, B.; Bartoszyk, G.</span><span> </span><span class="NLM_article-title">Safinamide in the Treatment of Dyskinesia</span>. WO 2011098456A1,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=F.+Von+Raison&author=D.+Weiner&author=A.+Roach&author=B.+Cuenoud&author=G.+Bartoszyk&title=Safinamide+in+the+Treatment+of+Dyskinesia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BRaison%26aufirst%3DF.%26atitle%3DSafinamide%2520in%2520the%2520Treatment%2520of%2520Dyskinesia%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Mueller, T.</span><span> </span><span class="NLM_article-title">Current Status of Safinamide for the Drug Portfolio of Parkinson’s Disease Therapy</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">969</span><span class="NLM_x">–</span> <span class="NLM_lpage">977</span><span class="refDoi"> DOI: 10.1586/14737175.2013.827488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1586%2F14737175.2013.827488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24053341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqsbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=969-977&author=T.+Mueller&title=Current+Status+of+Safinamide+for+the+Drug+Portfolio+of+Parkinson%E2%80%99s+Disease+Therapy&doi=10.1586%2F14737175.2013.827488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of safinamide for the drug portfolio of Parkinson's disease therapy</span></div><div class="casAuthors">Mueller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">969-977</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is characterized by a slowly ongoing neuronal death.  This alters dopaminergic and glutamatergic neurotransmission and causes a wide variety of motor and non-motor features.  Safinamide has a unique pharmacol. profile, which combines modulation of dopamine metab. by reversible, highly specific monoamine oxidase-B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release induced by abnormal neuronal activity.  Therefore, safinamide represents an ideal candidate for the treatment of PD.  This compd. asks for one time daily intake only within an optimum dose range between 50 and 100 mg.  In clin. trials, safinamide was well tolerated and safe, improved motor behavior even in combination with dopamine agonist only, ameliorated levodopa-assocd. motor complications.  Safinamide has the potential to become an important compd. for the therapy of PD, since its symptomatic efficacy appears to be superior to available monoamine oxidase-B inhibitors or N-methyl-d-aspartate receptor antagonists like amantadine, according to available trial outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrepGBJXUO_RbVg90H21EOLACvtfcHk0lj-xp3vEkhqsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqsbzM&md5=5fad5977d10a9896d0856e4632c19f28</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1586%2F14737175.2013.827488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2013.827488%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DT.%26atitle%3DCurrent%2520Status%2520of%2520Safinamide%2520for%2520the%2520Drug%2520Portfolio%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%2520Therapy%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2013%26volume%3D13%26spage%3D969%26epage%3D977%26doi%3D10.1586%2F14737175.2013.827488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Caccia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maj, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabresi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maestroni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faravelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curatolo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fariello, R. G.</span><span> </span><span class="NLM_article-title">Safinamide From Molecular Targets to a New Anti-Parkinson Drug</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">S18</span><span class="NLM_x">–</span> <span class="NLM_lpage">S23</span><span class="refDoi"> DOI: 10.1212/WNL.67.7_suppl_2.S18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1212%2FWNL.67.7_suppl_2.S18" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=S18-S23&author=C.+Cacciaauthor=R.+Majauthor=M.+Calabresiauthor=S.+Maestroniauthor=L.+Faravelliauthor=L.+Curatoloauthor=P.+Salvatiauthor=R.+G.+Fariello&title=Safinamide+From+Molecular+Targets+to+a+New+Anti-Parkinson+Drug&doi=10.1212%2FWNL.67.7_suppl_2.S18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1212%2FWNL.67.7_suppl_2.S18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.67.7_suppl_2.S18%26sid%3Dliteratum%253Aachs%26aulast%3DCaccia%26aufirst%3DC.%26aulast%3DMaj%26aufirst%3DR.%26aulast%3DCalabresi%26aufirst%3DM.%26aulast%3DMaestroni%26aufirst%3DS.%26aulast%3DFaravelli%26aufirst%3DL.%26aulast%3DCuratolo%26aufirst%3DL.%26aulast%3DSalvati%26aufirst%3DP.%26aulast%3DFariello%26aufirst%3DR.%2BG.%26atitle%3DSafinamide%2520From%2520Molecular%2520Targets%2520to%2520a%2520New%2520Anti-Parkinson%2520Drug%26jtitle%3DNeurology%26date%3D2006%26volume%3D67%26spage%3DS18%26epage%3DS23%26doi%3D10.1212%2FWNL.67.7_suppl_2.S18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szasz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanzione, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meshram, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirilineau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">N/A Two-year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson’s Disease</span> <span class="citation_source-journal">Mov. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1273</span><span class="NLM_x">–</span> <span class="NLM_lpage">1280</span><span class="refDoi"> DOI: 10.1002/mds.25961</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fmds.25961" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=1273-1280&author=R.+Borgohainauthor=J.+Szaszauthor=P.+Stanzioneauthor=C.+Meshramauthor=M.+H.+Bhattauthor=D.+Chirilineauauthor=F.+Stocchiauthor=V.+Luciniauthor=R.+Giulianiauthor=E.+Forrestauthor=P.+Riceauthor=R.+Anand&title=N%2FA+Two-year%2C+Randomized%2C+Controlled+Study+of+Safinamide+as+Add-on+to+Levodopa+in+Mid+to+Late+Parkinson%E2%80%99s+Disease&doi=10.1002%2Fmds.25961"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56a&amp;dbid=16384&amp;doi=10.1002%2Fmds.25961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25961%26sid%3Dliteratum%253Aachs%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DSzasz%26aufirst%3DJ.%26aulast%3DStanzione%26aufirst%3DP.%26aulast%3DMeshram%26aufirst%3DC.%26aulast%3DBhatt%26aufirst%3DM.%2BH.%26aulast%3DChirilineau%26aufirst%3DD.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DForrest%26aufirst%3DE.%26aulast%3DRice%26aufirst%3DP.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DN%252FA%2520Two-year%252C%2520Randomized%252C%2520Controlled%2520Study%2520of%2520Safinamide%2520as%2520Add-on%2520to%2520Levodopa%2520in%2520Mid%2520to%2520Late%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DMov.%2520Disord.%26date%3D2014%26volume%3D29%26spage%3D1273%26epage%3D1280%26doi%3D10.1002%2Fmds.25961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit56b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szasz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanzione, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meshram, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirilineau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">Randomized Trial of Safinamide Add-on to Levodopa in Parkinson’s Disease with Motor Fluctuations</span> <span class="citation_source-journal">Mov. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">237</span><span class="refDoi"> DOI: 10.1002/mds.25751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fmds.25751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24323641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1ymsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=229-237&author=R.+Borgohainauthor=J.+Szaszauthor=P.+Stanzioneauthor=C.+Meshramauthor=M.+Bhattauthor=D.+Chirilineauauthor=F.+Stocchiauthor=V.+Luciniauthor=R.+Giulianiauthor=E.+Forrestauthor=P.+Riceauthor=R.+Anand&title=Randomized+Trial+of+Safinamide+Add-on+to+Levodopa+in+Parkinson%E2%80%99s+Disease+with+Motor+Fluctuations&doi=10.1002%2Fmds.25751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56bR"><div class="casContent"><span class="casTitleNuber">56b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations</span></div><div class="casAuthors">Borgohain, Rupam; Szasz, J.; Stanzione, P.; Meshram, C.; Bhatt, M.; Chirilineau, D.; Stocchi, F.; Lucini, V.; Giuliani, R.; Forrest, E.; Rice, P.; Anand, R.</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">229-237</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Levodopa is effective for the motor symptoms of Parkinson's disease (PD), but is assocd. with motor fluctuations and dyskinesia.  Many patients require add-on therapy to improve motor fluctuations without exacerbating dyskinesia.  The objective of this Phase III, multicenter, double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy and safety of safinamide, an α-aminoamide with dopaminergic and nondopaminergic mechanisms, as add-on to Ldopa in the treatment of patients with PD and motor fluctuations.  Patients were randomized to oral safinamide 100 mg/day (n = 224), 50 mg/day (n = 223), or placebo (n = 222) for 24 wk.  The primary endpoint was total on time with no or nontroublesome dyskinesia (assessed using the Hauser patient diaries).  Secondary endpoints included off time, Unified Parkinson's Disease Rating Scale (UPDRS) Part III (motor) scores, and Clin. Global Impression-Change (CGI-C).  At week 24, mean ± SD increases in total on time with no or nontroublesome dyskinesia were 1.36 ± 2.625 h for safinamide 100 mg/day, 1.37 ± 2.745 h for safinamide 50 mg/day, and 0.97 ± 2.375 h for placebo.  Least squares means differences in both safinamide groups were significantly higher vs. placebo.  Improvements in off time, UPDRS Part III, and CGI-C were significantly greater in both safinamide groups vs. placebo.  There were no significant between-group differences for incidences of treatment-emergent adverse events (TEAEs) or TEAEs leading to discontinuation.  The addn. of safinamide 50 mg/day or 100 mg/day to L-dopa in patients with PD and motor fluctuations significantly increased total on time with no or nontroublesome dyskinesia, decreased off time, and improved parkinsonism, indicating that safinamide improves motor symptoms and parkinsonism without worsening dyskinesia. © 2013 International Parkinson and Movement Disorder Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM1jhniIed4bVg90H21EOLACvtfcHk0lgE6ZkKxoBq7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1ymsL4%253D&md5=6b69b2ce44f29f27be5a43ef7c0be826</span></div><a href="/servlet/linkout?suffix=cit56b&amp;dbid=16384&amp;doi=10.1002%2Fmds.25751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.25751%26sid%3Dliteratum%253Aachs%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DSzasz%26aufirst%3DJ.%26aulast%3DStanzione%26aufirst%3DP.%26aulast%3DMeshram%26aufirst%3DC.%26aulast%3DBhatt%26aufirst%3DM.%26aulast%3DChirilineau%26aufirst%3DD.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DForrest%26aufirst%3DE.%26aulast%3DRice%26aufirst%3DP.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DRandomized%2520Trial%2520of%2520Safinamide%2520Add-on%2520to%2520Levodopa%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%2520with%2520Motor%2520Fluctuations%26jtitle%3DMov.%2520Disord.%26date%3D2014%26volume%3D29%26spage%3D229%26epage%3D237%26doi%3D10.1002%2Fmds.25751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onofrj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">A Randomized, Double-blind, Placebo-controlled Trial of Safinamide as Add-on Therapy in Early Parkinson’s Disease Patients</span> <span class="citation_source-journal">Mov. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1002/mds.23954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fmds.23954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=21913224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWmsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=106-112&author=F.+Stocchiauthor=R.+Borgohainauthor=M.+Onofrjauthor=A.+H.+V.+Schapiraauthor=M.+Bhattauthor=V.+Luciniauthor=R.+Giulianiauthor=R.+Anand&title=A+Randomized%2C+Double-blind%2C+Placebo-controlled+Trial+of+Safinamide+as+Add-on+Therapy+in+Early+Parkinson%E2%80%99s+Disease+Patients&doi=10.1002%2Fmds.23954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57aR"><div class="casContent"><span class="casTitleNuber">57a</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients</span></div><div class="casAuthors">Stocchi, Fabrizio; Borgohain, Rupam; Onofrj, Marco; Schapira, Anthony H. V.; Bhatt, Mohit; Lucini, Valentina; Giuliani, Rodolfo; Anand, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Movement Disorders</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">106-112</span>CODEN:
                <span class="NLM_cas:coden">MOVDEA</span>;
        ISSN:<span class="NLM_cas:issn">0885-3185</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Safinamide is an α-aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add-on to dopamine agonist (DA) therapy in early-stage PD.  In this 24-wk, double-blind study, patients with early PD receiving a stable dose of a single DA were randomized to once-daily safinamide 100 mg, safinamide 200 mg, or placebo.  The primary efficacy variable was UPDRS part III (motor examn.) total score.  Anal. was hierarchical: 200 mg of safinamide vs. placebo was tested first; the success of safinamide 100 mg vs. placebo was contingent on this.  Two hundred sixty-nine patients received safinamide 100 mg (n = 90), safinamide 200 mg (n = 89), or placebo (n = 90); 70, 81, and 81 patients, resp., completed the study.  Mean improvements from baseline to week 24 in UPDRS III total scores were -3.90 for safinamide 200 mg, -6.0 for safinamide 100 mg and -3.60 for placebo.  The difference between safinamide 200 mg and placebo was not significant [point est.: -0.4; 95% confidence interval (CI): -2.3-1.4; P = 0.6504].  Although the difference between 100 mg/day and placebo was significant (point est.: -1.9; 95% CI: -3.7 to -0.1; P = 0.0419), these results are considered exploratory.  No clin. meaningful differences from placebo were obsd. for any safety variables.  This study did not demonstrate a significant improvement of the primary endpoint for safinamide 200 mg/day.  Exploratory anal. of the primary endpoint for 100 mg/day demonstrated that the addn. of safinamide to a stable dose of DA improves motor symptoms in early PD and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPC0oQPAUMJLVg90H21EOLACvtfcHk0lgE6ZkKxoBq7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWmsL7J&md5=8472a24b3d72016247cf6ba2b8abecda</span></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=10.1002%2Fmds.23954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.23954%26sid%3Dliteratum%253Aachs%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DOnofrj%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26aulast%3DBhatt%26aufirst%3DM.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DA%2520Randomized%252C%2520Double-blind%252C%2520Placebo-controlled%2520Trial%2520of%2520Safinamide%2520as%2520Add-on%2520Therapy%2520in%2520Early%2520Parkinson%25E2%2580%2599s%2520Disease%2520Patients%26jtitle%3DMov.%2520Disord.%26date%3D2012%26volume%3D27%26spage%3D106%26epage%3D112%26doi%3D10.1002%2Fmds.23954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit57b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onofrj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">Long-term Efficacy and Safety of Safinamide as Add-on Therapy in Early Parkinson’s Disease</span> <span class="citation_source-journal">Eur. J. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1111/j.1468-1331.2012.03840.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fj.1468-1331.2012.03840.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22967035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC38bmtV2qsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=271-280&author=A.+H.+V.+Schapiraauthor=F.+Stocchiauthor=R.+Borgohainauthor=M.+Onofrjauthor=M.+Bhattauthor=P.+Lorenzanaauthor=V.+Luciniauthor=R.+Giulianiauthor=R.+Anand&title=Long-term+Efficacy+and+Safety+of+Safinamide+as+Add-on+Therapy+in+Early+Parkinson%E2%80%99s+Disease&doi=10.1111%2Fj.1468-1331.2012.03840.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57bR"><div class="casContent"><span class="casTitleNuber">57b</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease</span></div><div class="casAuthors">Schapira A H V; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology : the official journal of the European Federation of Neurological Societies</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Safinamide is an α-aminoamide with both dopaminergic and non-dopaminergic mechanisms of action in Phase III clinical development as a once-daily add-on to dopamine agonist (DA) therapy for early Parkinson's disease (PD).  METHODS:  Study 017 was a 12-month, randomized, double-blind, placebo-controlled pre-planned extension study to the previously reported Study 015.  Patients received safinamide 100 or 200 mg/day or placebo added to a single DA in early PD.  The primary efficacy endpoint was the time from baseline (Study 015 randomization) to 'intervention', defined as increase in DA dose; addition of another DA, levodopa or other PD treatment; or discontinuation due to lack of efficacy.  Safinamide groups were pooled for the primary efficacy endpoint analysis; post hoc analyses were performed on each separate dose group.  RESULTS:  Of the 269 patients randomized in Study 015, 227 (84%) enrolled in Study 017 and 187/227 (82%) patients completed the extension study.  Median time to intervention was 559 and 466 days in the pooled safinamide and placebo groups, respectively (log-rank test; P = 0.3342).  In post hoc analyses, patients receiving safinamide 100 mg/day experienced a significantly lower rate of intervention compared with placebo (25% vs. 51%, respectively) and a delay in median time to intervention of 9 days (P < 0.05; 240- to 540-day analysis).  CONCLUSIONS:  The pooled data from the safinamide groups failed to reach statistical significance for the primary endpoint of median time from baseline to additional drug intervention.  Post hoc analyses indicate that safinamide 100 mg/day may be effective as add-on treatment to DA in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTW8Q7CptAmznthwrmtH4OBfW6udTcc2eYLSQeR7VWfkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bmtV2qsw%253D%253D&md5=ae238c6d3d0f0952fc6993bd03615335</span></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1331.2012.03840.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1331.2012.03840.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DOnofrj%26aufirst%3DM.%26aulast%3DBhatt%26aufirst%3DM.%26aulast%3DLorenzana%26aufirst%3DP.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DLong-term%2520Efficacy%2520and%2520Safety%2520of%2520Safinamide%2520as%2520Add-on%2520Therapy%2520in%2520Early%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2013%26volume%3D20%26spage%3D271%26epage%3D280%26doi%3D10.1111%2Fj.1468-1331.2012.03840.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonsignori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidempergher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinciroli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fariello, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span> </span><span class="NLM_article-title">Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">590</span><span class="refDoi"> DOI: 10.1021/jm970599m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm970599m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADyaK1cXms1Oitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=579-590&author=P.+Pevarelloauthor=A.+Bonsignoriauthor=P.+Dostertauthor=F.+Heidempergherauthor=V.+Pinciroliauthor=M.+Colomboauthor=R.+A.+McArthurauthor=P.+Salvatiauthor=C.+Postauthor=R.+G.+Farielloauthor=M.+Varasi&title=Synthesis+and+Anticonvulsant+Activity+of+a+New+Class+of+2-%5B%28Arylalkyl%29amino%5Dalkanamide+Derivatives&doi=10.1021%2Fjm970599m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58aR"><div class="casContent"><span class="casTitleNuber">58a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanamide Derivatives</span></div><div class="casAuthors">Pevarello, Paolo; Bonsignori, Alberto; Dostert, Philippe; Heidempergher, Franco; Pinciroli, Vittorio; Colombo, Maristella; McArthur, Robert A.; Salvati, Patricia; Post, Claes; Fariello, Ruggero G.; Varasi, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-590</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from milacemide, a weak anticonvulsant, trying to elucidate its mechanism of action a structurally novel class of potent and preclinically safe anticonvulsants was discovered.  The structure-activity relationship study within this series of compds was reported.  Different parts of the structural lead 2-[[4-(3-chlorobenzoxy)benzyl]amino]acetamide were varied, and many potent anticonvulsants were found.  (S)-2-[[4-(3-fluorobenzoxy)benzyl]amino]propanamide methanesulfonate, (PNU-151774E), emerged as the promising candidate for further development for its potent anticonvulsant activity and outstanding therapeutic indexes in different animal tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy8FzAw312mrVg90H21EOLACvtfcHk0lhppfCdXalOsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1Oitw%253D%253D&md5=2297e82ce9a4feb069a761bd0a1d87f5</span></div><a href="/servlet/linkout?suffix=cit58a&amp;dbid=16384&amp;doi=10.1021%2Fjm970599m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm970599m%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBonsignori%26aufirst%3DA.%26aulast%3DDostert%26aufirst%3DP.%26aulast%3DHeidempergher%26aufirst%3DF.%26aulast%3DPinciroli%26aufirst%3DV.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DMcArthur%26aufirst%3DR.%2BA.%26aulast%3DSalvati%26aufirst%3DP.%26aulast%3DPost%26aufirst%3DC.%26aulast%3DFariello%26aufirst%3DR.%2BG.%26aulast%3DVarasi%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Anticonvulsant%2520Activity%2520of%2520a%2520New%2520Class%2520of%25202-%255B%2528Arylalkyl%2529amino%255Dalkanamide%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D579%26epage%3D590%26doi%3D10.1021%2Fjm970599m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit58b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dostert, P.; Pevarello, P.; Heidempergher, F.; Varasi, M.; Bonsignori, A.; Roncucci, R.</span><span> </span><span class="NLM_article-title">Preparation of α-(phenylalkylamino)carboxamides as drugs</span>. EP 400495A1,<span class="NLM_x"> </span><span class="NLM_year">1990</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1990&author=P.+Dostert&author=P.+Pevarello&author=F.+Heidempergher&author=M.+Varasi&author=A.+Bonsignori&author=R.+Roncucci&title=Preparation+of+%CE%B1-%28phenylalkylamino%29carboxamides+as+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDostert%26aufirst%3DP.%26atitle%3DPreparation%2520of%2520%25CE%25B1-%2528phenylalkylamino%2529carboxamides%2520as%2520drugs%26date%3D1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Barbanti, E.; Caccia, C.; Salvati, P.; Velardi, F.; Ruffilli, T.; Bogogna, L.</span><span> </span><span class="NLM_article-title">Process for the Production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino]propanamides</span>. WO 20090156678A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=E.+Barbanti&author=C.+Caccia&author=P.+Salvati&author=F.+Velardi&author=T.+Ruffilli&author=L.+Bogogna&title=Process+for+the+Production+of+2-%5B4-%283-+and+2-fluorobenzyloxy%29+benzylamino%5Dpropanamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbanti%26aufirst%3DE.%26atitle%3DProcess%2520for%2520the%2520Production%2520of%25202-%255B4-%25283-%2520and%25202-fluorobenzyloxy%2529%2520benzylamino%255Dpropanamides%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit59b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barbanti, E.; Faravelli, L.; Salvati, P.; Canevotti, R.; Ponzini, F.</span><span> </span><span class="NLM_article-title">Process for the Production of Highly Pure 2-[4-(3- or 2-Fluorobenzyloxy)benzylamino]propanamides as Cytochrome P450 Inhibitors and Their Pharmaceutical Compositions and Use in the Treatment of Diseases</span>. WO 2009074478A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=E.+Barbanti&author=L.+Faravelli&author=P.+Salvati&author=R.+Canevotti&author=F.+Ponzini&title=Process+for+the+Production+of+Highly+Pure+2-%5B4-%283-+or+2-Fluorobenzyloxy%29benzylamino%5Dpropanamides+as+Cytochrome+P450+Inhibitors+and+Their+Pharmaceutical+Compositions+and+Use+in+the+Treatment+of+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbanti%26aufirst%3DE.%26atitle%3DProcess%2520for%2520the%2520Production%2520of%2520Highly%2520Pure%25202-%255B4-%25283-%2520or%25202-Fluorobenzyloxy%2529benzylamino%255Dpropanamides%2520as%2520Cytochrome%2520P450%2520Inhibitors%2520and%2520Their%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Diseases%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit59c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Barbanti, E.; Caccia, C.; Salvati, P.; Velardi, F.; Rufilli, T.; Bogogna, L.</span><span> </span><span class="NLM_article-title">Process for the Production of 2-[4-(3- and 2-Fluorobenzyloxy)benzylamino]propanamides (Safinamide and Ralfinamide) of High Purity by Catalytic Hydrogenation of Schiff Base Intermediates and Their Use for Treating CNS Disorders</span>. WO 2007147491A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=E.+Barbanti&author=C.+Caccia&author=P.+Salvati&author=F.+Velardi&author=T.+Rufilli&author=L.+Bogogna&title=Process+for+the+Production+of+2-%5B4-%283-+and+2-Fluorobenzyloxy%29benzylamino%5Dpropanamides+%28Safinamide+and+Ralfinamide%29+of+High+Purity+by+Catalytic+Hydrogenation+of+Schiff+Base+Intermediates+and+Their+Use+for+Treating+CNS+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbanti%26aufirst%3DE.%26atitle%3DProcess%2520for%2520the%2520Production%2520of%25202-%255B4-%25283-%2520and%25202-Fluorobenzyloxy%2529benzylamino%255Dpropanamides%2520%2528Safinamide%2520and%2520Ralfinamide%2529%2520of%2520High%2520Purity%2520by%2520Catalytic%2520Hydrogenation%2520of%2520Schiff%2520Base%2520Intermediates%2520and%2520Their%2520Use%2520for%2520Treating%2520CNS%2520Disorders%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Eluxadoline: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1305</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span><span class="refDoi"> DOI: 10.1007/s40265-015-0436-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0436-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26149369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCjt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1305-1310&author=K.+P.+Garnock-Jones&title=Eluxadoline%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0436-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Eluxadoline: First Global Approval</span></div><div class="casAuthors">Garnock-Jones, Karly P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1305-1310</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Eluxadoline (Viberzi), developed by Actavis (now Allergan), is an orally administered, first-in-class compd. that functions as both a μ-opioid receptor agonist and a δ-opioid receptor antagonist, and is indicated for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in adults.  The agent was originally developed by Janssen Pharmaceutica.  Eluxadoline has been approved in the US, and submissions to other global authorities are being contemplated or planned.  This article summarizes the milestones in the development of eluxadoline leading to this first approval for IBS-D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5dpEIm3WsLrVg90H21EOLACvtfcHk0liXx1KRGDvhWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCjt7jF&md5=bf9bac23ac14a233f703f2d0565558f9</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0436-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0436-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DEluxadoline%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1305%26epage%3D1310%26doi%3D10.1007%2Fs40265-015-0436-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Davenport, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonifacio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venitz, J.</span><span> </span><span class="NLM_article-title">Effect of Uptake Transporters OAT3 and OATP1B1 and Efflux Transporter MRP2 on the Pharmacokinetics of Eluxadoline</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.1002/jcph.442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fjcph.442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25491493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslKhtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=534-542&author=J.+M.+Davenportauthor=P.+Covingtonauthor=L.+Bonifacioauthor=G.+McIntyreauthor=J.+Venitz&title=Effect+of+Uptake+Transporters+OAT3+and+OATP1B1+and+Efflux+Transporter+MRP2+on+the+Pharmacokinetics+of+Eluxadoline&doi=10.1002%2Fjcph.442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline</span></div><div class="casAuthors">Davenport, J. Michael; Covington, Paul; Bonifacio, Laura; McIntyre, Gail; Venitz, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">534-542</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The effects of OATP1B1, OAT3, and MRP2 on the pharmacokinetics of eluxadoline, an oral, locally active, opioid receptor agonist/antagonist being developed for treatment of IBS-d were assessed in vivo.  Coadministration of a single 200 mg dose of eluxadoline with cyclosporine, and probenecid increased eluxadoline systemic exposure [AUC(0-inf)] by 4.4- and 1.4-fold, resp., whereas peak exposure (Cmax) increased 6.2-fold and 1.3-fold, resp.  Cyclosporine had little effect on renal clearance (CLren) of eluxadoline whereas probenecid reduced CLren by nearly 50%.  These study results suggested that sinusoidal OATP1B1-mediated hepatic uptake of eluxadoline (during first-pass and systemic extn.) plays a major role in its absorption and disposition, whereas OAT3-mediated basolateral uptake in the proximal renal tubules and MRP2-mediated canalicular and renal tubular apical efflux play only minor roles in its overall disposition.  All treatments were safe and well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGornZGN3p0yFrVg90H21EOLACvtfcHk0liXx1KRGDvhWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslKhtLY%253D&md5=a45df657a815cd10239dd7da2f8cc5be</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fjcph.442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.442%26sid%3Dliteratum%253Aachs%26aulast%3DDavenport%26aufirst%3DJ.%2BM.%26aulast%3DCovington%26aufirst%3DP.%26aulast%3DBonifacio%26aufirst%3DL.%26aulast%3DMcIntyre%26aufirst%3DG.%26aulast%3DVenitz%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520Uptake%2520Transporters%2520OAT3%2520and%2520OATP1B1%2520and%2520Efflux%2520Transporter%2520MRP2%2520on%2520the%2520Pharmacokinetics%2520of%2520Eluxadoline%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D55%26spage%3D534%26epage%3D542%26doi%3D10.1002%2Fjcph.442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Wade, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKenney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenigs, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevalier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabus, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornby, P. J.</span><span> </span><span class="NLM_article-title">Modulation of Gastrointestinal Function by MuDelta, a Mixed μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1125</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02068.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fj.1476-5381.2012.02068.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22671931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1111-1125&author=P.+R.+Wadeauthor=J.+M.+Palmerauthor=S.+McKenneyauthor=V.+Kenigsauthor=K.+Chevalierauthor=B.+A.+Mooreauthor=J.+R.+Mabusauthor=P.+R.+Saundersauthor=N.+H.+Wallaceauthor=C.+R.+Schneiderauthor=E.+S.+Kimballauthor=H.+J.+Breslinauthor=W.+Heauthor=P.+J.+Hornby&title=Modulation+of+Gastrointestinal+Function+by+MuDelta%2C+a+Mixed+%CE%BC+Opioid+Receptor+Agonist%2F%CE%B4+Opioid+Receptor+Antagonist&doi=10.1111%2Fj.1476-5381.2012.02068.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/δ opioid receptor antagonist</span></div><div class="casAuthors">Wade, P. R.; Palmer, J. M.; McKenney, S.; Kenigs, V.; Chevalier, K.; Moore, B. A.; Mabus, J. R.; Saunders, P. R.; Wallace, N. H.; Schneider, C. R.; Kimball, E. S.; Breslin, H. J.; He, W.; Hornby, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1111-1125</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background & Purpose: Loperamide is a selective μ opioid receptor agonist acting locally in the gastrointestinal (GI) tract as an effective anti-diarrheal but can cause constipation.  We tested whether modulating μ opioid receptor agonism with δ opioid receptor antagonism, by combining ref. compds. or using a novel compd. ("MuDelta"), could normalize GI motility without constipation.  Exptl. Approach: MuDelta was characterized in vitro as a potent μ opioid receptor agonist and high-affinity δ opioid receptor antagonist.  Ref. compds., MuDelta and loperamide were assessed in the following ex vivo and in vivo expts.: guinea pig intestinal smooth muscle contractility, mouse intestinal epithelial ion transport and upper GI tract transit, entire GI transit or fecal output in novel environment stressed mice, or four weeks after intracolonic mustard oil (post-inflammatory).  Colonic δ opioid receptor immunoreactivity was quantified.  Key Results: δ Opioid receptor antagonism opposed μ opioid receptor agonist inhibition of intestinal contractility and motility.  MuDelta reduced intestinal contractility and inhibited neurogenically-mediated secretion.  Very low plasma levels of MuDelta were detected after oral administration.  Stress up-regulated δ opioid receptor expression in colonic epithelial cells.  In stressed mice, MuDelta normalized GI transit and fecal output to control levels over a wide dose range, whereas loperamide had a narrow dose range.  MuDelta and loperamide reduced upper GI transit in the post-inflammatory model.  Conclusions and Implications: MuDelta normalizes, but does not prevent, perturbed GI transit over a wide dose-range in mice.  These data support the subsequent assessment of MuDelta in a clin. phase II trial in patients with diarrhea-predominant irritable bowel syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQG0V55ljlfbVg90H21EOLACvtfcHk0liXx1KRGDvhWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7fI&md5=5afeecf803cf0cbf8860ab13f23807c8</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02068.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02068.x%26sid%3Dliteratum%253Aachs%26aulast%3DWade%26aufirst%3DP.%2BR.%26aulast%3DPalmer%26aufirst%3DJ.%2BM.%26aulast%3DMcKenney%26aufirst%3DS.%26aulast%3DKenigs%26aufirst%3DV.%26aulast%3DChevalier%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DB.%2BA.%26aulast%3DMabus%26aufirst%3DJ.%2BR.%26aulast%3DSaunders%26aufirst%3DP.%2BR.%26aulast%3DWallace%26aufirst%3DN.%2BH.%26aulast%3DSchneider%26aufirst%3DC.%2BR.%26aulast%3DKimball%26aufirst%3DE.%2BS.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DHornby%26aufirst%3DP.%2BJ.%26atitle%3DModulation%2520of%2520Gastrointestinal%2520Function%2520by%2520MuDelta%252C%2520a%2520Mixed%2520%25CE%25BC%2520Opioid%2520Receptor%2520Agonist%252F%25CE%25B4%2520Opioid%2520Receptor%2520Antagonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1111%26epage%3D1125%26doi%3D10.1111%2Fj.1476-5381.2012.02068.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Lembo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacy, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuckerman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dove, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrae, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davenport, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, P. S.</span><span> </span><span class="NLM_article-title">Eluxadoline for Irritable Bowel Syndrome with Diarrhea</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1056/NEJMoa1505180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1056%2FNEJMoa1505180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26789872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2murzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=242-253&author=A.+J.+Lemboauthor=B.+E.+Lacyauthor=M.+J.+Zuckermanauthor=R.+Scheyauthor=L.+S.+Doveauthor=D.+A.+Andraeauthor=J.+M.+Davenportauthor=G.+McIntyreauthor=R.+Lopezauthor=L.+Turnerauthor=P.+S.+Covington&title=Eluxadoline+for+Irritable+Bowel+Syndrome+with+Diarrhea&doi=10.1056%2FNEJMoa1505180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Eluxadoline for irritable bowel syndrome with diarrhea</span></div><div class="casAuthors">Lembo, Anthony J.; Lacy, Brian E.; Zuckerman, Marc J.; Schey, Ron; Dove, Leonard S.; Andrae, David A.; Davenport, J. Michael; McIntyre, Gail; Lopez, Rocio; Turner, Lisa; Covington, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-253</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea.  We conducted two phase 3 trials to assess the efficacy and safety of eluxadoline, a new oral agent with mixed opioid effects (μ- and κ-opioid receptor agonist and d-opioid receptor antagonist), in patients with IBS with diarrhea.  METHODS We randomly assigned 2427 adults who had IBS with diarrhea to eluxadoline (at a dose of 75 mg or 100 mg) or placebo twice daily for 26 wk (IBS-3002 trial) or 52 wk (IBS-3001 trial).  The primary end point was the proportion of patients who had a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50% of the days from weeks 1 through 12 and from weeks 1 through 26.  RESULTS For weeks 1 through 12, more patients in the eluxadoline groups (75 mg and 100 mg) than in the placebo group reached the primary end point (IBS-3001 trial, 23.9% with the 75-mg dose and 25.1% with the 100-mg dose vs. 17.1% with placebo; P = 0.01 and P = 0.004, resp.; IBS-3002 trial, 28.9% and 29.6%, resp., vs. 16.2%; P<0.001 for both comparisons).  For weeks 1 through 26, the corresponding rates in IBS-3001 were 23.4% and 29.3% vs. 19.0% (P = 0.11 and P<0.001, resp.), and the corresponding rates in IBS-3002 were 30.4% and 32.7% vs. 20.2% (P = 0.001 and P<0.001, resp.).  The most common adverse events assocd. with 75 mg of eluxadoline and 100 mg of eluxadoline, as compared with placebo, were nausea (8.1% and 7.5% vs. 5.1%), constipation (7.4% and 8.6% vs. 2.5%), and abdominal pain (5.8% and 7.2% vs. 4.1%).  Pancreatitis developed in 5 (2 in the 75-mg group and 3 in the 100-mg group) of the 1666 patients in the safety population (0.3%).  CONCLUSIONS Eluxadoline is a new therapeutic agent that reduced symptoms of IBS with diarrhea in men and women, with sustained efficacy over 6 mo in patients who received the 100-mg dose twice daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_84WD0f6Ic7Vg90H21EOLACvtfcHk0liFaqNxd34nFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2murzL&md5=9f9c72c794d938e8117d8a961daed793</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1505180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1505180%26sid%3Dliteratum%253Aachs%26aulast%3DLembo%26aufirst%3DA.%2BJ.%26aulast%3DLacy%26aufirst%3DB.%2BE.%26aulast%3DZuckerman%26aufirst%3DM.%2BJ.%26aulast%3DSchey%26aufirst%3DR.%26aulast%3DDove%26aufirst%3DL.%2BS.%26aulast%3DAndrae%26aufirst%3DD.%2BA.%26aulast%3DDavenport%26aufirst%3DJ.%2BM.%26aulast%3DMcIntyre%26aufirst%3DG.%26aulast%3DLopez%26aufirst%3DR.%26aulast%3DTurner%26aufirst%3DL.%26aulast%3DCovington%26aufirst%3DP.%2BS.%26atitle%3DEluxadoline%2520for%2520Irritable%2520Bowel%2520Syndrome%2520with%2520Diarrhea%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D242%26epage%3D253%26doi%3D10.1056%2FNEJMoa1505180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Breslin, H. J.; Cai, C.; He, W.; Kavash, R. W.</span><span> </span><span class="NLM_article-title">Preparation of Imidazole Derivatives as Opioid Receptor Modulators</span>. WO 20050203143A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=H.+J.+Breslin&author=C.+Cai&author=W.+He&author=R.+W.+Kavash&title=Preparation+of+Imidazole+Derivatives+as+Opioid+Receptor+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26atitle%3DPreparation%2520of%2520Imidazole%2520Derivatives%2520as%2520Opioid%2520Receptor%2520Modulators%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Cai, C.; He, W.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Amino Acid Derivatives as Opioid Modulators</span>. WO 2006099060A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=C.+Cai&author=W.+He&title=Process+for+the+Preparation+of+Amino+Acid+Derivatives+as+Opioid+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DC.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Amino%2520Acid%2520Derivatives%2520as%2520Opioid%2520Modulators%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Anzalone, L.; Villani, F. J.; Teleha, C. A.; Feibush, P.; Fegely, B.</span><span> </span><span class="NLM_article-title">Novel Crystals and Process of Making 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1<i>H</i>-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxybenzoic Acid</span>. WO 2009009480A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=L.+Anzalone&author=F.+J.+Villani&author=C.+A.+Teleha&author=P.+Feibush&author=B.+Fegely&title=Novel+Crystals+and+Process+of+Making+5-%28%7B%5B2-Amino-3-%284-carbamoyl-2%2C6-dimethyl-phenyl%29-propionyl%5D-%5B1-%284-phenyl-1H-imidazol-2-yl%29-ethyl%5D-amino%7D-methyl%29-2-methoxybenzoic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAnzalone%26aufirst%3DL.%26atitle%3DNovel%2520Crystals%2520and%2520Process%2520of%2520Making%25205-%2528%257B%255B2-Amino-3-%25284-carbamoyl-2%252C6-dimethyl-phenyl%2529-propionyl%255D-%255B1-%25284-phenyl-1H-imidazol-2-yl%2529-ethyl%255D-amino%257D-methyl%2529-2-methoxybenzoic%2520Acid%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Syed, Y. Y.</span><span> </span><span class="NLM_article-title">Rolapitant: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1941</span><span class="NLM_x">–</span> <span class="NLM_lpage">1945</span><span class="refDoi"> DOI: 10.1007/s40265-015-0485-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0485-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26467681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1941-1945&author=Y.+Y.+Syed&title=Rolapitant%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0485-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant: First Global Approval</span></div><div class="casAuthors">Syed, Yahiya Y.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1941-1945</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Rolapitant (Varubi) is an orally active neurokinin-1 receptor antagonist developed by TESARO and approved in the USA for use in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.  Unlike other approved agents in this class, rolapitant does not interact with cytochrome P 450 (CYP) enzyme CYP3A4.  It also has a long elimination half-life which means that a single dose could prevent CINV during the entire at-risk period (0-120 h).  An i.v. formulation of rolapitant is under clin. development in the USA.  Phase II development of rolapitant in postoperative nausea and vomiting, and cough appears to have been discontinued.  This article summarizes the milestones in the development of rolapitant leading to the first approval for the prevention of CINV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYwyS3mfly17Vg90H21EOLACvtfcHk0liFaqNxd34nFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yltbvM&md5=053f47d986332d2442b6fc8a08066814</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0485-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0485-8%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DY.%2BY.%26atitle%3DRolapitant%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1941%26epage%3D1945%26doi%3D10.1007%2Fs40265-015-0485-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Duffy, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varty, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, E. M.</span><span> </span><span class="NLM_article-title">Rolapitant (SCH 619734): A Potent, Selective and Orally Active Neurokinin NK1 Receptor Antagonist with Centrally-mediated Antiemetic Effects in Ferrets</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1016/j.pbb.2012.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.pbb.2012.03.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22497992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2012&pages=95-100&author=R.+A.+Duffyauthor=C.+Morganauthor=R.+Naylorauthor=G.+A.+Higginsauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=E.+M.+Parker&title=Rolapitant+%28SCH+619734%29%3A+A+Potent%2C+Selective+and+Orally+Active+Neurokinin+NK1+Receptor+Antagonist+with+Centrally-mediated+Antiemetic+Effects+in+Ferrets&doi=10.1016%2Fj.pbb.2012.03.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant (SCH 619734): A potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets</span></div><div class="casAuthors">Duffy, Ruth A.; Morgan, Cynthia; Naylor, Robert; Higgins, Guy A.; Varty, Geoffrey B.; Lachowicz, Jean E.; Parker, Eric M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-100</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NK1 receptor antagonists have been shown to have a variety of physiol. and potential therapeutic effects in animal models and in humans.  The present studies demonstrate that Rolapitant (SCH 619734, (5S)-8(S)-[[1(R)-[3,5 bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one) is a selective, bioavailable, CNS penetrant neurokinin NK1 receptor antagonist that shows behavioral effects in animals models of emesis.  In vitro studies indicate that rolapitant has a high affinity for the human NK1 receptor of 0.66 nM and high selectivity over the human NK2 and NK3 subtypes of > 1000-fold, as well as preferential affinity for human, guinea pig, gerbil and monkey NK1 receptors over rat, mouse and rabbit.  Rolapitant is a functionally competitive antagonist, as measured by calcium efflux, with a calcd. Kb of 0.17 nM.  Rolapitant reversed NK1 agonist-induced foot tapping in gerbils following both i.v. and oral administration up to 24 h at a minimal ED (MED) of 0.1 mg/kg.  Rolapitant was active at 0.1 and 1 mg/kg in both acute and delayed emesis models in ferrets, resp., consistent with clin. data for other NK1 antagonists.  Clin. efficacy of anti-emetics is highly correlated with efficacy in the ferret emesis model, suggesting rolapitant is a viable clin. candidate for this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeOZ_Iy_LTMLVg90H21EOLACvtfcHk0lgEwaWapu1ZSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFagu7w%253D&md5=a2eeef1c15adfb885e89c0c2a5ab4cbe</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2012.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2012.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DDuffy%26aufirst%3DR.%2BA.%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DNaylor%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DParker%26aufirst%3DE.%2BM.%26atitle%3DRolapitant%2520%2528SCH%2520619734%2529%253A%2520A%2520Potent%252C%2520Selective%2520and%2520Orally%2520Active%2520Neurokinin%2520NK1%2520Receptor%2520Antagonist%2520with%2520Centrally-mediated%2520Antiemetic%2520Effects%2520in%2520Ferrets%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2012%26volume%3D102%26spage%3D95%26epage%3D100%26doi%3D10.1016%2Fj.pbb.2012.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Janelsins, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tejani, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peoples, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustian, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, G. R.</span><span> </span><span class="NLM_article-title">Current Pharmacotherapy for Chemotherapy-induced Nausea and Vomiting in Cancer Patients</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">757</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span><span class="refDoi"> DOI: 10.1517/14656566.2013.776541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14656566.2013.776541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=23496347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=757-766&author=M.+C.+Janelsinsauthor=M.+A.+Tejaniauthor=C.+Kamenauthor=A.+R.+Peoplesauthor=K.+M.+Mustianauthor=G.+R.+Morrow&title=Current+Pharmacotherapy+for+Chemotherapy-induced+Nausea+and+Vomiting+in+Cancer+Patients&doi=10.1517%2F14656566.2013.776541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients</span></div><div class="casAuthors">Janelsins, Michelle C.; Tejani, Mohamedtaki A.; Kamen, Charles; Peoples, Anita R.; Mustian, Karen M.; Morrow, Gary R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">757-766</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Nausea and vomiting are two of the most frequent and troubling side effects patients experience during chemotherapy, interfering with compliance with cancer therapies and quality of life.  While newly available treatments have improved our ability to manage nausea and vomiting, anticipatory and delayed nausea and vomiting are still major problems for patients receiving chemotherapy.  Many cancer patients consider delaying future chemotherapy cycles and some contemplate stopping chemotherapy altogether because of their fear of experiencing further nausea and vomiting.Areas covered: The purpose of this article is to provide an overview of the pathopsychophysiol. of chemotherapy-induced nausea and vomiting (CINV), the recommended guidelines for treatment, and current agents in late-stage clin. trials, and future research needs to address the continued challenges of treatment-related nausea and vomiting.Expert opinion: Despite advances in pharmaceutical and behavioral therapies, and the provision of std. clin. guidelines for effectively managing CINV, patients continue to experience it.  Moreover, control of nausea, acute and delayed, and anticipatory nausea and vomiting remains an important, unmet need among cancer patients.  It is crit. to focus attention on better understanding the mechanisms underlying nausea, anticipatory symptoms and delayed symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGxPTxNlvA_LVg90H21EOLACvtfcHk0lgEwaWapu1ZSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKmsLs%253D&md5=d012824f6f138da7286175cf9253141f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.776541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.776541%26sid%3Dliteratum%253Aachs%26aulast%3DJanelsins%26aufirst%3DM.%2BC.%26aulast%3DTejani%26aufirst%3DM.%2BA.%26aulast%3DKamen%26aufirst%3DC.%26aulast%3DPeoples%26aufirst%3DA.%2BR.%26aulast%3DMustian%26aufirst%3DK.%2BM.%26aulast%3DMorrow%26aufirst%3DG.%2BR.%26atitle%3DCurrent%2520Pharmacotherapy%2520for%2520Chemotherapy-induced%2520Nausea%2520and%2520Vomiting%2520in%2520Cancer%2520Patients%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D757%26epage%3D766%26doi%3D10.1517%2F14656566.2013.776541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Navari, R. M.</span><span> </span><span class="NLM_article-title">Rolapitant for the Treatment of Chemotherapy-induced Nausea and Vomiting</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1133</span><span class="refDoi"> DOI: 10.1586/14737140.2015.1088787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1586%2F14737140.2015.1088787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26366937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCmsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1127-1133&author=R.+M.+Navari&title=Rolapitant+for+the+Treatment+of+Chemotherapy-induced+Nausea+and+Vomiting&doi=10.1586%2F14737140.2015.1088787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Rolapitant for the treatment of chemotherapy-induced nausea and vomiting</span></div><div class="casAuthors">Navari, Rudolph M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1127-1133</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Chemotherapy-induced nausea and vomiting is a significant clin. issue which affects patient's quality of life and treatment decisions.  Significant improvements in the control of chemotherapy-induced nausea and vomiting have occurred in the past 15 years with the introduction of new antiemetic agents 5-HT3, receptor antagonists, neurokinin-1 (NK-1) receptor antagonists, and olanzapine.  Aprepitant was the first NK-1 receptor antagonist introduced (2003) for the prevention of chemotherapy-induced nausea and vomiting in combination with a 5-HT3 receptor antagonist and dexamethasone.  A second NK-1 receptor antagonist netupitant was approved for use in Oct. 2014.  Phase III clin. trials of an addnl. NK-1 receptor antagonist rolapitant have been completed, and the data have been submitted for regulatory approval.  A description of rolapitant and its role in chemotherapy-induced nausea and vomiting will be presented, along with a comparison of the other neurolinin-1 receptor antagonists aprepitant and netupitant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAnPqNsv07zrVg90H21EOLACvtfcHk0lgEwaWapu1ZSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCmsb%252FM&md5=2014c10630544b888f3500a82d62e03e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1586%2F14737140.2015.1088787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2015.1088787%26sid%3Dliteratum%253Aachs%26aulast%3DNavari%26aufirst%3DR.%2BM.%26atitle%3DRolapitant%2520for%2520the%2520Treatment%2520of%2520Chemotherapy-induced%2520Nausea%2520and%2520Vomiting%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2015%26volume%3D15%26spage%3D1127%26epage%3D1133%26doi%3D10.1586%2F14737140.2015.1088787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Romero, D.</span><span> </span><span class="NLM_article-title">Chemotherapy Rolapitant - a New and Safer Antiemetic Agent</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">562</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2015.144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1038%2Fnrclinonc.2015.144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26305036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVahtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=562&author=D.+Romero&title=Chemotherapy+Rolapitant+-+a+New+and+Safer+Antiemetic+Agent&doi=10.1038%2Fnrclinonc.2015.144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy Rolapitant - a new and safer antiemetic agent</span></div><div class="casAuthors">Romero, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">562</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chemotherapy rolapitant is a new and safer antiemetic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUJb9EH4aWrVg90H21EOLACvtfcHk0lgEwaWapu1ZSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVahtLzJ&md5=41f53e4afa8d1aff98f97a7b846f29f2</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.144%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%26atitle%3DChemotherapy%2520Rolapitant%2520-%2520a%2520New%2520and%2520Safer%2520Antiemetic%2520Agent%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D562%26doi%3D10.1038%2Fnrclinonc.2015.144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schwartzberg, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modiano, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rapoport, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chasen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gridelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navari, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnadig, I. D.</span><span> </span><span class="NLM_article-title">Safety and Efficacy of Rolapitant for Prevention of Chemotherapy-induced Nausea and Vomiting after Administration of Moderately Emetogenic Chemotherapy or Anthracycline and Cyclophosphamide Regimens in Patients with Cancer: a Randomised, Active-controlled, Double-blind, Phase 3 Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1071</span><span class="NLM_x">–</span> <span class="NLM_lpage">1078</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00034-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS1470-2045%2815%2900034-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26272768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlWgt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1071-1078&author=L.+S.+Schwartzbergauthor=M.+R.+Modianoauthor=B.+L.+Rapoportauthor=M.+R.+Chasenauthor=C.+Gridelliauthor=L.+Urbanauthor=A.+Pomaauthor=S.+Aroraauthor=R.+M.+Navariauthor=I.+D.+Schnadig&title=Safety+and+Efficacy+of+Rolapitant+for+Prevention+of+Chemotherapy-induced+Nausea+and+Vomiting+after+Administration+of+Moderately+Emetogenic+Chemotherapy+or+Anthracycline+and+Cyclophosphamide+Regimens+in+Patients+with+Cancer%3A+a+Randomised%2C+Active-controlled%2C+Double-blind%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2815%2900034-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72aR"><div class="casContent"><span class="casTitleNuber">72a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial</span></div><div class="casAuthors">Schwartzberg, Lee S.; Modiano, Manuel R.; Rapoport, Bernardo L.; Chasen, Martin R.; Gridelli, Cesare; Urban, Laszlo; Poma, Allen; Arora, Sujata; Navari, Rudolph M.; Schnadig, Ian D.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1071-1078</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Chemotherapy-induced nausea and vomiting is a common side-effect of many antineoplastic regimens and can occur for several days after treatment.  We aimed to assess the neurokinin-1 receptor antagonist rolapitant, in combination with a serotonin (5-HT3) receptor antagonist and dexamethasone, for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of moderately emetogenic chemotherapy or regimens contg. an anthracycline and cyclophosphamide.  We conducted a global, randomised, double-blind, active-controlled, phase 3 study at 170 cancer centers in 23 countries.  We included patients with cancer aged 18 years or older, who had not received moderately or highly emetogenic chemotherapy before, with a Karnofsky performance score of 60 or higher, and a predicted life expectancy of 4 mo or longer.  We used an interactive web-based randomisation system to randomly allocate patients to receive either oral rolapitant (one 180 mg dose; rolapitant group) or a placebo that was identical in appearance (active control group) 1-2 h before administration of moderately emetogenic chemotherapy.  Patients were stratified by sex.  All patients also received granisetron (2 mg orally) and dexamethasone (20 mg orally) on day 1 (except for patients receiving taxanes as part of moderately emetogenic chemotherapy, who received dexamethasone according to the package insert) and granisetron (2 mg orally) on days 2-3.  Every cycle was a min. of 14 days.  In up to five subsequent cycles, patients received the same study drug they were assigned in cycle 1, unless they chose to leave the study or were removed at the treating clinician's discretion.  Efficacy anal. was done in the modified intention-to-treat population (comprising all patients who received at least one dose of study drug at a study site compliant with Good Clin. Practice [GCP]).  The primary endpoint was the proportion of patients achieving a complete response (defined as no emesis or use of rescue medication) in the delayed phase (>24-120 h after initiation of chemotherapy) in cycle 1.  This study is registered with ClinicalTrials.gov, no. NCT01500226.  The study has been completed.  Between March 5, 2012, and Sept 6, 2013, 1369 patients were randomised to receive either rolapitant (n=684) or active control (n=685). 666 patients in each group received at least one dose of study drug at a GCP-compliant site and were included in the modified intention-to-treat population.  A significantly greater proportion of patients receiving rolapitant had complete responses in the delayed phase than did those receiving active control (475 [71%] vs 410 [62%]; odds ratio 1·6, 95% CI 1·2-2·0; p=0·0002).  The incidence of adverse events was similar in the rolapitant and control groups, with the most frequently reported treatment-related treatment-emergent adverse events being fatigue, constipation, and headache.  For cycle 1, the most common grade 3-4 adverse event in the rolapitant vs. active control groups was neutropenia (32 [5%] vs 23 [3%] patients).  No serious adverse event was treatment-related, and no treatment-related treatment-emergent adverse event resulted in death.  Rolapitant in combination with a 5-HT3 receptor antagonist and dexamethasone is well tolerated and shows superiority over active control for the prevention of chemotherapy-induced nausea and vomiting during the 5-day (0-120 h) at-risk period after administration of moderately emetogenic chemotherapy or regimens contg. an anthracycline and cyclophosphamide.TESARO, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD1Gd_H8w0YbVg90H21EOLACvtfcHk0liOu4JltsDQvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlWgt7zO&md5=ff42f7d4553124c60386e186fcac1da5</span></div><a href="/servlet/linkout?suffix=cit72a&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900034-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900034-0%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartzberg%26aufirst%3DL.%2BS.%26aulast%3DModiano%26aufirst%3DM.%2BR.%26aulast%3DRapoport%26aufirst%3DB.%2BL.%26aulast%3DChasen%26aufirst%3DM.%2BR.%26aulast%3DGridelli%26aufirst%3DC.%26aulast%3DUrban%26aufirst%3DL.%26aulast%3DPoma%26aufirst%3DA.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DNavari%26aufirst%3DR.%2BM.%26aulast%3DSchnadig%26aufirst%3DI.%2BD.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Rolapitant%2520for%2520Prevention%2520of%2520Chemotherapy-induced%2520Nausea%2520and%2520Vomiting%2520after%2520Administration%2520of%2520Moderately%2520Emetogenic%2520Chemotherapy%2520or%2520Anthracycline%2520and%2520Cyclophosphamide%2520Regimens%2520in%2520Patients%2520with%2520Cancer%253A%2520a%2520Randomised%252C%2520Active-controlled%252C%2520Double-blind%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2015%26volume%3D16%26spage%3D1071%26epage%3D1078%26doi%3D10.1016%2FS1470-2045%2815%2900034-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit72b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rapoport, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartzberg, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chasen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnadig, I.</span><span> </span><span class="NLM_article-title">Efficacy and Safety of Rolapitant for Prevention of Chemotherapy-induced Nausea and Vomiting Over Multiple Cycles of Moderately or Highly Emetogenic Chemotherapy</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1016/j.ejca.2015.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.ejca.2015.12.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=23-30&author=B.+Rapoportauthor=L.+Schwartzbergauthor=M.+Chasenauthor=D.+Powersauthor=S.+Aroraauthor=R.+Navariauthor=I.+Schnadig&title=Efficacy+and+Safety+of+Rolapitant+for+Prevention+of+Chemotherapy-induced+Nausea+and+Vomiting+Over+Multiple+Cycles+of+Moderately+or+Highly+Emetogenic+Chemotherapy&doi=10.1016%2Fj.ejca.2015.12.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2015.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2015.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DRapoport%26aufirst%3DB.%26aulast%3DSchwartzberg%26aufirst%3DL.%26aulast%3DChasen%26aufirst%3DM.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DNavari%26aufirst%3DR.%26aulast%3DSchnadig%26aufirst%3DI.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Rolapitant%2520for%2520Prevention%2520of%2520Chemotherapy-induced%2520Nausea%2520and%2520Vomiting%2520Over%2520Multiple%2520Cycles%2520of%2520Moderately%2520or%2520Highly%2520Emetogenic%2520Chemotherapy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D57%26spage%3D23%26epage%3D30%26doi%3D10.1016%2Fj.ejca.2015.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Wu, G. G.; Werne, G.; Fu, X.; Orr, R. K.; Chen, F. X.; Cui, J.; Sprague, V. M.; Zhang, F.; Xie, J.; Zeng, L.; Castellanos, L. P.; Chen, Y.; Poirier, M.; Mergelsberg, I.</span><span> </span><span class="NLM_article-title">Process and Intermediates for the Synthesis of 8-[[1-[3,5-bis-(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one Compounds</span>. WO 2010028232A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=G.+G.+Wu&author=G.+Werne&author=X.+Fu&author=R.+K.+Orr&author=F.+X.+Chen&author=J.+Cui&author=V.+M.+Sprague&author=F.+Zhang&author=J.+Xie&author=L.+Zeng&author=L.+P.+Castellanos&author=Y.+Chen&author=M.+Poirier&author=I.+Mergelsberg&title=Process+and+Intermediates+for+the+Synthesis+of+8-%5B%5B1-%5B3%2C5-bis-%28trifluoromethyl%29phenyl%5Dethoxy%5Dmethyl%5D-8-phenyl-1%2C7-diazaspiro%5B4.5%5Ddecan-2-one+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%2BG.%26atitle%3DProcess%2520and%2520Intermediates%2520for%2520the%2520Synthesis%2520of%25208-%255B%255B1-%255B3%252C5-bis-%2528trifluoromethyl%2529phenyl%255Dethoxy%255Dmethyl%255D-8-phenyl-1%252C7-diazaspiro%255B4.5%255Ddecan-2-one%2520Compounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Dikshit, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheshwari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panday, S. K.</span><span> </span><span class="NLM_article-title">Self Reproduction of Chirality in Pyroglutamates: Reactions at α-Position with Electrophiles</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">6131</span><span class="NLM_x">–</span> <span class="NLM_lpage">6134</span><span class="refDoi"> DOI: 10.1016/0040-4039(95)01160-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2F0040-4039%2895%2901160-J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=6131-6134&author=D.+K.+Dikshitauthor=A.+Maheshwariauthor=S.+K.+Panday&title=Self+Reproduction+of+Chirality+in+Pyroglutamates%3A+Reactions+at+%CE%B1-Position+with+Electrophiles&doi=10.1016%2F0040-4039%2895%2901160-J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2895%2901160-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252895%252901160-J%26sid%3Dliteratum%253Aachs%26aulast%3DDikshit%26aufirst%3DD.%2BK.%26aulast%3DMaheshwari%26aufirst%3DA.%26aulast%3DPanday%26aufirst%3DS.%2BK.%26atitle%3DSelf%2520Reproduction%2520of%2520Chirality%2520in%2520Pyroglutamates%253A%2520Reactions%2520at%2520%25CE%25B1-Position%2520with%2520Electrophiles%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26spage%3D6131%26epage%3D6134%26doi%3D10.1016%2F0040-4039%2895%2901160-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">O’Donnell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffman, J. C.</span><span> </span><span class="NLM_article-title">New Methodology for the Synthesis of α,α-Dialkylamino Acids Using the ″Self-regeneration of Stereocenters″ Method: α-Ethyl-α-phenylglycine</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">630</span><span class="refDoi"> DOI: 10.3987/COM-97-S83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.3987%2FCOM-97-S83" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1997&pages=617-630&author=M.+J.+O%E2%80%99Donnellauthor=Z.+Fangauthor=X.+Maauthor=J.+C.+Huffman&title=New+Methodology+for+the+Synthesis+of+%CE%B1%2C%CE%B1-Dialkylamino+Acids+Using+the+%E2%80%B3Self-regeneration+of+Stereocenters%E2%80%B3+Method%3A+%CE%B1-Ethyl-%CE%B1-phenylglycine&doi=10.3987%2FCOM-97-S83"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.3987%2FCOM-97-S83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-97-S83%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DM.%2BJ.%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DHuffman%26aufirst%3DJ.%2BC.%26atitle%3DNew%2520Methodology%2520for%2520the%2520Synthesis%2520of%2520%25CE%25B1%252C%25CE%25B1-Dialkylamino%2520Acids%2520Using%2520the%2520%25E2%2580%25B3Self-regeneration%2520of%2520Stereocenters%25E2%2580%25B3%2520Method%253A%2520%25CE%25B1-Ethyl-%25CE%25B1-phenylglycine%26jtitle%3DHeterocycles%26date%3D1997%26volume%3D46%26spage%3D617%26epage%3D630%26doi%3D10.3987%2FCOM-97-S83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Paliwal, S.; Reichard, G. A.; Wang, C.; Xiao, D.; Tsui, H.-C.; Shih, N.-Y.; Arredondo, J. D.; Wrobleski, M. L.; Palani, A.</span><span> </span><span class="NLM_article-title">Preparation of Pyrrolidine and Piperidine Derivatives for Therapeutic Use as Neurokinin 1 (NK1) Receptor Antagonists</span>. WO 2003051840A1,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=S.+Paliwal&author=G.+A.+Reichard&author=C.+Wang&author=D.+Xiao&author=H.-C.+Tsui&author=N.-Y.+Shih&author=J.+D.+Arredondo&author=M.+L.+Wrobleski&author=A.+Palani&title=Preparation+of+Pyrrolidine+and+Piperidine+Derivatives+for+Therapeutic+Use+as+Neurokinin+1+%28NK1%29+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPaliwal%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Pyrrolidine%2520and%2520Piperidine%2520Derivatives%2520for%2520Therapeutic%2520Use%2520as%2520Neurokinin%25201%2520%2528NK1%2529%2520Receptor%2520Antagonists%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, E. S.</span><span> </span><span class="NLM_article-title">Lusutrombopag: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.1007/s40265-015-0525-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0525-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=155-158&author=E.+S.+Kim&title=Lusutrombopag%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0525-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0525-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0525-4%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DLusutrombopag%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D155%26epage%3D158%26doi%3D10.1007%2Fs40265-015-0525-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit77b"><span><span class="NLM_label">(b) </span>Shionogi Receives Marketing and Manufacturing Approval in Japan for Mulpleta Tablets 3 mg for Improvement of Thrombocytopenia; <span class="NLM_publisher-name">Shionogi and Co., Ltd.</span>: <span class="NLM_publisher-loc">Osaka</span>, September 28,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.shionogi.co.jp/en/company/news/2015/pmrltj0000002g0l-att/e_150928.pdf" class="extLink">http://www.shionogi.co.jp/en/company/news/2015/pmrltj0000002g0l-att/e_150928.pdf</a> (accessed August 2, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Shionogi+Receives+Marketing+and+Manufacturing+Approval+in+Japan+for+Mulpleta+Tablets+3+mg+for+Improvement+of+Thrombocytopenia%3B+Shionogi+and+Co.%2C+Ltd.%3A+Osaka%2C+September+28%2C+2015%3B+http%3A%2F%2Fwww.shionogi.co.jp%2Fen%2Fcompany%2Fnews%2F2015%2Fpmrltj0000002g0l-att%2Fe_150928.pdf+%28accessed+August+2%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DShionogi%2520Receives%2520Marketing%2520and%2520Manufacturing%2520Approval%2520in%2520Japan%2520for%2520Mulpleta%2520Tablets%25203%2520mg%2520for%2520Improvement%2520of%2520Thrombocytopenia%26pub%3DShionogi%2520and%2520Co.%252C%2520Ltd%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Poordad, F.</span><span> </span><span class="NLM_article-title">Review Article: Thrombocytopenia in Chronic Liver Disease</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">s1</span><span class="NLM_x">) </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1111/j.1365-2036.2007.03510.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fj.1365-2036.2007.03510.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=17958514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVyjt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5-11&issue=s1&author=F.+Poordad&title=Review+Article%3A+Thrombocytopenia+in+Chronic+Liver+Disease&doi=10.1111%2Fj.1365-2036.2007.03510.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Review article: thrombocytopenia in chronic liver disease</span></div><div class="casAuthors">Poordad, F.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">5-11</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: Thrombocytopenia is a common finding in advanced liver disease.  It is predominantly a result of portal hypertension and platelet sequestration in the enlarged spleen, but other mechanisms may contribute.  The liver is the site of thrombopoietin (TPO) synthesis, a hormone that leads to proliferation and differentiation of megakaryocytes and platelet formation.  Reduced TPO prodn. further reduces measurable serum platelet counts.  Aim: This paper describes the scope of thrombocytopenia in chronic liver disease and assesses the clin. impact in this patient population.  Methods: A medline review of the literature was performed pertaining to thrombocytopenia and advanced liver disease.  This data is compiled into a review of the impact of low platelets in liver disease.  Results: The incidence of thrombocytopenia, its impact on clin. decision making and the use of platelet transfusions are addressed.  Emerging novel therapeutics for thrombocytopenia is also discussed.  Conclusions: Thrombocytopenia is a common and challenging clin. disorder in patients with chronic liver disease.  New therapeutic options are needed to safely increase platelet counts prior to invasive medical procedures as well as to counteract therapies that further exacerbate low platelets, such as interferon.  An ideal compd. would be orally available and safe, with rapid onset of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNXdgpRG6LjrVg90H21EOLACvtfcHk0lh1mlcLDrs_nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVyjt7fI&md5=d79c936da344709430146538569862d9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2007.03510.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2007.03510.x%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26atitle%3DReview%2520Article%253A%2520Thrombocytopenia%2520in%2520Chronic%2520Liver%2520Disease%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2007%26volume%3D26%26issue%3Ds1%26spage%3D5%26epage%3D11%26doi%3D10.1111%2Fj.1365-2036.2007.03510.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Maan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Knegt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veldt, B. J.</span><span> </span><span class="NLM_article-title">Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1981</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1007/s40265-015-0480-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0480-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1981-1992&author=R.+Maanauthor=R.+J.+de+Knegtauthor=B.+J.+Veldt&title=Management+of+Thrombocytopenia+in+Chronic+Liver+Disease%3A+Focus+on+Pharmacotherapeutic+Strategies&doi=10.1007%2Fs40265-015-0480-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0480-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0480-0%26sid%3Dliteratum%253Aachs%26aulast%3DMaan%26aufirst%3DR.%26aulast%3Dde%2BKnegt%26aufirst%3DR.%2BJ.%26aulast%3DVeldt%26aufirst%3DB.%2BJ.%26atitle%3DManagement%2520of%2520Thrombocytopenia%2520in%2520Chronic%2520Liver%2520Disease%253A%2520Focus%2520on%2520Pharmacotherapeutic%2520Strategies%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1981%26epage%3D1992%26doi%3D10.1007%2Fs40265-015-0480-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Fukui, Y.; Maegawa, Y.; Matsuura, T.; Kurita, T.</span><span> </span><span class="NLM_article-title">Methods Respectively for Producing Optically Active Compound Having Agonistic Activity on Thrombopoietin Receptors and Intermediate of Said Compound</span>. WO 2015093586A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Fukui&author=Y.+Maegawa&author=T.+Matsuura&author=T.+Kurita&title=Methods+Respectively+for+Producing+Optically+Active+Compound+Having+Agonistic+Activity+on+Thrombopoietin+Receptors+and+Intermediate+of+Said+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFukui%26aufirst%3DY.%26atitle%3DMethods%2520Respectively%2520for%2520Producing%2520Optically%2520Active%2520Compound%2520Having%2520Agonistic%2520Activity%2520on%2520Thrombopoietin%2520Receptors%2520and%2520Intermediate%2520of%2520Said%2520Compound%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Takayama, M.; Kurose, N.</span><span> </span><span class="NLM_article-title">Pharmaceutical Composition Containing Optically Active Compound Having Thrombopoietin Receptor Agonist Activity, and Intermediate Therefor</span>. US 20130217885A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Takayama&author=N.+Kurose&title=Pharmaceutical+Composition+Containing+Optically+Active+Compound+Having+Thrombopoietin+Receptor+Agonist+Activity%2C+and+Intermediate+Therefor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTakayama%26aufirst%3DM.%26atitle%3DPharmaceutical%2520Composition%2520Containing%2520Optically%2520Active%2520Compound%2520Having%2520Thrombopoietin%2520Receptor%2520Agonist%2520Activity%252C%2520and%2520Intermediate%2520Therefor%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Takayama, M.; Yoshida, Y.</span><span> </span><span class="NLM_article-title">Compounds Exhibiting Thrombopoietin Receptor Agonism</span>. US 20070043087A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Takayama&author=Y.+Yoshida&title=Compounds+Exhibiting+Thrombopoietin+Receptor+Agonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTakayama%26aufirst%3DM.%26atitle%3DCompounds%2520Exhibiting%2520Thrombopoietin%2520Receptor%2520Agonism%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Duncan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotunda, A. M.</span><span> </span><span class="NLM_article-title">Injectable Therapies for Localized Fat Loss: State of the Art</span> <span class="citation_source-journal">Clin. Plastic Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1016/j.cps.2011.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.cps.2011.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=21824545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC3Mjks1KgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=489-501&author=D.+Duncanauthor=A.+M.+Rotunda&title=Injectable+Therapies+for+Localized+Fat+Loss%3A+State+of+the+Art&doi=10.1016%2Fj.cps.2011.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Injectable therapies for localized fat loss: state of the art</span></div><div class="casAuthors">Duncan Diane; Rotunda Adam M</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in plastic surgery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">489-501, vii</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review presents mechanisms of action and a review of the clinical applications of injections currently in development for localized fat reduction.  After being received with initial enthusiasm earlier in the decade, mesotherapy and other injectable methods for fat loss (Lipodissolve, PC/DC, DC, injection lipolysis, adipolysis) have been subjects of critical scrutiny by the media and the US Food and Drug Administration.  Several medications with novel detergent and lipolytic activity are in development and have demonstrated potential as minimally invasive fat reducing treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYfkom1nzjE91QT_1O5WBYfW6udTcc2eYbpQppvX-Mgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mjks1KgtQ%253D%253D&md5=e21b0e3067a169afb91defb87f61132b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.cps.2011.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cps.2011.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DDuncan%26aufirst%3DD.%26aulast%3DRotunda%26aufirst%3DA.%2BM.%26atitle%3DInjectable%2520Therapies%2520for%2520Localized%2520Fat%2520Loss%253A%2520State%2520of%2520the%2520Art%26jtitle%3DClin.%2520Plastic%2520Surg.%26date%3D2011%26volume%3D38%26spage%3D489%26epage%3D501%26doi%3D10.1016%2Fj.cps.2011.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Wollina, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, A.</span><span> </span><span class="NLM_article-title">ATX-101 for Reduction of Submental Fat</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span><span class="refDoi"> DOI: 10.1517/14656566.2015.1019465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14656566.2015.1019465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25724831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktlCisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=755-762&author=U.+Wollinaauthor=A.+Goldman&title=ATX-101+for+Reduction+of+Submental+Fat&doi=10.1517%2F14656566.2015.1019465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">ATX-101 for reduction of submental fat</span></div><div class="casAuthors">Wollina, Uwe; Goldman, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">755-762</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Facial esthetics are important for self-esteem.  Undesired submental fat (SMF) deposits lead to an unappealing submental profile assocd. with aging and overweight.  Compd. is a proprietary formulation of purified synthetic deoxycholic acid for pharmacol. submental contouring.  Review areas covered: This reviews covers anatomy of SMF, biochem. of deoxycholic acid related to adipose tissue and tissue response to injection of ATX-101.  Data from clin. trials were analyzed for efficacy and safety.  Methodol.: Published studies using PubMed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ5EozonBD8rVg90H21EOLACvtfcHk0lhnEzbPX5pP9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktlCisrc%253D&md5=352cd9b44db592a9e770c5467ce9825f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1019465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1019465%26sid%3Dliteratum%253Aachs%26aulast%3DWollina%26aufirst%3DU.%26aulast%3DGoldman%26aufirst%3DA.%26atitle%3DATX-101%2520for%2520Reduction%2520of%2520Submental%2520Fat%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D755%26epage%3D762%26doi%3D10.1517%2F14656566.2015.1019465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Moriarty, R. M.; Reid, J. G.; Swaringen, J. R. A.</span><span> </span><span class="NLM_article-title">Methods for the Purification of Deoxycholic Acid</span>. WO 2011075701A3,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=R.+M.+Moriarty&author=J.+G.+Reid&author=J.+R.+A.+Swaringen&title=Methods+for+the+Purification+of+Deoxycholic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DR.%2BM.%26atitle%3DMethods%2520for%2520the%2520Purification%2520of%2520Deoxycholic%2520Acid%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Evogliptin: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2049</span><span class="refDoi"> DOI: 10.1007/s40265-015-0496-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0496-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=2045-2049&author=P.+L.+McCormack&title=Evogliptin%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0496-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0496-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0496-5%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DEvogliptin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D2045%26epage%3D2049%26doi%3D10.1007%2Fs40265-015-0496-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kim, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chae, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Son, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. J.</span><span> </span><span class="NLM_article-title">Discovery of DA-1229: a Potent, Long Acting Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3809</span><span class="NLM_x">–</span> <span class="NLM_lpage">3812</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.bmcl.2011.04.029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3809-3812&author=H.+J.+Kimauthor=W.+Y.+Kwakauthor=J.+P.+Minauthor=J.+Y.+Leeauthor=T.+H.+Yoonauthor=H.+D.+Kimauthor=C.+Y.+Shinauthor=M.+K.+Kimauthor=S.+H.+Choiauthor=H.+S.+Kimauthor=E.+K.+Yangauthor=Y.+H.+Cheongauthor=Y.+N.+Chaeauthor=K.+J.+Parkauthor=J.+M.+Jangauthor=S.+J.+Choiauthor=M.+H.+Sonauthor=S.+H.+Kimauthor=M.+Yooauthor=B.+J.+Lee&title=Discovery+of+DA-1229%3A+a+Potent%2C+Long+Acting+Dipeptidyl+Peptidase-4+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1016%2Fj.bmcl.2011.04.029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.029%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DKwak%26aufirst%3DW.%2BY.%26aulast%3DMin%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DYoon%26aufirst%3DT.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BD.%26aulast%3DShin%26aufirst%3DC.%2BY.%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DYang%26aufirst%3DE.%2BK.%26aulast%3DCheong%26aufirst%3DY.%2BH.%26aulast%3DChae%26aufirst%3DY.%2BN.%26aulast%3DPark%26aufirst%3DK.%2BJ.%26aulast%3DJang%26aufirst%3DJ.%2BM.%26aulast%3DChoi%26aufirst%3DS.%2BJ.%26aulast%3DSon%26aufirst%3DM.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DYoo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DB.%2BJ.%26atitle%3DDiscovery%2520of%2520DA-1229%253A%2520a%2520Potent%252C%2520Long%2520Acting%2520Dipeptidyl%2520Peptidase-4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3809%26epage%3D3812%26doi%3D10.1016%2Fj.bmcl.2011.04.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit87b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kwak, W. Y.; Kim, H. J.; Min, J. P.; Yoon, T. H.; Yoo, M.</span><span> </span><span class="NLM_article-title">Improved Method for Preparing Dipeptidyl Peptidase-IV Inhibitor and Intermediate</span>. WO 2010114291A2,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=W.+Y.+Kwak&author=H.+J.+Kim&author=J.+P.+Min&author=T.+H.+Yoon&author=M.+Yoo&title=Improved+Method+for+Preparing+Dipeptidyl+Peptidase-IV+Inhibitor+and+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DW.%2BY.%26atitle%3DImproved%2520Method%2520for%2520Preparing%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitor%2520and%2520Intermediate%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit87c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shin, C. Y.; Choi, S. H.; Chae, Y. N.; Yang, E. K.; Ahn, G. J.</span><span> </span><span class="NLM_article-title">Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and Other Antidiabetic or Antiobesity Agents as Active Ingredients</span>. WO 2010044637A2,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+Y.+Shin&author=S.+H.+Choi&author=Y.+N.+Chae&author=E.+K.+Yang&author=G.+J.+Ahn&title=Pharmaceutical+Composition+for+Prevention+and+Treatment+of+Diabetes+or+Obesity+Comprising+a+Compound+that+Inhibits+Activity+of+Dipeptidyl+Peptidase-IV%2C+and+Other+Antidiabetic+or+Antiobesity+Agents+as+Active+Ingredients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DC.%2BY.%26atitle%3DPharmaceutical%2520Composition%2520for%2520Prevention%2520and%2520Treatment%2520of%2520Diabetes%2520or%2520Obesity%2520Comprising%2520a%2520Compound%2520that%2520Inhibits%2520Activity%2520of%2520Dipeptidyl%2520Peptidase-IV%252C%2520and%2520Other%2520Antidiabetic%2520or%2520Antiobesity%2520Agents%2520as%2520Active%2520Ingredients%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit87d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kim, H. J.; Kwak, W. Y.; Shin, C. Y.; Kim, H.; Min, J. P.; Park, K. J.; Lee, J. Y.; Choi, S. H.; Yoon, T. H.; Kim, H. S.</span><span> </span><span class="NLM_article-title">Dpp-IV Inhibitor Including Beta-Amino Group, Preparation Method Thereof and Pharmaceutical Composition Containing the Same for Preventing and Treating a Diabetes or an Obesity</span>. WO 2008130151A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=H.+J.+Kim&author=W.+Y.+Kwak&author=C.+Y.+Shin&author=H.+Kim&author=J.+P.+Min&author=K.+J.+Park&author=J.+Y.+Lee&author=S.+H.+Choi&author=T.+H.+Yoon&author=H.+S.+Kim&title=Dpp-IV+Inhibitor+Including+Beta-Amino+Group%2C+Preparation+Method+Thereof+and+Pharmaceutical+Composition+Containing+the+Same+for+Preventing+and+Treating+a+Diabetes+or+an+Obesity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26atitle%3DDpp-IV%2520Inhibitor%2520Including%2520Beta-Amino%2520Group%252C%2520Preparation%2520Method%2520Thereof%2520and%2520Pharmaceutical%2520Composition%2520Containing%2520the%2520Same%2520for%2520Preventing%2520and%2520Treating%2520a%2520Diabetes%2520or%2520an%2520Obesity%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Kwak, W. Y.; Kim, H. J.; Min, J. P.; Yoon, T. H.; Shim, H. J.; Yoo, M.</span><span> </span><span class="NLM_article-title">Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate</span>. US 20120016126A1,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=W.+Y.+Kwak&author=H.+J.+Kim&author=J.+P.+Min&author=T.+H.+Yoon&author=H.+J.+Shim&author=M.+Yoo&title=Method+for+Manufacturing+Dipeptidyl+Peptidase-IV+Inhibitor+and+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DW.%2BY.%26atitle%3DMethod%2520for%2520Manufacturing%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitor%2520and%2520Intermediate%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Kwak, W. Y.; Kim, H. J.; Min, J. P.; Yoon, T. H.; Shim, H. J.; Yoo, M.</span><span> </span><span class="NLM_article-title">Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate</span>. EP 2415754A2,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=W.+Y.+Kwak&author=H.+J.+Kim&author=J.+P.+Min&author=T.+H.+Yoon&author=H.+J.+Shim&author=M.+Yoo&title=Improved+Method+for+Manufacturing+Dipeptidyl+Peptidase-IV+Inhibitor+and+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DW.%2BY.%26atitle%3DImproved%2520Method%2520for%2520Manufacturing%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitor%2520and%2520Intermediate%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Hoy, S. M.</span><span> </span><span class="NLM_article-title">Lesinurad: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span><span class="refDoi"> DOI: 10.1007/s40265-016-0550-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-016-0550-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26861027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=509-516&author=S.+M.+Hoy&title=Lesinurad%3A+First+Global+Approval&doi=10.1007%2Fs40265-016-0550-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Lesinurad: First Global Approval</span></div><div class="casAuthors">Hoy, Sheridan M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">509-516</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Lesinurad (ZURAMPIC) is an oral urate-anion exchanger transporter 1 (URAT1) inhibitor developed by Ardea Biosciences (a subsidiary of AstraZeneca) for the treatment of hyperuricemia assocd. with gout.  It reduces serum uric acid (sUA) levels by inhibiting the function of the transporter proteins (URAT1 and org. anion transporter 4) involved in uric acid reabsorption in the kidney.  In Dec. 2015, lesinurad was approved in the USA as combination therapy with a xanthine oxidase inhibitor for the treatment of hyperuricemia assocd. with gout in patients who have not achieved sUA target levels with a xanthine oxidase inhibitor alone.  Lesinurad has also received a pos. opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for this indication and is in phase III development as a combination therapy in several other countries.  This article summarizes the milestones in the development of lesinurad leading to this first approval for hyperuricemia assocd. with gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYLnXR_1pferVg90H21EOLACvtfcHk0ljFqbDJ8s1iBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGrsr4%253D&md5=adff81ec4e67f65711573f15444765c8</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0550-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0550-y%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DLesinurad%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D509%26epage%3D516%26doi%3D10.1007%2Fs40265-016-0550-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, Y.; Xu, H.; Zhang, Y.; Zheng, F.</span><span> </span><span class="NLM_article-title">Axially Chiral Enantiomers of Drug Lesinurad</span>. CN 105399694A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Huang&author=H.+Xu&author=Y.+Zhang&author=F.+Zheng&title=Axially+Chiral+Enantiomers+of+Drug+Lesinurad"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26atitle%3DAxially%2520Chiral%2520Enantiomers%2520of%2520Drug%2520Lesinurad%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit91b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fan, L.; Chen, K.; Li, X.; Chen, Y.</span><span> </span><span class="NLM_article-title">Compound for Treating Gout</span>. WO 2016000568A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Fan&author=K.+Chen&author=X.+Li&author=Y.+Chen&title=Compound+for+Treating+Gout"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DL.%26atitle%3DCompound%2520for%2520Treating%2520Gout%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit91c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wang, P.; Li, P.; GU, X.</span><span> </span><span class="NLM_article-title">Gout Drug Lesinurad Preparation Method, and Lesinurad Intermediate</span>. WO 2015054960A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+Wang&author=P.+Li&author=X.+GU&title=Gout+Drug+Lesinurad+Preparation+Method%2C+and+Lesinurad+Intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26atitle%3DGout%2520Drug%2520Lesinurad%2520Preparation%2520Method%252C%2520and%2520Lesinurad%2520Intermediate%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit91d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Chen, W.; Luo, J.; Liu, L.; Fan, Y.</span><span> </span><span class="NLM_article-title">Thio-1,2,4-triazole Derivatives and Method for Preparing the Same</span>. WO 2014198241A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=W.+Chen&author=J.+Luo&author=L.+Liu&author=Y.+Fan&title=Thio-1%2C2%2C4-triazole+Derivatives+and+Method+for+Preparing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%26atitle%3DThio-1%252C2%252C4-triazole%2520Derivatives%2520and%2520Method%2520for%2520Preparing%2520the%2520Same%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit91e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Gunic, E.; Girardet, J. L.; Vernier, J. M.; Tedder, M. E.; Paisner, D. A.</span><span> </span><span class="NLM_article-title">Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels</span>. US 20100056464A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=E.+Gunic&author=J.+L.+Girardet&author=J.+M.+Vernier&author=M.+E.+Tedder&author=D.+A.+Paisner&title=Compounds%2C+Compositions+and+Methods+of+Using+Same+for+Modulating+Uric+Acid+Levels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGunic%26aufirst%3DE.%26atitle%3DCompounds%252C%2520Compositions%2520and%2520Methods%2520of%2520Using%2520Same%2520for%2520Modulating%2520Uric%2520Acid%2520Levels%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit91f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Gunic, E.; Girardet, J. L.; Vernier, J. M.; Tedder, M. E.; Paisner, D. A.</span><span> </span><span class="NLM_article-title">Compounds</span>. US 20100056465A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=E.+Gunic&author=J.+L.+Girardet&author=J.+M.+Vernier&author=M.+E.+Tedder&author=D.+A.+Paisner&title=Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGunic%26aufirst%3DE.%26atitle%3DCompounds%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit91g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Quart, B. D.; Girardet, J. L.; Gunic, E.; Yeh, L. T.</span><span> </span><span class="NLM_article-title">Novel Compounds and Compositions and Methods of Use</span>. WO 2009070740A2,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=B.+D.+Quart&author=J.+L.+Girardet&author=E.+Gunic&author=L.+T.+Yeh&title=Novel+Compounds+and+Compositions+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DQuart%26aufirst%3DB.%2BD.%26atitle%3DNovel%2520Compounds%2520and%2520Compositions%2520and%2520Methods%2520of%2520Use%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Gunic, E.; Galvin, G.</span><span> </span><span class="NLM_article-title">Manufacture of 2-(5-Bromo-4 (-cyclopropylnaphthalen-1-yl)-4<i>H</i>-1,2,4-triazol-3-ylthio) Acetic Acid</span>. WO 2014008295A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=E.+Gunic&author=G.+Galvin&title=Manufacture+of+2-%285-Bromo-4+%28-cyclopropylnaphthalen-1-yl%29-4H-1%2C2%2C4-triazol-3-ylthio%29+Acetic+Acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGunic%26aufirst%3DE.%26atitle%3DManufacture%2520of%25202-%25285-Bromo-4%2520%2528-cyclopropylnaphthalen-1-yl%2529-4H-1%252C2%252C4-triazol-3-ylthio%2529%2520Acetic%2520Acid%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Burness, C. B.</span><span> </span><span class="NLM_article-title">Omarigliptin: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1947</span><span class="NLM_x">–</span> <span class="NLM_lpage">1952</span><span class="refDoi"> DOI: 10.1007/s40265-015-0493-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0493-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26507988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyksrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1947-1952&author=C.+B.+Burness&title=Omarigliptin%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0493-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Omarigliptin: First Global Approval</span></div><div class="casAuthors">Burness, Celeste B.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1947-1952</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Omarigliptin [Marizev (Japan)] is a small-mol. dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck for the oral treatment of type 2 diabetes (T2DM).  Unlike the majority of other approved agents of its class, which are usually administered once daily, omarigliptin can be administered once weekly.  Once-weekly omarigliptin has received its first global approval in this indication in Japan, for use in adults.  Phase III clin. development of the product is underway in several other countries.  This article summarizes the milestones in the development of omarigliptin leading to this first approval for the treatment of T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgSdQVZsR52bVg90H21EOLACvtfcHk0ljzrMa3cA2z-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyksrrF&md5=23bed0f5d7cf0db1595b520d8b22cc08</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0493-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0493-8%26sid%3Dliteratum%253Aachs%26aulast%3DBurness%26aufirst%3DC.%2BB.%26atitle%3DOmarigliptin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1947%26epage%3D1952%26doi%3D10.1007%2Fs40265-015-0493-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, Y.</span><span> </span><span class="NLM_article-title">Synthetic Method for Omarigliptin</span>. CN 105399744A,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Huang&title=Synthetic+Method+for+Omarigliptin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26atitle%3DSynthetic%2520Method%2520for%2520Omarigliptin%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit94b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chung, J. Y. L.; Peng, F.; Chen, Y.; Kassim, A. M.; Chen, C. Y.; Maust, M.; Mclaughlin, M.; Zacuto, M. J.; Chen, Q.; Tan, L.</span><span> </span><span class="NLM_article-title">Process for Preparing Chiral Dipeptidyl Peptidase-IV Inhibitors</span>. WO 2016014324A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Y.+L.+Chung&author=F.+Peng&author=Y.+Chen&author=A.+M.+Kassim&author=C.+Y.+Chen&author=M.+Maust&author=M.+Mclaughlin&author=M.+J.+Zacuto&author=Q.+Chen&author=L.+Tan&title=Process+for+Preparing+Chiral+Dipeptidyl+Peptidase-IV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26atitle%3DProcess%2520for%2520Preparing%2520Chiral%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit94c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Schwink, L.; Buning, C.; Glombik, H.; Gossel, M.; Kadereit, D.; Halland, N.; Lohmann, M.; Pöverlein, C.; Ritter, K.</span><span> </span><span class="NLM_article-title">Isoindolinone Compounds as Gpr119 Modulators For the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders</span>. WO 2015150565A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+Schwink&author=C.+Buning&author=H.+Glombik&author=M.+Gossel&author=D.+Kadereit&author=N.+Halland&author=M.+Lohmann&author=C.+P%C3%B6verlein&author=K.+Ritter&title=Isoindolinone+Compounds+as+Gpr119+Modulators+For+the+Treatment+of+Diabetes%2C+Obesity%2C+Dyslipidemia+and+Related+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchwink%26aufirst%3DL.%26atitle%3DIsoindolinone%2520Compounds%2520as%2520Gpr119%2520Modulators%2520For%2520the%2520Treatment%2520of%2520Diabetes%252C%2520Obesity%252C%2520Dyslipidemia%2520and%2520Related%2520Disorders%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit94d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">De, L. O.; Rosso, E.; Zaramella, S.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Key Intermediates of Omarigliptin</span>. WO 2015139859A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+O.+De&author=E.+Rosso&author=S.+Zaramella&title=Process+for+the+Preparation+of+Key+Intermediates+of+Omarigliptin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%26aufirst%3DL.%2BO.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Key%2520Intermediates%2520of%2520Omarigliptin%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit94e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Biftu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinha-Roy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuethe, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krueger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sewall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">Omarigliptin (MK-3102): a Novel Long-acting DPP-4 Inhibitor for Once-weekly Treatment of Type 2 Diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3205</span><span class="NLM_x">–</span> <span class="NLM_lpage">3212</span><span class="refDoi"> DOI: 10.1021/jm401992e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401992e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslaltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3205-3212&author=T.+Biftuauthor=R.+Sinha-Royauthor=P.+Chenauthor=X.+Qianauthor=D.+Fengauthor=J.+T.+Kuetheauthor=G.+Scapinauthor=Y.+D.+Gaoauthor=Y.+Yanauthor=D.+Kruegerauthor=A.+Bakauthor=G.+Eiermannauthor=J.+Heauthor=J.+Coxauthor=J.+Hicksauthor=K.+Lyonsauthor=H.+Heauthor=G.+Salituroauthor=S.+Tongauthor=S.+Patelauthor=G.+Dossauthor=A.+Petrovauthor=J.+Wuauthor=S.+S.+Xuauthor=C.+Sewallauthor=X.+Zhangauthor=B.+Zhangauthor=N.+A.+Thornberryauthor=A.+E.+Weber&title=Omarigliptin+%28MK-3102%29%3A+a+Novel+Long-acting+DPP-4+Inhibitor+for+Once-weekly+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm401992e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94eR"><div class="casContent"><span class="casTitleNuber">94e</span><div class="casTitle"><span class="NLM_cas:atitle">Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Biftu, Tesfaye; Sinha-Roy, Ranabir; Chen, Ping; Qian, Xiaoxia; Feng, Dennis; Kuethe, Jeffrey T.; Scapin, Giovanna; Gao, Ying Duo; Yan, Youwei; Krueger, Davida; Bak, Annette; Eiermann, George; He, Jiafang; Cox, Jason; Hicks, Jacqueline; Lyons, Kathy; He, Huaibing; Salituro, Gino; Tong, Sharon; Patel, Sangita; Doss, George; Petrov, Aleksandr; Wu, Joseph; Xu, Shiyao Sherrie; Sewall, Charles; Zhang, Xiaoping; Zhang, Bei; Thornberry, Nancy A.; Weber, Ann E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3205-3212</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our effort to discover DPP-4 inhibitors with added benefits over currently com. available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clin. development candidate.  This manuscript summarizes the mechanism of action, scientific rationale, medicinal chem., pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGeQnvAA8cBbVg90H21EOLACvtfcHk0ljzrMa3cA2z-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslaltb4%253D&md5=14b15f61cd5cd6c981d93459ad372e62</span></div><a href="/servlet/linkout?suffix=cit94e&amp;dbid=16384&amp;doi=10.1021%2Fjm401992e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401992e%26sid%3Dliteratum%253Aachs%26aulast%3DBiftu%26aufirst%3DT.%26aulast%3DSinha-Roy%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DKuethe%26aufirst%3DJ.%2BT.%26aulast%3DScapin%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DY.%2BD.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DKrueger%26aufirst%3DD.%26aulast%3DBak%26aufirst%3DA.%26aulast%3DEiermann%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DJ.%26aulast%3DHicks%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DDoss%26aufirst%3DG.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%2BS.%26aulast%3DSewall%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DOmarigliptin%2520%2528MK-3102%2529%253A%2520a%2520Novel%2520Long-acting%2520DPP-4%2520Inhibitor%2520for%2520Once-weekly%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3205%26epage%3D3212%26doi%3D10.1021%2Fjm401992e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit94f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zacuto, M. J.; Dunn, R. F.; Moment, A. J.; Janey, J. M.; Lieberman, D.; Sheen, F.; Bremeyer, N.; Scott, J.; Kuethe, J. T.; Tan, L.</span><span> </span><span class="NLM_article-title">Process for Preparing Chiral Dipeptidyl Peptidase-IV Inhibitors</span>. WO 2013003250A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+J.+Zacuto&author=R.+F.+Dunn&author=A.+J.+Moment&author=J.+M.+Janey&author=D.+Lieberman&author=F.+Sheen&author=N.+Bremeyer&author=J.+Scott&author=J.+T.+Kuethe&author=L.+Tan&title=Process+for+Preparing+Chiral+Dipeptidyl+Peptidase-IV+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZacuto%26aufirst%3DM.%2BJ.%26atitle%3DProcess%2520for%2520Preparing%2520Chiral%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit94g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Biftu, T.; Chen, P.; Cox, J. M.; Weber, A. E.</span><span> </span><span class="NLM_article-title">Aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes</span>. US 20100120863A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=T.+Biftu&author=P.+Chen&author=J.+M.+Cox&author=A.+E.+Weber&title=Aminotetrahydropyrans+as+Dipeptidyl+Peptidase-IV+Inhibitors+for+the+Treatment+or+Prevention+of+Diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBiftu%26aufirst%3DT.%26atitle%3DAminotetrahydropyrans%2520as%2520Dipeptidyl%2520Peptidase-IV%2520Inhibitors%2520for%2520the%2520Treatment%2520or%2520Prevention%2520of%2520Diabetes%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Chung, J. Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bremeyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lieberman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moment, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacuto, M.</span><span> </span><span class="NLM_article-title">Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1760</span><span class="NLM_x">–</span> <span class="NLM_lpage">1768</span><span class="refDoi"> DOI: 10.1021/acs.oprd.5b00267</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00267" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2ltL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=1760-1768&author=J.+Y.+L.+Chungauthor=J.+P.+Scottauthor=C.+Andersonauthor=B.+Bishopauthor=N.+Bremeyerauthor=Y.+Caoauthor=Q.+Chenauthor=R.+Dunnauthor=A.+Kassimauthor=D.+Liebermanauthor=A.+J.+Momentauthor=F.+Sheenauthor=M.+Zacuto&title=Evolution+of+a+Manufacturing+Route+to+Omarigliptin%2C+A+Long-Acting+DPP-4+Inhibitor+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Facs.oprd.5b00267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Chung, John Y. L.; Scott, Jeremy P.; Anderson, Camille; Bishop, Brian; Bremeyer, Nadine; Cao, Yang; Chen, Qinghao; Dunn, Robert; Kassim, Amude; Lieberman, David; Moment, Aaron J.; Sheen, Faye; Zacuto, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1760-1768</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of a convergent synthesis of omarigliptin [MK-3102, I (R = H; Ms = MeSO2)] suitable for com. manuf. is described.  I (R = H) was prepd. by the diastereoselective reductive amination of a nonracemic Boc-protected amino(aryl)pyranone II with mesylated pyrrolopyrazole III•PhSO3H (R1 = H) [generated in situ from its Boc-protected precursor III (R1 = Boc) due to its instability and potential genotoxicity] followed by Boc deprotection.  The synthesis of II relies on three Ru-catalyzed reactions: the dynamic kinetic resoln./hydrogenation of a rac-α-aminoketone in the presence of an areneruthenium diamine complex, cycloisomerization of the bis-homopropargylic alc. product to a dihydropyran, and ruthenium-catalyzed oxidn. of a pyranol (generated by hydroboration of the dihydropyran).  III (R1 = Boc) was prepd. regioselectively in 30:1 regioselectivity by mesylation followed by base-promoted isomerization.  The Boc deprotection of III (R1 = Boc) and its reductive amination reaction with II were telescoped by using the crystn. of I (R = Boc) to remove byproducts, allowing handling of III•PhSO3H (R1 = H) to be avoided and improving the overall diastereoselectivity and efficiency of the route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpob8Zs2c4xP7Vg90H21EOLACvtfcHk0ljWliwLX_MPIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2ltL%252FF&md5=a2728e45654628f53385f711f4ee9b91</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00267%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26aulast%3DScott%26aufirst%3DJ.%2BP.%26aulast%3DAnderson%26aufirst%3DC.%26aulast%3DBishop%26aufirst%3DB.%26aulast%3DBremeyer%26aufirst%3DN.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DDunn%26aufirst%3DR.%26aulast%3DKassim%26aufirst%3DA.%26aulast%3DLieberman%26aufirst%3DD.%26aulast%3DMoment%26aufirst%3DA.%2BJ.%26aulast%3DSheen%26aufirst%3DF.%26aulast%3DZacuto%26aufirst%3DM.%26atitle%3DEvolution%2520of%2520a%2520Manufacturing%2520Route%2520to%2520Omarigliptin%252C%2520A%2520Long-Acting%2520DPP-4%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D1760%26epage%3D1768%26doi%3D10.1021%2Facs.oprd.5b00267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McKeage, K.</span><span> </span><span class="NLM_article-title">Trelagliptin: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1164</span><span class="refDoi"> DOI: 10.1007/s40265-015-0431-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0431-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26115728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCjsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1161-1164&author=K.+McKeage&title=Trelagliptin%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0431-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96aR"><div class="casContent"><span class="casTitleNuber">96a</span><div class="casTitle"><span class="NLM_cas:atitle">Trelagliptin: First Global Approval</span></div><div class="casAuthors">McKeage, Kate</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1161-1164</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Trelagliptin (Zafatek) is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus (T2DM).  Unlike other approved agents of its class, which are usually administered once daily, trelagliptin can be administered once weekly.  Phase II development of trelagliptin was discontinued in the USA and EU, as Takeda considered that the costs assocd. with obtaining approval in these markets were prohibitive.  This article summarizes the milestones in the development of trelagliptin leading to this first approval for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZLxvdSf4LZLVg90H21EOLACvtfcHk0ljWliwLX_MPIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCjsrjF&md5=0b23f6b1990e67f8e475c377c12112e1</span></div><a href="/servlet/linkout?suffix=cit96a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0431-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0431-9%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeage%26aufirst%3DK.%26atitle%3DTrelagliptin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1161%26epage%3D1164%26doi%3D10.1007%2Fs40265-015-0431-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit96b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kaku, K.</span><span> </span><span class="NLM_article-title">First Novel Once-Weekly DPP-4 Inhibitor, Trelagliptin, for the Treatment of Type 2 Diabetes Mellitus</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2539</span><span class="NLM_x">–</span> <span class="NLM_lpage">2547</span><span class="refDoi"> DOI: 10.1517/14656566.2015.1099630</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14656566.2015.1099630" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26523434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWntb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=2539-2547&author=K.+Kaku&title=First+Novel+Once-Weekly+DPP-4+Inhibitor%2C+Trelagliptin%2C+for+the+Treatment+of+Type+2+Diabetes+Mellitus&doi=10.1517%2F14656566.2015.1099630"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96bR"><div class="casContent"><span class="casTitleNuber">96b</span><div class="casTitle"><span class="NLM_cas:atitle">First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Kaku, Kohei</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2539-2547</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Dipeptidyl peptidase-4 (DPP-4) inhibitors are wt. neutral and well tolerated, and provide better glycemic control for a longer period compared to conventional therapies.  Despite the fact that various drugs are available, glycemic control remains suboptimal in approx. half of patients with type 2 diabetes mellitus; one of the major reasons for low medication adherence.: A novel DPP-4 inhibitor, trelagliptin, was approved in Japan in March 2015, and is the first once-weekly oral antidiabetic agent in the world.  In this review, current issues concerning medication adherence for the treatment of diabetes are discussed followed by a summary of the characteristics and future expectations of trelagliptin, by reviewing the recent phase I, II, and III clin. studies of trelagliptin.: Trelagliptin has demonstrated superiority to placebo and non-inferiority to alogliptin, indicating its efficacy and tolerance in Japanese patients.  Trelagliptin is expected to improve adherence and prevent complications.  Due to the convenient dosing regimen, it is expected to be widely used in the clin. setting.  A large-scale long-term study will help further confirm its long-term efficacy and safety, patients' satisfaction, and medication adherence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVV5QAW5eQc7Vg90H21EOLACvtfcHk0lgjG4zLJthwBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWntb%252FF&md5=12f32e70a258b92cae700e1d09c91504</span></div><a href="/servlet/linkout?suffix=cit96b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1099630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1099630%26sid%3Dliteratum%253Aachs%26aulast%3DKaku%26aufirst%3DK.%26atitle%3DFirst%2520Novel%2520Once-Weekly%2520DPP-4%2520Inhibitor%252C%2520Trelagliptin%252C%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D2539%26epage%3D2547%26doi%3D10.1517%2F14656566.2015.1099630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Grimshaw, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishigaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinugawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koumura, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span> </span><span class="NLM_article-title">Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0157509</span><span class="refDoi"> DOI: 10.1371/journal.pone.0157509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1371%2Fjournal.pone.0157509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27328054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOntrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0157509&author=C.+E.+Grimshawauthor=A.+Jenningsauthor=R.+Kamranauthor=H.+Uenoauthor=N.+Nishigakiauthor=T.+Kosakaauthor=A.+Taniauthor=H.+Sanoauthor=Y.+Kinugawaauthor=E.+Koumuraauthor=L.+Shiauthor=K.+Takeuchi&title=Trelagliptin+%28SYR-472%2C+Zafatek%29%2C+Novel+Once-Weekly+Treatment+for+Type+2+Diabetes%2C+Inhibits+Dipeptidyl+Peptidase-4+%28DPP-4%29+via+a+Non-Covalent+Mechanism&doi=10.1371%2Fjournal.pone.0157509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Trelagliptin (SYR-472, zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (DPP-4) via a non-covalent mechanism</span></div><div class="casAuthors">Grimshaw, Charles E.; Jennings, Andy; Kamran, Ruhi; Ueno, Hikaru; Nishigaki, Nobuhiro; Kosaka, Takuo; Tani, Akiyoshi; Sano, Hiroki; Kinugawa, Yoshinobu; Koumura, Emiko; Shi, Lihong; Takeuchi, Koji</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0157509/1-e0157509/14</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients.  In this study, we characterized in vitro properties of trelagliptin, which exhibited approx. 4- and 12-fold more potent inhibition against human dipeptidyl peptidase-4 than alogliptin and sitagliptin, resp., and >10,000-fold selectivity over related proteases including dipeptidyl peptidase-8 and dipeptidyl peptidase-9.  Kinetic anal. revealed reversible, competitive and slow-binding inhibition of dipeptidyl peptidase-4 by trelagliptin (t1/2 for dissocn. ≈ 30 min).  X-ray diffraction data indicated a noncovalent interaction between dipeptidyl peptidase and trelagliptin.  Taken together, potent dipeptidyl peptidase inhibitionmay partially contribute to sustained efficacy of trelagliptin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl6c2Doi2qG7Vg90H21EOLACvtfcHk0lgjG4zLJthwBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOntrnK&md5=8eeb09f31af53706b0f6a6b40bd4c590</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0157509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0157509%26sid%3Dliteratum%253Aachs%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DKamran%26aufirst%3DR.%26aulast%3DUeno%26aufirst%3DH.%26aulast%3DNishigaki%26aufirst%3DN.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DTani%26aufirst%3DA.%26aulast%3DSano%26aufirst%3DH.%26aulast%3DKinugawa%26aufirst%3DY.%26aulast%3DKoumura%26aufirst%3DE.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DTakeuchi%26aufirst%3DK.%26atitle%3DTrelagliptin%2520%2528SYR-472%252C%2520Zafatek%2529%252C%2520Novel%2520Once-Weekly%2520Treatment%2520for%2520Type%25202%2520Diabetes%252C%2520Inhibits%2520Dipeptidyl%2520Peptidase-4%2520%2528DPP-4%2529%2520via%2520a%2520Non-Covalent%2520Mechanism%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0157509%26doi%3D10.1371%2Fjournal.pone.0157509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Inagaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onouchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maezawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaku, K.</span><span> </span><span class="NLM_article-title">Once-weekly Trelagliptin Versus Daily Alogliptin in Japanese Patients with Type 2 Diabetes: a Randomised, Double-blind, Phase 3, Non-inferiority Study</span> <span class="citation_source-journal">Lancet Diabetes Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">197</span><span class="refDoi"> DOI: 10.1016/S2213-8587(14)70251-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS2213-8587%2814%2970251-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25609193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFelur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=191-197&author=N.+Inagakiauthor=H.+Onouchiauthor=H.+Maezawaauthor=S.+Kurodaauthor=K.+Kaku&title=Once-weekly+Trelagliptin+Versus+Daily+Alogliptin+in+Japanese+Patients+with+Type+2+Diabetes%3A+a+Randomised%2C+Double-blind%2C+Phase+3%2C+Non-inferiority+Study&doi=10.1016%2FS2213-8587%2814%2970251-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study</span></div><div class="casAuthors">Inagaki, Nobuya; Onouchi, Hitoshi; Maezawa, Hideaki; Kuroda, Shingo; Kaku, Kohei</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Diabetes & Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-197</span>CODEN:
                <span class="NLM_cas:coden">LDEAAS</span>;
        ISSN:<span class="NLM_cas:issn">2213-8587</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Trelagliptin is a novel once-weekly oral DPP-4 inhibitor.  We assessed the efficacy and safety of trelagliptin vs. the daily oral DPP-4 inhibitor alogliptin in Japanese patients with type 2 diabetes.  We did a randomised, double-blind, active-controlled, parallel-group, phase 3, non-inferiority study at 26 sites in Japan.  We included individuals with type 2 diabetes inadequately controlled by diet and exercise.  We randomly assigned patients (2:2:1) to receive trelagliptin (100 mg) once per wk, alogliptin (25 mg) once per day, or placebo for 24 wk.  Randomisation was done electronically and independently from the study with permuted blocks of ten patients.  Patients and clinicians were masked to group assignment.  Patients in the trelagliptin group were given trelagliptin once a week and oral alogliptin placebo every day, whereas patients in the alogliptin group were given oral trelagliptin placebo once a week and oral alogliptin every day (double-dummy design).  Patients in the placebo group were given an oral alogliptin placebo once a day and an oral trelagliptin placebo once a week.  Our primary outcome was between-groups difference in change in HbA1c concn. from baseline to the end of treatment.  The non-inferiority margin was 0·4%.  Our anal. included all patients who were randomised and received at least one dose of study drug.  The study is registered with ClinicalTrials.gov, no. NCT01632007.  Between May 26, 2012, and Nov 20, 2012, we enrolled 357 patients. 243 patients were included in the anal. (101 for trelagliptin, 92 for alogliptin, and 50 for placebo).  In the primary anal., the least squares mean change in HbA1c concn. was -0·33% in the trelagliptin group (SE 0·059) and -0·45% in the alogliptin group (0·061) based on the ANCOVA model.  The least squares mean difference (trelagliptin minus alogliptin) of change from baseline in HbA1c concn. was 0·11% (95% CI -0·054 to 0·281).  Trelagliptin was non-inferior to alogliptin.  Both active groups had significantly reduced mean HbA1c concns. at end of treatment compared with placebo (p<0·0001).  The frequency of adverse events was similar between groups.  No hypoglycemia was reported with trelagliptin and the drug was well tolerated.  The once-weekly DPP-4 inhibitor trelagliptin showed similar efficacy and safety to alogliptin once daily in Japanese patients with type 2 diabetes.  Trelagliptin could be a useful new antidiabetes drug that needs to be given once a week.Takeda Pharmaceutical Company.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWOQAmwxxS57Vg90H21EOLACvtfcHk0lgjG4zLJthwBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFelur8%253D&md5=d902f6a2ec1c0b04806c44b28ab0e49b</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2FS2213-8587%2814%2970251-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-8587%252814%252970251-7%26sid%3Dliteratum%253Aachs%26aulast%3DInagaki%26aufirst%3DN.%26aulast%3DOnouchi%26aufirst%3DH.%26aulast%3DMaezawa%26aufirst%3DH.%26aulast%3DKuroda%26aufirst%3DS.%26aulast%3DKaku%26aufirst%3DK.%26atitle%3DOnce-weekly%2520Trelagliptin%2520Versus%2520Daily%2520Alogliptin%2520in%2520Japanese%2520Patients%2520with%2520Type%25202%2520Diabetes%253A%2520a%2520Randomised%252C%2520Double-blind%252C%2520Phase%25203%252C%2520Non-inferiority%2520Study%26jtitle%3DLancet%2520Diabetes%2520Endocrinol.%26date%3D2015%26volume%3D3%26spage%3D191%26epage%3D197%26doi%3D10.1016%2FS2213-8587%2814%2970251-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gwaltney, S. L.</span><span> </span><span class="NLM_article-title">Design and Synthesis of Pyrimidinone and Pyrimidinedione Inhibitors of Dipeptidyl Peptidase IV</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">510</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span><span class="refDoi"> DOI: 10.1021/jm101016w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101016w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1WgtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=510-524&author=Z.+Zhangauthor=M.+B.+Wallaceauthor=J.+Fengauthor=J.+A.+Staffordauthor=R.+J.+Skeneauthor=L.+Shiauthor=B.+Leeauthor=K.+Aertgeertsauthor=A.+Jenningsauthor=R.+Xuauthor=D.+B.+Kasselauthor=S.+W.+Kaldorauthor=M.+Navreauthor=D.+R.+Webbauthor=S.+L.+Gwaltney&title=Design+and+Synthesis+of+Pyrimidinone+and+Pyrimidinedione+Inhibitors+of+Dipeptidyl+Peptidase+IV&doi=10.1021%2Fjm101016w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV</span></div><div class="casAuthors">Zhang, Zhi-Yuan; Wallace, Michael B.; Feng, Jun; Stafford, Jeffrey A.; Skene, Robert J.; Shi, Li-Hong; Lee, Bum-Sup; Aertgeerts, Kathleen; Jennings, Andy; Xu, Rong-Da; Kassel, Daniel B.; Kaldor, Stephen W.; Navre, Marc; Webb, David R.; Gwaltney, Stephen L., II</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">510-524</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described.  After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained redn. of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes.  Compds. I, II, and III were selected for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxInStuMRjfbVg90H21EOLACvtfcHk0lhztHxCX16INw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1WgtL7M&md5=7e3b66916acf243ad7943add0eaf6b1f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm101016w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101016w%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWallace%26aufirst%3DM.%2BB.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DKaldor%26aufirst%3DS.%2BW.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DWebb%26aufirst%3DD.%2BR.%26aulast%3DGwaltney%26aufirst%3DS.%2BL.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Pyrimidinone%2520and%2520Pyrimidinedione%2520Inhibitors%2520of%2520Dipeptidyl%2520Peptidase%2520IV%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D510%26epage%3D524%26doi%3D10.1021%2Fjm101016w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Kushwaha, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haq, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katti, S.</span><span> </span><span class="NLM_article-title">Discovery of 17 Gliptins in 17 Years of Research for the Treatment of Type 2 Diabetes: A Synthetic Overview</span> <span class="citation_source-journal">Chem. Biol. Interface</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=137-162&author=R.+N.+Kushwahaauthor=W.+Haqauthor=S.+Katti&title=Discovery+of+17+Gliptins+in+17+Years+of+Research+for+the+Treatment+of+Type+2+Diabetes%3A+A+Synthetic+Overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: a synthetic overview</span></div><div class="casAuthors">Kushwaha, Ram Najar; Haq, W.; Katti, S. B.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology Interface</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">137-162, 26 pp.</span>CODEN:
                <span class="NLM_cas:coden">CBIHAO</span>;
        ISSN:<span class="NLM_cas:issn">2249-4820</span>.
    
            (<span class="NLM_cas:orgname">Indian Society of Chemists and Biologist</span>)
        </div><div class="casAbstract">A review.  Gliptins, commonly known as clin. DPP-IV inhibitors have become a new class of potential drug candidate and are being hoped as a permanent eraser for type 2 diabetes.  Therefore, gliptins have been a center of research and development.  As a result of the efforts made towards developing effective gliptins, the first clin. proof of concept for efficacy was confirmed in 1998 when NVP-DPP728 came into focus.  Thus, from 1998 to 2014, these 17-years of the heightened research towards drug discovery has resulted in seventeen gliptins.  Among these, eight gliptins are currently approved and in clin. usages for type 2 diabetes therapies, while others are in different stages of clin. trials.  This review covers the various approaches and methodologies used in the syntheses of only those DPP-IV inhibitors in clin. uses having suffix gliptin.  In addn., it also encompasses their biol. activity and their binding interactions in the active site of DPP-IV that are responsible for their drug candidacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUzq9ENsKIBbVg90H21EOLACvtfcHk0lhztHxCX16INw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelsrrK&md5=d7e444bb8bac3247b8227c981b1d5e8b</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKushwaha%26aufirst%3DR.%2BN.%26aulast%3DHaq%26aufirst%3DW.%26aulast%3DKatti%26aufirst%3DS.%26atitle%3DDiscovery%2520of%252017%2520Gliptins%2520in%252017%2520Years%2520of%2520Research%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%253A%2520A%2520Synthetic%2520Overview%26jtitle%3DChem.%2520Biol.%2520Interface%26date%3D2014%26volume%3D4%26spage%3D137%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Deacon, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebovitz, H. E.</span><span> </span><span class="NLM_article-title">Comparative Review of Dipeptidyl Peptidase-4 Inhibitors and Sulphonylureas</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">347</span><span class="refDoi"> DOI: 10.1111/dom.12610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1111%2Fdom.12610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26597596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=333-347&author=C.+F.+Deaconauthor=H.+E.+Lebovitz&title=Comparative+Review+of+Dipeptidyl+Peptidase-4+Inhibitors+and+Sulphonylureas&doi=10.1111%2Fdom.12610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas</span></div><div class="casAuthors">Deacon, C. F.; Lebovitz, H. E.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-347</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent does not generally provide durable glycemic control over the long term.  Sulfonylurea (SU) drugs have a history stretching back over 60 years, and have traditionally been the mainstay choice as second-line agents to be added to metformin once glycemic control with metformin monotherapy deteriorates; however, they are assocd. with undesirable side effects, including increased hypoglycemia risk and wt. gain.  Dipeptidyl peptidase (DPP)-4 inhibitors are, by comparison, more recent, with the first compd. being launched in 2006, but the class now globally encompasses at least 11 different compds.  DPP-4 inhibitors improve glycemic control with similar efficacy to SUs, but do not usually provoke hypoglycemia or wt. gain, are relatively free from adverse side effects, and have recently been shown not to increase cardiovascular risk in large prospective safety trials.  Because of these factors, DPP-4 inhibitors have become an established therapy for T2DM and are increasingly being positioned earlier in treatment algorithms.  The present article reviews these two classes of oral antidiabetic drugs (DPP-4 inhibitors and SUs), highlighting differences and similarities between members of the same class, as well as discussing the potential advantages and disadvantages of the two drug classes.  While both classes have their merits, the choice of which to use depends on the characteristics of each individual patient; however, for the majority of patients, DPP-4 inhibitors are now the preferred choice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPNH17i_BaXbVg90H21EOLACvtfcHk0lhztHxCX16INw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFGhtbo%253D&md5=bab1171a0f304fc52296637feb9ffbbf</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1111%2Fdom.12610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12610%26sid%3Dliteratum%253Aachs%26aulast%3DDeacon%26aufirst%3DC.%2BF.%26aulast%3DLebovitz%26aufirst%3DH.%2BE.%26atitle%3DComparative%2520Review%2520of%2520Dipeptidyl%2520Peptidase-4%2520Inhibitors%2520and%2520Sulphonylureas%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26spage%3D333%26epage%3D347%26doi%3D10.1111%2Fdom.12610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Feng, J.; Gwaltney, S. L.; Stafford, J. A.; Zhang, Z.; Elder, B. J.; Isbester, P. K.; Palmer, G. J.; Salsbury, J. S.; Ulysse, L.; Fornicola, R. S.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Pyrimidinedione Derivatives</span>. WO 2007035629A2,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Feng&author=S.+L.+Gwaltney&author=J.+A.+Stafford&author=Z.+Zhang&author=B.+J.+Elder&author=P.+K.+Isbester&author=G.+J.+Palmer&author=J.+S.+Salsbury&author=L.+Ulysse&author=R.+S.+Fornicola&title=Process+for+the+Preparation+of+Pyrimidinedione+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Pyrimidinedione%2520Derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Wallace, M. B.; Cody, J.; Fornicola, R.; Garcia-Rubio, S.; Kisanga, P. B.; Reeve, M. M.; Wilson, C.</span><span> </span><span class="NLM_article-title">Preparation of (<i>R</i>)-3-Aminopiperidine Dihydrochloride</span>. WO 2007112368A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+B.+Wallace&author=J.+Cody&author=R.+Fornicola&author=S.+Garcia-Rubio&author=P.+B.+Kisanga&author=M.+M.+Reeve&author=C.+Wilson&title=Preparation+of+%28R%29-3-Aminopiperidine+Dihydrochloride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DM.%2BB.%26atitle%3DPreparation%2520of%2520%2528R%2529-3-Aminopiperidine%2520Dihydrochloride%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Kelly, R. C.; Koztecki, L. H.</span><span> </span><span class="NLM_article-title">Polymorphs of Succinate Salt of 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2<i>H</i>-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and Methods of Use Therefor</span>. WO 2008067465A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=R.+C.+Kelly&author=L.+H.+Koztecki&title=Polymorphs+of+Succinate+Salt+of+2-%5B6-%283-Amino-piperidin-1-yl%29-3-methyl-2%2C4-dioxo-3%2C4-dihydro-2H-pyrimidin-1-ylmethy%5D-4-fluor-benzonitrile+and+Methods+of+Use+Therefor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DR.%2BC.%26atitle%3DPolymorphs%2520of%2520Succinate%2520Salt%2520of%25202-%255B6-%25283-Amino-piperidin-1-yl%2529-3-methyl-2%252C4-dioxo-3%252C4-dihydro-2H-pyrimidin-1-ylmethy%255D-4-fluor-benzonitrile%2520and%2520Methods%2520of%2520Use%2520Therefor%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span> </span><span class="NLM_article-title">Anonymous In Brief: Uridine Triacetate (Xuriden) for Hereditary Orotic Aciduria</span>.  <span class="citation_source-journal">Med. Lett. Drugs Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span>, <span class="NLM_issue">1491</span><span class="NLM_x">) </span> <span class="NLM_fpage">e49</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27027693" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Anonymous+In+Brief%3A+Uridine+Triacetate+%28Xuriden%29+for+Hereditary+Orotic+Aciduria.+Med.+Lett.+Drugs+Ther.+2016%2C+58%2C+1491%29+e49."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DAnonymous%2520In%2520Brief%253A%2520Uridine%2520Triacetate%2520%2528Xuriden%2529%2520for%2520Hereditary%2520Orotic%2520Aciduria%26jtitle%3DMed.%2520Lett.%2520Drugs%2520Ther.%26date%3D2016%26volume%3D58%26issue%3D1491%26spage%3De49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">McEvilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popelas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tremmel, B.</span><span> </span><span class="NLM_article-title">Use of Uridine Triacetate for the Management of Fluorouracil Overdose</span> <span class="citation_source-journal">Am. J. Health-Syst. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1806</span><span class="NLM_x">–</span> <span class="NLM_lpage">1809</span><span class="refDoi"> DOI: 10.2146/ajhp100434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2146%2Fajhp100434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=21930638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFKhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=1806-1809&author=M.+McEvillyauthor=C.+Popelasauthor=B.+Tremmel&title=Use+of+Uridine+Triacetate+for+the+Management+of+Fluorouracil+Overdose&doi=10.2146%2Fajhp100434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106aR"><div class="casContent"><span class="casTitleNuber">106a</span><div class="casTitle"><span class="NLM_cas:atitle">Use of uridine triacetate for the management of fluorouracil overdose</span></div><div class="casAuthors">McEvilly, Margaret; Popelas, Carl; Tremmel, Bob</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1806-1809</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">Purpose: The use of uridine triacetate for the management of fluorouracil toxicity is reported.  Summary: A 55-yr-old man with malignant neoplasm of the sigmoid colon (stage IIIC) was seen in an outpatient chemotherapy center for his first six-month regimen of leucovorin calcium, fluorouracil, and oxaliplatin.  Fluorouracil 2400 mg/m2 i.v. was prescribed to be given over the next 46 h at a home infusion center.  Due to a medication error, a home infusion pharmacist incorrectly programmed the 46-h infusion of fluorouracil to be administered over 4 h.  To manage the fluorouracil overdose, the physician decided to start the patient on uridine triacetate.  The patient received his first dose of uridine triacetate 18 h after the fluorouracil overdose.  He was admitted to the hospital for observation and daily lab. tests during treatment with uridine triacetate.  He received ondansetron (as the hydrochloride salt) 8 mg orally 20 min before each dose of uridine triacetate to prevent nausea and vomiting.  Uridine triacetate 11 g every 6 h was administered orally for a total of 20 doses.  It was mixed with applesauce at the time of administration and followed with 8 oz of water.  The patient's lab. values remained stable.  The patient did not experience any nausea or vomiting during treatment.  He was discharged from the hospital on day 5, with no clin. complications and an Eastern Cooperative Oncol. Group Performance score of 0.  Conclusion: A patient with colon cancer who had received an overdose of fluorouracil was successfully treated with a five-day course of oral uridine triacetate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzZgNd_hTZT7Vg90H21EOLACvtfcHk0lgWF_omyA7yUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFKhu78%253D&md5=c9c529a8b49a769acab45fc33cb7aced</span></div><a href="/servlet/linkout?suffix=cit106a&amp;dbid=16384&amp;doi=10.2146%2Fajhp100434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fajhp100434%26sid%3Dliteratum%253Aachs%26aulast%3DMcEvilly%26aufirst%3DM.%26aulast%3DPopelas%26aufirst%3DC.%26aulast%3DTremmel%26aufirst%3DB.%26atitle%3DUse%2520of%2520Uridine%2520Triacetate%2520for%2520the%2520Management%2520of%2520Fluorouracil%2520Overdose%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2011%26volume%3D68%26spage%3D1806%26epage%3D1809%26doi%3D10.2146%2Fajhp100434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit106b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O’Malley, P. A.</span><span> </span><span class="NLM_article-title">Vistogard (Uridine Triacetate): The First and Only Drug Approved for the Treatment of 5-Fluorouracil or Capecitabine Overdose: Implications for the Clinical Nurse Specialist</span> <span class="citation_source-journal">CNS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">147</span><span class="refDoi"> DOI: 10.1097/NUR.0000000000000198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1097%2FNUR.0000000000000198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27055035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28fotVChtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=145-147&author=P.+A.+O%E2%80%99Malley&title=Vistogard+%28Uridine+Triacetate%29%3A+The+First+and+Only+Drug+Approved+for+the+Treatment+of+5-Fluorouracil+or+Capecitabine+Overdose%3A+Implications+for+the+Clinical+Nurse+Specialist&doi=10.1097%2FNUR.0000000000000198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106bR"><div class="casContent"><span class="casTitleNuber">106b</span><div class="casTitle"><span class="NLM_cas:atitle">Vistogard (Uridine Triacetate): The First and Only Drug Approved for the Treatment of 5-Fluorouracil or Capecitabine Overdose: Implications for the Clinical Nurse Specialist</span></div><div class="casAuthors">O'Malley Patricia Anne</div><div class="citationInfo"><span class="NLM_cas:title">Clinical nurse specialist CNS</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">145-7; quiz E11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR7cJg5Kf8S1Qqdek-gHSrIfW6udTcc2eYvwv2F2qeO6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fotVChtg%253D%253D&md5=9975bbd95ef1efcc8c9111629ba1de34</span></div><a href="/servlet/linkout?suffix=cit106b&amp;dbid=16384&amp;doi=10.1097%2FNUR.0000000000000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FNUR.0000000000000198%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DP.%2BA.%26atitle%3DVistogard%2520%2528Uridine%2520Triacetate%2529%253A%2520The%2520First%2520and%2520Only%2520Drug%2520Approved%2520for%2520the%2520Treatment%2520of%25205-Fluorouracil%2520or%2520Capecitabine%2520Overdose%253A%2520Implications%2520for%2520the%2520Clinical%2520Nurse%2520Specialist%26jtitle%3DCNS%26date%3D2016%26volume%3D30%26spage%3D145%26epage%3D147%26doi%3D10.1097%2FNUR.0000000000000198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit106c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Saif, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diasio, R. B.</span><span> </span><span class="NLM_article-title">Benefit of Uridine Triacetate (Vistogard) in Rescuing Severe 5-Fluorouracil Toxicity in Patients with Dihydropyrimidine Dehydrogenase (DPYD) Deficiency</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1007/s00280-016-3063-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs00280-016-3063-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27278667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Sitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=151-156&author=M.+W.+Saifauthor=R.+B.+Diasio&title=Benefit+of+Uridine+Triacetate+%28Vistogard%29+in+Rescuing+Severe+5-Fluorouracil+Toxicity+in+Patients+with+Dihydropyrimidine+Dehydrogenase+%28DPYD%29+Deficiency&doi=10.1007%2Fs00280-016-3063-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106cR"><div class="casContent"><span class="casTitleNuber">106c</span><div class="casTitle"><span class="NLM_cas:atitle">Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency</span></div><div class="casAuthors">Saif, Muhammad Wasif; Diasio, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-156</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: 5-Fluorouracil (5-FU), an analog of uracil, is one of the most commonly used chemotherapeutic agents and like other agents has a narrow therapeutic index limited by toxicity.  Compared to previous attempts, uridine triacetate (Vistogard) has shown to increase the potential efficacy of 5-FU by allowing administering a higher dose and decreasing the toxicity.  Recently, Vistogard received orphan drug designation from the FDA as an antidote in the treatment of 5-FU poisoning and from the European Medicines Agency as a treatment for 5-FU overdose.  However, no data have been published to date in humans who were rescued by this agent following severe toxicity assocd. with 5-FU due to dihydropyrimidine dehydrogenase (DPYD) deficiency, the enzyme which is responsible for the elimination of approx. 80 % of the administered dose of 5-FU.  Patients and methods: We identified two patients with advanced pancreatic cancer who were referred to us for testing of DPYD status following severe toxicity assocd. with 5-FU administered at a dose of 1400 mg/m2 weekly bolus high-dose 5-FU followed by oral uridine triacetate as a part of a clin. trail.  One patient developed grade 3 thrombocytopenia and grade 3 skin rash that resolved with discontinuation of 5-FU and supportive care, while second patient developed grade 4 thrombocytopenia, grade 3 coagulopathy and grade 3 neurol. toxicity with a fatal outcome.  DPYD status was evaluated as we have previously published.  Results: The first patient was found to have an abnormally low DPYD activity of 0.087-nmol/min/mg protein by radioisotopic assay (ref. normal range 0.182-0.688 nmol/min/mg protein).  Because of pancytopenia, DPYD enzyme activity could not be assessed in patient 2; genotypic anal. of DPYD during autopsy revealed the presence of the heterozygous mutation, IVS14+1 G>A, DPYD*2A, now recognized as the most common cause of DPYD deficiency.  Conclusion: These two patients present the first two cases of DPYD deficiency that had either delay in severe toxicity or recovered from severe toxicity as they received oral Vistogard as a part of the conical trial.  Toxicity was delayed in both patients by a mean of 3.5 wk (range 3-4 wk), indicating that Vistogard might be able to delay 5-FU toxicity despite higher doses than std. bolus dose of 5-FU used in gastrointestinal malignancies and the appearance of a potentially less toxic adverse effect of 5-FU at an unusual site (cutaneous) in one patient.  The role of uridine triacetate with 5-FU in DPYD-deficient patients needs further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosGx07She5BrVg90H21EOLACvtfcHk0lgjf0ImDrqlaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Sitrs%253D&md5=057d96a1f452a6b52135d3cd09e7e78f</span></div><a href="/servlet/linkout?suffix=cit106c&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3063-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3063-1%26sid%3Dliteratum%253Aachs%26aulast%3DSaif%26aufirst%3DM.%2BW.%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26atitle%3DBenefit%2520of%2520Uridine%2520Triacetate%2520%2528Vistogard%2529%2520in%2520Rescuing%2520Severe%25205-Fluorouracil%2520Toxicity%2520in%2520Patients%2520with%2520Dihydropyrimidine%2520Dehydrogenase%2520%2528DPYD%2529%2520Deficiency%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D78%26spage%3D151%26epage%3D156%26doi%3D10.1007%2Fs00280-016-3063-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Rajabalee, F. J. M.</span><span> </span><span class="NLM_article-title">Convenient Synthesis of 2′,3′,5′-Tri-O-acetyladenosine and -Uridine</span> <span class="citation_source-journal">Angew. Chem., Int. Ed. Engl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="refDoi"> DOI: 10.1002/anie.197100751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fanie.197100751" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1971&pages=75&author=F.+J.+M.+Rajabalee&title=Convenient+Synthesis+of+2%E2%80%B2%2C3%E2%80%B2%2C5%E2%80%B2-Tri-O-acetyladenosine+and+-Uridine&doi=10.1002%2Fanie.197100751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1002%2Fanie.197100751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.197100751%26sid%3Dliteratum%253Aachs%26aulast%3DRajabalee%26aufirst%3DF.%2BJ.%2BM.%26atitle%3DConvenient%2520Synthesis%2520of%25202%25E2%2580%25B2%252C3%25E2%2580%25B2%252C5%25E2%2580%25B2-Tri-O-acetyladenosine%2520and%2520-Uridine%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1971%26volume%3D10%26spage%3D75%26doi%3D10.1002%2Fanie.197100751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108a"><span><span class="NLM_label">(a) </span>Teijin Pharma to Co-market New Anti-inflammatory Analgesic Patch Formulation; <span class="NLM_publisher-name">Teijin Ltd.</span>: <span class="NLM_publisher-loc">Tokyo</span>, February 1,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.teijin.com/news/2016/ebd160201_28.html" class="extLink">http://www.teijin.com/news/2016/ebd160201_28.html</a> (accessed June 26,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Teijin+Pharma+to+Co-market+New+Anti-inflammatory+Analgesic+Patch+Formulation%3B+Teijin+Ltd.%3A+Tokyo%2C+February+1%2C+2016%3B+http%3A%2F%2Fwww.teijin.com%2Fnews%2F2016%2Febd160201_28.html+%28accessed+June+26%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DTeijin%2520Pharma%2520to%2520Co-market%2520New%2520Anti-inflammatory%2520Analgesic%2520Patch%2520Formulation%26pub%3DTeijin%2520Ltd%26date%3D2016%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit108b"><span><span class="NLM_label">(b) </span>Acquisition of Manufacturing and Marketing Approval in Japan for the Transdermal Anti-inflammatory Analgesic Patch Formulation LOQOA Tape; <span class="NLM_publisher-name">Taisho Pharmaceutical Holdings</span>: <span class="NLM_publisher-loc">Tokyo</span>, September 28,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://www.evaluategroup.com/Universal/View.aspx?type=Story&amp;id=618759" class="extLink">https://www.evaluategroup.com/Universal/View.aspx?type=Story&id=618759</a> (accessed June 26, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Acquisition+of+Manufacturing+and+Marketing+Approval+in+Japan+for+the+Transdermal+Anti-inflammatory+Analgesic+Patch+Formulation+LOQOA+Tape%3B+Taisho+Pharmaceutical+Holdings%3A+Tokyo%2C+September+28%2C+2015%3B+https%3A%2F%2Fwww.evaluategroup.com%2FUniversal%2FView.aspx%3Ftype%3DStory%26id%3D618759+%28accessed+June+26%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DAcquisition%2520of%2520Manufacturing%2520and%2520Marketing%2520Approval%2520in%2520Japan%2520for%2520the%2520Transdermal%2520Anti-inflammatory%2520Analgesic%2520Patch%2520Formulation%2520LOQOA%2520Tape%26pub%3DTaisho%2520Pharmaceutical%2520Holdings%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Smith, H. J.; Williams, H.</span> <span class="citation_source-book">Smith and Williams’ Introduction to the Principles of Drug Design and Action</span>, <span class="NLM_edition">4th</span> ed.; <span class="NLM_publisher-name">CRC Press</span>: <span class="NLM_publisher-loc">Boca Raton, FL</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=H.+J.+Smith&author=H.+Williams&title=Smith+and+Williams%E2%80%99+Introduction+to+the+Principles+of+Drug+Design+and+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DH.%2BJ.%26btitle%3DSmith%2520and%2520Williams%25E2%2580%2599%2520Introduction%2520to%2520the%2520Principles%2520of%2520Drug%2520Design%2520and%2520Action%26pub%3DCRC%2520Press%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Alder, C. M.; Baldwin, I. R.; Barton, N. P.; Campbell, A. J.; Champigny, A. C.; Harling, J. D.; Maxwell, A. C.; Simpson, J. K.; Smith, I. E. D.; Tame, C. J.</span><span> </span><span class="NLM_article-title">Pyrimidine Derivatives Used as ITK Inhibitors</span>. WO 2010106016A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=C.+M.+Alder&author=I.+R.+Baldwin&author=N.+P.+Barton&author=A.+J.+Campbell&author=A.+C.+Champigny&author=J.+D.+Harling&author=A.+C.+Maxwell&author=J.+K.+Simpson&author=I.+E.+D.+Smith&author=C.+J.+Tame&title=Pyrimidine+Derivatives+Used+as+ITK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlder%26aufirst%3DC.%2BM.%26atitle%3DPyrimidine%2520Derivatives%2520Used%2520as%2520ITK%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="b8fccacddfcbf8fefcf9">[email protected]</a>: FDA Approved Drug Products; <span class="NLM_publisher-name">U.S. Food and Drug Administratio</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails" class="extLink">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails</a> (accessed June 26, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs%40FDA%3A+FDA+Approved+Drug+Products%3B+U.S.+Food+and+Drug+Administratio%3A+Silver+Spring%2C+MD%2C+2016%3B+http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdrugsatfda%2Findex.cfm%3Ffuseaction%3DSearch.DrugDetails+%28accessed+June+26%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%2540FDA%253A%2520FDA%2520Approved%2520Drug%2520Products%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administratio%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Reid, G.</span><span> </span><span class="NLM_article-title">Process for the Manufacture of <i>S</i>-(+)-Flurbiprofen</span>. WO 2015145163A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=G.+Reid&title=Process+for+the+Manufacture+of+S-%28%2B%29-Flurbiprofen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReid%26aufirst%3DG.%26atitle%3DProcess%2520for%2520the%2520Manufacture%2520of%2520S-%2528%252B%2529-Flurbiprofen%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Hirankarn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alamuddin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FitzGerald, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skarke, C.</span><span> </span><span class="NLM_article-title">GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies</span> <span class="citation_source-journal">Clin. Pharmacol. Drug Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">386</span><span class="refDoi"> DOI: 10.1002/cpdd.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1002%2Fcpdd.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27121942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=379-386&author=S.+Hirankarnauthor=J.+S.+Barrettauthor=N.+Alamuddinauthor=G.+A.+FitzGeraldauthor=C.+Skarke&title=GCG100649%2C+A+Novel+Cyclooxygenase-2+Inhibitor%2C+Exhibits+a+Drug+Disposition+Profile+in+Healthy+Volunteers+Compatible+With+High+Affinity+to+Carbonic+Anhydrase-I%2FII%3A+Preliminary+Dose-Exposure+Relationships+to+Define+Clinical+Development+Strategies&doi=10.1002%2Fcpdd.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">GCG100649, a novel cyclooxygenase-2 inhibitor, exhibits a drug disposition profile in healthy volunteers compatible with high affinity to carbonic anhydrase-I/II: preliminary dose-exposure relationships to define clinical development strategies</span></div><div class="casAuthors">Hirankarn, Sarapee; Barrett, Jeffrey S.; Alamuddin, Naji; FitzGerald, Garret A.; Skarke, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">379-386, 8</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">CG100649, proposed as a dual inhibitor of cyclooxygenase (COX)-2 and carbonic anhydrase (CA)-I/-II, is long-lived in plasma and whole blood.  The mean ± SD half-lives were 131 ± 19 and 127 ± 33 h, resp., after administration of oral single doses of 2 or 8 mg CG100649 to healthy volunteers.  The whole blood to plasma concn. ratio (78 ± 23) for CG100649 is linear over the dosing interval reflecting a biodistribution pattern consistent with other strong CA-inhibitors (e.g., acetazolamide, methazolamide).  A one compartment model with first order absorption and elimination described CG100649 concn.-time profiles well.  Ests. (%relative SD) between plasma and whole blood were in agreement for the absorption rate const., 1.54 (58.6) and 1.43 (28.0) hour-1, resp., but considerably different for clearance, 3.29 (10.4) and 0.04 (7.7) L/h/70 kg, and for vol. of distribution, 559 (6.7) and 7.6 (2.4) L/70 kg, resp.  The extent to which these unique PK characteristics of CG100649 discriminate it from other COX-2 inhibitors will be the subject of future investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYcIXe7ZmAH7Vg90H21EOLACvtfcHk0lgncTBDX4dGrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gtLnK&md5=17e5e4422b53f5f4f9490077d6427166</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.47%26sid%3Dliteratum%253Aachs%26aulast%3DHirankarn%26aufirst%3DS.%26aulast%3DBarrett%26aufirst%3DJ.%2BS.%26aulast%3DAlamuddin%26aufirst%3DN.%26aulast%3DFitzGerald%26aufirst%3DG.%2BA.%26aulast%3DSkarke%26aufirst%3DC.%26atitle%3DGCG100649%252C%2520A%2520Novel%2520Cyclooxygenase-2%2520Inhibitor%252C%2520Exhibits%2520a%2520Drug%2520Disposition%2520Profile%2520in%2520Healthy%2520Volunteers%2520Compatible%2520With%2520High%2520Affinity%2520to%2520Carbonic%2520Anhydrase-I%252FII%253A%2520Preliminary%2520Dose-Exposure%2520Relationships%2520to%2520Define%2520Clinical%2520Development%2520Strategies%26jtitle%3DClin.%2520Pharmacol.%2520Drug%2520Dev.%26date%3D2013%26volume%3D2%26spage%3D379%26epage%3D386%26doi%3D10.1002%2Fcpdd.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Shin, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moh, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, Y. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noh, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, S.</span><span> </span><span class="NLM_article-title">In Vitro Structure-Activity Relationship and In Vivo Studies for a Novel Class of Cyclooxygenase-2 Inhibitors: 5-Aryl-2,2-dialkyl-4-phenyl-3(2H)furanone Derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">792</span><span class="NLM_x">–</span> <span class="NLM_lpage">804</span><span class="refDoi"> DOI: 10.1021/jm020545z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020545z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=792-804&author=S.+S.+Shinauthor=Y.+Byunauthor=K.+M.+Limauthor=J.+K.+Choiauthor=K.+W.+Leeauthor=J.+H.+Mohauthor=J.+K.+Kimauthor=Y.+S.+Jeongauthor=J.+Y.+Kimauthor=Y.+H.+Choiauthor=H.+J.+Kohauthor=Y.+H.+Parkauthor=Y.+I.+Ohauthor=M.+S.+Nohauthor=S.+Chung&title=In+Vitro+Structure-Activity+Relationship+and+In+Vivo+Studies+for+a+Novel+Class+of+Cyclooxygenase-2+Inhibitors%3A+5-Aryl-2%2C2-dialkyl-4-phenyl-3%282H%29furanone+Derivatives&doi=10.1021%2Fjm020545z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm020545z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020545z%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DS.%2BS.%26aulast%3DByun%26aufirst%3DY.%26aulast%3DLim%26aufirst%3DK.%2BM.%26aulast%3DChoi%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DMoh%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BK.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DChoi%26aufirst%3DY.%2BH.%26aulast%3DKoh%26aufirst%3DH.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DOh%26aufirst%3DY.%2BI.%26aulast%3DNoh%26aufirst%3DM.%2BS.%26aulast%3DChung%26aufirst%3DS.%26atitle%3DIn%2520Vitro%2520Structure-Activity%2520Relationship%2520and%2520In%2520Vivo%2520Studies%2520for%2520a%2520Novel%2520Class%2520of%2520Cyclooxygenase-2%2520Inhibitors%253A%25205-Aryl-2%252C2-dialkyl-4-phenyl-3%25282H%2529furanone%2520Derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D792%26epage%3D804%26doi%3D10.1021%2Fjm020545z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margalit, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holla, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DuBois, R. N.</span><span> </span><span class="NLM_article-title">CG100649, a Novel COX-2 Inhibitor, Inhibits Colorectal Adenoma and Carcinoma Growth in Mouse Models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1105</span><span class="NLM_x">–</span> <span class="NLM_lpage">1112</span><span class="refDoi"> DOI: 10.1007/s10637-014-0144-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs10637-014-0144-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1105-1112&author=S.+H.+Kimauthor=O.+Margalitauthor=H.+Katohauthor=D.+Wangauthor=H.+Wuauthor=D.+Xiaauthor=V.+R.+Hollaauthor=P.+Yangauthor=R.+N.+DuBois&title=CG100649%2C+a+Novel+COX-2+Inhibitor%2C+Inhibits+Colorectal+Adenoma+and+Carcinoma+Growth+in+Mouse+Models&doi=10.1007%2Fs10637-014-0144-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0144-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0144-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DMargalit%26aufirst%3DO.%26aulast%3DKatoh%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DD.%26aulast%3DHolla%26aufirst%3DV.%2BR.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DDuBois%26aufirst%3DR.%2BN.%26atitle%3DCG100649%252C%2520a%2520Novel%2520COX-2%2520Inhibitor%252C%2520Inhibits%2520Colorectal%2520Adenoma%2520and%2520Carcinoma%2520Growth%2520in%2520Mouse%2520Models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2014%26volume%3D32%26spage%3D1105%26epage%3D1112%26doi%3D10.1007%2Fs10637-014-0144-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Kearney, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baigent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halls, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emberson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrono, C.</span><span> </span><span class="NLM_article-title">Do Selective Cyclo-oxygenase-2 Inhibitors and Traditional Non-steroidal Anti-inflammatory Drugs Increase the Risk of Atherothrombosis? Meta-analysis of Randomised Trials</span> <span class="citation_source-journal">BMJ</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x"> (</span><span class="NLM_issue">7553</span><span class="NLM_x">) </span> <span class="NLM_fpage">1302</span><span class="NLM_x">–</span> <span class="NLM_lpage">1308</span><span class="refDoi"> DOI: 10.1136/bmj.332.7553.1302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1136%2Fbmj.332.7553.1302" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2006&pages=1302-1308&issue=7553&author=P.+M.+Kearneyauthor=C.+Baigentauthor=J.+Godwinauthor=H.+Hallsauthor=J.+R.+Embersonauthor=C.+Patrono&title=Do+Selective+Cyclo-oxygenase-2+Inhibitors+and+Traditional+Non-steroidal+Anti-inflammatory+Drugs+Increase+the+Risk+of+Atherothrombosis%3F+Meta-analysis+of+Randomised+Trials&doi=10.1136%2Fbmj.332.7553.1302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1136%2Fbmj.332.7553.1302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.332.7553.1302%26sid%3Dliteratum%253Aachs%26aulast%3DKearney%26aufirst%3DP.%2BM.%26aulast%3DBaigent%26aufirst%3DC.%26aulast%3DGodwin%26aufirst%3DJ.%26aulast%3DHalls%26aufirst%3DH.%26aulast%3DEmberson%26aufirst%3DJ.%2BR.%26aulast%3DPatrono%26aufirst%3DC.%26atitle%3DDo%2520Selective%2520Cyclo-oxygenase-2%2520Inhibitors%2520and%2520Traditional%2520Non-steroidal%2520Anti-inflammatory%2520Drugs%2520Increase%2520the%2520Risk%2520of%2520Atherothrombosis%253F%2520Meta-analysis%2520of%2520Randomised%2520Trials%26jtitle%3DBMJ%26date%3D2006%26volume%3D332%26issue%3D7553%26spage%3D1302%26epage%3D1308%26doi%3D10.1136%2Fbmj.332.7553.1302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Prasit, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brideau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charleson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cromlish, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford-Hutchinson, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gresser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kargman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leblanc, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouellet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riendeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodger, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickers, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamboni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupniak, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D.</span><span> </span><span class="NLM_article-title">The Discovery of Rofecxib, [MK 966, Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an Orally Active Cyclooxygenase-2-inhibitor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1773</span><span class="NLM_x">–</span> <span class="NLM_lpage">1778</span><span class="refDoi"> DOI: 10.1016/S0960-894X(99)00288-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0960-894X%2899%2900288-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=1773-1778&author=P.+Prasitauthor=Z.+Wangauthor=C.+Brideauauthor=C.+C.+Chanauthor=S.+Charlesonauthor=W.+Cromlishauthor=D.+Ethierauthor=J.+F.+Evansauthor=A.+W.+Ford-Hutchinsonauthor=J.+Y.+Gauthierauthor=R.+Gordonauthor=J.+Guayauthor=M.+Gresserauthor=S.+Kargmanauthor=B.+Kennedyauthor=Y.+Leblancauthor=S.+Legerauthor=J.+Manciniauthor=G.+P.+O%E2%80%99Neillauthor=M.+Ouelletauthor=M.+D.+Percivalauthor=H.+Perrierauthor=D.+Riendeauauthor=I.+Rodgerauthor=P.+Tagariauthor=M.+Therienauthor=P.+Vickersauthor=E.+Wongauthor=L.-J.+Xuauthor=R.+N.+Youngauthor=R.+Zamboniauthor=S.+Boyceauthor=N.+Rupniakauthor=M.+Forrestauthor=D.+Viscoauthor=D.+Patrick&title=The+Discovery+of+Rofecxib%2C+%5BMK+966%2C+Vioxx%2C+4-%284%E2%80%B2-Methylsulfonylphenyl%29-3-phenyl-2%285H%29-furanone%5D%2C+an+Orally+Active+Cyclooxygenase-2-inhibitor&doi=10.1016%2FS0960-894X%2899%2900288-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900288-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900288-7%26sid%3Dliteratum%253Aachs%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBrideau%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DC.%2BC.%26aulast%3DCharleson%26aufirst%3DS.%26aulast%3DCromlish%26aufirst%3DW.%26aulast%3DEthier%26aufirst%3DD.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DFord-Hutchinson%26aufirst%3DA.%2BW.%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGuay%26aufirst%3DJ.%26aulast%3DGresser%26aufirst%3DM.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DKennedy%26aufirst%3DB.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DLeger%26aufirst%3DS.%26aulast%3DMancini%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DG.%2BP.%26aulast%3DOuellet%26aufirst%3DM.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DPerrier%26aufirst%3DH.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DRodger%26aufirst%3DI.%26aulast%3DTagari%26aufirst%3DP.%26aulast%3DTherien%26aufirst%3DM.%26aulast%3DVickers%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DXu%26aufirst%3DL.-J.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26aulast%3DZamboni%26aufirst%3DR.%26aulast%3DBoyce%26aufirst%3DS.%26aulast%3DRupniak%26aufirst%3DN.%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DVisco%26aufirst%3DD.%26aulast%3DPatrick%26aufirst%3DD.%26atitle%3DThe%2520Discovery%2520of%2520Rofecxib%252C%2520%255BMK%2520966%252C%2520Vioxx%252C%25204-%25284%25E2%2580%25B2-Methylsulfonylphenyl%2529-3-phenyl-2%25285H%2529-furanone%255D%252C%2520an%2520Orally%2520Active%2520Cyclooxygenase-2-inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D1773%26epage%3D1778%26doi%3D10.1016%2FS0960-894X%2899%2900288-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit117b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertenshaw, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Docter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graneto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malecha, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogier, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogburn, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboldt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veenhuizen, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakson, P. C.</span><span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze Nesulfonamide (SC-58635, Celecoxib)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1365</span><span class="refDoi"> DOI: 10.1021/jm960803q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960803q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1347-1365&author=T.+D.+Penningauthor=J.+J.+Talleyauthor=S.+R.+Bertenshawauthor=J.+S.+Carterauthor=P.+W.+Collinsauthor=S.+Docterauthor=M.+J.+Granetoauthor=L.+F.+Leeauthor=J.+W.+Malechaauthor=J.+M.+Miyashiroauthor=R.+S.+Rogersauthor=D.+J.+Rogierauthor=S.+S.+Yuauthor=G.+D.+Andersonauthor=E.+G.+Burtonauthor=J.+N.+Cogburnauthor=S.+A.+Gregoryauthor=C.+M.+Koboldtauthor=W.+E.+Perkinsauthor=K.+Seibertauthor=A.+W.+Veenhuizenauthor=Y.+Y.+Zhangauthor=P.+C.+Isakson&title=Synthesis+and+Biological+Evaluation+of+the+1%2C5-Diarylpyrazole+Class+of+Cyclooxygenase-2+inhibitors%3A+Identification+of+4-%5B5-%284-methylphenyl%29-3-%28trifluoromethyl%29-1H-pyrazol-1-yl%5Dbenze+Nesulfonamide+%28SC-58635%2C+Celecoxib%29&doi=10.1021%2Fjm960803q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117b&amp;dbid=16384&amp;doi=10.1021%2Fjm960803q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960803q%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DTalley%26aufirst%3DJ.%2BJ.%26aulast%3DBertenshaw%26aufirst%3DS.%2BR.%26aulast%3DCarter%26aufirst%3DJ.%2BS.%26aulast%3DCollins%26aufirst%3DP.%2BW.%26aulast%3DDocter%26aufirst%3DS.%26aulast%3DGraneto%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DL.%2BF.%26aulast%3DMalecha%26aufirst%3DJ.%2BW.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BM.%26aulast%3DRogers%26aufirst%3DR.%2BS.%26aulast%3DRogier%26aufirst%3DD.%2BJ.%26aulast%3DYu%26aufirst%3DS.%2BS.%26aulast%3DAnderson%26aufirst%3DG.%2BD.%26aulast%3DBurton%26aufirst%3DE.%2BG.%26aulast%3DCogburn%26aufirst%3DJ.%2BN.%26aulast%3DGregory%26aufirst%3DS.%2BA.%26aulast%3DKoboldt%26aufirst%3DC.%2BM.%26aulast%3DPerkins%26aufirst%3DW.%2BE.%26aulast%3DSeibert%26aufirst%3DK.%26aulast%3DVeenhuizen%26aufirst%3DA.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DIsakson%26aufirst%3DP.%2BC.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520the%25201%252C5-Diarylpyrazole%2520Class%2520of%2520Cyclooxygenase-2%2520inhibitors%253A%2520Identification%2520of%25204-%255B5-%25284-methylphenyl%2529-3-%2528trifluoromethyl%2529-1H-pyrazol-1-yl%255Dbenze%2520Nesulfonamide%2520%2528SC-58635%252C%2520Celecoxib%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1347%26epage%3D1365%26doi%3D10.1021%2Fjm960803q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit117c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Talley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graneto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboldt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masferrer, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibert, K.</span><span> </span><span class="NLM_article-title">4-[5-Methyl-3-Phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">777</span><span class="refDoi"> DOI: 10.1021/jm990577v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990577v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1aiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=775-777&author=J.+J.+Talleyauthor=D.+L.+Brownauthor=J.+S.+Carterauthor=M.+J.+Granetoauthor=C.+M.+Koboldtauthor=J.+L.+Masferrerauthor=W.+E.+Perkinsauthor=R.+S.+Rogersauthor=A.+F.+Shafferauthor=Y.+Y.+Zhangauthor=B.+S.+Zweifelauthor=K.+Seibert&title=4-%5B5-Methyl-3-Phenylisoxazol-4-yl%5D-benzenesulfonamide%2C+Valdecoxib%3A+A+Potent+and+Selective+Inhibitor+of+COX-2&doi=10.1021%2Fjm990577v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117cR"><div class="casContent"><span class="casTitleNuber">117c</span><div class="casTitle"><span class="NLM_cas:atitle">4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2</span></div><div class="casAuthors">Talley, John J.; Brown, David L.; Carter, Jeffery S.; Graneto, Matthew J.; Koboldt, Carol M.; Masferrer, Jaime L.; Perkins, William E.; Rogers, Roland S.; Shaffer, Alexander F.; Zhang, Yan Y.; Zweifel, Ben S.; Seibert, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">775-777</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Valdecoxib (SC 65872) was a highly selective and potent inhibitor of COX-2 in human whole blood and against the recombinant human enzyme with an IC50 = 140 ± 19 μM (n = 10).  In animal models of acute and chronic inflammation, valdecoxib showed exceptional potency after oral administration.  An active metabolite of valdecoxib, formed in rodents and dogs, was also found to be a COX-2 selective inhibitor.  Valdecoxib is currently in clin. evaluation for the treatment of arthritis and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK0MUnhzUFEbVg90H21EOLACvtfcHk0ljwjapHpX4Haw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1aiurw%253D&md5=61255dca3e0b7d879de06a3185e69d7c</span></div><a href="/servlet/linkout?suffix=cit117c&amp;dbid=16384&amp;doi=10.1021%2Fjm990577v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990577v%26sid%3Dliteratum%253Aachs%26aulast%3DTalley%26aufirst%3DJ.%2BJ.%26aulast%3DBrown%26aufirst%3DD.%2BL.%26aulast%3DCarter%26aufirst%3DJ.%2BS.%26aulast%3DGraneto%26aufirst%3DM.%2BJ.%26aulast%3DKoboldt%26aufirst%3DC.%2BM.%26aulast%3DMasferrer%26aufirst%3DJ.%2BL.%26aulast%3DPerkins%26aufirst%3DW.%2BE.%26aulast%3DRogers%26aufirst%3DR.%2BS.%26aulast%3DShaffer%26aufirst%3DA.%2BF.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DZweifel%26aufirst%3DB.%2BS.%26aulast%3DSeibert%26aufirst%3DK.%26atitle%3D4-%255B5-Methyl-3-Phenylisoxazol-4-yl%255D-benzenesulfonamide%252C%2520Valdecoxib%253A%2520A%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520COX-2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D775%26epage%3D777%26doi%3D10.1021%2Fjm990577v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Friesen, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brideau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charleson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschenes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dube, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethier, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riendeau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savoie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. N.</span><span> </span><span class="NLM_article-title">2-Pyridinyl-3-(4-Methylsulfonyl)phenylpyridines: Selective and Orally Active Cyclooxygenase-2 Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2777</span><span class="NLM_x">–</span> <span class="NLM_lpage">2782</span><span class="refDoi"> DOI: 10.1016/S0960-894X(98)00499-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS0960-894X%2898%2900499-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=9873621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADyaK1cXntFSitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=2777-2782&author=R.+W.+Friesenauthor=C.+Brideauauthor=C.+C.+Chanauthor=S.+Charlesonauthor=D.+Deschenesauthor=D.+Dubeauthor=D.+Ethierauthor=R.+Fortinauthor=J.+Y.+Gauthierauthor=Y.+Girardauthor=R.+Gordonauthor=G.+M.+Greigauthor=D.+Riendeauauthor=C.+Savoieauthor=Z.+Wangauthor=E.+Wongauthor=D.+Viscoauthor=L.+J.+Xuauthor=R.+N.+Young&title=2-Pyridinyl-3-%284-Methylsulfonyl%29phenylpyridines%3A+Selective+and+Orally+Active+Cyclooxygenase-2+Inhibitors&doi=10.1016%2FS0960-894X%2898%2900499-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">2-Pyridinyl-3-[4-(methylsulfonyl)phenyl]pyridines: selective and orally active cyclooxygenase-2 inhibitors</span></div><div class="casAuthors">Friesen, Richard W.; Brideau, Christine; Chan, Chi Chung; Charleson, Stella; Deschenes, Denis; Dube, Daniel; Ethier, Diane; Fortin, Rejean; Gauthier, Jacques Yves; Girard, Yves; Gordon, Robert; Greig, Gillian M.; Riendeau, Denis; Savoie, Chantal; Wang, Zhaoyin; Wong, Elizabeth; Visco, Denise; Xu, Li Jing; Young, Robert N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2777-2782</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The title compds. were prepd. and evaluated for their ability to inhibit the isoenzymes of cyclooxygenase, COX-1 and COX-2.  Optimum COX-2 activity was obsd. by introduction of a substituent at C5 of the central pyridine.  Pyridine deriv. I was identified as the optimum compd. in this series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmMcvhjPWNvLVg90H21EOLACvtfcHk0lhubTB8syR5ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFSitb0%253D&md5=b424a5b5c095d49b6dc1410a7c7335e4</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900499-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900499-5%26sid%3Dliteratum%253Aachs%26aulast%3DFriesen%26aufirst%3DR.%2BW.%26aulast%3DBrideau%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DC.%2BC.%26aulast%3DCharleson%26aufirst%3DS.%26aulast%3DDeschenes%26aufirst%3DD.%26aulast%3DDube%26aufirst%3DD.%26aulast%3DEthier%26aufirst%3DD.%26aulast%3DFortin%26aufirst%3DR.%26aulast%3DGauthier%26aufirst%3DJ.%2BY.%26aulast%3DGirard%26aufirst%3DY.%26aulast%3DGordon%26aufirst%3DR.%26aulast%3DGreig%26aufirst%3DG.%2BM.%26aulast%3DRiendeau%26aufirst%3DD.%26aulast%3DSavoie%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DE.%26aulast%3DVisco%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DL.%2BJ.%26aulast%3DYoung%26aufirst%3DR.%2BN.%26atitle%3D2-Pyridinyl-3-%25284-Methylsulfonyl%2529phenylpyridines%253A%2520Selective%2520and%2520Orally%2520Active%2520Cyclooxygenase-2%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D2777%26epage%3D2782%26doi%3D10.1016%2FS0960-894X%2898%2900499-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span>Cobimetinib; <span class="NLM_publisher-name">Exelixis</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.exelixis.com/pipeline/GDC_0973_xl518" class="extLink">http://www.exelixis.com/pipeline/GDC_0973_xl518</a>; accessed August 2, 2016.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cobimetinib%3B+Exelixis%3A+San+Francisco%2C+CA%2C+2016%3B+http%3A%2F%2Fwww.exelixis.com%2Fpipeline%2FGDC_0973_xl518%3B+accessed+August+2%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DCobimetinib%26pub%3DExelixis%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rice, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aay, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blazey, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowles, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussenius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costanzo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtis, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defina, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubenko, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koltun, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manalo, J.-C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuss, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peto, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, S.</span><span> </span><span class="NLM_article-title">Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span><span class="refDoi"> DOI: 10.1021/ml300049d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300049d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=416-421&author=K.+D.+Riceauthor=N.+Aayauthor=N.+K.+Anandauthor=C.+M.+Blazeyauthor=O.+J.+Bowlesauthor=J.+Busseniusauthor=S.+Costanzoauthor=J.+K.+Curtisauthor=S.+C.+Definaauthor=L.+Dubenkoauthor=S.+Engstauthor=A.+A.+Joshiauthor=A.+R.+Kennedyauthor=A.+I.+Kimauthor=E.+S.+Koltunauthor=J.+C.+Lougheedauthor=J.-C.+L.+Manaloauthor=J.-F.+Martiniauthor=J.+M.+Nussauthor=C.+J.+Petoauthor=T.+H.+Tsangauthor=P.+Yuauthor=S.+Johnston&title=Novel+Carboxamide-Based+Allosteric+MEK+Inhibitors%3A+Discovery+and+Optimization+Efforts+toward+XL518+%28GDC-0973%29&doi=10.1021%2Fml300049d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120aR"><div class="casContent"><span class="casTitleNuber">120a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)</span></div><div class="casAuthors">Rice, Kenneth D.; Aay, Naing; Anand, Neel K.; Blazey, Charles M.; Bowles, Owen J.; Bussenius, Joerg; Costanzo, Simona; Curtis, Jeffry K.; Defina, Steven C.; Dubenko, Larisa; Engst, Stefan; Joshi, Anagha A.; Kennedy, Abigail R.; Kim, Angie I.; Koltun, Elena S.; Lougheed, Julie C.; Manalo, Jean-Claire L.; Martini, Jean-Francois; Nuss, John M.; Peto, Csaba J.; Tsang, Tsze H.; Yu, Peiwen; Johnston, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">416-421</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types.  Mutations assocd. with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK.  Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer.  Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metab. and safety profile vs. PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (I).  I exhibits robust in vitro and in vivo potency and efficacy in preclin. models with sustained duration of action and is currently in early stage clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOx-Upr00b8LVg90H21EOLACvtfcHk0lhubTB8syR5ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D&md5=04aa82afd24efe83a3b888140781bfc6</span></div><a href="/servlet/linkout?suffix=cit120a&amp;dbid=16384&amp;doi=10.1021%2Fml300049d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300049d%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DK.%2BD.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DAnand%26aufirst%3DN.%2BK.%26aulast%3DBlazey%26aufirst%3DC.%2BM.%26aulast%3DBowles%26aufirst%3DO.%2BJ.%26aulast%3DBussenius%26aufirst%3DJ.%26aulast%3DCostanzo%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%2BK.%26aulast%3DDefina%26aufirst%3DS.%2BC.%26aulast%3DDubenko%26aufirst%3DL.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%2BA.%26aulast%3DKennedy%26aufirst%3DA.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BI.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DManalo%26aufirst%3DJ.-C.%2BL.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DPeto%26aufirst%3DC.%2BJ.%26aulast%3DTsang%26aufirst%3DT.%2BH.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DS.%26atitle%3DNovel%2520Carboxamide-Based%2520Allosteric%2520MEK%2520Inhibitors%253A%2520Discovery%2520and%2520Optimization%2520Efforts%2520toward%2520XL518%2520%2528GDC-0973%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D416%26epage%3D421%26doi%3D10.1021%2Fml300049d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit120b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Den Otter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, N.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F0008-5472.CAN-11-1515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22084396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=210-219&author=K.+P.+Hoeflichauthor=M.+Merchantauthor=C.+Orrauthor=J.+Chanauthor=D.+Den+Otterauthor=L.+Berryauthor=I.+Kasmanauthor=H.+Koeppenauthor=K.+Riceauthor=N.-Y.+Yangauthor=S.+Engstauthor=S.+Johnstonauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Intermittent+Administration+of+MEK+Inhibitor+GDC-0973+plus+PI3K+Inhibitor+GDC-0941+Triggers+Robust+Apoptosis+and+Tumor+Growth+Inhibition&doi=10.1158%2F0008-5472.CAN-11-1515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120bR"><div class="casContent"><span class="casTitleNuber">120b</span><div class="casTitle"><span class="NLM_cas:atitle">Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition</span></div><div class="casAuthors">Hoeflich, Klaus P.; Merchant, Mark; Orr, Christine; Chan, Jocelyn; Den Otter, Doug; Berry, Leanne; Kasman, Ian; Koeppen, Hartmut; Rice, Ken; Yang, Nai-Ying; Engst, Stefan; Johnston, Stuart; Friedman, Lori S.; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-219</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclin. cancer models, leading to the initiation of clin. trials cotargeting these two key cancer signaling pathways.  GDC-0973, a novel selective MEK inhibitor, and GDC-0941, a class I PI3K inhibitor, are in early stage clin. trials as both single agents and in combination.  The discovery of these selective inhibitors has allowed investigation into the precise effects of combining inhibitors of two major signaling branches downstream of RAS.  Here, we investigated multiple biomarkers in the mitogen-activated protein kinase (MAPK) and PI3K pathway to search for points of convergence that explain the increased apoptosis seen in combination.  Using washout studies in vitro and alternate dosing schedules in mice, we showed that intermittent inhibition of the PI3K and MAPK pathway is sufficient for efficacy in BRAF and KRAS mutant cancer cells.  The combination of GDC-0973 with the PI3K inhibitor GDC-0941 resulted in combination efficacy in vitro and in vivo via induction of biomarkers assocd. with apoptosis, including Bcl-2 family proapoptotic regulators.  Therefore, these data suggest that continuous exposure of MEK and PI3K inhibitors in combination is not required for efficacy in preclin. cancer models and that sustained effects on downstream apoptosis biomarkers can be obsd. in response to intermittent dosing.  Cancer Res; 72(1); 210-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHbA7g6hLGrVg90H21EOLACvtfcHk0lhubTB8syR5ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D&md5=40032bf35d5e6335856a645d5c331df8</span></div><a href="/servlet/linkout?suffix=cit120b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1515%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DDen%2BOtter%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DN.-Y.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DIntermittent%2520Administration%2520of%2520MEK%2520Inhibitor%2520GDC-0973%2520plus%2520PI3K%2520Inhibitor%2520GDC-0941%2520Triggers%2520Robust%2520Apoptosis%2520and%2520Tumor%2520Growth%2520Inhibition%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D210%26epage%3D219%26doi%3D10.1158%2F0008-5472.CAN-11-1515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernillet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martini, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Rosario, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aftab, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prescott, J.</span><span> </span><span class="NLM_article-title">Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3090</span><span class="NLM_x">–</span> <span class="NLM_lpage">3099</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F1078-0432.CCR-12-0445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22496205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3090-3099&author=H.+Wongauthor=L.+Vernilletauthor=A.+Petersonauthor=J.+A.+Wareauthor=L.+Leeauthor=J.-F.+Martiniauthor=P.+Yuauthor=C.+Liauthor=G.+Del+Rosarioauthor=E.+F.+Chooauthor=K.+P.+Hoeflichauthor=Y.+Shiauthor=B.+T.+Aftabauthor=R.+Aoyamaauthor=S.+T.+Lamauthor=M.+Belvinauthor=J.+Prescott&title=Bridging+the+Gap+between+Preclinical+and+Clinical+Studies+Using+Pharmacokinetic-Pharmacodynamic+Modeling%3A+An+Analysis+of+GDC-0973%2C+a+MEK+Inhibitor&doi=10.1158%2F1078-0432.CCR-12-0445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor</span></div><div class="casAuthors">Wong, Harvey; Vernillet, Laurent; Peterson, Amy; Ware, Joseph A.; Lee, Lillian; Martini, Jean-Francois; Yu, Peiwen; Li, Congfen; Del Rosario, Geoffrey; Choo, Edna F.; Hoeflich, Klaus P.; Shi, Yongchang; Aftab, Blake T.; Aoyama, Ron; Lam, Sanh Tan; Belvin, Marcia; Prescott, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3090-3099</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling was used to relate GDC-0973 plasma and tumor concns., tumor pharmacodynamics and antitumor efficacy to establish pharmacokinetic endpoints and predict active doses in the clinic.  Exptl. Design: A PK-PD model was used to characterize GDC-0973 tumor disposition and in vivo potency in WM-266-4 xenograft mice.  Simulations were conducted using the PK-PD model along with human pharmacokinetics to identify a target plasma concn. and predict active doses.  In vivo potency and antitumor efficacy were characterized in A375 melanoma xenograft mice, and a population-based integrated PK-PD-efficacy model was used to relate tumor pharmacodynamics (%pERK decrease) to antitumor activity.  Results: GDC-0973 showed a sustained tumor pharmacodynamic response due to longer residence in tumor than in plasma.  Following single doses of GDC-0973, estd. in vivo IC50 values of %pERK decrease based on tumor concns. in xenograft mice were 0.78 (WM-266-4) and 0.52 μmol/L (A375).  Following multiple doses of GDC-0973, the estd. in vivo IC50 value in WM-266-4 increased (3.89 μmol/L).  Human simulations predicted a min. target plasma concn. of 83 nmol/L and an active dose range of 28 to 112 mg.  The steep relationship between tumor pharmacodynamics (%pERK decrease) and antitumor efficacy suggests a pathway modulation threshold beyond which antitumor efficacy switches on.  Conclusions: Clin. observations of %pERK decrease and antitumor activity were consistent with model predictions.  This article illustrates how PK-PD modeling can improve the translation of preclin. data to humans by providing a means to integrate preclin. and early clin. data.  Clin Cancer Res; 18(11); 3090-9. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq36HE1lLsI8bVg90H21EOLACvtfcHk0lhXN5xIKbNkXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOgtbg%253D&md5=9ae14cf08c84e63fcdf98e3507a92cd0</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0445%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DH.%26aulast%3DVernillet%26aufirst%3DL.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DDel%2BRosario%26aufirst%3DG.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DAftab%26aufirst%3DB.%2BT.%26aulast%3DAoyama%26aufirst%3DR.%26aulast%3DLam%26aufirst%3DS.%2BT.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DPrescott%26aufirst%3DJ.%26atitle%3DBridging%2520the%2520Gap%2520between%2520Preclinical%2520and%2520Clinical%2520Studies%2520Using%2520Pharmacokinetic-Pharmacodynamic%2520Modeling%253A%2520An%2520Analysis%2520of%2520GDC-0973%252C%2520a%2520MEK%2520Inhibitor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3090%26epage%3D3099%26doi%3D10.1158%2F1078-0432.CCR-12-0445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Baudy, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores-Mercado, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Bruggen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S.-P.</span><span> </span><span class="NLM_article-title">FDG-PET is a Good Biomarker of Both Early Response and Acquired Resistance in BRAFV600 Mutant Melanomas Treated with Vemurafenib and the MEK Inhibitor GDC-0973</span> <span class="citation_source-journal">EJNMMI Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="refDoi"> DOI: 10.1186/2191-219X-2-22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1186%2F2191-219X-2-22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22651703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyitbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=22&author=A.+R.+Baudyauthor=T.+Doganauthor=J.+E.+Flores-Mercadoauthor=K.+P.+Hoeflichauthor=F.+Suauthor=N.+van+Bruggenauthor=S.-P.+Williams&title=FDG-PET+is+a+Good+Biomarker+of+Both+Early+Response+and+Acquired+Resistance+in+BRAFV600+Mutant+Melanomas+Treated+with+Vemurafenib+and+the+MEK+Inhibitor+GDC-0973&doi=10.1186%2F2191-219X-2-22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973</span></div><div class="casAuthors">Baudy, Andreas R.; Dogan, Taner; Flores-Mercado, Judith E.; Hoeflich, Klaus P.; Su, Fei; van Bruggen, Nicholas; Williams, Simon-Peter</div><div class="citationInfo"><span class="NLM_cas:title">EJNMMI Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22/1-22/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">ERJEAI</span>;
        ISSN:<span class="NLM_cas:issn">2191-219X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Background: The BRAF inhibitor, vemurafenib, has recently been approved for the treatment of metastatic melanoma in patients harboring BRAFV600 mutations.  Currently, dual BRAF and MEK inhibition are ongoing in clin. trials with the goal of overcoming the acquired resistance that has unfortunately developed in some vemurafenib patients.  FDG-PET measures of metabolic activity are increasingly employed as a pharmacodynamic biomarker for guiding single-agent or combination therapies by gauging initial drug response and monitoring disease progression.  However, since tumors are inherently heterogeneous, investigating the effects of BRAF and MEK inhibition on FDG uptake in a panel of different melanomas could help interpret imaging outcomes.  Methods: 18F-FDG uptake was measured in vitro in cells with wild-type and mutant (V600) BRAF, and in melanoma cells with an acquired resistance to vemurafenib.  We treated the cells with vemurafenib alone or in combination with MEK inhibitor GDC-0973.  PET imaging was used in mice to measure FDG uptake in A375 melanoma xenografts and in A375 R1, a vemurafenib-resistant deriv.  Histol. and biochem. studies of glucose transporters, the MAPK and glycolytic pathways were also undertaken.  Results: We demonstrate that vemurafenib is equally effective at reducing FDG uptake in cell lines harboring either heterozygous or homozygous BRAFV600 but ineffective in cells with acquired resistance or having WT BRAF status.  However, combination with GDC-0973 results in a highly significant increase of efficacy and inhibition of FDG uptake across all twenty lines.  Drug-induced changes in FDG uptake were assocd. with altered levels of membrane GLUT-1, and cell lines harboring RAS mutations displayed enhanced FDG uptake upon exposure to vemurafenib.  Interestingly, we found that vemurafenib treatment in mice bearing drug-resistant A375 xenografts also induced increased FDG tumor uptake, accompanied by increases in Hif-1α, Sp1 and Ksr protein levels.  Vemurafenib and GDC-0973 combination efficacy was assocd. with decreased levels of hexokinase II, c-RAF, Ksr and p-MEK protein.  Conclusions: We have demonstrated that 18F-FDG-PET imaging reflects vemurafenib and GDC-0973 action across a wide range of metastatic melanomas.  A delayed post-treatment increase in tumor FDG uptake should be considered carefully as it may well be an indication of acquired drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFfhSHK_0cVbVg90H21EOLACvtfcHk0lhXN5xIKbNkXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyitbbP&md5=915b9a76a80aab9c7d7944a539512b1f</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1186%2F2191-219X-2-22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2191-219X-2-22%26sid%3Dliteratum%253Aachs%26aulast%3DBaudy%26aufirst%3DA.%2BR.%26aulast%3DDogan%26aufirst%3DT.%26aulast%3DFlores-Mercado%26aufirst%3DJ.%2BE.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DSu%26aufirst%3DF.%26aulast%3Dvan%2BBruggen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DS.-P.%26atitle%3DFDG-PET%2520is%2520a%2520Good%2520Biomarker%2520of%2520Both%2520Early%2520Response%2520and%2520Acquired%2520Resistance%2520in%2520BRAFV600%2520Mutant%2520Melanomas%2520Treated%2520with%2520Vemurafenib%2520and%2520the%2520MEK%2520Inhibitor%2520GDC-0973%26jtitle%3DEJNMMI%2520Res.%26date%3D2012%26volume%3D2%26spage%3D22%26doi%3D10.1186%2F2191-219X-2-22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Luke, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodi, F. S.</span><span> </span><span class="NLM_article-title">Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F1078-0432.CCR-11-2197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=22083257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=9-14&author=J.+J.+Lukeauthor=F.+S.+Hodi&title=Vemurafenib+and+BRAF+Inhibition%3A+A+New+Class+of+Treatment+for+Metastatic+Melanoma&doi=10.1158%2F1078-0432.CCR-11-2197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma</span></div><div class="casAuthors">Luke, Jason J.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-14</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The U.S. Food and Drug Administration recently approved vemurafenib for the treatment of BRAF valine in exon 15, at codon 600 (V600E) mutant metastatic melanoma.  Vemurafenib is a competitive small-mol. serine-threonine kinase inhibitor that functions by binding to the ATP-binding domain of mutant BRAF.  Compared with dacarbazine chemotherapy, vemurafenib significantly improved the 6-mo overall survival of patients from 64% to 84% and exhibited a response rate of approx. 50%.  Median progression-free survival was also significantly improved with vemurafenib as compared with dacarbazine (5.3 vs. 1.6 mo, resp.), and this was consistent among groups analyzed, including age, sex, geog., Eastern Cooperative Oncol. Group status, disease stage, and serum lactate dehydrogenase.  The success of targeting melanoma genomics has created a paradigm shift for future drug development.  Currently, the elucidation of resistant mechanisms to vemurafenib therapy remains an important area of active investigation that will shape rational drug treatments for melanoma.  The development of vemurafenib, the role of BRAF targeting, and the changing landscape of treatment for melanoma provide a new foundation for clin. investigation.  Clin Cancer Res; 18(1); 9-14.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSUtT4uGz8MbVg90H21EOLACvtfcHk0lhXN5xIKbNkXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsQ%253D%253D&md5=e3e3a4623a5120026adc3c0aca4136ee</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2197%26sid%3Dliteratum%253Aachs%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DVemurafenib%2520and%2520BRAF%2520Inhibition%253A%2520A%2520New%2520Class%2520of%2520Treatment%2520for%2520Metastatic%2520Melanoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D9%26epage%3D14%26doi%3D10.1158%2F1078-0432.CCR-11-2197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Keating, G. M.</span><span> </span><span class="NLM_article-title">Cobimetinib Plus Vemurafenib: A Review in BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">615</span><span class="refDoi"> DOI: 10.1007/s40265-016-0562-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-016-0562-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=605-615&author=G.+M.+Keating&title=Cobimetinib+Plus+Vemurafenib%3A+A+Review+in+BRAFV600+Mutation-Positive+Unresectable+or+Metastatic+Melanoma&doi=10.1007%2Fs40265-016-0562-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0562-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0562-7%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DCobimetinib%2520Plus%2520Vemurafenib%253A%2520A%2520Review%2520in%2520BRAFV600%2520Mutation-Positive%2520Unresectable%2520or%2520Metastatic%2520Melanoma%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D605%26epage%3D615%26doi%3D10.1007%2Fs40265-016-0562-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit124b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dossett, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudchadkar, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zager, J. S.</span><span> </span><span class="NLM_article-title">BRAF and MEK Inhibition in Melanoma</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span><span class="refDoi"> DOI: 10.1517/14740338.2015.1011618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14740338.2015.1011618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25648338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVOrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=559-570&author=L.+A.+Dossettauthor=R.+R.+Kudchadkarauthor=J.+S.+Zager&title=BRAF+and+MEK+Inhibition+in+Melanoma&doi=10.1517%2F14740338.2015.1011618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124bR"><div class="casContent"><span class="casTitleNuber">124b</span><div class="casTitle"><span class="NLM_cas:atitle">BRAF and MEK inhibition in melanoma</span></div><div class="casAuthors">Dossett, Lesly A.; Kudchadkar, Ragini R.; Zager, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">559-570</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Selective inhibition of the MAPK pathway with either BRAF or MEK inhibition has emerged as a key component for the treatment of BRAF-mutant metastatic melanoma.  New evidence suggests that the combination of BRAF and MEK inhibitors improves tumor response rate and progression-free survival, while potentially attenuating some of the serious adverse events obsd. with monotherapy.  Areas covered: This review covers the current data on the efficacy and safety of the selective BRAF (vemurafenib and dabrafenib) and MEK (trametinib) inhibitors as well as the available data on BRAF inhibitor + MEK inhibitor combination therapy (dabrafenib + trametinib and vemurafenib + cobimetinib).  The efficacy, safety and toxicity data are discussed from Phase I, Phase II and Phase III trials of these drugs.  Expert opinion: Combination therapy with the BRAF and MEK inhibitors improves response rates and progression-free survival in patients with BRAF-mutant metastatic melanoma.  Some of the serious adverse events, in particular, the incidence of cutaneous squamous cell carcinoma, are attenuated with combination therapy, whereas milder side effects such as pyrexia can be more common with combination therapy.  Although dose redns. and dose interruptions are slightly more common with combination therapy, overall data supports the notion that combination therapy is safe and improves the outcomes for patients compared to single agent BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowwkN6ePq_TbVg90H21EOLACvtfcHk0lh0EIIIsBdNpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVOrt70%253D&md5=9485736bc70be9bec4e396756113113b</span></div><a href="/servlet/linkout?suffix=cit124b&amp;dbid=16384&amp;doi=10.1517%2F14740338.2015.1011618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2015.1011618%26sid%3Dliteratum%253Aachs%26aulast%3DDossett%26aufirst%3DL.%2BA.%26aulast%3DKudchadkar%26aufirst%3DR.%2BR.%26aulast%3DZager%26aufirst%3DJ.%2BS.%26atitle%3DBRAF%2520and%2520MEK%2520Inhibition%2520in%2520Melanoma%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2015%26volume%3D14%26spage%3D559%26epage%3D570%26doi%3D10.1517%2F14740338.2015.1011618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liszkay, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroyakovskiy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Cruz-Merino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutriaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sovak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choong, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hack, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span> </span><span class="NLM_article-title">Combined Vemurafenib and Cobimetinib in BRAF-mutated Melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">1867</span><span class="NLM_x">–</span> <span class="NLM_lpage">1876</span><span class="refDoi"> DOI: 10.1056/NEJMoa1408868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1056%2FNEJMoa1408868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=25265494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1867-1876&author=J.+Larkinauthor=P.+A.+Asciertoauthor=B.+Drenoauthor=V.+Atkinsonauthor=G.+Liszkayauthor=M.+Maioauthor=M.+Mandalaauthor=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=M.+A.+Sovakauthor=I.+Changauthor=N.+Choongauthor=S.+P.+Hackauthor=G.+A.+McArthurauthor=A.+Ribas&title=Combined+Vemurafenib+and+Cobimetinib+in+BRAF-mutated+Melanoma&doi=10.1056%2FNEJMoa1408868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span></div><div class="casAuthors">Larkin, James; Ascierto, Paolo A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.; McArthur, Grant A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1876, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The combined inhibition of BRAF and MEK is hypothesized to improve clin. outcomes in patients with melanoma by preventing or delaying the onset of resistance obsd. with BRAF inhibitors alone.  This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib.  We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-pos. melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).  The primary end point was investigator-assessed progression-free survival.  The median progression-free survival was 9.9 mo in the combination group and 6.2 mo in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001).  The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group.  Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival.  Interim analyses of overall survival showed 9-mo survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group.  Vemurafenib and cobimetinib was assocd. with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation.  The no. of secondary cutaneous cancers decreased with the combination therapy.  The addn. of cobimetinib to vemurafenib was assocd. with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpErdkeTyZ9rVg90H21EOLACvtfcHk0lh0EIIIsBdNpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D&md5=9b6fb4f9ea883da579d6435ccb5742eb</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408868%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DChoong%26aufirst%3DN.%26aulast%3DHack%26aufirst%3DS.%2BP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DCombined%2520Vemurafenib%2520and%2520Cobimetinib%2520in%2520BRAF-mutated%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1867%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1408868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lamb, P.</span><span> </span><span class="NLM_article-title"><i>N</i>-Acylazetidine Derivatives as MEK Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Cancer</span>. WO 2008076415A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Lamb&title=N-Acylazetidine+Derivatives+as+MEK+Inhibitors+and+Their+Preparation%2C+Pharmaceutical+Compositions+and+Use+in+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DP.%26atitle%3DN-Acylazetidine%2520Derivatives%2520as%2520MEK%2520Inhibitors%2520and%2520Their%2520Preparation%252C%2520Pharmaceutical%2520Compositions%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Cancer%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Beak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. K.</span><span> </span><span class="NLM_article-title">α-Lithioamine Synthetic Equivalents: Syntheses of Diastereoisomers from the Boc-piperidines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2578</span><span class="NLM_x">–</span> <span class="NLM_lpage">2580</span><span class="refDoi"> DOI: 10.1021/jo00296a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00296a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1990&pages=2578-2580&author=P.+Beakauthor=W.+K.+Lee&title=%CE%B1-Lithioamine+Synthetic+Equivalents%3A+Syntheses+of+Diastereoisomers+from+the+Boc-piperidines&doi=10.1021%2Fjo00296a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126b&amp;dbid=16384&amp;doi=10.1021%2Fjo00296a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00296a008%26sid%3Dliteratum%253Aachs%26aulast%3DBeak%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DW.%2BK.%26atitle%3D%25CE%25B1-Lithioamine%2520Synthetic%2520Equivalents%253A%2520Syntheses%2520of%2520Diastereoisomers%2520from%2520the%2520Boc-piperidines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1990%26volume%3D55%26spage%3D2578%26epage%3D2580%26doi%3D10.1021%2Fjo00296a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Royer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husson, H. P.</span><span> </span><span class="NLM_article-title">2-Cyano-6-oxazolopiperidine: A Powerful Tool for the Asymmetric Synthesis of Piperidine Derivatives</span> <span class="citation_source-journal">Janssen Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADyaK2cXkvVelurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1993&pages=3-8&author=J.+Royerauthor=H.+P.+Husson&title=2-Cyano-6-oxazolopiperidine%3A+A+Powerful+Tool+for+the+Asymmetric+Synthesis+of+Piperidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127aR"><div class="casContent"><span class="casTitleNuber">127a</span><div class="casTitle"><span class="NLM_cas:atitle">2-Cyano-6-oxazolopiperidine: a powerful tool for the asymmetric synthesis of piperidine derivatives</span></div><div class="casAuthors">Royer, J.; Husson, H. P.</div><div class="citationInfo"><span class="NLM_cas:title">Janssen Chimica Acta</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">JCACEN</span>;
        ISSN:<span class="NLM_cas:issn">0771-4602</span>.
    </div><div class="casAbstract">The title compd. (-)-I, a synthetic equiv. of 1,4-dihydropyridine, was prepd. by reaction of R-(-)-phenylglycinol with OHC(CH2)3CHO and KCN, followed by equilibration with ZnBr2.  (-)-I was used in the synthesis of natural piperidine alkaloids and derivs.  E.g., deprotonation of (-)-I, followed by treatment with PrBr and reductive ring opening with NaBH4 gave (+)-coniine (II) in 90% overall yield and 95% ee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3CfCcwfLOF7Vg90H21EOLACvtfcHk0lgcptFeWac9Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvVelurg%253D&md5=ccf09c4611158358601f7faf65632a14</span></div><a href="/servlet/linkout?suffix=cit127a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoyer%26aufirst%3DJ.%26aulast%3DHusson%26aufirst%3DH.%2BP.%26atitle%3D2-Cyano-6-oxazolopiperidine%253A%2520A%2520Powerful%2520Tool%2520for%2520the%2520Asymmetric%2520Synthesis%2520of%2520Piperidine%2520Derivatives%26jtitle%3DJanssen%2520Chim.%2520Acta%26date%3D1993%26volume%3D11%26spage%3D3%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit127b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Husson, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Royer, J.</span><span> </span><span class="NLM_article-title">Chiral Non-racemic N-cyanomethyloxazolidines: the Pivotal System of the CN(R,S) Method</span> <span class="citation_source-journal">Chem. Soc. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">383</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span><span class="refDoi"> DOI: 10.1039/a900153k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1039%2Fa900153k" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1999&pages=383-394&author=H.-P.+Hussonauthor=J.+Royer&title=Chiral+Non-racemic+N-cyanomethyloxazolidines%3A+the+Pivotal+System+of+the+CN%28R%2CS%29+Method&doi=10.1039%2Fa900153k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127b&amp;dbid=16384&amp;doi=10.1039%2Fa900153k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fa900153k%26sid%3Dliteratum%253Aachs%26aulast%3DHusson%26aufirst%3DH.-P.%26aulast%3DRoyer%26aufirst%3DJ.%26atitle%3DChiral%2520Non-racemic%2520N-cyanomethyloxazolidines%253A%2520the%2520Pivotal%2520System%2520of%2520the%2520CN%2528R%252CS%2529%2520Method%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D1999%26volume%3D28%26spage%3D383%26epage%3D394%26doi%3D10.1039%2Fa900153k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Naganathan, S.; Guz, N.; Pfeiffer, M.</span><span> </span><span class="NLM_article-title">Preparation of Phenylaminophenylhydroxypiperidinylazetidinylmethanone Derivatives for Use as MEK Inhibitors</span>. WO 2014059422A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+Naganathan&author=N.+Guz&author=M.+Pfeiffer&title=Preparation+of+Phenylaminophenylhydroxypiperidinylazetidinylmethanone+Derivatives+for+Use+as+MEK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNaganathan%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Phenylaminophenylhydroxypiperidinylazetidinylmethanone%2520Derivatives%2520for%2520Use%2520as%2520MEK%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit128b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Aay, N.; Anand, N. K.; Bowles, O. J.; Bussenius, J.; Costanzo, S.; Curtis, J. K.; Dubenko, L.; Joshi, A. A.; Kennedy, A. R.; Kim, A. I.; Koltun, E.; Manalo, J.-C. L.; Peto, C. J.; Rice, K. D.; Tsang, T. H.</span><span> </span><span class="NLM_article-title">Preparation of Azetidines as MEK Kinase Inhibitors for the Treatment of Proliferative Diseases, Especially Cancer</span>. WO 2007044515A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+Aay&author=N.+K.+Anand&author=O.+J.+Bowles&author=J.+Bussenius&author=S.+Costanzo&author=J.+K.+Curtis&author=L.+Dubenko&author=A.+A.+Joshi&author=A.+R.+Kennedy&author=A.+I.+Kim&author=E.+Koltun&author=J.-C.+L.+Manalo&author=C.+J.+Peto&author=K.+D.+Rice&author=T.+H.+Tsang&title=Preparation+of+Azetidines+as+MEK+Kinase+Inhibitors+for+the+Treatment+of+Proliferative+Diseases%2C+Especially+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAay%26aufirst%3DN.%26atitle%3DPreparation%2520of%2520Azetidines%2520as%2520MEK%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Proliferative%2520Diseases%252C%2520Especially%2520Cancer%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Guz, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeiffer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickman, D.</span><span> </span><span class="NLM_article-title">A Kilolaboratory Preparation of the CNRS Chiral Auxiliary</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1476</span><span class="NLM_x">–</span> <span class="NLM_lpage">1478</span><span class="refDoi"> DOI: 10.1021/op1002227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op1002227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=1476-1478&author=N.+R.+Guzauthor=M.+Pfeifferauthor=D.+Dickman&title=A+Kilolaboratory+Preparation+of+the+CNRS+Chiral+Auxiliary&doi=10.1021%2Fop1002227"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Fop1002227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop1002227%26sid%3Dliteratum%253Aachs%26aulast%3DGuz%26aufirst%3DN.%2BR.%26aulast%3DPfeiffer%26aufirst%3DM.%26aulast%3DDickman%26aufirst%3DD.%26atitle%3DA%2520Kilolaboratory%2520Preparation%2520of%2520the%2520CNRS%2520Chiral%2520Auxiliary%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2010%26volume%3D14%26spage%3D1476%26epage%3D1478%26doi%3D10.1021%2Fop1002227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span>Cotellic; <span class="NLM_publisher-name">Genentech USA, Inc.</span>: <span class="NLM_publisher-loc">South San Francisco, CA</span>, November<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf</a>; accessed August 4, 2016.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cotellic%3B+Genentech+USA%2C+Inc.%3A+South+San+Francisco%2C+CA%2C+November+2015%3B+http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F206192s000lbl.pdf%3B+accessed+August+4%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DCotellic%26pub%3DGenentech%2520USA%252C%2520Inc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Moreau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masszi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grzasko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahlis, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pour, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganly, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoppa, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gimsing, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garderet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Touzeau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buadi, F. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laubach, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bacco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Velde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. G.</span><span> </span><span class="NLM_article-title">Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">1621</span><span class="NLM_x">–</span> <span class="NLM_lpage">1634</span><span class="refDoi"> DOI: 10.1056/NEJMoa1516282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1056%2FNEJMoa1516282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=27119237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOltLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1621-1634&author=P.+Moreauauthor=T.+Massziauthor=N.+Grzaskoauthor=N.+J.+Bahlisauthor=M.+Hanssonauthor=L.+Pourauthor=I.+Sandhuauthor=P.+Ganlyauthor=B.+W.+Bakerauthor=S.+R.+Jacksonauthor=A.+M.+Stoppaauthor=D.+R.+Simpsonauthor=P.+Gimsingauthor=A.+Palumboauthor=L.+Garderetauthor=M.+Cavoauthor=S.+Kumarauthor=C.+Touzeauauthor=F.+K.+Buadiauthor=J.+P.+Laubachauthor=D.+T.+Bergauthor=J.+Linauthor=A.+Di+Baccoauthor=A.+M.+Huiauthor=H.+van+de+Veldeauthor=P.+G.+Richardson&title=Oral+Ixazomib%2C+Lenalidomide%2C+and+Dexamethasone+for+Multiple+Myeloma&doi=10.1056%2FNEJMoa1516282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma</span></div><div class="casAuthors">Moreau, P.; Masszi, T.; Grzasko, N.; Bahlis, N. J.; Hansson, M.; Pour, L.; Sandhu, I.; Ganly, P.; Baker, B. W.; Jackson, S. R.; Stoppa, A.-M.; Simpson, D. R.; Gimsing, P.; Palumbo, A.; Garderet, L.; Cavo, M.; Kumar, S.; Touzeau, C.; Buadi, F. K.; Laubach, J. P.; Berg, D. T.; Lin, J.; Di Bacco, A.; Hui, A.-M.; van de Velde, H.; Richardson, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1621-1634</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.  In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group).  The primary end point was progression-free survival.  Progression-free survival was significantly longer in the ixazomib group than in the placebo group at a median follow-up of 14.7 mo (median progression-free survival, 20.6 mo vs. 14.7 mo; hazard ratio for disease progression or death in the ixazomib group, 0.74; P = 0.01); a benefit with respect to progression-free survival was obsd. with the ixazomib regimen, as compared with the placebo regimen, in all prespecified patient subgroups, including in patients with high-risk cytogenetic abnormalities.  The overall rates of response were 78% in the ixazomib group and 72% in the placebo group, and the corresponding rates of complete response plus very good partial response were 48% and 39%.  The median time to response was 1.1 mo in the ixazomib group and 1.9 mo in the placebo group and the corresponding median duration of response was 20.5 mo and 15.0 mo.  At a median follow-up of approx. 23 mo, the median overall survival has not been reached in either study group, and follow-up is ongoing.  The rates of serious adverse events were similar in the two study groups (47% in the ixazomib group and 49% in the placebo group), as were the rates of death during the study period (4% and 6%, resp.); adverse events of at least grade 3 severity occurred in 74% and 69% of the patients, resp.  Thrombocytopenia of grade 3 and grade 4 severity occurred more frequently in the ixazomib group (12% and 7% of the patients, resp.) than in the placebo group (5% and 4% of the patients, resp.).  Rash occurred more frequently in the ixazomib group than in the placebo group (36% vs. 23% of the patients), as did gastrointestinal adverse events, which were predominantly low grade.  The incidence of peripheral neuropathy was 27% in the ixazomib group and 22% in the placebo group (grade 3 events occurred in 2% of the patients in each study group).  Patient-reported quality of life was similar in the two study groups.  The addn. of ixazomib to a regimen of lenalidomide and dexamethasone was assocd. with significantly longer progression-free survival; the addnl. toxic effects with this all-oral regimen were limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe5omTDIjGVLVg90H21EOLACvtfcHk0ljpXhessXviRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOltLjN&md5=b71bd9b8d3afd6c02e1c541abdb44c0e</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1516282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1516282%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DGrzasko%26aufirst%3DN.%26aulast%3DBahlis%26aufirst%3DN.%2BJ.%26aulast%3DHansson%26aufirst%3DM.%26aulast%3DPour%26aufirst%3DL.%26aulast%3DSandhu%26aufirst%3DI.%26aulast%3DGanly%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DB.%2BW.%26aulast%3DJackson%26aufirst%3DS.%2BR.%26aulast%3DStoppa%26aufirst%3DA.%2BM.%26aulast%3DSimpson%26aufirst%3DD.%2BR.%26aulast%3DGimsing%26aufirst%3DP.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DGarderet%26aufirst%3DL.%26aulast%3DCavo%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DTouzeau%26aufirst%3DC.%26aulast%3DBuadi%26aufirst%3DF.%2BK.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DBerg%26aufirst%3DD.%2BT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DDi%2BBacco%26aufirst%3DA.%26aulast%3DHui%26aufirst%3DA.%2BM.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DOral%2520Ixazomib%252C%2520Lenalidomide%252C%2520and%2520Dexamethasone%2520for%2520Multiple%2520Myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1621%26epage%3D1634%26doi%3D10.1056%2FNEJMoa1516282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Cvek, B.</span><span> </span><span class="NLM_article-title">IXAZOMIB CITRATE Proteasome Inhibitor Oncolytic</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">565</span><span class="refDoi"> DOI: 10.1358/dof.2012.037.08.1835040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdof.2012.037.08.1835040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFSgurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2012&pages=561-565&author=B.+Cvek&title=IXAZOMIB+CITRATE+Proteasome+Inhibitor+Oncolytic&doi=10.1358%2Fdof.2012.037.08.1835040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Ixazomib citrate: proteasome inhibitor oncolytic</span></div><div class="casAuthors">Cvek, B.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">561-565</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Thomson Reuters</span>)
        </div><div class="casAbstract">A review.  Ixazomib citrate, produced and patented by Millennium Pharmaceuticals, is one of the "new-generation" proteasome inhibitors following the success story of the first-in-class proteasome inhibitor bortezomib.  Today, bortezomib is approved for multiple myeloma and mantle cell lymphoma, but has failed In clin. trials in patients with solid tumors.  According to available preclin. data, ixazomib citrate may be more active in solid tumors.  It also appears to be better tolerated by patients, as the most serious adverse event for bortezomib, neuropathy, has not yet been obsd. in clin. trials with ixazomib citrate.  Ixazomib citrate can be administered both i.v. and orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ8hnaYJsr-bVg90H21EOLACvtfcHk0ljpXhessXviRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFSgurg%253D&md5=a0b5ca7386027e57384b5f52b3e65aa9</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1358%2Fdof.2012.037.08.1835040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2012.037.08.1835040%26sid%3Dliteratum%253Aachs%26aulast%3DCvek%26aufirst%3DB.%26atitle%3DIXAZOMIB%2520CITRATE%2520Proteasome%2520Inhibitor%2520Oncolytic%26jtitle%3DDrugs%2520Future%26date%3D2012%26volume%3D37%26spage%3D561%26epage%3D565%26doi%3D10.1358%2Fdof.2012.037.08.1835040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Elliott, E. L.; Ferdous, A. J.; Kaufman, M. J.; Komar, S. A.; Mazaik, D. L.; McCubbin, Q. J.; Nguyen, P.; Palaniappan, V.; Skwierczynski, R. D.; Truong, N. T.</span><span> </span><span class="NLM_article-title">Boronate Ester Compounds and Pharmaceutical Compositions Thereof</span>. US 20090325903A1,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=E.+L.+Elliott&author=A.+J.+Ferdous&author=M.+J.+Kaufman&author=S.+A.+Komar&author=D.+L.+Mazaik&author=Q.+J.+McCubbin&author=P.+Nguyen&author=V.+Palaniappan&author=R.+D.+Skwierczynski&author=N.+T.+Truong&title=Boronate+Ester+Compounds+and+Pharmaceutical+Compositions+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DElliott%26aufirst%3DE.%2BL.%26atitle%3DBoronate%2520Ester%2520Compounds%2520and%2520Pharmaceutical%2520Compositions%2520Thereof%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Pickersgill, I. F.; Bishop, J.; Koellner, C.; Gomez, J. M.; Geiser, A.; Hett, R.; Ammoscato, V.; Munk, S.; Lo, Y.; Chui, F. T.</span><span> </span><span class="NLM_article-title">Synthesis of Boronic Ester and Acid Compounds</span>. WO 2005097809A2,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=I.+F.+Pickersgill&author=J.+Bishop&author=C.+Koellner&author=J.+M.+Gomez&author=A.+Geiser&author=R.+Hett&author=V.+Ammoscato&author=S.+Munk&author=Y.+Lo&author=F.+T.+Chui&title=Synthesis+of+Boronic+Ester+and+Acid+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPickersgill%26aufirst%3DI.%2BF.%26atitle%3DSynthesis%2520of%2520Boronic%2520Ester%2520and%2520Acid%2520Compounds%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Matsui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uenaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuruoka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span> </span><span class="NLM_article-title">Multi-kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5459</span><span class="NLM_x">–</span> <span class="NLM_lpage">5465</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-5270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F1078-0432.CCR-07-5270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=18765537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=5459-5465&author=J.+Matsuiauthor=Y.+Funahashiauthor=T.+Uenakaauthor=T.+Watanabeauthor=A.+Tsuruokaauthor=M.+Asada&title=Multi-kinase+Inhibitor+E7080+Suppresses+Lymph+Node+and+Lung+Metastases+of+Human+Mammary+Breast+Tumor+MDA-MB-231+via+Inhibition+of+Vascular+Endothelial+Growth+Factor-Receptor+%28VEGF-R%29+2+and+VEGF-R3+Kinase&doi=10.1158%2F1078-0432.CCR-07-5270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase</span></div><div class="casAuthors">Matsui, Junji; Funahashi, Yasuhiro; Uenaka, Toshimitsu; Watanabe, Tatsuo; Tsuruoka, Akihiko; Asada, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5459-5465</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Vascular endothelial growth factor (VEGF)-C/VEGF-receptor 3 (VEGF-R3) signal plays a significant role in lymphangiogenesis and tumor metastasis based on its effects on lymphatic vessels.  However, little is known about the effect of inhibiting VEGF-R3 on lymphangiogenesis and lymph node metastases using a small-mol. kinase inhibitor.  Exptl. Design: We evaluated the effect of E7080, a potent inhibitor of both VEGF-R2 and VEGF-R3 kinase, and bevacizumab on lymphangiogenesis and angiogenesis in a mammary fat pad xenograft model of human breast cancer using MDA-MB-231 cells that express excessive amts. of VEGF-C.  Lymphangiogenesis was detd. by lymphatic vessel d. (LVD) and angiogenesis by microvessel d. (MVD).  RESULTS: In contrast to MDA-MB-435 cells, which expressed a similar amt. of VEGF to MDA-MB-231 cells with an undetectable amt. of VEGF-C, only MDA-MB-231 exhibited lymphangiogenesis in the primary tumor.  E7080 but not bevacizumab significantly decreased LVD within the MDA-MB-231 tumor.  E7080 and bevacizumab decreased MVD in both the MDA-MB-231 and MDA-MB-435 models.  E7080 significantly suppressed regional lymph nodes and distant lung metastases of MDA-MB-231, whereas bevacizumab significantly inhibited only lung metastases.  E7080 also decreased both MVD and LVD within the metastatic nodules at lymph nodes after resection of the primary tumor.  CONCLUSIONS: Inhibition of VEGF-R3 kinase with E7080 effectively decreased LVD within MDA-MB-231 tumors, which express VEGF-C.  Simultaneous inhibition of both VEGF-R2 and VEGF-R3 kinases by E7080 may be a promising new strategy to control regional lymph node and distant lung metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrBisu80xI7Vg90H21EOLACvtfcHk0ljpXhessXviRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKmsbjP&md5=0a73511c46d0f668f09f84d89c718417</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-5270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-5270%26sid%3Dliteratum%253Aachs%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DFunahashi%26aufirst%3DY.%26aulast%3DUenaka%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DTsuruoka%26aufirst%3DA.%26aulast%3DAsada%26aufirst%3DM.%26atitle%3DMulti-kinase%2520Inhibitor%2520E7080%2520Suppresses%2520Lymph%2520Node%2520and%2520Lung%2520Metastases%2520of%2520Human%2520Mammary%2520Breast%2520Tumor%2520MDA-MB-231%2520via%2520Inhibition%2520of%2520Vascular%2520Endothelial%2520Growth%2520Factor-Receptor%2520%2528VEGF-R%2529%25202%2520and%2520VEGF-R3%2520Kinase%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D5459%26epage%3D5465%26doi%3D10.1158%2F1078-0432.CCR-07-5270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span>Lenvatinib in Combination with Everolimus; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, May 16,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span><a href="http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501070.htm" class="extLink">http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501070.htm</a> (accessed March 1, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lenvatinib+in+Combination+with+Everolimus%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+May+16%2C+2016%3B+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm501070.htm+%28accessed+March+1%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DLenvatinib%2520in%2520Combination%2520with%2520Everolimus%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Sakaguchi, T.; Tsuruoka, A.</span><span> </span><span class="NLM_article-title">Amorphous Salt of 4-(3-Chloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and Process for Preparing the Same</span>. US 20070004773A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Sakaguchi&author=A.+Tsuruoka&title=Amorphous+Salt+of+4-%283-Chloro-4-%28cycloproplylaminocarbonyl%29aminophenoxy%29-7-method-6-quinolinecarboxamide+and+Process+for+Preparing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSakaguchi%26aufirst%3DT.%26atitle%3DAmorphous%2520Salt%2520of%25204-%25283-Chloro-4-%2528cycloproplylaminocarbonyl%2529aminophenoxy%2529-7-method-6-quinolinecarboxamide%2520and%2520Process%2520for%2520Preparing%2520the%2520Same%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">Matsushima, T.; Nakamura, T.; Yoshizawa, K.; Kamada, A.; Ayata, Y.; Suzuki, N.; Arimoto, I. E. C. L.; Sakaguchi, T.; Gotoda, M.</span><span> </span><span class="NLM_article-title">Crystal of Salt of 4-(3-Chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of Solvate Thereof and Processes for Producing These</span>. EP 1698623A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=T.+Matsushima&author=T.+Nakamura&author=K.+Yoshizawa&author=A.+Kamada&author=Y.+Ayata&author=N.+Suzuki&author=I.+E.+C.+L.+Arimoto&author=T.+Sakaguchi&author=M.+Gotoda&title=Crystal+of+Salt+of+4-%283-Chloro-4-%28cyclopropylaminocarbonyl%29amino-phenoxy%29-7-methoxy-6-quinolinecarboxamide+or+of+Solvate+Thereof+and+Processes+for+Producing+These"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushima%26aufirst%3DT.%26atitle%3DCrystal%2520of%2520Salt%2520of%25204-%25283-Chloro-4-%2528cyclopropylaminocarbonyl%2529amino-phenoxy%2529-7-methoxy-6-quinolinecarboxamide%2520or%2520of%2520Solvate%2520Thereof%2520and%2520Processes%2520for%2520Producing%2520These%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Barker, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huddleston, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Thienopyridines. Part 2. Application of the Conrad–Limpach and Gould–Jacobs reactions to the synthesis of thieno[3,4-<i>b</i>]pyridin-4(1<i>H</i>)-ones</span> <span class="citation_source-journal">J. Chem. Res., Synop.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1980&pages=4-5&author=J.+M.+Barkerauthor=P.+R.+Huddlestonauthor=A.+W.+Jonesauthor=M.+Edwards&title=Thienopyridines.+Part+2.+Application+of+the+Conrad%E2%80%93Limpach+and+Gould%E2%80%93Jacobs+reactions+to+the+synthesis+of+thieno%5B3%2C4-b%5Dpyridin-4%281H%29-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DJ.%2BM.%26aulast%3DHuddleston%26aufirst%3DP.%2BR.%26aulast%3DJones%26aufirst%3DA.%2BW.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DThienopyridines.%2520Part%25202.%2520Application%2520of%2520the%2520Conrad%25E2%2580%2593Limpach%2520and%2520Gould%25E2%2580%2593Jacobs%2520reactions%2520to%2520the%2520synthesis%2520of%2520thieno%255B3%252C4-b%255Dpyridin-4%25281H%2529-ones%26jtitle%3DJ.%2520Chem.%2520Res.%252C%2520Synop.%26date%3D1980%26volume%3D1%26spage%3D4%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Brouet, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peet, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. D.</span><span> </span><span class="NLM_article-title">Survey of Solvents for the Conrad–Limpach Synthesis of 4-Hydroxyquinolones</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1563</span><span class="NLM_x">–</span> <span class="NLM_lpage">1569</span><span class="refDoi"> DOI: 10.1080/00397910802542044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1080%2F00397910802542044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFCisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=1563-1569&author=J.-C.+Brouetauthor=S.+Guauthor=N.+P.+Peetauthor=J.+D.+Williams&title=Survey+of+Solvents+for+the+Conrad%E2%80%93Limpach+Synthesis+of+4-Hydroxyquinolones&doi=10.1080%2F00397910802542044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Survey of solvents for the Conrad-Limpach synthesis of 4-hydroxyquinolines</span></div><div class="casAuthors">Brouet, Jean-Cristophe; Gu, Shen; Peet, Norton P.; Williams, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1563-1569</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A study of the synthesis of a 4-hydroxyquinoline deriv. using the Conrad-Limpach reaction led to the identification of inexpensive and user-friendly solvents for this thermal condensation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIPa3qHEVOWrVg90H21EOLACvtfcHk0lhZvVkT0_nLvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFCisL4%253D&md5=94f46df0795fc34f2277c3157e954f1d</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1080%2F00397910802542044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910802542044%26sid%3Dliteratum%253Aachs%26aulast%3DBrouet%26aufirst%3DJ.-C.%26aulast%3DGu%26aufirst%3DS.%26aulast%3DPeet%26aufirst%3DN.%2BP.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26atitle%3DSurvey%2520of%2520Solvents%2520for%2520the%2520Conrad%25E2%2580%2593Limpach%2520Synthesis%2520of%25204-Hydroxyquinolones%26jtitle%3DSynth.%2520Commun.%26date%3D2009%26volume%3D39%26spage%3D1563%26epage%3D1569%26doi%3D10.1080%2F00397910802542044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span>Dowtherm Synthetic Organic Fluids; <span class="NLM_publisher-name">Dow Chemical Company</span>: <span class="NLM_publisher-loc">Midland, MI</span>,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">; </span><a href="http://www.dow.com/heattrans/products/synthetic/dowtherm.htm" class="extLink">http://www.dow.com/heattrans/products/synthetic/dowtherm.htm</a> (accessed March 1, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Dowtherm+Synthetic+Organic+Fluids%3B+Dow+Chemical+Company%3A+Midland%2C+MI%2C+2017%3B+http%3A%2F%2Fwww.dow.com%2Fheattrans%2Fproducts%2Fsynthetic%2Fdowtherm.htm+%28accessed+March+1%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDowtherm%2520Synthetic%2520Organic%2520Fluids%26pub%3DDow%2520Chemical%2520Company%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Thomas, A. P.; Hennequin, L. F. A.; Ple, P.</span><span> </span><span class="NLM_article-title">Quinoline Derivatives Inhibiting the Effect of Growth Factors Such as VEGF</span>. US 6809097B1,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=A.+P.+Thomas&author=L.+F.+A.+Hennequin&author=P.+Ple&title=Quinoline+Derivatives+Inhibiting+the+Effect+of+Growth+Factors+Such+as+VEGF"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BP.%26atitle%3DQuinoline%2520Derivatives%2520Inhibiting%2520the%2520Effect%2520of%2520Growth%2520Factors%2520Such%2520as%2520VEGF%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Greig, S. L.</span><span> </span><span class="NLM_article-title">Osimertinib: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1007/s40265-015-0533-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0533-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26729184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=263-273&author=S.+L.+Greig&title=Osimertinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0533-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib: First Global Approval</span></div><div class="casAuthors">Greig, Sarah L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-273</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Osimertinib (Tagrisso, AZD9291) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC).  Osimertinib has been designed to target the EGFR T790M mutation that is often present in NSCLC patients with acquired EGFR TKI resistance, while sparing wild-type EGFR.  In Nov. 2015, the tablet formulation of osimertinib was granted accelerated approval in the USA for the treatment of patients with metastatic EGFR T790M mutation-pos. NSCLC (as detected by an FDA-approved test) who have progressed on or after EGFR TKI therapy.  Osimertinib has also been granted accelerated assessment status for this indication in the EU, and is in phase III development for first- and second-line and adjuvant treatment of advanced EGFR mutation-pos. NSCLC in several countries.  Phase I trials in patients with advanced solid tumors are also being conducted.  This article summarizes the milestones in the development of osimertinib leading to this first approval for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD-OV6l6JC5rVg90H21EOLACvtfcHk0lhZvVkT0_nLvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvFymtA%253D%253D&md5=fb46898918bdfe76320c26177710fb11</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0533-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0533-4%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DS.%2BL.%26atitle%3DOsimertinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D263%26epage%3D273%26doi%3D10.1007%2Fs40265-015-0533-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, W. S.; Gong, Y.; Li, F.; Bencivenga, N. E.; Dalgarno, D. C.; Kohlmann, A.; Shakespeare, W. C.; Thomas, R. M.; Zhu, X.; West, A. V.</span><span> </span><span class="NLM_article-title">Heteroaryl Compounds for Kinase Inhibition</span>. WO 2015195228A1,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=W.+S.+Huang&author=Y.+Gong&author=F.+Li&author=N.+E.+Bencivenga&author=D.+C.+Dalgarno&author=A.+Kohlmann&author=W.+C.+Shakespeare&author=R.+M.+Thomas&author=X.+Zhu&author=A.+V.+West&title=Heteroaryl+Compounds+for+Kinase+Inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26atitle%3DHeteroaryl%2520Compounds%2520for%2520Kinase%2520Inhibition%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Xu, X.</span><span> </span><span class="NLM_article-title">AZD9291 Intermediates and Preparation Method</span>. CN 104910049B,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=X.+Xu&title=AZD9291+Intermediates+and+Preparation+Method"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26atitle%3DAZD9291%2520Intermediates%2520and%2520Preparation%2520Method%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ji, M.; Li, Y.; Liu, H.; Li, R.; Cai, J.; Hu, H.</span><span> </span><span class="NLM_article-title">Synthetic Method of Anti-tumor Medicine</span>. CN 104817541A,<span class="NLM_x"> </span><span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Ji&author=Y.+Li&author=H.+Liu&author=R.+Li&author=J.+Cai&author=H.+Hu&title=Synthetic+Method+of+Anti-tumor+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DM.%26atitle%3DSynthetic%2520Method%2520of%2520Anti-tumor%2520Medicine%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, M.</span><span> </span><span class="NLM_article-title">A Novel and Efficient Synthesis of Anti-cancer Agent, Mereletinib</span> <span class="citation_source-journal">J. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span><span class="refDoi"> DOI: 10.3184/174751915X14320297505570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.3184%2F174751915X14320297505570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KqtrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=318-320&author=H.+Liuauthor=Y.+Lvauthor=Y.+Liauthor=J.+Caiauthor=J.+Chenauthor=Y.+Qinauthor=M.+Ji&title=A+Novel+and+Efficient+Synthesis+of+Anti-cancer+Agent%2C+Mereletinib&doi=10.3184%2F174751915X14320297505570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144dR"><div class="casContent"><span class="casTitleNuber">144d</span><div class="casTitle"><span class="NLM_cas:atitle">A novel and efficient synthesis of anti-cancer agent, mereletinib</span></div><div class="casAuthors">Liu, Haidong; Lv, Yongfeng; Li, Yuan; Cai, Jin; Chen, Junqing; Qin, Yu; Ji, Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">318-320</span>CODEN:
                <span class="NLM_cas:coden">JCROA4</span>;
        ISSN:<span class="NLM_cas:issn">1747-5198</span>.
    
            (<span class="NLM_cas:orgname">Science Reviews 2000 Ltd.</span>)
        </div><div class="casAbstract">A convenient route for the synthesis of a third-generation epidermal growth factor receptor inhibitor, mereletinib (AZD9291) using starting materials that are com. available has been achieved through reactions that are readily conducted under mild conditions.  Importantly, a 5 g scale synthesis was also accomplished and this method could therefore be useful in the synthesis of similar drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxwgrrR3p59LVg90H21EOLACvtfcHk0lj53AonpV_4xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KqtrfN&md5=c48ac88282a3c3b8efd84ed55de2f27c</span></div><a href="/servlet/linkout?suffix=cit144d&amp;dbid=16384&amp;doi=10.3184%2F174751915X14320297505570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3184%252F174751915X14320297505570%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLv%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DM.%26atitle%3DA%2520Novel%2520and%2520Efficient%2520Synthesis%2520of%2520Anti-cancer%2520Agent%252C%2520Mereletinib%26jtitle%3DJ.%2520Chem.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D318%26epage%3D320%26doi%3D10.3184%2F174751915X14320297505570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations that Spares the Wild Type Form of the Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8249</span><span class="NLM_x">–</span> <span class="NLM_lpage">8267</span><span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+Potent+and+Selective+EGFR+Inhibitor+%28AZD9291%29+of+Both+Sensitizing+and+T790M+Resistance+Mutations+that+Spares+the+Wild+Type+Form+of+the+Receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144eR"><div class="casContent"><span class="casTitleNuber">144e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lj53AonpV_4xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit144e&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520EGFR%2520Inhibitor%2520%2528AZD9291%2529%2520of%2520Both%2520Sensitizing%2520and%2520T790M%2520Resistance%2520Mutations%2520that%2520Spares%2520the%2520Wild%2520Type%2520Form%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Butterworth, S.; Finlay, M. R. V.; Ward, R. A.; Kadambar, V. K.; Chandrashekar, R. C.; Murugan, A.; Redfearn, H. M.</span><span> </span><span class="NLM_article-title">2-(2-, 4-, 5-Substituted-anilino) Pyrimidine Derivatives as EGFR Modulators Useful for Treating Cancer</span>. WO 2013014448A1,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Butterworth&author=M.+R.+V.+Finlay&author=R.+A.+Ward&author=V.+K.+Kadambar&author=R.+C.+Chandrashekar&author=A.+Murugan&author=H.+M.+Redfearn&title=2-%282-%2C+4-%2C+5-Substituted-anilino%29+Pyrimidine+Derivatives+as+EGFR+Modulators+Useful+for+Treating+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DButterworth%26aufirst%3DS.%26atitle%3D2-%25282-%252C%25204-%252C%25205-Substituted-anilino%2529%2520Pyrimidine%2520Derivatives%2520as%2520EGFR%2520Modulators%2520Useful%2520for%2520Treating%2520Cancer%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Beaver, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiri-Kordestani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlab, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tilley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zirkelbach, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloomquist, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluetz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortazar, P.</span><span> </span><span class="NLM_article-title">FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4760</span><span class="NLM_x">–</span> <span class="NLM_lpage">4766</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1158%2F1078-0432.CCR-15-1185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26324739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4760-4766&author=J.+A.+Beaverauthor=L.+Amiri-Kordestaniauthor=R.+Charlabauthor=W.+Chenauthor=T.+Palmbyauthor=A.+Tilleyauthor=J.+F.+Zirkelbachauthor=J.+Yuauthor=Q.+Liuauthor=L.+Zhaoauthor=J.+Crichauthor=X.+H.+Chenauthor=M.+Hughesauthor=E.+Bloomquistauthor=S.+Tangauthor=R.+Sridharaauthor=P.+G.+Kluetzauthor=G.+Kimauthor=A.+Ibrahimauthor=R.+Pazdurauthor=P.+Cortazar&title=FDA+Approval%3A+Palbociclib+for+the+Treatment+of+Postmenopausal+Patients+with+Estrogen+Receptor-Positive%2C+HER2-Negative+Metastatic+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-15-1185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146aR"><div class="casContent"><span class="casTitleNuber">146a</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer</span></div><div class="casAuthors">Beaver, Julia A.; Amiri-Kordestani, Laleh; Charlab, Rosane; Chen, Wei; Palmby, Todd; Tilley, Amy; Zirkelbach, Jeanne Fourie; Yu, Jingyu; Liu, Qi; Zhao, Liang; Crich, Joyce; Chen, Xiao Hong; Hughes, Minerva; Bloomquist, Erik; Tang, Shenghui; Sridhara, Rajeshwari; Kluetz, Paul G.; Kim, Geoffrey; Ibrahim, Amna; Pazdur, Richard; Cortazar, Patricia</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4760-4766</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Feb. 3, 2015, the FDA granted accelerated approval to palbociclib (IBRANCE, Pfizer Inc.), an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-pos., HER2-neg. advanced breast cancer as initial endocrine-based therapy for their metastatic disease.  The approval is based on a randomized, multicenter, open-label phase I/II trial (PALOMA-1) in 165 patients randomized to palbociclib (125 mg orally daily for 21 consecutive days, followed by 7 days off treatment) plus letrozole (2.5 mg orally daily) or letrozole alone.  The phase II portion of the trial was divided into two cohorts: cohort 1 enrolled 66 biomarker-unselected patients and cohort 2 enrolled 99 biomarker-pos. patients.  The major efficacy outcome measure was investigator-assessed progression-free survival (PFS).  A large magnitude of improvement in PFS was obsd. in patients receiving palbociclib plus letrozole compared with patients receiving letrozole alone (HR, 0.488; 95% confidence interval, 0.319-0.748).  Multiple sensitivity analyses were supportive of clin. benefit.  The most common adverse reaction in patients receiving palbociclib plus letrozole was neutropenia.  This article summarizes the FDA thought process and data supporting accelerated approval based on PALOMA-1 that may be contingent upon verification and description of clin. benefit in the ongoing and fully accrued confirmatory trial PALOMA-2.  Clin Cancer Res; 21(21); 4760-6. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTc7NV9QVmZ7Vg90H21EOLACvtfcHk0liUsjzGilXRvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsrvO&md5=1c82d9a1d34b061f2c0bbc6833561c07</span></div><a href="/servlet/linkout?suffix=cit146a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1185%26sid%3Dliteratum%253Aachs%26aulast%3DBeaver%26aufirst%3DJ.%2BA.%26aulast%3DAmiri-Kordestani%26aufirst%3DL.%26aulast%3DCharlab%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DPalmby%26aufirst%3DT.%26aulast%3DTilley%26aufirst%3DA.%26aulast%3DZirkelbach%26aufirst%3DJ.%2BF.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DCrich%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%2BH.%26aulast%3DHughes%26aufirst%3DM.%26aulast%3DBloomquist%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DKluetz%26aufirst%3DP.%2BG.%26aulast%3DKim%26aufirst%3DG.%26aulast%3DIbrahim%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26aulast%3DCortazar%26aufirst%3DP.%26atitle%3DFDA%2520Approval%253A%2520Palbociclib%2520for%2520the%2520Treatment%2520of%2520Postmenopausal%2520Patients%2520with%2520Estrogen%2520Receptor-Positive%252C%2520HER2-Negative%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4760%26epage%3D4766%26doi%3D10.1158%2F1078-0432.CCR-15-1185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit146b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Owsley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, J. R.</span><span> </span><span class="NLM_article-title">Palbociclib: CDK4/6 Inhibition in the Treatment of ER-positive Breast Cancer</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1358/dot.2016.52.2.2440528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdot.2016.52.2.2440528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC28bhsVarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=119-129&author=J.+Owsleyauthor=A.+Jimenoauthor=J.+R.+Diamond&title=Palbociclib%3A+CDK4%2F6+Inhibition+in+the+Treatment+of+ER-positive+Breast+Cancer&doi=10.1358%2Fdot.2016.52.2.2440528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146bR"><div class="casContent"><span class="casTitleNuber">146b</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer</span></div><div class="casAuthors">Owsley J; Jimeno A; Diamond J R</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-29</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Maintaining cell-cycle control has become a mainstay in treatment for many cancers.  Cell-cycle manipulation can be especially valuable in breast cancer tumor cells that will often express hormone receptors that are amenable to anti-hormone receptor-targeted therapies.  Despite these treatments, patients often progress, leading to other targeted agents being investigated to help promote progression-free survival.  Cyclin-dependent kinases (CDKs) have been identified as contributors in the process of cell division.  Combining inhibitors of CDKs with traditional endocrine treatments has shown significant progression-free survival in patients with metastatic breast cancer.  One such CDK inhibitor, palbociclib, has shown great promise in the treatment of hormone receptor-positive breast cancer.  In this article we review the traditional hormonal treatments of breast cancer, how CDK inhibition is beneficial in the treatment of this disease, and the preclinical and clinical data supporting the use of this medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPNpp60_KrnkodMGTatQ7LfW6udTcc2eapnc6r1z7dILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhsVarug%253D%253D&md5=4b95fd49ae63b35a2c87d0d0cbce0b93</span></div><a href="/servlet/linkout?suffix=cit146b&amp;dbid=16384&amp;doi=10.1358%2Fdot.2016.52.2.2440528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2016.52.2.2440528%26sid%3Dliteratum%253Aachs%26aulast%3DOwsley%26aufirst%3DJ.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26atitle%3DPalbociclib%253A%2520CDK4%252F6%2520Inhibition%2520in%2520the%2520Treatment%2520of%2520ER-positive%2520Breast%2520Cancer%26jtitle%3DDrugs%2520Today%26date%3D2016%26volume%3D52%26spage%3D119%26epage%3D129%26doi%3D10.1358%2Fdot.2016.52.2.2440528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Mangini, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesolowski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaswamy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lustberg, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, M. J.</span><span> </span><span class="NLM_article-title">Palbociclib: a Novel Cyclin-dependent Kinase Inhibitor for Hormone Receptor-positive Advanced Breast Cancer</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span><span class="refDoi"> DOI: 10.1177/1060028015602273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1177%2F1060028015602273" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2015&pages=1252-1260&author=N.+S.+Manginiauthor=R.+Wesolowskiauthor=B.+Ramaswamyauthor=M.+B.+Lustbergauthor=M.+J.+Berger&title=Palbociclib%3A+a+Novel+Cyclin-dependent+Kinase+Inhibitor+for+Hormone+Receptor-positive+Advanced+Breast+Cancer&doi=10.1177%2F1060028015602273"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1177%2F1060028015602273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028015602273%26sid%3Dliteratum%253Aachs%26aulast%3DMangini%26aufirst%3DN.%2BS.%26aulast%3DWesolowski%26aufirst%3DR.%26aulast%3DRamaswamy%26aufirst%3DB.%26aulast%3DLustberg%26aufirst%3DM.%2BB.%26aulast%3DBerger%26aufirst%3DM.%2BJ.%26atitle%3DPalbociclib%253A%2520a%2520Novel%2520Cyclin-dependent%2520Kinase%2520Inhibitor%2520for%2520Hormone%2520Receptor-positive%2520Advanced%2520Breast%2520Cancer%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2015%26volume%3D49%26spage%3D1252%26epage%3D1260%26doi%3D10.1177%2F1060028015602273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Cristofanilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colleoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMichele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeck, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theall, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D.</span><span> </span><span class="NLM_article-title">Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-receptor-positive, HER2-negative Metastatic Breast Cancer that Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-blind, Phase 3 Randomised Controlled Trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/S1470-2045(15)00613-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2FS1470-2045%2815%2900613-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26947331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=425-439&author=M.+Cristofanilliauthor=N.+C.+Turnerauthor=I.+Bondarenkoauthor=J.+Roauthor=S.-A.+Imauthor=N.+Masudaauthor=M.+Colleoniauthor=A.+DeMicheleauthor=S.+Loiauthor=S.+Vermaauthor=H.+Iwataauthor=N.+Harbeckauthor=K.+Zhangauthor=K.+P.+Theallauthor=Y.+Jiangauthor=C.+H.+Bartlettauthor=M.+Koehlerauthor=D.+Slamon&title=Fulvestrant+plus+Palbociclib+versus+Fulvestrant+plus+Placebo+for+Treatment+of+Hormone-receptor-positive%2C+HER2-negative+Metastatic+Breast+Cancer+that+Progressed+on+Previous+Endocrine+Therapy+%28PALOMA-3%29%3A+Final+Analysis+of+the+Multicentre%2C+Double-blind%2C+Phase+3+Randomised+Controlled+Trial&doi=10.1016%2FS1470-2045%2815%2900613-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial</span></div><div class="casAuthors">Cristofanilli, Massimo; Turner, Nicholas C.; Bondarenko, Igor; Ro, Jungsil; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Zhang, Ke; Theall, Kathy Puyana; Jiang, Yuqiu; Bartlett, Cynthia Huang; Koehler, Maria; Slamon, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-439</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was assocd. with significant improvements in progression-free survival compared with fulvestrant plus placebo in patients with metastatic breast cancer.  Identification of patients most suitable for the addn. of palbociclib to endocrine therapy after tumor recurrence is crucial for treatment optimization in metastatic breast cancer.  We aimed to confirm our earlier findings with this extended follow-up and show our results for subgroup and biomarker analyses.  In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with hormone-receptor-pos., HER2-neg. metastatic breast cancer that had progressed on previous endocrine therapy were stratified by sensitivity to previous hormonal therapy, menopausal status, and presence of visceral metastasis at 144 centers in 17 countries.  Eligible patients-ie, any menopausal status, Eastern Cooperative Oncol. Group performance status 0-1, measurable disease or bone disease only, and disease relapse or progression after previous endocrine therapy for advanced disease during treatment or within 12 mo of completion of adjuvant therapy-were randomly assigned (2:1) via a centralised interactive web-based and voice-based randomisation system to receive oral palbociclib (125 mg daily for 3 wk followed by a week off over 28-day cycles) plus 500 mg fulvestrant (i.m. injection on days 1 and 15 of cycle 1; then on day 1 of subsequent 28-day cycles) or placebo plus fulvestrant.  The primary endpoint was investigator-assessed progression-free survival.  Anal. was by intention to treat.  We also assessed endocrine therapy resistance by clin. parameters, quant. hormone-receptor expression, and tumor PIK3CA mutational status in circulating DNA at baseline.  This study is registered with ClinicalTrials.gov, NCT01942135.  Between Oct 7, 2013, and Aug 26, 2014, 521 patients were randomly assigned, 347 to fulvestrant plus palbociclib and 174 to fulvestrant plus placebo.  Study enrolment is closed and overall survival follow-up is in progress.  By March 16, 2015, 259 progression-free-survival events had occurred (145 in the fulvestrant plus palbociclib group and 114 in the fulvestrant plus placebo group); median follow-up was 8·9 mo (IQR 8·7-9·2).  Median progression-free survival was 9·5 mo (95% CI 9·2-11·0) in the fulvestrant plus palbociclib group and 4·6 mo (3·5-5·6) in the fulvestrant plus placebo group (hazard ratio 0·46, 95% CI 0·36-0·59, p<0·0001).  Grade 3 or 4 adverse events occurred in 251 (73%) of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fulvestrant plus placebo group.  The most common grade 3 or 4 adverse events were neutropenia (223 [65%] in the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus placebo group), anemia (ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]).  Serious adverse events (all causalities) occurred in 44 patients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) of 172 patients in the fulvestrant plus placebo group.  PIK3CA mutation was detected in the plasma DNA of 129 (33%) of 395 patients for whom these data were available.  Neither PIK3CA status nor hormone-receptor expression level significantly affected treatment response.  Fulvestrant plus palbociclib was assocd. with significant and consistent improvement in progression-free survival compared with fulvestrant plus placebo, irresp. of the degree of endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status.  The combination could be considered as a therapeutic option for patients with recurrent hormone-receptor-pos., HER2-neg. metastatic breast cancer that has progressed on previous endocrine therapy.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmN_mxQq1lWrVg90H21EOLACvtfcHk0lh_ahH2qaZEbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yhsLo%253D&md5=393ef72549634e00f26a0a1916565472</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900613-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900613-0%26sid%3Dliteratum%253Aachs%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DRo%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DLoi%26aufirst%3DS.%26aulast%3DVerma%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DTheall%26aufirst%3DK.%2BP.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DBartlett%26aufirst%3DC.%2BH.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DSlamon%26aufirst%3DD.%26atitle%3DFulvestrant%2520plus%2520Palbociclib%2520versus%2520Fulvestrant%2520plus%2520Placebo%2520for%2520Treatment%2520of%2520Hormone-receptor-positive%252C%2520HER2-negative%2520Metastatic%2520Breast%2520Cancer%2520that%2520Progressed%2520on%2520Previous%2520Endocrine%2520Therapy%2520%2528PALOMA-3%2529%253A%2520Final%2520Analysis%2520of%2520the%2520Multicentre%252C%2520Double-blind%252C%2520Phase%25203%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D425%26epage%3D439%26doi%3D10.1016%2FS1470-2045%2815%2900613-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span><span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+Potent+and+Selective+Inhibitor+of+Cyclin-Dependent+Kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lh_ahH2qaZEbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Cyclin-Dependent%2520Kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Coutable, L.</span><span> </span><span class="NLM_article-title">Method of Producing Palbociclib and Pharmaceutical Compositions Comprising the Same</span>. WO 2016030439A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Coutable&title=Method+of+Producing+Palbociclib+and+Pharmaceutical+Compositions+Comprising+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCoutable%26aufirst%3DL.%26atitle%3DMethod%2520of%2520Producing%2520Palbociclib%2520and%2520Pharmaceutical%2520Compositions%2520Comprising%2520the%2520Same%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit150b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Erdman, D. T.; Flamme, C. M.; Nelson, J. D.</span><span> </span><span class="NLM_article-title">Preparation of 2-(Pyridin-2-ylamino)-pyrido[2,3-<i>d</i>]pyrimidin-7-ones</span>. WO 2008032157A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+T.+Erdman&author=C.+M.+Flamme&author=J.+D.+Nelson&title=Preparation+of+2-%28Pyridin-2-ylamino%29-pyrido%5B2%2C3-d%5Dpyrimidin-7-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErdman%26aufirst%3DD.%2BT.%26atitle%3DPreparation%2520of%25202-%2528Pyridin-2-ylamino%2529-pyrido%255B2%252C3-d%255Dpyrimidin-7-ones%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit150c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tyagi, V.; Mohammad, K.; Rai, B. P.; Prasad, M.</span><span> </span><span class="NLM_article-title">Process for the Preparation of Palbociclib</span>. WO 2016016769A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=V.+Tyagi&author=K.+Mohammad&author=B.+P.+Rai&author=M.+Prasad&title=Process+for+the+Preparation+of+Palbociclib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DV.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Palbociclib%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chekal, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guinness, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ide, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Withbroe, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keane, J.</span><span> </span><span class="NLM_article-title">Palbociclib Commercial Manufacturing Process Development. Part III. Deprotection Followed by Crystallization for API Particle Property Control</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1226</span><span class="refDoi"> DOI: 10.1021/acs.oprd.6b00071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1217-1226&author=B.+P.+Chekalauthor=J.+Ewersauthor=S.+M.+Guinnessauthor=N.+D.+Ideauthor=K.+R.+Leemanauthor=R.+J.+Postauthor=A.+M.+Raneauthor=K.+Sutherlandauthor=K.+Wangauthor=M.+Websterauthor=G.+J.+Withbroeauthor=J.+Draperauthor=D.+Lynchauthor=M.+McAuliffeauthor=J.+Keane&title=Palbociclib+Commercial+Manufacturing+Process+Development.+Part+III.+Deprotection+Followed+by+Crystallization+for+API+Particle+Property+Control&doi=10.1021%2Facs.oprd.6b00071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151aR"><div class="casContent"><span class="casTitleNuber">151a</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib Commercial Manufacturing Process Development. Part III. Deprotection Followed by Crystallization for API Particle Property Control</span></div><div class="casAuthors">Chekal, Brian P.; Ewers, Jason; Guinness, Steven M.; Ide, Nathan D.; Leeman, Kyle R.; Post, Ronald J.; Rane, Anil M.; Sutherland, Karen; Wang, Ke; Webster, Mark; Withbroe, Gregory J.; Draper, John; Lynch, Denis; McAuliffe, Marie; Keane, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1217-1226</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A three-step com. manufg. route has been developed for palbociclib, a highly selective, reversible inhibitor of CDK 4/6.  The third step of the palbociclib process is composed of an acid-catalyzed deprotection reaction telescoped through extractive workup and distn. operations into a controlled crystn. process.  The selection of n-butanol and anisole as the cosolvents for this step allowed for the development of a robust process for each unit operation and for tight control of the API particle size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8gzyM12cOILVg90H21EOLACvtfcHk0lj9tA2XCJQ_Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSntbc%253D&md5=80e7571615687e4a026bf9555d8c9587</span></div><a href="/servlet/linkout?suffix=cit151a&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00071%26sid%3Dliteratum%253Aachs%26aulast%3DChekal%26aufirst%3DB.%2BP.%26aulast%3DEwers%26aufirst%3DJ.%26aulast%3DGuinness%26aufirst%3DS.%2BM.%26aulast%3DIde%26aufirst%3DN.%2BD.%26aulast%3DLeeman%26aufirst%3DK.%2BR.%26aulast%3DPost%26aufirst%3DR.%2BJ.%26aulast%3DRane%26aufirst%3DA.%2BM.%26aulast%3DSutherland%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWebster%26aufirst%3DM.%26aulast%3DWithbroe%26aufirst%3DG.%2BJ.%26aulast%3DDraper%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DD.%26aulast%3DMcAuliffe%26aufirst%3DM.%26aulast%3DKeane%26aufirst%3DJ.%26atitle%3DPalbociclib%2520Commercial%2520Manufacturing%2520Process%2520Development.%2520Part%2520III.%2520Deprotection%2520Followed%2520by%2520Crystallization%2520for%2520API%2520Particle%2520Property%2520Control%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1217%26epage%3D1226%26doi%3D10.1021%2Facs.oprd.6b00071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit151b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chekal, B. P.; Ide, N. D.</span><span> </span><span class="NLM_article-title">Preparation of Acetylcyclopentylmethylpiperazinylpyridinylaminopyridopyrimidinone Derivatives for Use as Selective CDK4/6 Inhibitors</span>. WO 2014128588A1,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=B.+P.+Chekal&author=N.+D.+Ide&title=Preparation+of+Acetylcyclopentylmethylpiperazinylpyridinylaminopyridopyrimidinone+Derivatives+for+Use+as+Selective+CDK4%2F6+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChekal%26aufirst%3DB.%2BP.%26atitle%3DPreparation%2520of%2520Acetylcyclopentylmethylpiperazinylpyridinylaminopyridopyrimidinone%2520Derivatives%2520for%2520Use%2520as%2520Selective%2520CDK4%252F6%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit151c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Duan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Place, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perfect, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ide, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price Wiglesworth, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blunt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAuliffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Sullivan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D.</span><span> </span><span class="NLM_article-title">Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1191</span><span class="NLM_x">–</span> <span class="NLM_lpage">1202</span><span class="refDoi"> DOI: 10.1021/acs.oprd.6b00070</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00070" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslCqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1191-1202&author=S.+Duanauthor=D.+Placeauthor=H.+H.+Perfectauthor=N.+D.+Ideauthor=M.+Maloneyauthor=K.+Sutherlandauthor=K.+E.+Price+Wiglesworthauthor=K.+Wangauthor=M.+Olivierauthor=F.+Kongauthor=K.+Leemanauthor=J.+Bluntauthor=J.+Draperauthor=M.+McAuliffeauthor=M.+O%E2%80%99Sullivanauthor=D.+Lynch&title=Palbociclib+Commercial+Manufacturing+Process+Development.+Part+I%3A+Control+of+Regioselectivity+in+a+Grignard-Mediated+SNAr+Coupling&doi=10.1021%2Facs.oprd.6b00070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151cR"><div class="casContent"><span class="casTitleNuber">151c</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling</span></div><div class="casAuthors">Duan, Shengquan; Place, David; Perfect, Hahdi H.; Ide, Nathan D.; Maloney, Mark; Sutherland, Karen; Price Wiglesworth, Kristin E.; Wang, Ke; Olivier, Mark; Kong, Fangming; Leeman, Kyle; Blunt, Jon; Draper, John; McAuliffe, Marie; O'Sullivan, Maria; Lynch, Denis</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1191-1202</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is the first in a series of three papers describing com. manufg. process development for palbociclib (I).  This manuscript focuses on the SNAr coupling between aminopyridine II and chloropyrimidine III.  The regioselectivity of the SNAr coupling was studied from a synthetic and mechanistic perspective.  Grignard bases were identified as the preferred class of bases for this reaction, allowing for a simplified process and reduced usage factor for aminopyridine II.  The development of this SNAr reaction into a scalable com. manufg. process is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQyIHT73K4u7Vg90H21EOLACvtfcHk0lj9tA2XCJQ_Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslCqtbs%253D&md5=0ce25584ce0f099fbeded818cdb74249</span></div><a href="/servlet/linkout?suffix=cit151c&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00070%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DPlace%26aufirst%3DD.%26aulast%3DPerfect%26aufirst%3DH.%2BH.%26aulast%3DIde%26aufirst%3DN.%2BD.%26aulast%3DMaloney%26aufirst%3DM.%26aulast%3DSutherland%26aufirst%3DK.%26aulast%3DPrice%2BWiglesworth%26aufirst%3DK.%2BE.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DOlivier%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DF.%26aulast%3DLeeman%26aufirst%3DK.%26aulast%3DBlunt%26aufirst%3DJ.%26aulast%3DDraper%26aufirst%3DJ.%26aulast%3DMcAuliffe%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DM.%26aulast%3DLynch%26aufirst%3DD.%26atitle%3DPalbociclib%2520Commercial%2520Manufacturing%2520Process%2520Development.%2520Part%2520I%253A%2520Control%2520of%2520Regioselectivity%2520in%2520a%2520Grignard-Mediated%2520SNAr%2520Coupling%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1191%26epage%3D1202%26doi%3D10.1021%2Facs.oprd.6b00070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit151d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Maloney, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivier, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ide, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palm, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bill, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keane, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuohy, J.</span><span> </span><span class="NLM_article-title">Palbociclib Commercial Manufacturing Process Development. Part II: Regioselective Heck Coupling with Polymorph Control for Processability</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1203</span><span class="NLM_x">–</span> <span class="NLM_lpage">1216</span><span class="refDoi"> DOI: 10.1021/acs.oprd.6b00069</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00069" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=1203-1216&author=M.+T.+Maloneyauthor=B.+P.+Jonesauthor=M.+A.+Olivierauthor=J.+Maganoauthor=K.+Wangauthor=N.+D.+Ideauthor=A.+S.+Palmauthor=D.+R.+Billauthor=K.+R.+Leemanauthor=K.+Sutherlandauthor=J.+Draperauthor=A.+M.+Dalyauthor=J.+Keaneauthor=D.+Lynchauthor=M.+O%E2%80%99Brienauthor=J.+Tuohy&title=Palbociclib+Commercial+Manufacturing+Process+Development.+Part+II%3A+Regioselective+Heck+Coupling+with+Polymorph+Control+for+Processability&doi=10.1021%2Facs.oprd.6b00069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151d&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00069%26sid%3Dliteratum%253Aachs%26aulast%3DMaloney%26aufirst%3DM.%2BT.%26aulast%3DJones%26aufirst%3DB.%2BP.%26aulast%3DOlivier%26aufirst%3DM.%2BA.%26aulast%3DMagano%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DIde%26aufirst%3DN.%2BD.%26aulast%3DPalm%26aufirst%3DA.%2BS.%26aulast%3DBill%26aufirst%3DD.%2BR.%26aulast%3DLeeman%26aufirst%3DK.%2BR.%26aulast%3DSutherland%26aufirst%3DK.%26aulast%3DDraper%26aufirst%3DJ.%26aulast%3DDaly%26aufirst%3DA.%2BM.%26aulast%3DKeane%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%26aulast%3DTuohy%26aufirst%3DJ.%26atitle%3DPalbociclib%2520Commercial%2520Manufacturing%2520Process%2520Development.%2520Part%2520II%253A%2520Regioselective%2520Heck%2520Coupling%2520with%2520Polymorph%2520Control%2520for%2520Processability%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D1203%26epage%3D1216%26doi%3D10.1021%2Facs.oprd.6b00069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Atadja, P.</span><span> </span><span class="NLM_article-title">Development of the Pan-DAC Inhibitor Panobinostat (LBH589): Successes and Challenges</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.1016/j.canlet.2009.02.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.canlet.2009.02.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=19344997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=233-241&author=P.+Atadja&title=Development+of+the+Pan-DAC+Inhibitor+Panobinostat+%28LBH589%29%3A+Successes+and+Challenges&doi=10.1016%2Fj.canlet.2009.02.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152aR"><div class="casContent"><span class="casTitleNuber">152a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges</span></div><div class="casAuthors">Atadja, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-241</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The histone deacetylase (HDAC) inhibitors are emerging as a highly useful class of anticancer agents that inhibit the enzyme HDAC involved in the deacetylation of histone and non-histone cellular proteins.  The HDAC inhibitor, panobinostat (LBH589, Novartis Pharmaceuticals), achieves potent inhibition of all HDAC enzymes implicated in cancer and has demonstrated potent anti-tumor activity in preclin. models and promising clin. efficacy in cancer patients.  In this review we discuss the successes and challenges surrounding the development of panobinostat, focusing on its proposed mechanism of action, preclin. anti-tumor activity, and early clin. efficacy in hematol. and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSTYxNKUMt7bVg90H21EOLACvtfcHk0ljLpnYhRpalHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtL4%253D&md5=4c487a2f8dc13f72cecf105d9fae97d9</span></div><a href="/servlet/linkout?suffix=cit152a&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.019%26sid%3Dliteratum%253Aachs%26aulast%3DAtadja%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520the%2520Pan-DAC%2520Inhibitor%2520Panobinostat%2520%2528LBH589%2529%253A%2520Successes%2520and%2520Challenges%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D233%26epage%3D241%26doi%3D10.1016%2Fj.canlet.2009.02.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit152b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cheng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasse, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, J.</span><span> </span><span class="NLM_article-title">Panobinostat, a Pan-histone Deacetylase Inhibitor: Rationale for and Application to Treatment of Multiple Myeloma</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">491</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span><span class="refDoi"> DOI: 10.1358/dot.2015.51.8.2362311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdot.2015.51.8.2362311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A280%3ADC%252BC283js1WlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=491-504&author=T.+Chengauthor=L.+Grasseauthor=J.+Chandraauthor=J.+Shah&title=Panobinostat%2C+a+Pan-histone+Deacetylase+Inhibitor%3A+Rationale+for+and+Application+to+Treatment+of+Multiple+Myeloma&doi=10.1358%2Fdot.2015.51.8.2362311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152bR"><div class="casContent"><span class="casTitleNuber">152b</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma</span></div><div class="casAuthors">Cheng T; Grasse L; Chandra J; Shah J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">491-504</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Histone deacetylase inhibitors (HDACis) have emerged as novel therapeutic agents for cancer.  Currently, four HDACis are approved by the Food and Drug Administration (FDA) to treat various hematologic malignancies.  Panobinostat (LBH-589, trade name Farydak®, developed and marketed by Novartis) is a potent pan-HDACi with demonstrated anticancer activities against multiple myeloma, a B-cell malignancy, at a low nanomolar range in preclinical settings, and in 2015 was granted FDA approval for the treatment of relapsed and refractory multiple myeloma.  Here, we review the development of HDACis, the unique features of panobinostat, and the rationale for developing panobinostat in a combination setting for the treatment of multiple myeloma.  We also review the completed and ongoing clinical trials testing the efficacy of panobinostat in combination therapies and highlight future therapeutically relevant strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdrHqiOVCAxdts4TFFB11gfW6udTcc2eYLys2y14rCSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283js1WlsA%253D%253D&md5=6840a213c7bcd49b260ad853d1c66fcc</span></div><a href="/servlet/linkout?suffix=cit152b&amp;dbid=16384&amp;doi=10.1358%2Fdot.2015.51.8.2362311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2015.51.8.2362311%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DT.%26aulast%3DGrasse%26aufirst%3DL.%26aulast%3DChandra%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DJ.%26atitle%3DPanobinostat%252C%2520a%2520Pan-histone%2520Deacetylase%2520Inhibitor%253A%2520Rationale%2520for%2520and%2520Application%2520to%2520Treatment%2520of%2520Multiple%2520Myeloma%26jtitle%3DDrugs%2520Today%26date%3D2015%26volume%3D51%26spage%3D491%26epage%3D504%26doi%3D10.1358%2Fdot.2015.51.8.2362311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit152c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Revill, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mealy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serradell, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosa, E.</span><span> </span><span class="NLM_article-title">Panobinostat: Histone Deacetylase (HDAC) Inhibitor Apoptosis Inducer Oncolytic</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1358/dof.2007.032.04.1094476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1358%2Fdof.2007.032.04.1094476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslOjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2007&pages=315-322&author=P.+Revillauthor=N.+Mealyauthor=N.+Serradellauthor=J.+Bolosauthor=E.+Rosa&title=Panobinostat%3A+Histone+Deacetylase+%28HDAC%29+Inhibitor+Apoptosis+Inducer+Oncolytic&doi=10.1358%2Fdof.2007.032.04.1094476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152cR"><div class="casContent"><span class="casTitleNuber">152c</span><div class="casTitle"><span class="NLM_cas:atitle">Panobinostat: histone deacetylase (HDAC) inhibitor apoptosis inducer oncolytic</span></div><div class="casAuthors">Revill, P.; Mealy, N.; Serradell, N.; Bolos, J.; Rosa, E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Panobinostat (LBH-589) is a member of the hydroxamic acid group of histone deacetylase (HDAC) inhibitors that have been shown to impede multiple pathways implicated in cancer and reverse epigenetic events assocd. with cancer, thereby reducing survival and inducing apoptosis in cancer cells.  Panobinostat is being investigated in various hematol. malignancies, including chronic myelogenous leukemia (CML) and multiple myeloma, and in solid tumors.  Preclin. data indicate efficacy against drug-resistant cancer cells, both as a single agent and in combination with other therapies.  A phase I clin. study has demonstrated activity in treatment-experienced patients with cutaneous T-cell lymphoma (CTCL) and phase II/III trials for this condition and other hematol. malignancies are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbKnZsI4DrhrVg90H21EOLACvtfcHk0ljLpnYhRpalHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslOjt7k%253D&md5=6356345859a9e34eebecacc0088cb062</span></div><a href="/servlet/linkout?suffix=cit152c&amp;dbid=16384&amp;doi=10.1358%2Fdof.2007.032.04.1094476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2007.032.04.1094476%26sid%3Dliteratum%253Aachs%26aulast%3DRevill%26aufirst%3DP.%26aulast%3DMealy%26aufirst%3DN.%26aulast%3DSerradell%26aufirst%3DN.%26aulast%3DBolos%26aufirst%3DJ.%26aulast%3DRosa%26aufirst%3DE.%26atitle%3DPanobinostat%253A%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitor%2520Apoptosis%2520Inducer%2520Oncolytic%26jtitle%3DDrugs%2520Future%26date%3D2007%26volume%3D32%26spage%3D315%26epage%3D322%26doi%3D10.1358%2Fdof.2007.032.04.1094476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Anne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sammartino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barginear, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Budman, D.</span><span> </span><span class="NLM_article-title">Profile of Panobinostat and Its Potential for Treatment in Solid Tumors: an Update</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1613</span><span class="NLM_x">–</span> <span class="NLM_lpage">1624</span><span class="refDoi"> DOI: 10.2147/OTT.S30773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.2147%2FOTT.S30773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24265556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntVartLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1613-1624&author=M.+Anneauthor=D.+Sammartinoauthor=M.+F.+Barginearauthor=D.+Budman&title=Profile+of+Panobinostat+and+Its+Potential+for+Treatment+in+Solid+Tumors%3A+an+Update&doi=10.2147%2FOTT.S30773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of panobinostat and its potential for treatment in solid tumors: an update</span></div><div class="casAuthors">Anne, Madhurima; Sammartino, Daniel; Barginear, Myra F.; Budman, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1613-1624</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer.  Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase inhibitor that is being evaluated in both i.v. and oral formulations across multiple tumor types.  Comparable to the other HDACs, panobinostat leads to hyperacetylation of histones and other intracellular proteins, allowing for the expression of otherwise repressed genes, leading to inhibition of cellular proliferation and induction of apoptosis in malignant cells.  Panobinostat, analogous to other HDAC inhibitors, also induces apoptosis by directly activating cellular death receptor pathways.  Preclin. data suggests that panobinostat has inhibitory activity at nanomolar concns. and appears to be the most potent clin. available HDAC inhibitor.  Here we review the current status of panobinostat and discuss its role in the treatment of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhDG-Z7mmMb7Vg90H21EOLACvtfcHk0ljLpnYhRpalHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntVartLo%253D&md5=1747201adba8ef6d10e729cc13015117</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.2147%2FOTT.S30773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S30773%26sid%3Dliteratum%253Aachs%26aulast%3DAnne%26aufirst%3DM.%26aulast%3DSammartino%26aufirst%3DD.%26aulast%3DBarginear%26aufirst%3DM.%2BF.%26aulast%3DBudman%26aufirst%3DD.%26atitle%3DProfile%2520of%2520Panobinostat%2520and%2520Its%2520Potential%2520for%2520Treatment%2520in%2520Solid%2520Tumors%253A%2520an%2520Update%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D1613%26epage%3D1624%26doi%3D10.2147%2FOTT.S30773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Acemoglu, M.; Bajwa, J. S.; Parker, D. J.; Slade, J.</span><span> </span><span class="NLM_article-title">Process for Preparation of (2<i>E</i>)-<i>N</i>-Hydroxy-3-[4-[[[2-(2-methyl-1<i>H</i>-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide</span>. WO 2007146718A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=M.+Acemoglu&author=J.+S.+Bajwa&author=D.+J.+Parker&author=J.+Slade&title=Process+for+Preparation+of+%282E%29-N-Hydroxy-3-%5B4-%5B%5B%5B2-%282-methyl-1H-indol-3-yl%29ethyl%5Damino%5Dmethyl%5Dphenyl%5D-2-propenamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAcemoglu%26aufirst%3DM.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520%25282E%2529-N-Hydroxy-3-%255B4-%255B%255B%255B2-%25282-methyl-1H-indol-3-yl%2529ethyl%255Damino%255Dmethyl%255Dphenyl%255D-2-propenamide%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit154b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bair, K. W.; Green, M. A.; Perez, L. B.; Remiszewski, S. W.; Sambucetti, L.; Versace, R. W.; Sharma, S. K.</span><span> </span><span class="NLM_article-title">Preparation of Hydroxamic Acids as Deacetylase Inhibitors</span>. WO 2002022577A1,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=K.+W.+Bair&author=M.+A.+Green&author=L.+B.+Perez&author=S.+W.+Remiszewski&author=L.+Sambucetti&author=R.+W.+Versace&author=S.+K.+Sharma&title=Preparation+of+Hydroxamic+Acids+as+Deacetylase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBair%26aufirst%3DK.%2BW.%26atitle%3DPreparation%2520of%2520Hydroxamic%2520Acids%2520as%2520Deacetylase%2520Inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Slade, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girgis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repic, O.</span><span> </span><span class="NLM_article-title">Optimization and Scale-Up of the Grandberg Synthesis of 2-Methyltryptamine</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1021/op7000518</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op7000518" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=721-725&author=J.+Sladeauthor=D.+Parkerauthor=M.+Girgisauthor=R.+Wuauthor=S.+Josephauthor=O.+Repic&title=Optimization+and+Scale-Up+of+the+Grandberg+Synthesis+of+2-Methyltryptamine&doi=10.1021%2Fop7000518"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Fop7000518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop7000518%26sid%3Dliteratum%253Aachs%26aulast%3DSlade%26aufirst%3DJ.%26aulast%3DParker%26aufirst%3DD.%26aulast%3DGirgis%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DS.%26aulast%3DRepic%26aufirst%3DO.%26atitle%3DOptimization%2520and%2520Scale-Up%2520of%2520the%2520Grandberg%2520Synthesis%2520of%25202-Methyltryptamine%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2007%26volume%3D11%26spage%3D721%26epage%3D725%26doi%3D10.1021%2Fop7000518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Bajwa, J. S.; Parker, D. J.; Slade, J.</span><span> </span><span class="NLM_article-title">Preparation of Salts of <i>N</i>-Hydroxy-3-[4-[[[2-(2-methyl-1<i>H</i>-indol-3-yl)ethyl]amino]methyl]phenyl]-2<i>E</i>-2-propenamide</span>. WO 2007146717A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+S.+Bajwa&author=D.+J.+Parker&author=J.+Slade&title=Preparation+of+Salts+of+N-Hydroxy-3-%5B4-%5B%5B%5B2-%282-methyl-1H-indol-3-yl%29ethyl%5Damino%5Dmethyl%5Dphenyl%5D-2E-2-propenamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBajwa%26aufirst%3DJ.%2BS.%26atitle%3DPreparation%2520of%2520Salts%2520of%2520N-Hydroxy-3-%255B4-%255B%255B%255B2-%25282-methyl-1H-indol-3-yl%2529ethyl%255Damino%255Dmethyl%255Dphenyl%255D-2E-2-propenamide%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Burness, C. B.</span><span> </span><span class="NLM_article-title">Sonidegib: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1559</span><span class="NLM_x">–</span> <span class="NLM_lpage">1566</span><span class="refDoi"> DOI: 10.1007/s40265-015-0458-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs40265-015-0458-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1559-1566&author=C.+B.+Burness&title=Sonidegib%3A+First+Global+Approval&doi=10.1007%2Fs40265-015-0458-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0458-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0458-y%26sid%3Dliteratum%253Aachs%26aulast%3DBurness%26aufirst%3DC.%2BB.%26atitle%3DSonidegib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1559%26epage%3D1566%26doi%3D10.1007%2Fs40265-015-0458-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit157b"><span><span class="NLM_label">(b) </span>FDA Approves New Treatment for Most Common Form of Advanced Skin Cancer; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, July 24,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm</a> (accessed September 8, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+New+Treatment+for+Most+Common+Form+of+Advanced+Skin+Cancer%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+July+24%2C+2015%3B+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm455862.htm+%28accessed+September+8%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520New%2520Treatment%2520for%2520Most%2520Common%2520Form%2520of%2520Advanced%2520Skin%2520Cancer%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Dreier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felderer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nageli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunstfeld, R.</span><span> </span><span class="NLM_article-title">Emerging Drugs and Combination Strategies for Basal Cell Carcinoma</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span><span class="refDoi"> DOI: 10.1517/14728214.2014.914171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1517%2F14728214.2014.914171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24773312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyjtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=353-365&author=J.+Dreierauthor=R.+Dummerauthor=L.+Feldererauthor=M.+Nageliauthor=S.+Gobbiauthor=R.+Kunstfeld&title=Emerging+Drugs+and+Combination+Strategies+for+Basal+Cell+Carcinoma&doi=10.1517%2F14728214.2014.914171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs and combination strategies for basal cell carcinoma</span></div><div class="casAuthors">Dreier, Jil; Dummer, Reinhard; Felderer, Lea; Naegeli, Mirjam; Gobbi, Sharon; Kunstfeld, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-365</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Basal cell carcinoma (BCC) is a malignancy that is driven by an activated Hedgehog (Hh) pathway.  Smoothened inhibitors are a new promising treatment option for patients with locally advanced or metastatic BCC or basal cell nevus syndrome.  But long-term data are still limited, the optimal treatment duration is not yet defined and there are already documented cases with acquired resistance.  Areas covered: Treatment modalities with Hh inhibitors, side effects and potential pharmacol. combination options are discussed.  The current literature, including PubMed, Cochrane database and registered trials on ClinicalTrials.gov, was searched.  Expert opinion: BCCs typically regress during therapy with Hh inhibitors.  Muscle toxicity, dysgeusia and hair loss can be considered as on target adverse reactions.  Muscle toxicity is the dose-limiting toxicity of sonidegib.  It was not seen with vismodegib because of its high binding to plasma protein α-1-acid glycoprotein.  Sonidegib is different and shows a clear dose-toxicity relationship, which allows to address the question of whether there is a dose dependency of regression rate, cure rate and progression-free survival.  In addn., basic research has offered strategies to enhance efficacy by the combination with other mols., such as EGFR inhibitors, MEK inhibitors or immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozaVeQjReUuLVg90H21EOLACvtfcHk0liQLj_XJRYA7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyjtbzL&md5=aace7f145ff3d7628420b12092b29b7c</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1517%2F14728214.2014.914171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2014.914171%26sid%3Dliteratum%253Aachs%26aulast%3DDreier%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DFelderer%26aufirst%3DL.%26aulast%3DNageli%26aufirst%3DM.%26aulast%3DGobbi%26aufirst%3DS.%26aulast%3DKunstfeld%26aufirst%3DR.%26atitle%3DEmerging%2520Drugs%2520and%2520Combination%2520Strategies%2520for%2520Basal%2520Cell%2520Carcinoma%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2014%26volume%3D19%26spage%3D353%26epage%3D365%26doi%3D10.1517%2F14728214.2014.914171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Brechbiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller-Moslin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Crosstalk Between Hedgehog and Other Signaling Pathways as a Basis for Combination Therapies in Cancer</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">750</span><span class="NLM_x">–</span> <span class="NLM_lpage">759</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2014.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1016%2Fj.ctrv.2014.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=24613036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVWjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=750-759&author=J.+Brechbielauthor=K.+Miller-Moslinauthor=A.+A.+Adjei&title=Crosstalk+Between+Hedgehog+and+Other+Signaling+Pathways+as+a+Basis+for+Combination+Therapies+in+Cancer&doi=10.1016%2Fj.ctrv.2014.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159aR"><div class="casContent"><span class="casTitleNuber">159a</span><div class="casTitle"><span class="NLM_cas:atitle">Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer</span></div><div class="casAuthors">Brechbiel, Jillian; Miller-Moslin, Karen; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">750-759</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The hedgehog (Hh) pathway is aberrantly activated in a no. of tumors.  In medulloblastoma, basal cell carcinoma, and rhabdomyosarcoma, mutations in Hh pathway genes lead to ligand-independent pathway activation.  In many other tumor types, ligand-dependent activation of Hh signaling is potentiated through crosstalk with other crit. mol. signaling pathways.  Among such pathways, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch are of particular interest because agents that selectively inhibit these pathways are available and can be readily combined with agents such as vismodegib, sonidegib (LDE225), and BMS-833923, which target smoothened-a key Hh pathway regulator.  Numerous preclin. studies have revealed the ways in which Hh intersects with each of these pathways, and combination therapies have resulted in improved antitumor efficacy and survival in animal models.  Hh also plays an important role in hematopoiesis and in the maintenance of BCR-ABL-driven leukemic stem cells.  Thus, combined inhibition of the Hh pathway and BCR-ABL has emerged as a promising potential therapeutic strategy in chronic myeloid leukemia (CML).  A no. of clin. trials evaluating combinations of Hh inhibitors with other targeted agents are now underway in CML and a variety of solid tumors.  This review highlights these trials and summarizes preclin. evidence of crosstalk between Hh and four other actionable pathways-RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch-as well as the role of Hh in the maintenance of BCR-ABL-driven leukemic stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0QBuqlma6TbVg90H21EOLACvtfcHk0lhwzrlE_3nStw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVWjsbY%253D&md5=f3975d97baf71723f2c4fc62779844e0</span></div><a href="/servlet/linkout?suffix=cit159a&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DBrechbiel%26aufirst%3DJ.%26aulast%3DMiller-Moslin%26aufirst%3DK.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DCrosstalk%2520Between%2520Hedgehog%2520and%2520Other%2520Signaling%2520Pathways%2520as%2520a%2520Basis%2520for%2520Combination%2520Therapies%2520in%2520Cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D750%26epage%3D759%26doi%3D10.1016%2Fj.ctrv.2014.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit159b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gan, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span> </span><span class="NLM_article-title">Emerging from Their Burrow: Hedgehog Pathway Inhibitors for Cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1166</span><span class="refDoi"> DOI: 10.1080/13543784.2016.1216973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1080%2F13543784.2016.1216973" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1153-1166&author=G.+N.+Ganauthor=A.+Jimeno&title=Emerging+from+Their+Burrow%3A+Hedgehog+Pathway+Inhibitors+for+Cancer&doi=10.1080%2F13543784.2016.1216973"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159b&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1216973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1216973%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DG.%2BN.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DEmerging%2520from%2520Their%2520Burrow%253A%2520Hedgehog%2520Pathway%2520Inhibitors%2520for%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1153%26epage%3D1166%26doi%3D10.1080%2F13543784.2016.1216973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Burness, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, L. J.</span><span> </span><span class="NLM_article-title">Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma</span> <span class="citation_source-journal">Targ. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span><span class="refDoi"> DOI: 10.1007/s11523-016-0418-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1007%2Fs11523-016-0418-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=26867946" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=239-246&author=C.+B.+Burnessauthor=L.+J.+Scott&title=Sonidegib%3A+A+Review+in+Locally+Advanced+Basal+Cell+Carcinoma&doi=10.1007%2Fs11523-016-0418-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1007%2Fs11523-016-0418-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-016-0418-9%26sid%3Dliteratum%253Aachs%26aulast%3DBurness%26aufirst%3DC.%2BB.%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DSonidegib%253A%2520A%2520Review%2520in%2520Locally%2520Advanced%2520Basal%2520Cell%2520Carcinoma%26jtitle%3DTarg.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3D239%26epage%3D246%26doi%3D10.1007%2Fs11523-016-0418-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1038/nrd3714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=10.1038%2Fnrd3714" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=257-258&author=M.+Guha&title=Hedgehog+inhibitor+gets+landmark+skin+cancer+approval%2C+but+questions+remain+for+wider+potential&doi=10.1038%2Fnrd3714"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fnrd3714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3714%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DHedgehog%2520inhibitor%2520gets%2520landmark%2520skin%2520cancer%2520approval%252C%2520but%2520questions%2520remain%2520for%2520wider%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D257%26epage%3D258%26doi%3D10.1038%2Fnrd3714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Englund, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peukert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller-Moslin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vattay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniara, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelleher, J. F.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsch, M.</span><span> </span><span class="NLM_article-title">Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1021/ml1000307</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1000307" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1Cqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=130-134&author=S.+Panauthor=X.+Wuauthor=J.+Jiangauthor=W.+Gaoauthor=Y.+Wanauthor=D.+Chengauthor=D.+Hanauthor=J.+Liuauthor=N.+P.+Englundauthor=Y.+Wangauthor=S.+Peukertauthor=K.+Miller-Moslinauthor=J.+Yuanauthor=R.+Guoauthor=M.+Matsumotoauthor=A.+Vattayauthor=Y.+Jiangauthor=J.+Tsaoauthor=F.+Sunauthor=A.+C.+Pferdekamperauthor=S.+Doddauthor=T.+Tuntlandauthor=W.+Maniaraauthor=J.+F.+Kelleherauthor=Y.+M.+Yaoauthor=M.+Warmuthauthor=J.+Williamsauthor=M.+Dorsch&title=Discovery+of+NVP-LDE225%2C+a+Potent+and+Selective+Smoothened+Antagonist&doi=10.1021%2Fml1000307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162aR"><div class="casContent"><span class="casTitleNuber">162a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist</span></div><div class="casAuthors">Pan, Shifeng; Wu, Xu; Jiang, Jiqing; Gao, Wenqi; Wan, Yongqin; Cheng, Dai; Han, Dong; Liu, Jun; Englund, Nathan P.; Wang, Yan; Peukert, Stefan; Miller-Moslin, Karen; Yuan, Jing; Guo, Ribo; Matsumoto, Melissa; Vattay, Anthony; Jiang, Yun; Tsao, Jeffrey; Sun, Fangxian; Pferdekamper, AnneMarie C.; Dodd, Stephanie; Tuntland, Tove; Maniara, Wieslawa; Kelleher, Joseph F., III; Yao, Yung-mae; Warmuth, Markus; Williams, Juliet; Dorsch, Marion</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">130-134</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The blockade of aberrant hedgehog (Hh) signaling has shown promise for therapeutic intervention in cancer.  A cell-based phenotypic high-throughput screen was performed, and the lead structure (1) was identified as an inhibitor of the Hh pathway via antagonism of the Smoothened receptor (Smo).  Structure-activity relation studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl-3-carboxamide (5m, NVP-LDE225), which is currently in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkXrdZB74WfbVg90H21EOLACvtfcHk0lhwzrlE_3nStw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1Cqt7c%253D&md5=c4d1348e8d47ed9561151ce59305531e</span></div><a href="/servlet/linkout?suffix=cit162a&amp;dbid=16384&amp;doi=10.1021%2Fml1000307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1000307%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DD.%26aulast%3DHan%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DEnglund%26aufirst%3DN.%2BP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPeukert%26aufirst%3DS.%26aulast%3DMiller-Moslin%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DVattay%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DTsao%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DDodd%26aufirst%3DS.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DManiara%26aufirst%3DW.%26aulast%3DKelleher%26aufirst%3DJ.%2BF.%26aulast%3DYao%26aufirst%3DY.%2BM.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DDorsch%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520NVP-LDE225%252C%2520a%2520Potent%2520and%2520Selective%2520Smoothened%2520Antagonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D130%26epage%3D134%26doi%3D10.1021%2Fml1000307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit162b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gao, W.; Jiang, J.; Wan, Y.; Cheng, D.; Han, D.; Wu, X.; Pan, S.</span><span> </span><span class="NLM_article-title">Compounds and Compositions as Hedgehog Pathway Modulators</span>. WO 2008/154259A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=W.+Gao&author=J.+Jiang&author=Y.+Wan&author=D.+Cheng&author=D.+Han&author=X.+Wu&author=S.+Pan&title=Compounds+and+Compositions+as+Hedgehog+Pathway+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DW.%26atitle%3DCompounds%2520and%2520Compositions%2520as%2520Hedgehog%2520Pathway%2520Modulators%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit162c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dierks, C.; Warmuth, M.; Wu, X.</span><span> </span><span class="NLM_article-title">Biphenylcarboxamide Derivatives as Hedgehog Pathway Modulators</span>. WO 2008154259A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Dierks&author=M.+Warmuth&author=X.+Wu&title=Biphenylcarboxamide+Derivatives+as+Hedgehog+Pathway+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDierks%26aufirst%3DC.%26atitle%3DBiphenylcarboxamide%2520Derivatives%2520as%2520Hedgehog%2520Pathway%2520Modulators%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit162d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Fritze, A.; Corcelle, K.; Grubesa, M. E.</span><span> </span><span class="NLM_article-title">Pharmaceutical Compositions</span>. WO 2011009852A2,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+Fritze&author=K.+Corcelle&author=M.+E.+Grubesa&title=Pharmaceutical+Compositions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFritze%26aufirst%3DA.%26atitle%3DPharmaceutical%2520Compositions%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Bajwa, J. S.; De, L. C. M.; Dodd, S. K.; Waykole, L. M.; Wu, R.</span><span> </span><span class="NLM_article-title">Salts of <i>N</i>-[6-<i>cis</i>-2,6-Dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide</span>. WO 2010033481A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+S.+Bajwa&author=L.+C.+M.+De&author=S.+K.+Dodd&author=L.+M.+Waykole&author=R.+Wu&title=Salts+of+N-%5B6-cis-2%2C6-Dimethylmorpholin-4yl%29pyridine-3yl%5D-2-methyl-4%E2%80%B2-%28trifluoromethoxy%29%5B1%2C1%E2%80%B2-biphenyl%5D-3-carboxamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBajwa%26aufirst%3DJ.%2BS.%26atitle%3DSalts%2520of%2520N-%255B6-cis-2%252C6-Dimethylmorpholin-4yl%2529pyridine-3yl%255D-2-methyl-4%25E2%2580%25B2-%2528trifluoromethoxy%2529%255B1%252C1%25E2%2580%25B2-biphenyl%255D-3-carboxamide%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-15%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00010%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00010" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679956dd2c2b2458","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
